

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:53:43 ; Search time 64.1754 Seconds
(without alignments)
761.757 Million cell updates/sec

Title: US-10-735-916A-83
Perfect score: 625
Sequence: 1 QVQLQESGPGLVKPSSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA Main: *
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	625	100.0	117	5	US-10-735-916A-83 Sequence 83, Appl
2	625	100.0	135	5	US-10-735-916A-85 Sequence 85, Appl
3	615	98.4	117	5	US-10-735-916A-79 Sequence 79, Appl
4	615	98.4	135	5	US-10-735-916A-81 Sequence 81, Appl
5	611	97.8	117	5	US-10-735-916A-75 Sequence 75, Appl
6	611	97.8	135	5	US-10-735-916A-77 Sequence 77, Appl
7	529	84.6	117	5	US-10-735-916A-69 Sequence 69, Appl
8	529	84.6	127	5	US-10-735-916A-52 Sequence 52, Appl
9	517	82.7	119	4	US-10-309-762-143 Sequence 143, Appl
10	514.5	82.3	118	4	US-10-292-088-109 Sequence 109, Appl
11	514.5	82.3	120	4	US-10-383-447-26 Sequence 26, Appl
12	513.5	82.2	121	5	US-10-805-177-56 Sequence 56, Appl
13	513.5	82.2	122	4	US-10-309-762-25 Sequence 25, Appl
14	513.5	82.2	122	4	US-10-309-762-29 Sequence 29, Appl
15	512.5	82.0	120	4	US-10-309-762-128 Sequence 128, Appl
16	510.5	81.7	116	4	US-10-309-762-127 Sequence 127, Appl
17	510.5	81.7	121	4	US-10-010-729-11 Sequence 11, Appl
18	510.5	81.7	122	4	US-10-309-762-24 Sequence 24, Appl
19	510.5	81.7	122	4	US-10-309-762-27 Sequence 27, Appl
20	510	81.6	119	4	US-10-125-687-5 Sequence 5, Appl
21	510	81.6	119	5	US-10-996-191-5 Sequence 23, Appl
22	508	81.3	119	5	US-10-937-596-23 Sequence 2, Appl
23	507	81.1	117	5	US-10-890-945-2 Sequence 82, Appl
24	507	81.1	121	4	US-10-292-088-82 Sequence 86, Appl
25	507	81.1	466	4	US-10-292-088-86 Sequence 35, Appl
26	507	81.1	580	4	US-10-310-719-35 Sequence 37, Appl
27	507	81.1	580	4	US-10-310-719-37

ALIGNMENTS

RESULT 1
US-10-735-916A-83
; Sequence 83, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HARUM, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 83
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-83

Query Match 100.0%; Score 625; DB 5; Length 117;
Best Local Similarity 100.0%; Pred. No. 5e-48;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLQESGPGLVKPSSETLSLCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
QY 61 KPSLKDRTVTSVDTSKNQFSLKLSSTVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117
Db 61 KPSLKDRTVTSVDTSKNQFSLKLSSTVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117

RESULT 2
US-10-735-916A-85
; Sequence 85, Application US/10735916A
; Publication No. US20050084906A1

GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 85
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-85

Query Match 100.0%; Score 625; DB 5; Length 135;
Best Local Similarity 100.0%; Pred. No. 5.8e-48;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKLEWIGYISYDGTNNY 78
QY 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 135

RESULT 3
US-10-735-916A-79
; Sequence 79, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 79
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens

US-10-735-916A-79
Query Match 98.4%; Score 615; DB 5; Length 117;
Best Local Similarity 98.3%; Pred. No. 3.9e-47;
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60
QY 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 117
Db 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 117
RESULT 4
US-10-735-916A-81
; Sequence 81, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 81
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-81
Query Match 98.4%; Score 615; DB 5; Length 135;
Best Local Similarity 98.3%; Pred. No. 4.5e-47;
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNNWIRQPPGKLEWIGYISYDGTNNY 78
QY 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 135
RESULT 5
US-10-735-916A-75
; Sequence 75, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF


```
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 52
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-735-916A-52

Query Match      84.6%; Score 529; DB 5; Length 127;
Best Local Similarity 82.8%; Pred. No. 1.9e-39;
Matches 96; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy 2 VQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLMNWIROPKGLWIGYISYDGTNNYK 61
Db 12 VQLQESGPGLVKPSQSLTCTSVTGSITGGYLMNWIROPKGLWIGYISYDGTNNYK 71

Qy 62 PSLKDRVTISVDTSKNQFSLKSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
Db 72 PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCARYGRVFFDYWGQGLTVTVSS 127

RESULT 9
US-10-309-762-143
; Sequence 143, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Peltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX
; FILE REFERENCE: AGENIX 027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 143
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-143

Query Match      82.7%; Score 517; DB 4; Length 119;
Best Local Similarity 85.0%; Pred. No. 2.1e-38;
Matches 102; Conservative 4; Mismatches 10; Indels 4; Gaps 2;

Qy 1 VQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLMNWIROPKGLWIGYISYDGTNNYK 60
Db 1 VQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPKGLWIGYISYSGSTNY 59

Qy 61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVYYCARYGRV---FFDYWGQGLTVTVSS 117
Db 60 NPSLKSRTVISVDTSKNQFSLKSSVTAADTAVYYCARYDILTGYFFDYWGQGLTVTVSS 119

RESULT 10
US-10-292-088-109
; Sequence 109, Application US/10292088
; Publication No. US20030211100A1
; GENERAL INFORMATION:
; APPLICANT: BEDIAN, VAHE
; APPLICANT: GLADUE, RONALD P.
; APPLICANT: CORVALAN, JOSE
; APPLICANT: JIA, XIAO-CHI
; APPLICANT: FENG, XIAO

; TITLE OF INVENTION: ANTIBODIES TO CD40
; FILE REFERENCE: ABX-PF/3 US
; CURRENT APPLICATION NUMBER: US/10/292,088
; CURRENT FILING DATE: 2003-03-14
; PRIOR APPLICATION NUMBER: 60/348,980
; PRIOR FILING DATE: 2001-11-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 109
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-292-088-109

Query Match      82.3%; Score 514.5; DB 4; Length 118;
Best Local Similarity 85.7%; Pred. No. 3.5e-38;
Matches 102; Conservative 3; Mismatches 11; Indels 3; Gaps 2;

Qy 1 VQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLMNWIROPKGLWIGYISYDGTNNYK 60
Db 1 VQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPKGLWIGYISYSGSTNY 59

Qy 61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVYYCAR--YGRVFFDYWGQGLTVTVSS 117
Db 60 NPSLKSRTVISVDTSKNQFSLKSSVTAADTAVYYCARDYGGNSYFDYWGQGLTVTVSS 118

RESULT 11
US-10-383-447-26
; Sequence 26, Application US/10383447
; Publication No. US20040096392A1
; GENERAL INFORMATION:
; APPLICANT: Bhaskar, Vinay
; APPLICANT: de la Calle, Agustin
; APPLICANT: Law, Debbie
; APPLICANT: Caras, Ingrid
; APPLICANT: Ramakrishnan, Vanitha
; APPLICANT: Murray, Richard
; APPLICANT: Afar, Daniel
; APPLICANT: Powers, David
; TITLE OF INVENTION: Antibodies Against Cancer Antigen TWEPP2 and Uses Thereof
; FILE REFERENCE: 05982.0138.NPUS00
; CURRENT APPLICATION NUMBER: US/10/383,447
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: US 60/362,837
; PRIOR FILING DATE: 2002-03-08
; PRIOR APPLICATION NUMBER: US 60/463,812
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: Patent In version 3.2
; SEQ ID NO 26
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Variable heavy chain region 3.0
US-10-383-447-26

Query Match      82.3%; Score 514.5; DB 4; Length 120;
Best Local Similarity 82.4%; Pred. No. 3.5e-38;
Matches 98; Conservative 7; Mismatches 11; Indels 3; Gaps 1;

Qy 2 VQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLMNWIROPKGLWIGYISYDGTNNYK 61
Db 2 VQLQESGPGLVKPSSETLSLTCAVSGYSITSGYYSWIRQPPKGLWIGYISYDGSNKNY 61

Qy 62 PSLKDRVTISVDTSKNQFSLKSSVTAADTAVYYCA---RYGRVFFDYWGQGLTVTVSS 117
Db 62 PSLKNRITISRTSKNQFSLKSSVTAADTAVYYCARGLRGRDYSMDYWGQGLTVTVSS 120

RESULT 12
US-10-805-177-56
```



```
; Sequence 56, Application US/10805177
; Publication No. US2005008449A1
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Chen, Francine
; APPLICANT: Bezabeh, Binyam
; APPLICANT: Foltz, Ian
; APPLICANT: Tse, Kam Fai
; APPLICANT: Jeffers, Michael
; APPLICANT: Mesri, Mehdi
; APPLICANT: Starling, Gary
; APPLICANT: Mezes, Peter
; APPLICANT: Khrantsov, Nikolai
; TITLE OF INVENTION: ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN
; TITLE OF INVENTION: DOMAIN AND MUCIN DOMAIN 1 (TIM-1) ANTIGEN AND USES THEREOF
; FILE REFERENCE: ABXCUR.006A
; CURRENT APPLICATION NUMBER: US/10/805,177
; CURRENT FILING DATE: 2004-03-19
; PRIOR APPLICATION NUMBER: 60/456,652
; PRIOR FILING DATE: 2003-03-19
; NUMBER OF SEQ ID NOS: 141
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 56
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-805-177-56

Query Match      82.2%; Score 513.5; DB 5; Length 121;
Best Local Similarity 85.0%; Pred. No. 4.4e-38;
Matches 102; Conservative 3; Mismatches 12; Indels 3; Gaps 2;

Qy      1 QVQLQESGPGLVKPSSETLSLTCTVSGYSI-SGGYLNWIRQPPGKGLEWIGYISYDGTNN 59
Db      1 QVQLQESGPGLVKPSSETLSLTCTVSGGVSIGGYWIRQPPGKGLEWIGYIYSGSTN 60

Qy      60 YKPSLKDRVTISVDTSKNQFSLKSSVTAADTAVVYCARYG--RVFFDYWGQGLTIVTSS 117
Db      61 YNPSLKSRTVISVDTSKNQFSLKSSVTAADTAVVYCARNNNNNFDYWGQGLTIVTSS 120

RESULT 13
US-10-309-762-25
; Sequence 25, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Foltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYC ANHYDRASE IX
; TITLE OF INVENTION: (CA IX) TUMOR ANTIGEN
; FILE REFERENCE: ABGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-25

Query Match      82.2%; Score 513.5; DB 4; Length 122;
Best Local Similarity 83.7%; Pred. No. 4.4e-38;
Matches 103; Conservative 2; Mismatches 11; Indels 7; Gaps 2;

Qy      1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60
Db      1 QVQLQESGPGLVKPSSETLSLTCTVSGGIS-SYTWIRQPPGKGLEWIGYIYSGSTNY 59

; Sequence 56, Application US/10805177
; Publication No. US2005008449A1
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Chen, Francine
; APPLICANT: Bezabeh, Binyam
; APPLICANT: Foltz, Ian
; APPLICANT: Tse, Kam Fai
; APPLICANT: Jeffers, Michael
; APPLICANT: Mesri, Mehdi
; APPLICANT: Starling, Gary
; APPLICANT: Mezes, Peter
; APPLICANT: Khrantsov, Nikolai
; TITLE OF INVENTION: ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN
; TITLE OF INVENTION: DOMAIN AND MUCIN DOMAIN 1 (TIM-1) ANTIGEN AND USES THEREOF
; FILE REFERENCE: ABXCUR.006A
; CURRENT APPLICATION NUMBER: US/10/805,177
; CURRENT FILING DATE: 2004-03-19
; PRIOR APPLICATION NUMBER: 60/456,652
; PRIOR FILING DATE: 2003-03-19
; NUMBER OF SEQ ID NOS: 141
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 56
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-805-177-56

Query Match      82.2%; Score 513.5; DB 5; Length 121;
Best Local Similarity 85.0%; Pred. No. 4.4e-38;
Matches 102; Conservative 3; Mismatches 12; Indels 3; Gaps 2;

Qy      1 QVQLQESGPGLVKPSSETLSLTCTVSGYSI-SGGYLNWIRQPPGKGLEWIGYISYDGTNN 59
Db      1 QVQLQESGPGLVKPSSETLSLTCTVSGGVSIGGYWIRQPPGKGLEWIGYIYSGSTN 60

Qy      60 YKPSLKDRVTISVDTSKNQFSLKSSVTAADTAVVYCARYG--RVFFDYWGQGLTIVTSS 117
Db      61 YNPSLKSRTVISVDTSKNQFSLKSSVTAADTAVVYCARNNNNNFDYWGQGLTIVTSS 120

RESULT 13
US-10-309-762-25
; Sequence 25, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Foltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYC ANHYDRASE IX
; TITLE OF INVENTION: (CA IX) TUMOR ANTIGEN
; FILE REFERENCE: ABGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-25

Query Match      82.2%; Score 513.5; DB 4; Length 122;
Best Local Similarity 83.7%; Pred. No. 4.4e-38;
Matches 103; Conservative 2; Mismatches 11; Indels 7; Gaps 2;

Qy      1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60
Db      1 QVQLQESGPGLVKPSSETLSLTCTVSGGIS-SYTWIRQPPGKGLEWIGYIYSGSTNY 59
```

```
Qy      61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVVYCARYGRVF-----FDYWGQGLTIVT 114
Db      60 NPSLKSRTVISVDTSKNQFSLKSSVTAADTAVVYCARRGYDLTGTDYFDYWGQGLTIVT 119

Qy      115 VSS 117
Db      120 VSS 122

RESULT 14
US-10-309-762-29
; Sequence 29, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Foltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYC ANHYDRASE IX
; TITLE OF INVENTION: (CA IX) TUMOR ANTIGEN
; FILE REFERENCE: ABGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-29

Query Match      82.2%; Score 513.5; DB 4; Length 122;
Best Local Similarity 83.7%; Pred. No. 4.4e-38;
Matches 103; Conservative 2; Mismatches 11; Indels 7; Gaps 2;

Qy      1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60
Db      1 QVQLQESGPGLVKPSSETLSLTCTVSGGIS-SYTWIRQPPGKGLEWIGYIYSGSTNY 59

Qy      61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVVYCARYGRVF-----FDYWGQGLTIVT 114
Db      60 NPSLKSRTVISVDTSKNQFSLKSSVTAADTAVVYCARRGYDLTGTDYFDYWGQGLTIVT 119

Qy      115 VSS 117
Db      120 VSS 122

RESULT 15
US-10-309-762-128
; Sequence 128, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Foltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYC ANHYDRASE IX
; TITLE OF INVENTION: (CA IX) TUMOR ANTIGEN
; FILE REFERENCE: ABGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 128
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-128
```

Query Match 82.0%; Score 512.5; DB 4; Length 120;
Best Local Similarity 85.0%; Pred. No. 5.3e-38;
Matches 102; Conservative 4; Mismatches 11; Indels 3; Gaps 2;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYS- ISGGYLMNWIROPKGLWIGYISYDGTNN 59
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGSVISGGYWSWIRQPPKGLWIGYIYSGSSN 60

Qy 60 YKPSLKDRVTISVDTSKNQFSLKSSVTAADTAVYYCAR--YGRVFPDYWGQGLTVTVSS 117
Db 61 YNPSLKSRVTISVDASKNQFSLRLSSVTAADTAVYYCARSMVRGVSFQDYWGQGLTVTVSS 120

Search completed: January 10, 2006, 21:35:33
Job time : 64.1754 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:55:23 ; Search time 5.96642 Seconds
(without alignments)
166.558 Million cell updates/sec

Title: US-10-735-916A-83
Perfect score: 625
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 61141 seqs, 8493638 residues

Total number of hits satisfying chosen parameters: 61141

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA_New.*

- 1: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pap.*
- 2: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pap.*
- 3: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pap.*
- 4: /cgn2_6/ptodata/1/pubpaa/PT_NEW_PUB.pap.*
- 5: /cgn2_6/ptodata/1/pubpaa/US05_NEW_PUB.pap.*
- 6: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pap.*
- 7: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pap.*
- 8: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pap.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	625	100.0	117	7	US-11-012-353-83
2	625	100.0	135	7	US-11-012-353-85
3	615	98.4	117	7	US-11-012-353-79
4	615	98.4	135	7	US-11-012-353-81
5	611	97.8	117	7	US-11-012-353-75
6	611	97.8	135	7	US-11-012-353-77
7	546	87.4	117	7	US-11-012-353-162
8	529	84.6	117	7	US-11-012-353-69
9	529	84.6	127	7	US-11-012-353-52
10	492	78.7	123	7	US-11-012-353-73
11	491.5	78.6	247	7	US-11-054-515-1651
12	491.5	78.6	250	7	US-11-054-515-1548
13	483	77.3	117	7	US-11-012-353-72
14	482	77.1	253	7	US-11-054-515-1619
15	479.5	76.7	146	6	US-10-721-763-17
16	477.5	76.4	252	7	US-11-054-515-1394
17	475.5	76.1	252	7	US-11-054-515-1329
18	471.5	75.4	116	7	US-11-054-669-112
19	471.5	75.4	250	7	US-11-054-669-110
20	470.5	75.3	118	7	US-11-012-353-70
21	470	75.2	251	7	US-11-054-515-990
22	469	75.0	253	7	US-11-054-515-1339
23	468	74.9	120	7	US-11-102-201-1
24	466.5	74.6	154	6	US-10-721-763-25
25	465.5	74.5	254	7	US-11-054-515-1578

ALIGNMENTS

RESULT 1

US-11-012-353-83
; Sequence 83, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILLIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEU, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012.353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: Patent In Ver. 3.3
; SEQ ID NO 83
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-83

Query Match 100.0%; Score 625; DB 7; Length 117;
Best Local Similarity 100.0%; Pred. No. 2.2e-48;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGFLVKPSETLSLCTVSGYISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGFLVKPSETLSLCTVSGYISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
QY 61 KPSLKDRTVISVDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117
Db 61 KPSLKDRTVISVDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117

```
RESULT 2
US-11-012-353-85
; Sequence 85, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; PRIOR FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 85
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-85

Query Match      100.0%; Score 625; DB 7; Length 135;
Best Local Similarity 100.0%; Pred. No. 2.6e-48;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYISGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 3
US-11-012-353-79
; Sequence 79, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; PRIOR FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 85
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-85

Query Match      100.0%; Score 625; DB 7; Length 135;
Best Local Similarity 100.0%; Pred. No. 2.6e-48;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYISGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 4
US-11-012-353-81
; Sequence 81, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; PRIOR FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 81
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-81

Query Match      98.4%; Score 615; DB 7; Length 135;
Best Local Similarity 98.3%; Pred. No. 1.9e-47;
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYISGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 135
```

```

; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 77
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-77

Query Match      97.8%; Score 611; DB 7; Length 135;
Best Local Similarity 96.6%; Pred. No. 4.2e-47;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78
Qy 61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 135

RESULT 7
US-11-012-353-162
; Sequence 162, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 162
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-162

Query Match      87.4%; Score 546; DB 7; Length 117;
Best Local Similarity 88.0%; Pred. No. 1.7e-41;
Matches 103; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGSIFHSGSSY 60
Qy 61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117

```

```

; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 77
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-77

Query Match      97.8%; Score 611; DB 7; Length 135;
Best Local Similarity 96.6%; Pred. No. 3.7e-47;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Qy 61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 135

RESULT 6
US-11-012-353-77
; Sequence 77, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20

```


Db 61 NPSSLKSRVTISVDTSKNQPSLQLRSVTAADTAVVYCAR-GRYCSSTSCNWFDPWGGTLV 119
QY 114 TVSS 117
Db 120 TVSS 123

RESULT 11
US-11-054-515-1651
; Sequence 1651, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1651
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1651

Query Match 78.6%; Score 491.5; DB 7; Length 247;
Best Local Similarity 79.0%; Pred. No. 1.8e-36;
Matches 98; Conservative 4; Mismatches 15; Indels 7; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSNYSISSGYWGIRQPPGKLEWIGISYISGSTYY 60
QY 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVVYCAR-GRVP-FDYWGQGTLLV 113
Db 61 NPSSLKSRVTISVDTSKNQPSLKLSSVTAADTAVVYCARPRYDILGTGYYDMVWCGRTLV 120

QY 114 TVSS 117
Db 121 TVSS 124

RESULT 12
US-11-054-515-1548
; Sequence 1548, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10

; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1548
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1548

Query Match 78.6%; Score 491.5; DB 7; Length 250;
Best Local Similarity 79.0%; Pred. No. 1.9e-36;
Matches 98; Conservative 5; Mismatches 14; Indels 7; Gaps 2;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCAVSGYSISSGYWGIRQPPGKLEWIGISYHSGSTYY 60
QY 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVVYCAR-GRVP-FDYWGQGTLLV 113
Db 61 NPSSLKSRVTISVDTSKNQPSLKLSSVTAADTAVVYCARVHYDILTGYLWAFDIMGQTMV 120
QY 114 TVSS 117
Db 121 TVSS 124

RESULT 13
US-11-012-353-72
; Sequence 72, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILLIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18

```
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 72
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: MOD RES
; LOCATION: (59)
; OTHER INFORMATION: Variable amino acid
US-11-012-353-72

Query Match      77.3%; Score 483; DB 7; Length 117;
Best Local Similarity 81.2%; Pred. No. 5e-36;
Matches 95; Conservative 5; Mismatches 17; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSQTLSTCTVSGYSISGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSQTLSTCTVSGGSSVSSYWSNWIROPQPGKLEWIGRIYYSGSTY 60

Qy 61 KPSLKDRVTISVDTSKNQFSLKSSVTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 117
Db 61 NPSLSRVTTISVDTSKNQFSLKSSVTAADTAVVYCARLPGGYDVWGQGLTVTVSS 117

RESULT 14
US-11-054-515-1619
; Sequence 1619, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunoespecifically Bind BlyS
; FILE REFERENCE: PFS23P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; PRIOR FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-16
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1619
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1619

Query Match      77.1%; Score 482; DB 7; Length 253;
Best Local Similarity 77.2%; Pred. No. 1.3e-35;
Matches 98; Conservative 6; Mismatches 13; Indels 10; Gaps 3;

Qy 1 QVQLQESGPGLVKPSQTLSTCTVSGYSI-SCGYLWNWIRQPPGKLEWIGYISYDGTNN 59
Db 1 QVQLQESGPGLVKPSQTLSTCTVSGGSISSGGYWSNWIROPQPGKLEWIGYIYYSGSTY 60

Qy 60 YKPSLKDRVTISVDTSKNQFSLKSSVTAADTAVVYCAR-----YGRVFF---FDYWGQG 110
Db 60 YKPSLKDRVTISVDTSKNQFSLKSSVTAADTAVVYCARLTVAEFDYWGQGLTVTVSS 144
```

```
Db 61 YNPSLSKSRVTISIDTSKNQFSLKSSVTAADTAVVYCVRSYYDILTGRPYTDAFDWKGK 120

Qy 111 TLTVTSS 117
Db 121 TLTVTSS 127

RESULT 15
US-10-721-763-17
; Sequence 17, Application US/10721763
; Publication No. US20050249729A1
; GENERAL INFORMATION:
; APPLICANT: KIRIN BEER KABUSHIKI KAISHA
; TITLE OF INVENTION: ANTI TRAIL-R ANTIBODY
; FILE REFERENCE: PH-1573-PCT
; CURRENT APPLICATION NUMBER: US/10/721,763
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: JP2001-150213
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: JP2001-243040
; PRIOR FILING DATE: 2001-08-09
; PRIOR APPLICATION NUMBER: JP2001-314489
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 146
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-721-763-17

Query Match      76.7%; Score 479.5; DB 6; Length 146;
Best Local Similarity 82.2%; Pred. No. 1.2e-35;
Matches 97; Conservative 2; Mismatches 18; Indels 1; Gaps 1;

Qy 1 QVQLQESGPGLVKPSQTLSTCTVSGYS-ISGYLWNWIRQPPGKLEWIGYISYDGTNN 59
Db 27 QLQLQESGPGLVKPSQTLSTCTVSGGSIISKSSYWGWIROPQPGKLEWIGIYYSGSTF 86

Qy 60 YKPSLKDRVTISVDTSKNQFSLKSSVTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 117
Db 87 YNPSLSKSRVTISVDTSKNQFSLKSSVTAADTAVVYCARLTVAEFDYWGQGLTVTVSS 144

Search completed: January 10, 2006, 21:36:24
Job time : 5.96642 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:34:27 ; Search time 22.847 Seconds
(without alignments)
423.384 Million cell updates/sec

Title: US-10-735-916A-83
Perfect score: 625
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents_AA*
1: /cgn2_6/ptodata/1/1aa/5 COMB.pep.*
2: /cgn2_6/ptodata/1/1aa/6 COMB.pep.*
3: /cgn2_6/ptodata/1/1aa/H COMB.pep.*
4: /cgn2_6/ptodata/1/1aa/pCTUS COMB.pep.*
5: /cgn2_6/ptodata/1/1aa/RE COMB.pep.*
6: /cgn2_6/ptodata/1/1aa/backfiles.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	510	81.6	119	2 US-09-025-769B-39	Sequence 39, Appl
2	510	81.6	119	2 US-09-025-769B-65	Sequence 65, Appl
3	510	81.6	119	2 US-09-490-070A-39	Sequence 39, Appl
4	510	81.6	119	2 US-09-490-070A-65	Sequence 65, Appl
5	510	81.6	119	2 US-09-490-153-39	Sequence 39, Appl
6	510	81.6	119	2 US-09-490-153-65	Sequence 65, Appl
7	510	81.6	119	2 US-09-490-324-39	Sequence 39, Appl
8	510	81.6	119	2 US-09-490-324-65	Sequence 65, Appl
9	507	81.1	117	2 US-09-720-493-2	Sequence 2, Appl
10	497	79.5	117	2 US-10-330-613A-13	Sequence 13, Appl
11	493.5	79.0	118	2 US-09-025-769B-25	Sequence 25, Appl
12	493.5	79.0	118	2 US-09-490-070A-25	Sequence 25, Appl
13	493.5	79.0	118	2 US-09-490-153-25	Sequence 25, Appl
14	493.5	79.0	118	2 US-09-490-324-25	Sequence 25, Appl
15	492.5	78.8	244	2 US-08-918-148-79	Sequence 79, Appl
16	492.5	78.8	244	2 US-09-138-091A-77	Sequence 77, Appl
17	492.5	78.8	473	2 US-09-049-672A-4	Sequence 4, Appl
18	485	77.6	121	2 US-10-330-613A-1	Sequence 1, Appl
19	485	77.6	121	2 US-10-330-613A-17	Sequence 17, Appl
20	484.5	77.5	487	2 US-09-800-729-145	Sequence 145, App
21	483	77.3	117	2 US-10-330-613A-5	Sequence 5, Appl
22	482.5	77.2	118	2 US-09-343-698-6	Sequence 6, Appl
23	482.5	77.2	118	2 US-08-325-955-6	Sequence 6, Appl
24	481.5	77.0	832	2 US-08-630-820-7	Sequence 7, Appl
25	481.5	77.0	832	2 US-09-273-453-7	Sequence 7, Appl
26	481	77.0	121	2 US-10-330-613A-9	Sequence 9, Appl
27	478.5	76.6	139	2 US-09-471-276-837	Sequence 837, App

28	478.5	76.6	278	2	US-09-260-527-3	Sequence 3, Appl
29	477	76.3	142	1	US-08-480-774A-2	Sequence 2, Appl
30	476	76.2	119	1	US-08-360-125-5	Sequence 5, Appl
31	476	76.2	119	1	US-08-450-578-5	Sequence 5, Appl
32	476	76.2	119	1	US-09-017-628-5	Sequence 5, Appl
33	476	76.2	119	1	US-09-014-880-5	Sequence 5, Appl
34	476	76.2	119	2	US-08-450-363-5	Sequence 5, Appl
35	476	76.2	119	2	US-09-467-903-5	Sequence 5, Appl
36	475.5	76.1	122	1	US-08-360-125-11	Sequence 11, Appl
37	475.5	76.1	122	1	US-08-450-578-11	Sequence 11, Appl
38	475.5	76.1	122	1	US-09-017-628-11	Sequence 11, Appl
39	475.5	76.1	122	1	US-09-014-880-11	Sequence 11, Appl
40	475.5	76.1	122	2	US-08-450-363-11	Sequence 11, Appl
41	475.5	76.1	122	2	US-09-467-903-11	Sequence 11, Appl
42	474	75.8	123	1	US-08-137-117D-64	Sequence 64, Appl
43	474	75.8	123	1	US-08-436-717-64	Sequence 64, Appl
44	474	75.8	138	1	US-08-137-117D-69	Sequence 69, Appl
45	474	75.8	138	1	US-08-436-717-69	Sequence 69, Appl

ALIGNMENTS

RESULT 1
US-09-025-769B-39
; Sequence 39, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-025-769B-39

Query Match 81.6%; Score 510; DB 2; Length 119;
Best Local Similarity 85.0%; Pred. No. 2.8e-43;
Matches 102; Conservative 3; Mismatches 11; Indels 4; Gaps 2;

White & McAuliffe
STREET: 1666 K Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20006

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,070A
FILING DATE: 24-Jan-2000

PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995

ATTORNEY/AGENT INFORMATION:
NAME: Colin G. Sandercock, Esq.
REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 37629-0005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 912-2000
TELEFAX: (202) 912-2020

SEQUENCE CHARACTERISTICS:
LENGTH: 119 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-490-070A-65

Query Match 81.6%; Score 510; DB 2; Length 119;
Best Local Similarity 85.0%; Pred. No. 2.8e-43;
Matches 102; Conservative 3; Mismatches 11; Indels 4; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNY 59
QY 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFF---DYWGQGLTLVTSS 117
DB 60 NPSLSKRVITISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFF---DYWGQGLTLVTSS 119

RESULT 5
US-09-490-153-39
Sequence 39, Application US/09490153
Patent No. 6706484
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSER: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,153

FILING DATE: 24-Jan-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769B
FILING DATE: 18-FEB-1998
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9090
INFORMATION FOR SEQ ID NO: 39:
SEQUENCE CHARACTERISTICS:
LENGTH: 119 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 39:
US-09-490-153-39

Query Match 81.6%; Score 510; DB 2; Length 119;
Best Local Similarity 85.0%; Pred. No. 2.8e-43;
Matches 102; Conservative 3; Mismatches 11; Indels 4; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNY 59
QY 61 KPSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFF---DYWGQGLTLVTSS 117
DB 60 NPSLSKRVITISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFF---DYWGQGLTLVTSS 119

RESULT 6
US-09-490-153-65
Sequence 65, Application US/09490153
Patent No. 6706484
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSER: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,153
FILING DATE: 24-Jan-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769B
FILING DATE: 18-FEB-1998
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5

```
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-490-153-65

Query Match      81.6%; Score 510; DB 2; Length 119;
Best Local Similarity 85.0%; Pred. No. 2.8e-43;
Matches 102; Conservative 3; Mismatches 11; Indels 4; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYVMSWIRQPPGKLEWIGYIYSGSTNY 59

QY 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVVYCARVGRVFF---DYWGQGLTVTVSS 117
DB 60 NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVVYCARWGGDGFYAMDYWGQGLTVTVSS 119

RESULT 7
US-09-490-324-39
; Sequence 39, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 39:

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYVMSWIRQPPGKLEWIGYIYSGSTNY 59

QY 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVVYCARVGRVFF---DYWGQGLTVTVSS 117

US-09-490-324-65
; Sequence 65, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-490-324-65

Query Match      81.6%; Score 510; DB 2; Length 119;
Best Local Similarity 85.0%; Pred. No. 2.8e-43;
Matches 102; Conservative 3; Mismatches 11; Indels 4; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYVMSWIRQPPGKLEWIGYIYSGSTNY 59

QY 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVVYCARVGRVFF---DYWGQGLTVTVSS 117
DB 60 NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVVYCARWGGDGFYAMDYWGQGLTVTVSS 119
```

Db 60 NPSLSKRVITISVDTSKNQFSLKSSVTAADTAVVYCARWGGDFYAMDYWGQGLTLTVSS 117
|||||
RESULT 9
US-09-720-493-2
; Sequence 2, Application US/09720493
; Patent No. 6827925
; GENERAL INFORMATION:
; APPLICANT: Cambridge Antibody Technology Limited
; APPLICANT: Williams, Andrew J
; APPLICANT: Tempest, Philip R
; APPLICANT: Holtet, Thor L
; APPLICANT: Main, Sarah H
; APPLICANT: Jackson, Helen
; APPLICANT: Daromola, Olalekan
; TITLE OF INVENTION: Improvements relating to antibodies
; FILE REFERENCE: AHB/CP5775333
; CURRENT APPLICATION NUMBER: US/09/720,493
; PRIOR FILING DATE: 2002-10-23
; PRIOR FILING DATE: 1998-07-02
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-720-493-2
Query Match 81.1%; Score 507; DB 2; Length 117;
Best Local Similarity 84.6%; Pred. No. 5.5e-43;
Matches 99; Conservative 2; Mismatches 16; Indels 0; Gaps 0;
Qy 1 QVQLQESGFLVKPSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGFLVKPSETLSLTCAVSGYSISSGYWIRQPPGKLEWIGSYHSGSY 60
Qy 61 KPSLKDRTVITISVDTSKNQFSLKSSVTAADTAVVYCARVFFDYWGQGLTLTVSS 117
Db 61 NPSLSKRVITISVDTSKNQFSLKSSVTAADTAVVYCARGKWSKFDYWGQGLTLTVSS 117
RESULT 10
US-10-330-613A-13
; Sequence 13, Application US/10330613A
; Patent No. 6924360
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN
; FILE REFERENCE: ABGENIX.022A
; CURRENT APPLICATION NUMBER: US/10/330,613A
; CURRENT FILING DATE: 2002-12-26
; PRIOR APPLICATION NUMBER: 60/346299
; PRIOR FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-330-613A-13
Query Match 79.5%; Score 497; DB 2; Length 117;
Best Local Similarity 84.7%; Pred. No. 5.4e-42;
Matches 100; Conservative 3; Mismatches 13; Indels 2; Gaps 2;
Qy 1 QVQLQESGFLVKPSETLSLTCTVSGYSI-SGGYLNWIRQPPGKLEWIGYISYDGTNN 59
Db 1 QVQLQESGFLVKPSETLSLTCTVSGSISGGYVWIRQHPGKLEWIGIYISGSY 60
Qy 60 YKPSLKDRTVITISVDTSKNQFSLKSSVTAADTAVVYCARVFFDYWGQGLTLTVSS 117
|||||

Db 61 YNPSLSKRVITISVDTSKNQFSLKSSVTAADTAVVYCAREGD-GFDYWGQGLTLTVSS 117
RESULT 11
US-09-025-769B-25
; Sequence 25, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-25
Query Match 79.0%; Score 493.5; DB 2; Length 118;
Best Local Similarity 84.0%; Pred. No. 1.2e-41;
Matches 100; Conservative 3; Mismatches 13; Indels 3; Gaps 2;
Qy 1 QVQLQESGFLVKPSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGFLVKPSETLSLTCTVSGSIS-SYVMSWIRQPPGKLEWIGIYHSGSTNY 59
Qy 61 KPSLKDRTVITISVDTSKNQFSLKSSVTAADTAVVYCA--RYGRVFFDYWGQGLTLTVSS 117
Db 60 NPSLSKRVITISVDTSKNQFSLKSSVTAADTAVVYCARGGGGVFDYWGQGLTLTVSS 118
RESULT 12
US-09-490-070A-25
; Sequence 25, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon


```
;
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-490-324-25

Query Match          79.0%; Score 493.5; DB 2; Length 118;
Best Local Similarity 84.0%; Pred. No. 1.2e-41;
Matches 100; Conservative 3; Mismatches 13; Indels 3; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKGLEWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPGKGLEWIGEIYHSGSTNY 59
QY 61 KPSLKDRTYISVDTSKNQFSLKLSVTAADTAVYYCA--RYGRVFPFDYWGQGTLLTVSS 117
DB 60 NPSLKSRTYISVDTSKNQFSLKLSVTAADTAVYYCARGRGGGGVFDYWGQGTLLTVSS 118

RESULT 15
US-08-918-148-79
; Sequence 79, Application US/08918148A
; Patent No. 6342220
; GENERAL INFORMATION:
; APPLICANT: W.
; APPLICANT: Adams, Camellia
; APPLICANT: Carter, Paul J.
; APPLICANT: Fendly, Brian M.
; APPLICANT: Gurney, Austin L.
; TITLE OF INVENTION: Agonist Antibodies
; FILE REFERENCE: P0979
; CURRENT APPLICATION NUMBER: US/08/918,148A
; CURRENT FILING DATE: 1997-08-25
; NUMBER OF SEQ ID NOS: 79
; SEQ ID NO 79
; LENGTH: 244
; TYPE: PRT
; ORGANISM: artificial
US-08-918-148-79

Query Match          78.8%; Score 492.5; DB 2; Length 244;
Best Local Similarity 83.8%; Pred. No. 3.7e-41;
Matches 98; Conservative 7; Mismatches 9; Indels 3; Gaps 3;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNNWIRQPPGKGLEWIGYISYDGTNNY 60
DB 3 QVQLQESGPGLVKPSSETLSLTCTVSGDSIS-SYYWSWIRQPPGKGLEWIGEIYHSGSTNY 61
QY 61 KPSLKDRTYISVDTSKNQFSLKLSVTAADTAVYYCARYGRVFPFDYWGQGTLLTVSS 117
DB 62 NPSLKSRTYISVDTSKNQFSLKLSVTAADTAVYYCAR-GR-YFDVWGRTWTVSS 116
```

Search completed: January 10, 2006, 20:58:05
Job time : 22.847 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:07:41 ; Search time 80.7649 Seconds
(without alignments)
636.505 Million cell updates/sec

Title: US-10-735-916A-83
Perfect score: 625
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYWGQGLVTIVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

- Database : A_Geneseq 21.*
- 1: Geneseqp1980s.*
 - 2: Geneseqp1990s.*
 - 3: Geneseqp2000s.*
 - 4: Geneseqp2001s.*
 - 5: Geneseqp2002s.*
 - 6: Geneseqp2003as.*
 - 7: Geneseqp2003bs.*
 - 8: Geneseqp2004s.*
 - 9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	625	100.0	117	7	Adj76917 Anti-IGF-
2	625	100.0	117	9	Adz67087 Human ant
3	625	100.0	135	7	Adj76919 Anti-IGF-
4	625	100.0	135	9	Adz67089 Human ant
5	615	98.4	117	7	Adj76913 Anti-IGF-
6	615	98.4	117	9	Adz67083 Human ant
7	615	98.4	135	7	Adj76915 Anti-IGF-
8	615	98.4	135	9	Adz67085 Human ant
9	611	97.8	117	7	Adj76909 Anti-IGF-
10	611	97.8	117	9	Adz67079 Human ant
11	611	97.8	135	7	Adj76911 Anti-IGF-
12	611	97.8	135	9	Adz67081 Human ant
13	529	84.6	117	7	Adj76903 Anti-IGF-
14	529	84.6	117	9	Adz67073 Murine im
15	529	84.6	127	7	Adj76886 Anti-IGF-
16	529	84.6	127	9	Adz67056 Murine im
17	519.5	83.1	246	3	Aay15126 Anti-mur
18	517	82.7	119	7	Adp03973 Murine-ex
19	516.5	82.6	121	8	AdS16559 Human ant
20	514.5	82.3	120	7	AdC27457 Humanised
21	513.5	82.2	122	7	Adp03885 Murine-ex
22	513.5	82.2	122	7	Adp03889 Murine-ex
23	512.5	82.0	120	7	Adp03958 Murine-ex
24	510.5	81.7	116	7	Adp03957 Murine-ex

25	510.5	81.7	121	5	ABB07171	ebvHlgM M
26	510.5	81.7	121	8	AD126658	Human ant
27	510.5	81.7	122	7	ADP03887	Murine-ex
28	510.5	81.7	122	7	ADP03884	Murine-ex
29	510	81.6	119	2	AAW27554	Human Ab
30	510	81.6	119	6	ABJ18676	Antibody
31	508	81.3	119	9	ADY74798	Human IGS
32	507	81.1	117	3	AA44615	Human ant
33	507	81.1	121	7	ADE28455	Human ant
34	507	81.1	466	7	ADE28479	Human ant
35	507	81.1	580	6	AAO30915	dI-NHS76
36	507	81.1	580	6	AAO30913	dI-NHS76
37	505.5	80.9	122	9	AEA21456	Human ant
38	505.5	80.9	139	9	ADX98267	Human ant
39	504.5	80.7	121	8	ADS16505	Human ant
40	504.5	80.7	169	8	ADS16613	Human ant
41	504	80.6	121	7	ADE28491	Human ant
42	504	80.6	466	7	ADE28471	Human ant
43	503	80.5	121	9	ADX01828	SARS coro
44	503	80.5	123	7	ADP03870	Murine-ex
45	503	80.5	248	9	ADX01838	SARS coro

ALIGNMENTS

RESULT 1
ADJ76917
ID ADJ76917 standard; protein; 117 AA.
XX
AC ADJ76917;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-IGF-IR related protein #26.
XX
KW cytostatic; antipsoariatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDR.
XX Homo sapiens.
XX WO2003059951-A2.
XX
XX 24-JUL-2003.
XX
XX 20-JAN-2003; 2003WO-FR000178.
XX
XX 18-JAN-2002; 2002FR-00000653.
XX 18-JAN-2002; 2002FR-00000654.
XX 07-MAY-2002; 2002FR-00005753.
XX (FABR) FABRE MEDICAMENT SA PIERRE.
XX Goetsch L, Corvaia N, Leger O;
XX WPI; 2003-569653/53.
XX
XX New antibodies that bind to human insulin-like growth factor receptor,
XX useful for treatment, prevention and diagnosis of cancers.
XX
XX Disclosure; SEQ ID NO 83; 164pp; French.
XX
XX The invention relates to an isolated antibody (Ab), and its functional
XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
XX IR) and optionally: (i) inhibit natural binding of insulin-like growth
XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
XX kinase activity of IGF-IR. Ab and its fragments are used to prevent or
XX treat diseases associated with overexpression and/or abnormal activity of
XX IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with
XX hyperactivity of signal transduction pathways mediated by interaction of

PF 20-JAN-2003; 2003WO-FR000178.
 XX 18-JAN-2002; 2002FR-00000653.
 PR 18-JAN-2002; 2002FR-00000654.
 PR 07-MAY-2002; 2002FR-00005753.
 XX (FABR) FABRE MEDICAMENT SA PIERRE.
 PA Goetsch L, Corvaia N, Leger O;
 XX WPI; 2003-569653/53.
 XX New antibodies that bind to human insulin-like growth factor receptor,
 PT useful for treatment, prevention and diagnosis of cancers.
 PT Disclosure; SEQ ID NO 85; 164pp; French.
 XX The invention relates to an isolated antibody (Ab), and its functional
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
 CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
 CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
 CC treat diseases associated with overexpression and/or abnormal activity of
 CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
 CC hyperactivity of signal transduction pathways mediated by interaction of
 CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.
 XX Sequence 135 AA;
 SQ

Query Match 100.0%; Score 625; DB 7; Length 135;
 Best Local Similarity 100.0%; Pred. No. 2.2e-49;
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSFTSLTCTVSGYSISGGYLNWIQPPKGLGWIGYISYDGTNNY 60
 DB 19 QVQLQESGPGLVKPSFTSLTCTVSGYSISGGYLNWIQPPKGLGWIGYISYDGTNNY 78

QY 61 KPSLKDRTVISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYGQGLTVTVSS 117
 DB 79 KPSLKDRTVISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYGQGLTVTVSS 135

RESULT 4
 ID ADZ67089
 XX ADZ67089 standard; protein; 135 AA.
 AC ADZ67089;
 XX 30-JUN-2005 (first entry)
 XX Human antibody 7C10 3 heavy chain variable region SEQ ID NO:85.
 XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW heavy chain variable region.
 XX Homo sapiens.
 OS
 XX Location/Qualifiers
 PH Key
 FT Peptide
 FT 1..18 /note= "leader peptide"
 FT 49..54 /note= "CDR1"

FT Region 69..84
 FT /note= "CDR2"
 FT 117..124
 FT /note= "CDR3"
 XX US2005084906-A1.
 XX 21-APR-2005.
 XX 16-DEC-2003; 2003US-00735916.
 XX 18-JAN-2002; 2002FR-00000653.
 PR 18-JAN-2002; 2002FR-00000654.
 PR 07-MAY-2002; 2002FR-00005753.
 PR 20-JAN-2003; 2003WO-FR000178.
 PR 11-JUL-2003; 2003FR-00008538.
 XX (GOET/) GOETSCH L.
 PA (CORV/) CORVAIA N.
 PA (LEGE/) LEGER O.
 PA (DUFL/) DUFLOS A.
 PA (HAUW/) HAEUW J.
 PA (BECK/) BECK A.
 XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
 PI WPI; 2005-321968/33.
 XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 PT antibody or its functional fragment, being capable of binding human IGF-
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,
 PT useful for treating cancer.
 XX Example 13; SEQ ID NO 85; 125pp; English.
 XX The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-IR and, if necessary, capable of
 CC specifically inhibiting tyrosine kinase activity of the receptor,
 CC comprising a light or heavy chain having at least one complementary
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-IR and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
 CC the administration of the medicament does not induce or only slightly
 CC induces secondary effects connected with inhibition of the insulin
 CC receptor. The antibody is useful for preparation of a medicament intended
 CC to inhibit the transformation of normal cells into cells with tumoral
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
 CC useful for preparation of a medicament intended to inhibit the growth
 CC and/or the proliferation of tumor cells, preferably IGF-dependent and/or
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a
 CC medicament intended for prevention or for the treatment of cancer, where
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 CC preparation of a medicament intended for the prevention or for the
 CC treatment of psoriasis. (I) is useful in preparation of a medicament
 CC intended for the specific targeting of a biologically active compound to
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
 CC is useful for in vitro diagnosis of illnesses induced by an
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
 CC starting from a biological sample in which the abnormal presence, of IGF-
 CC IR and/or EGFR receptor is suspected, which involves contacting the
 CC biological sample with (I), which is optionally labeled. The present
 CC sequence is used in the exemplification of the invention.
 XX Sequence 135 AA;
 SQ

CC induces secondary effects connected with inhibition of the insulin
CC receptor. The antibody is useful for preparation of a medicament intended
CC to inhibit the transformation of normal cells into cells with tumoral
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
CC useful for preparation of a medicament intended to inhibit the growth
CC and/or the proliferation of tumor cells, preferably IGF-dependent,
CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
CC HER2/neu-dependent cells. (I) is useful in the preparation of a
CC medicament intended for prevention or for the treatment of cancer, where
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
CC preparation of a medicament intended for the prevention or for the
CC treatment of psoriasis. (I) is useful in preparation of a medicament
CC intended for the specific targeting of a biologically active compound to
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
CC is useful for in vitro diagnosis of illnesses induced by an
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
CC starting from a biological sample in which the abnormal presence, of IGF-
CC IR and/or EGFR receptor is suspected, which involves contacting the
CC biological sample with (I), which is optionally labeled. The present
CC sequence is used in the exemplification of the invention.

SQ Sequence 117 AA;
Query Match 98.4%; Score 615; DB 9; Length 117;
Best Local Similarity 98.3%; Pred. No. 1.6e-48;
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60
QY 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTLVTSS 117
DB 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTLVTSS 117

RESULT 7

ADJ76915
ID ADJ76915 standard; protein; 135 AA.

XX AC ADJ76915;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-IR related protein #25.

XX KW cytostatic; antipsoriatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDR.

XX OS Homo sapiens.

XX PN WO2003059951-A2.

XX PD 24-JUL-2003.

XX PF 20-JAN-2003; 2003WO-FR000178.

XX PR 18-JAN-2002; 2002FR-00000653.

XX PR 18-JAN-2002; 2002FR-00000654.

XX PR 07-MAY-2002; 2002FR-00005753.

XX (FABR) FABRE MEDICAMENT SA PIERRE.

XX PI Goetsch L, Corvaia N, Leger O;

XX DR WPI; 2003-569653/53.

XX PT New antibodies that bind to human insulin-like growth factor receptor,

PT useful for treatment, prevention and diagnosis of cancers.

XX Disclosure; SEQ ID NO 81; 164pp; French.

XX The invention relates to an isolated antibody (Ab), and its functional
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
CC IR) and optionally: (i) inhibit natural binding of insulin-like growth
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or
CC treat diseases associated with overexpression and/or abnormal activity of
CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with
CC hyperactivity of signal transduction pathways mediated by interaction of
CC these receptors with their ligands. Especially they inhibit
CC transfection of normal cells to tumor cells, inhibit growth and/or
CC proliferation of tumor cells, so are useful against cancers of the
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
CC also for treating psoriasis. Ab are also used to diagnose diseases caused
CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
CC protein sequence used to generate the Ab of the invention.

XX SQ Sequence 135 AA;

Query Match 98.4%; Score 615; DB 7; Length 135;
Best Local Similarity 98.3%; Pred. No. 1.8e-48;
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60

DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 78

QY 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTLVTSS 117

DB 79 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTLVTSS 135

RESULT 8

ADZ67085

ID ADZ67085 standard; protein; 135 AA.

XX AC ADZ67085;

XX DT 30-JUN-2005 (first entry)

XX DE Human antibody 7C10 2 heavy chain variable region SEQ ID NO:81.

XX KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
KW musculoskeletal disease; respiratory disease; lung tumor;
KW endocrine disease; gynecology and obstetrics; breast tumor;
KW endometroid carcinoma; gastrointestinal disease; colon tumor;
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
KW heavy chain variable region.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT Peptide 1..18

FT /note= "leader peptide"

FT Region 49..54

FT /note= "CDR1"

FT Region 69..84

FT /note= "CDR2"

FT Region 117..124

FT /note= "CDR3"

XX US2005084906-A1.

XX PD 21-APR-2005.

XX PF 16-DEC-2003; 2003US-00735916.

XX PR 18-JAN-2002; 2002FR-00000653.

XX PR 18-JAN-2002; 2002FR-00000654.

```
PR 07-MAY-2002; 2002FR-00005753.
PR 20-JAN-2003; 2003WO-FR000178.
PR 11-JUL-2003; 2003FR-00008538.
XX
PA (GOET/) GOETSCH L.
PA (CORV/) CORVAIA N.
PA (LEGE/) LEGER O.
PA (DUF/) DUFLOS A.
PA (HAEU/) HAEUW J.
PA (BECK/) BECK A.
XX
PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
XX WPI; 2005-321968/33.
XX N-PSDB; ADZ67084.
XX
PT Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
PT antibody or its functional fragment, being capable of binding human IGF-
PT IR and specifically inhibiting tyrosine kinase activity of receptor,
PT useful for treating cancer.
XX
PS Example 13; SEQ ID NO 81; 125pp; English.
XX
CC The invention relates to a novel isolated anti-insulin-like growth factor
CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
CC capable of binding to human IGF-IR and, if necessary, capable of
CC specifically inhibiting tyrosine kinase activity of the receptor,
CC comprising a light or heavy chain having at least one complementary
CC determining region (CDR) consisting of one of two fully defined 16 amino
CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
CC the preparation of a medicament intended for the prevention or treatment
CC of an illness connected with an overexpression and/or an abnormal
CC activation of the IGF-IR and/or EGFR, and/or connected with a
CC hyperactivation of the transduction pathway of the signal mediated by the
CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
CC the administration of the medicament does not induce or only slightly
CC induces secondary effects connected with inhibition of the insulin
CC receptor. The antibody is useful for preparation of a medicament intended
CC to inhibit the transformation of normal cells into cells with tumoral
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
CC useful for preparation of a medicament intended to inhibit the growth
CC and/or the proliferation of tumor cells, preferably IGF-dependent,
CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
CC HER2/neu-dependent cells. (I) is useful in the preparation of a
CC medicament intended for prevention or for the treatment of cancer, where
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
CC preparation of a medicament intended for the prevention or for the
CC treatment of psoriasis. (I) is useful in preparation of a medicament
CC intended for the specific targeting of a biologically active compound to
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
CC is useful for in vitro diagnosis of illnesses induced by an
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
CC starting from a biological sample in which the abnormal presence, of IGF-
CC IR and/or EGFR receptor is suspected, which involves contacting the
CC biological sample with (I), which is optionally labeled. The present
CC sequence is used in the exemplification of the invention.
XX
SQ Sequence 135 AA;
Query Match 98.4%; Score 615; DB 9; Length 135;
Best Local Similarity 98.3%; Pred. No. 1.8e-48;
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 78
QY 61 KPSLKDRVTISVDTSKNQFSLKLSSTVAADTAIVYICARYGRVFFDYWGQGLTVTVSS 117
DB 79 KPSLKDRVTISRDTSKNQFSLKLSSTVAADTAIVYICARYGRVFFDYWGQGLTVTVSS 135
```

```
RESULT 9
ADJ76909
ID ADJ76909 standard; protein; 117 AA.
XX
AC ADJ76909;
XX
DT 06-MAY-2004 (first entry)
DE Anti-IGF-IR related protein #22.
XX
KW cytostatic; antipsoriatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDK.
XX
OS Homo sapiens.
XX
PN WO2003059951-A2.
XX
PD 24-JUL-2003.
XX
PF 20-JAN-2003; 2003WO-FR000178.
XX
PR 18-JAN-2002; 2002FR-00000653.
XX
PR 07-MAY-2002; 2002FR-00005753.
XX
PA (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
PI Goetsch L, Corvaia N, Leger O;
XX WPI; 2003-569653/53.
XX
PT New antibodies that bind to human insulin-like growth factor receptor,
PT useful for treatment, prevention and diagnosis of cancers.
XX
PS Disclosure; SEQ ID NO 75; 164pp; French.
XX
CC The invention relates to an isolated antibody (Ab), and its functional
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
CC IR) and optionally: (i) inhibit natural binding of insulin-like growth
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
CC treat diseases associated with overexpression and/or abnormal activity of
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
CC hyperactivity of signal transduction pathways mediated by interaction of
CC these receptors with their ligands. Especially they inhibit
CC transformation of normal cells to tumor cells, inhibit growth and/or
CC proliferation of tumor cells, so are useful against cancers of the
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
CC also for treating psoriasis. Ab are also used to diagnose diseases caused
CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
CC protein sequence used to generate the Ab of the invention.
XX
SQ Sequence 117 AA;
Query Match 97.8%; Score 611; DB 7; Length 117;
Best Local Similarity 96.6%; Pred. No. 3.7e-48;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
QY 61 KPSLKDRVTISVDTSKNQFSLKLSSTVAADTAIVYICARYGRVFFDYWGQGLTVTVSS 117
DB 61 KPSLKDRVTISRDTSKNQFSLKLSSTVAADTAIVYICARYGRVFFDYWGQGLTVTVSS 117
RESULT 10
ADZ67079
```

ID AD267079 standard; protein; 117 AA.
XX AD267079;
AC
XX
XX
XX 30-JUN-2005 (first entry)
DT
XX
XX Human antibody 7C10 1 heavy chain variable region SEQ ID NO:75.
DE
XX
XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
KW musculoskeletal disease; respiratory disease; lung tumor;
KW endocrine disease; gynecology and obstetrics; breast tumor;
KW endometrial carcinoma; gastrointestinal disease; colon tumor;
KW antiproliferative; psoriasis; dermatological disease; immune disorder;
KW heavy chain variable region.
XX
XX Homo sapiens.
OS
XX
XX US2005084906-A1.
FN
XX
XX 21-APR-2005.
PD
XX
XX 16-DEC-2003; 2003US-00735916.
PF
XX
XX 18-JAN-2002; 2002FR-00000653.
PR
XX 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
PR 20-JAN-2003; 2003WO-FR000178.
PR 11-JUL-2003; 2003FR-00008538.
XX
XX (GORT/) GORTSCH L.
PA (CORV/) CORVAIA N.
PA (LEGE/) LEGER O.
PA (DUFL/) DUFLOS A.
PA (HAEU/) HAEUW J.
PA (BECK/) BECK A.
XX
XX
XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
PI WPI; 2005-321968/33.
XX
XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
PT antibody or its functional fragment, being capable of binding human IGF-
PT IR and specifically inhibiting tyrosine kinase activity of receptor,
PT useful for treating cancer.
XX
XX
XX Example 13; SEQ ID NO 75; 125pp; English.
PS
XX
XX The invention relates to a novel isolated anti-insulin-like growth factor
CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
CC capable of binding to human IGF-IR and, if necessary, capable of
CC specifically inhibiting tyrosine kinase activity of the receptor,
CC comprising a light or heavy chain having at least one complementary
CC determining region (CDR) consisting of one of two fully defined 16 amino
CC acids (AD267006 and AD267014). An antibody of the invention is useful in
CC the preparation of a medicament intended for the prevention or treatment
CC of an illness connected with an overexpression and/or an abnormal
CC activation of the IGF-IR and/or EGFR, and/or connected with a
CC hyperactivation of the transduction pathway of the signal mediated by the
CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
CC the administration of the medicament does not induce or only slightly
CC induces secondary effects connected with inhibition of the insulin
CC receptor. The antibody is useful for preparation of a medicament intended
CC to inhibit the transformation of normal cells into cells with tumoral
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
CC useful for preparation of a medicament intended to inhibit the growth
CC and/or the proliferation of tumor cells, preferably IGF-dependent,
CC especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or
CC HER2/neu-dependent cells. (I) is useful in the preparation of a
CC medicament intended for prevention or for the treatment of cancer, where
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the

CC preparation of a medicament intended for the prevention or for the
CC treatment of psoriasis. (I) is useful in preparation of a medicament
CC intended for the specific targeting of a biologically active compound to
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
CC is useful for in vitro diagnosis of illnesses induced by an
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
CC starting from a biological sample in which the abnormal presence, of IGF-
CC IR and/or EGFR receptor is suspected, which involves contacting the
CC biological sample with (I), which is optionally labeled. The present
CC sequence is used in the exemplification of the invention.
XX
XX Sequence 117 AA;
SQ
XX
XX Query Match 97.8%; Score 611; DB 9; Length 117;
Best Local Similarity 96.6%; Pred. No. 3.7e-48;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGLWNMTIRQPPGKLEWIGVISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGLWNMTIRQPPGKLEWIGVISYDGTNNY 60
QY 61 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTIVTSS 117
DB 61 KPSLKDRITTSRDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTIVTSS 117
XX
XX RESULT 11
ADJ76911
ID ADJ76911 standard; protein; 135 AA.
XX
XX AC ADJ76911;
XX
XX DT 06-MAY-2004 (first entry)
XX
XX DE Anti-IGF-IR related protein #23.
XX
XX KW Cytostatic; antiproliferative; antibody;
KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
XX CDR.
XX
XX OS Homo sapiens.
XX
XX FN WO2003059951-A2.
XX
XX PD 24-JUL-2003.
XX
XX PF 20-JAN-2003; 2003WO-FR000178.
XX
XX PR 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
XX
XX PA (FABR) FABRE MEDICAMENT SA PIERRE.
XX
XX PI Goetsch L, Corvaia N, Leger O;
XX WPI; 2003-569653/53.
XX
XX DR New antibodies that bind to human insulin-like growth factor receptor,
PT useful for treatment, prevention and diagnosis of cancers.
XX
XX PS Disclosure; SEQ ID NO 77; 164pp; French.
XX
XX The invention relates to an isolated antibody (Ab), and its functional
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
CC IR) and optionally: (i) inhibit natural binding of insulin-like growth
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or
CC treat diseases associated with overexpression and/or abnormal activity of
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
CC hyperactivity of signal transduction pathways mediated by interaction of

CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.
 XX
 XX SQ Sequence 135 AA;

Query Match 97.8%; Score 611; DB 7; Length 135;
 Best Local Similarity 96.6%; Pred. No. 4.3e-48;
 Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGGLVKPSETLSLTCTVSGYSISGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60

Db 19 QVQLQESGPGGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKLEWGWYISYDGTNNY 78

Qy 61 KPSLKDRVTISVDTSKNQFSLKLSSTVAADTAIVYVCARYGRVFFDYWGQGLTVTVSS 117

Db 79 KPSLKDRITISRDTSKNQFSLKLSSTVAADTAIVYVCARYGRVFFDYWGQGLTVTVSS 135

RESULT 12

ADZ67081
 ID ADZ67081 standard; protein; 135 AA.

XX AC ADZ67081;

XX DT 30-JUN-2005 (first entry)

XX DE Human antibody 7C10 1 heavy chain variable region SEQ ID NO:77.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW heavy chain variable region.

XX OS Homo sapiens.

Key	Location/Qualifiers
Peptide	1..18
Region	/note= "leader peptide"
Region	49..54
Region	/note= "CDR1"
Region	69..84
Region	/note= "CDR2"
Region	117..124
Region	/note= "CDR3"

XX US2005084906-A1.

XX PD 21-APR-2005.

XX PF 16-DEC-2003; 2003US-00735916.

XX PR 18-JAN-2002; 2002FR-00000653.

XX PR 18-JAN-2002; 2002FR-00000654.

XX PR 07-MAY-2002; 2002FR-00005753.

XX PR 20-JAN-2003; 2003WO-FR0001178.

XX PR 11-JUL-2003; 2003FR-00008538.

XX PA (GOET/) GOETSCH L.

XX PA (CORV/) CORVAIA N.

XX PA (LEGE/) LEGER O.

XX PA (DUFL/) DUFLOS A.

XX PA (HAEU/) HAEUW J.

XX WI; 2005-321968/33.
 DR N-PSDB; ADZ67080.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 PT antibody or its functional fragment, being capable of binding human IGF-
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,
 PT useful for treating cancer.

XX Example 13; SEQ ID NO 77; 125pp; English.

XX The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-IR and, if necessary, capable of
 CC specifically inhibiting tyrosine kinase activity of the receptor.
 CC comprising a light or heavy chain having at least one complementary
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-IR and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
 CC the administration of the medicament does not induce or only slightly
 CC induces secondary effects connected with inhibition of the insulin
 CC receptor. The antibody is useful for preparation of a medicament intended
 CC to inhibit the transformation of normal cells into cells with tumoral
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
 CC dependent and/or EGF-dependent and/or HIR2/neu-dependent cells. (I) is
 CC useful for preparation of a medicament intended to inhibit the growth
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a
 CC medicament intended for prevention or for the treatment of cancer, where
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 CC preparation of a medicament intended for the prevention or for the
 CC treatment of psoriasis. (I) is useful in preparation of a medicament
 CC intended for the specific targeting of a biologically active compound to
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
 CC is useful for in vitro diagnosis of illnesses induced by an
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
 CC starting from a biological sample in which the abnormal presence, of IGF-
 CC IR and/or EGFR receptor is suspected, which involves contacting the
 CC biological sample with (I), which is optionally labeled. The present
 CC sequence is used in the exemplification of the invention.

SQ Sequence 135 AA;

Query Match 97.8%; Score 611; DB 9; Length 135;
 Best Local Similarity 96.6%; Pred. No. 4.3e-48;
 Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGGLVKPSETLSLTCTVSGYSISGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60

Db 19 QVQLQESGPGGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKLEWGWYISYDGTNNY 78

Qy 61 KPSLKDRVTISVDTSKNQFSLKLSSTVAADTAIVYVCARYGRVFFDYWGQGLTVTVSS 117

Db 79 KPSLKDRITISRDTSKNQFSLKLSSTVAADTAIVYVCARYGRVFFDYWGQGLTVTVSS 135

RESULT 13

ADJ76903

ID ADJ76903 standard; protein; 117 AA.

XX AC ADJ76903;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-IR related protein #16.

XX KW cytostatic; antipsoriatic; antibody;

KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
 KW CDR.
 XX
 OS Homo sapiens.
 XX
 PN WO2003059951-A2.
 XX
 PD 24-JUL-2003.
 XX
 XX 20-JAN-2003; 2003WO-PR000178.
 XX
 PR 18-JAN-2002; 2003FR-00000653.
 PR 18-JAN-2002; 2003FR-00000654.
 PR 07-MAY-2002; 2003FR-00005753.
 XX
 PA (FABR) FABRE MEDICAMENT SA PIERRE.
 XX
 PI Goetsch L, Corvaia N, Leger O;
 XX
 DR WPI; 2003-569653/53.
 XX
 PT New antibodies that bind to human insulin-like growth factor receptor,
 PT useful for treatment, prevention and diagnosis of cancers.
 XX
 PS Disclosure; SEQ ID NO 69; 164pp; French.
 XX
 CC The invention relates to an isolated antibody (Ab), and its functional
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
 CC IR) and optionally: (i) inhibit natural binding of insulin-like growth
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
 CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
 CC treat diseases associated with overexpression and/or abnormal activity of
 CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
 CC hyperactivity of signal transduction pathways mediated by interaction of
 CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.
 XX
 SQ Sequence 117 AA;
 Query Match 84.6%; Score 529; DB 7; Length 117;
 Best Local Similarity 82.8%; Pred. No. 1.2e-40;
 Matches 96; Conservative 11; Mismatches 9; Indels 0; Gaps 0;
 QY 2 VOLQSGGLVKPSETLSLTCTVSGYSISGGYLMNWIROPKGLWIGYISYDGTNNYK 61
 DB 2 VOLQSGGLVKPSSLSLTCTVSGYISGGYLMNWIROPKGLWIGYISYDGTNNYK 61
 QY 62 PSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYGQSTLTVSS 117
 DB 62 PSLKDRISITRDTSKNQPFKLNSVNTEDTATYICARYGRVFFDYGQSTLTVSS 117
 RESULT 14
 ADZ67073
 ID ADZ67073 standard; protein; 117 AA.
 XX
 AC ADZ67073;
 XX
 DT 30-JUN-2005 (first entry)
 XX
 DE Murine immunoglobulin heavy chain variable region 7C10 VH SEQ ID NO:69.
 KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;

KW endometroid carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW immunoglobulin; heavy chain variable region.
 XX
 OS Mus musculus.
 XX
 PN US2005084906-A1.
 XX
 PD 21-APR-2005.
 XX
 XX 16-DEC-2003; 2003US-00735916.
 XX
 PR 18-JAN-2002; 2002FR-00000653.
 PR 18-JAN-2002; 2002FR-00000654.
 PR 07-MAY-2002; 2002FR-00005753.
 PR 20-JAN-2003; 2003WO-PR000178.
 PR 11-JUL-2003; 2003FR-00008538.
 XX
 PA (GOET/) GOETSCH L.
 PA (CORV/) CORVAIA N.
 PA (LEGE/) LEGER O.
 PA (DUFL/) DUFLOS A.
 PA (HAEU/) HAEUW J.
 PA (BECK/) BECK A.
 XX
 PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
 XX
 DR WPI; 2005-321968/33.
 XX
 CC Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 CC antibody or its functional fragment, being capable of binding human IGF-
 CC IR and specifically inhibiting tyrosine kinase activity of receptor,
 CC useful for treating cancer.
 XX
 PS Example 13; SEQ ID NO 69; 125pp; English.
 XX
 CC The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-IR and, if necessary, capable of
 CC specifically inhibiting tyrosine kinase activity of the receptor,
 CC comprising a light or heavy chain having at least one complementary
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (AD267006 and AD267014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-IR and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
 CC the administration of the medicament does not induce or only slightly
 CC induces secondary effects connected with inhibition of the insulin
 CC receptor. The antibody is useful for preparation of a medicament intended
 CC to inhibit the transformation of normal cells into cells with tumoral
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
 CC useful for preparation of a medicament intended to inhibit the growth
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a
 CC medicament intended for prevention or for the treatment of cancer, where
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 CC preparation of a medicament intended for the prevention or for the
 CC treatment of psoriasis. (I) is useful in preparation of a medicament
 CC intended for the specific targeting of a biologically active compound to
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
 CC is useful for in vitro diagnosis of illnesses induced by an
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
 CC starting from a biological sample in which the abnormal presence, of IGF-
 CC IR and/or EGFR receptor is suspected, which involves contacting the
 CC biological sample with (I), which is optionally labeled. The present
 CC sequence is used in the exemplification of the invention.
 XX
 SQ Sequence 117 AA;

Query Match 84.6%; Score 529; DB 9; Length 117;
Best Local Similarity 82.8%; Pred. No. 1.2e-40;
Matches 96; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy 2 VOLQESGPGLVKPSQSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNYK 61
Db 2 VOLQESGPGLVKPSQSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNYK 61

Qy 62 PSLKDRVTISVDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQGTTLTVSS 117
Db 62 PSLKDRISITRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQGTTLTVSS 117

RESULT 15

ADJ76886
ID ADJ76886 standard; protein; 127 AA.

XX AC ADJ76886;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-1R related protein #4.

XX KW cytostatic; antipsoxiatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
XX CDR.

XX OS Mus musculus.

XX PN WO2003059951-A2.

XX XX

XX PD 24-JUL-2003.

XX PF 20-JAN-2003; 2003WO-FR000178.

XX PR 18-JAN-2002; 2002FR-00000653.

XX PR 18-JAN-2002; 2002FR-00000654.

XX PR 07-MAY-2002; 2002FR-00005753.

XX PA (FABR) FABRE MEDICAMENT SA PIERRE.

XX PI Goetsch L, Corvaia N, Leger O;

XX XX

XX DR WPI; 2003-569653/53.

XX PT New antibodies that bind to human insulin-like growth factor receptor,

XX PT useful for treatment, prevention and diagnosis of cancers.

XX PS Disclosure; SEQ ID NO 52; 164pp; French.

XX XX

CC The invention relates to an isolated antibody (Ab), and its functional
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
CC treat diseases associated with overexpression and/or abnormal activity of
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
CC hyperactivity of signal transduction pathways mediated by interaction of
CC these receptors with their ligands. Especially they inhibit
CC transformation of normal cells to tumor cells, inhibit growth and/or
CC proliferation of tumor cells, so are useful against cancers of the
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
CC also for treating psoriasis. Ab are also used to diagnose diseases caused
CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
CC protein sequence used to generate the Ab of the invention.

XX SQ Sequence 127 AA;

Query Match 84.6%; Score 529; DB 7; Length 127;
Best Local Similarity 82.8%; Pred. No. 1.3e-40;

Matches 96; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy 2 VOLQESGPGLVKPSQSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNYK 61
Db 12 VOLQESGPGLVKPSQSLTCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNYK 71

Qy 62 PSLKDRVTISVDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQGTTLTVSS 117
Db 72 PSLKDRISITRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQGTTLTVSS 127

Search completed: January 10, 2006, 20:44:18
Job time : 81.7649 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:28:02 ; Search time 14.1157 Seconds
(without alignments)
797.508 Million cell updates/sec

Title: US-10-735-916A-83
Perfect score: 625
Sequence: 1 QVQLQESGPGLVKPSSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 80:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	519	83.0	140	2 I37782	Ig variable region
2	504	80.6	130	2 S31690	Ig heavy chain V r
3	491	78.6	123	2 S30530	Ig heavy chain V r
4	488	78.1	147	2 S13519	Ig heavy chain V r
5	478	76.5	155	2 S31511	Ig heavy chain - h
6	473.5	75.8	118	2 S24443	Ig heavy chain V r
7	473.5	75.8	130	2 S30534	Ig heavy chain V r
8	473.5	75.8	139	2 S31586	Ig heavy chain V r
9	472	75.5	155	2 S31512	Ig heavy chain - h
10	471.5	75.4	140	2 S78052	Ig heavy chain pre
11	469.5	75.1	145	2 S78055	Ig heavy chain pre
12	467	74.7	121	2 S44113	Ig heavy chain V r
13	466.5	74.6	129	2 S44114	Ig heavy chain V r
14	466	74.6	140	2 A49045	Ig heavy chain V r
15	465	74.4	135	2 S78051	Ig heavy chain pre
16	462.5	74.0	137	2 S31676	Ig heavy chain V r
17	462	73.9	146	2 S09711	Ig heavy chain V r
18	460.5	73.7	126	2 S47010	Ig heavy chain V4.
19	457.5	73.2	118	2 S20780	Ig heavy chain V r
20	456	73.0	140	2 A24770	hypothetical hybr
21	449.5	71.9	118	2 A26340	Ig heavy chain pre
22	449	71.8	146	2 S09710	Ig heavy chain V r
23	448	71.7	98	2 S12421	Ig heavy chain V r
24	448	71.7	139	2 S31696	Ig heavy chain V r
25	446	71.4	121	2 S37200	Ig heavy chain V r
26	444.5	71.1	97	2 S26906	Ig heavy chain V r
27	444.5	71.1	105	2 S44125	Ig lambda chain V
28	444	71.0	123	2 S30529	Ig heavy chain V r
29	444	71.0	134	2 S54906	Ig heavy chain V r

30	443.5	71.0	116	2 B26340	Ig heavy chain pre
31	443.5	71.0	136	2 S07637	Ig heavy chain V r
32	443	70.9	98	2 S26902	Ig heavy chain V r
33	443	70.9	127	2 S19668	Ig heavy chain V r
34	442	70.7	137	1 AVMS35	Ig heavy chain pre
35	441.5	70.6	97	2 S12416	Ig heavy chain V r
36	441.5	70.6	116	2 S38718	Ig heavy chain V r
37	439.5	70.3	99	2 S26802	Ig heavy chain V r
38	439.5	70.3	99	2 S26803	Ig heavy chain V r
39	439	70.2	143	2 B49028	Ig heavy chain V-I
40	438	70.1	116	2 S37456	Ig mu chain - huma
41	438	70.1	117	2 S28195	Ig heavy chain V r
42	437	69.9	128	2 S31514	Ig heavy chain - h
43	436.5	69.8	99	2 S26801	Ig heavy chain V r
44	436.5	69.8	122	2 S69912	Ig V-D-J region (N
45	436.5	69.8	139	2 A41287	Ig heavy chain pre

ALIGNMENTS

RESULT 1

I37782
Ig variable region (VDJ) (clone T23-9) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 16-Feb-1996 #sequence_revision 13-Mar-1997 #text_change 23-Jul-1999
C:Accession: I37782; S25476
R:Demaision, C.; Chastagner, P.; Theze, J.; Zouali, M.
Proc. Natl. Acad. Sci. U.S.A. 91, 514-518, 1994
A:Title: Somatic diversification in the heavy chain variable region genes expressed by i
A:Reference number: A36876; MUID:94119917; PMID:8290556
A:Accession: I37782
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-140 <RES>
A:Cross-references: UNIPARC:UPI0000176B83; EMBL:X67906; NID:g33582; PIDN:CAA48104.1; PFI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:46-128/Domain: immunoglobulin homology <IMM>

Query Match 83.0%; Score 519; DB 2; Length 140;
Best Local Similarity 84.6%; Pred. No. 5.7e-40;
Matches 104; Conservative 3; Mismatches 8; Indels 8; Gaps 3;

Qy	1	QVQLQESGPGLVKPSSETLSLCTVSGYSISGGYLNWIRQPPGKGLWIGYISYDGTNNY	60
Db	20	QVQLQESGPGLVKPSSETLSLCTVSGGIS-SYHSWIRQPPGKGLWIGYIYSGSTNY	78
Qy	61	KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVYYCAR-----YCRVFDDYWGQGLTVT	114
Db	79	NPSLSKRVITISVDTSKNQFSLKLSVTAADTAVYYCARHNSSSWYGR-YFDYWGQGLTVT	137
Qy	115	VSS 117	
Db	138	VSS 140	

RESULT 2

S31690
Ig heavy chain V region - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S31690
R:Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A:Description: Mechanisms that generate human immunoglobulin diversity operate from the
A:Reference number: S31585
A:Accession: S31690
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-130 <CUI>
A:Cross-references: UNIPARC:UPI0000116471; EMBL:214199; NID:g30984; PIDN:CAA78568.1; PFI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin

RESULT 4
S13519
IG heavy chain V region precursor - human
C/Species: Homo sapiens (man)
C/Date: 25-Feb-1994 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C/Accession: S13519
R/Mortari, F.; Ochs, H.D.; Wedgwood, R.J.P.; Schroeder Jr., H.W.
Nucleic Acids Res. 19, 673, 1991
A/Title: Immunoglobulin variable heavy chain cDNA sequence from a patient with X-linked
A/Reference number: S13519; MUID:91187691; PMID:2011536
A/Accession: S13519
A/Status: Preliminary
A/Molecule type: mRNA
A/Residues: 1-147 <MOR>
A/Cross-references: UNIPARC:UPI0000115EB5; EMBL:X56158; NID:g37724; PIDN:CAA39626.1; PID
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F/41-125/Domain: immunoglobulin homology <IMM>

A;Residues: 1-55,57-118 <MAR>

Query Match 75.8%; Score 473.5; DB 2; Length 139;

RESULT 10

S78052

Ig heavy chain precursor V-D-J region (clone mAb 63VH) - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 19-Nov-1997 #sequence_revision 05-Dec-1997 #text_change 23-Jul-1999

C:Accession: S78052; S23717

R:Harindranath, N.

submitted to the EMBL Data Library, August 1990

A:Reference number: S78051

A:Accession: S78052

A:Molecule type: mRNA

A:Residues: 1-140 <HAR>

A:Cross-references: UNIPARC:UPI0000115E89; EMBL:X54441; NID:g37815; PIDN:CAA393

R:Harindranath, N.; Goldfarb, I. S.; Ikematsu, H.; Burastero, S. E.; Wilder, R. L.

Int. Immunol. 3, 865-875, 1991

A:Title: Complete sequence of the genes encoding the V(H) and V(L) regions of 1

patient.

A:Reference number: S23716; MUID:92031262; PMID:1718404

A:Accession: S23717

A:Molecule type: mRNA

A:Residues: 15-111 <HAW>

Search completed: January 10, 2006, 20:55:16
Job time : 15.1157 secs

	Query Match	74.6%	Score 466;	DB 2;	Length 140;	
	Best Local Similarity	77.0%	Pred. No. 3.5e-35;			
	Matches	94;	Conservative	6;	Mismatches 16;	Indels 6; Gaps 2
Qy	1	QVQLQESGPGLVKPSETLSLTCTVSGYISGGYLNNWIRQPPGKGLEWIGYISDYGTNNY	60			
Dd	20	QVQLQQMGAGLLKPSETLSLTCAVYGGSFS-GYWSWIRQPPGKGLEWIGEINHSSTNY	78			
Qy	61	KPSLKDRVTIISVDTSKNQFSLKSSVTAADTAVYYCARYGRV-----FFDYGQGTLTVT	115			
Dd	79	NPSLKSRTVISVDTSKNQFSLKSSVTAADTAVYYCARGGPAATIVESFDYGQGTLTVT	138			
Qy	116	SS 117				
Dd	139	SS 140				

RESULT 15

S78051
Ig heavy chain precursor V-D-J region (clone mAB 61VH) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 19-Nov-1997 #sequence_revision 05-Dec-1997 #text_change 23-Jul-1999
C;Accession: S78051; S23716
R;Harindranath, N.
submitted to the EMBL Data Library, August 1990
A;Reference number: S78051
A;Accession: S78051
A:Molecule type: mRNA
A;Residues: 1-135 <HAR>
A;Cross-references: UNIPARC:UPT0000115E87; EMBL:X54437; NID:g37814; PIDN:CAA38306.1; PIDN:CAA38306.1; PIDN:CAA38306.1; Notkins R;Harindranath, N.; Goldfarb, I.S.; Ikematsu, H.; Burastero, S.E.; Wilder, R.L.; Notkins Int. Immunol. 3, 865-875, 1991
A;Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and patient.

A;Reference number: S23716; MUID:92031262; PMID:1718404
A;Accession: S23716
A:Molecule type: mRNA
A;Residues: 13-111 <HAW>
A;Cross-references: UNIPARC:UPT00001769D5; EMBL:X54437
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: immunoglobulin
F;1-13/Domain: signal sequence (fragment) #status predicted <SIG>
F;14-135/Product: Ig heavy chain (fragment) #status predicted <MAT>
F;27-111/Domain: immunoglobulin homology <IMM>

	Query Match	74.4%;	Score 465;	DB 2;	Length 135;
	Best Local Similarity	77.2%;	Pred. No. 4.1e-35;		
	Matches	95;	Conservative	4;	Mismatches 18; Indels 6; Gaps 2
Qy	1	QVQLQESGPGLVKPKSETLSLCTVSGYGIS	-GGYLWNWIRQPPGKLEWIGHSYDGTNN	59	
		: :	: :		
Db	13	QLQLQESGPGLVKPKSETLSLCTVSGGISRGS	HYGMIRQPPGKLEWIGSIYSGNTY	72	
		: :	: :		
Qy	60	YKPSLKRVTISVDTSKNQPSLKLSVTAADTA	VYTCARYGRVFF-----	DYWGQGTTLVT	114
		: :	: :		
Db	73	FNPSLKSRTVTSVDTSKNQPSLKLSVTAADTA	VYTCARYGLRPPDDTLDGMDYWGQGTTLVT	132	
		: :	: :		

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:26:41 ; Search time 78.8731 Seconds
(without alignments)
1046.577 Million cell updates/sec

Title: US-10-735-916A-83
Perfect score: 625
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFPDYWGQGLVTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt_05.80.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	496	79.4	119	Q9UL73 HUMAN	Q9ul73 homo sapien
2	493.5	79.0	465	Q6GMX6 HUMAN	Q6gmxx6 homo sapien
3	473	75.7	476	Q6GMX1 HUMAN	Q6gmxx1 homo sapien
4	468.5	75.0	477	Q6GMX7 HUMAN	Q6gmxx7 homo sapien
5	464.5	74.3	150	Q95973 HUMAN	Q95973 homo sapien
6	464.5	74.3	576	Q6P4I8 HUMAN	Q6p4i8 homo sapien
7	459	73.4	479	Q99M22 MOUSE	Q99m22 mus musculus
8	457.5	73.2	620	Q66EY0 HUMAN	Q66ey0 homo sapien
9	448.5	71.8	478	Q72379 HUMAN	Q72379 homo sapien
10	448	71.7	492	Q72374 HUMAN	Q72374 homo sapien
11	444.5	71.1	139	Q86SX2 HUMAN	Q86sx2 homo sapien
12	444.5	71.1	496	Q96KX8 HUMAN	Q96kx8 homo sapien
13	443.5	71.0	136	Q6LBU5 MOUSE	Q6lbu5 mus musculus
14	443.5	71.0	483	Q5U413 MOUSE	Q5u413 mus musculus
15	442	70.7	137	HV46 MOUSE	P01822 mus musculus
16	435	69.6	119	Q53VQ5 MOUSE	Q53vq5 mus musculus
17	434	69.4	595	Q8WUX4 HUMAN	Q8wux4 homo sapien
18	434	69.4	597	Q9BU10 HUMAN	Q9bu10 homo sapien
19	434	69.4	597	Q6GMX5 HUMAN	Q6gmxx5 homo sapien
20	434	69.4	625	Q6GAA6 HUMAN	Q6gaa6 homo sapien
21	433.5	69.4	146	HV21 HUMAN	P06331 homo sapien
22	432	69.1	597	Q9QB08 HUMAN	Q9qb08 homo sapien
23	423.5	67.8	130	Q81ZD7 HUMAN	Q81zd7 homo sapien
24	421	67.4	115	Q53VQ1 MOUSE	Q53vq1 mus musculus
25	419	67.0	478	Q6NYH3 HUMAN	Q6nyh3 homo sapien
26	418.5	67.0	120	Q53VR7 MOUSE	Q53vr7 mus musculus
27	418	66.9	615	Q569B6 RAT	Q569b6 rattus norv
28	416	66.6	590	Q569B8 RAT	Q569b8 rattus norv
29	413	66.1	119	Q53VR3 MOUSE	Q53vr3 mus musculus
30	412	65.9	117	HV2G HUMAN	P01825 homo sapien
31	409	65.4	116	HV60_MOUSE	P18531 mus musculus

32	403.5	64.6	116	2	Q723Y6 HUMAN	Q723y6 homo sapien
33	403	64.5	98	2	Q53VQ4_MOUSE	Q53vq4 mus musculus
34	402	64.3	129	1	HV2F_HUMAN	P01824 homo sapien
35	400	64.0	476	2	Q6MZX7_HUMAN	Q6mzx7 homo sapien
36	397.5	63.6	122	2	Q9UL75_HUMAN	Q9ul75 homo sapien
37	396	63.4	119	2	Q53VQ9_MOUSE	Q53vq9 mus musculus
38	396	63.4	477	2	Q510J1_RAT	Q510j1 rattus norv
39	395.5	63.3	473	2	Q8TC63_HUMAN	Q8tc63 homo sapien
40	390	62.4	98	2	Q53VR6_MOUSE	Q53vr6 mus musculus
41	386.5	61.8	591	2	Q510I9_RAT	Q510i9 rattus norv
42	386	61.8	98	2	Q53VQ0_MOUSE	Q53vq0 mus musculus
43	385	61.6	98	2	Q53VR2_MOUSE	Q53vr2 mus musculus
44	385	61.6	469	2	Q5M839_RAT	Q5m839 rattus norv
45	381	61.0	113	1	HV47_MOUSE	P01823 mus musculus

ALIGNMENTS

RESULT 1
Q9UL73_HUMAN PRELIMINARY; PRT; 119 AA.
AC Q9UL73;
DT 01-MAY-2000 (Tremblrel. 13, Created)
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus."
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1660528;
RA Manheimer-Lory A., Katz J.B., Pillinger M., Ghossein C., Smith A., Diamond B.;
RT "Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype."
RL J. Exp. Med. 174:1639-1652(1991).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=2511001;
RA Sanz I., Kelly P., Williams C., Scholl S., Tucker P., Capra J.D.;
RT "The smaller human VH gene families display remarkably little polymorphism."
RL EMBO J. 8:3741-3748(1989).
DR EMBL; AF035041; AAD56277.1; -, mRNA.
DR PIR; PH0876; PH0876.
DR PIR; S12416; S12416.
DR HSRF; P01820; IG7J.
DR SMR; Q9UL73; 1-119.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 119
SQ SEQUENCE 119 AA; 13219 MW; 1BDB86B6420EA0BE CRC64;

Query Match 79.4%; Score 496; DB 2; Length 119;
Best Local Similarity 80.8%; Pred No. 2,6e-42;
Matches 97; Conservative 7; Mismatches 12; Indels 4; Gaps 2;

```
Qy 1 QVQLQESGPGLVKPESETLSLTCTVSGSYISGGYLNWIRQPPGKLEWIGVISYDGTNNY 60
D 1 QVQLQESGPGLVKPESETLSLTCTVSGSYISGGYLNWIRQPPGKLEWIGVISYDGTNNY 59
D 1 QVQLQESGPGLVKPESETLSLTCTVSGSYISGGYLNWIRQPPGKLEWIGVISYDGTNNY 59
Qy 61 KPSLKDRVTISVDTSKNQFSLKLSSTAAADTAVYICAR---YGRVFPDYWGQGLTIVTSS 117
D 60 TPLSLKSRVTISVDTSKNQFSLKLSSTAAADTAVYICARLSSNWPYFYFDYWGQGLTIVTSS 119

RESULT 2
Q6GMX6 HUMAN PRELIMINARY; PRT; 465 AA.
ID Q6GMX6 HUMAN PRELIMINARY; PRT; 465 AA.
AC Q6GMX6;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M.J., Udell T.B., Toshlyuk S., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Raha S.S., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Bosak S.A., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Whiting J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Buttefield Y.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC073766; AAH73766.1; -, mRNA.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG_c1.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 4.
DR PROSITE; PS0290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 465 AA; 51083 MW; B3A9B7D0FDB1386E CRC64;

Query Match 79.0%; Score 493.5; DB 2; Length 465;
Best Local Similarity 83.8%; Pred. No. 2.1e-41;
Matches 98; Conservative 4; Mismatches 14; Indels 1; Gaps 1;

Qy 1 QVQLQESGPGLVKPESETLSLTCTVSGSYISGGYLNWIRQPPGKLEWIGVISYDGTNNY 60
D 1 QVQLQESGPGLVKPESETLSLTCTVSGSYISGGYLNWIRQPPGKLEWIGVISYDGTNNY 59
D 1 QVQLQESGPGLVKPESETLSLTCTVSGSYISGGYLNWIRQPPGKLEWIGVISYDGTNNY 59
```

```
Db 20 QVQLQESGPGLVKPESETLSLTCTVSGSYISGGYLNWIRQPPGKLEWIGVISYDGTNNY 78
Qy 61 KPSLKDRVTISVDTSKNQFSLKLSSTAAADTAVYICARVGRVFPDYWGQGLTIVTSS 117
D 79 NPSLSKSRVTISVDTSKNQFSLKLSSTAAADTAVYICARGRTYFDYWGQGLTIVTSS 135

RESULT 3
Q6GMX1 HUMAN PRELIMINARY; PRT; 476 AA.
ID Q6GMX1 HUMAN PRELIMINARY; PRT; 476 AA.
AC Q6GMX1;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M.J., Udell T.B., Toshlyuk S., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Raha S.S., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Bosak S.A., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Whiting J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Buttefield Y.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC073773; AAH73773.1; -, mRNA.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR InterPro; IPR003599; IG-like.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG_c1.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 4.
DR PROSITE; PS0290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 476 AA; 52286 MW; 622AABA5C62DDE9D CRC64;

Query Match 75.7%; Score 473; DB 2; Length 476;
Best Local Similarity 74.8%; Pred. No. 2.6e-39;
Matches 95; Conservative 10; Mismatches 12; Indels 10; Gaps 3;

Qy 1 QVQLQESGPGLVKPESETLSLTCTVSGSYISGGYLNWIRQPPGKLEWIGVISYDGTNNY 59
D 20 QVQLQESGPGLVKPESETLSLTCTVSGSYISGGYLNWIRQPPGKLEWIGVISYDGTNNY 79
```

Db	20	QVQLQESGPGLVKPSSETLSLTCTCTSGGSIS--SYTWSWIRQTACKGLEWIGYISHSGSTTY	78
Qy	61	KPSLKDRVTISVDTSKNQPSFKLSVTAADTAIVYCARVRF---FDYWGQGTLLTVSS	117
Db	79	NPSLKSRVTLSDTTSKNQPSFKLSLNSVTAADTAIVYCA-HGSSMDFAFDYWGQGTLLTVSS	137

RESULT 5	OC95973_HUMAN	OC95973_HUMAN PRELIMINARY;	PRT; 150 AA.
AC	OC95973;		
DT	01-MAY-1999	(TrEMBLrel. 10, Created)	
DT	01-MAY-1999	(TrEMBLrel. 10, Last sequence update)	
DT	01-MAY-2004	(TrEMBLrel. 26, Last annotation update)	
DE	VH4 heavy chain variable region precursor (Fragment).		
GN	Names=IGM;		
OS	Homo sapiens (Human).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;		
OC	Homo.		
OC	NCBI_TaxID=9606;		
RN	[1]		
RP	NUCLEOTIDE SEQUENCE.		
RA	Shh C.-H., Song C.-H., Lee C.-H., Lee S.-K.;		
RT	"Clonal proliferation of IGM secreting B cell in the synovium of		
RL	Behcet's patient with arthritis."		
RL	Submitted (OCT-1998) to the EMBL/GenBank/DBJ databases.		

FT SIGNAL	1	19	Potential.
FT CHAIN	20	>150	VH4 heavy chain variable region.
FT NON TER	150	150	
SQ SEQUENCE	150 AA;	16315 MW;	85664E04938AA7C9 CRC64;
Query Match		74.3%;	Score 464.5; DB 2; Length 150;
Best Local Similarity		77.1%;	Pred. No. 5.4e-39;
Matches	91; Conservative		8; Mismatches 18; Indels 1; Gaps

QY	1	QVQLQESGPGLVKPSSETLSLTCTVSGYSISG-CYLNWNIRQPPGKGLEWIGIYSYDGTNN	5
Db	20	QLQLQESGPGLVKPSSETLSLCTVSGGISSTWYVWGIRQPPGKGLEWIGSLHNSGSDY	75
QY	60	YKPSLKDRVTISVDTSKNQFSLKLSVTAADTAVVYCARYGRVFFYWGQGLTVTVSS	117
Db	80	YNPFLSKSRVTISVDTSKNQFSLFLSSVTAADTAVVYCARIEMGAFDFWGHGTVTVSS	137

RESULT 6	
Q6P418_HUMAN	
ID	Q6P418_HUMAN PRELIMINARY; PRT; 576 AA.
AC	Q6P418;
DT	05-JUL-2004 (TrEMBLrel. 27, Created)
DT	05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT	05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE	IGHD protein.

```

GN Name=IGHD;
OS Homo sapiens (Human);
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN (1)
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner K.H., Schaefer C.F., Schuler G.D.,
RA Altschul S.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Richards S., Worley K.C., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN (2)
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RA Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC063384; AAH63384.1; -, mRNA.
DR HSSP; P01820; 1A7N.
DR Ensembl; ENSG00000196122; Homo sapiens.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.c1.
DR InterPro; IPR003006; Ig MHC.
DR InterPro; IPR003596; Ig v.
DR Pfam; PF07654; C1-set; 1.
DR Pfam; PF00047; Ig; 2.
DR SMART; SM00409; Ig; 1.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG MHC; UNKNOWN 2.
SQ SEQUENCE 576 AA; 63364 MW; FBB97C949D720F1E CRC64;

Query Match 74.3%; Score 464.5; DB 2; Length 576;
Best Local Similarity 75.8%; Pred. No. 2.3e-38;
Matches 91; Conservative 7; Mismatches 19; Indels 3; Gaps 1;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 27 QVQLQESGPGLVKPSGTLSTLCAVSGGSISSNWMWVRQPPGKLEWIGIYHSNSTNY 86

Qy 61 KPSLKDRVTISVDTSKQNFSLKLSVTAADTAVYVCARYGRVFF---DYWGQGLTVTVSS 117
Db 87 NPSLSKRVTVISVDKSKQNFSLKLSVTAADTAVYVCASLGIIYYIGMDVWGQGLTVTVSS 146

RESULT 7
Q99M22_MOUSE
ID Q99M22_MOUSE PRELIMINARY; PRT; 479 AA.
AC Q99M22
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DI 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE LOC238447 protein.

```

```

GN Name=LOC238447;
OS Mus musculus (Mouse);
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN (1)
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Mix FVB/N;
RX TISSUE=Mammary tumor. WAP-TGF alpha model. 7 months old;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner K.H., Schaefer C.F., Schuler G.D.,
RA Altschul S.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Richards S., Worley K.C., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Hulyk S.W.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN (2)
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Mix FVB/N;
RX TISSUE=Mammary tumor. WAP-TGF alpha model. 7 months old;
RG NIH MGC Project;
RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC002091; AAH02091.1; -, mRNA.
DR HSSP; P01820; 1G7J.
DR GO; GO:0003823; F-antigen binding; IEA.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.c1.
DR InterPro; IPR003006; Ig MHC.
DR InterPro; IPR003596; Ig v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG MHC; UNKNOWN 2.
KW Immunoglobulin domain.
SQ SEQUENCE 479 AA; 51992 MW; 768E39A138918892 CRC64;

Query Match 73.4%; Score 459; DB 2; Length 479;
Best Local Similarity 72.4%; Pred. No. 6.9e-38;
Matches 84; Conservative 15; Mismatches 17; Indels 0; Gaps 0;

Qy 2 VQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
Db 20 VQLQESGPGLVKPSQSLSLTCSVTGYSITSGYYNNWIRQPPGKLEWGYINYGNNYN 79

Qy 62 PSLKDRVTISVDTSKQNFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117
Db 80 PSLKDRVTISVDTSKQNFSLKLSVTAADTAVYVCASLGIIYYIGMDVWGQGLTVTVSA 135

RESULT 8
Q96EY0_HUMAN
ID Q96EY0_HUMAN PRELIMINARY; PRT; 620 AA.
AC Q96EY0
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DI 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHM protein.
GN Name=IGHM;

```


RC TISSUE=Human rectum tumor;
RA Bloeker H., Boecher M., Mewes H.W., Weil B., Amid C., Oeanger A.,
RA Fobo G., Han M., Wiemann S.; ENBL/GenBank/DBJ databases.
RL Submitted (JUN-2003) to the ENBL/GenBank/DBJ databases.
DR EMBL; BX538077; CAD98001.1; -, mRNA.
DR HSSP; P01820; 1G7J.
DR SMR; Q72374; 262-470.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG-cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; Cl-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
FT NON_TER 1
SQ SEQUENCE 492 AA; 53776 MW; 1E7A15760F0CA74B CRC64;

Query Match 71.1%; Score 448; DB 2; Length 492;
Best Local Similarity 74.0%; Pred. No. 9.3e-37;
Matches 91; Conservative 7; Mismatches 17; Indels 8; Gaps 3;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISG-GYLWNWIRPPGKLEWIGYISYDGTNN 59
Db 32 QLQLQESGPGLVKPSSETLSLTCTVSGGSVNRNYWGWIRPPGKLEWIGSIYNNY 91

Qy 60 YKPSLKRVTISVDTSKNQFSLKSSVTAADTAVYCAR-----YGRVFFYWGQGLT 114
Db 92 YSPSLKRLTTFVDTSKNHFSLRLTSVTAADTAVYCVRHVEGPGY--WFPDQGGTL 149

Qy 115 VSS 117
Db 150 VSS 152

RESULT 11
ID Q86SX2 HUMAN PRELIMINARY; PRT; 139 AA.
AC Q86SX2;
RC TISSUE=B cells;
RP Li W.B., Gruber C., Jesse J., Polayes D.;
RL Submitted (FEB-2003) to the ENBL/GenBank/DBJ databases.
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=B cells;
RL Submitted (FEB-2003) to the ENBL/GenBank/DBJ databases.
RA Ensembl; BX248300; CAD62627.1; -, mRNA.
DR EMBL; BX248300; CAD62627.1; -, mRNA.
DR HSSP; P01820; 1G7J.
DR SMR; Q86SX2; 33-129.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
FT NON_TER 1
SQ SEQUENCE 139 AA; 15573 MW; 7D1E2302410B4F8C CRC64;

Query Match 71.1%; Score 444.5; DB 2; Length 139;
Best Local Similarity 73.4%; Pred. No. 2.1e-36;
Matches 91; Conservative 4; Mismatches 22; Indels 7; Gaps 2;

Best Local Similarity 88.8%; Pred. No. 5.3e-37;
Matches 87; Conservative 2; Mismatches 8; Indels 1; Gaps 1;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGLWNWIRPPGKLEWIGYISYDGTNNY 60
Db 33 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS--SYWISWIRPPGKLEWIGYISYSGSTNY 91

Qy 61 KPSLKRVTISVDTSKNQFSLKSSVTAADTAVYCAR 98
Db 92 NPSLKRVTISVDTSKNQFSLKSSVTAADTAVYCAR 129

RESULT 12
ID Q96KX8 HUMAN PRELIMINARY; PRT; 496 AA.
AC Q96KX8;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE MGC27165 protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udutin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Smit
RA Fahy J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Adar R.A., Grimwood J., Schmutz J., Myers R.M.,
RA Butlerfield Y.S.N., Krzywinski M.I., Skalska U., Smalish D.E.,
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RA Strausberg R.;
RL Submitted (OCT-2001) to the ENBL/GenBank/DBJ databases.
DR EMBL; BC016369; AAH16369.1; -, mRNA.
DR HSSP; P01876; 1OW0.
DR SMR; Q96KX8; 266-474.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG-cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; Cl-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain.
SQ SEQUENCE 496 AA; 53392 MW; D346929849040D69 CRC64;

Query Match 71.1%; Score 444.5; DB 2; Length 496;
Best Local Similarity 73.4%; Pred. No. 2.1e-36;
Matches 91; Conservative 4; Mismatches 22; Indels 7; Gaps 2;

```

QY 1 QVQLESGPGLVKPSETLSLCTVSGYSI -SGGYLWNIWIRQPPGKGLWIGYISYDGTNN 59
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
20 QVQLESGPGLVKPSETLSLCTVSGYSI -SSSYWGWIRQPPGKGLWIANITYSGITY 79
QY 60 YKPSLKDRTVTSVDTSKNQFSLKSSVTAADTAATVYCARYG-----RVFFDYWGQGLV 113
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
80 YNPSLKSRTVTSVDTSKNQFSLKSSVTAADTAATVYCARHGYSGRGTGADYWGQGLV 139
QY 114 TVSS 117
Db :|||||:
140 TVSS 143

RESULT 13
Q6LBQ5 MOUSE
ID Q6LBQ5 MOUSE PRELIMINARY; PRT; 136 AA.
AC Q6LBQ5;
DT 05-JUL-2004 (TREMBLrel. 27, Created)
DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update)
DE VH gene product (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=90067954; PubMed=2587273;
RA Urakov D.N., Deev S.M., Polyakovskiy O.L.;
RT "The structure of the expressible VH gene from a hybridoma producing
monoclonal antibodies against porcine transferrin.";
RL Nucleic Acids Res. 17:9481-9481(1989).
DR EMBL; X16740; CAA34714.1; -; Genomic_DNA.
DR HSSP; P18532; 1KCV.
DR SMR; Q6LBQ5; 20-136.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON TER 1
SQ SEQUENCE 136 AA; 15307 MW; 5B0F439CCFB15C3A CRC64;

Query Match 71.0%; Score 443.5; DB 2; Length 136;
Best Local Similarity 70.9%; Pred. No. 6.5e-37;
Matches 83; Conservative 15; Mismatches 18; Indels 1; Gaps 1;

QY 2 VQLESGPGLVKPSETLSLCTVSGYSI -SGGYLWNIWIRQPPGKGLWIGYISYDGTNNYK 61
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
20 VQLESGPGLVKPSETLSLCTVSGYSI -SGGYLWNIWIRQPPGKGLWIGYISYDGSNGYN 79
QY 62 PSLKDRVTISVDTSKNQFSLKSSVTAADTAATVYCAR -YGRVFFDYWGQGLVTVSS 117
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
80 PSLKRNISITRDTSKNQFSLKSSVTTEDTATYCTRGDGYHFTYWGQGLVTVSA 136

RESULT 14
Q5U413 MOUSE
ID Q5U413 MOUSE PRELIMINARY; PRT; 483 AA.
AC Q5U413;
DT 01-FEB-2005 (TREMBLrel. 29, Created)
DT 01-FEB-2005 (TREMBLrel. 29, Last sequence update)
DT 01-FEB-2005 (TREMBLrel. 29, Last annotation update)
DE LOC544903 protein.
GN Name=LOC544903;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]

```

```

RP NUCLEOTIDE SEQUENCE.
RX STRAIN=FVB/N; TISSUE=Colon;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.L., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=FVB/N; TISSUE=Colon;
RG NIH MGC Project;
RL Submitted (OCT-2004) to the EMBL/GenBank/DBSJ databases.
DR EMBL; BC085312; AAH85312.1; -; mRNA.
DR Ensembl; ENSMUSG0000054328; Mus musculus.
GO: GO:0003823; F:antigen binding; IEA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG.cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; CI-set; 2.
DR SMART; SM00409; IG; 3.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
SQ SEQUENCE 483 AA; 52714 MW; 7C272DA501AA0D1 CRC64;

Query Match 71.0%; Score 443.5; DB 2; Length 483;
Best Local Similarity 70.6%; Pred. No. 2.6e-36;
Matches 84; Conservative 13; Mismatches 19; Indels 3; Gaps 1;

QY 2 VQLESGPGLVKPSETLSLCTVSGYSI -SGGYLWNIWIRQPPGKGLWIGYISYDGTNNYK 61
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
20 VQLESGPGLVKPSETLSLCTVSGYSI -SGGYLWNIWIRQPPGKGLWIGYISYSGNNYN 79
QY 62 PSLKDRVTISVDTSKNQFSLKSSVTAADTAATVYCAR -YGRVFFDYWGQGLVTVSS 117
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
80 PSLKRNISITRDTSKNQFSLKSSVTTEDTATYCTRGDGYHFTYWGQGLVTVSS 138

RESULT 15
HV46 MOUSE
ID HV46 MOUSE STANDARD; PRT; 137 AA.
AC P01822;
DT 21-JUL-1986 (Rel. 01, Created)
DT 01-AUG-1992 (Rel. 23, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V region MOPC 315 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=89238351; PubMed=2497341; DOI=10.1016/0161-5890(89)90133-8;

```


GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:55:23 ; Search time 5.96642 Seconds
(without alignments)
166.558 Million cell updates/sec

Title: US-10-735-916A-79

Perfect score: 627

Sequence: 1 QVQLQESGPGLVKPSSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 61141 seqs, 8493638 residues

Total number of hits satisfying chosen parameters: 61141

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA New:*

- 1: /cgn2_6/ptodata/1/pubpaa/US08 NEW PUB.pap.*
- 2: /cgn2_6/ptodata/1/pubpaa/US06 NEW PUB.pap.*
- 3: /cgn2_6/ptodata/1/pubpaa/US07 NEW PUB.pap.*
- 4: /cgn2_6/ptodata/1/pubpaa/ECT_NEW_PUB.pap.*
- 5: /cgn2_6/ptodata/1/pubpaa/US09 NEW PUB.pap.*
- 6: /cgn2_6/ptodata/1/pubpaa/US10 NEW PUB.pap.*
- 7: /cgn2_6/ptodata/1/pubpaa/US11 NEW PUB.pap.*
- 8: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pap.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	627	100.0	117	7	US-11-012-353-79
2	627	100.0	135	7	US-11-012-353-81
3	623	99.4	117	7	US-11-012-353-75
4	623	99.4	135	7	US-11-012-353-77
5	615	98.1	135	7	US-11-012-353-83
6	615	98.1	135	7	US-11-012-353-85
7	541	86.3	117	7	US-11-012-353-69
8	541	86.3	127	7	US-11-012-353-52
9	536	85.5	117	7	US-11-012-353-162
10	482.5	77.0	118	7	US-11-012-353-70
11	482	76.9	123	7	US-11-012-353-73
12	481.5	76.8	247	7	US-11-054-515-1651
13	481.5	76.8	250	7	US-11-054-515-1548
14	473	75.4	117	7	US-11-012-353-72
15	473	75.4	120	7	US-11-102-201-1
16	473	75.4	253	7	US-11-054-515-1619
17	469.5	74.9	146	6	US-10-721-763-17
18	469.5	74.9	259	6	US-10-512-184-34
19	469.5	74.9	371	6	US-10-512-184-71
20	469.5	74.9	626	6	US-10-512-184-49
21	467.5	74.6	252	7	US-11-054-515-1994
22	465.5	74.2	252	7	US-11-054-515-1329
23	461.5	73.6	116	7	US-11-054-669-112
24	461.5	73.6	250	7	US-11-054-669-110
25	461	73.5	255	7	US-11-054-515-841

ALIGNMENTS

RESULT 1

US-11-012-353-79
; Sequence 79, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUM, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 79
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-79

Query Match 100.0%; Score 627; DB 7; Length 117;
Best Local Similarity 100.0%; Pred. No. 1.2e-46;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNWIRQPPGKGLWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNWIRQPPGKGLWIGYISYDGTNNY 60
QY 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAATVYVCARYGRVFFDYWGQGLTVTVSS 117
DB 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAATVYVCARYGRVFFDYWGQGLTVTVSS 117

```
RESULT 2
US-11-012-353-81
; Sequence 81, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR FILING DATE: 2004-12-16
; PRIOR FILING DATE: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 81
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-81

Query Match          100.0%; Score 627; DB 7; Length 135;
Best Local Similarity 100.0%; Pred. No. 1.4e-46;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db      19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy      61 KPSLKDRVTISRDTSKNQFSLKLSSTVAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
Db      79 KPSLKDRVTISRDTSKNQFSLKLSSTVAADTAVYYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 3
US-11-012-353-75
; Sequence 75, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR FILING DATE: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 75
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-75

Query Match          99.4%; Score 623; DB 7; Length 135;
Best Local Similarity 98.3%; Pred. No. 3.1e-48;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db      19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy      61 KPSLKDRVTISRDTSKNQFSLKLSSTVAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
Db      79 KPSLKDRVTISRDTSKNQFSLKLSSTVAADTAVYYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 4
US-11-012-353-77
; Sequence 77, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR FILING DATE: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 77
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-77

Query Match          99.4%; Score 623; DB 7; Length 135;
Best Local Similarity 98.3%; Pred. No. 3.1e-48;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db      19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy      61 KPSLKDRVTISRDTSKNQFSLKLSSTVAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
Db      79 KPSLKDRVTISRDTSKNQFSLKLSSTVAADTAVYYCARYGRVFFDYWGQGLTVTVSS 135
```

```
RESULT 5
US-11-012-353-83
; Sequence 83, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 83
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-83

Query Match      98.1%; Score 615; DB 7; Length 117;
Best Local Similarity 98.3%; Pred. No. 1.4e-47;
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      1  QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      1  QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY      61  KPSLKDRTVISRDTSKNQFSLKSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      61  KPSLKDRTVISRDTSKNQFSLKSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 135
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 6
US-11-012-353-85
; Sequence 85, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 85
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-85

Query Match      86.3%; Score 541; DB 7; Length 117;
Best Local Similarity 84.5%; Pred. No. 3.8e-41;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

QY      2  VQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      2  VQLQESGPGLVKPSQSLTCTSVTSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY      62  PSLKDRTVISRDTSKNQFSLKSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
```

```
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: Patentin Ver. 3.3
; SEQ ID NO 85
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-85

Query Match      98.1%; Score 615; DB 7; Length 135;
Best Local Similarity 98.3%; Pred. No. 1.6e-47;
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      1  QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      19  QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY      61  KPSLKDRTVISRDTSKNQFSLKSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      79  KPSLKDRTVISRDTSKNQFSLKSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 135
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 7
US-11-012-353-69
; Sequence 69, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: Patentin Ver. 3.3
; SEQ ID NO 69
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-69

Query Match      86.3%; Score 541; DB 7; Length 117;
Best Local Similarity 84.5%; Pred. No. 3.8e-41;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

QY      2  VQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      2  VQLQESGPGLVKPSQSLTCTSVTSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY      62  PSLKDRTVISRDTSKNQFSLKSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
```

Db 62 PSLKDRVITSRDTSKNQFFLKLNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117

RESULT 8

US-11-012-353-52
; Sequence 52, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 52
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-52

Query Match 86.3%; Score 541; DB 7; Length 127;
Best Local Similarity 84.5%; Pred. No. 4.1e-41;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;
Qy 2 VOLQESGPGLVKPSLTSITCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
Db 12 VOLQESGPGLVKPSLSLTSCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 71
Qy 62 PSLKDRVITSRDTSKNQFSLKSSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 117
Db 72 PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 127

RESULT 9

US-11-012-353-162
; Sequence 162, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178

; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 162
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-162

Query Match 85.5%; Score 536; DB 7; Length 117;
Best Local Similarity 86.3%; Pred. No. 1e-40;
Matches 101; Conservative 5; Mismatches 11; Indels 0; Gaps 0;
Qy 1 QVOLQESGPGLVKPSLTSITCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVOLQESGPGLVKPSLTSITCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Qy 61 KPSLKDRVITSRDTSKNQFSLKSSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 117
Db 61 NPSLKSRVITSRDTSKNQFSLKSSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 117

RESULT 10

US-11-012-353-70
; Sequence 70, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 70
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-70

Query Match 77.0%; Score 482.5; DB 7; Length 118;
Best Local Similarity 76.1%; Pred. No. 4.8e-36;
Matches 89; Conservative 12; Mismatches 15; Indels 1; Gaps 1;
Qy 2 VOLQESGPGLVKPSLTSITCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
Db 2 VOLQESGPGLVKPSLSLTSCTVSGYSITGGYLNWIRQPPGKLEWIGYINIDGNNYK 61
Qy 62 PSLKDRVITSRDTSKNQFSLKSSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 117

```

RESULT 13
US-11-054-515-1548
; Sequence 1548, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BlyS
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1548
; LENGTH: 250
;

```

```
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1548

Query Match      76.8%; Score 481.5; DB 7; Length 250;
Best Local Similarity 77.4%; Pred. No. 1.2e-35;
Matches 96; Conservative 6; Mismatches 15; Indels 7; Gaps 2;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCAVSGYSISGGYWGWRQPPGKLEWIGSYIHSGSTYY 60

Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAVVYCARY-----GRVF-PDYWGQGLTV 113
Db 61 NPSLSKRVTVISVDTSKNQFSLKLSVTAADTAVVYCARVHVDILTGLYLAEDINGQGTNV 120

Qy 114 TVSS 117
Db 121 TVSS 124

RESULT 14
US-11-012-353-72
; Sequence 72, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: Patentin Ver. 3.3
; SEQ ID NO 72
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MOD RES
; LOCATION: {59}
; OTHER INFORMATION: Variable amino acid
US-11-012-353-72

Query Match      75.4%; Score 473; DB 7; Length 117;
Best Local Similarity 79.5%; Pred. No. 3.2e-35;
Matches 93; Conservative 6; Mismatches 18; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSQTLSTLTCTVSGSVSSVSWNNWIRQPPGKLEWIGRIYSGSTXY 60

Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117
Db 61 NPSLSKRVTVISVDTSKNQFSLKLSVTAADTAVVYCARLPGDYDVGQGLTVTVSS 117

RESULT 15
US-11-102-201-1
; Sequence 1, Application US/11102201
; Publication No. US20050265994A1
; GENERAL INFORMATION:
; APPLICANT: MANTYH, Patrick W.
; APPLICANT: SHELTON, David L.
; TITLE OF INVENTION: METHODS FOR TREATING BONE CANCER PAIN BY
; TITLE OF INVENTION: ADMINISTERING A NERVE GROWTH FACTOR ANTAGONIST
; FILE REFERENCE: 51471-20021.00
; CURRENT APPLICATION NUMBER: US/11/102,201
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: US 60/620,654
; PRIOR FILING DATE: 2004-10-19
; PRIOR APPLICATION NUMBER: US 60/560,781
; PRIOR FILING DATE: 2004-04-07
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-11-102-201-1

Query Match      75.4%; Score 473; DB 7; Length 120;
Best Local Similarity 78.5%; Pred. No. 3.3e-35;
Matches 95; Conservative 7; Mismatches 13; Indels 6; Gaps 2;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGFSLI-GYDLNWIROPFGKLEWIGIWDGTTDY 59

Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAVVYCARYG-----RVFFDYWGQGLTVTV 115
Db 60 NSAVKSRVTISKDTSKNQFSLKLSVTAADTAVVYCARGGYWYATSYFFDYWGQGLTVTV 119

Qy 116 S 116
Db 120 S 120

Search completed: January 10, 2006, 21:36:24
Job time : 5.96642 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:53:43 ; Search time 64.1754 Seconds
(without alignments)
761.757 Million cell updates/sec

Title: US-10-735-916A-79

Perfect score: 627

Sequence: 1 QVQLQESGPGLVKPESETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : Published Applications AA Main:

- 1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pcp.*
- 2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pcp.*
- 3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pcp.*
- 4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pcp.*
- 5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pcp.*
- 6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pcp.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	627	100.0	117	5	US-10-735-916A-79
2	627	100.0	135	5	US-10-735-916A-81
3	623	99.4	117	5	US-10-735-916A-75
4	623	99.4	135	5	US-10-735-916A-77
5	615	98.1	117	5	US-10-735-916A-83
6	615	98.1	135	5	US-10-735-916A-85
7	541	86.3	117	5	US-10-735-916A-69
8	541	86.3	127	5	US-10-735-916A-52
9	526.5	84.0	120	4	US-10-383-447-26
10	507	80.9	119	4	US-10-309-762-143
11	506.5	80.8	120	4	US-10-383-447-24
12	504.5	80.5	118	4	US-10-292-088-109
13	503.5	80.3	120	4	US-10-383-447-28
14	503.5	80.3	121	5	US-10-805-177-56
15	503.5	80.3	122	4	US-10-309-762-25
16	503.5	80.3	122	4	US-10-309-762-29
17	502.5	80.1	120	4	US-10-309-762-128
18	500.5	79.8	116	4	US-10-309-762-127
19	500.5	79.8	121	4	US-10-010-729-11
20	500.5	79.8	122	4	US-10-309-762-24
21	500.5	79.8	122	4	US-10-309-762-27
22	500	79.7	119	5	US-10-125-687-5
23	500	79.7	119	5	US-10-996-191-5
24	500	79.7	121	4	US-10-292-088-82
25	500	79.7	466	4	US-10-292-088-86
26	498	79.4	119	5	US-10-537-596-23
27	497	79.3	117	5	US-10-890-945-2

28	497	79.3	121	4	US-10-292-088-98
29	497	79.3	466	4	US-10-292-088-70
30	497	79.3	580	4	US-10-310-719-35
31	497	79.3	580	4	US-10-310-719-37
32	495.5	79.0	122	5	US-10-984-960A-20
33	495.5	79.0	139	5	US-10-893-576-39
34	494.5	78.9	121	5	US-10-805-177-2
35	494.5	78.9	169	5	US-10-805-177-114
36	494	78.8	121	4	US-10-292-088-66
37	493.5	78.7	116	5	US-10-822-306A-5
38	493.5	78.7	116	5	US-10-822-306A-14
39	493	78.6	123	4	US-10-309-762-10
40	492.5	78.5	118	4	US-10-309-762-138
41	492.5	78.5	118	5	US-10-706-689-10
42	492.5	78.5	118	5	US-10-988-360-10
43	491.5	78.4	116	5	US-10-822-306A-9
44	491.5	78.4	116	5	US-10-822-306A-11
45	491.5	78.4	118	4	US-10-292-088-142

ALIGNMENTS

RESULT 1
US-10-735-916A-79
; Sequence 79, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10735-916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 79
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-79

Query Match	100.0%;	Score 627;	DB 5;	Length 117;
Best Local Similarity	100.0%;	Pred. No. 8.7e-48;		
Matches	117;	Conservative	0;	Mismatches 0;
			Indels	0;
			Gaps	0;
QY	1	QVQLQESGPGLVKPESETLSLCTVSGYSITGGLWNWIRQPPGKLEWIGYISYDGTNNY	60	
DB	1	QVQLQESGPGLVKPESETLSLCTVSGYSITGGLWNWIRQPPGKLEWIGYISYDGTNNY	60	
QY	61	KPSLKDRVTISGRDTSKNQFSKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS	117	
DB	61	KPSLKDRVTISGRDTSKNQFSKLSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS	117	
RESULT 2				
US-10-735-916A-81				
; Sequence 81, Application US/10735916A				
; Publication No. US20050084906A1				

```

; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 81
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-81

Query Match 100.0%; Score 627; DB 5; Length 135;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 3
US-10-735-916A-75
; Sequence 75, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 75
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-75

Query Match 100.0%; Score 627; DB 5; Length 135;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 4
US-10-735-916A-77
; Sequence 77, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 77
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-77

Query Match 99.4%; Score 623; DB 5; Length 135;
Best Local Similarity 98.3%; Pred. No. 2.3e-47;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78

Qy 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 5
US-10-735-916A-83
; Sequence 83, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
```


FILE REFERENCE: 017753-183
CURRENT APPLICATION NUMBER: US/10/735,916A
CURRENT FILING DATE: 2003-12-16
PRIOR APPLICATION NUMBER: FR 03/08 538
PRIOR FILING DATE: 2003-07-11
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
PRIOR FILING DATE: 2003-01-20
PRIOR APPLICATION NUMBER: FR 02/00 653
PRIOR FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: FR 02/00 654
PRIOR FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: FR 02/05 753
PRIOR FILING DATE: 2002-05-07
NUMBER OF SEQ ID NOS: 156
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 83
LENGTH: 117
TYPE: PRT
ORGANISM: Homo sapiens
US-10-735-916A-83

Query Match 98.1%; Score 615; DB 5; Length 117;
Best Local Similarity 98.3%; Pred. No. 9.9e-47;
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWIGYISYDGTNNY 60

QY 61 KPSLKDRTVTSRDTSKNQFSLKSSVTAADTAVVYCYGRVFFDYWGQGLTVTVSS 117
DB 61 KPSLKDRTVTSRDTSKNQFSLKSSVTAADTAVVYCYGRVFFDYWGQGLTVTVSS 117

RESULT 6
US-10-735-916A-85
Sequence 85, Application US/10735916A
Publication No. US20050084906A1
GENERAL INFORMATION:
APPLICANT: GOETSCH, Liliane
APPLICANT: CORVAIA, Nathalie
APPLICANT: LEGER, Olivier
APPLICANT: DUFLOS, Alain
APPLICANT: BECK, Alain
APPLICANT: HAEUW, Jean-Francois
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USBS THEREOF
FILE REFERENCE: 017753-183
CURRENT APPLICATION NUMBER: US/10/735,916A
PRIOR FILING DATE: 2003-12-16
PRIOR APPLICATION NUMBER: FR 03/08 538
PRIOR FILING DATE: 2003-07-11
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
PRIOR FILING DATE: 2003-01-20
PRIOR APPLICATION NUMBER: FR 02/00 653
PRIOR FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: FR 02/00 654
PRIOR FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: FR 02/05 753
NUMBER OF SEQ ID NOS: 156
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 85
LENGTH: 135
TYPE: PRT
ORGANISM: Homo sapiens
US-10-735-916A-85

Query Match 98.1%; Score 615; DB 5; Length 135;
Best Local Similarity 98.3%; Pred. No. 1.1e-46;
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWIGYISYDGTNNY 60

DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWIGYISYDGTNNY 78
QY 61 KPSLKDRTVTSRDTSKNQFSLKSSVTAADTAVVYCYGRVFFDYWGQGLTVTVSS 117
DB 79 KPSLKDRTVTSRDTSKNQFSLKSSVTAADTAVVYCYGRVFFDYWGQGLTVTVSS 135

RESULT 7
US-10-735-916A-69
Sequence 69, Application US/10735916A
Publication No. US20050084906A1
GENERAL INFORMATION:
APPLICANT: GOETSCH, Liliane
APPLICANT: CORVAIA, Nathalie
APPLICANT: LEGER, Olivier
APPLICANT: DUFLOS, Alain
APPLICANT: BECK, Alain
APPLICANT: HAEUW, Jean-Francois
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
FILE REFERENCE: 017753-183
CURRENT APPLICATION NUMBER: US/10/735,916A
PRIOR FILING DATE: 2003-12-16
PRIOR APPLICATION NUMBER: FR 03/08 538
PRIOR FILING DATE: 2003-07-11
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
PRIOR FILING DATE: 2003-01-20
PRIOR APPLICATION NUMBER: FR 02/00 653
PRIOR FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: FR 02/00 654
PRIOR FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: FR 02/05 753
PRIOR FILING DATE: 2002-05-07
NUMBER OF SEQ ID NOS: 156
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 69
LENGTH: 117
TYPE: PRT
ORGANISM: Mus musculus
US-10-735-916A-69

Query Match 86.3%; Score 541; DB 5; Length 117;
Best Local Similarity 84.5%; Pred. No. 3.4e-40;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

QY 2 VQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWIGYISYDGTNNYK 61
DB 2 VQLQESGPGLVKPSQSLSLTCTVSGYSITGGYLNWIRQPPGKGLWIGYISYDGTNNYK 61

QY 62 PSLKDRTVTSRDTSKNQFSLKSSVTAADTAVVYCYGRVFFDYWGQGLTVTVSS 117
DB 62 PSLKDRTVTSRDTSKNQFSLKSSVTAADTAVVYCYGRVFFDYWGQGLTVTVSS 117

RESULT 8
US-10-735-916A-52
Sequence 52, Application US/10735916A
Publication No. US20050084906A1
GENERAL INFORMATION:
APPLICANT: GOETSCH, Liliane
APPLICANT: CORVAIA, Nathalie
APPLICANT: LEGER, Olivier
APPLICANT: DUFLOS, Alain
APPLICANT: BECK, Alain
APPLICANT: HAEUW, Jean-Francois
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
FILE REFERENCE: 017753-183
CURRENT APPLICATION NUMBER: US/10/735,916A
CURRENT FILING DATE: 2003-12-16
PRIOR APPLICATION NUMBER: FR 03/08 538
PRIOR FILING DATE: 2003-07-11
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
PRIOR FILING DATE: 2003-01-20
PRIOR APPLICATION NUMBER: FR 02/00 653

```
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 52
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-735-916A-52

Query Match      86.3%; Score 541; DB 5; Length 127;
Best Local Similarity 84.5%; Pred. No. 3.7e-40;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

Qy  2  VQLQESGGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db  12  VQLQESGGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 71

Qy  62  PSLKDRVTISRDTSKNQFSLKSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 117
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db  72  PSLKDRVTISRDTSKNQFSLKSSVTAADTAVYYCARYGRVFFDYWGQGLTVTVSS 127

RESULT 9
US-10-383-447-26
; Sequence 26, Application US/10383447
; Publication No. US20040096392A1
; GENERAL INFORMATION:
; APPLICANT: Bhaekar, Vinay
; APPLICANT: de la Calle, Agustín
; APPLICANT: Law, Debbie
; APPLICANT: Caras, Ingrid
; APPLICANT: Ramakrishnan, Vanitha
; APPLICANT: Murray, Richard
; APPLICANT: Afar, Daniel
; APPLICANT: Powers, David
; TITLE OF INVENTION: Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
; FILE REFERENCE: 05882.0138.NPUS00
; CURRENT APPLICATION NUMBER: US/10/383,447
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: US 60/362,837
; PRIOR FILING DATE: 2002-03-08
; PRIOR APPLICATION NUMBER: US 60/463,812
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Variable heavy chain region 3.0
US-10-383-447-26

Query Match      84.0%; Score 526.5; DB 4; Length 120;
Best Local Similarity 84.0%; Pred. No. 6.7e-39;
Matches 100; Conservative 6; Mismatches 10; Indels 3; Gaps 1;

Qy  2  VQLQESGGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db  2  VQLQESGGLVKPSETLSLTCAVSGYSITSGYNSWIRQPPGKLEWIGYISYDGSNNYK 61

Qy  62  PSLKDRVTISRDTSKNQFSLKSSVTAADTAVYYCA---RYGRVFFDYWGQGLTVTVSS 117
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db  62  PSLKDRVTISRDTSKNQFSLKSSVTAADTAVYYCARGLRGRDYSMDYWGQGLTVTVSS 120

RESULT 10
US-10-309-762-143
; Sequence 143, Application US/10309762
```

```
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Foltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX
; FILE REFERENCE: AGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 143
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-143

Query Match      80.9%; Score 507; DB 4; Length 119;
Best Local Similarity 83.3%; Pred. No. 3.5e-37;
Matches 100; Conservative 5; Mismatches 11; Indels 4; Gaps 2;

Qy  1  QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db  1  QVQLQESGPGLVKPSSETLSLTCTVSGGSIS--SYTWSWIRQPPGKLEWIGYIYSGSTNY 59

Qy  61  KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVYYCARYGRV---FFDYWGQGLTVTVSS 117
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db  60  NPSLKSRVTISVDTSKNQFSLKSSVTAADTAVYYCARYDILTYGYFDYWGQGLTVTVSS 119

RESULT 11
US-10-383-447-24
; Sequence 24, Application US/10383447
; Publication No. US20040096392A1
; GENERAL INFORMATION:
; APPLICANT: Bhaekar, Vinay
; APPLICANT: de la Calle, Agustín
; APPLICANT: Law, Debbie
; APPLICANT: Caras, Ingrid
; APPLICANT: Ramakrishnan, Vanitha
; APPLICANT: Murray, Richard
; APPLICANT: Afar, Daniel
; APPLICANT: Powers, David
; TITLE OF INVENTION: Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
; FILE REFERENCE: 05882.0138.NPUS00
; CURRENT APPLICATION NUMBER: US/10/383,447
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: US 60/362,837
; PRIOR FILING DATE: 2002-03-08
; PRIOR APPLICATION NUMBER: US 60/463,812
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 24
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Variable heavy chain region 2.0
US-10-383-447-24

Query Match      80.8%; Score 506.5; DB 4; Length 120;
Best Local Similarity 79.8%; Pred. No. 3.9e-37;
Matches 95; Conservative 10; Mismatches 11; Indels 3; Gaps 1;

Qy  2  VQLQESGGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db  2  VQLQESGGLVKPSETLSLTCAVTGYTSITSGYNSWIRQPPGKLEWIGYISYDGSNNYK 61
```



```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-25

Query Match      80.3%; Score 503.5; DB 4; Length 122;
Best Local Similarity 82.1%; Pred. No. 7,3e-37;
Matches 101; Conservative 3; Mismatches 12; Indels 7; Gaps 2;

QY      1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGCGYLNWIRQPPGKGLEWIGYISYDGTNNY 60
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-syyWSWIRQPPGKGLEWIGYIYSGSTNY 59
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY      61 KPSLKDRVTIISDTSKNQFSLKLSVTAADTAVYYCARYGRVF-----FDYWGQGTLVLT 114
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      60 NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVYYCARRGYDFLTGTDYFDYWGQGTLVLT 119
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY      115 VSS 117
      |||
Db      120 VSS 122
```

Search completed: January 10, 2006, 21:35:33
Job time : 65.1754 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:34:27 ; Search time 22.847 Seconds
(without alignments)
423.384 Million cell updates/sec

Title: US-10-735-916A-79
Perfect score: 627
Sequence: 1 QVQLGSGPLVKPSETLSL.....RYGRVFFDYWGQGLTLVTSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA:*
1: /cgn2_6/prodata/1/iaa/5 COMB.pep.*
2: /cgn2_6/prodata/1/iaa/6 COMB.pep.*
3: /cgn2_6/prodata/1/iaa/H COMB.pep.*
4: /cgn2_6/prodata/1/iaa/PCUS COMB.pep.*
5: /cgn2_6/prodata/1/iaa/RE COMB.pep.*
6: /cgn2_6/prodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	500	79.7	119	2	US-09-025-769B-39
2	500	79.7	119	2	US-09-025-769B-65
3	500	79.7	119	2	US-09-490-070A-39
4	500	79.7	119	2	US-09-490-070A-65
5	500	79.7	119	2	US-09-490-153-39
6	500	79.7	119	2	US-09-490-153-65
7	500	79.7	119	2	US-09-490-324-39
8	500	79.7	119	2	US-09-490-324-65
9	497	79.3	117	2	US-09-720-493-2
10	487	77.7	117	2	US-10-330-613A-13
11	486.5	77.6	473	2	US-09-049-672A-4
12	486	77.5	123	1	US-08-137-117D-64
13	486	77.5	123	1	US-08-436-717-64
14	486	77.5	138	1	US-08-137-117D-69
15	486	77.5	138	1	US-08-436-717-69
16	483.5	77.1	118	2	US-09-025-769B-25
17	483.5	77.1	118	2	US-09-490-070A-25
18	483.5	77.1	118	2	US-09-490-153-25
19	483.5	77.1	118	2	US-09-490-324-25
20	482.5	77.0	244	2	US-08-918-148-79
21	482.5	77.0	244	2	US-09-138-091A-77
22	475	75.8	118	2	US-09-065-059-11
23	475	75.8	118	2	US-08-913-555-11
24	475	75.8	121	2	US-10-330-613A-1
25	475	75.8	121	2	US-10-330-613A-17
26	474.5	75.7	487	2	US-09-800-729-145
27	473	75.4	117	2	US-10-330-613A-5

28	472.5	75.4	118	2	US-09-343-698-6	Sequence 6, Appli
29	472.5	75.4	118	2	US-08-325-955-6	Sequence 6, Appli
30	471.5	75.2	832	2	US-08-630-820-7	Sequence 7, Appli
31	471.5	75.2	832	2	US-09-273-453-7	Sequence 9, Appli
32	471	75.1	121	2	US-10-330-613A-9	Sequence 5, Appli
33	470	75.0	119	1	US-08-360-125-5	Sequence 5, Appli
34	470	75.0	119	1	US-08-450-578-5	Sequence 5, Appli
35	470	75.0	119	1	US-09-017-628-5	Sequence 5, Appli
36	470	75.0	119	2	US-09-014-880-5	Sequence 5, Appli
37	470	75.0	119	2	US-08-450-363-5	Sequence 5, Appli
38	470	75.0	119	2	US-09-467-903-5	Sequence 837, App
39	468.5	74.7	139	2	US-09-471-276-837	Sequence 3, Appli
40	468.5	74.7	278	2	US-09-260-527-3	Sequence 2, Appli
41	467	74.3	142	1	US-08-480-774A-2	Sequence 13, Appli
42	466	74.3	121	1	US-08-275-053-13	Sequence 11, Appli
43	465.5	74.2	122	1	US-08-360-125-11	Sequence 11, Appli
44	465.5	74.2	122	1	US-08-450-578-11	Sequence 11, Appli
45	465.5	74.2	122	1	US-09-017-628-11	Sequence 11, Appli

ALIGNMENTS

RESULT 1
US-09-025-769B-39
; Sequence 39, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-025-769B-39

Query Match 79.7%; Score 500; DB 2; Length 119;
Best Local Similarity 83.3%; Pred. No. 4.6e-42;
Matches 100; Conservative 4; Mismatches 12; Indels 4; Gaps 2;


```
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-490-153-65

Query Match 79.7%; Score 500; DB 2; Length 119;
Best Local Similarity 83.3%; Pred. No. 4.6e-42;
Matches 100; Conservative 4; Mismatches 12; Indels 4; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59

QY 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVYYCARYGRVFF---DYWGQGLTLVTYSS 117
DB 60 NPSLSKRVITISVDTSKNQFSLKSSVTAADTAVYYCARWGGDGFYAMDYWGQGLTLVTYSS 119

RESULT 7
US-09-490-324-39
; Sequence 39, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 39:

US-09-490-324-39

Query Match 79.7%; Score 500; DB 2; Length 119;
Best Local Similarity 83.3%; Pred. No. 4.6e-42;
Matches 100; Conservative 4; Mismatches 12; Indels 4; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59

QY 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVYYCARYGRVFF---DYWGQGLTLVTYSS 117
DB 60 NPSLSKRVITISVDTSKNQFSLKSSVTAADTAVYYCARWGGDGFYAMDYWGQGLTLVTYSS 119

RESULT 8
US-09-490-324-65
; Sequence 65, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-490-324-65

Query Match 79.7%; Score 500; DB 2; Length 119;
Best Local Similarity 83.3%; Pred. No. 4.6e-42;
Matches 100; Conservative 4; Mismatches 12; Indels 4; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59

QY 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVYYCARYGRVFF---DYWGQGLTLVTYSS 117
DB 60 NPSLSKRVITISVDTSKNQFSLKSSVTAADTAVYYCARWGGDGFYAMDYWGQGLTLVTYSS 119
```



```

Db      61  YNP SLKSRVTISVDTSKNQFSLKSLSSVTAADTAVVYCAREGD-GFDYWGQGLTVTVSS 111
RESULT 11
US-09-049-672A-4
; Sequence 4, Application US/09049672A
; Patent No. 6135941
; GENERAL INFORMATION:
; APPLICANT: Hillman, Jennifer L.
; APPLICANT: Lal, Preeti
; APPLICANT: Tang, Y. Tom
; APPLICANT: Yue, Henry
; APPLICANT: Au-Young, Janice
; APPLICANT: Corley, Neil C.
; APPLICANT: Guegler, Karl J.
; APPLICANT: Baughn, Mariah R.
; TITLE OF INVENTION: HUMAN IMMUNE SYSTEM ASSOCIATED PROTEINS
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/049,672A
; FILING DATE: HEREWITH
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Cerrone, Michael C
; REGISTRATION NUMBER: 39,132
; REFERENCE/DOCKET NUMBER: PF-0497 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-855-0555
; TELEFAX: 650-845-4166
; TELEX:
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 473 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; LIBRARY: PANTUT01
; CLONE: 1513264
US-09-049-672A-4

Query Match      77.6%; Score 486.5; DB 2; Length 473;
Best Local Similarity 78.7%; Pred. No. 5.1e-40;
Matches 100; Conservative 2; Mismatches 12; Indels 13; Gaps

Qy      1  QVQLQESGPGLVKPSETLSITCTVSGYSIT-GGYLWNWIRPPGKGLEWIGYISYDGTNN 5
Db      20  QVQLQESGPGLVKPSETLSITCAVSGSITSGGYWISWIRPPGKGLEWIGYIYSGSTL 7
Qy      60  YKPSLKDRTVTSRDTSKNQFSLKSLSSVTAADTAVVYCAREG-----YGRVFDYWGQ 1
Db      80  YNP SLKSRVTISVDTSKNQFSLKSLSSVTAADTAVVYCAREG-----MDVWGQ 1
Qy      111  TLTVTVSS 117
Db      137  TLTVTVSS 143

```

```
RESULT 12
US-08-137-117D-64
; Sequence 64, Application US/08137117D
; Patent No. 5795965
; GENERAL INFORMATION:
; APPLICANT: TSUCHIYA, Masayuki
; APPLICANT: BENDIG, Steven
; APPLICANT: SATO, Koh
; APPLICANT: JONES, Steven
; APPLICANT: SALDANHA, Jose
; TITLE OF INVENTION: RESHAPED HUMAN ANTIBODY TO HUMAN
; TITLE OF INVENTION: INTERLEUKIN-6 RECEPTOR
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/137,117D
; FILING DATE: 20-DEC-1993
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO PCT/JP92/00544
; FILING DATE: 24-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 4-32084
; FILING DATE: 19-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 3-95476
; FILING DATE: 25-APR-1991
; NAME: WEGNER, Harold C.
; REGISTRATION NUMBER: 25,258
; REFERENCE/DOCKET NUMBER: 53466/126/AAOK
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 123 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-137-117D-64

Query Match 77.5%; Score 486; DB 1; Length 123;
Best Local Similarity 77.3%; Pred. No. 1.1e-40;
Matches 92; Conservative 9; Mismatches 16; Indels 2; Gaps 1;

QY 1 QVQLQESGPGLVKPSQTLCTVSGYSITGGYLWNIRQPPGKGLWIGYISYDGTNNY 60
Db 5 QVQLQESGPGLVKPSQTLCTVSGYSITSDHANSWVRQPPGKGLWIGYISYSGITTY 64

QY 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAAADTAIVYTCAR--YGRVFDYWGQGLTVTVSS 117
Db 65 NPSLKSRTVLMRLDTSKNQPSLRLSSVTAAADTAIVYTCARSLARTTAMDYWGQGLTVTVSS 123

RESULT 13
US-08-436-717-64
; Sequence 64, Application US/08436717
; Patent No. 5817790
; GENERAL INFORMATION:
; APPLICANT: TSUCHIYA, Masayuki
```

```
; APPLICANT: SATO, Koh
; APPLICANT: BENDIG, Steven
; APPLICANT: JONES, Steven
; APPLICANT: SALDANHA, Jose
; TITLE OF INVENTION: RESHAPED HUMAN ANTIBODY TO HUMAN
; TITLE OF INVENTION: INTERLEUKIN-6 RECEPTOR
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/436,717
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/137,117
; FILING DATE: 20-DEC-1993
; APPLICATION NUMBER: WO PCT/JP92/00544
; FILING DATE: 24-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 4-32084
; FILING DATE: 19-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 3-95476
; FILING DATE: 25-APR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: WEGNER, Harold C.
; REGISTRATION NUMBER: 25,258
; REFERENCE/DOCKET NUMBER: 53466/126/AAOK
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 123 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-436-717-64

Query Match 77.5%; Score 486; DB 1; Length 123;
Best Local Similarity 77.3%; Pred. No. 1.1e-40;
Matches 92; Conservative 9; Mismatches 16; Indels 2; Gaps 1;

QY 1 QVQLQESGPGLVKPSQTLCTVSGYSITGGYLWNIRQPPGKGLWIGYISYDGTNNY 60
Db 5 QVQLQESGPGLVKPSQTLCTVSGYSITSDHANSWVRQPPGKGLWIGYISYSGITTY 64

QY 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAAADTAIVYTCAR--YGRVFDYWGQGLTVTVSS 117
Db 65 NPSLKSRTVLMRLDTSKNQPSLRLSSVTAAADTAIVYTCARSLARTTAMDYWGQGLTVTVSS 123

RESULT 14
US-08-137-117D-69
; Sequence 69, Application US/08137117D
; Patent No. 5795965
; GENERAL INFORMATION:
; APPLICANT: TSUCHIYA, Masayuki
; APPLICANT: SATO, Koh
; APPLICANT: BENDIG, Steven
; APPLICANT: JONES, Steven
; APPLICANT: SALDANHA, Jose
```


THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:28:02 ; Search time 14.1157 Seconds
(without alignments)
797.508 Million cell updates/sec

Title: US-10-735-916A-79
Perfect score: 627
Sequence: 1 QVQLQESGPGLVKPKSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 80:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	509	81.2	140	2 I37782	Ig variable region
2	494	78.8	130	2 S31690	Ig heavy chain V r
3	481	76.7	123	2 S30530	Ig heavy chain V r
4	478	76.2	147	2 S13519	Ig heavy chain V r
5	469.5	74.9	118	2 S24443	Ig heavy chain V r
6	468	74.6	155	2 S31511	Ig heavy chain - h
7	463.5	73.9	130	2 S30534	Ig heavy chain V r
8	463.5	73.9	139	2 S31586	Ig heavy chain V r
9	462.5	73.8	129	2 S44114	Ig heavy chain V r
10	462	73.7	155	2 S31512	Ig heavy chain - h
11	461.5	73.6	140	2 S78052	Ig heavy chain pre
12	459.5	73.3	145	2 S78055	Ig heavy chain pre
13	458	73.0	121	2 S37200	Ig heavy chain V r
14	457	72.9	121	2 S44113	Ig heavy chain V r
15	456	72.7	140	2 A49045	Ig heavy chain V r
16	455.5	72.6	136	2 S07637	Ig heavy chain pre
17	455	72.6	135	2 S07637	Ig heavy chain pre
18	454	72.4	137	1 AVMS35	Ig heavy chain pre
19	453.5	72.3	116	2 S38718	Ig heavy chain V r
20	452.5	72.2	137	2 S31676	Ig heavy chain V r
21	452	72.1	146	2 S09711	Ig heavy chain V r
22	450.5	71.9	126	2 S47010	Ig heavy chain V4.
23	450	71.8	117	2 I28195	Ig heavy chain V r
24	447.5	71.4	118	2 S20780	Ig heavy chain V r
25	447	71.3	119	2 E25114	Ig heavy chain V r
26	446	71.1	140	2 A24770	hypothetical hybri
27	439.5	70.1	118	2 A26340	Ig heavy chain pre
28	439	70.0	119	2 C53285	Ig heavy chain V a
29	439	70.0	146	2 S09710	Ig heavy chain V r

ALIGNMENTS

RESULT 1

I37782
Ig variable region (VDJ) (clone T23-9) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 16-Feb-1996 #sequence_revision 13-Mar-1997 #text_change 23-Jul-1999
C:Accession: I37782; S25476
R:Demaision, C.; Chastagner, P.; Theze, J.; Zouali, M.
Proc. Natl. Acad. Sci. U.S.A. 91, 514-518, 1994
A>Title: Somatic diversification in the heavy chain variable region genes expressed by T
A:Reference number: A36876; MUID:94119917; PMID:8290556
A:Accession: I37782
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-140 <RES>
A:Cross-references: UNIPARC:UPI0000176B83; EMBL:X67906; NID:g33582; PIDN:CAA48104.1; PFI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:46-128/Domain: immunoglobulin homology <IMM>

Query Match 81.2%; Score 509; DB 2; Length 140;
Best Local Similarity 82.9%; Pred. No. 1.9e-39;
Matches 102; Conservative 4; Mismatches 9; Indels 8; Gaps 3;

QY	1	QVQLQESGPGLVKPKSETLSLCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY	60
Db	20	QVQLQESGPGLVKPKSETLSLCTVSGGSIS-SYYWSWIRQPPGKLEWIGYIYSGSTNY	78
QY	61	KPSLRDRTVTSRDTSKNQFSLKLSVTAADTAVYYCAR-----YGRVFFDYWGQGLTVT	114
Db	79	NPSLKSRTVISVDTSKNQFSLKLSVTAADTAVYYCARHNSSSWYGR-YFDYWGQGLTVT	137
QY	115	VSS 117	
Db	138	VSS 140	

RESULT 2

S31690
Ig heavy chain V region - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S31690
R:Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnel, C.
submitted to the EMBL Data Library, June 1992
A:Description: Mechanisms that generate human immunoglobulin diversity operate from the
A:Reference number: S31585
A:Accession: S31690
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-130 <CUI>
A:Cross-references: UNIPARC:UPI0000116471; EMBL:Z14199; NID:g30984; PIDN:CAA78568.1; PFI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin

F:20-102/Domain: immunoglobulin homology <IMM>

Query Match 78.8%; Score 494; DB 2; Length 130;
Best Local Similarity 78.6%; Pred. No. 4.1e-38;
Matches 99; Conservative 6; Mismatches 11; Indels 10; Gaps 3;
Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWIGYISYDGTNNY 60
Db QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYMSWSRQPPGKGLWIGYIYSGSTNY 64
Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAIVYCAR-----YGRV--FFDYWGQGT 111
Db 65 NPSLKSRVTISVDTSKNQFSLKLSVTAADTAIVYCARSSVLLWFGELLYFDYWGQGT 124
Qy 112 LVTSS 117
Db 125 LVTSS 130

RESULT 3

Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C:Date: 03-Mar-1994 #sequence_revision 10-Nov-1995 #text_change 16-Aug-1996
C:Accession: S30530
R:Marlette, X.
submitted to the EMBL Data Library, October 1992
A:Reference number: S30520
A:Accession: S30530
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-123 <MAR>
A:Cross-references: UNIPARC:UPI0000176C83; EMBL:Z18316
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 76.7%; Score 481; DB 2; Length 123;
Best Local Similarity 77.4%; Pred. No. 6e-37;
Matches 96; Conservative 7; Mismatches 13; Indels 8; Gaps 2;
Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSTSSGYWGIRQPPGKGLWIGSMFHSSTY 60
Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAIVYCARGV-----FFDYWGQGT 113
Db 61 NPSLKSRVTISVDTSKNQFSLKLSVTAADTAIVYCAR-GRYCSSTSCNWFDPWGQGT 119
Qy 114 TVSS 117
Db 120 TVSS 123

RESULT 4

Ig heavy chain V region precursor - human
C:Species: Homo sapiens (man)
C:Date: 25-Feb-1994 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S13519
R:Mortari, F.; Ochs, H.D.; Wedgwood, R.J.P.; Schroeder Jr., H.W.
Nucleic Acids Res. 19, 673, 1991
A:Title: Immunoglobulin variable heavy chain cDNA sequence from a patient with X-linked
A:Reference number: S13519; MUID:91187691; PMID:2011536
A:Accession: S13519
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-147 <MOR>
A:Cross-references: UNIPARC:UPI0000115EB5; EMBL:X56158; NID:g37724; PIDN:CAA39626.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:41-125/Domain: immunoglobulin homology <IMM>

Query Match 76.2%; Score 478; DB 2; Length 147;
Best Local Similarity 79.5%; Pred. No. 1.4e-36;
Matches 97; Conservative 5; Mismatches 14; Indels 6; Gaps 3;
Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSI-TGGYLNWIRQPPGKGLWIGYISYDGTNN 59
Db 27 QVQLQESGPGLVKPSSETLSLTCTVSGGSISSSSYWGIRQPPGKGLWIGIYISYSGSY 86
Qy 60 YKPSLKDRVTISRDTSKNQFSLKLSVTAADTAIVYCAR----YGRVFFDYWGQGT 115
Db 87 YNPSLKSRVTISVDTSKNQFSLKLSVTAADTAIVYCARPLWFGEL-FDYWGQGT 145
Qy 116 SS 117
Db 146 SS 147

RESULT 5

Ig heavy chain V region (VH4DJ) - human
C:Species: Homo sapiens (man)
C:Date: 22-Jan-1993 #sequence_revision 22-Jan-1993 #text_change 20-Jun-2000
C:Accession: S24443; S19667
R:Jones, P.F.
submitted to the EMBL Data Library, October 1991
A:Reference number: S24442
A:Accession: S24443
A:Molecule type: mRNA
A:Residues: 1-118 <JON>
A:Cross-references: UNIPARC:UPI0000115FE9; EMBL:X61650; NID:g37720; PIDN:CAA43831.1; PID
R:Marks, J.D.; Hoogenboom, H.R.; Bonnert, T.P.; McCafferty, J.; Griffiths, A.D.; Winter, J. Mol. Biol. 222, 581-597, 1991
A:Title: By-passing immunization. Human antibodies from V-gene libraries displayed on ph
A:Reference number: S19663; MUID:92085276; PMID:1748994
A:Accession: S19667
A:Molecule type: mRNA
A:Residues: 1-55, 57-118 <MAR>
A:Cross-references: UNIPARC:UPI0000176B52; EMBL:X61650
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-97/Domain: immunoglobulin homology <IMM>

Query Match 74.9%; Score 469.5; DB 2; Length 118;
Best Local Similarity 79.0%; Pred. No. 6.4e-36;
Matches 94; Conservative 6; Mismatches 16; Indels 3; Gaps 2;
Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSISFY-WGIRQPPGKGLWIGYISHRGSTDY 59
Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAIVYCAR--YGRVFFDYWGQGT 117
Db 60 NSSLSQSRVTISADTSKQFSLKLSVTAADTAIVYCARSPNSFFFGWGQGT 118

RESULT 6

Ig heavy chain - human
C:Species: Homo sapiens (man)
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 23-Jul-1999
C:Accession: S31511
R:Chastagner, P.; Demaison, C.; Theze, J.; Zouali, M.
submitted to the EMBL Data Library, December 1992
A:Description: Dominance of clonotypic patterns and variable gene usage of anti-DNA auto
A:Reference number: S31509
A:Accession: S31511
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-155 <CHA>
A:Cross-references: UNIPARC:UPI00001160FF; EMBL:X69866; NID:g33094; PIDN:CAA49500.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:47-129/Domain: immunoglobulin homology <IMM>

Query Match 74.6%; Score 468; DB 2; Length 155;
Best Local Similarity 76.6%; Pred. No. 1.2e-35;
Matches 95; Conservative 7; Mismatches 14; Indels 8; Gaps 3;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLYLNWIRQPPGKGLEWIGIISYDGTNNY 60
DB 33 QVQLQESGPGLVKPSSETLSLTCTVSGGIS-SYWSWIRQPPGKGLEWIGIYITGSATY 91
QY 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAATVAVYCARVGRV--PFDDY-----WGQGLTV 113
DB 92 NPPLKSRVTISVDTSKNQFSLKLSVTAADTAATVAVYCARGGGSSWIDYIGMDVWGQGLTV 151
QY 114 TVSS 117
DB 152 TVSS 155

RESULT 7
S30534
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C:Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 16-Aug-1996
C:Accession: S30534
R:Marlette, X.
submitted to the EMBL Data Library, October 1992
A:Reference number: S30520
A:Accession: S30534
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-130 <MAR>
A:Cross-references: UNIPARC:UPI0000113P45; EMBL:Z18320
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-99/Domain: immunoglobulin homology <IMM>

Query Match 73.9%; Score 463.5; DB 2; Length 130;
Best Local Similarity 73.1%; Pred. No. 2.5e-35;
Matches 95; Conservative 5; Mismatches 17; Indels 13; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSI-TGGLYLNWIRQPPGKGLEWIGIISYDGTNN 59
DB 1 QVQLQESGPGLVKPSQTLSTCTVSGGISISSGYSYWSWIRQPPGKGLEWIGRIYTSGSTN 60
QY 60 YKPSLKDRVTISRDTSKNQFSLKLSVTAADTAATVAVYCA-----RYGRVFFDYW 107
DB 61 YNPSLKSRVTISVDTSKNQFSLKLSVTAADTAATVAVYCARDKGGFWSGYVYTRNSRAAFDIW 120
QY 108 GQGLTVTVSS 117
DB 121 GQGLTVTVSS 130

RESULT 8
S31586
Ig heavy chain V region - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S31586
R:Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A:Description: Mechanisms that generate human immunoglobulin diversity operate from the
A:Reference number: S31585
A:Accession: S31586
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-139 <CUI>
A:Cross-references: UNIPARC:UPI000011646E; EMBL:Z14196; NID:G30978; PIDN:CAA78565.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:34-116/Domain: immunoglobulin homology <IMM>

Query Match 73.9%; Score 463.5; DB 2; Length 139;

Best Local Similarity 78.5%; Pred. No. 2.7e-35;
Matches 95; Conservative 5; Mismatches 16; Indels 5; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLYLNWIRQPPGKGLEWIGIISYDGTNNY 60
DB 20 QVQLQESGPGLVKPSSETLSLTCTVSGGIS-SYWSWIRQPPGKGLEWIGRIYTSGSTNY 78
QY 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAATVAVYCARYG-----RVFFDYWGQGLTVTVS 116
DB 79 NPPLKSRVTISVDTSKNQFSLKLSVTAADTAATVAVYCARGGGLGIRGAFDIWGQGLTVTVS 138
QY 117 S 117
DB 139 S 139

RESULT 9
S44114
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 24-May-2001
C:Accession: S44114
R:Hawkins, R.E.; Zhu, D.; Ovecka, M.; Winter, G.; Hamblin, T.J.; Stevenson, F.K.
submitted to the EMBL Data Library, March 1994
A:Description: Idiotypic vaccination against human B-cell lymphoma: rescue of variable r
A:Reference number: S44105
A:Accession: S44114
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-129 <HAW>
A:Cross-references: UNIPARC:UPI0000116639; EMBL:Z31579; NID:G472968; PIDN:CAA83451.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 73.8%; Score 462.5; DB 2; Length 129;
Best Local Similarity 73.4%; Pred. No. 3e-35;
Matches 91; Conservative 7; Mismatches 19; Indels 7; Gaps 1;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLYLNWIRQPPGKGLEWIGIISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGISISSNWSWIRQPPGKGLEWIGIYHSGSTNY 60
QY 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAATVAVYCARVGRV-----FDYWGQGLTV 113
DB 61 NPSPKSRVTISRDTSKNQFSLKLSVTAADTAATVAVYCARNDYDFWSGGDPPDYWGQGLTV 120
QY 114 TVSS 117
DB 121 TVSS 124

RESULT 10
S31512
Ig heavy chain - human
C:Species: Homo sapiens (man)
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 23-Jul-1999
C:Accession: S31512
R:Chastagner, P.; Demaison, C.; Theze, J.; Zouali, M.
submitted to the EMBL Data Library, December 1992
A:Description: Dominance of clonotypic patterns and variable gene usage of anti-DNA auto
A:Reference number: S31509
A:Accession: S31512
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-155 <CHA>
A:Cross-references: UNIPARC:UPI00001160F9; EMBL:X69860; NID:G33082; PIDN:CAA49494.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:47-129/Domain: immunoglobulin homology <IMM>

Query Match 73.7%; Score 462; DB 2; Length 155;
Best Local Similarity 75.0%; Pred. NO. 4.1e-35;

```
Matches 93; Conservative 6; Mismatches 17; Indels 8; Gaps 2;
Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60
Db 33 QVQLQESGPGLVKPSSETLSLTCTVSGGSGIS-SYVWSWIRQPPGKGLEWIGYIYTGSAFY 91
Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAATVYYCARYGRVF-----FDYWGQGLTV 113
Db 92 NPPIKSRVTISVDTSKQFSLKLSVSSVTAADTAATVYYCARGGSGISWYVYGHVDVWGQGITV 151
Qy 114 TVSS 117
Db 152 TVSS 155

RESULT 11
S78052
Ig heavy chain precursor V-D-J region (clone mAb 63VH) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 19-Nov-1997 #sequence_revision 05-Dec-1997 #text_change 23-Jul-1999
C:Accession: S78052; S23717
R:Harindranath, N.
A:Reference number: S78051
A:Reference number: S78052
A:Accession: S78052
A:Molecule type: mRNA
A:Residues: 1-140 <HAW>
A:Cross-references: UNIPARC:UPI0000115B89; EMBL:X54441; NID:g37815; PIDN:CAA38308.1; PID
R:Harindranath, N.; Goldfarb, I.S.; Ikematsu, H.; Buraistero, S.E.; Wilder, R.L.; Notkins
Int. Immunol. 3, 865-875, 1991
A:Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and h
patient.
A:Reference number: S23716; MUID:92031262; PMID:1718404
A:Accession: S23717
A:Molecule type: mRNA
A:Residues: 15-111 <HAW>
A:Cross-references: UNIPARC:UPI0000116417; EMBL:X54441
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:1-14/Domain: signal sequence (fragment) #status predicted <SIG>
F:15-140/Product: Ig heavy chain (fragment) #status predicted <MAT>
F:29-111/Domain: immunoglobulin homology <IMM>

Query Match 73.6%; Score 461.5; DB 2; Length 140;
Best Local Similarity 73.2%; Pred. No. 4.1e-35;
Matches 93; Conservative 7; Mismatches 16; Indels 11; Gaps 2;
Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60
Db 15 QVQLQWAGLLKPSSETLSLTCAVYGSFSGS-GYYWSWIRQPPGKGLEWIGIHNHSGSTNY 73
Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAATVYYCARYGRVF-----FDYWGQGLTV 110
Db 74 NPPLKSRVTISVDTSKQFSLKLSVSSVTAADTAATVYYCARGGSGVIRFLEWLLYPAPFYWGQGLTV 133
Qy 111 TLTVSS 117
Db 134 TLTVSS 140

RESULT 12
S78055
Ig heavy chain precursor V-D-J region (clone mAb 67VH) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 19-Nov-1997 #sequence_revision 05-Dec-1997 #text_change 23-Jul-1999
C:Accession: S78055; S23720
R:Harindranath, N.
A:Reference number: S78051
A:Reference number: S78055
A:Accession: S78055
A:Molecule type: mRNA
A:Residues: 1-145 <HAW>
A:Cross-references: UNIPARC:UPI0000115B8C; EMBL:X54445; NID:g37817; PIDN:CAA38312.1; PID
```

```
R:Harindranath, N.; Goldfarb, I.S.; Ikematsu, H.; Buraistero, S.E.; Wilder, R.L.; Notkins
Int. Immunol. 3, 865-875, 1991
A:Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and h
patient.
A:Reference number: S23716; MUID:92031262; PMID:1718404
A:Accession: S23720
A:Molecule type: mRNA
A:Residues: 18-115 <HAW>
A:Cross-references: UNIPARC:UPI00001769D2; EMBL:X54445
A:Note: the authors translated the codon GCA for residue 67 as Arg
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:1-17/Domain: signal sequence (fragment) #status predicted <SIG>
F:18-145/Product: Ig heavy chain (fragment) #status predicted <MAT>
F:32-115/Domain: immunoglobulin homology <IMM>

Query Match 73.3%; Score 459.5; DB 2; Length 145;
Best Local Similarity 72.7%; Pred. No. 6.5e-35;
Matches 93; Conservative 6; Mismatches 18; Indels 11; Gaps 2;
Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60
Db 18 QVQLQESGPGLVKPSSETLSLTCAVSGGSISSNWSWVRQPPGKGLEWIGIYHSGSTNY 77
Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAATVYYCAR-----YGR-VFFDYWGQGLTV 109
Db 78 NPPLKSAVTISVDTSKQFSLKLSVTAADTAATVYYCARVTGTFWSGYTRGYFDYWGQGLTV 137
Qy 110 TLTVSS 117
Db 138 TLTVSS 145

RESULT 13
S37200
Ig heavy chain V region - mouse
C:Species: Mus musculus (house mouse)
C>Date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 21-Jan-2000
C:Accession: S37200
R:Fischer, R.; Voss, A.; Hunziker, W.; Stierhof, Y.D.; Kreuzaler, F.
submitted to the EMBL Data Library, August 1993
A:Description: Production and cloning of TMV-specific monoclonal antibodies.
A:Reference number: S37200
A:Accession: S37200
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-121 <FIS>
A:Cross-references: UNIPARC:UPI00001161AC; EMBL:X74587; NID:g402639; PID:g402640
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 73.0%; Score 458; DB 2; Length 121;
Best Local Similarity 71.7%; Pred. No. 7.3e-35;
Matches 86; Conservative 13; Mismatches 17; Indels 4; Gaps 1;
Qy 2 VQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYK 61
Db 2 VQLQESGPGLVKPSQSLSLTCSVTGYSITSSYYWNWIRQPPGKLEWNGYISYDGRNDYN 61
Qy 62 PSLKDRVTISRDTSKNQFSLKLSVTAADTAATVYYCARYGRV---FFDYWGQGLTVTVSS 117
Db 62 PSLKNRISITRDTSKNQFSLKNSVTEDTATYYCARGGIYGYDDYFDSWGQGLTVTVSS 121

RESULT 14
S44113
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 24-May-2001
C:Accession: S44113
R:Hawkins, R.E.; Zhu, D.; Ovecka, M.; Winter, G.; Hamblin, T.J.; Stevenson, F.K.
submitted to the EMBL Data Library, March 1994
A:Description: Idiotypic vaccination against human B-cell lymphoma: rescue of variable r
```


Search completed: January 10, 2006, 20:55:15
Job time : 14.1157 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:26:41 ; Search time 78.8731 Seconds
(without alignments)
1046.577 Million cell updates/sec

Title: US-10-735-916A-79
Perfect score: 627
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYWGQGITLVTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Uniprot 05.80.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	489	78.0	119	2 Q9UL73_HUMAN	Q9ul73 homo sapien
2	483.5	77.1	465	2 Q6GMX6_HUMAN	Q6gmx6 homo sapien
3	471	75.1	479	2 Q99M22_MOUSE	Q99m22 mus musculus
4	467	74.5	476	2 Q6GMX1_HUMAN	Q6gmx1 homo sapien
5	462.5	73.8	477	2 Q6GMX7_HUMAN	Q6gmx7 homo sapien
6	455.5	72.6	136	2 Q6LBQ5_MOUSE	Q6lbq5 mus musculus
7	455.5	72.6	483	2 Q5U413_MOUSE	Q5u413 mus musculus
8	454.5	72.5	150	2 Q95973_HUMAN	Q95973 homo sapien
9	454.5	72.5	576	2 Q6P418_HUMAN	Q6p418 homo sapien
10	454	72.4	137	1 HV46_MOUSE	P01822 mus musculus
11	447.5	71.4	620	2 Q96EY0_HUMAN	Q96ey0 homo sapien
12	447	71.3	119	2 Q53VQ5_MOUSE	Q53vq5 mus musculus
13	439.5	70.1	478	2 Q72379_HUMAN	Q72379 homo sapien
14	438	69.9	492	2 Q72374_HUMAN	Q72374 homo sapien
15	434.5	69.3	139	2 Q86SX2_HUMAN	Q86sx2 homo sapien
16	434.5	69.3	496	2 Q96KX8_HUMAN	Q96kx8 homo sapien
17	430.5	68.7	120	2 Q53VR7_MOUSE	Q53vr7 mus musculus
18	430	68.6	115	2 Q53VQ1_MOUSE	Q53vq1 mus musculus
19	430	68.6	615	2 Q569B6_RAT	Q569b6 rattus norv
20	428	68.3	590	2 Q569B8_RAT	Q569b8 rattus norv
21	427.5	68.2	146	1 HV21_HUMAN	P06331 homo sapien
22	425	67.8	119	2 Q53VR3_MOUSE	Q53vr3 mus musculus
23	424	67.6	595	2 Q8WUX4_HUMAN	Q8wux4 homo sapien
24	424	67.6	597	2 Q9BU10_HUMAN	Q9bu10 homo sapien
25	424	67.6	597	2 Q6GMX5_HUMAN	Q6gmx5 homo sapien
26	424	67.6	625	2 Q96AA6_HUMAN	Q96aa6 homo sapien
27	422	67.3	597	2 Q9BQB8_HUMAN	Q9bqb8 homo sapien
28	421	67.1	116	1 HV60_MOUSE	P18531 mus musculus
29	415	66.2	98	2 Q53VQ4_MOUSE	Q53vq4 mus musculus
30	413.5	65.9	130	2 Q81ZD7_HUMAN	Q81zd7 homo sapien
31	411	65.6	478	2 Q6NYH3_HUMAN	Q6nyh3 homo sapien

32	404	64.4	477	2 Q51QJ1_RAT	Q51qj1 rattus norv
33	403	64.3	119	2 Q53VQ3_MOUSE	Q53vq3 mus musculus
34	402	64.1	98	2 Q53VR6_MOUSE	Q53vr6 mus musculus
35	402	64.1	117	1 HV2G_HUMAN	P01825 homo sapien
36	398.5	63.6	591	2 Q51OL9_RAT	Q51ol9 rattus norv
37	397	63.3	98	2 Q53VR2_MOUSE	Q53vr2 mus musculus
38	397	63.3	469	2 Q5M839_RAT	Q5m839 rattus norv
39	395	63.0	98	2 Q53VQ0_MOUSE	Q53vq0 mus musculus
40	395	63.0	129	1 HV2F_HUMAN	P01824 homo sapien
41	394.5	62.9	122	1 HV2F_HUMAN	Q9ul75 homo sapien
42	393.5	62.8	116	2 Q723Y6_HUMAN	Q723y6 homo sapien
43	393	62.7	113	1 HV47_MOUSE	P01823 mus musculus
44	392	62.5	476	2 Q6MZX7_HUMAN	Q6mzx7 homo sapien
45	391.5	62.4	473	2 Q8TC63_HUMAN	Q8tc63 homo sapien

ALIGNMENTS

RESULT 1
Q9UL73_HUMAN
ID Q9UL73_HUMAN PRELIMINARY; PRT; 119 AA.
AC Q9UL73;
DT 01-MAY-2000 (Tremblrel. 13, Created)
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1660528;
RA Manheimer-Lory A., Katz J.B., Pillinger M., Ghousein C., Smith A., Diamond B.;
RT "Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype.";
RL J. Exp. Med. 174:1639-1652(1991).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=2511001;
RA Sanz I., Kelly P., Williams C., Scholl S., Tucker P., Capra J.D.;
RT "The smaller human VH gene families display remarkably little polymorphism.";
RL EMBO J. 8:3741-3748(1989).
DR EMBL; AF035041; AAD56277.1; -; mRNA.
DR PIR; PH0876; PH0876.
DR PIR; S12416; S12416.
DR HSSP; P01820; IG7J.
DR SMR; Q9UL73; 1-119.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 119
SQ SEQUENCE 119 AA; 13219 MW; 1BDB86B6420EA0BE CRC64;

Query Match 78.0%; Score 489; DB 2; Length 119;
Best Local Similarity 80.0%; Pred. No. 6.9e-43;
Matches 96; Conservative 7; Mismatches 13; Indels 4; Gaps 2;

```

Qy 1 QVQLQESGPGLVKPKSETSLTCTVSGYSITGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPKSETSLTCTVSGYSITGGYSIC-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59
Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAFTAVYCAR---YGRVFPDYWGQGLTIVTVSS 117
Db 60 TPSSLKSRVTISVDRSKNQFSLKLSVTAADTAFTAVYCARLSNNGPYFYDWGQGLTIVTVSS 119

RESULT 2
Q6GMX6_HUMAN
ID Q6GMX6_HUMAN PRELIMINARY; PRT; 465 AA.
AC Q6GMX6;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBSJ databases.
DR EMBL; BC073766; AAH3766.1; -; mRNA.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; CI-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 465 AA; 51083 MW; B3A9B7D0FDB1386E CRC64;

Query Match 77.1%; Score 483.5; DB 2; Length 465;
Best Local Similarity 82.1%; Pred. No. 1.2e-41;
Matches 96; Conservative 5; Mismatches 15; Indels 1; Gaps 1;

Qy 1 QVQLQESGPGLVKPKSETSLTCTVSGYSITGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPKSETSLTCTVSGYSITGGYLWNWIRQPPGKLEWIGYIYSGSTNY 59
Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAFTAVYCAR---YGRVFPDYWGQGLTIVTVSS 117
Db 60 TPSSLKSRVTISVDRSKNQFSLKLSVTAADTAFTAVYCARLSNNGPYFYDWGQGLTIVTVSS 119

RESULT 3
Q99M22_MOUSE
ID Q99M22_MOUSE PRELIMINARY; PRT; 479 AA.
AC Q99M22;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE LOC238447 protein.
GN Name=LOC238447;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Mix FVB/N;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Mix FVB/N;
RX NIH MGC Project;
RL Submitted (JAN-2001) to the EMBL/GenBank/DBSJ databases.
DR EMBL; BC002091; AAH02091.1; -; mRNA.
DR HSSP; P01820; 1G7J.
DR GO; GO:0003823; F:antigen binding; IEA.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; CI-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Immunoglobulin domain.
SQ SEQUENCE 479 AA; 51992 MW; 768E39A138918892 CRC64;

Query Match 75.1%; Score 471; DB 2; Length 479;
Best Local Similarity 74.1%; Pred. No. 2.4e-40;
Matches 86; Conservative 14; Mismatches 16; Indels 0; Gaps 0;

Qy 2 QVQLQESGPGLVKPKSETSLTCTVSGYSITGGYLWNWIRQPPGKLEWIGYISYDGTNNY 61
Db 20 QVQLQESGPGLVKPKSETSLTCTVSGYISYDGTNNY 79

```


Db 20 QVQLQSGPGLVKPSETLSLTCTVSGSGSIS-SYYWSWIRQTAGKLEWIGYISHSGSTTY 78
 QY 61 KPSLKDRTVTSRDTSKNQFSLKLSVTAADTAIVYCYGRVF---FDYWGQGLTVTVSS 117
 Db 79 NPSLSKRSVTLSDTSKNQFSLNSVTAADTAIVYCYA-HGSSWDPAFDYWGQGLTVTVSS 137

RESULT 6

OSLB05 MOUSE
 ID Q6LBQ5_MOUSE PRELIMINARY; PRT; 136 AA.
 AC Q6LBQ5;
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE VH gene product (Fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
 OC Muridae; Murinae; Mus.
 OC NCBI_TaxID=10090;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=90067954; PubMed=2587273;
 RA Urakov D.N., Deev S.M., Polyakovskiy O.L.;
 RT "The structure of the expressible VH gene from a hybridoma producing
 RT monoclonal antibodies against porcine transferrin.";
 RL Nucleic Acids Res. 17:9481-9481(1989).
 DR EMBL; X16740; CAA34714.1; -; Genomic_DNA.
 DR HSSP; P18532; 1KCV.
 DR SMR; Q6LBQ5; 20-136.
 DR InterPro; IPR003599; IG.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003596; IG_v.
 DR SMART; SM00409; IG; 1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS0835; IG LIKE; 1.
 FT NON TER 1
 SQ SEQUENCE 136 AA; 15307 MW; 5B0F439CCFB15C3A CRC64;

Query Match 72.6%; Score 455.5; DB 2; Length 136;
 Best Local Similarity 72.6%; Pred. No. 2.5e-39;
 Matches 85; Conservative 14; Mismatches 17; Indels 1; Gaps 1;

QY 2 VQLQSGPGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
 Db 20 VQLQSGPGLVKPQSLSLTCTVDFSTSGYHWHIRQPPGNKLEWIGYISYDGSNGYN 79
 QY 62 PSLKDRVTISRDTSKNQFSLKLSVTAADTAIVYCAR-YGRVFFDYWGQGLTVTVSS 117
 Db 80 PSLKNRISITRDTSKNQFSLKLSVTTEDTATYCTRGDGHFFTYWGQGLTVTVSA 136

RESULT 7

Q5U413 MOUSE
 ID Q5U413_MOUSE PRELIMINARY; PRT; 483 AA.
 AC Q5U413;
 DT 01-FEB-2005 (TrEMBLrel. 29, Created)
 DT 01-FEB-2005 (TrEMBLrel. 29, Last sequence update)
 DE LOC544903 protein.
 GN Name=LOC544903;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
 OC Muridae; Murinae; Mus.
 OC NCBI_TaxID=10090;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.

RC STRAIN=FVB/N; TISSUE=Colon;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.2426038899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altshul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,

RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Stapchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA DiStaple M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.A., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.S., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Pahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butlerfield V.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
 RN [2]
 RP NUCLEOTIDE SEQUENCE.

RC STRAIN=FVB/N; TISSUE=Colon;

RG NIH MGC Project;

RL Submitted (OCT-2004) to the EMBL/GenBank/DBJ databases.

DR EMBL; BC085312; AAH85312.1; -; mRNA.

DR Ensembl; ENSMUSG0000054328; Mus musculus.

DR GO; GO:0003823; P:antigen binding; IEA.

DR InterPro; IPR003599; IG.

DR InterPro; IPR007110; IG-like.

DR InterPro; IPR003597; IG.cl.

DR InterPro; IPR003006; IG_MHC.

DR InterPro; IPR003596; IG_v.

DR Pfam; PF07654; CI-set; 2.

DR SMART; SM00409; IG; 3.

DR SMART; SM00407; IGV; 3.

DR SMART; SM00406; IGV; 1.

DR PROSITE; PS0835; IG LIKE; 4.

DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.

SQ SEQUENCE 483 AA; 52714 MW; 7C272DA501A4A0D1 CRC64;

Query Match 72.6%; Score 455.5; DB 2; Length 483;

Best Local Similarity 72.3%; Pred. No. 1e-38;

Matches 86; Conservative 12; Mismatches 18; Indels 3; Gaps 1;

QY 2 VQLQSGPGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
 Db 20 VQLQSGPGLVKPQSLSLTCTVGYTSYSGHWHIRQPPGNKLEWIGYISYSGSNYN 79
 QY 62 PSLKDRVTISRDTSKNQFSLKLSVTAADTAIVYCYGRVF---FDYWGQGLTVTVSS 117
 Db 80 PSLKSRISITRDTSKNQFFLQNSVTTEDTATYCYRGEYNDYAMDYWGQGLTVTVSS 138

RESULT 8

O95973 HUMAN
 ID O95973_HUMAN PRELIMINARY; PRT; 150 AA.
 AC O95973;
 DT 01-MAY-1999 (TrEMBLrel. 10, Created)
 DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
 DE VH4 heavy chain variable region precursor (fragment).
 GN Name=IGH;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OC NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.

RA Suh C.-H., Song C.-H., Lee C.-H., Lee S.-K.;

RT "Clonal proliferation of IgM secreting B cell in the synovium of

RT Behcet's patient with arthritis.";

RL Submitted (OCT-1998) to the EMBL/GenBank/DBJ databases.

RN [2]

RP NUCLEOTIDE SEQUENCE.

```

RX PubMed=1718404;
RA Harindranath N., Goldfarb I.S., Ikematsu H., Burastero S.E.,
RA Wilder R.L., Notkins A.L., Casali P.;
RT "Complete sequence of the genes encoding the VH and VL regions of low-
RT and high-affinity monoclonal IgM and IgA1 rheumatoid factors produced
RT by CD5+ B cells from a rheumatoid arthritis patient.";
RL Int. Immunol. 3:865-875(1991).
DR EMBL; AF103795; AAC79084.1; -; mRNA.
DR PIR; S31673; S31673.
DR PIR; S78056; S78056.
DR HSSP; P01820; 1G7J.
DR SMR; O95973; 20-147.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Signal.
FT SIGNAL. 1 19 Potential.
FT CHAIN 20 >150 VH4 heavy chain variable region.
FT NON TER 150
FT SEQUENCE 150 AA; 16315 MW; 85664E804938AA7C9 CRC64;
SQ

Query Match 72.5%; Score 454.5; DB 2; Length 150;
Best Local Similarity 75.4%; Pred. No. 3.5e-39;
Matches 89; Conservative 9; Mismatches 19; Indels 1; Gaps 1;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITG-GYLWNWIRQPPGKLEWIGVISYDGTNN 59
DB 20 QLQLQESGPGLVKPSSETLSLTCTVSGGSSISTNYWGVIQPPGKLEWIGSLHNSGSDY 79

QY 60 YKPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCYARYGVFF--DYWGQGLTVTVSS 117
DB 80 YNPSLKSRVTISVDTSKQFSLRLSSVTAADTAVVYCYARLNGAFDFWGHGNTVTVSS 137

RESULT 9
Q6P4I8 HUMAN PRELIMINARY; PRT; 576 AA.
AC Q6P4I8;
DT 05-JUL-2004 (TREMBLrel. 27, Created)
DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
DE IGHD protein.
GN Name=IGHD;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Alteschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Ioshizuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S.E., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywicki M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RP Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

```

```

RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (DSC-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC063384; AAH63384.1; -; mRNA.
DR HSSP; P01820; 1A7N.
DR Ensembl; ENSG00000196122; Homo sapiens.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF07654; Cl-set; 1.
DR Pfam; PF00047; Ig; 2.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGV; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
SQ SEQUENCE 576 AA; 63364 MW; FBB97C949D720F1E CRC64;

Query Match 72.5%; Score 454.5; DB 2; Length 576;
Best Local Similarity 74.2%; Pred. No. 1.6e-38;
Matches 89; Conservative 8; Mismatches 20; Indels 3; Gaps 1;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITG-GYLWNWIRQPPGKLEWIGVISYDGTNNY 60
DB 27 QVQLQESGPGLVKPSSETLSLTCTVSGGSSISSNWSWVRQPPGKLEWIGELIYHSGSTNY 86

QY 61 KPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCYARYGVFF--DYWGQGLTVTVSS 117
DB 87 NPSLKSRVTISVDTSKQFSLKSSVTAADTAVVYCASLDGIYYGVMDVWGQGLTVTVSS 146

RESULT 10
HV46 MOUSE
ID HV46 MOUSE STANDARD; PRT; 137 AA.
AC P01822;
DT 21-JUL-1986 (Rel. 01, Created)
DT 01-AUG-1992 (Rel. 23, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V region MOPC 315 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridea; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC MEDLINE=89238351; PubMed=2497341; DOI=10.1016/0161-5890(89)90133-8;
RA Rinfret A., Horne C., Dorrington K.J., Klein M.;
RT "Cloning, sequencing and expression of the rearranged MOPC 315 VH gene
RT segment.";
RL Mol. Immunol. 26:431-434(1989).
RN [2]
RP PROTEIN SEQUENCE OF 1-31.
RX MEDLINE=78094475; PubMed=414225;
RA Jilka R.L., Pestka S.;
RT "Amino acid sequence of the precursor region of MOPC-315 mouse
RT immunoglobulin heavy chain.";
RL Proc. Natl. Acad. Sci. U.S.A. 74:5692-5696(1977).
RN [3]
RP PROTEIN SEQUENCE OF 1-21.
RX MEDLINE=79148758; PubMed=428562;
RA Schechter I., Wolf O., Zemall R., Burstein Y.;
RT "Structure and function of immunoglobulin genes and precursors.";
RL Fed. Proc. 38:1839-1845(1979).
RN [4]
RP PROTEIN SEQUENCE OF 19-136.
RX MEDLINE=74170779; PubMed=4524622;
RA Francis S.H., Leslie R.G.Q., Hood L., Eisen H.N.;
RT "Amino-acid sequence of the variable region of the heavy (alpha) chain

```

of a mouse myeloma protein with anti-hapten activity.";
Proc. Natl. Acad. Sci. U.S.A. 71:1123-1127(1974).

SEQUENCE REVISION TO 53;
MEDLINE=77244979; PubMed=268248;
Hood L., Margolies M.N., Givol D., Zakut R.;
Unpublished results, cited by:
Padlan E.A., Davies D.R., Peck I., Givol D., Wright C.;
Cold Spring Harb. Symp. Quant. Biol. 41:627-637(1977).
-I- MISCELLANEOUS: This alpha chain was isolated from a myeloma
protein that has anti-dinitrophenyl activity.

This Swiss-Prot entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use as long as its content is in no way modified and this statement is not
removed.

EMBL; M27638; AAA61337.1; -; Genomic DNA.

EMBL; X07880; CAA30727.1; -; Genomic DNA.

PIR; P0102; AVMS35.

HSP; P01820; IG7J.

SMR; P01822; 20-137.

Ensembl; ENSMUSG00000057049; Mus musculus.

InterPro; IPR007110; Ig-like.

SMART; SM00406; IGV; 1.

PROSITE; PS0835; IG_LIKE; 1.

Direct protein sequencing; Immunoglobulin domain;

Immunoglobulin V region; Signal.

SIGNAL 1 18

CHAIN 19 137 Ig heavy chain V region MOPC 315.

REGION 19 48 Framework-1.

REGION 49 54 Complementarity-determining-1.

REGION 55 68 Framework-2.

REGION 69 84 Complementarity-determining-2.

REGION 85 116 Framework-3.

REGION 117 126 Complementarity-determining-3.

REGION 127 137 Framework-4.

DISULFID 40 114 By similarity.

CONFLICT 15 15 G -> GG (in Ref. 1; CAA30727).

CONFLICT 15 15 G -> H (in Ref. 2).

CONFLICT 77 78 N -> YG (in Ref. 4).

CONFLICT 102 102 N -> D (in Ref. 4).

CONFLICT 123 123 Missing (in Ref. 4).

NON_TER 137 137

SEQUENCE 137 AA; 15399 MW; FB3828304C2B81DC CRC64;

Query Match 72.4%; Score 454; DB 1; Length 137;
Best Local Similarity 71.2%; Pred. No. 3.6e-39;
Matches 84; Conservative 14; Mismatches 18; Indels 2; Gaps 1;

2 VOLQESGGLVKPSETLSLCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61

20 VOLQESGGLVKPQSLTCTVSGYSITSGYFNWIRQPPGKLEWIGYIKYDGSNGYN 79

62 PSLKDRVTISRDTSKNQPSLKLSSVTAADTAVYYCA--RYGRVFFDYWGQGLTVTVSS 117

80 PSLKRVISITRDTSENQPFKLNSVTTEDTATYYCAGDNDHLYFPDYWGQGLTVTVSS 137

RESULT 11

ID Q96EY0 HUMAN PRELIMINARY; PRT; 620 AA.

AC Q96EY0;

DT 01-DEC-2001 (TrEMBLrel. 19, Created)

DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)

DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)

DE IGHM protein.

GN Name=IGHM;

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;

OC Homo.

NCBI_TaxID=9606;

RP NUCLEOTIDE SEQUENCE.

TISSUE=Primary B-Cells;

MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;

Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,

Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,

Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,

Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,

Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,

Brannstein M.J., Ugin T.B., Toshiyuki S., Carninci P., Prange C.,

Raba S.A., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,

Boesak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,

Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,

Villaillon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,

Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,

Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,

Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,

Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalios D.E.,

Schuerch A., Schein J.E., Jones S.J.M., Marra M.A.;

"Generation and initial analysis of more than 15,000 full-length human

and mouse cDNA sequences.";

Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

RP NUCLEOTIDE SEQUENCE.

TISSUE=Primary B-Cells;

NIH MGC Project;

Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.

[3]

RP NUCLEOTIDE SEQUENCE.

PubMed=1904154;

Neale G.A., Kitchingman G.R.;

"mRNA transcripts initiating within the human immunoglobulin mu heavy

chain enhancer region contain a non-translatable exon and are

extremely heterogeneous at the 5' end.";

Nucleic Acids Res. 19:2427-2433(1991).

EMBL; BC011857; AHH1857.2; -; mRNA.

PIR; S15590; S15590.

HSP; P01820; IG7J.

SMR; Q96EY0; 27-251.

Ensembl; ENSG00000130076; Homo sapiens.

InterPro; IPR003599; Ig-like.

InterPro; IPR007110; Ig-like.

InterPro; IPR003597; Ig.cl.

InterPro; IPR003006; Ig.MHC.

Pfam; PF07654; C1-set; 4.

SMART; SM00409; IG; 2.

SMART; SM00407; IGC1; 4.

SMART; SM00406; IGV; 1.

PROSITE; PS0835; IG_LIKE; 5.

PROSITE; PS00290; IG.MHC; UNKNOWN 3.

SEQUENCE 620 AA; 68125 MW; 990A1A4A6E8FF27B CRC64;

Query Match 71.4%; Score 447.5; DB 2; Length 620;
Best Local Similarity 76.9%; Pred. No. 9e-38;
Matches 93; Conservative 4; Mismatches 19; Indels 5; Gaps 2;

1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60

27 QVQLQESGPGLVKPSSETLSLCTVSGGSIS-SYTSWIRQAGKLEWIGYISYSGTNY 85

61 KPSLKDRVTISRDTSKNQPSLKLSSVTAADTAVYYCA----RYGRVFFDYWGQGLTVTVS 116

86 NPSLKSRVTSVSDTSKNQPSLKLSSVTAADTAVYYCASQPWELPTVGLFYWGQGLTVTVS 145

117 S 117

146 S 146


```
RESULT 12
Q53VQ5 MOUSE
ID Q53VQ5 MOUSE PRELIMINARY; PRT; 119 AA.
AC Q53VQ5
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE VH-D-JH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Some G., There J., Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
RT a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
RT antibodies in the GAT system.";
RL EMBO J. 4:3681-3688 (1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DDBJ databases.
DR EMBL; X03378; CAA27095.1; -; mRNA.
FT NON_TER 1
FT NON_TER 119
SQ SEQUENCE 119 AA; 13931 MW; 502E51A5213F056E CRC64;

Query Match 71.3%; Score 447; DB 2; Length 119;
Best Local Similarity 70.3%; Pred. No. 1.6e-38;
Matches 83; Conservative 14; Mismatches 13; Indels 8; Gaps 2;

QY 2 VOLQESGGLVKPSETLSLCTCTGYSITGGYLNWIRPPGKGLWIGYISYDGTNNYK 61
DB 2 VOLQESGGLVKPSETLSLCTCTGYSITGGYLNWIRPPGKGLWIGYISYDGTNNYK 61
QY 62 PSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCAR---RYGRVFF---DYGQGT 111
DB 62 PSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCAR---RYGRVFF---DYGQGT 111
QY 62 PSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCAR---RYGRVFF---DYGQGT 111
DB 62 PSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCAR---RYGRVFF---DYGQGT 111

RESULT 13
Q7Z379 HUMAN
ID Q7Z379 HUMAN PRELIMINARY; PRT; 478 AA.
AC Q7Z379
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein DKFZp686K04218 (Fragment).
GN Name=DKFZp686K04218;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX TISSUE=Human rectum tumor;
RA Bloecker H., Boecher M., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
DR EMBL; BX538066; CAD97996.1; -; mRNA.
DR HSSP; P01820; 1G7J.
DR SMR; Q7Z379; 248-456.
DR Ensemble; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein DKFZp686K04218 (Fragment).
GN Name=DKFZp686K04218;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX TISSUE=Human rectum tumor;
RA Bloecker H., Boecher M., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
DR EMBL; BX538066; CAD97996.1; -; mRNA.
DR HSSP; P01820; 1G7J.
DR SMR; Q7Z379; 248-456.
DR Ensemble; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; C1-set; 2.

Query Match 69.9%; Score 438; DB 2; Length 492;
Best Local Similarity 72.4%; Pred. No. 6.8e-37;
Matches 89; Conservative 8; Mismatches 18; Indels 8; Gaps 3;

QY 1 QVOLQESGGLVKPSETLSLCTCTGYSITG-GYLNWIRPPGKGLWIGYISYDGTNN 59
DB 32 QLQLOESGGLVKPSETLSLCTCTGYSITG-GYLNWIRPPGKGLWIGYISYDGTNN 91
QY 60 YKPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCAR-----YGRVFFDYGQGT 114
DB 92 YKPSLKDRVTISRDTSKNQFSLKSSVTAADTAVVYCAR-----YGRVFFDYGQGT 114
QY 115 VSS 117
```

```

Db          150 VSS 152
||||
RESULT 15
Q86SX2_HUMAN
ID Q86SX2_HUMAN PRELIMINARY; PRT; 139 AA.
AC Q86SX2;
DT 01-JUN-2003 (TReMBLrel. 24, Created)
DT 01-JUN-2003 (TReMBLrel. 24, Last sequence update)
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
DE Full-length cDNA clone CS0DL004YM19 of B cells (Ramos cell line) of
DE Homo sapiens (human) (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=B cells;
RA Li W.B., Gruber C., Jessee J., Polayes D.;
RL Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=B cells;
RA Genoscope;
RL Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
DR EMBL; BX248300; CAD62627.1; -; mRNA.
DR HSSP; F01820; 1G7J.
DR SMR; Q86SX2; 33-129.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
SQ SEQUENCE 139 AA; 15573 MW; 7D1E2302410E4F8C CRC64;

Query Match          69.3%; Score 434.5; DB 2; Length 139;
Best Local Similarity 86.7%; Pred. No. 3.9e-37;
Matches 85; Conservative 3; Mismatches 9; Indels 1; Gaps 1;

Qy 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSTGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60
Db |||||
Qy 33 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYVWSWIRQPPGKLEWIGYIYSGSTNY 91
Db |||||

Qy 61 KPSLKDRVTISRDTSKNQFSLKLSVTAADTAVYYCAR 98
Db |||||
Qy 92 NPSLKSRVTISRDTSKNQFSLKLSVTAADTAVYYCAR 129
Db |||||

Search completed: January 10, 2006, 20:53:27
Job time : 78.8731 secs

```

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:07:41 ; Search time 80.7649 Seconds
(without alignments)
636.505 Million cell updates/sec

Title: US-10-735-916A-79
Perfect score: 627
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_21.*
1: Geneseqp1980s.*
2: Geneseqp1990s.*
3: Geneseqp2000s.*
4: Geneseqp2001s.*
5: Geneseqp2002s.*
6: Geneseqp2003as.*
7: Geneseqp2003bs.*
8: Geneseqp2004s.*
9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	627	100.0	117	7	ADJ76913 Anti-IGF-
2	627	100.0	117	7	ADZ67083 Human ant
3	627	100.0	135	7	ADJ76915 Anti-IGF-
4	627	100.0	135	9	ADZ67085 Human ant
5	623	99.4	117	7	ADJ76909 Anti-IGF-
6	623	99.4	117	9	ADZ67079 Human ant
7	623	99.4	135	7	ADJ76911 Anti-IGF-
8	623	99.4	135	9	ADZ67081 Human ant
9	615	98.1	117	7	ADJ76917 Anti-IGF-
10	615	98.1	117	9	ADZ67087 Human ant
11	615	98.1	135	7	ADJ76919 Anti-IGF-
12	615	98.1	135	9	ADZ67089 Human ant
13	541	86.3	117	7	ADJ76903 Anti-IGF-
14	541	86.3	117	9	ADZ67073 Murine im
15	541	86.3	127	7	ADJ76886 Anti-IGF-
16	541	86.3	127	9	ADZ67056 Murine im
17	526.5	84.0	120	7	ADC27457 Humanised
18	509.5	81.3	246	3	AAY15126 Anti-mur1
19	507	80.9	119	7	ADP03973 Murine-ex
20	506.5	80.8	120	7	ADC27455 Humanised
21	506.5	80.8	121	8	ADSL6559 Human ant
22	503.5	80.3	120	7	ADC27459 Humanised
23	503.5	80.3	122	7	ADP03885 Murine-ex
24	503.5	80.3	122	7	ADP03889 Murine-ex

25	502.5	80.1	120	7	ADP03958	Adp03958 Murine-ex
26	500.5	79.8	116	7	ADP03957	Adp03957 Murine-ex
27	500.5	79.8	121	5	ABB07171	Abb07171 ebvHgm M
28	500.5	79.8	121	8	ADI26658	Adi26658 Human ant
29	500.5	79.8	122	7	ADP03887	Adp03887 Murine-ex
30	500.5	79.8	122	7	ADP03884	Adp03884 Murine-ex
31	500	79.7	119	2	AAW27554	Aaw27554 Human Ab
32	500	79.7	119	6	ABJ18676	Abj18676 Antibody
33	500	79.7	121	6	ABE28455	Abe28455 Human ant
34	500	79.7	466	7	ADE28479	Ade28479 Human ant
35	498	79.4	119	9	ADY74798	Ady74798 Human Igg
36	497	79.3	117	3	AAy44615	Aay44615 Human ant
37	497	79.3	121	7	ADE28491	Ade28491 Human ant
38	497	79.3	466	7	ADE28471	Ade28471 Human ant
39	497	79.3	580	6	AAO30915	Aao30915 dl-NHS76
40	497	79.3	580	6	AAO30913	Aao30913 dl-NHS76
41	495.5	79.0	122	9	AEA21456	Aea21456 Human ant
42	495.5	79.0	139	9	ADX98267	Adx98267 Human ant
43	494.5	78.9	121	8	ADS16505	Adsl6505 Human ant
44	494.5	78.9	169	8	ADS16613	Adsl6613 Human ant
45	494	78.8	121	7	ADE28447	Ade28447 Human ant

ALIGNMENTS

RESULT 1
ADJ76913
ID ADJ76913 standard; protein; 117 AA.
XX
AC ADJ76913;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-IGF-IR related protein #24.
XX
KW cytostatic; antipsoriatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDR.
XX
OS Homo sapiens.
XX
PN WO2003059951-A2.
XX
PD 24-JUL-2003.
XX
PF 20-JAN-2003; 2003WO-FR000178.
XX
PR 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
XX
PR 07-MAY-2002; 2002FR-00005753.
XX
PA (FABR) FABRE MEDICAMENT SA PIERRE.
PI
PI Goetsch L, Corvaia N, Leger O;
XX
WPI; 2003-569653/53.
XX
PT New antibodies that bind to human insulin-like growth factor receptor,
XX useful for treatment, prevention and diagnosis of cancers.
XX
PS Disclosure; SEQ ID NO 79; 164pp; French.
XX
CC The invention relates to an isolated antibody (Ab), and its functional
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
CC treat diseases associated with overexpression and/or abnormal activity of
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
CC hyperactivity of signal transduction pathways mediated by interaction of

CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.
 XX
 SQ Sequence 117 AA;

Query Match 100.0%; Score 627; DB 7; Length 117;
 Best Local Similarity 100.0%; Pred. No. 1.8e-48;
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60

DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60

QY 61 KPSLKDRVTISRDTSKNQFSLKLSVTTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 117

DB 61 KPSLKDRVTISRDTSKNQFSLKLSVTTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 117

RESULT 2
 ID ADZ67083 standard; protein; 117 AA.
 XX
 AC ADZ67083;

DT 30-JUN-2005 (first entry)

DE Human antibody 7C10 2 heavy chain variable region SEQ ID NO:79.

KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW heavy chain variable region.
 XX

OS Homo sapiens.

XX US2005084906-A1.

PN 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.

PR 07-MAY-2002; 2002FR-00005753.

PR 20-JAN-2003; 2003WO-FR000178.

PR 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.

PA (CORV/) CORVAIA N.

PA (LEGE/) LEGER O.

PA (DUF/) DUFLOS A.

PA (HAU/) HAEUW J.

PA (BECK/) BECK A.

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

XX WPI; 2005-321968/33.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-1R)
 PT antibody or its functional fragment, being capable of binding human IGF-
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,
 PT useful for treating cancer.
 XX
 XX Example 13; SEQ ID NO 79; 125pp; English.

CC The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-1R) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-1R and, if necessary, capable of
 CC specifically inhibiting tyrosine kinase activity of the receptor,
 CC comprising a light or heavy chain having at least one complementary
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-1R and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGF1 or IGF2 with IGF-1R and/or of EGF with EGFR, where
 CC the administration of the medicament does not induce or only slightly
 CC induces secondary effects connected with inhibition of the insulin
 CC receptor. The antibody is useful for preparation of a medicament intended
 CC to inhibit the transformation of normal cells into cells with tumoral
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
 CC useful for preparation of a medicament intended to inhibit the growth
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a
 CC medicament intended for prevention or for the treatment of cancer, where
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 CC preparation of a medicament intended for the prevention or for the
 CC treatment of psoriasis. (I) is useful in preparation of a medicament
 CC intended for the specific targeting of a biologically active compound to
 CC cells expressing or overexpressing the IGF-1R and/or EGFR receptor. (I)
 CC is useful for in vitro diagnosis of illnesses induced by an
 CC overexpression or an underexpression of the IGF-1R and/or EGFR receptor
 CC starting from a biological sample in which the abnormal presence, of IGF-
 CC IR and/or EGFR receptor is suspected, which involves contacting the
 CC biological sample with (I), which is optionally labeled. The present
 CC sequence is used in the exemplification of the invention.

SQ Sequence 117 AA;

Query Match 100.0%; Score 627; DB 9; Length 117;
 Best Local Similarity 100.0%; Pred. No. 1.8e-48;

Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60

DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNY 60

QY 61 KPSLKDRVTISRDTSKNQFSLKLSVTTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 117

DB 61 KPSLKDRVTISRDTSKNQFSLKLSVTTAADTAVVYCARVGRVFFDYWGQGLTVTVSS 117

RESULT 3

ADJ76915

ID ADJ76915 standard; protein; 135 AA.

XX ADJ76915;

XX 06-MAY-2004 (first entry)

XX Anti-IGF-1R related protein #25.

KW cytostatic; antipsoriatic; antibody;
 KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
 KW CDR.

XX Homo sapiens.

XX WO2003059951-A2.

PN 24-JUL-2003.

XX

```

PF 20-JAN-2003; 2003WO-FR000178.
XX 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
XX (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
XX Goetsch L, Corvaia N, Leger O;
XX WPI; 2003-569653/53.
XX
XX New antibodies that bind to human insulin-like growth factor receptor,
XX useful for treatment, prevention and diagnosis of cancers.
XX
XX Disclosure; SEQ ID NO 81; 164pp; French.
XX
XX The invention relates to an isolated antibody (Ab), and its functional
XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
XX IR) and optionally: (i) inhibit natural binding of insulin-like growth
XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
XX kinase activity of IGF-IR. Ab and its fragments are used to prevent or
XX treat diseases associated with overexpression and/or abnormal activity of
XX IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with
XX hyperactivity of signal transduction pathways mediated by interaction of
XX these receptors with their ligands. Especially they inhibit
XX transformation of normal cells to tumor cells, inhibit growth and/or
XX proliferation of tumor cells, so are useful against cancers of the
XX prostate, lung, breast, endometrium and colon, also osteosarcoma, and
XX also for treating psoriasis. Ab are also used to diagnose diseases caused
XX by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
XX protein sequence used to generate the Ab of the invention.
XX
XX Sequence 135 AA;
XX
XX Query Match 100.0%; Score 627; DB 7; Length 135;
XX Best Local Similarity 100.0%; Pred. No. 2e-48; Mismatches 0; Gaps 0;
XX Matches 117; Conservative 0; Indels 0;
XX
XX 1 QVQLQESGFLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 60
XX |||||
XX 19 QVQLQESGFLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNY 78
XX |||||
XX
XX 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYGQGTLLTVSS 117
XX |||||
XX 79 KPSLKDRVTISRDTSKNQPSLKLSSVTAADTAVYICARYGRVFFDYGQGTLLTVSS 135
XX |||||
XX
XX RESULT 4
XX ADZ67085
XX ID ADZ67085 standard; protein; 135 AA.
XX AC ADZ67085;
XX XX
XX DT 30-JUN-2005 (first entry)
XX XX
XX DE Human antibody 7C10 2 heavy chain variable region SEQ ID NO:81.
XX XX
XX KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
XX KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
XX KW musculoskeletal disease; respiratory disease; lung tumor;
XX KW endocrine disease; gynecology and obstetrics; breast tumor;
XX KW endometrial carcinoma; gastrointestinal disease; colon tumor;
XX KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
XX KW heavy chain variable region.
XX XX
XX OS Homo sapiens.
XX XX
XX FH Key Location/Qualifiers
XX FT Peptide 1..18
XX FT /note= "leader peptide"
XX FT 49..54
XX FT Region
XX FT /note= "CDRI"

```

```

FT Region 69..84
FT /note= "CDR2"
FT Region 117..124
FT /note= "CDR3"
XX
XX US2005084906-A1.
XX
XX 21-APR-2005.
XX
XX 16-DEC-2003; 2003US-00735916.
XX
XX 18-JAN-2002; 2002FR-00000653.
XX 18-JAN-2002; 2002FR-00000654.
XX 07-MAY-2002; 2002FR-00005753.
XX 20-JAN-2003; 2003WO-FR000178.
XX 11-JUL-2003; 2003FR-00008538.
XX
XX (GOET/) GOETSCH L.
XX PA (CORV/) CORVAIA N.
XX PA (LEGE/) LEGER O.
XX PA (DUFL/) DUFLOS A.
XX PA (HAEU/) HAEUW J.
XX PA (BECK/) BECK A.
XX
XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
XX WPI; 2005-321968/33.
XX N-PSDB; ADZ67084.
XX
XX Novel isolated anti-insulin-like growth factor 1 receptor (IGF-IR)
XX antibody or its functional fragment, being capable of binding human IGF-
XX IR and specifically inhibiting tyrosine kinase activity of receptor,
XX useful for treating cancer.
XX
XX Example 13; SEQ ID NO 81; 125pp; English.
XX
XX The invention relates to a novel isolated anti-insulin-like growth factor
XX I receptor (IGF-IR) antibody (I) or its functional fragment, being
XX capable of binding to human IGF-IR and, if necessary, capable of
XX specifically inhibiting tyrosine kinase activity of the receptor,
XX comprising a light or heavy chain having at least one complementary
XX determining region (CDR) consisting of one of two fully defined 16 amino
XX acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
XX the preparation of a medicament intended for the prevention or treatment
XX of an illness connected with an overexpression and/or an abnormal
XX activation of the IGF-IR and/or EGFR, and/or connected with a
XX hyperactivation of the transduction pathway of the signal mediated by the
XX interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
XX the administration of the medicament does not induce or only slightly
XX induces secondary effects connected with inhibition of the insulin
XX receptor. The antibody is useful for preparation of a medicament intended
XX to inhibit the transformation of normal cells into cells with tumoral
XX character, preferably IGF-dependent, especially IGF1 and/or IGF2-
XX dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
XX useful for preparation of a medicament intended to inhibit the growth
XX and/or the proliferation of tumor cells, preferably IGF-dependent,
XX especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
XX HER2/neu-dependent cells. (I) is useful in the preparation of a
XX medicament intended for prevention or for the treatment of cancer, where
XX the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
XX breast cancer, endometrial cancer or colon cancer. (I) is useful in the
XX preparation of a medicament intended for the prevention or for the
XX treatment of psoriasis. (I) is useful in preparation of a medicament
XX intended for the specific targeting of the IGF-IR and/or EGFR receptor. (I)
XX cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
XX is useful for in vitro diagnosis of illnesses induced by an
XX overexpression or an underexpression of the IGF-IR and/or EGFR receptor
XX starting from a biological sample in which the abnormal presence, of IGF-
XX IR and/or EGFR receptor is suspected, which involves contacting the
XX biological sample with (I), which is optionally labeled. The present
XX sequence is used in the exemplification of the invention.
XX
XX Sequence 135 AA;
XX

```

Query Match 100.0%; Score 627; DB 9; Length 135;
 Best Local Similarity 100.0%; Pred. No. 2e-48; Mismatches 0; Indels 0; Gaps 0;
 Matches 117; Conservative 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60
 DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKLEWIGYISYDGTNNY 78
 QY 61 KPSLKDRTVTSRDTSKNQPSLKLSSVTAADTAIVYVCARYGRVFFDYWGQGLTLVTSS 117
 DB 79 KPSLKDRTVTSRDTSKNQPSLKLSSVTAADTAIVYVCARYGRVFFDYWGQGLTLVTSS 135

RESULT 5
 ADJ76909
 ID ADJ76909 standard; protein; 117 AA.

XX AC ADJ76909;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-1R related protein #22.

XX KW cytostatic; antipsoriatic; antibody;
 KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
 KW CDR.

XX OS Homo sapiens.

XX PN WO2003059951-A2.

XX PD 24-JUL-2003.

XX PF 20-JAN-2003; 2003WO-FR000178.

XX PR 18-JAN-2002; 2002FR-00000653.

XX PR 18-JAN-2002; 2002FR-00000654.

XX PR 07-MAY-2002; 2002FR-00005753.

XX (FABR) FABRE MEDICAMENT SA PIERRE.

XX PI Goetsch L, Corvaia N, Leger O;

XX DR WPI; 2003-569653/53.

XX PT New antibodies that bind to human insulin-like growth factor receptor,

XX PT useful for treatment, prevention and diagnosis of cancers.

XX PS Disclosure; SEQ ID NO 75; 164pp; French.

XX CC The invention relates to an isolated antibody (Ab), and its functional
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
 CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
 CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
 CC treat diseases associated with overexpression and/or abnormal activity of
 CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
 CC hyperactivity of signal transduction pathways mediated by interaction of
 CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.

XX SQ Sequence 117 AA;

Query Match 99.4%; Score 623; DB 7; Length 117;
 Best Local Similarity 98.3%; Pred. No. 4e-48;

Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60
 DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLWNWIRQPPGKLEWIGYISYDGTNNY 60
 QY 61 KPSLKDRTVTSRDTSKNQPSLKLSSVTAADTAIVYVCARYGRVFFDYWGQGLTLVTSS 117
 DB 61 KPSLKDRTVTSRDTSKNQPSLKLSSVTAADTAIVYVCARYGRVFFDYWGQGLTLVTSS 117

RESULT 6
 ADZ67079

ID ADZ67079 standard; protein; 117 AA.

XX AC ADZ67079;

XX DT 30-JUN-2005 (first entry)

XX DE Human antibody 7C10 1 heavy chain variable region SEQ ID NO:75.

XX KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory diseases; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW heavy chain variable region.

XX OS Homo sapiens.

XX PN US2005084906-A1.

XX PD 21-APR-2005.

XX PF 16-DEC-2003; 2003US-00735916.

XX PR 18-JAN-2002; 2002FR-00000653.

XX PR 18-JAN-2002; 2002FR-00000654.

XX PR 07-MAY-2002; 2002FR-00005753.

XX PR 20-JAN-2003; 2003WO-FR000178.

XX PR 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.

XX PA (CORV/) CORVAIA N.

XX PA (LEGE/) LEGER O.

XX PA (DUFL/) DUFLOS A.

XX PA (HAEU/) HAEUW J.

XX PA (BECK/) BECK A.

XX PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

XX WPI; 2005-321968/33.

XX CC Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 CC antibody or its functional fragment, being capable of binding human IGF-
 CC IR and specifically inhibiting tyrosine kinase activity of receptor,
 CC useful for treating cancer.
 XX Example 13; SEQ ID NO 75; 125pp; English.
 XX CC The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-IR and, if necessary, capable of
 CC specifically inhibiting tyrosine kinase activity of the receptor,
 CC comprising a light or heavy chain having at least one complementary
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-IR and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where


```
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
PR 20-JAN-2003; 2003WO-FR000178.
PR 11-JUL-2003; 2003FR-00008538.
XX
XX (GOET/) GOETSCH L.
PA (CORV/) CORVAIA N.
PA (LEGE/) LEGER O.
PA (DUF/) DUFLOS A.
PA (HAEU/) HAEUW J.
PA (BECK/) BECK A.
XX
XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
XX
XX WPI: 2005-321968/33.
DR N-PSDB; ADZ67080.
XX
XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
PT antibody or its functional fragment, being capable of binding human IGF-
PT IR and specifically inhibiting tyrosine kinase activity of receptor,
PT useful for treating cancer.
XX
XX Example 13; SEQ ID NO 77; 125pp; English.
XX
XX The invention relates to a novel isolated anti-insulin-like growth factor
CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
CC capable of binding to human IGF-IR and, if necessary, capable of
CC specifically inhibiting tyrosine kinase activity of the receptor,
CC comprising a light or heavy chain having at least one complementary
CC determining region (CDR) consisting of one of two fully defined 16 amino
CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
CC the preparation of a medicament intended for the prevention or treatment
CC of an illness connected with an overexpression and/or an abnormal
CC activation of the IGF-IR and/or EGFR, and/or connected with a
CC hyperactivation of the transduction pathway of the signal mediated by the
CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
CC the administration of the medicament does not induce or only slightly
CC induces secondary effects connected with inhibition of the insulin
CC receptor. The antibody is useful for preparation of a medicament intended
CC to inhibit the transformation of normal cells into cells with tumoral
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
CC useful for preparation of a medicament intended to inhibit the growth
CC and/or the proliferation of tumor cells, preferably IGF-dependent,
CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
CC HER2/neu-dependent cells. (I) is useful in the preparation of a
CC medicament intended for prevention or for the treatment of cancer, where
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
CC preparation of a medicament intended for the prevention or for the
CC treatment of psoriasis. (I) is useful in preparation of a medicament
CC intended for the specific targeting of a biologically active compound to
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
CC is useful for in vitro diagnosis of illnesses induced by an
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
CC starting from a biological sample in which the abnormal presence, of IGF-
CC IR and/or EGFR receptor is suspected, which involves contacting the
CC biological sample with (I), which is optionally labeled. The present
CC sequence is used in the exemplification of the invention.
XX
XX Sequence 135 AA;
SQ
Query Match 99.4%; Score 623; DB 9; Length 135;
Best Local Similarity 98.3%; Pred. No. 4.7e-48;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLQESGPGLVKPKSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60
DB 19 QVQLQESGPGLVKPKSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWNGYISYDGTNNY 78
QY 61 KPSLKDRTVITSRDTSKNQPSLKLSSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117
DB 79 KPSLKDRTVITSRDTSKNQPSLKLSSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 135

us-10-735-916a-79.rag
RESULT 9
ADJ76917
ID ADJ76917 standard; protein; 117 AA.
XX
XX AC ADJ76917;
XX
XX DT 06-MAY-2004 (first entry)
XX
XX DE Anti-IGF-IR related protein #26.
XX
XX KW cytostatic; antipsoxiatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDR.
XX
XX OS Homo sapiens.
XX
XX PN WO2003059951-A2.
XX
XX PD 24-JUL-2003.
XX
XX PF 20-JAN-2003; 2003WO-FR000178.
XX
XX PR 18-JAN-2002; 2002FR-00000653.
XX
XX PR 18-JAN-2002; 2002FR-00000654.
XX
XX PR 07-MAY-2002; 2002FR-00005753.
XX
XX PA (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
XX PI Goetsch L, Corvaia N, Leger O;
XX
XX WPI: 2003-569653/53.
XX
XX New antibodies that bind to human insulin-like growth factor receptor,
PT useful for treatment, prevention and diagnosis of cancers.
XX
XX Disclosure; SEQ ID NO 83; 164pp; French.
XX
XX The invention relates to an isolated antibody (Ab), and its functional
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
CC treat diseases associated with overexpression and/or abnormal activity of
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
CC hyperactivity of signal transduction pathways mediated by interaction of
CC these receptors with their ligands. Especially they inhibit
CC transformation of normal cells to tumor cells, inhibit growth and/or
CC proliferation of tumor cells, so are useful against cancers of the
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
CC also for treating psoriasis. Ab are also used to diagnose diseases caused
CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
CC protein sequence used to generate the Ab of the invention.
XX
XX Sequence 117 AA;
SQ
Query Match 98.1%; Score 615; DB 7; Length 117;
Best Local Similarity 98.3%; Pred. No. 2.1e-47;
Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1 QVQLQESGPGLVKPKSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPKSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60
QY 61 KPSLKDRTVITSRDTSKNQPSLKLSSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117
DB 61 KPSLKDRTVITSRDTSKNQPSLKLSSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117

RESULT 10
```


ADZ67087
 ID ADZ67087 standard; protein; 117 AA.
 AC ADZ67087;
 XX
 DT 30-JUN-2005 (first entry)
 XX
 DE Human antibody 7C10 3 heavy chain variable region SEQ ID NO:83.
 XX
 KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW heavy chain variable region.
 XX
 OS Homo sapiens.
 XX
 PN US2005084906-A1.
 XX
 PD 21-APR-2005.
 XX
 PF 16-DEC-2003; 2003US-00735916.
 XX
 PR 18-JAN-2002; 2002FR-00000653.
 PR 18-JAN-2002; 2002FR-00000654.
 PR 07-MAY-2002; 2002FR-00005753.
 PR 20-JAN-2003; 2003WO-FR000178.
 PR 11-JUL-2003; 2003FR-00008538.
 XX
 PA (GORT/) GORTSCH L.
 PA (CORV/) CORVAIA N.
 PA (LEGE/) LEGER O.
 PA (DUFL/) DUFLOS A.
 PA (HAEU/) HAEUW J.
 PA (BECK/) BECK A.
 XX
 PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
 XX
 DR WPI; 2005-321968/33.
 XX
 PT Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 PT antibody or its functional fragment, being capable of binding human IGF-
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,
 PT useful for treating cancer.
 XX
 PS Example 13; SEQ ID NO 83; 125pp; English.
 XX
 CC The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-IR and, if necessary, capable of
 CC specifically inhibiting tyrosine kinase activity of the receptor,
 CC comprising a light or heavy chain having at least one complementary
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-IR and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGf1 or IGf2 with IGF-IR and/or of EGF with EGFR, where
 CC the administration of the medicament does not induce or only slightly
 CC induces secondary effects connected with inhibition of the insulin
 CC receptor. The antibody is useful for preparation of a medicament intended
 CC to inhibit the transformation of normal cells into cells with tumoral
 CC character, preferably IGF-dependent, especially IGf1 and/or IGf2-
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
 CC useful for preparation of a medicament intended to inhibit the growth
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,
 CC especially IGf1 and/or IGf2-dependent and/or EGF-dependent and/or
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a
 CC medicament intended for prevention or for the treatment of cancer, where
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 CC preparation of a medicament intended for the prevention or for the
 CC treatment of psoriasis. (I) is useful in preparation of a medicament
 CC intended for the specific targeting of the IGF-IR and/or EGFR receptor. (I)
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
 CC is useful for in vitro diagnosis of illnesses induced by an
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
 CC starting from a biological sample in which the abnormal presence, of IGF-
 CC IR and/or EGFR receptor is suspected, which involves contacting the
 CC biological sample with (I), which is optionally labeled. The present
 CC sequence is used in the exemplification of the invention.
 XX
 SQ Sequence 117 AA;
 Query Match 98.1%; Score 615; DB 9; Length 117;
 Best Local Similarity 98.3%; Pred. No. 2.1e-47;
 Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLWNWIRQPPGKLEWIGYISYDGTNNY 60
 Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGLWNWIRQPPGKLEWIGYISYDGTNNY 60
 QY 61 KPSLKDRVTIISRDTSKNOFSLKLSVTAADTAVVYCARYGRVFDYWGQGLTVTVSS 117
 Db 61 KPSLKDRVTIISRDTSKNOFSLKLSVTAADTAVVYCARYGRVFDYWGQGLTVTVSS 117
 RESULT 11
 ADJ76919
 ID ADJ76919 standard; protein; 135 AA.
 XX
 AC ADJ76919;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Anti-IGF-IR related protein #27.
 XX
 KW cytostatic; antipsoriatic; antibody;
 KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
 KW CDR.
 XX
 OS Homo sapiens.
 XX
 PN WO2003059951-A2.
 XX
 PD 24-JUL-2003.
 XX
 PF 20-JAN-2003; 2003WO-FR000178.
 XX
 PR 18-JAN-2002; 2002FR-00000653.
 PR 18-JAN-2002; 2002FR-00000654.
 PR 07-MAY-2002; 2002FR-00005753.
 XX
 PA (FABR) FABRE MEDICAMENT SA PIERRE.
 XX
 PI Goetsch L, Corvaia N, Leger O;
 XX
 DR WPI; 2003-569653/53.
 XX
 PT New antibodies that bind to human insulin-like growth factor receptor,
 PT useful for treatment, prevention and diagnosis of cancers.
 XX
 PS Disclosure; SEQ ID NO 85; 164pp; French.
 XX
 CC The invention relates to an isolated antibody (Ab), and its functional
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
 CC IR) and optionally: (i) inhibit natural binding of insulin-like growth
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
 CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or
 CC treat diseases associated with overexpression and/or abnormal activity of
 CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with

CC hyperactivity of signal transduction pathways mediated by interaction of
 CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.
 XX
 SQ Sequence 135 AA;

Query Match 98.1%; Score 615; DB 7; Length 135;
 Best Local Similarity 98.3%; Pred. No. 2.4e-47;
 Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLWNWIRQPPGKLEWIGYISYDGTNNY 60
 DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLWNWIRQPPGKLEWIGYISYDGTNNY 78
 QY 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAAADTAVYVCARYGRVFFDYWGQGLTLVTYSS 117
 DB 79 KPSLKDRVTISRDTSKNQPSLKLSSVTAAADTAVYVCARYGRVFFDYWGQGLTLVTYSS 135

RESULT 12
 ADZ67089
 ID ADZ67089 standard; protein; 135 AA.

XX ADZ67089;

XX 30-JUN-2005 (first entry)

XX Human antibody 7C10 3 heavy chain variable region SEQ ID NO:85.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW heavy chain variable region.

XX Homo sapiens.

Key	Location/Qualifiers
Peptide	1..18
Region	/note= "leader peptide"
Region	49..54
Region	/note= "CDR1"
Region	69..84
Region	/note= "CDR2"
Region	117..124
Region	/note= "CDR3"

XX US2005084906-A1.

XX 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.

XX 18-JAN-2002; 2002FR-00000654.

XX 07-MAY-2002; 2002FR-00005753.

XX 20-JAN-2003; 2003WO-FR000178.

XX 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.

XX (CORV/) CORVAIA N.

XX (LEGE/) LEGER O.

XX (DUFL/) DUFLOS A.

XX (HAEU/) HAEUW J.

XX (BECK/) BECK A.

PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
 XX WPI; 2005-321968/33.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 FT antibody or its functional fragment, being capable of binding human IGF-
 FT IR and specifically inhibiting tyrosine kinase activity of receptor,
 FT useful for treating cancer.

XX Example 13; SEQ ID NO 85; 125pp; English.

XX The invention relates to a novel isolated anti-insulin-like growth factor-
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-IR and, if necessary, capable of
 CC specifically inhibiting tyrosine kinase activity of the receptor.
 CC comprising a light or heavy chain having at least one complementary
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (AD267006 and AD267014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-IR and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
 CC the administration of the medicament does not induce or only slightly
 CC induces secondary effects connected with inhibition of the insulin
 CC receptor. The antibody is useful for preparation of a medicament intended
 CC to inhibit the transformation of normal cells into cells with tumoral
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
 CC useful for preparation of a medicament intended to inhibit the growth
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a
 CC medicament intended for prevention or for the treatment of a
 CC cancer chosen from prostate cancer, osteosarcoma, lung cancer,
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 CC preparation of a medicament intended for the prevention or for the
 CC treatment of psoriasis. (I) is useful in preparation of a medicament
 CC intended for the specific targeting of a biologically active compound to
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
 CC is useful for in vitro diagnosis of illnesses induced by an
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
 CC starting from a biological sample in which the abnormal presence, of IGF-
 CC IR and/or EGFR receptor is suspected, which involves contacting the
 CC biological sample with (I), which is optionally labeled. The present
 CC sequence is used in the exemplification of the invention.

XX Sequence 135 AA;

Query Match 98.1%; Score 615; DB 9; Length 135;
 Best Local Similarity 98.3%; Pred. No. 2.4e-47;
 Matches 115; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLWNWIRQPPGKLEWIGYISYDGTNNY 60

DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGLWNWIRQPPGKLEWIGYISYDGTNNY 78

QY 61 KPSLKDRVTISRDTSKNQPSLKLSSVTAAADTAVYVCARYGRVFFDYWGQGLTLVTYSS 117

DB 79 KPSLKDRVTISRDTSKNQPSLKLSSVTAAADTAVYVCARYGRVFFDYWGQGLTLVTYSS 135

RESULT 13

ADJ76903

ID ADJ76903 standard; protein; 117 AA.

XX AC ADJ76903;

XX DT 06-MAY-2004 (first entry)

XX XX Anti-IGF-IR related protein #16.

XX KW cytostatic; antipsoriatic; antibody;

KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
 KW CDR.
 XX Homo sapiens.
 XX WO2003059951-A2.
 XX 24-JUL-2003.
 XX 20-JAN-2003; 2003WO-FR000178.
 XX 18-JAN-2002; 2002FR-00000653.
 XX 18-JAN-2002; 2002FR-00000654.
 XX 07-MAY-2002; 2002FR-00005753.
 XX (FABR) FABRE MEDICAMENT SA PIERRE.
 XX Goetsch L, Corvaia N, Leger O;
 XX WPI; 2003-569653/53.
 XX New antibodies that bind to human insulin-like growth factor receptor,
 XX useful for treatment, prevention and diagnosis of cancers.
 XX Disclosure; SEQ ID NO 69; 164pp; French.
 XX The invention relates to an isolated antibody (Ab), and its functional
 XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
 XX IR) and optionally: (i) inhibit natural binding of insulin-like growth
 XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
 XX kinase activity of IGF-IR. Ab and its fragments are used to prevent or
 XX treat diseases associated with overexpression and/or abnormal activity of
 XX IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with
 XX hyperactivity of signal transduction pathways mediated by interaction of
 XX these receptors with their ligands. Especially they inhibit
 XX transformation of tumor cells to tumor cells, inhibit growth and/or
 XX proliferation of tumor cells, so are useful against cancers of the
 XX prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 XX also for treating psoriasis. Ab are also used to diagnose diseases caused
 XX by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
 XX protein sequence used to generate the Ab of the invention.
 XX Sequence 117 AA;
 Query Match 86.3%; Score 541; DB 7; Length 117;
 Best Local Similarity 84.5%; Pred. No. 9e-41;
 Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;
 QY 2 VQLQESGPGLVKPESTLSLTCTGYSITGGYLNNIRQPPGKLEWIGYISYDGTNNYK 61
 DB 2 VQLQESGPGLVKPEQSLSLTCTGYSITGGYLNNIRQPPGKLEWIGYISYDGTNNYK 61
 QY 62 PSLKDRVTTISRDTSKNQPSLKSSVTAADTAVYICARYGRVFFDYWGQGLTVTVSS 117
 DB 62 PSLKDRISITRDISKNQPFLLKNSVNTEDATYICARYGRVFFDYWGQGLTVTVSS 117
 RESULT 14
 ADZ67073
 ID ADZ67073 standard; protein; 117 AA.
 AC ADZ67073;
 XX 30-JUN-2005 (first entry)
 XX Murine immunoglobulin heavy chain variable region 7C10 VH SEQ ID NO:69.
 XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW immunoglobulin; heavy chain variable region.
 XX Mus musculus.
 XX US2005084906-A1.
 XX 21-APR-2005.
 XX 16-DEC-2003; 2003US-00735916.
 XX 18-JAN-2002; 2002FR-00000653.
 XX 07-MAY-2002; 2002FR-00000654.
 XX 20-JAN-2003; 2003WO-FR000178.
 XX 11-JUL-2003; 2003FR-00008538.
 XX (GOET/) GOETSCH L.
 XX (CORV/) CORVAIA N.
 XX (LEGE/) LEGER O.
 XX (DUF/) DUFLOS A.
 XX (HAEU/) HAEUW J.
 XX (BECK/) BECK A.
 XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
 XX WPI; 2005-321968/33.
 XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 XX antibody or its functional fragment, being capable of binding human IGF-
 XX IR and specifically inhibiting tyrosine kinase activity of receptor,
 XX useful for treating cancer.
 XX Example 13; SEQ ID NO 69; 125pp; English.
 XX The invention relates to a novel isolated anti-insulin-like growth factor
 XX I receptor (IGF-IR) antibody (I) or its functional fragment, being
 XX capable of binding to human IGF-IR and, if necessary, capable of
 XX specifically inhibiting tyrosine kinase activity of the receptor,
 XX comprising a light or heavy chain having at least one complementary
 XX determining region (CDR) consisting of one of two fully defined 16 amino
 XX acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 XX the preparation of a medicament intended for the prevention or treatment
 XX of an illness connected with an overexpression and/or an abnormal
 XX activation of the IGF-IR and/or EGFR, and/or connected with a
 XX hyperactivation of the transduction pathway of the signal mediated by the
 XX interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
 XX the administration of the medicament does not induce or only slightly
 XX induces secondary effects connected with inhibition of the insulin
 XX receptor. The antibody is useful for preparation of a medicament intended
 XX to inhibit the transformation of normal cells into cells with tumoral
 XX character, preferably IGF-dependent, especially IGF1 and/or IGF2-
 XX dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
 XX useful for preparation of a medicament intended to inhibit the growth
 XX and/or the proliferation of tumor cells, preferably IGF-dependent,
 XX especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
 XX HER2/neu-dependent cells. (I) is useful in the preparation of a
 XX medicament intended for prevention or for the treatment of cancer, where
 XX the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
 XX breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 XX preparation of a medicament intended for the prevention or for the
 XX treatment of psoriasis. (I) is useful in preparation of a medicament
 XX intended for the specific targeting of a biologically active compound to
 XX cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
 XX is useful for in vitro diagnosis of illnesses induced by an
 XX overexpression or an underexpression of the IGF-IR and/or EGFR receptor
 XX starting from a biological sample in which the abnormal presence, of IGF-
 XX IR and/or EGFR receptor is suspected, which involves contacting the
 XX biological sample with (I), which is optionally labeled. The present
 XX sequence is used in the exemplification of the invention.
 XX Sequence 117 AA;

Query Match 86.3%; Score 541; DB 9; Length 117;
Best Local Similarity 84.5%; Pred. No. 9e-41; 8; Indels 0; Gaps 0;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;
QY 2 VOLQESGPGLVKPSQSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
Db 2 VOLQESGPGLVKPSQSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
QY 62 PSLKDRVTISRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQTTLTVSS 117
Db 62 PSLKDRISITRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQTTLTVSS 117

RESULT 15
ADJ76886
ID ADJ76886 standard; protein; 127 AA.
XX AC ADJ76886;
XX DT 06-MAY-2004 (first entry)
XX DE Anti-IGF-1R related protein #4.
XX KW cytostatic; antipsoriatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDR.
XX OS Mus musculus.
XX PN WO2003059951-A2.
XX PD 24-JUL-2003.
XX PF 20-JAN-2003; 2003WO-FR000178.
XX PR 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
XX (FABR) FABRE MEDICAMENT SA PIERRE.
XX Goetsch L, Corvaia N, Leger O;
XX WPI; 2003-569653/53.

New antibodies that bind to human insulin-like growth factor receptor,
useful for treatment, prevention and diagnosis of cancers.
Disclosure; SEQ ID NO 52; 164pp; French.
The invention relates to an isolated antibody (Ab), and its functional
fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
1R) and optionally: (i) inhibit natural binding of insulin-like growth
factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
kinase activity of IGF-1R. Ab and its fragments are used to prevent or
treat diseases associated with overexpression and/or abnormal activity of
IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
hyperactivity of signal transduction pathways mediated by interaction of
these receptors with their ligands. Especially they inhibit
transformation of normal cells to tumor cells, inhibit growth and/or
proliferation of tumor cells, so are useful against cancers of the
prostate, lung, breast, endometrium and colon, also osteosarcoma, and
also for treating psoriasis. Ab are also used to diagnose diseases caused
by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
protein sequence used to generate the Ab of the invention.

Sequence 127 AA;
Query Match 86.3%; Score 541; DB 7; Length 127;
Best Local Similarity 84.5%; Pred. No. 9.8e-41;

Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;
QY 2 VOLQESGPGLVKPSQSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 61
Db 12 VOLQESGPGLVKPSQSLTCTVSGYSITGGYLNWIRQPPGKLEWIGYISYDGTNNYK 71
QY 62 PSLKDRVTISRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQTTLTVSS 117
Db 72 PSLKDRISITRDTSKNQFSLKSSVTAADTAVYICARYGRVFFDYWGQTTLTVSS 127
Search completed: January 10, 2006, 20:44:17
Job time : 80.7649 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:55:23 ; Search time 5.96642 Seconds
(without alignments)
166.558 Million cell updates/sec

Title: US-10-735-916A-75
Perfect score: 628
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYGQGLTVTVSS 117

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 61141 seqs, 8493638 residues

Total number of hits satisfying chosen parameters: 61141

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

- Database : Published Applications_AA_New.*
- 1: /cgn2_6/prodata1/pubpaa/US08_NEW_PUB.pap.*
 - 2: /cgn2_6/prodata1/pubpaa/US06_NEW_PUB.pap.*
 - 3: /cgn2_6/prodata1/pubpaa/US07_NEW_PUB.pap.*
 - 4: /cgn2_6/prodata1/pubpaa/US07_NEW_PUB.pap.*
 - 5: /cgn2_6/prodata1/pubpaa/US05_NEW_PUB.pap.*
 - 6: /cgn2_6/prodata1/pubpaa/US10_NEW_PUB.pap.*
 - 7: /cgn2_6/prodata1/pubpaa/US11_NEW_PUB.pap.*
 - 8: /cgn2_6/prodata1/pubpaa/US60_NEW_PUB.pap.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Length	ID	Description
1	628	100.0	117	US-11-012-353-75	Sequence 75, Appl
2	628	100.0	135	US-11-012-353-77	Sequence 77, Appl
3	623	99.2	117	US-11-012-353-79	Sequence 79, Appl
4	623	99.2	135	US-11-012-353-81	Sequence 81, Appl
5	611	97.3	117	US-11-012-353-83	Sequence 83, Appl
6	611	97.3	135	US-11-012-353-85	Sequence 85, Appl
7	546	86.9	117	US-11-012-353-69	Sequence 69, Appl
8	546	86.9	127	US-11-012-353-52	Sequence 52, Appl
9	532	84.7	117	US-11-012-353-162	Sequence 162, Appl
10	487.5	77.6	117	US-11-012-353-70	Sequence 70, Appl
11	478	76.1	123	US-11-012-353-73	Sequence 73, Appl
12	477.5	76.0	247	US-11-054-515-1651	Sequence 1651, Ap
13	477.5	76.0	250	US-11-054-515-1548	Sequence 1548, Ap
14	474.5	75.6	259	US-10-512-184-34	Sequence 34, Appl
15	474.5	75.6	371	US-10-512-184-71	Sequence 71, Appl
16	474.5	75.6	626	US-10-512-184-49	Sequence 49, Appl
17	469	74.7	117	US-11-012-353-72	Sequence 72, Appl
18	469	74.7	120	US-11-102-201-1	Sequence 1, Appl
19	469	74.7	253	US-11-054-515-1619	Sequence 1619, Ap
20	465.5	74.1	146	US-10-721-763-17	Sequence 17, Appl
21	463.5	73.8	252	US-11-054-515-1994	Sequence 1994, Ap
22	461.5	73.5	252	US-11-054-515-1329	Sequence 1329, Ap
23	459	73.1	255	US-11-054-515-841	Sequence 841, Appl
24	457.5	72.9	116	US-11-054-669-112	Sequence 112, Appl
25	457.5	72.9	250	US-11-054-669-110	Sequence 110, Appl

RESULT 1

US-11-012-353-75
; Sequence 75, Application US/11012353
; Publication No. US20050249730A1

GENERAL INFORMATION:

; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: Patentin Ver. 3.3
; SEQ ID NO 75
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens

US-11-012-353-75

Query Match 100.0%; Score 628; DB 7; Length 117;

Best Local Similarity 100.0%; Pred. No. 8.7e-49;

Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGFLVKPSETLSLCTVSGYSITGGYLNWIRQPPKGLWNGYISYDGTNNY 60

Db 1 QVQLQESGFLVKPSETLSLCTVSGYSITGGYLNWIRQPPKGLWNGYISYDGTNNY 60

QY 61 KPSLKDRIITISRDTSKNQFSLKSSVTAADTAVYCYGRVFFDYGQGLTVTVSS 117

Db 61 KPSLKDRIITISRDTSKNQFSLKSSVTAADTAVYCYGRVFFDYGQGLTVTVSS 117

Sequence 1339, Ap
Sequence 1578, Ap
Sequence 990, Appl
Sequence 1981, Ap
Sequence 25, Appl
Sequence 1659, Ap
Sequence 21, Appl
Sequence 1607, Ap
Sequence 12, Appl
Sequence 1745, Appl
Sequence 844, Appl
Sequence 1597, Ap
Sequence 1546, Ap
Sequence 55, Appl
Sequence 20, Appl
Sequence 20, Appl
Sequence 1510, Ap
Sequence 954, Appl
Sequence 1321, Ap
Sequence 1223, Ap

```
RESULT 2
US-11-012-353-77
; Sequence 77, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 77
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-77

Query Match      100.0%; Score 628; DB 7; Length 135;
Best Local Similarity 100.0%; Pred. No. 9.9e-49;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 78
QY 61 KPSLKDRITISRDTSKNQFSLKLSSTAAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRITISRDTSKNQFSLKLSSTAAADTAVVYCARYGRVFFDYWGQGLTVTVSS 135

RESULT 3
US-11-012-353-79
; Sequence 79, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 79
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-79

Query Match      99.2%; Score 623; DB 7; Length 135;
Best Local Similarity 98.3%; Pred. No. 2.7e-48;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 78
QY 61 KPSLKDRITISRDTSKNQFSLKLSSTAAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRITISRDTSKNQFSLKLSSTAAADTAVVYCARYGRVFFDYWGQGLTVTVSS 135
```

```
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 79
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-79

Query Match      99.2%; Score 623; DB 7; Length 117;
Best Local Similarity 98.3%; Pred. No. 2.4e-48;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 60
QY 61 KPSLKDRITISRDTSKNQFSLKLSSTAAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117
Db 61 KPSLKDRITISRDTSKNQFSLKLSSTAAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117

RESULT 4
US-11-012-353-81
; Sequence 81, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 81
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-81

Query Match      99.2%; Score 623; DB 7; Length 135;
Best Local Similarity 98.3%; Pred. No. 2.7e-48;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMMGYISYDGTNNY 78
QY 61 KPSLKDRITISRDTSKNQFSLKLSSTAAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRITISRDTSKNQFSLKLSSTAAADTAVVYCARYGRVFFDYWGQGLTVTVSS 135
```

```
RESULT 5
US-11-012-353-83
; Sequence 83, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 83
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-83

Query Match          97.3%; Score 611; DB 7; Length 117;
Best Local Similarity 96.6%; Pred. No. 2.6e-47;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWNGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 60
QY 61 KPSLKDRTITSRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTILVTVSS 117
Db 61 KPSLKDRTITSRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTILVTVSS 117

RESULT 6
US-11-012-353-85
; Sequence 85, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 85
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-85

Query Match          86.9%; Score 546; DB 7; Length 117;
Best Local Similarity 86.2%; Pred. No. 1.2e-41;
Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 2 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWNGYISYDGTNNY 61
Db 2 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWNGYISYDGTNNY 61
QY 62 PSLKDRITISRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTILVTVSS 117
Db 62 PSLKDRITISRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTILVTVSS 117
```

```
US-11-012-353-85
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 85
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-85

Query Match          97.3%; Score 611; DB 7; Length 135;
Best Local Similarity 96.6%; Pred. No. 3e-47;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWNGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWIGYISYDGTNNY 78
QY 61 KPSLKDRTITSRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTILVTVSS 117
Db 79 KPSLKDRTITSRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTILVTVSS 135

RESULT 7
US-11-012-353-69
; Sequence 69, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 69
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-69

Query Match          86.9%; Score 546; DB 7; Length 117;
Best Local Similarity 86.2%; Pred. No. 1.2e-41;
Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 2 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWNGYISYDGTNNY 61
Db 2 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWNGYISYDGTNNY 61
QY 62 PSLKDRITISRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTILVTVSS 117
Db 62 PSLKDRITISRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTILVTVSS 117
```

Db 62 PSLKDRISITRDTSKNQFSLKLSVNTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117

RESULT 8

US-11-012-353-52
; Sequence 52, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 52
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-52

Query Match 86.9%; Score 546; DB 7; Length 127;
Best Local Similarity 86.2%; Pred. No. 1.3e-41;
Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;
QY 2 VOLQESGPGLVKPSSETLSLCTCTVSGYSITGGYLNWIRQPPGKLEWGYISYDGTNNYK 61
Db 12 VOLQESGPGLVKPSQSLTSCVTSCTGYSITGGYLNWIRQPPGKLEWGYISYDGTNNYK 71
QY 62 PSLKDRITISRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 117
Db 72 PSLKDRISITRDTSKNQFSLKLSVNTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 127

RESULT 9

US-11-012-353-162
; Sequence 162, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178

; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 162
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-162
Query Match 84.7%; Score 532; DB 7; Length 117;
Best Local Similarity 84.6%; Pred. No. 2e-40;
Matches 99; Conservative 7; Mismatches 11; Indels 0; Gaps 0;
QY 1 QVOLQESGPGLVKPSSETLSLCTCTVSGYSITGGYLNWIRQPPGKLEWGYISYDGTNNY 60
Db 1 QVOLQESGPGLVKPSSETLSLCTCTVSGYSITGGYLNWIRQPPGKLEWGYISYDGTNNY 60
QY 61 KPSLKDRITISRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 117
Db 61 NPSLSKRSVTISVDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 117

RESULT 10

US-11-012-353-70
; Sequence 70, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 70
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-70

Query Match 77.6%; Score 487.5; DB 7; Length 118;
Best Local Similarity 77.8%; Pred. No. 1.6e-36;
Matches 91; Conservative 10; Mismatches 15; Indels 1; Gaps 1;
QY 2 VOLQESGPGLVKPSSETLSLCTCTVSGYSITGGYLNWIRQPPGKLEWGYISYDGTNNYK 61
Db 2 VOLQESGPGLVKPSQSLTSCVTSCTGYSITGGYLNWIRQPPGKLEWGYISYDGTNNYK 61
QY 62 PSLKDRITISRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 117

[illegible]

```
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1548

Query Match      76.0%; Score 477.5; DB 7; Length 250;
Best Local Similarity 75.2%; Pred. No. 2.3e-35;
Matches 94; Conservative 8; Mismatches 15; Indels 7; Gaps 2;

QY 1 QVQLESGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 QVQLESGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60
QY 61 KPSLKRITISRDTSKNQPSLKLSSVTAADTAVYICARY-----GRVP-FDYWGQGLTV 113
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
61 NPSLKRITISRDTSKNQPSLKLSSVTAADTAVYICARVHYDILGTGLWAFDINWGQTMV 120
QY 114 TVSS 117
Db |||||
121 TVSS 124

RESULT 14
US-10-512-184-34
; Sequence 34, Application US/10512184
; Publication No. US20050244901A1
; GENERAL INFORMATION:
; APPLICANT: Fraunhofer Gesellschaft zur Forderung der angewandten Forschung e.V.
; TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant
; TITLE OF INVENTION: antibody fragments and fusions mediated plant disease
; FILE REFERENCE: 3581.01US01
; CURRENT APPLICATION NUMBER: US/10/512,184
; CURRENT FILING DATE: 2004-10-22
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 34
; LENGTH: 259
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: scFv PL2 with
; OTHER INFORMATION: specificity against Phoma lingam; originates from
; OTHER INFORMATION: Mus musculus.
US-10-512-184-34

Query Match      75.6%; Score 474.5; DB 6; Length 259;
Best Local Similarity 75.2%; Pred. No. 4.4e-35;
Matches 91; Conservative 11; Mismatches 14; Indels 5; Gaps 2;

QY 2 VQLESGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNYK 61
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
4 VQLESGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNNN 63
QY 62 PSLKDRITISRDTSKNQPSLKLSSVTAADTAVYICAR----YGR-VFFDYWGQGLTVTS 116
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
64 PSLKDRITISRDTSKNQPSLKLSSVTAADTAVYICARVYKGTWFPYWGQGLTVTS 123
QY 117 S 117
Db ||
124 S 124

RESULT 15
US-10-512-184-71
; Sequence 71, Application US/10512184
; Publication No. US20050244901A1
; GENERAL INFORMATION:
; APPLICANT: Fraunhofer Gesellschaft zur Forderung der angewandten Forschung e.V.
; TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant
; TITLE OF INVENTION: antibody fragments and fusions mediated plant disease
; FILE REFERENCE: 3581.01US01
; CURRENT APPLICATION NUMBER: US/10/512,184
; CURRENT FILING DATE: 2004-10-22
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 71
; LENGTH: 371
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: precursor
; OTHER INFORMATION: fusion protein comprising ACE - linker -
; OTHER INFORMATION: scFv PL2.
US-10-512-184-71

Query Match      75.6%; Score 474.5; DB 6; Length 371;
Best Local Similarity 75.2%; Pred. No. 6.1e-35;
Matches 91; Conservative 11; Mismatches 14; Indels 5; Gaps 2;

QY 2 VQLESGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNYK 61
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
116 VQLESGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNNN 175
QY 62 PSLKDRITISRDTSKNQPSLKLSSVTAADTAVYICAR----YGR-VFFDYWGQGLTVTS 116
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
176 PSLKDRITISRDTSKNQPSLKLSSVTAADTAVYICARVYKGTWFPYWGQGLTVTS 235
QY 117 S 117
Db ||
236 S 236

Search completed: January 10, 2006, 21:36:24
Job time : 6.96642 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:53:43 ; Search time 64.1754 Seconds
(without alignments)
761.757 Million cell updates/sec

Title: US-10-735-916A-75

Perfect score: 628

Sequence: 1 QVQLQESGPGLVKPSSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications AA Main:*

1: /cgn2_6/protdata/1/pubpaa/US07_PUBCOMB.pep.*

2: /cgn2_6/protdata/1/pubpaa/US08_PUBCOMB.pep.*

3: /cgn2_6/protdata/1/pubpaa/US09_PUBCOMB.pep.*

4: /cgn2_6/protdata/1/pubpaa/US10A_PUBCOMB.pep.*

5: /cgn2_6/protdata/1/pubpaa/US10B_PUBCOMB.pep.*

6: /cgn2_6/protdata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	628	100.0	117	5	US-10-735-916A-75
2	628	100.0	135	5	US-10-735-916A-77
3	623	99.2	117	5	US-10-735-916A-79
4	623	99.2	135	5	US-10-735-916A-81
5	611	97.3	117	5	US-10-735-916A-83
6	611	97.3	135	5	US-10-735-916A-85
7	546	86.9	117	5	US-10-735-916A-69
8	546	86.9	127	5	US-10-735-916A-52
9	531.5	84.6	120	4	US-10-383-447-26
10	511.5	81.4	120	4	US-10-383-447-24
11	508.5	81.0	120	4	US-10-383-447-28
12	503	80.1	119	4	US-10-309-762-143
13	500.5	79.7	118	4	US-10-292-088-109
14	499.5	79.5	121	5	US-10-805-177-56
15	499.5	79.5	122	4	US-10-309-762-25
16	499.5	79.5	122	4	US-10-309-762-29
17	498.5	79.4	120	4	US-10-309-762-128
18	496.5	79.1	116	4	US-10-309-762-127
19	496.5	79.1	121	4	US-10-010-729-11
20	496.5	79.1	122	4	US-10-309-762-24
21	496.5	79.1	122	4	US-10-309-762-27
22	496	79.0	119	4	US-10-125-687-5
23	496	79.0	119	5	US-10-396-191-5
24	496	79.0	121	4	US-10-292-088-82
25	496	79.0	121	4	US-10-292-088-86
26	494	78.7	119	5	US-10-937-596-23
27	493	78.5	117	5	US-10-890-945-2

28	493	78.5	121	4	US-10-292-088-98	Sequence 98, Appl
29	493	78.5	466	4	US-10-292-088-70	Sequence 70, Appl
30	493	78.5	580	4	US-10-310-719-35	Sequence 35, Appl
31	493	78.5	580	4	US-10-310-719-37	Sequence 37, Appl
32	491.5	78.3	122	5	US-10-984-960A-20	Sequence 20, Appl
33	491.5	78.3	139	5	US-10-893-576-39	Sequence 39, Appl
34	490.5	78.1	121	5	US-10-805-177-2	Sequence 2, Appl
35	490.5	78.1	169	5	US-10-805-177-114	Sequence 114, App
36	490	78.0	121	4	US-10-292-088-66	Sequence 66, Appl
37	489.5	77.9	116	5	US-10-822-306A-5	Sequence 5, Appl
38	489.5	77.9	116	5	US-10-822-306A-14	Sequence 14, Appl
39	489.5	77.9	118	5	US-10-706-689-10	Sequence 10, Appl
40	489.5	77.9	118	5	US-10-988-360-10	Sequence 10, Appl
41	489	77.9	123	4	US-10-309-762-10	Sequence 10, Appl
42	488.5	77.8	118	4	US-10-309-762-138	Sequence 138, App
43	488.5	77.8	120	4	US-10-383-447-22	Sequence 22, Appl
44	487.5	77.6	116	5	US-10-822-306A-9	Sequence 9, Appl
45	487.5	77.6	116	5	US-10-822-306A-11	Sequence 11, Appl

ALIGNMENTS

RESULT 1
US-10-735-916A-75
; Sequence 75, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUPLON, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 75
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-75
Query Match 100.0%; Score 628; DB 5; Length 117;
Best Local Similarity 100.0%; Pred. No. 4.4e-49;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGLNWNHROPKGLGWNWGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLCTVSGYSITGGLNWNHROPKGLGWNWGYISYDGTNNY 60
QY 61 KPSLKDRTISRDTSKNQFSLKLSVVTADTAVYICARYGRVFFDYWGQGLTVTVSS 117
Db 61 KPSLKDRTISRDTSKNQFSLKLSVVTADTAVYICARYGRVFFDYWGQGLTVTVSS 117
RESULT 2
US-10-735-916A-77
; Sequence 77, Application US/10735916A
; Publication No. US20050084906A1

GENERAL INFORMATION:
APPLICANT: GOETSCH, Liliane
APPLICANT: CORVAIA, Nathalie
APPLICANT: LEGER, Olivier
APPLICANT: DUFLOS, Alain
APPLICANT: BECK, Alain
APPLICANT: HAEUW, Jean-Francois
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
FILE REFERENCE: 017753-183
CURRENT APPLICATION NUMBER: US/10/735,916A
CURRENT FILING DATE: 2003-12-16
PRIOR APPLICATION NUMBER: FR 03/08 538
PRIOR FILING DATE: 2003-07-11
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
PRIOR FILING DATE: 2003-01-20
PRIOR APPLICATION NUMBER: FR 02/00 653
PRIOR FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: FR 02/00 654
PRIOR FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: FR 02/05 753
PRIOR FILING DATE: 2002-05-07
NUMBER OF SEQ ID NOS: 156
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 77
LENGTH: 135
TYPE: PRT
ORGANISM: Homo sapiens
US-10-735-916A-77

Query Match 100.0%; Score 628; DB 5; Length 135;
Best Local Similarity 100.0%; Pred. No. 5.1e-49;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 78
QY 61 KPSLKDRTITISRDTSKNQFSLKSSVTAAADTAVYICARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRTITISRDTSKNQFSLKSSVTAAADTAVYICARYGRVFFDYWGQGLTVTVSS 135

RESULT 3
US-10-735-916A-79
Sequence 79, Application US/10735916A
Publication No. US20050084906A1
GENERAL INFORMATION:
APPLICANT: GOETSCH, Liliane
APPLICANT: CORVAIA, Nathalie
APPLICANT: LEGER, Olivier
APPLICANT: DUFLOS, Alain
APPLICANT: BECK, Alain
APPLICANT: HAEUW, Jean-Francois
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
FILE REFERENCE: 017753-183
CURRENT APPLICATION NUMBER: US/10/735,916A
CURRENT FILING DATE: 2003-12-16
PRIOR APPLICATION NUMBER: FR 03/08 538
PRIOR FILING DATE: 2003-07-11
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
PRIOR FILING DATE: 2003-01-20
PRIOR APPLICATION NUMBER: FR 02/00 653
PRIOR FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: FR 02/00 654
PRIOR FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: FR 02/05 753
PRIOR FILING DATE: 2002-05-07
NUMBER OF SEQ ID NOS: 156
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 79
LENGTH: 117
TYPE: PRT
ORGANISM: Homo sapiens

US-10-735-916A-79
Query Match 99.2%; Score 623; DB 5; Length 117;
Best Local Similarity 98.3%; Pred. No. 1.2e-48;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60
QY 61 KPSLKDRTITISRDTSKNQFSLKSSVTAAADTAVYICARYGRVFFDYWGQGLTVTVSS 117
Db 61 KPSLKDRTITISRDTSKNQFSLKSSVTAAADTAVYICARYGRVFFDYWGQGLTVTVSS 117

RESULT 4
US-10-735-916A-81
Sequence 81, Application US/10735916A
Publication No. US20050084906A1
GENERAL INFORMATION:
APPLICANT: GOETSCH, Liliane
APPLICANT: CORVAIA, Nathalie
APPLICANT: LEGER, Olivier
APPLICANT: DUFLOS, Alain
APPLICANT: BECK, Alain
APPLICANT: HAEUW, Jean-Francois
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
FILE REFERENCE: 017753-183
CURRENT APPLICATION NUMBER: US/10/735,916A
CURRENT FILING DATE: 2003-12-16
PRIOR APPLICATION NUMBER: FR 03/08 538
PRIOR FILING DATE: 2003-07-11
PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
PRIOR FILING DATE: 2003-01-20
PRIOR APPLICATION NUMBER: FR 02/00 653
PRIOR FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: FR 02/00 654
PRIOR FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: FR 02/05 753
PRIOR FILING DATE: 2002-05-07
NUMBER OF SEQ ID NOS: 156
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 81
LENGTH: 135
TYPE: PRT
ORGANISM: Homo sapiens
US-10-735-916A-81

Query Match 99.2%; Score 623; DB 5; Length 135;
Best Local Similarity 98.3%; Pred. No. 1.4e-48;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 78
QY 61 KPSLKDRTITISRDTSKNQFSLKSSVTAAADTAVYICARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRTITISRDTSKNQFSLKSSVTAAADTAVYICARYGRVFFDYWGQGLTVTVSS 135

RESULT 5
US-10-735-916A-83
Sequence 83, Application US/10735916A
Publication No. US20050084906A1
GENERAL INFORMATION:
APPLICANT: GOETSCH, Liliane
APPLICANT: CORVAIA, Nathalie
APPLICANT: LEGER, Olivier
APPLICANT: DUFLOS, Alain
APPLICANT: BECK, Alain
APPLICANT: HAEUW, Jean-Francois
TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF


```
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 52
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-735-916A-52

Query Match      86.9%; Score 546; DB 5; Length 127;
Best Local Similarity 86.2%; Pred. No. 1.2e-41;
Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY  2 VOLQSGPGLVKPSETLSLCTVSGYSITGGYLNWIRQPPGKGLWWMGYISYDGTNNYK 61
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db  12 VOLQSGPGLVKPQSLSLTCVSGYITGGYLNWIRQPPGKGLWWMGYISYDGTNNYK 71

QY  62 PSLKDRITTSRDTSKNQFSLKSSVTAADTAVYYCARYGRVFDYWGQGLTVTVSS 117
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db  72 PSLKDRITTSRDTSKNQFSLKSSVTAADTAVYYCARYGRVFDYWGQGLTVTVSS 127

RESULT 9
US-10-383-447-26
; Sequence 26, Application US/10383447
; Publication No. US20040096392A1
; GENERAL INFORMATION:
; APPLICANT: Bhaskar, Vinay
; APPLICANT: de la Calle, Agustin
; APPLICANT: Law, Debbie
; APPLICANT: Caras, Ingrid
; APPLICANT: Ramakrishnan, Vanitha
; APPLICANT: Murray, Richard
; APPLICANT: Afar, Daniel
; APPLICANT: Powers, David
; TITLE OF INVENTION: Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
; FILE REFERENCE: 05882.0138.NPUS00
; CURRENT APPLICATION NUMBER: US/10/383,447
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: US 60/362,837
; PRIOR FILING DATE: 2002-03-08
; PRIOR APPLICATION NUMBER: US 60/463,812
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Variable heavy chain region 3.0
US-10-383-447-26

Query Match      84.6%; Score 531.5; DB 4; Length 120;
Best Local Similarity 85.7%; Pred. No. 2.3e-40;
Matches 102; Conservative 4; Mismatches 10; Indels 3; Gaps 1;

QY  2 VOLQSGPGLVKPSETLSLCTVSGYSITGGYLNWIRQPPGKGLWWMGYISYDGTNNYK 61
Db  2 VOLQSGPGLVKPSETLSLCTCAVGSYISYGSYISYGSYISYGSYISYGSYISYGSYISY 61

QY  62 PSLKDRITTSRDTSKNQFSLKSSVTAADTAVYYCA---RYGRVFDYWGQGLTVTVSS 117
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db  62 PSLKDRITTSRDTSKNQFSLKSSVTAADTAVYYCARGLRGDSYNDYWGQGLTVTVSS 120

RESULT 10
US-10-383-447-24
; Sequence 24, Application US/10383447
; Publication No. US20040096392A1
; GENERAL INFORMATION:
; APPLICANT: Bhaskar, Vinay
; APPLICANT: de la Calle, Agustin
; APPLICANT: Law, Debbie
; APPLICANT: Caras, Ingrid
; APPLICANT: Ramakrishnan, Vanitha
; APPLICANT: Murray, Richard
; APPLICANT: Afar, Daniel
; APPLICANT: Powers, David
; TITLE OF INVENTION: Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
; FILE REFERENCE: 05882.0138.NPUS00
; CURRENT APPLICATION NUMBER: US/10/383,447
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: US 60/362,837
; PRIOR FILING DATE: 2002-03-08
; PRIOR APPLICATION NUMBER: US 60/463,812
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 24
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Variable heavy chain region 4.0
US-10-383-447-24

Query Match      81.0%; Score 508.5; DB 4; Length 120;
Best Local Similarity 81.5%; Pred. No. 1.5e-38;
Matches 97; Conservative 8; Mismatches 11; Indels 3; Gaps 1;

QY  2 VOLQSGPGLVKPSETLSLCTVSGYSITGGYLNWIRQPPGKGLWWMGYISYDGTNNYK 61
Db  2 VOLQSGPGLVKPSETLSLCTCAVTSYISYGSYISYGSYISYGSYISYGSYISYGSYISY 61

QY  62 PSLKDRITTSRDTSKNQFSLKSSVTAADTAVYYCA---RYGRVFDYWGQGLTVTVSS 117
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db  62 PSLKDRITTSRDTSKNQFSLKSSVTAADTAVYYCARGLRGDSYNDYWGQGLTVTVSS 120

RESULT 11
US-10-383-447-28
; Sequence 28, Application US/10383447
; Publication No. US20040096392A1
; GENERAL INFORMATION:
; APPLICANT: Bhaskar, Vinay
; APPLICANT: de la Calle, Agustin
; APPLICANT: Law, Debbie
; APPLICANT: Caras, Ingrid
; APPLICANT: Ramakrishnan, Vanitha
; APPLICANT: Murray, Richard
; APPLICANT: Afar, Daniel
; APPLICANT: Powers, David
; TITLE OF INVENTION: Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
; FILE REFERENCE: 05882.0138.NPUS00
; CURRENT APPLICATION NUMBER: US/10/383,447
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: US 60/362,837
; PRIOR FILING DATE: 2002-03-08
; PRIOR APPLICATION NUMBER: US 60/463,812
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Variable heavy chain region 4.0
US-10-383-447-28

Query Match      81.0%; Score 508.5; DB 4; Length 120;
Best Local Similarity 81.5%; Pred. No. 1.5e-38;
Matches 97; Conservative 8; Mismatches 11; Indels 3; Gaps 1;
```

Best Local Similarity 83.2%; Pred. No. 2.8e-38;
Matches 99; Conservative 4; Mismatches 13; Indels 3; Gaps 1;
QY 2 VOLQESGGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWGMGYISYDGTNNY 61
Db 2 VOLQESGGLVKPSETLSLTCAVSGYSITGGYWSWIRQPPGKLEWGMGFISYDGSNKN 61
QY 62 PSLKDRITISRDTSKNQFSLKSSVTAADTAVYYCA---RYGRVFPDYWGQGLTVTVSS 117
Db 62 PSLKDRITISRDTSKNQFSLKSSVTAADTATYTCARGLRGDYSMDYWGQGLTVTVSS 120

RESULT 12

US-10-309-762-143
; Sequence 143, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Foltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX
; TITLE OF INVENTION: (CA IX) TUMOR ANTIGEN
; FILE REFERENCE: ABGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 143
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-143

Query Match 80.1%; Score 503; DB 4; Length 119;
Best Local Similarity 81.7%; Pred. No. 8.7e-38;
Matches 98; Conservative 7; Mismatches 11; Indels 4; Gaps 2;

QY 1 VOLQESGGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWGMGYISYDGTNNY 60
Db 1 VOLQESGGLVKPSETLSLTCTVSGGSIS-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59
QY 61 KPSLKDRTITISRDTSKNQFSLKSSVTAADTAVYYCARYGRV---PFDYWGQGLTVTVSS 117
Db 60 NPSLKSRTISVDTSKNQFSLKSSVTAADTAVYYCARYDILTYGYFDYWGQGLTVTVSS 119

RESULT 13

US-10-292-088-109
; Sequence 109, Application US/10292088
; Publication No. US20030211100A1
; GENERAL INFORMATION:
; APPLICANT: BEDIAN, VAHE
; APPLICANT: GLADUE, RONALD P.
; APPLICANT: CORVALAN, JOSE
; APPLICANT: JIA, XIAO-CHI
; APPLICANT: FENG, XIAO
; TITLE OF INVENTION: ANTIBODIES TO CD40
; FILE REFERENCE: ABX-PF/3 US
; CURRENT APPLICATION NUMBER: US/10/292,088
; CURRENT FILING DATE: 2003-03-14
; PRIOR APPLICATION NUMBER: 60/348,980
; PRIOR FILING DATE: 2001-11-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 109
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-292-088-109

Query Match 79.7%; Score 500.5; DB 4; Length 118;
Best Local Similarity 82.4%; Pred. No. 1.5e-37;
Matches 98; Conservative 6; Mismatches 12; Indels 3; Gaps 2;
QY 1 VOLQESGGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWGMGYISYDGTNNY 60
Db 1 VOLQESGGLVKPSETLSLTCTVSGGSIS-SYYWSWIRQPPGKLEWIGYIYSGSTNY 59
QY 61 KPSLKDRTITISRDTSKNQFSLKSSVTAADTAVYYCAR---YGRVFPDYWGQGLTVTVSS 117
Db 60 NPSLKSRTISVDTSKNQFSLKSSVTAADTAVYYCARDYSGNSYFDYWGQGLTVTVSS 118

RESULT 14

US-10-805-177-56
; Sequence 56, Application US/10805177
; Publication No. US2005008449A1
; GENERAL INFORMATION:
; APPLICANT: Landes, Gregory M.
; APPLICANT: Chen, Francine
; APPLICANT: Bezabeh, Binyam
; APPLICANT: Foltz, Ian
; APPLICANT: Tse, Kam Fai
; APPLICANT: Jeffers, Michael
; APPLICANT: Mesri, Mehdi
; APPLICANT: Starling, Gary
; APPLICANT: Mezes, Peter
; APPLICANT: Khrantsov, Nikolai
; TITLE OF INVENTION: ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN
; TITLE OF INVENTION: DOMAIN AND MUCIN DOMAIN 1 (TIM-1) ANTIGEN AND USES THEREOF
; FILE REFERENCE: ABXCUR.006A
; CURRENT APPLICATION NUMBER: US/10/805,177
; CURRENT FILING DATE: 2004-03-19
; PRIOR APPLICATION NUMBER: 60/456,652
; PRIOR FILING DATE: 2003-03-19
; NUMBER OF SEQ ID NOS: 141
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 56
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-805-177-56

Query Match 79.5%; Score 499.5; DB 5; Length 121;
Best Local Similarity 81.7%; Pred. No. 1.8e-37;
Matches 98; Conservative 6; Mismatches 13; Indels 3; Gaps 2;

QY 1 VOLQESGGLVKPSETLSLTCTVSGYSI-TGGYLNWIRQPPGKLEWGMGYISYDGTNN 59
Db 1 VOLQESGGLVKPSETLSLTCTVSGGSYWSWIRQPPGKLEWIGYIYSGSTN 60
QY 60 KPSLKDRTITISRDTSKNQFSLKSSVTAADTAVYYCARYG--RVFPDYWGQGLTVTVSS 117
Db 61 YNPSLKSRTISVDTSKNQFSLKSSVTAADTAVYYCARNNNNNNFDYWGQGLTVTVSS 120

RESULT 15

US-10-309-762-25
; Sequence 25, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Foltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX
; TITLE OF INVENTION: (CA IX) TUMOR ANTIGEN
; FILE REFERENCE: ABGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246

```
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-25

Query Match      79.5%; Score 499.5; DB 4; Length 122;
Best Local Similarity 80.5%; Pred. No. 1.9e-37;
Matches 99; Conservative 5; Mismatches 12; Indels 7; Gaps 2;

QY      1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLMNWIQQPPKGLWMGYISYDGTNNY 60
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      1 QVQLQESGPGLVKPSSETLSLTCTVSGGIS-SYTWSWIRQPPKGLWIGIYIYSGSTNY 59
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY      61 KPSLKDRITISRDTSKNQPSLKLSSVTAADTAVYYCARYGRVP-----FDYWGQGLT 114
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      60 NPSLKSRVTISVDTSKNQPSLKLSSVTAADTAVYYCARRGYDFLTGYDYFDYWGQGLT 119
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY      115 VSS 117
      |||
Db      120 VSS 122
```

Search completed: January 10, 2006, 21:35:32
Job time : 64.1754 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:34:27 ; Search time 22.847 Seconds
(without alignments)
423.384 Million cell updates/sec

Title: US-10-735-916A-75
Perfect score: 628
Sequence: 1 QVQLQESGPGVKPSETLSL.....RYGRVFFDYWGQGLTVTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA: *
1: /cgn2_6/prodata/1/iaa/5_COMB.pep: *
2: /cgn2_6/prodata/1/iaa/6_COMB.pep: *
3: /cgn2_6/prodata/1/iaa/H_COMB.pep: *
4: /cgn2_6/prodata/1/iaa/PTCUS_COMB.pep: *
5: /cgn2_6/prodata/1/iaa/RE_COMB.pep: *
6: /cgn2_6/prodata/1/iaa/backfiles1.pep: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	496	79.0	119	2	US-09-025-769B-39
2	496	79.0	119	2	US-09-025-769B-65
3	496	79.0	119	2	US-09-490-070A-39
4	496	79.0	119	2	US-09-490-070A-65
5	496	79.0	119	2	US-09-490-153-39
6	496	79.0	119	2	US-09-490-153-65
7	496	79.0	119	2	US-09-490-324-39
8	496	79.0	119	2	US-09-490-324-65
9	493	78.5	117	2	US-09-720-493-2
10	483	76.9	117	2	US-10-330-613A-13
11	482.5	76.8	473	1	US-09-049-672A-4
12	482	76.8	123	1	US-08-137-117D-64
13	482	76.8	123	1	US-08-436-717-64
14	482	76.8	138	1	US-08-137-117D-69
15	482	76.8	138	1	US-08-436-717-69
16	480	76.4	118	2	US-09-065-059-11
17	480	76.4	118	2	US-08-913-555-11
18	479.5	76.4	118	2	US-09-025-769B-25
19	479.5	76.4	118	2	US-09-490-070A-25
20	479.5	76.4	118	2	US-09-490-153-25
21	479.5	76.4	118	2	US-09-490-324-25
22	478.5	76.2	244	2	US-08-918-148-79
23	478.5	76.2	244	2	US-09-138-091A-77
24	471	75.0	121	2	US-10-330-613A-1
25	471	75.0	121	2	US-10-330-613A-17
26	470.5	74.9	487	2	US-09-800-729-145
27	469	74.7	117	2	US-10-330-613A-5

28	468.5	74.6	118	2	US-09-343-698-6	Sequence 6, Appli
29	468.5	74.6	118	2	US-08-325-955-6	Sequence 6, Appli
30	467.5	74.4	832	2	US-08-630-820-7	Sequence 7, Appli
31	467.5	74.4	832	2	US-09-273-453-7	Sequence 7, Appli
32	467	74.4	121	2	US-10-330-613A-9	Sequence 9, Appli
33	466	74.2	119	1	US-08-360-125-5	Sequence 5, Appli
34	466	74.2	119	1	US-08-450-578-5	Sequence 5, Appli
35	466	74.2	119	1	US-09-017-628-5	Sequence 5, Appli
36	466	74.2	119	1	US-09-014-880-5	Sequence 5, Appli
37	466	74.2	119	1	US-08-450-363-5	Sequence 5, Appli
38	466	74.2	119	2	US-09-467-903-5	Sequence 5, Appli
39	465.5	74.1	120	2	US-08-554-840-5	Sequence 5, Appli
40	465.5	74.1	120	2	US-08-925-339-5	Sequence 5, Appli
41	465.5	74.1	120	2	US-09-332-595-5	Sequence 5, Appli
42	465	74.0	119	2	US-08-767-128-18	Sequence 18, Appli
43	464.5	74.0	139	2	US-09-471-276-837	Sequence 837, App
44	464.5	74.0	278	2	US-09-260-527-3	Sequence 3, Appli
45	463	73.7	142	1	US-08-480-774A-2	Sequence 2, Appli

ALIGNMENTS

RESULT 1
US-09-025-769B-39
; Sequence 39, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; FILING DATE: 18-FEB-1998
; PRIORITY APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-025-769B-39

Query Match 79.0%; Score 496; DB 2; Length 119;
Best Local Similarity 81.7%; Pred. No. 4.8e-42;
Matches 98; Conservative 6; Mismatches 12; Indels 4; Gaps 2;

```
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWGMGYSYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGISIS-SYYWSWIRQPPGKGLWIGIYYSGSTNY 59
QY 61 KPSLKDRTITSRDTSKNQFSLKLSVTAADTAIVYICARYGRVFF---DYWGQGLTLVTSS 117
Db 60 NPSLSKRVITISVDTSKNQFSLKLSVTAADTAIVYICARWGDFYAMDYWGQGLTLVTSS 119

RESULT 2
US-09-025-769B-65
; Sequence 65, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-65

Query Match 79.0%; Score 496; DB 2; Length 119;
Best Local Similarity 81.7%; Pred. No. 4.8e-42;
Matches 98; Conservative 6; Mismatches 12; Indels 4; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWGMGYSYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGISIS-SYYWSWIRQPPGKGLWIGIYYSGSTNY 59
QY 61 KPSLKDRTITSRDTSKNQFSLKLSVTAADTAIVYICARYGRVFF---DYWGQGLTLVTSS 117
Db 60 NPSLSKRVITISVDTSKNQFSLKLSVTAADTAIVYICARWGDFYAMDYWGQGLTLVTSS 119

RESULT 3
US-09-490-070A-39
; Sequence 39, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
```

```
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
White & McAuliffe
STREET: 1666 K Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20006
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,070A
FILING DATE: 24-Jan-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: Colin G. Sandercock, Esq.
REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 37629-0005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 912-2000
TELEFAX: (202) 912-2020
INFORMATION FOR SEQ ID NO: 39:
SEQUENCE CHARACTERISTICS:
LENGTH: 119 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 39:
US-09-490-070A-39

Query Match 79.0%; Score 496; DB 2; Length 119;
Best Local Similarity 81.7%; Pred. No. 4.8e-42;
Matches 98; Conservative 6; Mismatches 12; Indels 4; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWGMGYSYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGISIS-SYYWSWIRQPPGKGLWIGIYYSGSTNY 59
QY 61 KPSLKDRTITSRDTSKNQFSLKLSVTAADTAIVYICARYGRVFF---DYWGQGLTLVTSS 117
Db 60 NPSLSKRVITISVDTSKNQFSLKLSVTAADTAIVYICARWGDFYAMDYWGQGLTLVTSS 119

RESULT 4
US-09-490-070A-65
; Sequence 65, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
```

White & McAlliff
STREET: 1666 K Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20006

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,070A
FILING DATE: 24-Jan-2000

PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995

ATTORNEY/AGENT INFORMATION:
NAME: Colin G. Sandercock, Esq.
REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 37629-0005

TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 912-2000
TELEFAX: (202) 912-2020

INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 119 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-490-070A-65

Query Match 79.0%; Score 496; DB 2; Length 119;
Best Local Similarity 81.7%; Pred. No. 4.8e-42;
Matches 98; Conservative 6; Mismatches 12; Indels 4; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYNSWIRQPPGKGLWMGYISYDGTNNY 59

QY 61 KPSLKDRTITISDTSKNQPSLKSSTAAADTAVVYCARYGRVFF---DYWGQGLTVTVSS 117
Db 60 NPSLKSRTVTSVDTSKNQPSLKSSTAAADTAVVYCARYGRVFF---DYWGQGLTVTVSS 119

RESULT 5
US-09-490-153-39
Sequence 39, Application US/09490153
Patent No. 6706484

GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas

TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373

CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,153
FILING DATE: 24-Jan-2000

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769B
FILING DATE: 18-FEB-1998

ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5

FILING DATE: 24-Jan-2000

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769B
FILING DATE: 18-FEB-1998
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995

ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5

TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 596-9000
TELEFAX: (212) 596-9090

INFORMATION FOR SEQ ID NO: 39:
SEQUENCE CHARACTERISTICS:
LENGTH: 119 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 39:
US-09-490-153-39

Query Match 79.0%; Score 496; DB 2; Length 119;
Best Local Similarity 81.7%; Pred. No. 4.8e-42;
Matches 98; Conservative 6; Mismatches 12; Indels 4; Gaps 2;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLWMGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYNSWIRQPPGKGLWMGYISYDGTNNY 59

QY 61 KPSLKDRTITISDTSKNQPSLKSSTAAADTAVVYCARYGRVFF---DYWGQGLTVTVSS 117
Db 60 NPSLKSRTVTSVDTSKNQPSLKSSTAAADTAVVYCARYGRVFF---DYWGQGLTVTVSS 119

RESULT 6
US-09-490-153-65
Sequence 65, Application US/09490153
Patent No. 6706484

GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas

TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373

CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,153
FILING DATE: 24-Jan-2000

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769B
FILING DATE: 18-FEB-1998

ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5

```

;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-490-153-65
Query Match 79.0%; Score 496; DB 2; Length 119;
Best Local Similarity 81.7%; Pred. No. 4.8e-42;
Matches 98; Conservative 6; Mismatches 12; Indels 4; Gaps 2;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYMSWIRQPPGKLEWIGYIYSGSTNY 59
QY 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFF---DYWGQGLTVTVSS 117
DB 60 NPSLSKSRVTISVDTSKNQFSLKSSVTAADTAVVYCARYGRVFF---DYWGQGLTVTVSS 119

RESULT 7
US-09-490-324-39
; Sequence 39, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 39:
US-09-490-324-39
Query Match 79.0%; Score 496; DB 2; Length 119;
Best Local Similarity 81.7%; Pred. No. 4.8e-42;
Matches 98; Conservative 6; Mismatches 12; Indels 4; Gaps 2;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYMSWIRQPPGKLEWIGYIYSGSTNY 59
QY 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFF---DYWGQGLTVTVSS 117
DB 60 NPSLSKSRVTISVDTSKNQFSLKSSVTAADTAVVYCARYGRVFF---DYWGQGLTVTVSS 119

RESULT 8
US-09-490-324-65
; Sequence 65, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-490-324-65
Query Match 79.0%; Score 496; DB 2; Length 119;
Best Local Similarity 81.7%; Pred. No. 4.8e-42;
Matches 98; Conservative 6; Mismatches 12; Indels 4; Gaps 2;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGGSIS-SYYMSWIRQPPGKLEWIGYIYSGSTNY 59
QY 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVVYCARYGRVFF---DYWGQGLTVTVSS 117
DB 60 NPSLSKSRVTISVDTSKNQFSLKSSVTAADTAVVYCARYGRVFF---DYWGQGLTVTVSS 119
```

```
Db 60 NPSLKSRTVISVDTSKNQFSLKSLSSVTAADTAVVYCARWGSGDFYAMDYWGQGLTLTVSS 119
|||||:|||||
RESULT 9
US-09-720-493-2
; Sequence 2, Application US/09720493
; Patent No. 6827925
; GENERAL INFORMATION:
; APPLICANT: Cambridge Antibody Technology Limited
; APPLICANT: Williams, Andrew J
; APPLICANT: Tempest, Philip R
; APPLICANT: Holtet, Thor L
; APPLICANT: Main, Sarah H
; APPLICANT: Jackson, Helen
; APPLICANT: Daromola, Olalekan
; TITLE OF INVENTION: Improvements relating to antibodies
; FILE REFERENCE: AHB/CP575333
; CURRENT APPLICATION NUMBER: US/09/720,493
; CURRENT FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: GB 9814383.7
; PRIOR FILING DATE: 1998-07-02
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-720-493-2
Query Match 78.5%; Score 493; DB 2; Length 117;
Best Local Similarity 81.2%; Pred. No. 9.3e-42;
Matches 95; Conservative 5; Mismatches 17; Indels 0; Gaps 0;
QY 1 QVQLQSGGPGLVKPSSETLSLTCTVSGVSIITGGVYLNWIRQPPGKGLGWMGYISYDGTNNY 60
Db 1 QVQLQSGGPGLVKPSSETLSLTCTVSGVSIITGGVYLNWIRQPPGKGLGWMGYISYHSGSTY 60
QY 61 KPSLKDRTITSRDTSKNQFSLKSLSSVTAADTAVVYCARVGRVFFDYWGQGLTLTVSS 117
Db 61 NPSLKSRTVISVDTSKNQFSLKSLSSVTAADTAVVYCARGWKSKFDYWGQGLTLTVSS 117
RESULT 10
US-10-330-613A-13
; Sequence 13, Application US/10330613A
; Patent No. 6924360
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN
; FILE REFERENCE: ABGENIX.022A
; CURRENT APPLICATION NUMBER: US/10/330,613A
; CURRENT FILING DATE: 2002-12-26
; PRIOR APPLICATION NUMBER: 60/346299
; PRIOR FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: Fast-Seq for Windows Version 4.0
; SEQ ID NO 13
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-330-613A-13
Query Match 76.9%; Score 483; DB 2; Length 117;
Best Local Similarity 81.4%; Pred. No. 9.3e-41;
Matches 96; Conservative 6; Mismatches 14; Indels 2; Gaps 2;
QY 1 QVQLQSGGPGLVKPSSETLSLTCTVSGYSI-TGGVYLNWIRQPPGKGLGWMGYISYDGTNN 59
Db 1 QVQLQSGGPGLVKPSQTLSTLTCTVSGSISGGYVYTWIRQHPGKGLGWFYISGSTY 60
QY 60 YKPSLKDRTITSRDTSKNQFSLKSLSSVTAADTAVVYCARVGRVFFDYWGQGLTLTVSS 117
```

```
Db 61 YNPSLKSRTVISVDTSKNQFSLKSLSSVTAADTAVVYCAREGD-GFDYWGQGLTLTVSS 117
RESULT 11
US-09-049-672A-4
; Sequence 4, Application US/09049672A
; Patent No. 6135941
; GENERAL INFORMATION:
; APPLICANT: Hillman, Jennifer L.
; APPLICANT: Lal, Preeti
; APPLICANT: Tang, Y. Tom
; APPLICANT: Yue, Henry
; APPLICANT: Au-Young, Janice
; APPLICANT: Corley, Neil C.
; APPLICANT: Guegler, Karl J.
; APPLICANT: Baughn, Mariah R.
; TITLE OF INVENTION: HUMAN IMMUNE SYSTEM ASSOCIATED PROTEINS
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/049,672A
; FILING DATE: HERewith
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Cerrone, Michael C
; REGISTRATION NUMBER: 39,132
; REFERENCE/DOCKET NUMBER: PF-0497 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-855-0555
; TELEFAX: 650-845-4166
; TELEX:
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 473 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; LIBRARY: PANCUTUT01
; CLONE: 1513264
; US-09-049-672A-4
Query Match 76.8%; Score 482.5; DB 2; Length 473;
Best Local Similarity 77.2%; Pred. No. 5.6e-40;
Matches 98; Conservative 4; Mismatches 12; Indels 13; Gaps 3;
QY 1 QVQLQSGGPGLVKPSSETLSLTCTVSGYSIT-GGYLNWIRQPPGKGLGWMGYISYDGTNN 59
Db 20 QVQLQSGGPGLVKPSSETLSLTCAVSGSITSGGYVWSWIRQPPGKGLGWFYISGSTL 79
QY 60 YKPSLKDRTITSRDTSKNQFSLKSLSSVTAADTAVVYCAR-----YGRVFFDYWGQ 110
Db 80 YNPSLKSRTVISVDTSKNQFSLKSLSSVTAADTAVVYCARDDVGLRGNTG---MDVWGQ 136
QY 111 TLTVSS 117
Db 137 TLTVSS 143
```

RESULT 12
US-08-137-117D-64
; Sequence 64, Application US/08137117D
; Patent No. 5795965
; GENERAL INFORMATION:
; APPLICANT: TSUCHIYA, Masayuki
; APPLICANT: SATO, Koh
; APPLICANT: BENDIG, Mary
; APPLICANT: JONES, Steven
; APPLICANT: SALDANHA, Jose
; TITLE OF INVENTION: RESHAPED HUMAN ANTIBODY TO HUMAN
; TITLE OF INVENTION: INTERLEUKIN-6 RECEPTOR
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/137,117D
; FILING DATE: 20-DEC-1993
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO PCT/JP92/00544
; FILING DATE: 24-APR-1992
; PRIOR APPLICATION NUMBER: JP 4-32084
; FILING DATE: 19-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 3-95476
; FILING DATE: 25-APR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: WEGNER, Harold C.
; REGISTRATION NUMBER: 25,258
; REFERENCE/DOCKET NUMBER: 53466/126/AAOK
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 123 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-137-117D-64

Query Match 76.8%; Score 482; DB 1; Length 123;
Best Local Similarity 75.6%; Pred. No. 1.2e-40;
Matches 90; Conservative 11; Mismatches 16; Indels 2; Gaps 1;

QY 1 QVQLQESGFLVKPSETLSLTCTVSGYSITGGLYNWIRQPPGKGLWNGYISYDGTNNY 60
Db 5 QVQLQESGFLVKPSETLSLTCTVSGYSITSDHANSWVRQPPGRLGIEWIGYISYSGITTY 64

QY 61 KPSLKDRTITISDTSKNQPSLKLSSVTAAADTAATVYICAR--YGRVFDYWGQGLTVTVSS 117
Db 65 NPSLSRVTLMDRTSKNQPSLRLSSVTAAADTAATVYICARSLARTTAMDYWGQGLTVTVSS 123

RESULT 13
US-08-436-717-64
; Sequence 64, Application US/08436717
; Patent No. 5817790
; GENERAL INFORMATION:
; APPLICANT: TSUCHIYA, Masayuki

; APPLICANT: SATO, Koh
; APPLICANT: BENDIG, Mary
; APPLICANT: JONES, Steven
; APPLICANT: SALDANHA, Jose
; TITLE OF INVENTION: RESHAPED HUMAN ANTIBODY TO HUMAN
; TITLE OF INVENTION: INTERLEUKIN-6 RECEPTOR
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/436,717
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/137,117
; FILING DATE: 20-DEC-1993
; APPLICATION NUMBER: WO PCT/JP92/00544
; FILING DATE: 24-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 4-32084
; FILING DATE: 19-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 3-95476
; FILING DATE: 25-APR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: WEGNER, Harold C.
; REGISTRATION NUMBER: 25,258
; REFERENCE/DOCKET NUMBER: 53466/126/AAOK
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 123 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-436-717-64

Query Match 76.8%; Score 482; DB 1; Length 123;
Best Local Similarity 75.6%; Pred. No. 1.2e-40;
Matches 90; Conservative 11; Mismatches 16; Indels 2; Gaps 1;

QY 1 QVQLQESGFLVKPSETLSLTCTVSGYSITGGLYNWIRQPPGKGLWNGYISYDGTNNY 60
Db 5 QVQLQESGFLVKPSETLSLTCTVSGYSITSDHANSWVRQPPGRLGIEWIGYISYSGITTY 64

QY 61 KPSLKDRTITISDTSKNQPSLKLSSVTAAADTAATVYICAR--YGRVFDYWGQGLTVTVSS 117
Db 65 NPSLSRVTLMDRTSKNQPSLRLSSVTAAADTAATVYICARSLARTTAMDYWGQGLTVTVSS 123

RESULT 14
US-08-137-117D-69
; Sequence 69, Application US/08137117D
; Patent No. 5795965
; GENERAL INFORMATION:
; APPLICANT: TSUCHIYA, Masayuki
; APPLICANT: SATO, Koh
; APPLICANT: BENDIG, Mary
; APPLICANT: JONES, Steven
; APPLICANT: SALDANHA, Jose

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:07:41 ; Search time 80.7649 Seconds
(without alignments)
636.505 Million cell updates/sec

Title: US-10-735-916A-75
Perfect score: 628
Sequence: 1 QVQIQESGFLVKPSETLSL.....RYGRVFFDYWGQTLVTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_21:*
1: Geneseqp1980s:*
2: Geneseqp1990s:*
3: Geneseqp2000s:*
4: Geneseqp2001s:*
5: Geneseqp2002s:*
6: Geneseqp2003as:*
7: Geneseqp2003bs:*
8: Geneseqp2004s:*
9: Geneseqp2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	628	100.0	117	7	ADJ76909 Anti-IGF-
2	628	100.0	117	7	ADZ67079 Human ant
3	628	100.0	135	7	ADJ76911 Anti-IGF-
4	628	100.0	135	9	ADZ67081 Human ant
5	623	99.2	117	7	ADJ76913 Anti-IGF-
6	623	99.2	117	9	ADZ67083 Human ant
7	623	99.2	135	7	ADJ76915 Anti-IGF-
8	623	99.2	135	9	ADZ67085 Human ant
9	611	97.3	117	7	ADJ76917 Anti-IGF-
10	611	97.3	117	9	ADZ67087 Human ant
11	611	97.3	135	7	ADJ76919 Anti-IGF-
12	611	97.3	135	9	ADZ67089 Human ant
13	546	86.9	117	7	ADJ76903 Anti-IGF-
14	546	86.9	117	9	ADZ67073 Murine im
15	546	86.9	127	7	ADJ76886 Anti-IGF-
16	546	86.9	127	9	ADZ67056 Murine im
17	531.5	84.6	120	7	ADZ67457 Humanised
18	511.5	81.4	120	7	ADZ67455 Humanised
19	508.5	81.0	120	7	ADZ67459 Humanised
20	505.5	80.5	246	3	AAV15126 Anti-muri
21	503	80.1	119	7	ADP03973 Murine-ex
22	502.5	80.0	121	8	ADP03859 Human ant
23	499.5	79.5	122	7	ADP03885 Murine-ex
24	499.5	79.5	122	7	ADP03889 Murine-ex

25	498.5	79.4	120	7	ADP03958 Murine-ex
26	496.5	79.1	116	7	ADP03957 Murine-ex
27	496.5	79.1	121	5	ABD07171 ebvflgM M
28	496.5	79.1	121	8	ADI26658 Human ant
29	496.5	79.1	122	7	ADP03887 Murine-ex
30	496.5	79.1	122	7	ADP03884 Murine-ex
31	496	79.0	119	2	AAW27554 Human Ab
32	496	79.0	119	6	ABJ18676 Antibody
33	496	79.0	121	7	ADZ68455 Human ant
34	496	79.0	466	7	ADE28479 Human ant
35	494	78.7	119	9	ADY74798 Human Igg
36	493.5	78.6	118	9	AEC20804 Low+ mode
37	493.5	78.6	467	9	AEC20877 Human ant
38	493	78.5	117	3	AAV44615 Human ant
39	493	78.5	121	7	ADE28491 Human ant
40	493	78.5	466	7	ADE28471 Human ant
41	493	78.5	580	6	AAO30915 Human ant
42	493	78.5	580	6	AAO30913 Human ant
43	491.5	78.3	122	9	ABA21456 Human ant
44	491.5	78.3	139	9	ADX98267 Human ant
45	490.5	78.1	121	8	ADS16505 Human ant

ALIGNMENTS

RESULT 1
ADJ76909
ID ADJ76909 standard; protein; 117 AA.
XX
AC ADJ76909;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-IGF-IR related protein #22.
XX
KW cytostatic; antiprosoriatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDR.
XX
OS Homo sapiens.
XX
PN WO2003059951-A2.
XX
PD 24-JUL-2003.
XX
PF 20-JAN-2003; 2003WO-FR000178.
XX
PR 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
XX
XX 07-MAY-2002; 2002FR-00005753.
(FABR) FABRE MEDICAMENT SA PIERRE.
XX
PI Goetsch L, Corvaia N, Leger O;
XX
DR WPI; 2003-569653/53.
XX
PT New antibodies that bind to human insulin-like growth factor receptor,
XX useful for treatment, prevention and diagnosis of cancers.
XX
PS Disclosure; SEQ ID NO 75; 164pp; French.
XX
CC The invention relates to an isolated antibody (Ab), and its functional
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
CC treat diseases associated with overexpression and/or abnormal activity of
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
CC hyperactivity of signal transduction pathways mediated by interaction of

CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.
 XX
 SQ Sequence 117 AA;

Query Match 100.0%; Score 628; DB 7; Length 117;
 Best Local Similarity 100.0%; Pred. No. 3.2e-49;
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60
 DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60
 QY 61 KPSLKDRITISRDTSKNQFSLKLSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117
 DB 61 KPSLKDRITISRDTSKNQFSLKLSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117

RESULT 2
 ADZ67079
 ID ADZ67079 standard; protein; 117 AA.

AC ADZ67079;

DT 30-JUN-2005 (first entry)

DE Human antibody 7C10 1 heavy chain variable region SEQ ID NO:75.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW heavy chain variable region.

XX Homo sapiens.

PN US2005084906-A1.

XX 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.

PR 07-MAY-2002; 2002FR-00005753.

PR 20-JAN-2003; 2003WO-FR000178.

PR 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.

PA (CORV/) CORVAIA N.

PA (LEGE/) LIEGER O.

PA (DUF/) DUFLOS A.

PA (HAEU/) HAEUW J.

PA (BECK/) BECK A.

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

PI WPI; 2005-321968/33.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)

PT antibody or its functional fragment, being capable of binding human IGF-

CC The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-IR and, if necessary, capable of
 CC specifically inhibiting tyrosine kinase activity of the receptor,
 CC comprising a light or heavy chain having at least one complementary
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-IR and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
 CC the administration of the medicament does not induce or only slightly
 CC induces secondary effects connected with inhibition of the insulin
 CC receptor. The antibody is useful for preparation of a medicament intended
 CC to inhibit the transformation of normal cells into cells with tumoral
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
 CC dependent and/or EGF-dependent and/or HIR2/neu-dependent cells. (I) is
 CC useful for preparation of a medicament intended to inhibit the growth
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a
 CC medicament intended for prevention or for the treatment of cancer, where
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 CC preparation of a medicament intended for the prevention or for the
 CC treatment of psoriasis. (I) is useful in preparation of a medicament
 CC intended for the specific targeting of a biologically active compound to
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
 CC is useful for in vitro diagnosis of illnesses induced by an
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
 CC starting from a biological sample in which the abnormal presence, of IGF-
 CC IR and/or EGFR receptor is suspected, which involves contacting the
 CC biological sample with (I), which is optionally labeled. The present
 CC sequence is used in the exemplification of the invention.

XX Sequence 117 AA;

Query Match 100.0%; Score 628; DB 9; Length 117;
 Best Local Similarity 100.0%; Pred. No. 3.2e-49;
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60

DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWNGYISYDGTNNY 60

QY 61 KPSLKDRITISRDTSKNQFSLKLSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117

DB 61 KPSLKDRITISRDTSKNQFSLKLSVTAADTAVVYCARYGRVFFDYWGQGLTVTVSS 117

RESULT 3

ADJ76911

ID ADJ76911 standard; protein; 135 AA.

XX AC ADJ76911;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-IR related protein #23.

XX KW cytostatic; antipsoriatic; antibody;

KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;

KW or epidermal growth factor receptor; EGFR; signal transduction pathway;

KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;

XX CDR.

OS Homo sapiens.

XX WO2003059951-A2.

XX PD 24-JUL-2003.

```

PF 20-JAN-2003; 2003WO-FR000178.
XX
XX 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
XX
XX (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
XX Goetsch L, Corvaia N, Leger O;
XX
XX WPI; 2003-569653/53.
XX
XX New antibodies that bind to human insulin-like growth factor receptor,
XX useful for treatment, prevention and diagnosis of cancers.
XX
XX Disclosure; SEQ ID NO 77; 164pp; French.
XX
XX The invention relates to an isolated antibody (Ab), and its functional
XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
XX IR) and optionally: (i) inhibit natural binding of insulin-like growth
XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
XX kinase activity of IGF-1R. Ab and its fragments are used to prevent or
XX treat diseases associated with overexpression and/or abnormal activity of
XX IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
XX hyperactivity of signal transduction pathways mediated by interaction of
XX these receptors with their ligands. Especially they inhibit
XX transformation of normal cells to tumor cells, inhibit growth and/or
XX proliferation of tumor cells, so are useful against cancers of the
XX prostate, lung, breast, endometrium and colon, also osteosarcoma, and
XX also for treating psoriasis. Ab are also used to diagnose diseases caused
XX by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
XX protein sequence used to generate the Ab of the invention.
XX
XX Sequence 135 AA;
XX
XX Query Match 100.0%; Score 628; DB 7; Length 135;
XX Best Local Similarity 100.0%; Pred. No. 3.8e-49;
XX Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 QVQLQESGFLVKKPSETLSLCTVSGYSITGGYLWNWIRQPPGKLEWNGYISYDGTNNY 60
XX 19 QVQLQESGFLVKKPSETLSLCTVSGYSITGGYLWNWIRQPPGKLEWNGYISYDGTNNY 78
XX
XX 61 KPSLKDRITISRDTSKQFSLKSSVTAADTAVVYCARVGRVFPDYWGQGLTVTVSS 117
XX 79 KPSLKDRITISRDTSKQFSLKSSVTAADTAVVYCARVGRVFPDYWGQGLTVTVSS 135
XX
XX RESULT 4
XX ADZ67081
XX ID ADZ67081 standard; protein; 135 AA.
XX
XX AC ADZ67081;
XX
XX 30-JUN-2005 (first entry)
XX
XX Human antibody 7C10 1 heavy chain variable region SEQ ID NO:77.
XX
XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
XX neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
XX musculoskeletal disease; respiratory disease; lung tumor;
XX endocrine disease; gynecology and obstetrics; breast tumor;
XX endometroid carcinoma; gastrointestinal disease; colon tumor;
XX antipsoriatic; psoriasis; dermatological disease; immune disorder;
XX heavy chain variable region.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX Peptide 1..18
XX FT /note= "leader peptide"
XX FT 49..54
XX FT /note= "CDR1"
XX

```

```

FT Region 69..84
FT /note= "CDR2"
FT Region 117..124
FT /note= "CDR3"
XX
XX PN US2005084906-A1.
XX
XX PD 21-APR-2005.
XX
XX PF 16-DEC-2003; 2003US-00735916.
XX
XX PR 18-JAN-2002; 2002FR-00000653.
XX PR 18-JAN-2002; 2002FR-00000654.
XX PR 07-MAY-2002; 2002FR-00005753.
XX PR 20-JAN-2003; 2003WO-FR000178.
XX PR 11-JUL-2003; 2003FR-00008538.
XX
XX (GOET/) GOETSCH L.
XX (CORV/) CORVAIA N.
XX (LEGE/) LEGER O.
XX (DUFL/) DUFLOS J.
XX (HAEU/) HAEUW J.
XX (BECK/) BECK A.
XX
XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
XX
XX WPI; 2005-321968/33.
XX N-PSDB; ADZ67080.
XX
XX Novel isolated anti-insulin-like growth factor I receptor (IGF-1R)
XX antibody or its functional fragment, being capable of binding human IGF-
XX IR and specifically inhibiting tyrosine kinase activity of receptor,
XX useful for treating cancer.
XX
XX Example 13; SEQ ID NO 77; 125pp; English.
XX
XX The invention relates to a novel isolated anti-insulin-like growth factor
XX I receptor (IGF-1R) antibody (I) or its functional fragment, being
XX capable of binding to human IGF-1R and, if necessary, capable of
XX specifically inhibiting tyrosine kinase activity of the receptor,
XX comprising a light or heavy chain having at least one complementary
XX determining region (CDR) consisting of one of two fully defined 16 amino
XX acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
XX the preparation of a medicament intended for the prevention or treatment
XX of an illness connected with an overexpression and/or an abnormal
XX activation of the IGF-1R and/or EGFR, and/or connected with a
XX hyperactivation of the transduction pathway of the signal mediated by the
XX interaction of IGF1 or IGF2 with IGF-1R and/or of EGF with EGFR, where
XX the administration of the medicament does not induce or only slightly
XX induces secondary effects connected with inhibition of the insulin
XX receptor. The antibody is useful for preparation of a medicament intended
XX to inhibit the transformation of normal cells into cells with tumoral
XX character, preferably IGF-dependent, especially IGF1 and/or IGF2-
XX dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
XX useful for preparation of a medicament intended to inhibit the growth
XX and/or the proliferation of tumor cells, preferably IGF-dependent,
XX especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
XX HER2/neu-dependent cells. (I) is useful in the preparation of a
XX medicament intended for prevention or for the treatment of cancer, where
XX the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
XX breast cancer, endometrial cancer or colon cancer. (I) is useful in the
XX preparation of a medicament intended for the prevention or for the
XX treatment of psoriasis. (I) is useful in preparation of a medicament
XX intended for the specific targeting of a biologically active compound to
XX cells expressing or overexpressing the IGF-1R and/or EGFR receptor. (I)
XX is useful for in vitro diagnosis of illnesses induced by an
XX overexpression or an underexpression of the IGF-1R and/or EGFR receptor
XX starting from a biological sample in which the abnormal presence, of IGF-
XX IR and/or EGFR receptor is suspected, which involves contacting the
XX biological sample with (I), which is optionally labeled. The present
XX sequence is used in the exemplification of the invention.
XX
XX Sequence 135 AA;
XX

```

Query Match 100.0%; Score 628; DB 9; Length 135;
 Best Local Similarity 100.0%; Pred. No. 3.8e-49;
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWGWYISYDGTNNY 60
 DB 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWGWYISYDGTNNY 78

QY 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVVYCYGRVFFDYWGQGLTVTVSS 117
 DB 79 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVVYCYGRVFFDYWGQGLTVTVSS 135

RESULT 5
 ADJ76913
 ID ADJ76913 standard; protein; 117 AA.
 XX
 AC ADJ76913;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Anti-IGF-IR related protein #24.
 XX
 KW cytostatic; antipsoriatic; antibody;
 KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
 CDR.
 XX
 OS Homo sapiens.
 XX
 PN WO2003059951-A2.
 XX
 PD 24-JUL-2003.
 XX
 PF 20-JAN-2003; 2003WO-FR000178.
 XX
 PR 18-JAN-2002; 2002FR-00000653.
 PR 18-JAN-2002; 2002FR-00000654.
 PR 07-MAY-2002; 2002FR-000005753.
 XX
 PA (FABR) FABRE MEDICAMENT SA PIERRE.
 XX
 PI Goetsch L, Corvaia N, Leger O;
 XX
 DR WPI; 2003-569653/53.
 XX
 PT New antibodies that bind to human insulin-like growth factor receptor,
 XX useful for treatment, prevention and diagnosis of cancers.
 XX
 PS Disclosure; SEQ ID NO 79; 164pp; French.
 XX
 CC The invention relates to an isolated antibody (Ab), and its functional
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
 CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
 CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
 CC treat diseases associated with overexpression and/or abnormal activity of
 CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
 CC hyperactivity of signal transduction pathways mediated by interaction of
 CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.
 XX
 SQ Sequence 117 AA;

Query Match 99.2%; Score 623; DB 7; Length 117;
 Best Local Similarity 98.3%; Pred. No. 9.2e-49;

Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWGWYISYDGTNNY 60
 DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKLEWGWYISYDGTNNY 60

QY 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVVYCYGRVFFDYWGQGLTVTVSS 117
 DB 61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVVYCYGRVFFDYWGQGLTVTVSS 117

RESULT 6
 ADZ67083
 ID ADZ67083 standard; protein; 117 AA.
 XX
 AC ADZ67083;
 XX
 DT 30-JUN-2005 (first entry)
 XX
 DE Human antibody 7C10 2 heavy chain variable region SEQ ID NO:79.
 XX
 KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW heavy chain variable region.
 XX
 OS Homo sapiens.
 XX
 PN US2005084906-A1.
 XX
 PD 21-APR-2005.
 XX
 PF 16-DEC-2003; 2003US-00735916.
 XX
 PR 18-JAN-2002; 2002FR-00000653.
 PR 18-JAN-2002; 2002FR-00000654.
 PR 07-MAY-2002; 2002FR-00005753.
 PR 20-JAN-2003; 2003WO-FR000178.
 PR 11-JUL-2003; 2003FR-00008538.
 XX
 PA (GORT/) GOETSCH L.
 PA (CORV/) CORVAIA N.
 PA (LEGE/) LEGER O.
 PA (DUFLO/) DUFLOS A.
 PA (HAEU/) HAEUW J.
 PA (BECK/) BECK A.
 XX
 PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
 XX
 DR WPI; 2005-321968/33.
 XX
 CC Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 CC antibody or its functional fragment, being capable of binding human IGF-
 CC IR and specifically inhibiting tyrosine kinase activity of receptor,
 CC useful for treating cancer.
 XX
 PS Example 13; SEQ ID NO 79; 125pp; English.
 XX
 CC The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-IR and, if necessary, capable of
 CC specifically inhibiting tyrosine kinase activity of the receptor,
 CC comprising a light or heavy chain having at least one complementary
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-IR and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where

PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
PR 20-JAN-2003; 2003WO-FR000178.
PR 11-JUL-2003; 2003FR-00008538.
XX (GOET/) GOETSCH L.
PA (CORV/) CORVAIA N.
PA (LEGE/) LEGER O.
PA (DUPL/) DUFLOS A.
PA (HAEU/) HAEUW J.
PA (BECK/) BECK A.
XX
XX
PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
XX
XX WPI; 2005-321968/33.
DR N-PSDB; ADZ67084.
XX
XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
PT antibody or its functional fragment, being capable of binding human IGF-
PT IR and specifically inhibiting tyrosine kinase activity of receptor,
PT useful for treating cancer.
XX
PS Example 13; SEQ ID NO 81; 125pp; English.
XX
XX The invention relates to a novel isolated anti-insulin-like growth factor
CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
CC capable of binding to human IGF-IR and, if necessary, capable of
CC specifically inhibiting tyrosine kinase activity of the receptor,
CC comprising a light or heavy chain having at least one complementary
CC determining region (CDR) consisting of one of two fully defined 16 amino
CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
CC the preparation of a medicament intended for the prevention or treatment
CC of an illness connected with an overexpression and/or an abnormal
CC activation of the IGF-IR and/or EGFR, and/or connected with a
CC hyperactivation of the transduction pathway of the signal mediated by the
CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
CC the administration of the medicament does not induce or only slightly
CC induces secondary effects connected with inhibition of the insulin
CC receptor. The antibody is useful for preparation of a medicament intended
CC to inhibit the transformation of normal cells into cells with tumoral
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
CC useful for preparation of a medicament intended to inhibit the growth
CC and/or the proliferation of tumor cells, preferably IGF-dependent,
CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
CC HER2/neu-dependent cells. (I) is useful in the preparation of a
CC medicament intended for prevention or for the treatment of cancer, where
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
CC preparation of a medicament intended for the prevention or for the
CC treatment of psoriasis. (I) is useful in preparation of a medicament
CC intended for the specific targeting of a biologically active compound to
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
CC is useful for in vitro diagnosis of illnesses induced by an
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
CC starting from a biological sample in which the abnormal presence of IGF-
CC IR and/or EGFR receptor is suspected, which involves contacting the
CC biological sample with (I), which is optionally labeled. The present
CC sequence is used in the exemplification of the invention.
XX
SQ Sequence 135 AA;
Query Match 99.2%; Score 623; DB 9; Length 135;
Best Local Similarity 98.3%; Pred. No. 1.1e-48;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 1 QVQLQESGPGLVKPKSETLSLTCTVSGYSITGGLYLNWIRQPPGKLEWMGYISYDGTNNY 60
Db 19 QVQLQESGPGLVKPKSETLSLTCTVSGYSITGGLYLNWIRQPPGKLEWMGYISYDGTNNY 78
Qy 61 KPSLKDRITISRDTSKNQFSLKLSSTVAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117
Db 79 KPSLKDRVTISRDTSKNQFSLKLSSTVAADTAVYVCARYGRVFFDYWGQGLTVTVSS 135

RESULT 9
ADJ76917
ID ADJ76917 standard; protein; 117 AA.
XX
XX AC ADJ76917;
XX
XX DT 06-MAY-2004 (first entry)
XX
XX DE Anti-IGF-1R related protein #26.
XX
XX cytotatic; antipsoziatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDR.
XX
XX OS Homo sapiens.
XX
XX PN WO2003059951-A2.
XX
XX PD 24-JUL-2003.
XX
XX PF 20-JAN-2003; 2003WO-FR000178.
XX
XX PR 18-JAN-2002; 2002FR-00000653.
XX
XX PR 18-JAN-2002; 2002FR-00000654.
XX
XX PR 07-MAY-2002; 2002FR-00005753.
XX
XX PA (FABR) FABRE MEDICAMENT SA PIERRE.
XX
XX PI Goetsch L, Corvaia N, Leger O;
XX
XX DR WPI; 2003-569653/53.
XX
XX PT New antibodies that bind to human insulin-like growth factor receptor,
XX useful for treatment, prevention and diagnosis of cancers.
XX
XX PS Disclosure; SEQ ID NO 83; 164pp; French.
XX
XX The invention relates to an isolated antibody (Ab), and its functional
XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
XX IR) and optionally: (i) inhibit natural binding of insulin-like growth
XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
XX kinase activity of IGF-1R. Ab and its fragments are used to prevent or
XX treat diseases associated with overexpression and/or abnormal activity of
XX IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
XX hyperactivity of signal transduction pathways mediated by interaction of
XX these receptors with their ligands. Especially they inhibit
XX transformation of normal cells to tumor cells, inhibit growth and/or
XX proliferation of tumor cells, so are useful against cancers of the
XX prostate, lung, breast, endometrium and colon, also osteosarcoma, and
XX also for treating psoriasis. Ab are also used to diagnose diseases caused
XX by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
XX protein sequence used to generate the Ab of the invention.
XX
XX Sequence 117 AA;
Query Match 97.3%; Score 611; DB 7; Length 117;
Best Local Similarity 96.6%; Pred. No. 1.1e-47;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
Qy 1 QVQLQESGPGLVKPKSETLSLTCTVSGYSITGGLYLNWIRQPPGKLEWMGYISYDGTNNY 60
Db 1 QVQLQESGPGLVKPKSETLSLTCTVSGYSITGGLYLNWIRQPPGKLEWMGYISYDGTNNY 60
Qy 61 KPSLKDRITISRDTSKNQFSLKLSSTVAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117
Db 61 KPSLKDRVTISRDTSKNQFSLKLSSTVAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117
RESULT 10

ADZ67087
ID ADZ67087 standard; protein; 117 AA.
XX
AC ADZ67087;
XX
DT 30-JUN-2005 (first entry)
XX
DE Human antibody 7C10 3 heavy chain variable region SEQ ID NO:83.
XX
KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
KW musculoskeletal disease; respiratory disease; lung tumor;
KW endocrine disease; gynecology and obstetrics; breast tumor;
KW endometroid carcinoma; gastrointestinal disease; colon tumor;
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
KW heavy chain variable region.
XX
OS Homo sapiens.
XX
PN US2005084906-A1.
XX
PD 21-APR-2005.
XX
PF 16-DEC-2003; 2003US-00735916.
XX
PR 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
PR 20-JAN-2003; 2003WO-FR000178.
PR 11-JUL-2003; 2003FR-00008538.
XX
PA (GOET/) GOETSCH L.
PA (CORV/) CORVAIA N.
PA (LEGE/) LEGER O.
PA (DUFL/) DUFLOS A.
PA (HAEU/) HAEUW J.
PA (BECK/) BECK A.
XX
PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
XX WPI; 2005-321968/33.
XX
PT Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
PT antibody or its functional fragment, being capable of binding human IGF-
PT IR and specifically inhibiting tyrosine kinase activity of receptor,
PT useful for treating cancer.
XX
PS Example 13; SEQ ID NO 83; 125pp; English.
XX
CC The invention relates to a novel isolated anti-insulin-like growth factor
CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
CC capable of binding to human IGF-IR and, if necessary, capable of
CC specifically inhibiting tyrosine kinase activity of the receptor.
CC comprising a light or heavy chain having at least one complementary
CC determining region (CDR) consisting of one of two fully defined 16 amino
CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
CC the preparation of a medicament intended for the prevention or treatment
CC of an illness connected with an overexpression and/or an abnormal
CC activation of the IGF-IR and/or EGFR, and/or connected with a
CC hyperactivation of the transduction pathway of the signal mediated by the
CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
CC the administration of the medicament does not induce or only slightly
CC induces secondary effects connected with inhibition of the insulin
CC receptor. The antibody is useful for preparation of a medicament intended
CC to inhibit the transformation of normal cells into cells with tumoral
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
CC useful for preparation of a medicament intended to inhibit the growth
CC and/or the proliferation of tumor cells, preferably IGF-dependent,
CC especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or
CC HER2/neu-dependent cells. (I) is useful in the preparation of a
CC medicament intended for prevention or for the treatment of cancer, where
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
CC

CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
CC preparation of a medicament intended for the prevention or for the
CC treatment of psoriasis. (I) is useful in preparation of a medicament
CC intended for the specific targeting of a biologically active compound to
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
CC is useful for in vitro diagnosis of illnesses induced by an
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
CC starting from a biological sample in which the abnormal presence, of IGF-
CC IR and/or EGFR receptor is suspected, which involves contacting the
CC biological sample with (I), which is optionally labeled. The present
CC sequence is used in the exemplification of the invention.
XX
SQ Sequence 117 AA;
XX
Query Match 97.3%; Score 611; DB 9; Length 117;
Best Local Similarity 96.6%; Pred. No. 1.1e-47;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITGGYLNWIRQPPGKGLEWGYISYDGTNNY 60
DB 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGYLNWIRQPPGKGLEWGYISYDGTNNY 60
QY 61 KPSLKDRITISRDTSKNQFSKLSSVTAADTAVVYCARVGRVFDYWGQGLTVTVSS 117
DB 61 KPSLKDRVTISVDTSKNQFSKLSSVTAADTAVVYCARVGRVFDYWGQGLTVTVSS 117
RESULT 11
ADJ76919
ID ADJ76919 standard; protein; 135 AA.
XX
AC ADJ76919;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-IGF-IR related protein #27.
XX
KW cytostatic; antipsoriatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDR.
XX
OS Homo sapiens.
XX
PN WO2003059951-A2.
XX
PD 24-JUL-2003.
XX
PF 20-JAN-2003; 2003WO-FR000178.
XX
PR 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
XX
PA (FABR) FABRE MEDICAMENT SA PIERRE.
XX
PI Goetsch L, Corvaia N, Leger O;
XX WPI; 2003-569653/53.
XX
PT New antibodies that bind to human insulin-like growth factor receptor,
PT useful for treatment, prevention and diagnosis of cancers.
XX
PS Disclosure; SEQ ID NO 85; 164pp; French.
XX
CC The invention relates to an isolated antibody (Ab), and its functional
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
CC IR) and optionally: (i) inhibit natural binding of insulin-like growth
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
CC treat diseases associated with overexpression and/or abnormal activity of
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with

CC hyperactivity of signal transduction pathways mediated by interaction of
CC these receptors with their ligands. Especially they inhibit
CC transformation of normal cells to tumor cells, inhibit growth and/or
CC proliferation of tumor cells, so are useful against cancers of the
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
CC also for treating psoriasis. Ab are also used to diagnose diseases caused
CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
CC protein sequence used to generate the Ab of the invention.

XX Sequence 135 AA;

Query Match 97.3%; Score 611; DB 7; Length 135;
Best Local Similarity 96.6%; Pred. No. 1.3e-47;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITCGYLWNWIRQPPGKLEWMGYISYDGTNNY 60

Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGLYLNWIRQPPGKLEWIGYISYDGTNNY 78

QY 61 KPSLKDRITISRDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117

Db 79 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 135

RESULT 12

ADZ67089
ID ADZ67089 standard; protein; 135 AA.

XX AC ADZ67089;

XX DT 30-JUN-2005 (first entry)

XX DE Human antibody 7C10 3 heavy chain variable region SEQ ID NO:85.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
KW musculoskeletal disease; respiratory disease; lung tumor;
KW endocrine disease; gynecology and obstetrics; breast tumor;
KW endometroid carcinoma; gastrointestinal disease; colon tumor;
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
KW heavy chain variable region.

XX OS Homo sapiens.

EH Key Location/Qualifiers
FT Peptide 1..18 /note= "leader peptide"
FT Region 49..54 /note= "CDR1"
FT Region 69..84 /note= "CDR2"
FT Region 117..124 /note= "CDR3"

XX US2005084906-A1.

XX PN 21-APR-2005.

XX PD 16-DEC-2003; 2003US-00735916.

XX PR 18-JAN-2002; 2002FR-00000653.

XX PR 18-JAN-2002; 2002FR-00000654.

XX PR 07-MAY-2002; 2002FR-00005753.

XX PR 20-JAN-2003; 2003WO-FR000178.

XX PR 11-JUL-2003; 2003FR-00008538.

XX PA (GOETZ) GOETSCH L.

XX PA (CORVA) CORVAIA N.

XX PA (LEGE) LEGER O.

XX PA (DUFLO) DUFLOS J.

XX PA (HAEUW) HAEUW J.

PI

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

XX MPI; 2005-321968/33.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
FT antibody or its functional fragment, being capable of binding human IGF-
PT IR and specifically inhibiting tyrosine kinase activity of receptor,
PT useful for treating cancer.

XX Example 13; SEQ ID NO 85; 125pp; English.

XX The invention relates to a novel isolated anti-insulin-like growth factor-
CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
CC capable of binding to human IGF-IR and, if necessary, capable of
CC specifically inhibiting tyrosine kinase activity of the receptor,
CC comprising a light or heavy chain having at least one complementary
CC determining region (CDR) consisting of one of two fully defined 16 amino
CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
CC the preparation of a medicament intended for the prevention or treatment
CC of an illness connected with an overexpression and/or an abnormal
CC activation of the IGF-IR and/or EGFR, and/or connected with a
CC hyperactivation of the transduction pathway of the signal mediated by the
CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
CC the administration of the medicament does not induce or only slightly
CC induces secondary effects connected with inhibition of the insulin
CC receptor. The antibody is useful for preparation of a medicament intended
CC to inhibit the transformation of normal cells into cells with tumoral
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
CC useful for preparation of a medicament intended to inhibit the growth
CC and/or the proliferation of tumor cells, preferably IGF-dependent,
CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
CC HER2/neu-dependent cells. (I) is useful in the preparation of a
CC medicament intended for prevention or for the treatment of cancer, where
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
CC preparation of a medicament intended for the prevention or for the
CC treatment of psoriasis. (I) is useful in preparation of a medicament
CC intended for the specific targeting of a biologically active compound to
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
CC is useful for in vitro diagnosis of illnesses induced by an
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
CC starting from a biological sample in which the abnormal presence, of IGF-
CC IR and/or EGFR receptor is suspected, which involves contacting the
CC biological sample with (I), which is optionally labeled. The present
CC sequence is used in the exemplification of the invention.

XX Sequence 135 AA;

Query Match 97.3%; Score 611; DB 9; Length 135;
Best Local Similarity 96.6%; Pred. No. 1.3e-47;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQESGPGLVKPSSETLSLTCTVSGYSITCGYLWNWIRQPPGKLEWMGYISYDGTNNY 60

Db 19 QVQLQESGPGLVKPSSETLSLTCTVSGYSISGGLYLNWIRQPPGKLEWIGYISYDGTNNY 78

QY 61 KPSLKDRITISRDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 117

Db 79 KPSLKDRVTISVDTSKNQFSLKLSVTAADTAVYVCARYGRVFFDYWGQGLTVTVSS 135

RESULT 13

ADJ76903

ID ADJ76903 standard; protein; 117 AA.

XX AC ADJ76903;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-IR related protein #16.

XX KW cytostatic; antipsoriatic; antibody;

Query Match 86.9%; Score 546; DB 9; Length 117;
Best Local Similarity 86.2%; Pred. No. 8.9e-42;
Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;
QY 2 VQLQESGPGLVKPSLTLCTCTVSGYSITGGYLNWIRQPPGKGLWNGYISYDGTNNYK 61
DB 2 VQLQESGPGLVKPSLTLCTCTVSGYSITGGYLNWIRQPPGKGLWNGYISYDGTNNYK 61
QY 62 PSLKDRITISRDTSKNQFSLKLSSTAADTAVYTCARYGRVFFDYWGQGTTLTVSS 117
DB 62 PSLKDRISITRDTSKNQFSLKLSSTAADTAVYTCARYGRVFFDYWGQGTTLTVSS 117

RESULT 15
ADJ76886
ID ADJ76886 standard; protein; 127 AA.
XX AC ADJ76886;
XX DT 06-MAY-2004 (first entry)
XX DE Anti-IGF-1R related protein #4.
XX KW cytosolic; antipsoriatic; antibody;
XX KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
XX KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
XX KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
XX KW CDR.
XX OS Mus musculus.
XX PN WO2003059951-A2.
XX PD 24-JUL-2003.
XX PF 20-JAN-2003; 2003WO-FR000178.
XX PR 18-JAN-2002; 2002FR-00000653.
XX PR 18-JAN-2002; 2002FR-00000654.
XX PR 07-MAY-2002; 2002FR-00005753.
XX PA (FABR) FABRE MEDICAMENT SA PIERRE.
XX PI Goetsch L, Corvaia N, Leger O;
XX DR WPI; 2003-569653/53.
XX PT New antibodies that bind to human insulin-like growth factor receptor,
XX PT useful for treatment, prevention and diagnosis of cancers.
XX PS Disclosure; SEQ ID NO 52; 164pp; French.
XX CC The invention relates to an isolated antibody (Ab), and its functional
XX CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
XX CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth
XX CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
XX CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
XX CC treat diseases associated with overexpression and/or abnormal activity of
XX CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
XX CC hyperactivity of signal transduction pathways mediated by interaction of
XX CC these receptors with their ligands. Especially they inhibit
XX CC transformation of normal cells to tumor cells, inhibit growth and/or
XX CC proliferation of tumor cells, so are useful against cancers of the
XX CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
XX CC also for treating psoriasis. Ab are also used to diagnose diseases caused
XX CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
XX CC protein sequence used to generate the Ab of the invention.
XX SQ Sequence 127 AA;

Query Match 86.9%; Score 546; DB 7; Length 127;
Best Local Similarity 86.2%; Pred. No. 9.7e-42;

Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;
QY 2 VQLQESGPGLVKPSLTLCTCTVSGYSITGGYLNWIRQPPGKGLWNGYISYDGTNNYK 61
DB 12 VQLQESGPGLVKPSLTLCTCTVSGYSITGGYLNWIRQPPGKGLWNGYISYDGTNNYK 71
QY 62 PSLKDRITISRDTSKNQFSLKLSSTAADTAVYTCARYGRVFFDYWGQGTTLTVSS 117
DB 72 PSLKDRISITRDTSKNQFSLKLSSTAADTAVYTCARYGRVFFDYWGQGTTLTVSS 127
Search completed: January 10, 2006, 20:44:17
Job time : 81.7649 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:28:02 ; Search time 14.1157 Seconds
(without alignments)
797.508 Million cell updates/sec

Title: US-10-735-916a-75
Perfect score: 628
Sequence: 1 QVQLQESGPGLVKPSSETLSL.....RYGRVFFDYWGQGLVTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 80:.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	505	80.4	140	2 I37782	Ig variable region
2	490	78.0	130	2 S31690	Ig heavy chain V r
3	477	76.0	123	2 S30530	Ig heavy chain V r
4	474	75.5	147	2 S13519	Ig heavy chain V r
5	465.5	74.1	118	2 S24443	Ig heavy chain V r
6	464	73.9	155	2 S31511	Ig heavy chain - h
7	463	73.7	121	2 S37200	Ig heavy chain V r
8	460.5	73.3	136	2 S07637	Ig heavy chain V r
9	459.5	73.2	130	2 S30534	Ig heavy chain V r
10	459.5	73.2	139	2 S31586	Ig heavy chain V r
11	458.5	73.0	116	2 S38718	Ig heavy chain V r
12	458.5	73.0	129	2 S44114	Ig heavy chain - h
13	458	72.9	155	2 S31512	Ig heavy chain V r
14	457.5	72.9	140	2 S78052	Ig heavy chain pre
15	455.5	72.5	145	2 S78055	Ig heavy chain pre
16	455	72.5	117	2 I28195	Ig heavy chain V r
17	453	72.1	121	2 S44113	Ig heavy chain V r
18	453	72.1	137	1 AVMS35	Ig heavy chain pre
19	452	72.0	119	2 E25114	Ig heavy chain V r
20	452	72.0	140	2 A49045	Ig heavy chain V r
21	451	71.8	135	2 S78051	Ig heavy chain pre
22	448.5	71.4	137	2 S31676	Ig heavy chain V r
23	448	71.3	146	2 S09711	Ig heavy chain V r
24	446.5	71.1	126	2 S47010	Ig heavy chain V4.
25	444	70.7	119	2 C53285	Ig heavy chain V a
26	443.5	70.6	118	2 S20780	Ig heavy chain pre
27	443	70.5	149	2 S30752	Ig heavy chain pre
28	442	70.4	140	2 A24770	hypothetical hybri
29	441.5	70.3	134	2 B24672	Ig heavy chain pre

30	439.5	70.0	135	2 PL0100	Ig heavy chain pre
31	435.5	69.3	118	2 A26340	Ig heavy chain pre
32	435.5	69.3	120	2 A25114	Ig heavy chain V r
33	435	69.3	115	2 F25114	Ig heavy chain V r
34	435	69.3	146	2 S09710	Ig heavy chain V r
35	434	69.1	98	2 S12421	Ig heavy chain V r
36	434	69.1	134	2 S54906	Ig heavy chain V r
37	434	69.1	139	2 S31696	Ig heavy chain V r
38	430.5	68.6	97	2 S26906	Ig heavy chain V
39	430.5	68.6	105	2 S44125	Ig lambda chain V
40	430	68.5	119	2 C25114	Ig heavy chain V r
41	430	68.5	123	2 S30529	Ig heavy chain V r
42	429.5	68.4	116	2 B26340	Ig heavy chain pre
43	429	68.3	98	2 S26902	Ig heavy chain V r
44	429	68.3	127	2 S19668	Ig heavy chain V r
45	428.5	68.2	139	2 A41287	Ig heavy chain pre

ALIGNMENTS

RESULT 1

I37782
Ig variable region (VDJ) (clone T23-9) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 16-Feb-1996 #sequence_revision 13-Mar-1997 #text_change 23-Jul-1999
C:Accession: I37782; S25476
R:Demaision, C.; Chastagner, P.; Theze, J.; Zouali, M.
Proc. Natl. Acad. Sci. U.S.A. 91, 514-518, 1994
A>Title: Somatic diversification in the heavy chain variable region genes expressed by i
A:Reference number: A36876; MUID:94119917; PMID:8290556
A:Accession: I37782
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-140 <RES>
A:Cross-references: UNIPARC:UPI0000176583; EMBL:X67906; NID:g33582; PIDN:CAA48104.1; PFI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:46-128/Domain: immunoglobulin homology <IMM>

Query Match 80.4%; Score 505; DB 2; Length 140;
Best Local Similarity 81.3%; Pred. No. 3.2e-39;
Matches 100; Conservative 6; Mismatches 9; Indels 8; Gaps 3;

QY 1 QVQLQESGPGLVKPSSETLSLCTCTGSGYSITGGYLNWIRQPPKGLGWMGYISYDGTNNY 60

Db 20 QVQLQESGPGLVKPSSETLSLCTCTGSGGIS-SYYSWIRQPPKGLGWIYISGSTNY 78

QY 61 KPSLKDRITISRDTSKNQFSLKLSVVTAAADTAVYYCAR-----YGRVFFDYWGQGLTVT 114

Db 79 NPSLSRVITISVDTSKNQFSLKLSVVTAAADTAVYYCARHNSSSWYGR-YFDYWGQGLTVT 137

QY 115 VSS 117

Db 138 VSS 140

RESULT 2

S31690
Ig heavy chain V region - human (fragment)

C:Species: Homo sapiens (man)

C>Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999

C:Accession: S31690

R:Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.

submitted to the EMBL Data Library, June 1992

A:Description: Mechanisms that generate human immunoglobulin diversity operate from the

A:Reference number: S31585

A:Accession: S31690

A>Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-130 <CUI>

A:Cross-references: UNIPARC:UPI0000116471; EMBL:Z14199; NID:g30984; PIDN:CAA78568.1; PFI

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotrimer; immunoglobulin

F;20-102/Domain: immunoglobulin homology <IMM>

	Query Match	78.0%;	Score 490;	DB 2;	Length 130;
	Best Local Similarity	77.0%;	Pred. No.	7e-38;	
	Matches 97; Conservative	8; Mismatches 11;	Indels 10;	Gaps 3;	
a	y	: :	1 QVQLQESGFLVKPSETLSLTCVTSGYSTGTGGYLKNWIRPPKGLEWMGIYISDGTNNY	60	
b	b	: :	6 QVQLQESGFLVKPSETLSLTCVTSSGSIS-SYWWSRGRPPKGLRWIGIYYISGSTNY	64	
c	y	: :	61 KPSSLKRDIRTISRDTSKNPFSLKSSVTAADTAVYYCAR-----YGRVV--FFDYWGQST	111	
d	b	: :	65 NPSLKSRVTISVDTSKNQFSLKSSVTAADTAVYYCARGSVLLWFGEIIYYFDYWGQST	124	
e	y	: :	112 LVTVS 117		
f	y	: :	125 LTVS 130		

```

RESULT 3
S30530
Ig heavy chain V region - human
C/Species: Homo sapiens (man)
C/Date: 03-Mar-1994 #sequence_revision 10-Nov-1995 #text_change 16-Aug-1996
C/Accession: S30530
R/Mariette, X.
submitted to the EMBL Data Library, October 1992
A/Reference number: S30520
A/Accession: S30530
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-123 <MAR>
A/Cross-references: UNIPARC:UPI0000176C83; EMBL:Z18316
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

```

Query Match	76.0%	Score 477;	DB 2;	Length 123;
Best Local Similarity	75.8%	Pred. No. 1e-36;		
Matches	94;	Conservative	9;	Mismatches 13; Indels 8; Gaps 2;
Qy	1	QVQLQESGPGLVKPSETLSLTCTVSGSYISITCGYLWNWIRQPPGKGLEWMGVISYDGTNNY	60	
Db	1	QVQLQESGPGLVKPSETLSLTCTVSGSYISISGYTWGIRQPPGKLEWIGSMFHSGSYY	60	
Qy	61	KPSLKDRITISRDTSKQFSKLGSVTAADTAVYYCARGRV-----FFDYWGQGTLV	113	
Db	61	NPSLKSRTVISDVTISKQFSQLQSRVTAADTAVYYCAR-GRYCSSTCSNWDFPWGQGTIV	119	
Qy	114	TVSS	117	
Db	120	TVSS	123	

RESULT 4

S13519

Ig heavy chain V region precursor - human

C/Species: Homo sapiens (man)

C/Date: 25-Feb-1994 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999

C/Accession: S13519

R/Mortari, F.; Ochs, H.D.; Wedgwood, R.J.P.; Schroeder Jr., H.W.

Nucleic Acids Res. 19, 673, 1991

A/Title: Immunoglobulin variable heavy chain cDNA sequence from a patient with X-linked

A/Reference number: S13519; MUID:91187691; PMID:2011536

A/Accession: S13519

A/Status: preliminary

A/Molecule type: mRNA

A/Residues: 1-147 <MOR>

A/Cross-references: UNIPARC:UPT0000115EB5; EMBL:X56158; NID:g37724; PIDN:CAA39626.1; PIDC:CAAF341

C/Suprafamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F:41-125/Domain: immunoglobulin homology <IMM>

```

Query Match      75.5%; Score 474; DB 2; Length 147;
Best Local Similarity 77.9%; Pred. No. 2.3e-36;
Matches 95; Conservative 7; Mismatches 14; Indels 6; Gaps 3

QY 1 QVQLQSGGGLVRFPESETLSLTCTVSGYSI-TGGYLWNWIRQPPGKGLEWMCYISYDGTNN 59
   ||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 27 QLQLQSGGGLVRFPESETLSLTCTVSGGISISSSYWGWIRQPPGKGLEWIGSIYSGSTY 86
   ||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 60 YKPSLKDRIITISDRTSKNQPSLKLSSVTAADTAVYYCAR----YGRVFFDFWGQGLTVTV 115
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 87 YNPSLSKRVITISVDTSKNQPSLKLSSVTAADTAVYYCARPLLWFGEI-FDYWGQGLTVTV 145
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 116 SS 117
   |||
Db 146 SS 147
   |||

RESULT 5
S24443
Ig heavy chain V region (VH4DJ) - human
C;Species: Homo sapiens (man)
C;Date: 22-Jan-1993 #sequence_revision 22-Jan-1993 #text_change 20-Jun-2000
C;Accession: S24443; S19667
R;Jones, P. T.

```

```

RESULT 5
S24443
Ig heavy chain V region (VH4DJJ) - human
C:Species: Homo sapiens (man)
C:Date: 22-Jan-1993 #sequence_revision 22-Jan-1993 #text_change 20-Jun-2000
C:Accession: S24443; S15667
R:Jones, P.T.
submitted to the EMBL Data Library, October 1991
A:Reference number: S24442
A:Accession: S24443
A:Molecule type: mRNA
A:Residues: 1-118 <JON>
A:Cross-references: UNIPARC:UPI0000115FE9; EMBL:X61650; NID:G37720; PIDN:CAA430
R:Marks, J.D.; Hoogenboom, H.R.; Bonnert, T.P.; McCafferty, J.; Griffiths, A.D.
J. Mol. Biol. 222, 581-597, 1991
A:Title: By-passing immunization. Human antibodies from V-gene libraries displayed on phage
A:Reference number: S19663; MUID:92085276; PMID:1748994
A:Accession: S19667
A:Molecule type: mRNA
A:Residues: 1-55,57-118 <MAR>
A:Cross-references: UNIPARC:UPI0000176B52; EMBL:X61650
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotrimer; immunoglobulin
P:15-97/Domain: immunoglobulin homology <IMW>

```

Query Match	74.1%	Score 465.5	DB 2	Length 118
Best Local Similarity	77.3%	Pred. No. 1.1e-35		
Matches	92	Conservative 8	Mismatches 16	Indels 3
Gaps	2			
Qy	1	QVQLQSGPGLVPSSETLSLTCTVSGVSIITGGYLNWIRQPPGKGLEWGMVSIISDGTNNY	60	
Db	1	QVQLQSGPGLVPSSETLSLTCTVSGGSLFSY--WGIWIRQPPGKGLEWIGYISHRGSTDY	59	
Qy	61	KPSLKDRITISRDTSKNQFSLKLSSTVAADTAATVYICAR--YGRVFFDYWGQGLTLVTWSS	117	
Db	60	NSISLGRVITISADTSKNQFSLKLSSTVAADTAATVYICARSFNSPFFGWWGQGLTLVTWSS	118	

RESULT 6
S31511
Ig heavy chain - human
C:Species: Homo sapiens (man)
C/Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 23-Jul-1999
C/Accession: S31511
R:Castagner, P.; Demaison, C.; Theze, J.; Zouali, M.
submitted to the EMBL Data Library, December 1992
A:Description: Dominance of clonotypic patterns and variable gene usage of anti
A:Reference number: S31509
A:Accession: S31511
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-155 <CHA>
A:Cross-references: UNIPARC:UPI00001160FF; EMBL:X69866; NID:G33094; PIDN:CAA49
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
P:4-7/129/Domain: immunoglobulin homology <IMM>

A; Residues: 1-147 <W0K>
A; Cross-references: UNIPARC:UPT0000115EB5; EMBL:X56158; NID:G37724; PIDN:CAA39626.1; PIDN:CAA39626.2
C; Superfamily: immunoglobulin V region; immunoglobulin homology
C; keywords: heterotetramer; immunoglobulin
F: 41-125/Domain: immunoglobulin homology <IMW>

Query Match 73.9%; Score 464; DB 2; Length 155;
Best Local Similarity 75.0%; Pred. No. 2e-35;
Matches 93; Conservative 9; Mismatches 14; Indels 8; Gaps 3;

QY 1 QVLOESGGLVKPSETLSLCTVSGYSITGGYLNNWIRQPPGKLEWNGYISYDGTNNY 60
DB 33 QVLOESGGLVKPSETLSLCTVSGGIS-SYYSWIRQPPGKLEWIGIYYTGSAFY 91

QY 61 KPSLKDRIITISRDTSKNQFSLKSSVTAADTAVYICARYGRV--PFDY-----WQGGTLV 113
DB 92 NPLKSRVTISVDTSKNQFSLKSSVTAADTAVYICARGGSISSWYDYIGMDVWVGQITV 151

QY 114 TVSS 117
DB 152 TVSS 155

RESULT 7
S37200
Ig heavy chain V region - mouse
C:Species: Mus musculus (house mouse)
C:Date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 21-Jan-2000
C:Accession: S37200
R:Fischer, R.; Voss, A.; Hunziker, W.; Stierhof, Y.D.; Kreuzaler, F.
A:Submitted to the EMBL Data Library, August 1993
A:Description: Production and cloning of TMV-specific monoclonal antibodies.
A:Reference number: S37200
A:Accession: S37200
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-121 <PIS>
A:Cross-references: UNIPARC:UPI00001161AC; EMBL:X74587; NID:g402639; PID:g402640
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 73.7%; Score 463; DB 2; Length 121;
Best Local Similarity 73.3%; Pred. No. 1.9e-35;
Matches 88; Conservative 11; Mismatches 17; Indels 4; Gaps 1;

QY 2 QVLOESGGLVKPSETLSLCTVSGYSITGGYLNNWIRQPPGKLEWNGYISYDGTNNY 61
DB 2 QVLOESGGLVKPSETLSLCTVSGYSITSSYNNWIRQPPGKLEWNGYISYDGTNNY 61

QY 62 PSLKDRITISRDTSKNQFSLKSSVTAADTAVYICARYGRV---PFDYWGQGTTLTVSS 117
DB 62 PSLKNRISITRDTSKNQFSLKSSVTTEDTATYICARGGIYGVDDYFDSWGQGTTLTVSS 121

RESULT 8
S07637
Ig heavy chain V region (PTF 02) - mouse
C:Species: Mus musculus (house mouse)
C:Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 23-Jul-1999
C:Accession: S07637
R:Urakov, D.N.; Deev, S.M.; Polyakov, O.L.
Nucleic Acids Res. 17, 9481, 1989
A:Title: The structure of the expressible VH gene from a hybridoma producing monoclonal
A:Reference number: S07637; MUID:90067954; PMID:2587273
A:Accession: S07637
A:Molecule type: DNA
A:Residues: 1-136 <URA>
A:Cross-references: UNIPARC:UPI0000115E36; EMBL:X16740; NID:g52099; PIDN:CAA34714.1; PID
A:Note: the authors translated the codon TAT for residue 112 as Ile, TAC for residue 113
C:Genetics:
A:Introns: 15/3
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:33-116/Domain: immunoglobulin homology <IMM>

Query Match 73.3%; Score 460.5; DB 2; Length 136;
Best Local Similarity 74.4%; Pred. No. 3.7e-35;
Matches 87; Conservative 12; Mismatches 17; Indels 1; Gaps 1;

QY 2 QVLOESGGLVKPSETLSLCTVSGYSITGGYLNNWIRQPPGKLEWNGYISYDGTNNY 61
DB 20 QVLOESGGLVKPSETLSLCTVDFSTSGYNNWIRQPPGKLEWNGYISYDGTNNY 79

QY 62 PSLKDRITISRDTSKNQFSLKSSVTAADTAVYICAR-YGRVFFDYWGQGTTLTVSS 117
DB 80 PSLKNRISITRDTSKNQFSLKSSVTTEDTATYICRGGYHFFDYWGQGTTLTVSA 136

RESULT 9
S30534
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C:Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 16-Aug-1996
C:Accession: S30534
R:Marlette, X.
A:Submitted to the EMBL Data Library, October 1992
A:Reference number: S30520
A:Accession: S30534
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-130 <MAR>
A:Cross-references: UNIPARC:UPI0000113P45; EMBL:Z18320
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-99/Domain: immunoglobulin homology <IMM>

Query Match 73.2%; Score 459.5; DB 2; Length 130;
Best Local Similarity 71.5%; Pred. No. 4.3e-35;
Matches 93; Conservative 7; Mismatches 17; Indels 13; Gaps 2;

QY 1 QVLOESGGLVKPSETLSLCTVSGYGI-TGGYLNNWIRQPPGKLEWNGYISYDGTNN 59
DB 1 QVLOESGGLVKPSETLSLCTVSGGSTSGSYWIRQPPGKLEWIGIYITSGSTN 60

QY 60 KPSLKDRIITISRDTSKNQFSLKSSVTAADTAVYICA-----RYGRVFFDYW 107
DB 61 YNPSLKSITISVDTSKNQFSLKSSVTAADTAVYICARDKGFWSGYITRNSRAAFDIW 120

QY 108 GQGTTLTVSS 117
DB 121 GQGTWTVSS 130

RESULT 10
S31586
Ig heavy chain V region - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S31586
R:Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnel, C.
A:Submitted to the EMBL Data Library, June 1992
A:Description: Mechanisms that generate human immunoglobulin diversity operate from the
A:Reference number: S31585
A:Accession: S31586
A:Molecule type: mRNA
A:Residues: 1-139 <CUI>
A:Cross-references: UNIPARC:UPI000011646E; EMBL:Z14196; NID:g30978; PIDN:CAA78565.1; PTI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:34-116/Domain: immunoglobulin homology <IMM>

Query Match 73.2%; Score 459.5; DB 2; Length 139;
Best Local Similarity 76.9%; Pred. No. 4.6e-35;
Matches 93; Conservative 7; Mismatches 16; Indels 5; Gaps 2;

QY 1 QVLOESGGLVKPSETLSLCTVSGYSITGGYLNNWIRQPPGKLEWNGYISYDGTNNY 60
DB 20 QVLOESGGLVKPSETLSLCTVSGGIS-SYYSWIRQPPGKLEWIGIYITSGSTNY 78

QY 61 KPSLKDRIITISRDTSKNQFSLKSSVTAADTAVYICARYG-----RVFFDYWGQGTTLTVSS 116

Db 79 NPSLKSRVTMSVDTSKNQFSLKLSVTAADTAATVAVYCARGLGIRGAFFDWGQGTMTVTS 138
QY 117 S 117
Db 139 S 139

RESULT 11
Ig heavy chain V region - mouse
C:Species: Mus musculus (house mouse)
C>Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 20-Jun-2000
C:Accession: S38718
R:Cimanis, A.Y.
submitted to the EMBL Data Library, November 1993
A:Reference number: S38713
A:Accession: S38718
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-116 <CIM>
A:Cross-references: UNIPARC:UPI0000117542; EMBL:X76018; NID:g416102; PIDN:CAA53605.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 73.0%; Score 458.5; DB 2; Length 116;
Best Local Similarity 75.0%; Pred. No. 4.7e-35;
Matches 87; Conservative 9; Mismatches 19; Indels 1; Gaps 1;
QY 2 VQLQESGPGLVKPSSETLSLCTVSGYSITGGYLWNWIRQPPGKLEWGWYISYDGTNNYK 61
Db 2 VQLQESGPGLVKPSGSLSLCTCAVTGYSITSDYANWIRQPPGKLEWGWYISYSGTNNY 61
QY 62 PSLKDRITISRDTSKNQFSLKLSVTAADTAATVAVYCARGRVFFDYWGQGTTLTVSS 117
Db 62 PSLKSRISITRDTSKNQFPQLNSVTEDTATYYCAR-GGTGTFWGGTTLTVSA 116

RESULT 12
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 24-May-2001
C:Accession: S44114
R:Hawkins, R.E.; Zhu, D.; Ovecka, M.; Winter, G.; Hamblin, T.J.; Stevenson, F.K.
submitted to the EMBL Data Library, March 1994
A:Description: Idiotypic vaccination against human B-cell lymphoma: rescue of variable H
A:Reference number: S44105
A:Accession: S44114
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-129 <HAW>
A:Cross-references: UNIPARC:UPI0000116639; EMBL:X31579; NID:g472968; PIDN:CAA83451.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 73.0%; Score 458.5; DB 2; Length 129;
Best Local Similarity 71.8%; Pred. No. 5.3e-35;
Matches 89; Conservative 9; Mismatches 19; Indels 7; Gaps 1;
QY 1 VQLQESGPGLVKPSSETLSLCTVSGYSITGGYLWNWIRQPPGKLEWGWYISYDGTNNY 60
Db 1 VQLQESGPGLVKPSGSLSLCTCAVSGGSISSSNWMSWVRQPPGKLEWGWYIYHSGSTNY 60
QY 61 KPSLKDRTISRDTSKNQFSLKLSVTAADTAATVAVYCARGRVFFDYWGQGTTLV 113
Db 61 NFSFKSRVITISADTSKNQFSLKNSVTAADTAATVAVYCARNDYFWSGGDGFYWGQGTTLV 120

QY 114 TVSS 117
Db 121 TVSS 124

RESULT 13
Ig heavy chain - human
C:Species: Homo sapiens (man)
C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 23-Jul-1999
C:Accession: S31512
R:Chastagner, P.; Demaison, C.; Theze, J.; Zouali, M.
submitted to the EMBL Data Library, December 1992
A:Description: Dominance of clonotypic patterns and variable gene usage of anti-DNA auto
A:Reference number: S31509
A:Accession: S31512
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-155 <CHA>
A:Cross-references: UNIPARC:UPI00001160F9; EMBL:X69860; NID:g33082; PIDN:CAA49494.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:47-129/Domain: immunoglobulin homology <IMM>

Query Match 72.9%; Score 458; DB 2; Length 155;
Best Local Similarity 73.4%; Pred. No. 7.1e-35;
Matches 91; Conservative 8; Mismatches 17; Indels 8; Gaps 2;
QY 1 VQLQESGPGLVKPSSETLSLCTVSGYSITGGYLWNWIRQPPGKLEWGWYISYDGTNNY 60
Db 33 VQLQESGPGLVKPSSETLSLCTVSGGSISSYYWSWIRQPPGKLEWGWYIYYTGSATY 91
QY 61 KPSLKDRTISRDTSKNQFSLKLSVTAADTAATVAVYCARGRVFFDYWGQGTTLV 113
Db 92 NPPIKSRVITISVDTSKNQFSLKSVTAADTAATVAVYCARGGGSISSWVYVYGMVWGQGTTV 151
QY 114 TVSS 117
Db 152 TVSS 155

RESULT 14
Ig heavy chain precursor V-D-J region (clone mAB 63VH) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 19-Nov-1997 #sequence_revision 05-Dec-1997 #text_change 23-Jul-1999
C:Accession: S78052; S23717
R:Harindranath, N.
submitted to the EMBL Data Library, August 1990
A:Reference number: S78051
A:Accession: S78052
A:Molecule type: mRNA
A:Residues: 1-140 <HAR>
A:Cross-references: UNIPARC:UPI0000115E89; EMBL:X54441; NID:g37815; PIDN:CAA38308.1; PI
R:Harindranath, N.; Goldfarb, I.S.; Ikematsu, H.; Burastero, S.E.; Wilder, R.L.; Nockins
Int. Immunol. 3, 865-875, 1991
A:Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and i
patient.
A:Reference number: S23716; MUID:92031262; PMID:1718404
A:Accession: S23717
A:Molecule type: mRNA
A:Residues: 15-111 <HAW>
A:Cross-references: UNIPARC:UPI0000116417; EMBL:X54441
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:1-14/Domain: signal sequence (fragment) #status predicted <SIG>
F:15-140/Product: Ig heavy chain (fragment) #status predicted <MAT>
F:29-111/Domain: immunoglobulin homology <IMM>

Query Match 72.9%; Score 457.5; DB 2; Length 140;
Best Local Similarity 71.7%; Pred. No. 7.1e-35;
Matches 91; Conservative 9; Mismatches 16; Indels 11; Gaps 2;
QY 1 VQLQESGPGLVKPSSETLSLCTVSGYSITGGYLWNWIRQPPGKLEWGWYISYDGTNNY 60
Db 15 VQLQOQWAGGLKPSSETLSLCTCAVYGGGSISSYYWSWIRQPPGKLEWGWYIYHSGSTNY 73

```
QY      61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVYICARYGRVF-----FDYWGQG 110
      ||| : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db      74 NPSLKSRTVISVDTSKNQFSLKSSVTAADTAVYICARGSVLRFLFLEWLLYPADFYWGQ 133
      ||| : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY      111 TLVTVSS 117
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db      134 TLVTVSS 140
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 15
S78055
Ig heavy chain precursor V-D-J region (clone mAb 67VH) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 19-Nov-1997 #sequence_revision 05-Dec-1997 #text_change 23-Jul-1999
C:Accession: S78055; S23720
R:Harindranath, N.
submitted to the EMBL Data Library, August 1990
A:Reference number: S78051
A:Accession: S78055
A:Molecule type: mRNA
A:Residues: 1-145 <HAR>
A:Cross-references: UNIPARC:UPI0000115B8C; EMBL:X54445; NID:g37817; PIDN:CAA38312.1; PID
R:Harindranath, N.; Goldfarb, I.S.; Ikenatsu, H.; Burastero, S.E.; Wilder, R.L.; Notkine
int. Immunol. 3, 865-875, 1991
A:Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and h
patient.
A:Reference number: S23716; MUID:92031262; PMID:1718404
A:Accession: S23720
A:Molecule type: mRNA
A:Residues: 18-115 <HAW>
A:Cross-references: UNIPARC:UPI00001769D2; EMBL:X54445
A>Note: the authors translated the codon GCA for residue 67 as Arg
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:1-17/Domain: signal sequence (fragment) #status predicted <SIG>
F:18-145/Product: Ig heavy chain (fragment) #status predicted <MAT>
F:32-115/Domain: immunoglobulin homology <IMM>

Query Match          72.5%; Score 455.5; DB 2; Length 145;
Best Local Similarity 71.1%; Pred. No. 1.1e-34;
Matches 91; Conservative 8; Mismatches 18; Indels 11; Gaps 2;

QY      1 QVQLQESGPGLVKPSSETLSITCTVSGYSITGGLYMWIRQPPGKGLEWMGYISYDGTNNY 60
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db      18 QVQLQESGPGLVKPSGTLISITCAVSGSISSSNWSWVRQPPGKGLEWIGEIVHSGSTNY 77
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY      61 KPSLKDRITISRDTSKNQFSLKSSVTAADTAVYICAR-----YGR-VFPDYWGQ 109
      ||| : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db      78 NPSLKSARTISVDKSKNQFSLKSSVTAADTAVYICARVTGSTFWSGYTRGYFDYWGQ 137
      ||| : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY      110 GTLVTVSS 117
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db      138 GTLVTVSS 145
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

Search completed: January 10, 2006, 20:55:15
Job time : 15.1157 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:26:41 ; Search time 78.8731 Seconds
(without alignments)
1046.577 Million cell updates/sec

Title: US-10-735-916A-75
Perfect score: 628
Sequence: 1 QVQLQESGFLVKPSETLSL.....RYGRVFFDYWGQTLVTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt_05.80.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	485	77.2	119	Q9UL73_HUMAN	Q9ul73 homo sapien
2	479.5	76.4	465	Q6GMX6_MOUSE	Q6gmxx6 mus musculus
3	476	75.8	479	Q95M22_MOUSE	Q95m22 mus musculus
4	463	73.7	476	Q6GMX1_HUMAN	Q6gmxx1 homo sapien
5	460.5	73.3	136	Q6LBO5_MOUSE	Q6lbo5 mus musculus
6	460.5	73.3	483	Q5U413_MOUSE	Q5u413 mus musculus
7	458.5	73.0	477	Q6GMX7_HUMAN	Q6gmxx7 homo sapien
8	453	72.1	137	HV46_MOUSE	Hv46 mouse
9	452	72.0	119	Q53VQ5_MOUSE	Q53vq5 mus musculus
10	450.5	71.7	150	Q95973_HUMAN	Q95973 homo sapien
11	450.5	71.7	576	Q6P418_HUMAN	Q6p418 homo sapien
12	444.5	70.8	478	Q72379_HUMAN	Q72379 homo sapien
13	443.5	70.6	620	Q96EY0_HUMAN	Q96ey0 homo sapien
14	436	69.4	492	Q72374_HUMAN	Q72374 homo sapien
15	435.5	69.3	120	Q53VR7_MOUSE	Q53vr7 mus musculus
16	435	69.3	115	Q53VQ1_MOUSE	Q53vq1 mus musculus
17	433	68.9	590	Q569B8_RAT	Q569b8 rattus norv
18	430.5	68.6	139	Q86SX2_HUMAN	Q86sx2 homo sapien
19	430.5	68.6	496	Q96KX8_HUMAN	Q96kx8 homo sapien
20	430	68.5	119	Q53VR3_MOUSE	Q53vr3 mus musculus
21	428	68.2	615	Q569B6_RAT	Q569b6 rattus norv
22	426	67.8	116	HV60_MOUSE	Hv60 mouse
23	423.5	67.4	146	HV21_HUMAN	Hv21 homo sapien
24	420	66.9	98	Q53VQ4_MOUSE	Q53vq4 mus musculus
25	420	66.9	595	Q8WUX4_HUMAN	Q8wux4 homo sapien
26	420	66.9	597	Q9BU10_HUMAN	Q9bu10 homo sapien
27	420	66.9	597	Q6GMX5_HUMAN	Q6gmxx5 homo sapien
28	420	66.9	625	Q96AA6_HUMAN	Q96aa6 homo sapien
29	418	66.6	597	Q96QB8_HUMAN	Q96qb8 homo sapien
30	409.5	65.2	130	Q81ZD7_HUMAN	Q81zd7 homo sapien
31	409	65.1	477	Q510J1_RAT	Q510j1 rattus norv

32	408	65.0	119	2	Q53VQ9_MOUSE	Q53vq9 mus musculus
33	407	64.8	98	2	Q53VR6_MOUSE	Q53vr6 mus musculus
34	407	64.8	478	2	Q6NYH3_HUMAN	Q6nyh3 homo sapien
35	403.5	64.3	591	2	Q510L9_RAT	Q510l9 rattus norv
36	402	64.0	98	2	Q53VR2_MOUSE	Q53vr2 mus musculus
37	402	64.0	469	2	Q5M839_RAT	Q5m839 rattus norv
38	400	63.7	98	2	Q53VQ0_MOUSE	Q53vq0 mus musculus
39	398	63.4	113	1	HV47_MOUSE	Hv47 mouse
40	398	63.4	117	1	HV2G_HUMAN	Hv2g homo sapien
41	395.5	63.0	122	2	Q9UL75_HUMAN	Q9ul75 homo sapien
42	391	62.3	129	1	HV2F_HUMAN	Hv2f homo sapien
43	390	62.1	476	2	Q6MZK7_HUMAN	Q6mzx7 homo sapien
44	389.5	62.0	116	2	Q7Z3Y6_HUMAN	Q7z3y6 homo sapien
45	389	61.9	116	1	HV61_MOUSE	Hv61 mouse

ALIGNMENTS

RESULT 1

Q9UL73_HUMAN
ID Q9UL73_HUMAN PRELIMINARY; PRT; 119 AA.
AC Q9UL73;
DT 01-MAY-2000 (Tremblrel. 13, Created)
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M., Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
[2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1660528;
RA Manheimer-Lory A., Katz J.B., Pillinger M., Ghossein C., Smith A., Diamond B.;
RT "Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype";
RL J. Exp. Med. 174:1639-1652(1991).
[3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=2511001;
RA Sanz I., Kelly P., Williams C., Scholl S., Tucker P., Capra J.D.;
RT "The smaller human VH gene families display remarkably little polymorphism";
RL EMBO J. 8:3741-3748(1989).
DR EMBL; AF035041; AAD56277.1; -; mRNA.
DR PIR; PH0876; PH0876.
DR PIR; S12416; S12416.
DR HSP; P01820; IGTJ.
DR SMR; Q9UL73; 1-119.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
DR NON_TER 1
FT NON_TER 119 119
SQ SEQUENCE 119 AA; 13219 MW; 1BDB86B6420EA0BE CRC64;

Query Match 77.2%; Score 485; DB 2; Length 119;
Best Local Similarity 78.3%; Pred. No. 3 6e-42;
Matches 94; Conservative 9; Mismatches 13; Indels 4; Gaps 2;

Db	20	QVQLQESGPGSLVKPSETLSLTCTVSGGSSIS-GYYWSWIRQPAGKAGLEWIGRIYTSGSTNY	78
Qy	61	KPSLKDRITISRDTSKNQFSKLSSVTAADTAIVVYCARVGRVFDFYWGOGTLVTVSS	117
Db	79	NPSLSKRVTVMSVDTSTKNQFSKLSSVTAADTAIVVYCARGRFTYDFYWGOGTLVTVSS	135

ID	Q59M22_MOUSE PRELIMINARY;	PRT;	479 AA.
AC	Q59M22;		
DT	01-JUN-2001 (TrEMBLrel. 17, Created)		
DT	01-JUN-2001 (TrEMBLrel. 17, Last sequence update)		
DT	01-MAR-2004 (TrEMBLrel. 26, Last annotation update)		
DE	LOC2238447 protein.		
GN	Names=LOC238447;		
OS	Mus musculus (Mouse).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Theria; Euarchontoglires; Glires; Rodentia; Sciurognathi;		
OC	Muridae; Murinae; Mus.		
NCBI_TaxID=10090;			
RN	[1]		

RC STRAIN=Mix FVB/N;
RC TISSUE=mammary tumor. WAP-TGF alpha model. 7 months old;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RX Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Datschenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Scapleton M., Soares M.B., Donald M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mulltaly S.J.,
RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywiński M.I., Skalska U., Smalish D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.:
RT "generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]

RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Mix FVB/N;
RC TISSUE=Mammary tumor. WAP-TGF alpha model. 7 months old;
RG NIH MGC Project;
RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
RR EMBL; BC002091; AAH02091.1; -; mRNA.
DR HSSP; P01820; 1G7J.
DR GO; GO:0003823; F:antigen binding; IEA.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG_cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07854; C1-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Immunoglobulin domain.
SQ SEQUENCE 479 AA; 51992 MW; 76BE39A138918892 CRC64;

Best Local Similarity 75.9%; Pred. No. 1.4e-40;
Matches 88; Conservative 12; Mismatches 16; Indels 0; Gaps

Qy 2 VQLQESGGIVKPSKSLTCTVSGYSTGGVLLWNIRPPGKGLWGMGYISYDGTNNYK 61
|||:::|||||
Db 20 VQLQESGGIVKPSKSLTCTVSGYSTGGVLLWNIRPPGKGLWGMGYISYDGTNNYK 79

Db	80	YNPSLKSRTVTSLSLTSKQFSKQNSVTAADTAVYFCARAGVMSFRSMAIDGNIWGQ	139
Qy	111	TLVTYSS	117
Db	140	TLVTYSS	146

```

RESULT 5
Q6LEQ5_MOUSE Q6LEQ5_MOUSE PRELIMINARY; PRT; 136 AA.
ID Q6LEQ5_MOUSE AC Q6LBQ5;
DT DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE VH gene product (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
NC NUCLEOTIDE SEQUENCE.
RP MEDLINE=90067954; PubMed=2587273;
RA Urakov D.N., Deev S.M., Polyakovskiy O.L.;
RX "The structure of the expressible VH gene from a hybridoma producing
RT monoclonal antibodies against porcine transferrin.";
RL Nucleic Acids Res. 17:9481-9481(1989).
DR ENBL; X16740; CAA334714.1; -; Genomic_DNA.
DR HSSP; P18532; LKCV.
DR SMR; Q6LEQ5; 20-136.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
FO NON TER 1
SQ SEQUENCE 136 AA; 15307 MW; 5B0F439CCFB15C3A CRC64;

```

Query Match	73.3%;	Score	460.5;	DB	2;	Length	136;
Best Local Similarity	74.4%;	Pred.	No. 1.4e-39;				
Matches	87;	Conservative	12;	Mismatches	17;	Indels	1; Gaps 1

Qy	2	VQLQSGPGLVKPSTSLTCTVSGYSITGYLENNWIRQPFGKLEHWGVIISDGTNNYK	61
		::: ::: ::: ::: ::: ::: :::	
Db	20	VQLQSGPGLVKPSQLSLTCSVDTSITSGYYWHWIRQFPGNKLHWGVIISYDGSNGYN	79
		::: ::: ::: ::: ::: ::: :::	
Qy	62	PSLKORITISRDTSKNQPSLKLSSVTAAADTAIVYCAYR-YGRVPFDYGQGTLTVVSS	117
		::: ::: ::: ::: ::: ::: :::	
Db	80	PSIKNRIISITRTPTSKNOFFPKINSVVETEDTATYICTRGDGHYHFTYMGQGLTVTSA	136
		::: ::: ::: ::: ::: ::: :::	

RESULT 6

Q5U413_MOUSE	
ID	Q5U413_MOUSE PRELIMINARY; PRT; 483 AA.
AC	Q5U413;
DT	01-FEB-2005 (trEMBLrel. 29, Created)
DT	01-FEB-2005 (trEMBLrel. 29, Last sequence update)
DT	01-FEB-2005 (trEMBLrel. 29, Last annotation update)
DE	LOC544903 protein.
GN	Name=LOC544903;
OS	Mus musculus (Mouse).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC	Muroidea; Muridae; Murinae; Mus.
OX	NCBI_TaxID=10090;
OX	[1]
RP	NUCLEOTIDE SEQUENCE.
RC	STRAIN=FVB/N; TISSUE=Colon;
RC	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA	Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA	Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,

Altschul S.F., Zebberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Schetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
 RA "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RT Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP NUCLEOTIDE SEQUENCE.
 RC STRAIN=FVB/N; TISSUE=Colon;
 RA NTH MGC Project;
 RL Submitted (OCT-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC085312.1; -; mRNA.
 DR GO; GO:0003823; F:antigen binding; IEA.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig cl.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_Y.
 DR Pfam; PF07654; Cl-set; 2.
 DR SMART; SM00409; IG1; 3.
 DR SMART; SM00406; IGV; 1.
 DR SMART; SM00407; IG1; 3.
 DR PROSITE; PS50835; IG LIKE; 4.
 DR PROSITE; PS00230; IG_MHC; UNKNOWN 2.
 DR SQ SEQUENCE 483 AA; 52714 MW; 7C272DA501A4A0D1 CRC64;
 Query Match 73.3%; Score 460.5; DB 2; Length 483;
 Best Local Similarity 73.3%; Pred. No. 5.7e-39;
 Matches 88; Conservative 10; Mismatches 18; Indels 3; Gaps 1;
 Qy 2 VQLQESGPGVLKPSSETLSLCTVSGYSITGGYLMNWIROPKGLWGMGYSYDGTNNYK 61
 Db 20 VQLQESGPGVLKPSSETLSLCTVSGYSITGGYLMNWIROPKGLWGMGYSYDGTNNYK 79
 Qy 62 PSLKDRITISRTSKNQFSLKSLSVTAADTAATVYVCARYGRVF---FDYWGQGTTLTVSS 117
 Db 80 PSLKSRITISRTSKNQFSLKSLSVTAADTAATVYVCARYGRVF---FDYWGQGTTLTVSS 138
 RESULT 7
 Q6GMX7 HUMAN
 ID Q6GMX7 HUMAN PRELIMINARY; PRT; 477 AA.
 AC Q6GMX7
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE Hypothetical protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Primary B-Cells;
 RA MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.2426038899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.G., Schuler G.D.,
 RA Altschul S.F., Zebberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Schetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
 RA "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RT Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP NUCLEOTIDE SEQUENCE.
 RC STRAIN=FVB/N; TISSUE=Colon;
 RA NTH MGC Project;
 RL Submitted (OCT-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC085312.1; -; mRNA.
 DR GO; GO:0003823; F:antigen binding; IEA.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig cl.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_Y.
 DR Pfam; PF07654; Cl-set; 2.
 DR SMART; SM00409; IG1; 3.
 DR SMART; SM00406; IGV; 1.
 DR SMART; SM00407; IG1; 3.
 DR PROSITE; PS50835; IG LIKE; 4.
 DR PROSITE; PS00230; IG_MHC; UNKNOWN 2.
 DR SQ SEQUENCE 483 AA; 52714 MW; 7C272DA501A4A0D1 CRC64;
 Query Match 73.3%; Score 460.5; DB 2; Length 483;
 Best Local Similarity 73.3%; Pred. No. 5.7e-39;
 Matches 88; Conservative 10; Mismatches 18; Indels 3; Gaps 1;
 Qy 2 VQLQESGPGVLKPSSETLSLCTVSGYSITGGYLMNWIROPKGLWGMGYSYDGTNNYK 61
 Db 20 VQLQESGPGVLKPSSETLSLCTVSGYSITGGYLMNWIROPKGLWGMGYSYDGTNNYK 79
 Qy 62 PSLKDRITISRTSKNQFSLKSLSVTAADTAATVYVCARYGRVF---FDYWGQGTTLTVSS 117
 Db 80 PSLKSRITISRTSKNQFSLKSLSVTAADTAATVYVCARYGRVF---FDYWGQGTTLTVSS 138
 RESULT 7
 Q6GMX7 HUMAN
 ID Q6GMX7 HUMAN PRELIMINARY; PRT; 477 AA.
 AC Q6GMX7
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE Hypothetical protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Primary B-Cells;
 RA MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.2426038899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.G., Schuler G.D.,
 RA Altschul S.F., Zebberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Schetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
 RA "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RT Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP NUCLEOTIDE SEQUENCE.
 RC STRAIN=FVB/N; TISSUE=Colon;
 RA NTH MGC Project;
 RL Submitted (OCT-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC073765; AAH73765.1; -; mRNA.
 DR SMR; Q6GMX7; 247-455.
 DR GO; GO:0016021; C:integral to membrane; IEA.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig cl.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_Y.
 DR Pfam; PF07654; Cl-set; 2.
 DR SMART; SM00409; IG1; 3.
 DR SMART; SM00406; IGV; 1.
 DR SMART; SM00407; IG1; 3.
 DR PROSITE; PS50835; IG LIKE; 4.
 DR PROSITE; PS00230; IG_MHC; UNKNOWN 2.
 DR SQ SEQUENCE 477 AA; 51631 MW; 9F59C09C50CFF85 CRC64;
 Query Match 73.0%; Score 458.5; DB 2; Length 477;
 Best Local Similarity 75.8%; Pred. No. 9.1e-39;
 Matches 91; Conservative 11; Mismatches 13; Indels 5; Gaps 3
 Qy 1 VQLQESGPGVLKPSSETLSLCTVSGYSITGGYLMNWIROPKGLWGMGYSY

Altschul S.F., Zebberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Scapleton M.J., Usdin T.B., Toshitaki S., Carninci P., Prange C.,
RA Brownstein M.J., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Raha S.S., Loquellano N.A., Peters G.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnurch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=FVB/N; TISSUE=Colon;
RD NTH MGC Project;
RE Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RF ENSEMBL; ENSMUSG0000054328; Mus musculus.
RG GO; GO:0003823; F:antigen binding; IEA.
RH InterPro; IPR003599; Ig.
RI InterPro; IPR007110; Ig-like.
RJ InterPro; IPR003597; Ig cl.
RK InterPro; IPR003006; IG_MHC.
RL Pfam; PF07654; Cl-set; 2.
RM SMART; SM00409; IG; 3.
RN SMART; SM00407; ICG1; 3.
RO PROSITE; PS50835; IG LIKE; 4.
RR PROSITE; PS00230; IG_MHC; UNKNOWN_2.
RS SEQUENCE 483 AA; 52714 MW; 7C272DA501A4A0D1 CRC64;

Query Match 73.3%; Score 460.5; DB 2; Length 483;
Best Local Similarity 73.3%; Pred. No. 5.7e-39;
Matches 88; Conservative 10; Mismatches 18; Indels 3; Gaps 1;

Qy 2 VQLQESGPGVLKPSSETLSLTCTVSGYSITGGYLMNWIROPKGLEWGWYISYDGTTNNYK 61
Db 20 VQLQESGPGVLKPSSETLSLTCTVSGYSITGGYLMNWIROPFGNKLEWGWYISYSSNNYN 79

Qy 62 PSLKDRITTSRDTSKNQFSLKSLSVTAADTAVYYCARYGRVF---FDYWGQGTTLTVSS 117
Db 80 PSLKSRITSDTSKNQFSLKSLSVTAADTAVYYCARYEGNDYWDYGQGTSTVTSS 138

RESULT 7
Q6GMX7 HUMAN
ID O6GMX7 HUMAN PRELIMINARY; PRT; 477 AA.
AC O6GMX7
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominoidea;
OC Homo.
NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RD MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RX Strauberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shemmen C.M., Schuler G.D.,
RA Altschul S.F., Zebberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,

RL	Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.	
DR	EMBL; BC063384; AAH63384.1; -, mRNA.	
DR	HSSP; P01820; 1A7N.	
DR	Ensembl; ENSG00000196122; Homo sapiens.	
DR	InterPro; IPR003599; Ig.	
DR	InterPro; IPR007110; Ig-like.	
DR	InterPro; IPR003597; Ig cl.	
DR	InterPro; IPR003006; Ig_MHC.	
DR	InterPro; IPR003596; Ig_v.	
DR	Pfam; PF07654; C1-set; 1.	
DR	Pfam; PF00047; Ig; 2.	
DR	SMART; SM00409; Ig; 1.	
DR	SMART; SM00407; IGC1; 3.	
DR	SMART; SM00406; IGV; 1.	
DR	PROSITE; PS08335; IG_LIKE; 4.	
DR	PROSITE; PS00290; IG_MHC; UNKNOWN_2.	
DR	PROSITE; PS00290; IG_MHC; UNKNOWN_2.	
DR	Hypothetical protein.	
KW	Hypothetical protein.	
FT	NON_TER 1	
SQ	SEQUENCE 478 AA; 51620 MW; 4AFCE541P3217CA1 CRC64;	
	Query Match 71.7%; Score 450.5; DB 2; Length 576;	
	Best Local Similarity 72.5%; Pred. No. 7.5e-38;	
	Matches 87; Conservative 10; Mismatches 20; Indels 3; Gaps 1;	
QY	1 QVQLQSGGELVKPSETLSLTCTVSGVSIITGGVLYNNWIRPPGKGLEWMGVISYDGTNNY 60	
DB	27 QVQLQSGGELVKPSETLSLTCAVSGSISSSNWNWVRPPGKGLEWIEIYHSGSTNY 86	
QY	61 KPSELKDRITISRDTSKNQSFSLKLSVTAADTAVYYCARYGRVFF---DYRGQGGLTVTVSS 117	
DB	87 NFSLKSRVITISVDKSKNQFSLKLSVTAADTAVYYCASLGDIIYYGMDVNGQGTVTVTVSS 146	
RESULT 12		
ID	Q7Z379 HUMAN	
ID	Q7Z379 HUMAN PRELIMINARY; PRT; 478 AA.	
AC	Q7Z379;	
DT	01-OCT-2003 (TrEMBLrel. 25, Created)	
DT	01-OCT-2003 (TrEMBLrel. 25, Last sequence update)	
DT	01-MAR-2004 (TrEMBLrel. 26, Last annotation update)	
DE	Hypothetical protein DKFZp686K04218 (Fragment).	
GN	Name=DKFZp686K04218;	
OS	Homo sapiens (Human).	
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;	
OC	Homo.	
OX	NCBI_TaxID=9606;	
RN	[1]	
RP	NUCLEOTIDE SEQUENCE.	
RC	TISSUE=Human rectum tumor;	
RA	Bloecker H., Boecker M., Mewes H.W., Weil B., Amid C., Osanger A.,	
RA	Fobo G., Han M., Wiemann S.;	
RA	Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.	
DR	EMBL; BX538066; CAD97996.1; -, mRNA.	
DR	HSSP; P01820; 1G7J.	
DR	SMK; Q7Z379; 248-456.	
DR	Ensembl; ENSG00000130076; Homo sapiens.	
DR	InterPro; IPR007110; Ig-like.	
DR	InterPro; IPR003597; Ig cl.	
DR	InterPro; IPR003006; Ig_MHC.	
DR	InterPro; IPR003596; Ig_v.	
DR	Pfam; PF07654; C1-set; 2.	
DR	SMART; SM00406; IGV; 1.	
DR	PROSITE; PS08335; IG_LIKE; 4.	
DR	PROSITE; PS00290; IG_MHC; UNKNOWN_2.	
KW	Hypothetical protein.	
FT	NON_TER 1	
SQ	SEQUENCE 478 AA; 51620 MW; 4AFCE541P3217CA1 CRC64;	
	Query Match 70.8%; Score 444.5; DB 2; Length 478;	
	Best Local Similarity 72.7%; Pred. No. 2.6e-37;	
	Matches 88; Conservative 13; Mismatches 15; Indels 5; Gaps 3;	
QY	1 QVQLQSGGELVKPSETLSLTCTVSGVSI-TGGVLYNNWIRPPGKGLEWMGVISYDGTNN 59	

Db 150 VSS 152

```
RESULT 15
Q53VR7 MOUSE
ID Q53VR7 MOUSE PRELIMINARY; PRT; 120 AA.
AC Q53VR7.
DT 13-SEP-2005 (TREMBlrel. 31, Created)
DT 13-SEP-2005 (TREMBlrel. 31, Last sequence update)
DT 13-SEP-2005 (TREMBlrel. 31, Last annotation update)
DE VH-D-JH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RN NUCLEOTIDE SEQUENCE.
RP MEDLINE=86136012; PubMed=3937730;
RX Ollier P., Rocca-Serra J., Somme G., There J., Fougereau M.;
RA "The idiotypic network and the internal image: possible regulation of
RT a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
RT antibodies in the GAT system.";
RL EMBO J. 4:3681-3688(1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03375; CAA27077.1; -; mRNA.
DR EMBL; X03374; CAA27071.1; -; mRNA.
FT NON_TER 1
FT NON_TER 120
SQ SEQUENCE 120 AA; 13892 MW; 013452306EBA3BE CRC64;

Query Match 69.3%; Score 435.5; DB 2; Length 120;
Best Local Similarity 68.1%; Pred. No. 4.8e-37;
Matches 81; Conservative 15; Mismatches 14; Indels 9; Gaps 2;

QY 2 VOLQSGPGLVKPSETLSLTCTVSGYSITGGYLNWIRQPPKGLWNGYISYDGTNNYK 61
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
2 VHLQSGPGLVKPQSLSLTCSVTGYSITRGYNWNRFPKGLWNGYINYDGSNNYN 61
QY 62 PSLKDRITISRDTSKNPSLKLSSVTADTAVYCAR-----YGRVFP--DYWGQGT 111
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
62 PSLKNRISVTRDTSKNPFKGNVTTEDTATYCARLIPFSDGYEDYAMDYWGQGT 120
```

Search completed: January 10, 2006, 20:53:27
Job time : 79.8731 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:55:23 ; Search time 5.96642 Seconds
(without alignments)
166.558 Million cell updates/sec

Title: US-10-735-916A-69
Perfect score: 636
Sequence: 1 DVQLOESGGLVKPSQSL.....RYGRVFFDYWGQTTLTVSS 117

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 61141 seqs, 8493638 residues

Total number of hits satisfying chosen parameters: 61141

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA New:*
1: /cgn2_6/protdata/1/pubpaa/US08 NEW PUB.pbp:*
2: /cgn2_6/protdata/1/pubpaa/US06 NEW PUB.pbp:*
3: /cgn2_6/protdata/1/pubpaa/US07 NEW PUB.pbp:*
4: /cgn2_6/protdata/1/pubpaa/US09 NEW PUB.pbp:*
5: /cgn2_6/protdata/1/pubpaa/US10 NEW PUB.pbp:*
6: /cgn2_6/protdata/1/pubpaa/US11 NEW PUB.pbp:*
7: /cgn2_6/protdata/1/pubpaa/US12 NEW PUB.pbp:*
8: /cgn2_6/protdata/1/pubpaa/US60 NEW PUB.pbp:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	636	100.0	117	7	US-11-012-353-69
2	636	100.0	127	7	US-11-012-353-52
3	569.5	89.5	118	7	US-11-012-353-70
4	546	85.8	117	7	US-11-012-353-75
5	546	85.8	135	7	US-11-012-353-77
6	541	85.1	117	7	US-11-012-353-79
7	541	85.1	135	7	US-11-012-353-81
8	539.5	84.8	259	6	US-10-512-184-34
9	539.5	84.8	371	6	US-10-512-184-71
10	539.5	84.8	626	6	US-10-512-184-49
11	529	83.2	117	7	US-11-012-353-83
12	529	83.2	135	7	US-11-012-353-85
13	497.5	78.2	118	7	US-11-012-353-71
14	488.5	76.8	118	7	US-11-009-939-22
15	467	73.4	117	7	US-11-012-353-162
16	412.5	64.9	252	7	US-11-054-515-1548
17	408	64.2	107	7	US-11-185-615-2
18	405	63.7	253	7	US-11-054-515-1619
19	402.5	63.3	250	7	US-11-054-515-1548
20	400	62.9	123	7	US-11-012-353-73
21	399	62.7	255	7	US-11-054-515-841
22	397	62.4	102	7	US-11-185-615-4
23	395.5	62.2	247	7	US-11-054-515-1651
24	395	62.1	229	6	US-10-923-327-13
25	395	62.1	233	6	US-10-923-327-18

ALIGNMENTS

RESULT 1

US-11-012-353-69
; Sequence 69, Application US/11012353
; Publication No. US20050249730A1

GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 69
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-69

Query Match 100.0%; Score 636; DB 7; Length 117;
Best Local Similarity 100.0%; Pred. No. 8.9e-51;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVQLOESGGLVKPSQSLTCSVTGYSTGGYLNWIRQPPGNKLEWMGYISYDGTNNY 60
Db 1 DVQLOESGGLVKPSQSLTCSVTGYSTGGYLNWIRQPPGNKLEWMGYISYDGTNNY 60
QY 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYTCARYGRVFFDYWGQTTLTVSS 117
Db 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYTCARYGRVFFDYWGQTTLTVSS 117

RESULT 2
US-11-012-353-52
; Sequence 52, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT FILING DATE: 2004-12-16
; PRIOR FILING DATE: 2003-12-16
; PRIOR FILING DATE: 2003-12-16
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 52
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-52

Query Match 100.0%; Score 636; DB 7; Length 127;
Best Local Similarity 100.0%; Pred. No. 9.6e-51; Indels 0; Gaps 0;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 DVQLQESGGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
DB 11 DVQLQESGGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 70
QY 61 KPSLKDRIISITRDTSKNQFFLKNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
DB 71 KPSLKDRIISITRDTSKNQFFLKNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 127

RESULT 3
US-11-012-353-70
; Sequence 70, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT FILING DATE: 2004-12-16
; PRIOR FILING DATE: 2003-12-16
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753

; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 70
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-70

Query Match 89.5%; Score 569.5; DB 7; Length 118;
Best Local Similarity 90.7%; Pred. No. 7.8e-45;
Matches 107; Conservative 2; Mismatches 8; Indels 1; Gaps 1;
QY 1 DVQLQESGGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
DB 1 DVQLQESGGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
QY 61 KPSLKDRIISITRDTSKNQFFLKNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
DB 61 NPSLKNRISITRDTSKNQFFLKNSVTNEDTATYYCAREGYFFDYWGQGTTLTVSS 118

RESULT 4
US-11-012-353-75
; Sequence 75, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT FILING DATE: 2004-12-16
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 75
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-75

Query Match 85.8%; Score 546; DB 7; Length 117;
Best Local Similarity 86.2%; Pred. No. 9.7e-43;
Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;
QY 2 VQLQESGGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNYK 61
DB 2 VQLQESGGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNYK 61
QY 62 PSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
DB 62 PSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117

Db 80 PSLKDRVTISRTSKNQFSLKLSVTAADTAVYYCARYGRVFDYWGQGLTVTVSS 135
RESULT 8
US-10-512-184-34
; Sequence 34, Application US/10512184
; Publication No. US20050244901A1
; GENERAL INFORMATION:
; APPLICANT: Fraunhofer Gesellschaft zur F"rderung der angewandten Forschung e.V.
; TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant
; TITLE OF INVENTION: antibody fragments and fusions mediated plant disease
; TITLE OF INVENTION: resistance against fungi
; FILE REFERENCE: 3581.01US01
; CURRENT APPLICATION NUMBER: US/10/512,184
; CURRENT FILING DATE: 2004-10-22
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 34
; LENGTH: 259
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: scFv PL2 with
; OTHER INFORMATION: specificity against Phoma lingam; originates from
; OTHER INFORMATION: Mus musculus.
US-10-512-184-34
Query Match 84.8%; Score 539.5; DB 6; Length 259;
Best Local Similarity 84.4%; Pred. No. 7.8e-42;
Matches 103; Conservative 5; Mismatches 9; Indels 5; Gaps 2;
QY 1 DVQLQESGGLVKPQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60
Db 3 DVQLQESGGLVKPQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNN 62
QY 61 KPSLKDRISITRDTSKNQFSLKLSVTAADTAVYYCARYGRVFDYWGQGLTVTV 115
Db 63 NPSLKNRISITRDASKNQFSLKLSVTTEDTATYHCARGAPYVGKTFWPPYWGQGLTVTV 122
QY 116 SS 117
Db 123 SS 124
RESULT 9
US-10-512-184-71
; Sequence 71, Application US/10512184
; Publication No. US20050244901A1
; GENERAL INFORMATION:
; APPLICANT: Fraunhofer Gesellschaft zur F"rderung der angewandten Forschung e.V.
; TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant
; TITLE OF INVENTION: antibody fragments and fusions mediated plant disease
; TITLE OF INVENTION: resistance against fungi
; FILE REFERENCE: 3581.01US01
; CURRENT APPLICATION NUMBER: US/10/512,184
; CURRENT FILING DATE: 2004-10-22
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 71
; LENGTH: 371
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: precursor
; OTHER INFORMATION: fusion protein comprising ACE - linker -
; OTHER INFORMATION: scFv PL2.
US-10-512-184-71
Query Match 84.8%; Score 539.5; DB 6; Length 371;
Best Local Similarity 84.4%; Pred. No. 1.1e-41;
Matches 103; Conservative 5; Mismatches 9; Indels 5; Gaps 2;
QY 1 DVQLQESGGLVKPQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60

Db 115 DVQLQESGGLVKPQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNN 174
QY 61 KPSLKDRISITRDTSKNQFSLKLSVTTEDTATYHCARGAPYVGKTFWPPYWGQGLTVTV 115
Db 175 NPSLKNRISITRDASKNQFSLKLSVTTEDTATYHCARGAPYVGKTFWPPYWGQGLTVTV 234
QY 116 SS 117
Db 235 SS 236
RESULT 10
US-10-512-184-49
; Sequence 49, Application US/10512184
; Publication No. US20050244901A1
; GENERAL INFORMATION:
; APPLICANT: Fraunhofer Gesellschaft zur F"rderung der angewandten Forschung e.V.
; TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant
; TITLE OF INVENTION: antibody fragments and fusions mediated plant disease
; TITLE OF INVENTION: resistance against fungi
; FILE REFERENCE: 3581.01US01
; CURRENT APPLICATION NUMBER: US/10/512,184
; CURRENT FILING DATE: 2004-10-22
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 49
; LENGTH: 626
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: fusion protein
; OTHER INFORMATION: comprising the leader peptide - chitinase- linker
; OTHER INFORMATION: - scFv PL2 - cmyc/His6.
US-10-512-184-49
Query Match 84.8%; Score 539.5; DB 6; Length 626;
Best Local Similarity 84.4%; Pred. No. 1.8e-41;
Matches 103; Conservative 5; Mismatches 9; Indels 5; Gaps 2;
QY 1 DVQLQESGGLVKPQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60
Db 344 DVQLQESGGLVKPQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNN 403
QY 61 KPSLKDRISITRDTSKNQFSLKLSVTTEDTATYHCARGAPYVGKTFWPPYWGQGLTVTV 115
Db 404 NPSLKNRISITRDASKNQFSLKLSVTTEDTATYHCARGAPYVGKTFWPPYWGQGLTVTV 463
QY 116 SS 117
Db 464 SS 465
RESULT 11
US-11-012-353-83
; Sequence 83, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11


```
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-009-939-22

Query Match      76.8%; Score 488.5; DB 7; Length 118;
Best Local Similarity 76.9%; Pred. No. 1.3e-37;
Matches 93; Conservative 9; Mismatches 12; Indels 7; Gaps 2;

QY 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLWNWIRQPPGNKLEWMGYISYDGTNNY 60
   |||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|:
Db 1 DVQLQESGPDLIQPSQSLTCTVTGYSITGGYSWHWIRQPPGNKLEWMGYIHYSGYTD 60
   |||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|:
QY 61 KPSLKDRISTRDTSKNQFLKNSVTNEDTATYCYARY----GRVFFDYMGQGTTLTVS 116
   |||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|:
Db 61 NPSLKRISITRDTSKNQFLQLNSVTTEDTATYICARQPSDG---PPYMGQGTTLTVS 117
   |||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|:
QY 117 S 117
;
Db 118 A 118

RESULT 15
US-11-012-353-162
; Sequence 162, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HARUM, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 162
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-162

Query Match      73.4%; Score 467; DB 7; Length 117;
Best Local Similarity 74.1%; Pred. No. 1.1e-35;
Matches 86; Conservative 13; Mismatches 17; Indels 0; Gaps 0;

QY 2 VOLQESGPGLVKPSQSLTCSVTGYSITGGYLWNWIRQPPGNKLEWMGYISYDGTNNY 61
   |||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|:
Db 2 VOLQESGPGLVKPSQSLTCTVTGYSISSGYWGWIRQPPGNKLEWIGSIFHSGSYN 61
   |||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|:
QY 62 PSLKDRISITRDTSKNQFLKNSVTNEDTATYCYARYGRVFFDYMGQGTTLTVSS 117
   |||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|:
Db 62 PSLKSRVTISVDTSKNQPSLKLSVTAADTAVYCYARYGRVFFDYMGQGTTLTVSS 117
   |||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|||||:|:|:

Search completed: January 10, 2006, 21:36:23
Job time : 5.96642 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:53:43 ; Search time 64.1754 Seconds
(without alignments)
761.757 Million cell updates/sec

Title: US-10-735-916A-69
Perfect score: 636
Sequence: 1 DVQLQESGPGLVKPSQSL*.....RYGRVFDDYWGQTTLTIVSS 117

Scoring table: BLASTUM62
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications_AA_Main:*
1: /cgn2_6/prodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/prodata/1/pubpaa/US08_PUBCOMB.pep.*
3: /cgn2_6/prodata/1/pubpaa/US09_PUBCOMB.pep.*
4: /cgn2_6/prodata/1/pubpaa/US10A_PUBCOMB.pep.*
5: /cgn2_6/prodata/1/pubpaa/US10B_PUBCOMB.pep.*
6: /cgn2_6/prodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	636	100.0	117	5	US-10-735-916A-69
2	636	100.0	127	5	US-10-735-916A-52
3	569.5	89.5	118	5	US-10-735-916A-70
4	548.5	86.2	118	4	US-10-372-481-17
5	548.5	86.2	118	4	US-10-371-797-17
6	546	85.8	117	5	US-10-735-916A-75
7	546	85.8	135	5	US-10-735-916A-77
8	544.5	85.6	136	3	US-09-858-349-2
9	541	85.1	117	5	US-10-735-916A-79
10	541	85.1	135	5	US-10-735-916A-81
11	533.5	83.9	468	5	US-10-943-640-4
12	529	83.2	117	5	US-10-735-916A-83
13	529	83.2	135	5	US-10-735-916A-85
14	522.5	82.2	144	3	US-09-791-551-119
15	521.5	82.0	120	4	US-10-383-447-2
16	518	81.4	119	5	US-10-207-655-258
17	518	81.4	119	5	US-10-627-556-46
18	518	81.4	266	4	US-10-207-655-260
19	518	81.4	266	5	US-10-627-556-48
20	518	81.4	550	4	US-10-207-655-270
21	518	81.4	550	5	US-10-627-556-54
22	518	81.4	550	5	US-10-627-556-440
23	516.5	81.2	116	6	US-11-003-819-4
24	514.5	80.9	121	3	US-09-144-886-70
25	514.5	80.9	121	4	US-10-632-706-67
26	513	80.7	113	4	US-10-741-657A-21
27	513	80.7	141	3	US-09-791-551-109

28	512.5	80.6	118	4	US-10-184-300A-3	Sequence 3, Appli
29	511	80.3	121	3	US-09-920-171-2	Sequence 2, Appli
30	511	80.3	121	4	US-10-113-996-2	Sequence 2, Appli
31	511	80.3	121	5	US-10-791-619-2	Sequence 2, Appli
32	511	80.3	134	3	US-09-802-077-3	Sequence 3, Appli
33	511	80.3	134	3	US-09-802-096-3	Sequence 3, Appli
34	511	80.3	134	3	US-09-925-179-3	Sequence 3, Appli
35	511	80.3	134	5	US-10-968-237-3	Sequence 3, Appli
36	510	80.2	119	4	US-10-713-248-3	Sequence 7, Appli
37	510	80.2	119	4	US-10-713-248-7	Sequence 19, Appl
38	509	80.0	115	4	US-10-741-657A-19	Sequence 131, App
39	508.5	80.0	115	4	US-10-308-817-131	Sequence 131, App
40	508.5	80.0	115	4	US-10-453-698-131	Sequence 29, Appl
41	508	79.9	121	5	US-10-816-938-29	Sequence 36, Appl
42	507	79.7	121	4	US-10-310-674A-36	Sequence 12, Appl
43	507	79.7	121	4	US-10-389-679-12	Sequence 13, Appl
44	506	79.6	113	4	US-10-741-657A-13	Sequence 22, Appl
45	502.5	79.0	120	4	US-10-383-447-22	

ALIGNMENTS

RESULT 1
US-10-735-916A-69
; Sequence 69, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFOLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10735-916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 69
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-735-916A-69

Query Match	100.0%	Score 636;	DB 5;	Length 117;
Best Local Similarity	100.0%	Pred. No. 4.5e-51;		
Matches 117;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	DVQLQESGPGLVKPSQSLTCSVTGYSITGTYLWNWIRQFPGNKLEWNGYISYDGTNNY	60	
Db	1	DVQLQESGPGLVKPSQSLTCSVTGYSITGTYLWNWIRQFPGNKLEWNGYISYDGTNNY	60	
QY	61	KPSLXDRISITRDTSKNOFFLKLNSVTNEDTATYTCARYGRVFDDYWGQTTLTIVSS	117	
Db	61	KPSLXDRISITRDTSKNOFFLKLNSVTNEDTATYTCARYGRVFDDYWGQTTLTIVSS	117	
RESULT 2				
US-10-735-916A-52				
; Sequence 52, Application US/10735916A				
; Publication No. US20050084906A1				

```

; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 52
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-735-916A-52

Query Match      100.0%; Score 636; DB 5; Length 127;
Best Local Similarity 100.0%; Pred. No. 4.9e-51;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVQLQESGGLVKPQSLSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 11 DVQLQESGGLVKPQSLSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 70

QY 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
Db 71 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 127

RESULT 3
US-10-735-916A-70
; Sequence 70, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 70
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Mus musculus

```

```

US-10-735-916A-70

Query Match      89.5%; Score 569.5; DB 5; Length 118;
Best Local Similarity 90.7%; Pred. No. 6.4e-45;
Matches 107; Conservative 2; Mismatches 8; Indels 1; Gaps 1;

QY 1 DVQLQESGGLVKPQSLSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 1 DVQLQESGGLVKPQSLSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYINYGNNY 60

QY 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCARYG-RVFPDYWGQGTTLTVSS 117
Db 61 NPSLKNRISITRDTSKNQFFLKNSVTNEDTATYYCAREGYGFYFDYWGQGTTLTVSS 118

RESULT 4
US-10-372-481-17
; Sequence 17, Application US/10372481
; Publication No. US20030202975A1
; GENERAL INFORMATION:
; APPLICANT: Tedder, Thomas F.
; TITLE OF INVENTION: REAGENTS AND TREATMENT METHODS FOR AUTOIMMUNE DISEASES
; FILE REFERENCE: 5405.306
; CURRENT APPLICATION NUMBER: US/10/372.481
; CURRENT FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: PCT/US03/05549
; PRIOR FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: US 60/420,472
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: US 60/359,419
; PRIOR FILING DATE: 2002-02-21
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-372-481-17

Query Match      86.2%; Score 548.5; DB 4; Length 118;
Best Local Similarity 87.3%; Pred. No. 5.5e-43;
Matches 103; Conservative 5; Mismatches 9; Indels 1; Gaps 1;

QY 1 DVQLQESGGLVKPQSLSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 1 EVQLQESGGLVKPQSLSLTCSVTGYSITGGYWNWIRQFPGNKLEWNGYIRYGSNNY 60

QY 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCARYG-RVFPDYWGQGTTLTVSS 117
Db 61 NPSLKNRISITRDTSKNQFFLKNSVTNEDTATYYCARGGITVAMDYWGQGTSTVTVSS 118

RESULT 5
US-10-371-797-17
; Sequence 17, Application US/10371797
; Publication No. US20040001828A1
; GENERAL INFORMATION:
; APPLICANT: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
; APPLICANT: TUSCANO, Joseph
; APPLICANT: TEDDER, Thomas
; TITLE OF INVENTION: TREATMENT METHODS USING ANTI-CD22
; FILE OF INVENTION: ANTIBODIES
; FILE REFERENCE: 39754-0951
; CURRENT APPLICATION NUMBER: US/10/371,797
; CURRENT FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: US 60/420,472
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: US 60/359,419
; PRIOR FILING DATE: 2002-02-21
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 118

```



```
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-371-797-17

Query Match      86.2%; Score 548.5; DB 4; Length 118;
Best Local Similarity 87.3%; Pred. No. 5.5e-43;
Matches 103; Conservative 5; Mismatches 9; Indels 1; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYIRYDGSNNY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYCYARG-RVFFDYWGQGTTLTVSS 117
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 NPSLKNRISITRDTSKNQFFLKLNSVTNEDTATYCYARGGITVAMDYWGQGTSLTVSS 118

RESULT 6
US-10-735-916A-75
; Sequence 75, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 75
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-75

Query Match      85.8%; Score 546; DB 5; Length 117;
Best Local Similarity 86.2%; Pred. No. 9.4e-43;
Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 2 VOLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNYK 61
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 2 VOLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNYK 79
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 62 PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYCYARGRVFFDYWGQGTTLTVSS 117
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 62 PSLKDRITISRDTSKNQFSLKLSVTAADTAVYCYARGRVFFDYWGQGTTLTVSS 135
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 8
US-09-858-349-2
; Sequence 2, Application US/09858349
; Patent No. US20020012909A1
; GENERAL INFORMATION:
; APPLICANT: PLAKSIN, Daniel
; TITLE OF INVENTION: SMALL FUNCTIONAL UNITS OF ANTIBODY HEAVY CHAIN VARIABLE REGIONS
; FILE REFERENCE: 87534-2800
; CURRENT APPLICATION NUMBER: US/09/858,349
; CURRENT FILING DATE: 2000-06-02
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 136
; TYPE: PRT
; ORGANISM: mouse hybridoma specific for H-2D + RGPGRFVTI peptide
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (99)-(107)
; OTHER INFORMATION: variable
US-09-858-349-2

Query Match      85.6%; Score 544.5; DB 3; Length 136;
Best Local Similarity 85.0%; Pred. No. 1.5e-42;
Matches 102; Conservative 5; Mismatches 10; Indels 3; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGSNNY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYCYCAR---YGRVFFDYWGQGTTLTVSS 117
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 NPSLKNRISITRDTSKNQFFLKLNSVTNEDTATYCYCARXXXXXXXXXXDYWGQGTTLTVAA 120
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 9
US-10-735-916A-79
```

```
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 77
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-77

Query Match      85.8%; Score 546; DB 5; Length 135;
Best Local Similarity 86.2%; Pred. No. 1.1e-42;
Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 2 VOLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNYK 61
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 2 VOLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNYK 79
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 62 PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYCYARGRVFFDYWGQGTTLTVSS 117
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 62 PSLKDRITISRDTSKNQFSLKLSVTAADTAVYCYARGRVFFDYWGQGTTLTVSS 135
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 8
US-09-858-349-2
; Sequence 2, Application US/09858349
; Patent No. US20020012909A1
; GENERAL INFORMATION:
; APPLICANT: PLAKSIN, Daniel
; TITLE OF INVENTION: SMALL FUNCTIONAL UNITS OF ANTIBODY HEAVY CHAIN VARIABLE REGIONS
; FILE REFERENCE: 87534-2800
; CURRENT APPLICATION NUMBER: US/09/858,349
; CURRENT FILING DATE: 2000-06-02
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 136
; TYPE: PRT
; ORGANISM: mouse hybridoma specific for H-2D + RGPGRFVTI peptide
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (99)-(107)
; OTHER INFORMATION: variable
US-09-858-349-2

Query Match      85.6%; Score 544.5; DB 3; Length 136;
Best Local Similarity 85.0%; Pred. No. 1.5e-42;
Matches 102; Conservative 5; Mismatches 10; Indels 3; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQFPGNKLEWNGYISYDGSNNY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYCYCAR---YGRVFFDYWGQGTTLTVSS 117
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 NPSLKNRISITRDTSKNQFFLKLNSVTNEDTATYCYCARXXXXXXXXXXDYWGQGTTLTVAA 120
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 9
US-10-735-916A-79
```

```
; Sequence 79, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 79
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-79

Query Match      85.1%; Score 541; DB 5; Length 117;
Best Local Similarity 84.5%; Pred. No. 2.7e-42;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

Qy  2  VQLQESGPGLVKPSQSLTCTSVTGYSLTGGYLNWIRQPPGNKLEWNGYISYDGTNNYK 61
Db  2  VQLQESGPGLVKPSQSLTCTSVTGYSLTGGYLNWIRQPPGNKLEWNGYISYDGTNNYK 61

Qy  62  PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
Db  62  PSLKDRVTISRDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 117

; RESULT 10
US-10-735-916A-81
; Sequence 81, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 81
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-81

Query Match      85.1%; Score 541; DB 5; Length 135;
Best Local Similarity 84.5%; Pred. No. 3.1e-42;
Matches 98; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

Qy  2  VQLQESGPGLVKPSQSLTCTSVTGYSLTGGYLNWIRQPPGNKLEWNGYISYDGTNNYK 61
Db  20  VQLQESGPGLVKPSQSLTCTSVTGYSLTGGYLNWIRQPPGNKLEWNGYISYDGTNNYK 79

Qy  62  PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
Db  80  PSLKDRVTISRDTSKNQPSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 135

; RESULT 11
US-10-943-640-4
; Sequence 4, Application US/10943640
; Publication No. US20050152907A1
; GENERAL INFORMATION:
; APPLICANT: LIANG, Tony W.
; APPLICANT: LOO, Deryk T.
; APPLICANT: XU, Xiaolin
; TITLE OF INVENTION: KID3 AND KID3 ANTIBODIES THAT BIND
; TITLE OF INVENTION: THERETO
; FILE REFERENCE: 415072002700
; CURRENT APPLICATION NUMBER: US/10/943,640
; CURRENT FILING DATE: 2004-09-17
; PRIOR APPLICATION NUMBER: US 60/504,441
; PRIOR FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 468
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-943-640-4

Query Match      83.9%; Score 533.5; DB 5; Length 468;
Best Local Similarity 84.2%; Pred. No. 5.6e-41;
Matches 101; Conservative 6; Mismatches 10; Indels 3; Gaps 2;

Qy  1  DVQLQESGPGLVKPSQSLTCTSVTGYSLTGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60
Db  19  DVQLQESGPGLVKPSQSLTCTVTGYSLTSDYAWNIRQPPGNKLEWNGYISYSGSTSY 78

Qy  61  KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR--YGRV--FFDYWGQGTTLTVSS 117
Db  79  NPSLSKRSVITRDTSKNQFFLQLNSVTNEDTATYYCARFYRYADYFDYWGQGTTLTVSS 138

; RESULT 12
US-10-735-916A-83
; Sequence 83, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
```

```

; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 83
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-83

Query Match      83.2%; Score 529; DB 5; Length 117;
Best Local Similarity 82.8%; Pred. No. 3.5e-41;
Matches 96; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

QY 2 VOLQSGPGLVKPQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWGWYISYDGTNNYK 61
DB 2 VOLQSGPGLVKPSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGWYISYDGTNNYK 61

QY 62 PSLKDRISITRDTSKNQPFKLNSVTNEDTATYCYGRVFFDYWGQGTTLTVSS 117
DB 62 PSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYCYGRVFFDYWGQGTTLTVSS 117

RESULT 13
US-10-735-916A-85
; Sequence 85, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 85
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-85

Query Match      83.2%; Score 529; DB 5; Length 135;
Best Local Similarity 82.8%; Pred. No. 4e-41;
Matches 96; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

QY 2 VOLQSGPGLVKPQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWGWYISYDGTNNYK 61
DB 20 VOLQSGPGLVKPSETLSLTCTVSGYSISGGYLNWIRQPPGKLEWIGWYISYDGTNNYK 79

QY 62 PSLKDRISITRDTSKNQPFKLNSVTNEDTATYCYGRVFFDYWGQGTTLTVSS 117
DB 80 PSLKDRVTISVDTSKNQPSLKLSSVTAADTAVYCYGRVFFDYWGQGTTLTVSS 135
```

RESULT 14

```

US-09-791-551-119
; Sequence 119, Application US/09791551
; Publication No. US2003023584A1
; GENERAL INFORMATION:
; APPLICANT: KLOETZER, WILLIAM S.
; APPLICANT: HANNA, NABIL
; TITLE OF INVENTION: METHOD FOR PREPARING ANTI-MIF ANTIBODIES
; FILE REFERENCE: 037003/027869
; CURRENT APPLICATION NUMBER: US/09/791.551
; CURRENT FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: 60/185,390
; PRIOR FILING DATE: 2000-02-28
; PRIOR APPLICATION NUMBER: 60/233,625
; PRIOR FILING DATE: 2000-09-18
; NUMBER OF SEQ ID NOS: 119
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 119
; LENGTH: 144
; TYPE: PRT
; ORGANISM: Mus sp.
US-09-791-551-119
```

Query Match 82.2%; Score 522.5; DB 3; Length 144;
Best Local Similarity 78.2%; Pred. No. 1.7e-40;
Matches 97; Conservative 10; Mismatches 10; Indels 7; Gaps 1;

```

QY 1 DVQLQESGPGLVKPSQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWGWYISYDGTNNY 60
DB 19 DVQLQESGPDVLKPSQSLSLTCSTGYSITGGYLNWIRQPPGNKLEWGWYISYDGSKSH 78

QY 61 KPSLKDRISITRDTSKNQPFKLNSVTNEDTATYCYGRVFFDYWGQGTTL 113
DB 79 NPSLRNRISITRDPKSNQPFKLNSVTNEDTATYCYGRVFFDYWGQGTTLV 138

QY 114 TVSS 117
DB 139 TVSS 142
```

RESULT 15

```

US-10-383-447-2
; Sequence 2, Application US/10383447
; Publication No. US20040096392A1
; GENERAL INFORMATION:
; APPLICANT: Bhaekar, Vinay
; APPLICANT: de la Calle, Agustin
; APPLICANT: Law, Debbie
; APPLICANT: Caras, Ingrid
; APPLICANT: Ramakrishnan, Vanitha
; APPLICANT: Murray, Richard
; APPLICANT: Afar, Daniel
; APPLICANT: Powers, David
; TITLE OF INVENTION: Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
; FILE REFERENCE: 05882.0138.NPUS00
; CURRENT APPLICATION NUMBER: US/10/383,447
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: US 60/362,837
; PRIOR FILING DATE: 2002-03-08
; PRIOR APPLICATION NUMBER: US 60/463,812
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Heavy chain variable region
US-10-383-447-2
```

Query Match 82.0%; Score 521.5; DB 4; Length 120;

Best Local Similarity 81.7%; Pred. No. 1.8e-40;
Matches 98; Conservative 7; Mismatches 12; Indels 3; Gaps 1;
Qy 1 DVQLQESGGLVKPSQSLTCSVTGYSTGGYLNWIRQPPGNKLEWWMGYISYDGTNNY 60
Db 1 DVQLQESGGLVKPSQSLTCSVTGYSTGGYLNWIRQPPGNKLEWWMGYISYDGTNNY 60
Qy 61 KPSLKDRISITRDTSKNOFFLKLNSVTNEDTATYYCA---RYGRVFFDYWGQGTTLTVSS 117
Db 61 NPSLKNRISITRDTSENQFFLNLRSVTNEDTATYYCARGLRGDDYMDYWGQGTISVTYSS 120

Search completed: January 10, 2006, 21:35:32
Job time : 65.1754 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:34:27 ; Search time 22.847 Seconds
(without alignments)
423.384 Million cell updates/sec

Title: US-10-735-916A-69
Perfect score: 636
Sequence: 1 DVQLQSGPLVKPSQSLSL.....RYGRVFFDYWGQGTTLTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA: *
1: /cgn2_6/ptodata/1/1aa/5 COMB.pep.*
2: /cgn2_6/ptodata/1/1aa/6 COMB.pep.*
3: /cgn2_6/ptodata/1/1aa/H COMB.pep.*
4: /cgn2_6/ptodata/1/1aa/PCITUS COMB.pep.*
5: /cgn2_6/ptodata/1/1aa/RE COMB.pep.*
6: /cgn2_6/ptodata/1/1aa/backfiles1.pep.*

pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	550	86.5	118	2 US-09-065-059-11	Sequence 11, Appl
2	550	86.5	118	2 US-08-913-555-11	Sequence 11, Appl
3	540	84.9	119	2 US-08-767-128-18	Sequence 18, Appl
4	511	80.3	121	1 US-08-887-352B-2	Sequence 2, Appl
5	511	80.3	121	2 US-09-109-207C-2	Sequence 2, Appl
6	511	80.3	121	2 US-09-296-005-2	Sequence 2, Appl
7	511	80.3	121	2 US-09-920-171-2	Sequence 2, Appl
8	511	80.3	121	2 US-09-716-028-2	Sequence 2, Appl
9	511	80.3	121	2 US-10-113-996-2	Sequence 2, Appl
10	511	80.3	134	2 US-08-466-151-3	Sequence 3, Appl
11	511	80.3	134	2 US-08-466-163B-3	Sequence 3, Appl
12	511	80.3	134	2 US-09-802-096-3	Sequence 3, Appl
13	511	80.3	134	2 US-09-802-077-3	Sequence 3, Appl
14	511	80.3	134	2 US-09-925-179-3	Sequence 3, Appl
15	506.5	79.6	241	2 US-08-902-486-13	Sequence 13, Appl
16	506.5	79.6	496	2 US-08-902-486-15	Sequence 15, Appl
17	500	78.6	130	2 US-08-466-151-5	Sequence 5, Appl
18	500	78.6	130	2 US-08-466-163B-5	Sequence 5, Appl
19	500	78.6	130	2 US-09-802-096-5	Sequence 5, Appl
20	500	78.6	130	2 US-09-802-077-5	Sequence 5, Appl
21	500	78.6	130	2 US-09-925-179-5	Sequence 5, Appl
22	498.5	78.4	240	1 US-07-956-399-2	Sequence 2, Appl
23	491.5	77.3	117	1 US-08-308-494A-13	Sequence 13, Appl
24	485.5	76.3	114	1 US-08-111-080-23	Sequence 23, Appl
25	485.5	76.3	114	1 US-08-211-980-23	Sequence 23, Appl
26	485.5	76.3	114	4 PCT-US93-07967-23	Sequence 23, Appl
27	482	75.8	137	1 US-08-137-117D-31	Sequence 31, Appl

28	482	75.8	137	1 US-08-436-717-31	Sequence 31, Appl
29	478.5	75.2	137	2 US-08-466-151-7	Sequence 7, Appl
30	478.5	75.2	137	2 US-08-466-163B-7	Sequence 7, Appl
31	478.5	75.2	137	2 US-09-802-096-7	Sequence 7, Appl
32	478.5	75.2	137	2 US-09-802-077-7	Sequence 7, Appl
33	478.5	75.2	137	2 US-09-925-179-7	Sequence 7, Appl
34	478	75.2	137	1 US-08-672-345C-13	Sequence 13, Appl
35	478	75.2	117	2 US-09-214-095D-13	Sequence 13, Appl
36	478	75.2	117	2 US-09-940-727B-13	Sequence 13, Appl
37	477	75.0	213	2 US-09-170-769A-2	Sequence 2, Appl
38	463	72.8	117	2 US-09-232-290-32	Sequence 32, Appl
39	456.5	71.8	112	2 US-09-344-587-14	Sequence 14, Appl
40	456	71.7	117	1 US-08-672-345C-10	Sequence 10, Appl
41	456	71.7	117	1 US-08-672-345C-11	Sequence 11, Appl
42	456	71.7	117	1 US-08-672-345C-100	Sequence 100, App
43	456	71.7	117	1 US-08-672-345C-101	Sequence 101, App
44	456	71.7	117	2 US-09-214-095D-10	Sequence 10, Appl
45	456	71.7	117	2 US-09-214-095D-11	Sequence 11, Appl

ALIGNMENTS

RESULT 1
US-09-065-059-11
; Sequence 11, Application US/09065059
; Patent No. 6068841
; GENERAL INFORMATION:
; APPLICANT: SEINO, Ken-ichiro
; APPLICANT: KAYAGAKI, No. 6068841uhiko
; APPLICANT: YAGITA, Hideo
; APPLICANT: OKUMURA, Ko
; APPLICANT: NAKATA, Motomi
; TITLE OF INVENTION: THERAPEUTIC AGENT FOR HEPATITIS
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: McDermott, Will & Emery
; STREET: 99 Canal Center Plaza
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/065,059
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Bucca Ph.D., Daniel
; REGISTRATION NUMBER: P-42,368
; REFERENCE/DOCKET NUMBER: 50356-151
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-518-5100
; TELEFAX: 703-684-1124
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-09-065-059-11

Query Match 86.5%; Score 550; DB 2; Length 118;
Best Local Similarity 88.1%; Pred. No. 8.8e-51;
Matches 104; Conservative 3; Mismatches 9; Indels 2; Gaps 1;
QY 2 VOLQSGPLVKPSQSLSTCSVTGYSITGGYLNWIRQFGNKLMMGYISYDGTNNYK 61
|||||

Db 1 VOLQESGPGLVKPSQSLTCSVTGYSTGYNNWIRQFPGNKLEWNGYISYDGSNNYN 60
QY 62 PSLKDRISITRDTSKNQFFKLNSVTNEDTATYYCA--RYGRVFFDYNGQGTTLTVSS 117
Db 61 PSLKNRISITRDTSKNQFFKLNSVTNEDTATYYCAVYYDSSFDYNGQGTTLTVSS 118

RESULT 2
US-08-913-555-11
; Sequence 11, Application US/08913555
; Patent No. 6946255
; GENERAL INFORMATION:
; APPLICANT: KAYAGAKI, No. 6946255uhiko
; APPLICANT: YAGITA, Kideo
; APPLICANT: OKUMURA, Ko
; APPLICANT: NAKATA, Motomi
; TITLE OF INVENTION: MONOCLONAL ANTIBODY SPECIFICALLY
; TITLE OF INVENTION: REACTING WITH Fas LIGAND AND PRODUCTION PROCESS THEREOF
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: McDermott, Will & Emery
; STREET: 99 Canal Center Plaza, Suite 300
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/913,555
; FILING DATE: 19-SEP-1997
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Bucca Ph.D., Daniel
; REGISTRATION NUMBER: 42,368
; REFERENCE/DOCKET NUMBER: 50356-150
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-756-8600
; TELEFAX: 202-756-8699
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-913-555-11

Query Match 86.5%; Score 550; DB 2; Length 118;
Best Local Similarity 88.1%; Pred. No. 8.8e-51;
Matches 104; Conservative 3; Mismatches 9; Indels 2; Gaps 1;
QY 2 VOLQESGPGLVKPSQSLTCSVTGYSTGYNNWIRQFPGNKLEWNGYISYDGTNNYK 61
Db 1 VOLQESGPGLVKPSQSLTCSVTGYSTGYNNWIRQFPGNKLEWNGYISYDGSNNYN 60
QY 62 PSLKDRISITRDTSKNQFFKLNSVTNEDTATYYCA--RYGRVFFDYNGQGTTLTVSS 117
Db 61 PSLKNRISITRDTSKNQFFKLNSVTNEDTATYYCAVYYDSSFDYNGQGTTLTVSS 118

RESULT 3
US-08-767-128-18
; Sequence 18, Application US/08767128
; Patent No. 6111079
; GENERAL INFORMATION:
; APPLICANT: WYLIE, DWANE E.
; APPLICANT: LOPEZ, OSVALDO
; APPLICANT: MURRAY, PETER JOSEPH
; APPLICANT: GOEBEL, PETER

; TITLE OF INVENTION: LEAD BINDING POLYPEPTIDES AND
; TITLE OF INVENTION: NUCLEOTIDES CODING THEREFORE
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt
; STREET: 3100 No. 611079west Center, 90 South Seventh St
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/767,128
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE: 04-DEC-1996
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/09258
; FILING DATE: 05-JUN-1996
; APPLICATION NUMBER: 08/541,373
; FILING DATE: 10-OCT-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/462,798
; FILING DATE: 05-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Carter, Charles G.
; REGISTRATION NUMBER: 35,093
; REFERENCE/DOCKET NUMBER: 8648.49USF1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612/371-5278
; TELEFAX: 612/332-9081
; TELEX:
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
US-08-767-128-18

Query Match 84.9%; Score 540; DB 2; Length 119;
Best Local Similarity 84.9%; Pred. No. 1e-49;
Matches 101; Conservative 5; Mismatches 11; Indels 2; Gaps 1;
QY 1 DVQLQESGPGLVKPSQSLTCSVTGYSTGYNNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLTCTVTGYSTGYNNWIRQFPGNKLEWNGYISYSGSTSY 60
QY 61 KPSLKDRISITRDTSKNQFFKLNSVTNEDTATYYCARYGRV--PFDYWGQGTTLTVSS 117
Db 61 NPSLSRISITRDTSKNQFFLQLNSVTNEDTATYYCARGNYPWFYDWGQGTTLTVSS 119

RESULT 4
US-08-887-352B-2
; Sequence 2, Application US/08887352B
; Patent No. 5994511
; GENERAL INFORMATION:
; APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
; TITLE OF INVENTION: Improved Anti-IgB Antibodies and Method of

TITLE OF INVENTION: Improving Polypeptides
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinFatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/887,352B
FILING DATE: 03-Jul-1997
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Svoboda, Craig G.
REGISTRATION NUMBER: 39,044
REFERENCE/DOCKET NUMBER: P1123
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1489
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 121 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear

US-08-887-352B-2

Query Match 80.3%; Score 511; DB 1; Length 121;
Best Local Similarity 79.3%; Pred. No. 1.2e-46;
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNNWIRQPPGNKLEWNGYISYDGTNNY 60
DB 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNNWIRQPPGNKLEWNGYISYDGTNNY 60

QY 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCAR----YGRVFFDYWGQGTTLTVS 116
DB 61 NPSLKNRISVTRDTSQNOFFLKNSATAEDTATYYCARGSHYFGHHFAVWGAGTTTVTS 120

QY 117 S 117
DB 121 S 121

RESULT 5
US-09-109-207C-2
Sequence 2, Application US/09109207C
Patent No. 6172213
GENERAL INFORMATION:
APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of Improving Polypeptide
FILE REFERENCE: P112381
CURRENT APPLICATION NUMBER: US/09/109,207C
CURRENT FILING DATE: 1998-06-30
PRIOR APPLICATION NUMBER: US 60/051,554
PRIOR FILING DATE: 1997-07-03
NUMBER OF SEQ ID NOS: 44
SEQ ID NO 2
LENGTH: 121
TYPE: PRT
ORGANISM: Mus musculus
US-09-109-207C-2

Query Match 80.3%; Score 511; DB 2; Length 121;
Best Local Similarity 79.3%; Pred. No. 1.2e-46;
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNNWIRQPPGNKLEWNGYISYDGTNNY 60

DB 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNNWIRQPPGNKLEWNGYISYDGTNNY 60
QY 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCAR----YGRVFFDYWGQGTTLTVS 116
DB 61 NPSLKNRISVTRDTSQNOFFLKNSATAEDTATYYCARGSHYFGHHFAVWGAGTTTVTS 120

QY 117 S 117
DB 121 S 121

RESULT 6

US-09-296-005-2
Sequence 2, Application US/09296005
Patent No. 6290957
GENERAL INFORMATION:
APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of Improving Polypeptides
FILE REFERENCE: P1123C1r
CURRENT APPLICATION NUMBER: US/09/296,005
CURRENT FILING DATE: 1999-04-21
PRIOR APPLICATION NUMBER: US 08/887,352
PRIOR FILING DATE: 1997-07-02
NUMBER OF SEQ ID NOS: 26
SEQ ID NO 2
LENGTH: 121
TYPE: PRT
ORGANISM: Mus musculus
US-09-296-005-2

Query Match 80.3%; Score 511; DB 2; Length 121;
Best Local Similarity 79.3%; Pred. No. 1.2e-46;
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNNWIRQPPGNKLEWNGYISYDGTNNY 60
DB 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNNWIRQPPGNKLEWNGYISYDGTNNY 60

QY 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCAR----YGRVFFDYWGQGTTLTVS 116
DB 61 NPSLKNRISVTRDTSQNOFFLKNSATAEDTATYYCARGSHYFGHHFAVWGAGTTTVTS 120

QY 117 S 117
DB 121 S 121

RESULT 7

US-09-920-171-2
Sequence 2, Application US/09920171
Patent No. 6682735
GENERAL INFORMATION:
APPLICANT: Lowman, Henry B.
APPLICANT: Presta, Leonard G.
APPLICANT: Jardieu, Paula M.
APPLICANT: Lowe, John
TITLE OF INVENTION: Improved Anti-IgE Antibodies (as amended)
FILE REFERENCE: P1123C2US
CURRENT APPLICATION NUMBER: US/09/920,171
CURRENT FILING DATE: 2001-08-01
PRIOR APPLICATION NUMBER: US 08/887,352
PRIOR FILING DATE: 1997-07-02
PRIOR APPLICATION NUMBER: US 09/296,005
PRIOR FILING DATE: 1999-04-21
NUMBER OF SEQ ID NOS: 44
SEQ ID NO 2
LENGTH: 121
TYPE: PRT
ORGANISM: Mus musculus
US-09-920-171-2

Query Match 80.3%; Score 511; DB 2; Length 121;

```
Best Local Similarity 79.3%; Pred. No. 1.2e-46;
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGLYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGLYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Qy 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR----YGRVFFDYWGQGTTLTVS 116
Db 61 NPSLKNRISVTRDTSQNFQFLKLNSATAEDTATYYCARGSHYFGHWHFAVWGAGTTTVTS 120
Qy 117 S 117
Db 121 S 121

RESULT 8
US-09-716-028-2
; Sequence 2, Application US/09716028
; Patent No. 6723833
; GENERAL INFORMATION:
; APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
; TITLE OF INVENTION: Improved Anti-IgG Antibodies and Method of Improving Polypeptides
; FILE REFERENCE: P1123R1
; CURRENT APPLICATION NUMBER: US/09/716,028
; CURRENT FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: US 09/109,207
; PRIOR FILING DATE: 1998-06-30
; PRIOR APPLICATION NUMBER: US 60/051,554
; PRIOR FILING DATE: 1997-07-03
; NUMBER OF SEQ ID NOS: 44
; SEQ ID NO 2
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-716-028-2

Query Match 80.3%; Score 511; DB 2; Length 121;
Best Local Similarity 79.3%; Pred. No. 1.2e-46;
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGLYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGLYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Qy 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR----YGRVFFDYWGQGTTLTVS 116
Db 61 NPSLKNRISVTRDTSQNFQFLKLNSATAEDTATYYCARGSHYFGHWHFAVWGAGTTTVTS 120
Qy 117 S 117
Db 121 S 121

RESULT 9
US-10-113-996-2
; Sequence 2, Application US/10113996
; Patent No. 6761889
; GENERAL INFORMATION:
; APPLICANT: Lowman, Henry B.
; APPLICANT: Presta, Leonard G.
; APPLICANT: Jardieu, Paula M.
; APPLICANT: Lowe, John
; TITLE OF INVENTION: Improved Anti-IgG Antibodies
; FILE REFERENCE: P1123C3US
; CURRENT APPLICATION NUMBER: US/10/113,996
; CURRENT FILING DATE: 2002-04-01
; PRIOR APPLICATION NUMBER: US 08/887,352
; PRIOR FILING DATE: 1997-07-02
; PRIOR APPLICATION NUMBER: US 09/296,005
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: US 09/920,171
; PRIOR FILING DATE: 2001-08-01
```

```
; NUMBER OF SEQ ID NOS: 44
; SEQ ID NO 2
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-113-996-2

Query Match 80.3%; Score 511; DB 2; Length 121;
Best Local Similarity 79.3%; Pred. No. 1.2e-46;
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGLYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGLYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Qy 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR----YGRVFFDYWGQGTTLTVS 116
Db 61 NPSLKNRISVTRDTSQNFQFLKLNSATAEDTATYYCARGSHYFGHWHFAVWGAGTTTVTS 120
Qy 117 S 117
Db 121 S 121

RESULT 10
US-08-466-151-3
; Sequence 3, Application US/08466151
; Patent No. 6037453
; GENERAL INFORMATION:
; APPLICANT: Jardieu, Paula M.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Immunoglobulin Variants
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,151
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/466163
; FILING DATE: 06-Jun-1995
; APPLICATION NUMBER: 08/405617
; FILING DATE: 15-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/185899
; FILING DATE: 26-JAN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/879495
; FILING DATE: 07-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/744768
; FILING DATE: 14-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Svoboda, Craig G.
; REGISTRATION NUMBER: 39,044
; REFERENCE/DOCKET NUMBER: P0718P2C1D1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-1489
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 134 amino acids
```



```

; TYPE: Amino Acid
; TOPOLOGY: Linear
US-08-466-151-3

Query Match      80.3%; Score 511; DB 2; Length 134;
Best Local Similarity 79.3%; Pred. No. 1.4e-46;
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWNGSITYDGSNNY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCAR-----YGRVFFDYMGQGTTLTVS 116
Db 61 NPSLKNRISVTRDTSONQFFLKLSATAEDTATYYCARGSHYFGHHFAVWGAGTTTVTS 120

Qy 117 S 117
Db 121 S 121

RESULT 11
US-08-466-163B-3
; Sequence 3, Application US/08466163B
; Patent No. 6329509
; GENERAL INFORMATION:
; APPLICANT: Jardieu, Paula M.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Immunoglobulin Variants
; FILE REFERENCE: P0718P2C1D1
; CURRENT APPLICATION NUMBER: US/08/466,163B
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: US 08/185,899
; PRIOR FILING DATE: 1994-01-26
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 3
; LENGTH: 134
; TYPE: PRT
; ORGANISM: Mus musculus
US-08-466-163B-3

Query Match      80.3%; Score 511; DB 2; Length 134;
Best Local Similarity 79.3%; Pred. No. 1.4e-46;
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWNGSITYDGSNNY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCAR-----YGRVFFDYMGQGTTLTVS 116
Db 61 NPSLKNRISVTRDTSONQFFLKLSATAEDTATYYCARGSHYFGHHFAVWGAGTTTVTS 120

Qy 117 S 117
Db 121 S 121

RESULT 12
US-08-466-163B-3
; Sequence 3, Application US/08466163B
; Patent No. 6329509
; GENERAL INFORMATION:
; APPLICANT: Jardieu, Paula M.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Immunoglobulin Variants
; FILE REFERENCE: P0718P2C1D1
; CURRENT APPLICATION NUMBER: US/08/466,163B
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: US 08/185,899
; PRIOR FILING DATE: 1994-01-26
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 3
; LENGTH: 134
; TYPE: PRT
; ORGANISM: Mus musculus
US-08-466-163B-3

Query Match      80.3%; Score 511; DB 2; Length 134;
Best Local Similarity 79.3%; Pred. No. 1.4e-46;
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWNGSITYDGSNNY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCAR-----YGRVFFDYMGQGTTLTVS 116
Db 61 NPSLKNRISVTRDTSONQFFLKLSATAEDTATYYCARGSHYFGHHFAVWGAGTTTVTS 120

Qy 117 S 117
Db 121 S 121

RESULT 13
US-09-802-077-3
; Sequence 3, Application US/09802077
; Patent No. 6699472
; GENERAL INFORMATION:
; APPLICANT: Jardieu, Paula M.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Method of Treating Allergic Disorders (as amended)
; FILE REFERENCE: P0718P2C2US
; CURRENT APPLICATION NUMBER: US/09/802,077
; CURRENT FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: US 08/185,899
; PRIOR FILING DATE: 1994-01-26
; PRIOR APPLICATION NUMBER: PCT/US92/06860
; PRIOR FILING DATE: 1992-08-14
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 3
; LENGTH: 134
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-077-3

Query Match      80.3%; Score 511; DB 2; Length 134;
Best Local Similarity 79.3%; Pred. No. 1.4e-46;
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWNGSITYDGSNNY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCAR-----YGRVFFDYMGQGTTLTVS 116
Db 61 NPSLKNRISVTRDTSONQFFLKLSATAEDTATYYCARGSHYFGHHFAVWGAGTTTVTS 120

Qy 117 S 117
Db 121 S 121

RESULT 14
US-09-802-077-3
; Sequence 3, Application US/09802077
; Patent No. 6699472
; GENERAL INFORMATION:
; APPLICANT: Jardieu, Paula M.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Method of Treating Allergic Disorders (as amended)
; FILE REFERENCE: P0718P2C2US
; CURRENT APPLICATION NUMBER: US/09/802,077
; CURRENT FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: US 08/185,899
; PRIOR FILING DATE: 1994-01-26
; PRIOR APPLICATION NUMBER: PCT/US92/06860
; PRIOR FILING DATE: 1992-08-14
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 3
; LENGTH: 134
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-077-3

Query Match      80.3%; Score 511; DB 2; Length 134;
Best Local Similarity 79.3%; Pred. No. 1.4e-46;
Matches 96; Conservative 8; Mismatches 13; Indels 4; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWNGSITYDGSNNY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCAR-----YGRVFFDYMGQGTTLTVS 116
Db 61 NPSLKNRISVTRDTSONQFFLKLSATAEDTATYYCARGSHYFGHHFAVWGAGTTTVTS 120

Qy 117 S 117
Db 121 S 121
```

[illegible]

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:07:41 ; Search time 80.7649 Seconds
(without alignments)
636.505 Million cell updates/sec

Title: US-10-735-916A-69
Perfect score: 636
Sequence: 1 DVQLQSGPGIVKPSQSLSL.....RYGRVFFDYMGQGTTLTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A Geneseq 21.*
1: geneseqp1980s.*
2: geneseqp1990s.*
3: geneseqp2000s.*
4: geneseqp2001s.*
5: geneseqp2002s.*
6: geneseqp2003as.*
7: geneseqp2003bs.*
8: geneseqp2004s.*
9: geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	636	100.0	117	7	ADJ76903 Anti-IGF-
2	636	100.0	117	9	ADZ67073 Murine im
3	636	100.0	127	7	ADJ76886 Anti-IGF-
4	636	100.0	127	9	ADZ67056 Murine im
5	569.5	89.5	118	7	ADJ76904 Anti-IGF-
6	569.5	89.5	118	9	ADZ67074 Mouse ant
7	550	86.5	118	2	AAW00829 Variable
8	550	86.5	118	2	AAW19015 Anti-huma
9	549	86.3	114	9	AEA40137 resis
10	548.5	86.2	118	7	ABR82276 Hybridoma
11	548.5	86.2	118	7	ABR82886 Hybridoma
12	546	85.8	117	7	ADJ76909 Anti-IGF-
13	546	85.8	117	9	ADZ67079 Human ant
14	546	85.8	119	6	ABB98905 Variable
15	546	85.8	135	7	ADJ76911 Anti-IGF-
16	546	85.8	135	9	ADZ67081 Human ant
17	544.5	85.6	136	3	AAy94391 Mouse VH
18	542	85.2	119	6	ABB98906 Variable
19	541.5	85.1	369	4	ABb73388 Anti-VHS
20	541	85.1	117	7	ADZ97814 HEV relat
21	541	85.1	117	7	ADJ76913 Anti-IGF-
22	541	85.1	117	9	ADZ67083 Human ant
23	541	85.1	135	7	ADJ76915 Anti-IGF-
24	541	85.1	135	9	ADZ67085 Human ant

25	540	84.9	119	2	AAW01584	Aaw01584	Lead bind
26	539.5	84.8	259	7	ADG32325	Adg32325	Mouse scf
27	539.5	84.8	371	7	ADG32362	Adg32362	Precursor
28	539.5	84.8	626	7	ADG32340	Adg32340	Fusion pr
29	538	84.6	522	9	AEC20775	Asc20775	M-CSF spe
30	536	84.3	119	6	ABB98908	Abb98908	Variable
31	533.5	83.9	119	9	ADZ45405	Adz45405	Murine fa
32	533.5	83.9	468	9	ADY91369	Ady91369	Anti-KiD3
33	532	83.6	116	9	ADZ45341	Adz45341	Murine fa
34	532	83.6	116	9	ADZ51254	Adz51254	Amino aci
35	532	83.6	116	9	ADZ42128	Adz42128	Mouse ant
36	531.5	83.6	118	8	ADT07572	Adt07572	Polypepti
37	531.5	83.6	243	8	ADT07627	Adt07627	Polypepti
38	531.5	83.6	244	8	ADT07628	Adt07628	Polypepti
39	529	83.2	117	7	ADJ76917	Adj76917	Anti-IGF-
40	529	83.2	117	9	ADZ67087	Adz67087	Human ant
41	529	83.2	135	7	ADJ76919	Adj76919	Anti-IGF-
42	529	83.2	135	9	ADZ67089	Adz67089	Human ant
43	527.5	82.9	116	8	ADT89035	Adt89035	Murine pl
44	526	82.7	114	9	AEA40153	Aea40153	Mouse igh
45	524.5	82.5	118	9	ADZ81874	Adz81874	Anti-lami

ALIGNMENTS

RESULT 1
ADJ76903
ID ADJ76903 standard; protein; 117 AA.
XX
AC ADJ76903;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-IGF-1R related protein #16.
XX
KW cytosolic; antipsoriatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDR.
XX
OS Homo sapiens.
XX
FN WO2003059951-A2.
XX
PD 24-JUL-2003.
XX
PF 20-JAN-2003; 2003WO-FR000178.
XX
PR 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
XX
PA (FABR) FABRE MEDICAMENT SA PIERRE.
XX
PI Goetsch L, Corvaia N, Leger O;
XX
DR WPI; 2003-569653/53.
XX
PT New antibodies that bind to human insulin-like growth factor receptor,
XX useful for treatment, prevention and diagnosis of cancers.
PS Disclosure; SEQ ID NO 69; 164pp; French.
XX
CC The invention relates to an isolated antibody (Ab) and its functional
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
CC treat diseases associated with overexpression and/or abnormal activity of
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
CC hyperactivity of signal transduction pathways mediated by interaction of

CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.
 XX
 SQ Sequence 117 AA;

Query Match 100.0%; Score 636; DB 7; Length 117;
 Best Local Similarity 100.0%; Pred. No. 1.2e-51;
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 DVQLQESGPGVLKPSQSLTSCSVTGYISITGGYLNWIRQPGNKLEWVGYSYDGTNNY 60
 DB 1 DVQLQESGPGVLKPSQSLTSCSVTGYISITGGYLNWIRQPGNKLEWVGYSYDGTNNY 60
 QY 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYCYARYGRVFFDYWGQGTTLTVSS 117
 DB 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYCYARYGRVFFDYWGQGTTLTVSS 117

RESULT 2
 ADZ67073
 ID ADZ67073 standard; protein; 117 AA.

XX
 AC ADZ67073;

XX
 DT 30-JUN-2005 (first entry)

XX
 DE Murine immunoglobulin heavy chain variable region 7C10 VH SEQ ID NO:69.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;
 KW antiproliferative; psoriasis; dermatological disease; immune disorder;
 KW immunoglobulin; heavy chain variable region.

XX
 OS Mus musculus.

XX
 PN US2005084906-A1.

XX
 PD 21-APR-2005.

XX
 PF 16-DEC-2003; 2003US-00735916.

XX
 PR 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.

PR 07-MAY-2002; 2002FR-00005753.

PR 20-JAN-2003; 2003WO-FR000178.

PR 11-JUL-2003; 2003FR-00008538.

XX
 PA (GOETZ) GOETSCH L.

PA (CORV) CORVAIA N.

PA (LEGE) LEGER O.

PA (DUFL) DUFLOS A.

PA (HAEU) HAEUW J.

PA (BECK) BECK A.

XX
 DI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

XX
 DR WPI; 2005-321968/33.

PT Novel isolated anti-insulin-like growth factor I receptor (IGF-1R)
 PT antibody or its functional fragment, being capable of binding human IGF-
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,
 PT useful for treating cancer.

XX
 PS Example 13; SEQ ID NO 69; 125pp; English.

CC The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-1R) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-1R and, if necessary, capable of
 CC specifically inhibiting tyrosine kinase activity of the receptor,
 CC comprising a light or heavy chain having at least one complementary
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-1R and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGF1 or IGF2 with IGF-1R and/or of EGF with EGFR, where
 CC the administration of the medicament does not induce or only slightly
 CC induces secondary effects connected with inhibition of the insulin
 CC receptor. The antibody is useful for preparation of a medicament intended
 CC to inhibit the transformation of normal cells into cells with tumoral
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
 CC useful for preparation of a medicament intended to inhibit the growth
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a
 CC medicament intended for prevention or for the treatment of cancer, where
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 CC preparation of a medicament intended for the prevention or for the
 CC treatment of psoriasis. (I) is useful in preparation of a medicament
 CC intended for the specific targeting of a biologically active compound to
 CC cells expressing or overexpressing the IGF-1R and/or EGFR receptor. (I)
 CC is useful for in vitro diagnosis of illnesses induced by an
 CC overexpression or an underexpression of the IGF-1R and/or EGFR receptor
 CC starting from a biological sample in which the abnormal presence, of IGF-
 CC IR and/or EGFR receptor is suspected, which involves contacting the
 CC biological sample with (I), which is optionally labeled. The present
 CC sequence is used in the exemplification of the invention.

XX
 SQ Sequence 117 AA;

Query Match 100.0%; Score 636; DB 9; Length 117;
 Best Local Similarity 100.0%; Pred. No. 1.2e-51;
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVQLQESGPGVLKPSQSLTSCSVTGYISITGGYLNWIRQPGNKLEWVGYSYDGTNNY 60
 DB 1 DVQLQESGPGVLKPSQSLTSCSVTGYISITGGYLNWIRQPGNKLEWVGYSYDGTNNY 60
 QY 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYCYARYGRVFFDYWGQGTTLTVSS 117
 DB 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYCYARYGRVFFDYWGQGTTLTVSS 117

RESULT 3

ADJ76886

ID ADJ76886 standard; protein; 127 AA.

XX
 AC ADJ76886;

XX
 DT 06-MAY-2004 (first entry)

XX
 DE Anti-IGF-1R related protein #4.

XX
 KW cytosolic; antiproliferative; antibody;

KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
 KW CDR.

XX
 OS Mus musculus.

XX
 PN WO2003059951-A2.

XX
 PD 24-JUL-2003.

XX

```

PF 20-JAN-2003; 2003WO-FR000178.
XX
XX 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
XX
XX (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
XX Goetsch L, Corvaia N, Leger O;
PI
XX WPI; 2003-569653/53.
DR
XX
XX New antibodies that bind to human insulin-like growth factor receptor,
PT useful for treatment, prevention and diagnosis of cancers.
XX
XX Disclosure; SEQ ID NO 52; 164pp; French.
XX
XX The invention relates to an isolated antibody (Ab), and its functional
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
CC IR) and optionally: (i) inhibit natural binding of insulin-like growth
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or
CC treat diseases associated with overexpression and/or abnormal activity of
CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with
CC hyperactivity of signal transduction pathways mediated by interaction of
CC these receptors with their ligands. Especially they inhibit
CC transformation of normal cells to tumor cells, inhibit growth and/or
CC proliferation of tumor cells, so are useful against cancers of the
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
CC also for treating psoriasis. Ab are also used to diagnose diseases caused
CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
CC protein sequence used to generate the Ab of the invention.
XX
XX Sequence 127 AA;
SQ
Query Match 100.0%; Score 636; DB 7; Length 127;
Best Local Similarity 100.0%; Pred. No. 1.3e-51;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 DVQLQSGPLVKPQSLTCSVTGYSITGGLWNWIRQFPGNKLEWNGYISYDGTNNY 60
DB 11 DVQLQSGPLVKPQSLTCSVTGYSITGGLWNWIRQFPGNKLEWNGYISYDGTNNY 70
QY 61 KPFLKDRISITRDTSKNQFFLKNSVTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 117
DB 71 KPFLKDRISITRDTSKNQFFLKNSVTNEDTATYTCARYGRVFFDYWGQGTTLTVSS 127
RESULT 4
ADZ67056
ID ADZ67056 standard; protein; 127 AA.
XX
XX AC ADZ67056;
XX
XX 30-JUN-2005 (first entry)
XX
XX Murine immunoglobulin heavy chain variable region 7C10 VH SEQ ID NO:52.
XX
XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
XX neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
XX musculoskeletal disease; respiratory disease; lung tumor;
XX endocrine disease; gynecology and obstetrics; breast tumor;
XX endometroid carcinoma; gastrointestinal disease; colon tumor;
XX antipsoriatic; psoriasis; dermatological disease; immune disorder;
XX immunoglobulin; heavy chain variable region.
XX
XX Mus musculus.
XX
XX Key Location/Qualifiers
FH Peptide 1..10
FT Peptide /note= "leader peptide"
FT Region 41..46
FT /note= "CDRI"

```

```

FT Region 61..76
FT /note= "CDR2"
FT Region 109..116
FT /note= "CDR3"
XX
XX US2005084906-A1.
XX
XX 21-APR-2005.
XX
XX 16-DEC-2003; 2003US-00735916.
XX
XX 18-JAN-2002; 2002FR-00000653.
XX 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
PR 20-JAN-2003; 2003WO-FR000178.
XX 11-JUL-2003; 2003FR-00008538.
XX
XX (GOET/) GOETSCH L.
PA (CORV/) CORVAIA N.
PA (LEGE/) LEGER O.
PA (DUFL/) DUFLOS A.
PA (HAEU/) HAEUW J.
XX (BECK/) BECK A.
XX
XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
PI
XX WPI; 2005-321968/33.
XX N-PSDB; ADZ67055.
XX
XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
XX antibody or its functional fragment, being capable of binding human IGF-
XX IR and specifically inhibiting tyrosine kinase activity of receptor,
XX useful for treating cancer.
XX
XX Example 8; SEQ ID NO 52; 125pp; English.
XX
XX The invention relates to a novel isolated anti-insulin-like growth factor
XX I receptor (IGF-IR) antibody (I) or its functional fragment, being
XX capable of binding to human IGF-IR and, if necessary, capable of
XX specifically inhibiting tyrosine kinase activity of the receptor,
XX comprising a light or heavy chain having at least one complementary
XX determining region (CDR) consisting of one of two fully defined 16 amino
XX acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
XX the preparation of a medicament intended for the prevention or treatment
XX of an illness connected with an overexpression and/or an abnormal
XX activation of the IGF-IR and/or EGFR, and/or connected with a
XX hyperactivation of the transduction pathway of the signal mediated by the
XX interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
XX the administration of the medicament does not induce or only slightly
XX induces secondary effects connected with inhibition of the insulin
XX receptor. The antibody is useful for preparation of a medicament intended
XX to inhibit the transformation of normal cells into cells with tumoral
XX character, preferably IGF-dependent, especially IGF1 and/or IGF2-
XX dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
XX useful for preparation of a medicament intended to inhibit the growth
XX and/or the proliferation of tumor cells, preferably IGF-dependent,
XX especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
XX HER2/neu-dependent cells. (I) is useful in the preparation of a
XX medicament intended for prevention or for the treatment of cancer, where
XX the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
XX breast cancer, endometrial cancer or colon cancer. (I) is useful in the
XX preparation of a medicament intended for the prevention or for the
XX treatment of psoriasis. (I) is useful in preparation of a medicament
XX intended for the specific targeting of a biologically active compound to
XX cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
XX is useful for in vitro diagnosis of illnesses induced by an
XX overexpression or an underexpression of the IGF-IR and/or EGFR receptor,
XX starting from a biological sample in which the abnormal presence, of IGF-
XX IR and/or EGFR receptor is suspected, which involves contacting the
XX biological sample with (I), which is optionally labeled. The present
XX sequence is used in the exemplification of the invention.
XX
XX Sequence 127 AA;
SQ

```

Query Match 100.0%; Score 636; DB 9; Length 127;
 Best Local Similarity 100.0%; Pred. No. 1.3e-51;
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 DVQLQESGPGGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60
 Db 1 DVQLQESGPGGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 70
 Qy 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
 Db 71 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 127

RESULT 5
 ADJ76904
 ID ADJ76904 standard; protein; 118 AA.

XX AC ADJ76904;
 XX DT 06-MAY-2004 (first entry)
 XX DE Anti-IGF-IR related protein #17.
 XX KW cytostatic; antipsoriatic; antibody;
 KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
 KW CDR.

XX OS Mus musculus.
 XX PN WO2003059951-A2.
 XX PD 24-JUL-2003.

XX PF 20-JAN-2003; 2003WO-FR000178.
 XX PR 18-JAN-2002; 2002FR-00000653.
 XX PR 18-JAN-2002; 2002FR-00000654.
 XX PR 07-MAY-2002; 2002FR-00005753.
 XX PA (FABR) FABRE MEDICAMENT SA PIERRE.
 XX PI Goetsch L, Corvaia N, Leger O;
 XX DR WPI; 2003-569653/53.

XX PT New antibodies that bind to human insulin-like growth factor receptor,
 XX useful for treatment, prevention and diagnosis of cancers.
 XX PS Disclosure; SEQ ID NO 70; 164pp; French.

XX CC The invention relates to an isolated antibody (Ab), and its functional
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
 CC IR) and optionally: (i) inhibit natural binding of insulin-like growth
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
 CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or
 CC treat diseases associated with overexpression and/or abnormal activity of
 CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with
 CC hyperactivity of signal transduction pathways mediated by interaction of
 CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.

XX Sequence 118 AA;

Query Match 89.5%; Score 569.5; DB 7; Length 118;
 Best Local Similarity 90.7%; Pred. No. 1.9e-45;

Matches 107; Conservative 2; Mismatches 8; Indels 1; Gaps 1;
 Qy 1 DVQLQESGPGGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60
 Db 1 DVQLQESGPGGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWNGYINIDGNNY 60
 Qy 61 KPSLKDRISITRDTSKNQFFLKLSVNTNEDTATYYCARYG-RVFFDYWGQGTTLTVSS 117
 Db 61 NPSLKNRISITRDTSKNQFFLKLSVNTTDTATYYCAREGYGFYDYWGQGTTLTVSS 118

RESULT 6
 ADZ67074
 ID ADZ67074 standard; protein; 118 AA.

XX AC ADZ67074;
 XX DT 30-JUN-2005 (first entry)
 XX DE Mouse antibody heavy chain variable region SEQ ID NO:70.

XX KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW heavy chain variable region.

XX OS Mus musculus.
 XX PN US2005084906-A1.
 XX PD 21-APR-2005.

XX PF 16-DEC-2003; 2003US-00735916.
 XX PR 18-JAN-2002; 2002FR-00000653.
 XX PR 18-JAN-2002; 2002FR-00000654.
 XX PR 07-MAY-2002; 2002FR-00005753.
 XX PR 20-JAN-2003; 2003WO-FR000178.
 XX PR 11-JUL-2003; 2003FR-00008538.

XX PA (GOET/) GOETSCH L.
 XX PA (CORV/) CORVAIA N.
 XX PA (LEGE/) LEGER O.
 XX PA (DUFL/) DUFLOS A.
 XX PA (HAEU/) HAEUW J.
 XX PA (BECK/) BECK A.

XX PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
 XX DR WPI; 2005-321968/33.

XX PT Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 PT antibody or its functional fragment, being capable of binding human IGF-
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,
 PT useful for treating cancer.

XX Example 13; SEQ ID NO 70; 125pp; English.

XX CC The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-IR and, if necessary, capable of
 CC specifically inhibiting tyrosine kinase activity of the receptor,
 CC comprising a light or heavy chain having at least one complementary
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-IR and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where

CC the administration of the medicament does not induce or only slightly
 CC induces secondary effects connected with inhibition of the insulin
 CC receptor. The antibody is useful for preparation of a medicament intended
 CC to inhibit the transformation of normal cells into cells with tumoral
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
 CC useful for preparation of a medicament intended to inhibit the growth
 CC and/or the proliferation of tumor cells, preferably IGF-dependent and/or
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a
 CC medicament intended for prevention or for the treatment of cancer, where
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer, where
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 CC preparation of a medicament intended for the prevention or for the
 CC treatment of psoriasis. (I) is useful in preparation of a medicament
 CC intended for the specific targeting of a biologically active compound to
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
 CC is useful for in vitro diagnosis of illnesses induced by an
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
 CC starting from a biological sample in which the abnormal presence, of IGF-
 CC IR and/or EGFR receptor is suspected, which involves contacting the
 CC biological sample with (I), which is optionally labeled. The present
 CC sequence is used in the exemplification of the invention.

XX Sequence 118 AA;

Query Match 89.5%; Score 569.5; DB 9; Length 118;
 Best Local Similarity 90.7%; Pred. No. 1.9e-45; Indels 1; Gaps 1;
 Matches 107; Conservative 2; Mismatches 8;
 QY 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWMGYISYDGTNNY 60
 DB 1 DVQLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWMGYINYGNNY 60
 QY 61 KPSLKDRIISITRDTSKNQFFLNKNSVTNEDTATYTCARVG-RVPFDYWGQGTTLTVSS 117
 DB 61 NPSLKNRISITRDTSKNQFFLNKNSVTNEDTATYTCAREGYGYFFDYWGQGTTLTVSS 118

RESULT 7

AAW00829
 ID AAW00829 standard; protein; 118 AA.

XX AAW00829;

XX 19-MAY-1997 (first entry)

XX Variable heavy chain of anti-human Fas ligand antibody NOK-4.

XX Variable region; heavy chain; human; Fas ligand; monoclonal; antibody;
 KW NOK-4 hybridoma; inhibition; apoptosis; assay; diagnosis; disease;
 KW hepatitis; infectious mononucleosis; systemic lupus erythematosus.

XX Mus musculus.

XX WO9629350-A1.

XX 26-SEP-1996.

XX 21-MAR-1996; 96WO-JP000734.

XX 20-MAR-1995; 95JP-00087420.

XX 27-OCT-1995; 95JP-00303492.

XX (SUME) SUMITOMO ELECTRIC IND CO.

XX Kayagaki N, Yagita H, Okumura K, Nakata M;

XX WPI; 1996-443140/44.

XX N-PSDB; AAT39555.

XX Monoclonal antibody specifically recognising the Fas ligand - useful for
 PT the detection of Fas ligands either on cell surface or in solution.

XX PS

Claim 25; Page 86-87; 133pp; Japanese.

XX The present sequence is the heavy chain variable region of the anti-human
 CC Fas ligand monoclonal antibody (Mab) NOK-4. NOK-4 is produced by the
 CC hybridoma NOK-4 (FERM BP-5047), which was prepared by immunising mice
 CC with transformed human Fas ligand expressing COS cells, and fusing spleen
 CC cells isolated from the mice with myeloma P3x63Ag8.653 (ATCC CRU-1580)
 CC cells. The Mab recognises the human Fas ligand on the cell surface or in
 CC solution, and can be used to inhibit the apoptosis inducing cell surface
 CC Fas ligand/Fas reaction. The Mab can also be used for a Fas ligand assay
 CC in biological samples (e.g. human blood), especially for disease
 CC diagnosis, e.g. hepatitis, infectious mononucleosis and systemic lupus
 CC erythematosus

XX Sequence 118 AA;

Query Match 86.5%; Score 550; DB 2; Length 118;

Best Local Similarity 88.1%; Pred. No. 1.3e-43;

Matches 104; Conservative 3; Mismatches 9; Indels 2; Gaps 1;

QY 2 VOLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWMGYISYDGTNNYK 61

DB 1 VOLQESGPGLVKPSQSLTCSVTGYSITGGYLNWIRQPPGNKLEWMGYISYDGSNNYN 60

QY 62 PSLKDRISITRDTSKNQFFLNKNSVTNEDTATYCA--RYGRVFFDYWGQGTTLTVSS 117

DB 61 PSLKNRISITRDTSKNQFFLNKNSVTNEDTATYTCARVYVYDSSFDYWGQGTTLTVSS 118

RESULT 8

AAW19015

ID AAW19015 standard; protein; 118 AA.

XX AAW19015;

XX 14-JAN-1998 (first entry)

XX Anti-human FasL antibody (NOK4) heavy chain variable region.

XX Heavy chain; variable region; mouse; murine; human; Fas ligand; FasL;
 KW monoclonal antibody; MAB; hybridoma; treatment; hepatitis;
 KW hepatitis B virus; HBV; hepatitis C virus; HCV; apoptosis; liver cell;
 KW glutamate oxaloacetate; pyruvate transaminase.

XX Mus sp.

XX WO9715326-A1.

XX 01-MAY-1997.

XX 24-OCT-1996; 96WO-JP003089.

XX 27-OCT-1995; 95JP-00303491.

XX (SUME) SUMITOMO ELECTRIC IND CO.

XX Seino K, Kayagaki N, Yagita H, Okumura K, Nakata M;

XX WPI; 1997-258767/23.

XX N-PSDB; AAT69539.

XX Anti-human Fas Ligand antibody to treat hepatitis - controls apoptosis in
 PT liver cells and improves liver function.

XX Claim 6; Page 36-37; 51pp; Japanese.

XX The present sequence is the heavy chain variable region of the murine
 CC anti-human Fas ligand (FasL) monoclonal antibody (MAB) NOK4, which is
 CC expressed by the hybridoma NOK4 (FERM BP-5044). The Mab can be used in
 CC the preparation of a composition for the effective oral or parenteral
 CC treatment of hepatitis, including hepatitis caused by hepatitis B or C
 CC virus. The composition controls apoptosis in liver cells caused by the

CC binding of FasL to Fas expressing liver cells, and improves liver
CC function by improving blood glutamate oxaloacetate and pyruvate
CC transaminase levels. The composition is given in a dosage of 0.0001-1000,
CC preferably 0.01-600 mg/day. Spleen cells from mice immunised with FasL
CC expressing COS cells were fused with mouse myeloma cells to produce
CC hybridomas. The hybridomas were screened for anti-FasL activity, and the
CC active clones NOK1-5 isolated

XX SQ Sequence 118 AA;

Query Match 86.5%; Score 550; DB 2; Length 118;
Best Local Similarity 88.1%; Pred. No. 1.3e-43;
Matches 104; Conservative 3; Mismatches 9; Indels 2; Gaps 1;

QY 2 VQLQSGGLVKPSQSLSITCSVTGYSITGGYLNWIRQFPGNKLEWGWYISYDGTNNYK 61
DB 1 VQLQSGGLVKPSQSLSITCSVTGYSITGGYLNWIRQFPGNKLEWGWYISYDGSNNYN 60

QY 62 PSLKDRISITRDTSKNQFFLKLSVTNEDTATYYCA--RYGRVFFDYWGQGTTLTVSS 117
DB 61 PSLKNRISITRDTSKNQFFLKLSVTNEDTATYYCAVYYDGSFDYWGQGTTLTVSS 118

RESULT 9
AEA40137
ID AEA40137 standard; protein; 114 AA.
XX AEA40137;
AC AEA40137;
XX 28-JUL-2005 (first entry)
XX TNF resistant monoclonal antibody VH region, F6VH protein.
XX tumor necrosis factor; TNF; monoclonal antibody; F6 mAb;
KW light chain variable region; heavy chain variable region; F6VH.
XX Unidentified.
XX Key Location/Qualifiers
FH 28. .33
FT /note= "CDR1"
FT /note= "Specifically claimed in Claim 1"
FT 48. .63
FT /note= "CDR2"
FT /note= "Specifically claimed in Claim 1"
FT 96. .103
FT /note= "CDR3"
FT /note= "Specifically claimed in Claim 1"
XX CN1544466-A.
XX 10-NOV-2004.
XX 13-NOV-2003; 2003CN-01105919.
XX 13-NOV-2003; 2003CN-01105919.
XX (UYFO-) UNIV FOURTH MILITARY MEDICAL.
XX Jin B, Liu X, Zhu C;
XX WPI; 2005-153078/17.
DR N-PSDB; AEA40136.
XX Variable region gene of high affinity monoclonal antibody of tumor
PT necrosis factor and its preparation.
XX Claim 1; Page 2-3; 20pp; Chinese.
XX The invention relates to a method for preparing variable region genes of
CC high affinity tumor necrosis factor (TNF) resistant monoclonal antibody
CC (F6 mAb). The method comprises using recombinant human TNF immune BALB/c
CC mouse to prepare mouse anti-TNF monoclonal antibody, screening high

CC affinity F6 mAb using an indirect enzyme linked immunosorbent assay
CC (ELISA). By cloning the monoclonal antibody light chain and heavy chain
CC variable region (VL and VH respectively) genes, the monoclonal antibody
CC light chain and heavy chain variable region gene sequence and amino acid
CC sequence can be obtained, and the unicity of the gene sequence and
CC protein sequence can be confirmed. This sequence represents the amino
XX acid sequence for F6VH.

XX SQ Sequence 114 AA;

Query Match 86.3%; Score 549; DB 9; Length 114;
Best Local Similarity 88.6%; Pred. No. 1.5e-43;
Matches 101; Conservative 5; Mismatches 8; Indels 0; Gaps 0;

QY 4 LQESGGLVKPSQSLSITCSVTGYSITGGYLNWIRQFPGNKLEWGWYISYDGTNNYKPS 63
DB 1 LQESGGLVKPSQSLSITCSVTGYSITGGYLNWIRQFPGNKLEWGWYISYDGSNNYPS 60

QY 64 LKDRISITRDTSKNQFFLKLSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
DB 61 LKNRISITRDTSKNQFFLKLSVTNEDTATYYCARGDYDFDYWGQGTTLTVSS 114

RESULT 10
ABR82776
ID ABR82776 standard; protein; 118 AA.
XX ABR82776;
AC ABR82776;
XX 18-DEC-2003 (first entry)
XX Hybridoma HB22-33 anti-CD22 MAb heavy chain Vh-D-Jh junction sequence.
XX CD22; B-cell malignancy; anti-CD22 antibody; cytostatic; human; HB22-33.
KW Homo sapiens.
XX WO2003072036-A2.
XX 04-SEP-2003.
XX 20-FEB-2003; 2003WO-US005323.
XX 21-FEB-2002; 2002US-0359419P.
PR 21-OCT-2002; 2002US-0420472P.
XX (UYDU-) UNIV DUKE.
PA (REGC) UNIV CALIFORNIA.
XX Tedder T, Tuscano J;
XX WPI; 2003-712652/67.
DR N-PSDB; ACF36426.
XX Treating a human patient diagnosed with a B-cell malignancy by
PT administering a blocking anti-CD22 monoclonal antibody binding to the
PT first two Ig-like domains of native human CD22 (hCD22).
XX Claim 31; Fig 15; 72pp; English.
XX The invention relates to treating a human patient diagnosed with a B-cell
CC malignancy. The method involves (a) administering to the human patient a
CC blocking anti-CD22 monoclonal antibody binding to the first two Ig-like
CC domains, or to an epitope within the first two Ig-like domains of native
CC human CD22 (hCD22) (ABR82771) and (b) monitoring the response of the
CC malignancy to the treatment. The method is useful for treating a human
CC patient diagnosed with a B-cell malignancy comprising Hodgkin's lymphoma,
CC Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia, hairy
CC cell leukemia or polymphocytic leukemia. The present sequence represents
CC the amino acid sequence for heavy chain Vh-D-Jh junction for anti-CD22
CC antibody from hybridoma HB22-33
XX Sequence 118 AA;

Query Match	86.2%;	Score 548.5;	DB 7;	Length 118;	
Best Local Similarity	87.3%;	Pred. No. 1.8e-43;			
Matches 103;	Conservative	5;	Mismatches	9;	Indels 1; Gaps 1;

QY	1	DVQLQESGPGGLVKPSQSLTCSVTGYSITGGYLWNWIROPFGNKLWMGVIYSDGTNNY	60
	:		
Db	1	EVQLQESGPGGLVKPSQSLTCSVTGYSITGGYWNWIROPFGNKLWMGVIYRDGSNNY	60
	:		
QY	61	KPSLKDRIISITRDTSKNQPFKLNSVTNEDTATYYCARYG-RVFFDYWGQGTTLTVSS	117
	:		
Db	61	NPSLKNRISITRDTSKNQPFKLNSVTNEDTATYYCARGGITVAMDYWGQGTSTVTVSS	118
	:		

RESULT 11	
ABR82886	
ID	ABR82886 standard; protein; 118 AA.
XX	
AC	ABR82886;
XX	
DT	18-DEC-2003 (first entry)
XX	
DE	Hybridoma HB22-33 anti-CD22 MAb heavy chain (VH) fragment.
XX	
KW	CD22; autoimmune disease; anti-CD22 antibody; iImmunosuppressive;
KW	cytostatic; nephrotropic; dermatological; antiinflammatory; anti-ulcer;
KW	antirheumatic; antiarthritic; antiporiatic; thyromimetic; antianemic;
KW	antidiabetic; antiallergic; gene therapy; HB22-33.
XX	
OS	Homo sapiens.
XX	
PN	WO2003072736-A2.
XX	
PD	04-SEP-2003.
XX	
PF	21-FEB-2003; 2003WO-US005549.
XX	
PR	21-FEB-2002; 2002US-0359419P.
PR	21-OCT-2002; 2002US-0420472P.
XX	
PA	(UYDU-) UNIV DUKE.
XX	
PI	Tedder TF;
XX	
DR	WPI; 2003-721765/68.
DR	N-PSDB; ACF36494.
XX	

Treating an autoimmune disease or a B-cell malignancy in a human patient comprises administering an amount of an anti-CD22 monoclonal antibody to the patient and monitoring the response of the disease to the treatment.

Claim 1; Fig 15; 69pp; English.

The invention relates to treating a human patient diagnosed with an autoimmune disease. The method involves administering to the patient an amount of a blocking anti-CD22 monoclonal antibody and monitoring the response of the autoimmune disease to the treatment. The method is useful in treating autoimmune diseases (e.g. glomerulonephritis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, ulcerative colitis, Hashimoto's thyroiditis, autoimmune haemolytic anemias, diabetes or allergies) or B-cell malignancies (e.g. lymphomas or leukemias). The present sequence represents the amino acid sequence for heavy chain Vh-D-33

Uh junction for anti-CD22 antibody from hybridoma HB22-33

XX	
SQ	Sequence 118 AA;

Query Match	86.2%;	Score 548.5;	DB 7;	Length 118;	
Best Local Similarity	87.3%;	Pred. No. 1.8e-43;			
Matches 103;	Conservative	5;	Mismatches	9;	Indels 1; Gaps 1;

QY	1	DVQLQESGPGGLVKPSQSLTCSVTGYSITGGYLWNWIROPFGNKLWMGVIYSDGTNNY	60
	:		
Db	1	EVQLQESGPGGLVKPSQSLTCSVTGYSITGGYWNWIROPFGNKLWMGVIYRDGSNNY	60
	:		

Db 62 PSLKDRITISRDTSKNQFSLKSLSSVTAADTAVYICARYGRVFFDYWGQGLTLVTSS 117

RESULT 13

AD267079

ID AD267079 standard; protein; 117 AA.

AC AD267079;

XX

XX 30-JUN-2005 (first entry)

XX

XX Human antibody 7C10 1 heavy chain variable region SEQ ID NO:75.

XX

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;

KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;

KW musculoskeletal disease; respiratory disease; lung tumor;

KW endocrine disease; gynecology and obstetrics; breast tumor;

KW endometrial carcinoma; gastrointestinal disease; colon tumor;

KW antipsoriatic; psoriasis; dermatological disease; immune disorder;

KW heavy chain variable region.

XX

OS Homo sapiens.

XX

XX US2005084906-A1.

XX

XX 21-APR-2005.

XX

XX 16-DEC-2003; 2003US-00735916.

XX

XX 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.

PR 07-MAY-2002; 2002FR-00005753.

PR 20-JAN-2003; 2003WO-FR000178.

PR 11-JUL-2003; 2003FR-00008538.

XX

XX (GOET/) GOETSCH L.

PA (CORV/) CORVAIA N.

PA (LEGE/) LEGER O.

PA (DUEL/) DUFLOS A.

PA (HAEU/) HAEUW J.

PA (BECK/) BECK A.

XX

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

PI WPI; 2005-321968/33.

XX

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)

PT antibody or its functional fragment, being capable of binding human IGF-

PT IR and specifically inhibiting tyrosine kinase activity of receptor,

PT useful for treating cancer.

XX

XX Example 13; SEQ ID NO 75; 125pp; English.

XX

XX The invention relates to a novel isolated anti-insulin-like growth factor

CC I receptor (IGF-IR) antibody (I) or its functional fragment, being

CC capable of binding to human IGF-IR and, if necessary, capable of

CC specifically inhibiting tyrosine kinase activity of the receptor,

CC comprising a light or heavy chain having at least one complementary

CC determining region (CDR) consisting of one of two fully defined 16 amino

CC acids (AD267006 and AD267014). An antibody of the invention is useful in

CC the preparation of a medicament intended for the prevention or treatment

CC of an illness connected with an overexpression and/or an abnormal

CC activation of the IGF-IR and/or EGFR, and/or connected with a

CC hyperactivation of the transduction pathway of the signal mediated by the

CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where

CC the administration of the medicament does not induce or only slightly

CC induces secondary effects connected with inhibition of the insulin

CC receptor. The antibody is useful for preparation of a medicament intended

CC to inhibit the transformation of normal cells into cells with tumoral

CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-

CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is

CC useful for preparation of a medicament intended to inhibit the growth

CC and/or the proliferation of tumor cells, preferably IGF-dependent,

CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or

CC HER2/neu-dependent cells. (I) is useful in the preparation of a

CC medicament intended for prevention or for the treatment of cancer, where

CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,

CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the

CC preparation of a medicament intended for the prevention or for the

CC treatment of psoriasis. (I) is useful in preparation of a medicament

CC intended for the specific targeting of a biologically active compound to

CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)

CC is useful for in vitro diagnosis of illnesses induced by an

CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor

CC starting from a biological sample in which the abnormal presence, of IGF-

CC IR and/or EGFR receptor is suspected, which involves contacting the

CC biological sample with (I), which is optionally labeled. The present

CC sequence is used in the exemplification of the invention.

XX

XX Sequence 117 AA;

Query Match 85.8%; Score 546; DB 9; Length 117;

Best Local Similarity 86.2%; Pred. No. 3e-43;

Matches 100; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VQLQESGPGLVKPSQSLTCTSVTGYSITGGLNNWIRQFFGNKLEWNGYISYDGTNNYK 61

Db 2 VQLQESGPGLVKPSQSLTCTSVTGYSITGGLNNWIRQFFGNKLEWNGYISYDGTNNYK 61

Qy 62 PSLKDRITISRDTSKNQFSLKSLSSVTAADTAVYICARYGRVFFDYWGQGLTLVTSS 117

Db 62 PSLKDRITISRDTSKNQFSLKSLSSVTAADTAVYICARYGRVFFDYWGQGLTLVTSS 117

RESULT 14

ABB98905

ID ABB98905 standard; protein; 119 AA.

XX

AC ABB98905;

XX

DT 28-MAR-2003 (first entry)

XX

DE Variable region anti-bisphenol A antibody chain #1.

XX

KW Variable region; anti-bisphenol A; antibody; murine; heavy chain;

KW light chain.

XX

OS Mus sp

XX

XX JP2002253259-A.

XX

PD 10-SEP-2002.

XX

PF 02-MAR-2001; 2001JP-00058673.

XX

XX 02-MAR-2001; 2001JP-00058673.

XX

PA (BIOS-) BIO APPLIED SYSTEMS KK.

XX

DR WPI; 2003-096537/09.

XX

DR N-PSDB; ABZ21157.

XX

XX Gene encoding anti-bisphenol A antibody, a recombinant protein and its

PT preparation, a DNA, a vector, a transformant, preparation of a

PT recombinant protein, a kit for determining bisphenol A.

XX

PS Claim 1; Page 11; 19pp; Japanese.

XX

XX The present invention relates to sequences for murine heavy chain

CC variable region or light chain variable region of anti-bisphenol A

CC antibody (ABZ21157-ABZ21164 and ABB98905-ABB98912). The sequences are

CC useful for the preparation of recombinant protein

XX

SQ Sequence 119 AA;

XX

Query Match 85.8%; Score 546; DB 6; Length 119;

Best Local Similarity 87.4%; Pred. No. 3.1e-43;
Matches 104; Conservative 5; Mismatches 8; Indels 2; Gaps 2;

Qy 1 DVQLQESGPGLVKPSQSLSLTCSTGYSTGGYLWNWIRQPPGNKLEWNGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLSLTCSTGYSTGGYLWNWIRQPPGNKLEWNGYIRYDGSNNY 60
Qy 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR-YGRVP-FDYWGQGTTLTVSS 117
Db 61 NPSLKNRISITRDTSKNQFFLKLNSVTNEDTATYYCARVLGRGYGLDYWGQGTSTVSS 119

RESULT 15

ADJ76911
ID ADJ76911 standard; protein; 135 AA.

XX AC ADJ76911;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-IR related protein #23.

XX KW cytostatic; antipsoriatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDR.

XX OS Homo sapiens.

XX PN WO2003059951-A2.

XX PD 24-JUL-2003.

XX PF 20-JAN-2003; 2003WO-FR000178.

XX PR 18-JAN-2002; 2002FR-00000653.

XX PR 18-JAN-2002; 2002FR-00000654.

XX PR 07-MAY-2002; 2002FR-00005753.

XX PA (FABR) FABRE MEDICAMENT SA PIERRE.

XX PI Goetsch L, Corvaia N, Leger O;

XX DR WPI; 2003-569653/53.

XX PT New antibodies that bind to human insulin-like growth factor receptor,
XX useful for treatment, prevention and diagnosis of cancers.

XX PS Disclosure; SEQ ID NO 77; 164pp; French.

XX CC The invention relates to an isolated antibody (Ab), and its functional
XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
XX IR) and optionally: (i) inhibit natural binding of insulin-like growth
XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
XX kinase activity of IGF-IR. Ab and its fragments are used to prevent or
XX treat diseases associated with overexpression and/or abnormal activity of
XX IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with
XX hyperactivity of signal transduction pathways mediated by interaction of
XX these receptors with their ligands. Especially they inhibit
XX transformation of normal cells to tumor cells, inhibit growth and/or
XX proliferation of tumor cells, so are useful against cancers of the
XX prostate, lung, breast, endometrium and colon, also osteosarcoma, and
XX also for treating psoriasis. Ab are also used to diagnose diseases caused
XX by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
XX protein sequence used to generate the Ab of the invention.

XX SQ Sequence 135 AA;

Query Match 85.8%; Score 546; DB 7; Length 135;

Best Local Similarity 86.2%; Pred. No. 3.5e-43;

Matches 100; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

Qy 2 VOLQESGPGLVKPSQSLSLTCSTGYSTGGYLWNWIRQPPGNKLEWNGYISYDGTNNYK 61
Db 20 VOLQESGPGLVKPSQSETLSLTCTVSGYSTGGYLWNWIRQPPGNKLEWNGYISYDGTNNYK 79

Qy 62 PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
Db 80 PSLKDRITISRDTSKNQFSLKLSVTAADTAVYYCARYGRVFFDYWGQGTTLTVSS 135

Search completed: January 10, 2006, 20:44:16
Job time : 81.7649 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:28:02 ; Search time 14.1157 Seconds
(without alignments)
797.508 Million cell updates/sec

Title: US-10-735-916A-69
Perfect score: 636
Sequence: 1 DVQLQESGGLVKPSQSLSL.....RYGRVFFDYWGQGTTLTVSS 117
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 80:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	545	85.7	121	2 S37200	Ig heavy chain V r
2	535	84.1	137	1 AVMS35	Ig heavy chain pre
3	523	82.2	119	2 E25114	Ig heavy chain V r
4	521.5	82.0	116	2 S38718	Ig heavy chain V r
5	521	81.9	117	2 I28195	Ig heavy chain V r
6	519.5	81.7	136	2 S07637	Ig heavy chain V r
7	510	80.2	119	2 C53285	Ig heavy chain V a
8	508.5	80.0	120	2 A25114	Ig heavy chain V r
9	504	79.2	115	2 F25114	Ig heavy chain V r
10	503.5	79.2	135	2 PLO100	Ig heavy chain pre
11	503	79.1	119	2 C25114	Ig heavy chain V r
12	503	79.1	149	2 S30752	Ig heavy chain pre
13	499.5	78.5	114	2 T01262	Ig heavy chain V r
14	499.5	78.5	134	2 B24672	Ig heavy chain pre
15	499	78.5	116	1 HVMS31	Ig heavy chain pre
16	476	74.8	119	2 D25114	Ig heavy chain V r
17	470.5	74.0	104	2 S26467	Ig heavy chain V r
18	463	72.8	123	2 S42771	Ig heavy chain - m
19	462	72.6	117	2 I57810	gene C72-3A1 prote
20	461.5	72.6	106	2 S26464	Ig heavy chain V r
21	457	71.9	106	2 S59639	Ig heavy chain V r
22	455	71.5	116	1 HVMS1B	Ig heavy chain pre
23	447	70.3	113	1 G2MS60	Ig heavy chain V r
24	425	66.8	100	2 S14485	Ig heavy chain V r
25	423.5	66.6	101	2 S14484	Ig heavy chain V r
26	423	66.5	140	2 I37782	Ig variable region
27	422.5	66.4	115	2 D33932	Ig mu chain precu
28	420.5	66.1	102	2 S14488	Ig heavy chain V r
29	413	64.9	102	2 S14486	Ig heavy chain V r

30	408	64.2	130	2 S31690	Ig heavy chain V r
31	406	63.8	112	2 S13685	Ig heavy chain V r
32	404.5	63.6	117	1 HVMS73	Ig heavy chain pre
33	403	63.4	112	2 S13686	Ig heavy chain V r
34	401	63.1	102	2 S14487	Ig heavy chain V r
35	400	62.9	111	2 S13687	Ig heavy chain V r
36	399	62.7	123	2 S30530	Ig heavy chain V r
37	393	61.8	155	2 S31511	Ig heavy chain - h
38	392.5	61.7	129	2 S44114	Ig heavy chain V r
39	392	61.6	147	2 S13519	Ig heavy chain V r
40	388.5	61.1	116	2 S42484	Ig heavy chain V r
41	387	60.8	155	2 S31512	Ig heavy chain - h
42	385.5	60.6	130	2 S30534	Ig heavy chain V r
43	384	60.4	110	2 S13688	Ig heavy chain V r
44	383.5	60.3	118	2 S24443	Ig heavy chain V r
45	383.5	60.3	140	2 S78052	Ig heavy chain pre

ALIGNMENTS

RESULT 1

S37200
Ig heavy chain V region - mouse
C:Species: Mus musculus (house mouse)
C:Date: 19-Mar-1997 #sequence revision 19-Mar-1997 #text_change 21-Jan-2000
C:Accession: S37200
R:PiFischer, R.; Vosse, A.; Hunziker, W.; Stierhof, Y.D.; Kreuzaler, F.
submitted to the EMBL Data Library, August 1993
A:Description: Production and cloning of TMV-specific monoclonal antibodies.
A:Reference number: S37200
A:Accession: S37200
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-121 <PIS>
A:Cross-references: UNIPARC:UPI00001161AC; EMBL:X74587; NID:g402639; PID:g402640
A:Superfamily: immunoglobulin V region; immunoglobulin homology
F:15-98/Domain: immunoglobulin homology <INM>

Query Match 85.7%; Score 545; DB 2; Length 121;
Best Local Similarity 86.0%; Pred. No. 5.3e-43;
Matches 104; Conservative 3; Mismatches 10; Indels 4; Gaps 1;
QY 1 DVQLQESGGLVKPSQSLSLTCSVTGYSTGGYLNWIRQFPGNKLWNGYISYDGTNNY 60
Db 1 DVQLQESGGLVKPSQSLSLTCSVTGYSTGGYLNWIRQFPGNKLWNGYISYDGRNDY 60

QY 61 KPSLKDRIISITRDTSKNQFFKLNSVTNEDTATYYCARYGRV----FFDYWGQGTTLTVS 116
Db 61 NPSLKNRISITRDTSKNQFFKLNSVTNEDTATYYCARGGIYDYDFDSWGQGTTLTVS 120
QY 117 S 117
Db 121 S 121

RESULT 2

AVMS35
Ig heavy chain precursor V region (MOPC 315) - mouse
C:Species: Mus musculus (house mouse)
C:Date: 24-Apr-1984 #sequence revision 30-Jun-1992 #text change 09-Jul-2004
C:Accession: PL0102; A93814; A91462; A93787; S23599
R:Rinfret, A.; Horne, C.; Dorrington, K.J.; Klein, M.
Mol. Immunol. 26, 431-434, 1989
A:Title: Cloning, sequencing and expression of the rearranged MOPC 315 VH gene segment.
A:Reference number: PL0102; MUID:89238351; PMID:2497341
A:Accession: PL0102
A:Molecule type: mRNA
A:Residues: 1-137 <RIN>
A:Cross-references: UNIPROT:P01822; UNIPARC:UPI000002727B; GB:M27638; NID:g602706; PIDN
A:Experimental source: strain MOPC 315
R:Rinfret, A.; Dorrington, K.J.; Klein, M.
submitted to the EMBL Data Library, June 1988

A;Title: The idiotypic network and the internal image: possible regulation of a germ-line
A;Reference number: S03262
A;Accession: S03262
A;Molecule type: DNA
A;Residues: 1-15, 'G', 16-137 <RI2>
A;Cross-references: UNIPARC:UPI000016CB1C; EMBL:X07880; NID:G51760; PIDN:CAA30727.1; PID
R;Jilika, R.L.; Pestka, S.
Proc. Natl. Acad. Sci. U.S.A. 74, 5692-5696, 1977
A;Title: Amino acid sequence of the precursor region of MOPC-315 mouse immunoglobulin he
A;Reference number: A93814; MUID:78094475; PMID:414225
A;Accession: A93814
A;Molecule type: protein
A;Residues: 1-14, 'H', 16-31 <JIL>
A;Cross-references: UNIPARC:UPI000017373E
A;Note: the authors translated mRNA in vitro to obtain the precursor protein
R;Schechter, I.; Wolf, O.; Zemell, R.; Burstein, Y.
Fed. Proc. 38, 1839-1845, 1979
A;Title: Structure and function of immunoglobulin genes and precursors.
A;Reference number: A91462; MUID:79148758; PMID:428562
A;Accession: A91462
A;Molecule type: protein
A;Residues: 1, 'X', 3-11, 'X', 14-21 <SCH>
A;Cross-references: UNIPARC:UPI000017373F
A;Note: the authors translated mRNA in vitro to obtain the precursor protein
R;Francis, S.H.; Leslie, R.G.Q.; Hood, L.; Eisen, H.N.
Proc. Natl. Acad. Sci. U.S.A. 71, 1123-1127, 1974
A;Title: Amino-acid sequence of the variable region of the heavy (alpha) chain of a mouse
A;Reference number: A93787; MUID:74107079; PMID:4524622
A;Accession: A93787
A;Molecule type: protein
A;Residues: 19-52, 'K', 53-75, 'BYGB', 80-101, 'D', 103-106, 'ZB', 109-122, 124-137 <FRA>
A;Cross-references: UNIPARC:UPI0000173740
R;Hood, L.; Margolies, M.; Givol, D.; Zakut, R.
unpublished results, cited by Padlan, E.A., Davies, D.R., Pecht, I., Givol, D., and Wrig
A;Reference number: A94484
A;Contents: annotation; revision to residue 53
R;Chadler, C.; Hook, L.E.; Givol, D.; Ricca, G.A.
Mol. Immunol. 29, 21-30, 1992
A;Title: Cloning and expression of the variable regions of mouse myeloma protein MOPC315
A;Reference number: S23599; MUID:92114886; PMID:1731188
A;Accession: S23599
A;Molecule type: mRNA
A;Residues: 19-137 <CHE>
A;Cross-references: UNIPARC:UPI0000113794; EMBL:X63972; NID:G53532; PIDN:CAA45384.1; PID
C;Comment: This alpha chain was isolated from a myeloma protein that has anti-dinitrope
C;Genetics:
A;Introns: 15/1
A;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-18/Domain: signal sequence #status experimental <SIG>
F;19-136/Product: Ig heavy chain V region (MOPC 315) #status experimental <MAT>
F;33-116/Domain: immunoglobulin homology <IMM>

Query Match 84.1%; Score 535; DB 1; Length 137;
Best Local Similarity 83.2%; Pred. No. 5e-42;
Matches 99; Conservative 7; Mismatches 11; Indels 2; Gaps 1;

Qy 1 DVQLQESGFLVKPSQSLSLTCSTGYGYSITGGYLWNWIRQPGNKLEWMGYISYDGTNNY 60
Db 19 DVQLQESGFLVKPSQSLSLTCSTGYGYSITGGYLWNWIRQPGNKLEWMGYISYDGTNNY 78

Qy 61 KPSLKDRISITRDTSKNQFFLKLSNVTTEDTATYYCA--RYGRVFFDYWGQGTTLTVSS 117
Db 79 NPSLKNRISITRDTSENQFFLKLSNVTTEDTATYYCAGDNHLYYDFWQGQTLTVSS 137

RESULT 3
E25114
Ig heavy chain V region (HP25) - mouse
C;Species: Mus musculus (house mouse)
C;Date: 29-Aug-1987 #sequence_revision 29-Aug-1987 #text_change 20-Jun-2000
C;Accession: E25114
R;Ollier, P.; Rocca-Serra, J.; Somme, G.; These, J.; Fougereau, M.
EMBO J. 4, 3681-3688, 1985

A;Title: The idiotypic network and the internal image: possible regulation of a germ-line
A;Reference number: A91028; MUID:86136012; PMID:3937730
A;Accession: E25114
A;Molecule type: mRNA
A;Residues: 1-119 <OLL>
A;Cross-references: UNIPARC:UPI0000115D24; GB:X03378; NID:G52007; PIDN:CAA27095.1; PID:Y
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 82.2%; Score 523; DB 2; Length 119;
Best Local Similarity 83.2%; Pred. No. 5.3e-41;
Matches 99; Conservative 5; Mismatches 7; Indels 8; Gaps 2;

Qy 1 DVQLQESGFLVKPSQSLSLTCSTGYGYSITGGYLWNWIRQPGNKLEWMGYISYDGTNNY 60
Db 1 DVQLQESGFLVKPSQSLSLTCSTGYGYSITGGYLWNWIRQPGNKLEWMGYISYDGTNNY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKLSNVTTEDTATYYCA--RYGRVFF--DYWGQGT 111
Db 61 NPSLKNRISITRDTSKNQFFLKLSNVTTEDTATYYCARPLYRYDEEYYANDYWGQGT 119

RESULT 4
S38718
Ig heavy chain V region - mouse
C;Species: Mus musculus (house mouse)
C;Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 20-Jun-2000
C;Accession: S38718
R;Cimani, A.Y.
submitted to the EMBL Data Library, November 1993
A;Reference number: S38713
A;Accession: S38718
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-116 <CIM>
A;Cross-references: UNIPARC:UPI0000117542; EMBL:X76018; NID:G416102; PIDN:CAA53605.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 82.0%; Score 521.5; DB 2; Length 116;
Best Local Similarity 83.8%; Pred. No. 7.1e-41;
Matches 98; Conservative 5; Mismatches 13; Indels 1; Gaps 1;

Qy 1 DVQLQESGFLVKPSQSLSLTCSTGYGYSITGGYLWNWIRQPGNKLEWMGYISYDGTNNY 60
Db 1 DVQLQESGFLVKPSQSLSLTCSTGYGYSITGGYLWNWIRQPGNKLEWMGYISYDGTNNY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKLSNVTTEDTATYYCARVGRVFFDYWGQGTTLTVSS 117
Db 61 NPSLKNRISITRDTSKNQFFLKLSNVTTEDTATYYCAR--GGTGTFFWQGQTLTVTSA 116

RESULT 5
I28195
Ig heavy chain V region (anti-haloperidol antibody D) - mouse
C;Species: Mus musculus (house mouse)
C;Date: 01-Dec-1989 #sequence_revision 30-Sep-1991 #text_change 23-Jul-1999
C;Accession: I28195
R;Sherman, M.A.; Deane, R.J.; Bolger, M.B.
J. Biol. Chem. 263, 4059-4063, 1988
A;Title: Haloperidol binding to monoclonal antibodies. Hypervariable region amino acid
A;Reference number: A28195; MUID:88153717; PMID:3267217
A;Accession: I28195
A;Molecule type: mRNA
A;Residues: 1-117 <SHE>
A;Cross-references: UNIPARC:UPI0000114D72; GB:M19775; NID:G195526; PIDN:AAA38343.1; PID
A;Note: the authors translated the codon AAC for residue 61 as Thr, and did not translat
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

```
Query Match      81.9%; Score 521; DB 2; Length 117;
Best Local Similarity 83.8%; Pred. No. 8e-41;
Matches 98; Conservative 5; Mismatches 14; Indels 0; Gaps 0;

QY 1 DVQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60
DB 1 DVQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60

QY 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS 117
DB 61 NPSLXKRISITRDTSKNQFFLQLNSVTEDTATYYCARDNGCNGDYWGQGTSTVTSS 117

RESULT 6
A25114
Ig heavy chain V region (PTF.02) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 23-Jul-1999
C:Accession: S07637
R:Uraikov, D.N.; Deev, S.M.; Polyanovsky, O.L.
Nucleic Acids Res. 17, 9481, 1989
A:Title: The structure of the expressible VH gene from a hybridoma producing monoclonal
A:Reference number: S07637; MUID:90067954; PMID:2587273
A:Accession: S07637
A:Molecule type: DNA
A:Residues: 1-136 <URA>
A:Cross-references: UNIPARC:UPI0000115B36; EMBL:X16740; NID:952099; PIDN:CAA34714.1; PID
C:Keywords: the authors translated the codon TAT for residue 112 as Ile, TAC for residue 113
C:Genetics:
A:Introns: 15/3
Query Match      81.7%; Score 519.5; DB 2; Length 136;
Best Local Similarity 83.8%; Pred. No. 1.3e-40;
Matches 98; Conservative 6; Mismatches 12; Indels 1; Gaps 1;

QY 2 VQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNYK 61
DB 20 VQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGSNGYN 79

QY 62 PSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR-YGRVFFDYWGQGTTLTVSS 117
DB 80 PSLKDRISITRDTSKNQFFLKLNSVTEDTATYYCTRGDGHFFTYWGQGTTLTVTSA 136

RESULT 7
CS3285
Ig heavy chain V and J regions, monoclonal antibody OHP7D7.2.3 - mouse (fragment)
C:Species: Mus musculus (house mouse)
C>Date: 02-May-1994 #sequence_revision 18-Nov-1994 #text_change 20-Jun-2000
C:Accession: CS3285
R:Sawada, J.; Mizusawa, S.; Terao, T.; Naito, M.; Kurosawa, Y.
Mol. Immunol. 28, 1063-1072, 1991
A:Title: Molecular characterization of monoclonal anti-steroid antibodies: primary struc
and their pH-reactivity profiles.
A:Reference number: A53285; MUID:92017897; PMID:1922102
A:Accession: CS3285
A>Status: preliminary
A:Molecule type: mRNA; protein
A:Residues: 1-119 <SAW>
A:Cross-references: UNIPARC:UPI000011DOA5; GB:D12734; NID:9220548; PIDN:BA002226.1; PID:
A>Note: sequence extracted from NCBI backbone (NCBI:63297, NCBI:63302)
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match      80.2%; Score 510; DB 2; Length 119;
Best Local Similarity 78.2%; Pred. No. 8.3e-40;
Matches 93; Conservative 12; Mismatches 12; Indels 2; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60
```

```
DB 1 DVQLQESGPGLVKPSQSLSLTCVTGYSITSDHVNWVRQPPGNKLEWNGYINRGCTGY 60
QY 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCARYGRVFF--DYWGQGTTLTVSS 117
DB 61 NPSLXKRISITRDTSKNQFFLQLNSVTEDTATYYCSRGNYYYAMDYWGQGTSTVTSS 119

RESULT 8
A25114
Ig heavy chain V region (HP22, HP27) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 29-Aug-1987 #sequence_revision 29-Aug-1987 #text_change 21-Jul-2000
C:Accession: A25114
R:Ollier, P.; Rocca-Serra, J.; Somme, G.; Theze, J.; Fougereau, M.
EMBO J. 4, 3681-3688, 1985
A:Title: The idiotypic network and the internal image: possible regulation of a germ-lir
A:Reference number: A91028; MUID:86136012; PMID:3937730
A:Accession: A25114
A:Molecule type: mRNA
A:Residues: 1-120 <OLL>
A:Cross-references: UNIPARC:UPI0000115D15; GB:X03374; NID:951983; PIDN:CAA27071.1; PID:
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match      80.0%; Score 508.5; DB 2; Length 120;
Best Local Similarity 79.2%; Pred. No. 1.1e-39;
Matches 95; Conservative 8; Mismatches 8; Indels 9; Gaps 2;

QY 1 DVQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60
DB 1 DVHLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQPPGNKLEWNGYINYGDSNNY 60

QY 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR-----YGRVFF--DYWGQGT 111
DB 61 NPSLXKRISITRDTSKNQFFLKLNSVTEDTATYYCARLIPSDGYEDDYAMDYWGQGT 120

RESULT 9
F25114
Ig heavy chain V region (HP12) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 29-Aug-1987 #sequence_revision 29-Aug-1987 #text_change 20-Jun-2000
C:Accession: F25114
R:Ollier, P.; Rocca-Serra, J.; Somme, G.; Theze, J.; Fougereau, M.
EMBO J. 4, 3681-3688, 1985
A:Title: The idiotypic network and the internal image: possible regulation of a germ-lir
A:Reference number: A91028; MUID:86136012; PMID:3937730
A:Accession: F25114
A:Molecule type: mRNA
A:Residues: 1-115 <OLL>
A:Cross-references: UNIPARC:UPI0000115D28; GB:X03379; NID:952013; PIDN:CAA27101.1; PID:
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match      79.2%; Score 504; DB 2; Length 115;
Best Local Similarity 81.7%; Pred. No. 2.8e-39;
Matches 94; Conservative 5; Mismatches 12; Indels 4; Gaps 1;

QY 1 DVQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQPPGNKLEWNGYISYDGTNNY 60
DB 1 DVQLQESGPGLVKPSQSLSLTCVTGYSITGGYLNWIRQPPGNKLEWNGYIRYDGSNNY 60

QY 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCARYG----RVFFDYWGQGT 111
DB 61 NPSLXKRISITRDTSKNQFFLKLNSVTEDTATYYCAVFGYDMDYAMDYWGQGT 115

RESULT 10
PL0100
Ig heavy chain precursor V region (40-140) - mouse
```

C;Species: Mus musculus (house mouse)
C;Date: 07-Jun-1990 #sequence_revision 07-Jun-1990 #text_change 23-Jul-1999
C;Accession: FL0100
R;Near, R.I.; Haber, E.
Mol. Immunol. 26, 371-382, 1989
A;Title: Characterization of the heavy and light chain immunoglobulin variable region genes
A;Reference number: FL0100; MUID:89238344; PMID:2497340
A;Accession: FL0100
A;Molecule type: DNA
A;Residues: 1-135 <NEA>
A;Cross-references: UNIPARC:UPI0000114EA6; GB:M27660; NID:g341745; PIDN:AAA58746.1; PID:
A;Experimental source: strain A/J
A;Note: the VH40-140 gene segment is classified as a member of the 36-60 VH gene family
C;Genetics:
A;Introns: 15/1
C;Superfamily: immunoglobulin V region; immunoglobulin homology
F;1-18/Domain: signal sequence #status predicted <SIG>
F;19-115/Domain: V segment #status predicted <VRE>
F;33-116/Domain: immunoglobulin homology <IMM>
F;117-118/Domain: D segment #status predicted <DRE>
F;119-135/Domain: J segment #status predicted <JRE>

Query Match 79.2%; Score 503.5; DB 2; Length 135;
Best Local Similarity 80.3%; Pred. No. 3.7e-39;
Matches 94; Conservative 8; Mismatches 14; Indels 1; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLSLTCSTGYISITGGYLNNWIRQPPGNKLEWMGYISYDGTNNY 60
Db 19 DVQLQESGPGLVKPSQSLSLTCSTGYISITGGYLNNWIRQPPGNKLEWMGYISYDGTNNY 78

Qy 61 KPSLKDRISITRDTSKNQFFLKLSNVTNEDTATYYCARYGVRFDDYWGQGTTLTVSS 117
Db 79 NPSLKSRSITRDTSKNQFFLQLSSVTEDTATYYCAR-SYDYPDWGQGTTLTVSS 134

RESULT 11
C25114
Ig heavy chain V region (HP20) - mouse
C;Species: Mus musculus (house mouse)
C;Date: 29-Aug-1987 #sequence_revision 29-Aug-1987 #text_change 20-Jun-2000
C;Accession: C25114
R;Ollier, P.; Rocca-Serra, J.; Somme, G.; These, J.; Fougereau, M.
EMBO J. 4, 3681-3688, 1985
A;Title: The idiotypic network and the internal image: possible regulation of a germ-line
A;Reference number: A91028; MUID:86136012; PMID:3937730
A;Accession: C25114
A;Molecule type: mRNA
A;Residues: 1-119 <OLL>
A;Cross-references: UNIPARC:UPI0000115D1A; GB:X03376; NID:g51995; PIDN:CAA27083.1; PID:g
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 79.1%; Score 503; DB 2; Length 119;
Best Local Similarity 79.3%; Pred. No. 3.6e-39;
Matches 96; Conservative 5; Mismatches 8; Indels 12; Gaps 2;

Qy 1 DVQLQESGPGLVKPSQSLSLTCSTGYISITGGYLNNWIRQPPGNKLEWMGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLSLTCSTGYISITGGYLNNWIRQPPGNKLEWMGYIKYDGNNSY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKLSNVTNEDTATYYCARYGVRFDDYWGQGTTLTVSS 110
Db 61 NPSLKNRISITRDTSKNQFFLKLSNVTEDTATYYCAR--PLYFRHDEYYDVMWDYWGQ 118

Qy 111 T 111
Db 119 T 119

RESULT 12
S30752

Ig heavy chain precursor V region - mouse
C;Species: Mus musculus (house mouse)
C;Date: 31-Dec-1993 #sequence_revision 31-Dec-1993 #text_change 23-Jul-1999
C;Accession: S30752
R;Grant, F.J.; Levin, S.D.; Gilbert, T.; Kindsvogel, W.
Nucleic Acids Res. 15, 5496, 1987
A;Title: Improved RNA sequencing method to determine immunoglobulin mRNA sequence.
A;Reference number: S30751; MUID:87260030; PMID:3601683
A;Accession: S30752
A;Molecule type: mRNA
A;Residues: 1-149 <GRA>
A;Cross-references: UNIPARC:UPI0000115D92; EMBL:X05878; NID:g52526; PIDN:CAA29302.1; PID:
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;33-116/Domain: immunoglobulin homology <IMM>
F;138-149/Domain: C region (C-gamma 2b) (fragment) #status predicted <CRE>

Query Match 79.1%; Score 503; DB 2; Length 149;
Best Local Similarity 79.8%; Pred. No. 4.6e-39;
Matches 95; Conservative 8; Mismatches 14; Indels 2; Gaps 2;

Qy 1 DVQLQESGPGLVKPSQSLSLTCSTGYISITGGYLNNWIRQPPGNKLEWMGYISYDGTNNY 60
Db 19 DVQLQESGPGLVKPSQSLSLTCSTGYISITGGYLNNWIRQPPGNKLEWMGYISYDGTNNY 78

Qy 61 KPSLKDRISITRDTSKNQFFLKLSNVTNEDTATYYCAR-YGRVRFDDYWGQGTTLTVSS 117
Db 79 NPSLKSRSITRDTSKNQFFLQLNSVTAEADTATYYCARGYNNYAMDYWGQTSVTSS 137

RESULT 13
T01262
Ig heavy chain V region - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 12-Feb-1999 #sequence_revision 12-Feb-1999 #text_change 21-Jul-2000
C;Accession: T01262
R;Pirofski, L.A.; Thomas, E.K.; Scharff, M.D.
AIDS Res. Hum. Retroviruses 9, 41-49, 1993
A;Title: Variable region gene utilization and mutation in a group of neutralizing murine
A;Reference number: Z14285; MUID:93152285; PMID:7678971
A;Accession: T01262
A;Status: preliminary; translated from GB/EMBL/DBDJ
A;Molecule type: mRNA
A;Residues: 1-114 <PRA>
A;Cross-references: UNIPARC:UPI0000117638; EMBL:S54194; NID:g264864; PIDN:AAB25246.2; PI:
C;Superfamily: immunoglobulin V region; immunoglobulin homology
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 78.5%; Score 499.5; DB 2; Length 114;
Best Local Similarity 81.2%; Pred. No. 7.2e-39;
Matches 95; Conservative 6; Mismatches 13; Indels 3; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLSLTCSTGYISITGGYLNNWIRQPPGNKLEWMGYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLSLTCSTGYISITGGYLNNWIRQPPGNKLEWMGYISYDGTNNY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKLSNVTNEDTATYYCARYGVRFDDYWGQGTTLTVSS 117
Db 61 NPSLKSRSITRDTSKNLFLLQLNSVTEDTATYYCA---RGLPDYWGQGTTLTVSS 114

RESULT 14
B24672
Ig heavy chain precursor V region (VGAM3-2) - mouse
C;Species: Mus musculus (house mouse)
C;Date: 19-Nov-1988 #sequence_revision 19-Nov-1988 #text_change 18-Oct-1996
C;Accession: B24672
R;Winter, E.; Radbruch, A.; Krawinkel, U.
EMBO J. 4, 2861-2867, 1985
A;Reference number: A91022; MUID:86055722; PMID:2998759
A;Accession: B24672
A;Molecule type: DNA
A;Residues: 1-134 <WIN>

Search completed: January 10, 2006, 20:55:14
Job time : 14.1157 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:26:41 ; Search time 78.8731 Seconds
(without alignments)
1046.577 Million cell updates/sec

Title: US-10-735-916A-69
Perfect score: 636
Sequence: 1 DVQIQSGPGLVKPSQSLSL.....RYGRVFFDYWGQTTLTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt_05.80.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	541	85.1	479	2	Q99M22 MOUSE
2	535	84.1	137	1	HV46 MOUSE
3	526.5	82.8	483	2	Q5U413 MOUSE
4	523	82.2	119	2	Q53VQ5 MOUSE
5	519.5	81.7	136	2	Q6LBO5 MOUSE
6	508.5	80.0	120	2	Q53VR7 MOUSE
7	504	79.2	115	2	Q53VQ1 MOUSE
8	503	79.1	119	2	Q53VR3 MOUSE
9	499	78.5	116	1	HV60 MOUSE
10	492	77.4	590	2	Q569B8 RAT
11	491	77.2	98	2	Q53VQ4 MOUSE
12	489	76.9	615	2	Q569B6 RAT
13	480	75.5	98	2	Q53VR6 MOUSE
14	476	74.8	119	2	Q53VQ9 MOUSE
15	475	74.7	98	2	Q53VR2 MOUSE
16	469	73.7	98	2	Q53VQ0 MOUSE
17	455	71.5	116	1	HV61 MOUSE
18	453	71.2	98	2	Q53VQ8 MOUSE
19	447	70.3	113	1	HV47 MOUSE
20	446	70.1	262	2	Q65Z11 MOUSE
21	405	63.7	119	2	Q9UL73 HUMAN
22	404.5	63.6	117	1	HV62 MOUSE
23	400.5	63.0	478	2	Q72379 HUMAN
24	397.5	62.5	465	2	Q6GMX6 HUMAN
25	397	62.4	476	2	Q6GMX1 HUMAN
26	394.5	62.0	477	2	Q6GMX7 HUMAN
27	387.5	60.9	576	2	Q6P418 HUMAN
28	381	59.9	477	2	Q510J1 RAT
29	380.5	59.8	591	2	Q510L9 RAT
30	370.5	58.3	150	2	O95973 HUMAN
31	368	57.9	469	2	Q5M839 RAT

32	364	57.2	144	1	HV43 MOUSE	P01819 mus musculus
33	363.5	57.2	122	2	Q9UL75 HUMAN	Q9UL75 homo sapien
34	363.5	57.2	146	1	HV21 HUMAN	P06331 homo sapien
35	361.5	56.8	620	2	Q96EY0 HUMAN	Q96EY0 homo sapien
36	360	56.6	458	2	Q5M842 RAT	Q5M842 rattus norv
37	359	56.4	492	2	Q72374 HUMAN	Q72374 homo sapien
38	358	56.3	478	2	Q6NYH3 HUMAN	Q6NYH3 homo sapien
39	358	56.3	595	2	Q8WUX4 HUMAN	Q8WUX4 homo sapien
40	358	56.3	597	2	Q9BU10 HUMAN	Q9BU10 homo sapien
41	358	56.3	597	2	Q6GMX5 HUMAN	Q6GMX5 homo sapien
42	358	56.3	625	2	Q96AA6 HUMAN	Q96AA6 homo sapien
43	356.5	56.1	121	2	Q99NG4 MOUSE	Q99NG4 mus musculus
44	356.5	56.1	139	2	Q86SX2 HUMAN	Q86SX2 homo sapien
45	356	56.0	597	2	Q9BQB8 HUMAN	Q9BQB8 homo sapien

ALIGNMENTS

RESULT 1

Q99M22 MOUSE PRELIMINARY; PRT; 479 AA.

AC Q99M22, DT 01-JUN-2001 (Tremblrel. 17, Created)

DT 01-JUN-2001 (Tremblrel. 17, Last sequence update)

DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)

DE LOC238447 protein.

GN Name=LOC238447;

OS Mus musculus (Mouse);

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;

OC Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RC STRAIN=Mix FVB/N;

RC	TISSUE=Mammary tumor. WAP-TGF alpha model. 7 months old;	
RX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;	
RA	Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D., Straubeberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Altschul S.F., Zeeberg B., Buettow K.H., Schaefer C.F., Hsieh F., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hong L., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Schetz T.E., Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C., Bock S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A., Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalish D.E., Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;	
RT	"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences."	
RL	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).	
RN	[2]	
RP	NUCLEOTIDE SEQUENCE.	
RC	STRAIN=Mix FVB/N;	
RC	TISSUE=Mammary tumor. WAP-TGF alpha model. 7 months old;	
RG	NIH MGC Project;	
RL	Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.	
DR	EMBL; BC020291; AA02091.1; -; mRNA.	
DR	HSSP; P01820; 1G7J.	
DR	GO; GO:0003823; F:antigen binding; IEA.	
DR	InterPro; IPR007110; Ig-like.	
DR	InterPro; IPR003597; Ig.cl.	
DR	InterPro; IPR003006; Ig.MHC.	
DR	InterPro; IPR003596; Ig.v.	
DR	Pfam; PF07654; C1-set; 2.	
DR	SMART; SM00406; IGV; 1.	

```

DR PROSITE; PS00835; IG LIKE; 4.
KW PROSITE; PS00290; IG MHC; UNKNOWN_2.
DR Immunoglobulin domain.
SQ SEQUENCE 479 AA; 51992 MW; 768E39A138918892 CRC64;

Query Match      85.1%; Score 541; DB 2; Length 479;
Best Local Similarity 85.5%; Pred. No. 1.7e-47;
Matches 100; Conservative 6; Mismatches 11; Indels 0; Gaps 0;

Qy 1 DVQLQESGPGLVKPSQSLSLTCSTGYITGGYLNWIRQPGNKLWGWYISYDGTNNY 60
Db 19 DVQLQESGPGLVKPSQSLSLTCSTGYITGGYLNWIRQPGNKLWGWYINVDGSNNY 78

Qy 61 KPSLKDRISITRDTSKNQFFLKLSVTTEDTATYTCARYGRVFRDYWGQGTTLTVSS 117
Db 79 NPSLKNRISITRDTSKNQFFLKLSVTTEDTATYTCASRGYSWFPNMQGGLTVTVSA 135

RESULT 2
HV46 MOUSE
ID HV46 MOUSE STANDARD; PRT; 137 AA.
AC P01822;
DT 21-JUL-1986 (Rel. 01, Created)
DT 01-AUG-1992 (Rel. 23, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V region MOPC 315 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]_
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=8928351; PubMed=2497341; DOI=10.1016/0161-5890(89)90133-8;
RA Rinfret A., Horne C., Dorrington K.J., Klein M.;
RT "Cloning, sequencing and expression of the rearranged MOPC 315 VH gene
segment.";
RL Mol. Immunol. 26:431-434(1989).
RN [2]
RP PROTEIN SEQUENCE OF 1-31.
RX MEDLINE=78094475; PubMed=414225;
RA Jilka R.L., Pestka S.;
RT "Amino acid sequence of the precursor region of MOPC-315 mouse
immunoglobulin heavy chain.";
RL Proc. Natl. Acad. Sci. U.S.A. 74:5692-5696(1977).
RN [3]
RP PROTEIN SEQUENCE OF 1-21.
RX MEDLINE=79148758; PubMed=428562;
RA Schechter I., Wolf O., Zemell R., Burstein Y.;
RT "Structure and function of immunoglobulin genes and precursors.";
RL Fed. Proc. 38:1839-1845(1979).
RN [4]
RP PROTEIN SEQUENCE OF 19-136.
RX MEDLINE=7410779; PubMed=4524622;
RA Francis S.H., Leslie R.G.Q., Hood L., Eisen H.N.;
RT "Amino-acid sequence of the variable region of the heavy (alpha) chain
of a mouse myeloma protein with anti-hapten activity.";
RL Proc. Natl. Acad. Sci. U.S.A. 71:1123-1127(1974).
RN [5]
RP SEQUENCE REVISION TO 53.
RX MEDLINE=7724979; PubMed=268248;
RA Hood L., Margolies M.N., Givol D., Zakut R.;
RL Unpublished results, cited by:
RL Padlan E.A., Davies D.R., Pecht I., Givol D., Wright C.;
RL Cold Spring Harb. Symp. Quant. Biol. 41:627-637(1977).
CC -!- MISCELLANEOUS: This alpha chain was isolated from a myeloma
CC protein that has anti-dinitrophenyl activity.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.

```

```

CC -----
DR EMBL; M27638; AAA61337.1; -; Genomic_DNA.
DR EMBL; X07880; CAA30727.1; -; Genomic_DNA.
DR PIR; P0102; AVMS35.
DR HSP; P01820; 1G7J.
DR SMR; P01822; 20-137.
DR Ensembl; ENSMUSG0000057048; Mus musculus.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region; Signal.
FT SIGNAL 1 18
FT CHAIN 19 137
FT REGION 19 48
FT REGION 49 54
FT REGION 55 68
FT REGION 69 84
FT REGION 85 116
FT REGION 117 126
FT REGION 127 137
FT DISULFID 40 114
FT CONFLICT 15 15
FT CONFLICT 15 15
FT CONFLICT 77 78
FT CONFLICT 102 102
FT CONFLICT 123 123
FT NON_TER 137 137
SQ SEQUENCE 137 AA; 15399 MW; FB3828304C2B81DC CRC64;

Query Match      84.1%; Score 535; DB 1; Length 137;
Best Local Similarity 83.2%; Pred. No. 1.6e-47;
Matches 99; Conservative 7; Mismatches 11; Indels 2; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLSLTCSTGYITGGYLNWIRQPGNKLWGWYISYDGTNNY 60
Db 19 DVQLQESGPGLVKPSQSLSLTCSTGYITGGYLNWIRQPGNKLWGLFKYDGSNGY 78

Qy 61 KPSLKDRISITRDTSKNQFFLKLSVTTEDTATYTCARYGRVFRDYWGQGTTLTVSS 117
Db 79 NPSLKNRISITRDTSKNQFFLKLSVTTEDTATYTCAGDNHLYYFYDWGQGTTLTVSS 137

RESULT 3
Q5U413 MOUSE
ID Q5U413 MOUSE PRELIMINARY; PRT; 483 AA.
AC Q5U413;
DT 01-FEB-2005 (TrEMBLrel. 29, Created)
DT 01-FEB-2005 (TrEMBLrel. 29, Last sequence update)
DT 01-FEB-2005 (TrEMBLrel. 29, Last annotation update)
DE LOC544903 protein.
GN Name=LOC544903;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=FVB/N; TISSUE=Colon;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.A., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

```

RA Fahey J., Helton B., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
 RN [2]
 RP NUCLEOTIDE SEQUENCE.
 RC STRAIN=FVB/N; TISSUE=Colon;
 RG NIH MGC Project;
 RL Submitted (OCT-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC085312; AAH85312.1; -; mRNA.
 DR Ensembl; ENSMUSG0000054328; Mus musculus.
 DR GO; GO:0003823; F:antigen binding; IEA.
 DR InterPro; IPR003599; IG.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003597; IG.cl.
 DR InterPro; IPR003006; IG.MHC.
 DR InterPro; IPR003596; IG.V.
 DR Pfam; PF07654; C1-set; 2.
 DR SMART; SM00409; IG; 3.
 DR SMART; SM00407; IGcl; 3.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS0835; IG LIKE; 4.
 DR PROSITE; PS00290; IG.MHC; UNKNOWN 2.
 SQ SEQUENCE 483 AA; 52714 MW; 7C272DA501A4A0D1 CRC64;

 Query Match 82.8%; Score 526.5; DB 2; Length 483;
 Best Local Similarity 82.5%; Pred. No. 5.4e-46;
 Matches 99; Conservative 7; Mismatches 11; Indels 3; Gaps 1;

 QY 1 DVQLQESGPGLVKPSQSLSLTCVTSITGGLNWNIRQPPGNKLEWGYISYDGTNNY 60
 DB 19 DVQLQESGPDVLKPSQSLSLTCVTSITGGLNWNIRQPPGNKLEWGYISYSGNNY 78

 QY 61 KPSLKDRIISITRDTSKNQFFLKNSVTNEDTATYTCARVGFV---FDYWGQGTTLTVSS 117
 DB 79 NPSLKNRISITRDTSKNQFFLKNSVTNEDTATYTCARVGFV---FDYWGQGTTLTVSS 138

 RESULT 4
 Q53VQ05 MOUSE
 ID Q53VQ05_MOUSE PRELIMINARY; PRT; 119 AA.
 AC Q53VQ05;
 DT 13-SEP-2005 (TrEMBLrel. 31, Created)
 DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
 DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
 DE VH-D-JH region (Fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
 OC Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=86136012; PubMed=3937730;
 RA Ollier P., Rocca-Serra J., Somme G., These J., Fougereau M.;
 RT "The idiotypic network and the internal image: possible regulation of
 RT a germ-line network by paucigenic encoded Ab2 (anti-idiotypic)
 RT antibodies in the GAT system.";
 RL EMBO J. 4:3681-3688 (1985).
 RN [2]
 RP NUCLEOTIDE SEQUENCE OF 28-29.
 RA Fougereau M.;
 RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
 DR EMBL; X03378; CAA27095.1; -; mRNA.
 FT NON_TER 1 1
 FT NON_TER 119 119
 SQ SEQUENCE 119 AA; 13931 MW; 502E51A5213F056E CRC64;

Query Match 82.2%; Score 523; DB 2; Length 119;
 Best Local Similarity 83.2%; Pred. No. 2.5e-46;
 Matches 99; Conservative 5; Mismatches 7; Indels 8; Gaps 2;

 QY 1 DVQLQESGPGLVKPSQSLSLTCVTSITGGLNWNIRQPPGNKLEWGYISYDGTNNY 60
 DB 1 DVQLQESGPGLVKPSQSLSLTCVTSITGGLNWNIRQPPGNKLEWGYISYDGSNNY 60

 QY 61 KPSLKDRIISITRDTSKNQFFLKNSVTNEDTATYTCARVGFV---DYWGQGT 111
 DB 61 NPSLKNRISITRDTSKNQFFLKNSVTNEDTATYTCARVGFV---DYWGQGT 119

 RESULT 5
 Q6LBQ05 MOUSE
 ID Q6LBQ05_MOUSE PRELIMINARY; PRT; 136 AA.
 AC Q6LBQ05;
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE VH gene product (Fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
 OC Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=90067954; PubMed=2587273;
 RA Urakov D.N., Deev S.M., Polyakov O.L.;
 RT "The structure of the expressible VH gene from a hybridoma producing
 RT monoclonal antibodies against porcine transferrin.";
 RL Nucleic Acids Res. 17:9481-9481 (1989).
 DR EMBL; X16740; CAA34714.1; -; Genomic_DNA.
 DR HSP; P18532; 1KCV.
 DR SMR; Q6LBQ05; 20-136.
 DR InterPro; IPR003599; IG.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003596; IG.V.
 DR SMART; SM00409; IG; 1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS0835; IG LIKE; 1.
 FT NON_TER 1 1
 FT NON_TER 136 136
 SQ SEQUENCE 136 AA; 15307 MW; 5B0F439CCFB15C3A CRC64;

 Query Match 81.7%; Score 519.5; DB 2; Length 136;
 Best Local Similarity 83.8%; Pred. No. 6.7e-46;
 Matches 98; Conservative 6; Mismatches 12; Indels 1; Gaps 1;

 QY 2 VQLQESGPGLVKPSQSLSLTCVTSITGGLNWNIRQPPGNKLEWGYISYDGTNNY 61
 DB 20 VQLQESGPGLVKPSQSLSLTCVTSITGGLNWNIRQPPGNKLEWGYISYDGSNNY 79

 QY 62 PSLKDRIISITRDTSKNQFFLKNSVTNEDTATYTCARVGFV---DYWGQGTTLTVSS 117
 DB 80 PSLKNRISITRDTSKNQFFLKNSVTNEDTATYTCARVGFV---DYWGQGTTLTVSS 136

 RESULT 6
 Q53VR7 MOUSE
 ID Q53VR7_MOUSE PRELIMINARY; PRT; 120 AA.
 AC Q53VR7;
 DT 13-SEP-2005 (TrEMBLrel. 31, Created)
 DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
 DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
 DE VH-D-JH region (Fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
 OC Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.

```

RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., These J., Fougereau M.;
RT "The idiotypic network and the internal image; possible regulation of
RT a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
RT antibodies in the GAT system.";
RL EMBL; X03374; CAA27071.1; -; mRNA.
RN NCBI_TaxID=10090;
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03375; CAA27077.1; -; mRNA.
DR EMBL; X03374; CAA27071.1; -; mRNA.
FT NON_TER 1
FT NON_TER 120
SQ SEQUENCE 120 AA; 13892 MW; 013452306EBA3BE CRC64;

Query Match 80.0%; Score 508.5; DB 2; Length 120;
Best Local Similarity 79.2%; Pred. No. 8e-45;
Matches 95; Conservative 8; Mismatches 8; Indels 9; Gaps 2;

Qy 1 DVQLQESGPGGLVKPSQSLTCSVTGYSITGGLYLNWIRQPGNKLEWGYISYDGTNNY 60
Db 1 DVHLQESGPGGLVKPSQSLTCSVTGYSITRGNWNIWIRPFGNKLEWGYINVDGSNNY 60

Qy 61 KPSLKDRISITRDTSKNOFFLKLNSVTNEDTATYYCAR-----YGRVFF--DYWGQGT 111
Db 61 NPSLKNRISITRDTSKNOFFLKLNSVTNEDTATYYCARLIPFSDGYEDYAMDYWGQGT 120

RESULT 7
Q53VQ1_MOUSE PRELIMINARY; PRT; 115 AA.
AC Q53VQ1;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DE VH-D-JH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN NUCLEOTIDE SEQUENCE.
RP Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03379; CAA27101.1; -; mRNA.
FT NON_TER 1
FT NON_TER 115
SQ SEQUENCE 115 AA; 13257 MW; D465A5854DF459A3 CRC64;

Query Match 79.2%; Score 504; DB 2; Length 115;
Best Local Similarity 81.7%; Pred. No. 2.2e-44;
Matches 94; Conservative 5; Mismatches 12; Indels 4; Gaps 1;

Qy 1 DVQLQESGPGGLVKPSQSLTCSVTGYSITGGLYLNWIRQPGNKLEWGYISYDGTNNY 60
Db 1 DVQLQESGPGGLVKPSQSLTCSVTGYSITGGLYLNWIRQPGNKLEWGYIRYDGSNNY 60

Qy 61 KPSLKDRISITRDTSKNOFFLKLNSVTNEDTATYYCARYG-----RVFFDYWGQGT 111
Db 61 NPSLKNRISITRDTSKNOFFLKLNSVTNEDTATYYCAVFGYDMDYAMDYWGQGT 115

RESULT 8
```

```

Q53VR3_MOUSE PRELIMINARY; PRT; 119 AA.
AC Q53VR3;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE VH-D-JH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN NUCLEOTIDE SEQUENCE.
RP Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03376; CAA27083.1; -; mRNA.
FT NON_TER 1
FT NON_TER 119
SQ SEQUENCE 119 AA; 13799 MW; 36504D1665BFB59 CRC64;

Query Match 79.1%; Score 503; DB 2; Length 119;
Best Local Similarity 79.3%; Pred. No. 3e-44;
Matches 96; Conservative 5; Mismatches 8; Indels 12; Gaps 2;

Qy 1 DVQLQESGPGGLVKPSQSLTCSVTGYSITGGLYLNWIRQPGNKLEWGYISYDGTNNY 60
Db 1 DVQLQESGPGGLVKPSQSLTCSVTGYSITGGLYLNWIRQPGNKLEWGYIKYDGNNSY 60

Qy 61 KPSLKDRISITRDTSKNOFFLKLNSVTNEDTATYYCARYGRVFF-----DYWGQGT 110
Db 61 NPSLKNRISITRDTSKNOFFLKLNSVTNEDTATYYCAR--PLYFRHDEYYDMDYWGQGT 118

Qy 111 T 111
Db 119 T 119

RESULT 9
HV60_MOUSE STANDARD; PRT; 116 AA.
AC P18531;
DT 01-NOV-1990 (Rel. 16, Created)
DT 01-NOV-1990 (Rel. 16, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V region M315 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN NUCLEOTIDE SEQUENCE.
RP STRAIN=BALB/cJ;
RX MEDLINE=89279149; PubMed=2499654; DOI=10.1084/jem.169.6.2007;
RA Levy N.S., Malipiero U.V., Lebecque S.G., Gearhart P.J.;
RT "Early onset of somatic mutation in immunoglobulin VH genes during the
RT primary immune response.";
RL J. Exp. Med. 169:2007-2019 (1989).
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
```

```
CC -----
DR PIR; J0509; HVMS31.
DR PDB; 1BZV; X-ray; X=22-116.
DR SMR; P18531; 19-116.
DR Ensembl; ENSMUSG00000507048; Mus musculus.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 1.
KW 3D-structure; Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 18
FT CHAIN 19 116
FT REGION 19 48 Ig heavy chain V region M315.
FT REGION 19 48 Framework-1.
FT REGION 49 53 Complementarity-determining-1.
FT REGION 54 67 Framework-2.
FT REGION 68 84 Complementarity-determining-2.
FT REGION 85 116 Framework-3.
FT DISULFID 40 114 By similarity.
FT NON_TER 116 116
SQ SEQUENCE 116 AA; 13095 MW; 4562E03E53DC9E10 CRC64;

Query Match 78.5%; Score 499; DB 1; Length 116;
Best Local Similarity 93.9%; Pred. No. 7.5e-44;
Matches 92; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVQLQESGPGLVKPSQSLSLTCSTVGYISITGGLNNWIRQPGNKLWGWYISYDGTNNY 60
Db 19 DVQLQESGPGLVKPSQSLSLTCSTVGYISITGGLNNWIRQPGNKLWGWYISYDGSNNY 78

Qy 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCAR 98
Db 79 NPSLKNRISITRDTSKNQFFLKNSVTNEDTATYYCAR 116

RESULT 10
Q569B8 RAT PRELIMINARY; PRT; 590 AA.
AC Q569B8
DT 10-MAY-2005 (TrEMBLrel. 30, Created)
DT 10-MAY-2005 (TrEMBLrel. 30, Last sequence update)
DT 10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE Similar to Igh-6 protein.
GN Name=LOC29357;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridea; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny K.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Trichman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
```

```
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RG NIH MGC Project;
RL Submitted (APR-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC092580; AAH92580.1; -, mRNA.
DR GO; GO:0003823; P-antigen binding; IEA.
DR InterPro; IPR003599; Ig-like.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 4.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGV; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 5.
DR PROSITE; PS00290; IG.MHC; UNKNOWN 3.
SQ SEQUENCE 590 AA; 65088 MW; FAC77FFA82302304 CRC64;

Query Match 77.4%; Score 492; DB 2; Length 590;
Best Local Similarity 79.0%; Pred. No. 2.6e-42;
Matches 94; Conservative 7; Mismatches 16; Indels 2; Gaps 1;

Qy 1 DVQLQESGPGLVKPSQSLSLTCSTVGYISITGGLNNWIRQPGNKLWGWYISYDGTNNY 60
Db 17 EVQLQESGPGLVKPSQSLSLTCSTVGYISITGGLNNWIRQPGNKLWGWYISAGSTNY 76

Qy 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCARGRVF--FDYWGQGTTLTVSS 117
Db 77 NPSLKNRISITRDTSKNQFFLKNSVTNEDTATYYCARSPSTRFAIWGQGTTLTVSS 135

RESULT 11
Q53VQ4 MOUSE PRELIMINARY; PRT; 98 AA.
AC Q53VQ4;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE VH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., Theze J., Fougereau M.;
RT "The idiotypic network and the internal image; possible regulation of
a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
antibodies in the GAT system.";
RL EMBO J. 4:3681-3688 (1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03378; CAA27096.1; -, mRNA.
FT NON_TER 1 1
FT NON_TER 98 98
SQ SEQUENCE 98 AA; 11202 MW; 4049CF8C7BE8AAE0 CRC64;

Query Match 77.2%; Score 491; DB 2; Length 98;
Best Local Similarity 92.9%; Pred. No. 4.2e-43;
Matches 91; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVQLQESGPGLVKPSQSLSLTCSTVGYISITGGLNNWIRQPGNKLWGWYISYDGTNNY 60
Db 1 DVQLQESGPGLVKPSQSLSLTCSTVGYISITGGLNNWIRQPGNKLWGWYISYDGSNNY 60

Qy 61 KPSLKDRISITRDTSKNQFFLKNSVTNEDTATYYCAR 98
Db 61 NPSLKNRISITRDTSKNQFFLKNSVTNEDTATYYCAR 98
```

```
RESULT 12
Q569B6 RAT
ID Q569B6_RAT PRELIMINARY; PRT; 615 AA.
AC Q569B6;
DT 10-MAY-2005 (TrEMBLrel. 30, Created)
DT 10-MAY-2005 (TrEMBLrel. 30, Last sequence update)
DT 10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE LOC314509 protein.
GN Name=LOC314509;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=2388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Schein C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Mada A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grinwood J., Schmutz J., Myers R.M.,
RA Butlerfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RG NIH MGC Project;
RL Submitted (APR-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC02582; AAH2582.1; -; mRNA.
DR GO; GO:0003823; F:antigen binding; IEA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG cl.
DR InterPro; IPR003006; IG_MHC.
DR Pfam; PF07654; C1-set; 4.
DR SMART; SM00407; IGc1; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 615 AA; 67986 MW; B5C2483C69F186C CRC64;

Query Match 76.9%; Score 489; DB 2; Length 615;
Best Local Similarity 76.4%; Pred. No. 5, 7e-42;
Matches 94; Conservative 10; Mismatches 11; Indels 8; Gaps 3;

Qy 1 DVQLQESGFLVKPSQSLTCSVTGYISITGGYLNWIRQPGNKLEWGVISYDGTNNY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 19 EVQLQESGFLVKPSQSLTCSVTGYISITNSY-WGWRKFPGNKMEWIGHISYSGTSY 77
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 KPSLKDRISITRDTSKNQFFLKLSVTTEDTATYYCAR-----YGRVFPDYWGQGITLT 114
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 78 NPSLKRSITRDTSKNQFFLQLNSVTTEDTATYYCARHGGLTGR-YFDYWGQGVNMT 136
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 115 VSS 117
```

```
Db 137 VSS 139
||||
RESULT 13
Q53VR6 MOUSE
ID Q53VR6_MOUSE PRELIMINARY; PRT; 98 AA.
AC Q53VR6;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE VH-region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., Theze J., Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
antibodies in the GAT system."
RL EMBO J. 4:3681-3688 (1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03375; CAA27078.1; -; mRNA.
DR EMBL; X03374; CAA27072.1; -; mRNA.
FT NON_TER 1 1
FT NON_TER 98 98
SQ SEQUENCE 98 AA; 11255 MW; EBC71AA2F8F5FD60 CRC64;

Query Match 75.5%; Score 480; DB 2; Length 98;
Best Local Similarity 88.8%; Pred. No. 5.8e-42;
Matches 87; Conservative 6; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVQLQESGFLVKPSQSLTCSVTGYISITGGYLNWIRQPGNKLEWGVISYDGTNNY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DVHLQESGFLVKPSQSLTCSVTGYISITGYNNWIRFPGNKLEWGVINYGDSNNY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 KPSLKDRISITRDTSKNQFFLKLSVTTEDTATYYCAR 98
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 NPSLKRSITRDTSKNQFFLKLSVTTEDTATYYCAR 98
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 14
Q53VQ9 MOUSE
ID Q53VQ9_MOUSE PRELIMINARY; PRT; 119 AA.
AC Q53VQ9;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE VH-D-JH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., Theze J., Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
antibodies in the GAT system."
RL EMBO J. 4:3681-3688 (1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.

```



```
DR EMBL; X03377; CAA27089.1; -; mRNA.
FT NON_TER 1
FT NON_TER 119 119
SQ SEQUENCE 119 AA; 13844 MW; 6B1BC8C7DC77B147 CRC64;

Query Match 74.8%; Score 476; DB 2; Length 119;
Best Local Similarity 75.4%; Pred. No. 1.9e-41;
Matches 89; Conservative 9; Mismatches 12; Indels 8; Gaps 2;

Qy 1 DVQLQESGGLVKPQSLSLTCSTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 1 DVQLQESGGLVKPQSLSLTCSTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Qy 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCA-----RYGRVFF---DYWGQG 110
Db 61 NPSLKNRISITRDTSKNQFFLKLNSVTNEDTATYFCVRPLYYRFDDEYYIATDYWGQG 118

RESULT 15
Q53VR2 MOUSE
ID Q53VR2 MOUSE PRELIMINARY; PRT; 98 AA.
AC Q53VR2;
DT 13-SEP-2005 (TremBLrel. 31, Created)
DT 13-SEP-2005 (TremBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TremBLrel. 31, Last annotation update)
DE VH region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., Therez J., Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
RT a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
RT antibodies in the GAT system.";
RL EMBO J. 4:3681-3688(1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 28-29.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DDBJ databases.
DR EMBL; X03376; CAA27084.1; -; mRNA.
FT NON_TER 1
FT NON_TER 98 98
SQ SEQUENCE 98 AA; 11132 MW; 50878B9A4CF7298B CRC64;

Query Match 74.7%; Score 475; DB 2; Length 98;
Best Local Similarity 89.8%; Pred. No. 1.9e-41;
Matches 88; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DVQLQESGGLVKPQSLSLTCSTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Db 1 DVQLQESGGLVKPQSLSLTCSTGYSITGGYLNWIRQFPGNKLEWNGYISYDGTNNY 60
Qy 61 KPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCAR 98
Db 61 NPSLKNRISITRDTSKNQFFLKLNSVTNEDTATYYCAR 98
```

Search completed: January 10, 2006, 20:53:26
Job time : 79.8731 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:55:23 ; Search time 5.71144 Seconds
(without alignments)
166.558 Million cell updates/sec

Title: US-10-735-916A-65
Perfect score: 595
Sequence: 1 DIVMTQSPSLPVTTPGEPAS.....CFQGSHPVWTFQGQTKVEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 61141 seqs, 8493638 residues

Total number of hits satisfying chosen parameters: 61141

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA New:*

- 1: /cgn2_6/prodata/1/pubpaa/US08 NEW PUB.pap.*
- 2: /cgn2_6/prodata/1/pubpaa/US06 NEW PUB.pap.*
- 3: /cgn2_6/prodata/1/pubpaa/US07 NEW PUB.pap.*
- 4: /cgn2_6/prodata/1/pubpaa/PCT_NEW PUB.pap.*
- 5: /cgn2_6/prodata/1/pubpaa/US09 NEW PUB.pap.*
- 6: /cgn2_6/prodata/1/pubpaa/US10 NEW PUB.pap.*
- 7: /cgn2_6/prodata/1/pubpaa/US11 NEW PUB.pap.*
- 8: /cgn2_6/prodata/1/pubpaa/US60_NEW_PUB.pap.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	595	100.0	112	7	US-11-012-353-65
2	595	100.0	131	7	US-11-012-353-67
3	594	99.8	112	7	US-11-012-353-61
4	594	99.8	131	7	US-11-012-353-63
5	547	91.9	112	6	US-10-959-310-26
6	546	91.8	112	6	US-10-959-310-33
7	544	91.4	112	6	US-10-959-310-34
8	543	91.3	112	6	US-10-959-310-35
9	537	90.3	112	7	US-11-012-353-54
10	537	90.3	122	7	US-11-012-353-49
11	530	89.1	112	7	US-11-012-353-56
12	523	87.9	131	7	US-11-125-837-23
13	521	87.6	263	7	US-11-089-266-66
14	519	87.2	112	7	US-11-012-353-55
15	519	87.2	112	7	US-11-012-353-57
16	519	87.2	149	7	US-11-089-266-2
17	517	86.9	116	7	US-11-065-943-49
18	516	86.7	113	6	US-10-932-334-61
19	514	86.4	112	7	US-11-089-266-15
20	513	86.2	113	6	US-10-932-334-69
21	511	85.9	113	6	US-10-932-334-66
22	511	85.9	113	6	US-10-932-334-68
23	510	85.7	113	6	US-10-932-334-9
24	510	85.7	113	6	US-10-932-334-12
25	510	85.7	113	6	US-10-932-334-83

26	510	85.7	113	6	US-10-932-334-86	Sequence 86, Appl
27	510	85.7	113	6	US-10-932-334-90	Sequence 90, Appl
28	509	85.5	113	6	US-10-932-334-65	Sequence 65, Appl
29	509	85.5	251	6	US-10-512-184-30	Sequence 30, Appl
30	509	85.5	320	6	US-10-512-184-67	Sequence 67, Appl
31	509	85.5	569	6	US-10-512-184-66	Sequence 66, Appl
32	509	85.5	618	6	US-10-512-184-48	Sequence 48, Appl
33	508	85.4	113	6	US-10-932-334-60	Sequence 60, Appl
34	507	85.2	113	6	US-10-932-334-10	Sequence 10, Appl
35	507	85.2	113	6	US-10-932-334-11	Sequence 11, Appl
36	507	85.2	113	6	US-10-932-334-59	Sequence 59, Appl
37	507	85.2	113	6	US-10-932-334-84	Sequence 84, Appl
38	507	85.2	113	6	US-10-932-334-85	Sequence 85, Appl
39	507	85.2	113	6	US-10-932-334-94	Sequence 94, Appl
40	502	84.4	113	6	US-10-932-334-8	Sequence 8, Appl
41	502	84.4	113	6	US-10-932-334-58	Sequence 58, Appl
42	502	84.4	113	6	US-10-932-334-62	Sequence 62, Appl
43	502	84.4	113	6	US-10-932-334-82	Sequence 82, Appl
44	502	84.4	132	6	US-10-932-334-50	Sequence 50, Appl
45	501	84.2	112	7	US-11-012-353-58	Sequence 58, Appl

ALIGNMENTS

RESULT 1
US-11-012-353-65
; Sequence 65, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUELOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 65
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-65

Query Match 100.0%; Score 595; DB 7; Length 112;
Best Local Similarity 100.0%; Pred. No. 2.8e-40;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	DIVMTQSPSLPVTTPGEPASISCRSSQSIHNGNTYLOWYLOKPGQSPQLLIYKVSRL	60
Db	1	DIVMTQSPSLPVTTPGEPASISCRSSQSIHNGNTYLOWYLOKPGQSPQLLIYKVSRL	60
Qy	61	YGVPRFSGSGGTDFTLKISRVEADVGVYCFQGSHPVWTFQGQTKVEIK	112
Db	61	YGVPRFSGSGGTDFTLKISRVEADVGVYCFQGSHPVWTFQGQTKVEIK	112

```
RESULT 2
US-11-012-353-67
; Sequence 67, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 67
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-67

Query Match      100.0%; Score 595; DB 7; Length 131;
Best Local Similarity 100.0%; Pred. No. 3.2e-40;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1  DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLQKPGQSPQLLIYKVSNRL 60
DB      20  DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLQKPGQSPQLLIYKVSNRL 79

QY      61  YGVPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112
DB      80  YGVPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 131

RESULT 3
US-11-012-353-61
; Sequence 61, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
```

```
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 61
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-61

Query Match      99.8%; Score 594; DB 7; Length 112;
Best Local Similarity 99.1%; Pred. No. 3.4e-40;
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1  DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLQKPGQSPQLLIYKVSNRL 60
DB      1  DVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLQKPGQSPQLLIYKVSNRL 60

QY      61  YGVPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112
DB      61  YGVPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112

RESULT 4
US-11-012-353-63
; Sequence 63, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 63
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-63

Query Match      99.8%; Score 594; DB 7; Length 131;
Best Local Similarity 99.1%; Pred. No. 3.8e-40;
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1  DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLQKPGQSPQLLIYKVSNRL 60
DB      20  DVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLQKPGQSPQLLIYKVSNRL 79

QY      61  YGVPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112
DB      80  YGVPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 131
```

db 61 SGVPDRFSGSGGTFTLKISRVEAEDVGVYCFQGSLLPWTFGQGTKVEIK 112

RESULT 7

```

US-10-959-310-34
; Sequence 34, Application US/10959310
; Publication No. US20050287138A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD.
; TITLE OF INVENTION: CCR4-specific antibody composition
; FILE REFERENCE: 249-363
; CURRENT APPLICATION NUMBER: US/10/959,310
; CURRENT FILING DATE: 2004-10-07
; PRIOR APPLICATION NUMBER: JP 2003-350162
; PRIOR FILING DATE: 2003-10-08
; PRIOR APPLICATION NUMBER: US 60/572,784
; PRIOR FILING DATE: 2004-05-21
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 34
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic peptide
US-10-959-310-34

```

	Query Match	91.4%	Score 544;	DB 6;	Length 112;
	Best Local Similarity Matches	91.1%;	Pred. No. 2.5e-36;	Mismatches 6;	Indels 0; Gaps 0;
	Conservative				
Qy	1	DIVWTGSLPVTGPASISCRSSOSIVHSNGNTYLQWLYLKPGSGSPOLLIYKVNRL	60		
	:	: :	:	:	:
	:	:	:	:	:
Db	1	DILMTQSLSLPTGPASISCRSSRNVIHNGDTYLEWLYLKPGSGSPOLLIYKVNR	60		
Qy	61	YGVPDRFSGSGSDFTFLKI SRVAEDVGVYYCFQGSHVPTWGCTKVEIK	112		
	:	:	:	:	:
Db	61	SGVPDRFSGSGSDFTFLKI SRVAEDVGVYYCFQGLLPWMFGCTKVEIK	112		

RESULT 8

```

US-10-959-310-35
; Sequence 35, Application US/10959310
; Publication No. US20050287138A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD.
; TITLE OF INVENTION: CCR4-specific antibody composition
; FILE NUMBER: 249-363
; CURRENT APPLICATION NUMBER: US/10/959,310
; CURRENT FILING DATE: 2004-10-07
; PRIOR APPLICATION NUMBER: JP 2003-350162
; PRIOR FILING DATE: 2003-10-08
; PRIOR APPLICATION NUMBER: US 60/572,784
; PRIOR FILING DATE: 2004-05-21
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 35
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic peptide
US-10-959-310-35

```

```

Query Match      91.38; Score 543; DB 6; Length 112;
Best Local Similarity 90.2%; Pred. No. 2.9e-36;
Matches 101; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVMWQSPSLPVTGPGPASICRCSOSIVHSNGNTYLQWYLKPGGSPQLLIYKVSNRL 60
   ::::|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DVLMTQSPSLPVTGPGPASICRCSRNIHVHNGDITYLEWYLKPGGSPQLLIYKVSNRF 60

Qy 61 YGVPDRFGSGSGTDFTFLKISRVAEADVGYYVCFQGSHPVMTFQGGTKVEIK 112

```

RESULT 5

```

US-10-959-310-26
; Sequence 26, Application US/10959310
; Publication No. US20050287138A1
GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD.
; TITLE OF INVENTION: CCR4-specific antibody composition
; FILE REFERENCE: 249-363
; CURRENT APPLICATION NUMBER: US/10/959,310
; CURRENT FILING DATE: 2004-10-07
; PRIOR APPLICATION NUMBER: JP 2003-350162
; PRIOR FILING DATE: 2003-10-08
; PRIOR APPLICATION NUMBER: US 60/572,784
; PRIOR FILING DATE: 2004-05-21
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 26
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic peptide
US-10-959-310-26

```

	Query Match	91.9%	Score 547;	DB 6;	Length 112;
	Best Local Similarity	92.0%;	Pred. No. 1.4e-36;		
	Matches 103;	Conservative 5;	Mismatches 4;	Indels 0;	Gaps 0;
QY	1	DIVMTQSLPLVPTGPGPASICRSSOSIVHNSGNTYLQWYLRKPGSQPLLIIKVSNRL	60		
Db	1	DIVMTQSLPLVPTGPGPASICRSSRNIHNGDITLWYLRKPGSQPLLIIKVSNRF	60		
QY	61	YGVPDFRSGSGSGDFTLKLISRVAEADVGVYICFGGSHVPWTFGGTGKVEIK	112		
Db	61	SGVPDFRSGSGSGDFTLKLISRVAEADVGVYICFGGSLPLPWFGGTGKVEIK	112		

RESULT 6

```

US-10-959-310-33
; Sequence 33, Application US/10959310
; Publication No. US20050287138A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD.
; TITLE OF INVENTION: CCR4-specific antibody composition
; FILE REFERENCE: 249-363
; CURRENT APPLICATION NUMBER: US/10/959,310
; CURRENT FILING DATE: 2004-10-07
; PRIOR APPLICATION NUMBER: JP 2003-350162
; PRIOR FILING DATE: 2003-10-08
; PRIOR APPLICATION NUMBER: US 60/572,784
; PRIOR FILING DATE: 2004-05-21
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 33
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic peptide
US-10-959-310-33

```

```
Query Match      91.8%; Score 546; DB 6; Length 112;
Best Local Similarity 91.1%; Pred. No. 1.7e-36;
Matches 102; Conservative 6; Mismatches 4; Indels 0; Gaps 0

QY    1 DIVMTQPLSLPVTPGPPASISCRSSQSIVHSNGNTYLQWLXPQGSPQLLIYKVSURL 60
       :|::|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db     1 DVVMTQPLSLPVTPGPPASISCRSSRNIVHGDTYLEWLXPQGSPQLLIYKVSNRP 60
       :|::|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

QY    61 YGVPDFRFGSGSGTDFTLKISRVAEDGVYYCYCGSHVPWTFGGTKVEIK 112
       :|::|||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
```


RESULT 13
US-11-089-266-66
; Sequence 66, Application US/11089266
; Publication No. US20050287148A1
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Foon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/11/089,266
; FILING DATE: 23-Mar-2005
; CLASSIFICATION:
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US/10/153,401
; FILING DATE: 27-Aug-2002
; APPLICATION NUMBER: US 09/293,533
; FILING DATE: 1999-04-15

RESULT 14
US-11-012-353-55
; Sequence 55, Application US/11012353
; Publication No. US2005024970A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVALTA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND
; TITLE OF INVENTION: RECEPTORS ANTIBODIES
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PC7/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 55
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-55

Query Match	87.2%	Score 519;	DB 7;	Length 112;
Best Local Similarity	85.7%;	Pred. No. 2.1e-34;		
Matches 96;	Conservative	11;	Mismatches 5;	Indels 0;
				Gaps 0;

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:53:43 ; Search time 61.4328 Seconds
(without alignments)
761.757 Million cell updates/sec

Title: US-10-735-916A-65
Perfect score: 595
Sequence: 1 DIVMTQSPSLPVTGPGEPAAS.....CFQGSHPVPTFGQTKVEIK 112

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA Main:
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	595	100.0	112	5	US-10-735-916A-65
2	595	100.0	131	5	US-10-735-916A-67
3	594	99.8	112	5	US-10-735-916A-61
4	594	99.8	131	5	US-10-735-916A-63
5	564	94.8	112	4	US-10-308-817-182
6	564	94.8	112	4	US-10-453-698-182
7	564	94.8	112	4	US-10-434-469-19
8	564	94.8	112	5	US-10-482-105-17
9	564	94.8	112	5	US-10-500-207A-19
10	562	94.5	112	4	US-10-258-728-28
11	559	93.9	112	5	US-10-500-207A-47
12	559	93.9	132	4	US-10-388-214A-6
13	558	93.8	112	4	US-10-258-728-27
14	557	93.6	112	4	US-10-258-728-26
15	557	93.6	112	5	US-10-500-207A-46
16	556	93.4	112	4	US-10-434-469-41
17	556	93.4	112	5	US-10-482-105-39
18	556	93.4	112	5	US-10-858-855-7
19	556	93.4	112	5	US-10-500-207A-44
20	552	92.8	112	5	US-10-500-207A-42
21	549	92.3	112	4	US-10-308-817-180
22	549	92.3	112	4	US-10-453-698-180
23	547	91.9	112	4	US-10-231-452-8
24	547	91.9	112	4	US-10-453-698-181
25	547	91.9	112	5	US-10-505-980-12
26	547	91.9	112	5	US-10-500-207A-51
27	546	91.8	112	4	US-10-231-452-12

28	546	91.8	112	5	US-10-505-980-19	Sequence 19, Appl
29	546	91.8	112	5	US-10-500-207A-45	Sequence 45, Appl
30	545	91.6	112	5	US-10-500-207A-43	Sequence 43, Appl
31	544	91.4	112	4	US-10-231-452-13	Sequence 13, Appl
32	544	91.4	112	5	US-10-505-980-20	Sequence 20, Appl
33	544	91.4	116	3	US-09-753-436-66	Sequence 66, Appl
34	544	91.4	116	4	US-10-163-942-66	Sequence 66, Appl
35	544	91.4	116	5	US-10-745-115-66	Sequence 66, Appl
36	543	91.3	112	4	US-10-231-452-14	Sequence 14, Appl
37	543	91.3	112	4	US-10-434-469-40	Sequence 40, Appl
38	543	91.3	112	5	US-10-482-105-38	Sequence 38, Appl
39	543	91.3	112	5	US-10-505-980-21	Sequence 21, Appl
40	543	91.3	112	5	US-10-500-207A-50	Sequence 50, Appl
41	543	91.3	131	3	US-09-947-839-95	Sequence 95, Appl
42	538	90.4	112	4	US-10-434-469-21	Sequence 21, Appl
43	538	90.4	112	5	US-10-482-105-19	Sequence 19, Appl
44	538	90.4	112	5	US-10-500-207A-21	Sequence 21, Appl
45	537	90.3	112	5	US-10-735-916A-54	Sequence 54, Appl

ALIGNMENTS

RESULT 1
US-10-735-916A-65
; Sequence 65, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017553-183
; CURRENT APPLICATION NUMBER: US/10735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 65
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-735-916A-65

Query Match	100.0%	Score 595;	DB 5;	Length 112;
Best Local Similarity	100.0%;	Pred. No. 1.5e-46;		
Matches 112;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	DIVMTQSPSLPVTGPGEPAISCRSSQIVHSNGNTYLOWLYQKPGQSPOLLIKVSNRL	60	
Db	1	DIVMTQSPSLPVTGPGEPAISCRSSQIVHSNGNTYLOWLYQKPGQSPOLLIKVSNRL	60	
QY	61	YGVPDRFSGSGGTFTLKISRVEAEDVGVVYFCQGSHPVPTFGGTVEIK	112	
Db	61	YGVPDRFSGSGGTFTLKISRVEAEDVGVVYFCQGSHPVPTFGGTVEIK	112	

RESULT 2
US-10-735-916A-67
; Sequence 67, Application US/10735916A
; Publication No. US20050084906A1

GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 67
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-67

Query Match 100.0%; Score 595; DB 5; Length 131;
Best Local Similarity 100.0%; Pred. No. 1.8e-46;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPQLLIYKVSRL 60
DB 20 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPQLLIYKVSRL 79
QY 61 YGVDPFRFSGSGGTDFTLKISRVEADVGVIYCFQGSHPVPTFGGTVKEIK 112
DB 80 YGVDPFRFSGSGGTDFTLKISRVEADVGVIYCFQGSHPVPTFGGTVKEIK 131

RESULT 3
US-10-735-916A-61
; Sequence 61, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 61
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Homo sapiens

US-10-735-916A-61
Query Match 99.8%; Score 594; DB 5; Length 112;
Best Local Similarity 99.1%; Pred. No. 1.9e-46;
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPQLLIYKVSRL 60
DB 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPQLLIYKVSRL 60
QY 61 YGVDPFRFSGSGGTDFTLKISRVEADVGVIYCFQGSHPVPTFGGTVKEIK 112
DB 61 YGVDPFRFSGSGGTDFTLKISRVEADVGVIYCFQGSHPVPTFGGTVKEIK 112
RESULT 4
US-10-735-916A-63
; Sequence 63, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 63
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-63

Query Match 99.8%; Score 594; DB 5; Length 131;
Best Local Similarity 99.1%; Pred. No. 2.2e-46;
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPQLLIYKVSRL 60
DB 20 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPQLLIYKVSRL 79
QY 61 YGVDPFRFSGSGGTDFTLKISRVEADVGVIYCFQGSHPVPTFGGTVKEIK 112
DB 80 YGVDPFRFSGSGGTDFTLKISRVEADVGVIYCFQGSHPVPTFGGTVKEIK 131
RESULT 5
US-10-308-817-182
; Sequence 182, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37
; CURRENT APPLICATION NUMBER: US/10/308,817
; CURRENT FILING DATE: 2002-12-03
; NUMBER OF SEQ ID NOS: 195


```
; SEQ ID NO 19
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: LV.0, a designed amino acid sequence of VL of
; OTHER INFORMATION: an anti-FGF-8 CDR-grafted neutralizing antibody
US-10-500-207A-19

Query Match          94.8%; Score 564; DB 5; Length 112;
Best Local Similarity 94.6%; Pred. No. 1e-43;
Matches 106; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRL 60
DB 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRI 60

QY 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112
DB 61 SGVPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112

RESULT 10
US-10-258-728-28
; Sequence 28, Application US/10258728
; Publication No. US20040091485A1
; GENERAL INFORMATION:
; APPLICANT: Ellis, John Robert Maxwell
; APPLICANT: Durrant, Linda Gillian
; TITLE OF INVENTION: Humanised Antibodies to the Epidermal Growth Factor Receptor
; FILE REFERENCE: 28438-101US01
; CURRENT APPLICATION NUMBER: US/10/258,728
; CURRENT FILING DATE: 2003-06-18
; PRIOR FILING DATE: 2000-05-19
; PRIOR APPLICATION NUMBER: GB 0011981.8
; PRIOR FILING DATE: 2000-08-24
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-258-728-28

Query Match          94.5%; Score 562; DB 4; Length 112;
Best Local Similarity 92.9%; Pred. No. 1.5e-43;
Matches 104; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRL 60
DB 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRI 60

QY 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112
DB 61 SGVPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112

RESULT 11
US-10-500-207A-47
; Sequence 47, Application US/10500207A
; Publication No. US20050175608A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD
; TITLE OF INVENTION: AGENT FOR TREATING ARTHRITIS
; FILE REFERENCE: 1442
; CURRENT APPLICATION NUMBER: US/10/500,207A
; CURRENT FILING DATE: 2004-06-28
; PRIOR APPLICATION NUMBER: JP2001-400677
; PRIOR FILING DATE: 2001-12-28
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 47
```

```
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: LV.2-2, a designed amino acid sequence of VL of
; OTHER INFORMATION: an anti-FGF-8 CDR-grafted neutralizing antibody
US-10-500-207A-47

Query Match          93.9%; Score 559; DB 5; Length 112;
Best Local Similarity 92.9%; Pred. No. 2.9e-43;
Matches 104; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRL 60
DB 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRI 60

QY 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112
DB 61 SGVPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112

RESULT 12
US-10-388-214A-6
; Sequence 6, Application US/10388214A
; Publication No. US20040082762A1
; GENERAL INFORMATION:
; APPLICANT: Basi, Gurig
; APPLICANT: Saidanha, Jose
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE BETA
; FILE REFERENCE: ELN-004
; CURRENT APPLICATION NUMBER: US/10/388,214A
; CURRENT FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/363,751
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 132
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: humanized 12BaVLv1
; NAME/KEY: SIGNAL
; LOCATION: (1)...(20)
US-10-388-214A-6

Query Match          93.9%; Score 559; DB 4; Length 132;
Best Local Similarity 93.8%; Pred. No. 3.4e-43;
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRL 60
DB 21 DVVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLWYLQKPGQSPQLLIYKVSRI 80

QY 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKVEIK 112
DB 81 SGVPDRFSGSGGTFTLKISRVEAEDVGVYFCFGSHVPWTFGGTKLEIK 132

RESULT 13
US-10-258-728-27
; Sequence 27, Application US/10258728
; Publication No. US20040091485A1
; GENERAL INFORMATION:
; APPLICANT: Ellis, John Robert Maxwell
; APPLICANT: Durrant, Linda Gillian
; TITLE OF INVENTION: Humanised Antibodies to the Epidermal Growth Factor Receptor
; FILE REFERENCE: 28438-101US01
; CURRENT APPLICATION NUMBER: US/10/258,728
; CURRENT FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: GB 0011981.8
```


THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:34:27 ; Search time 21.8706 Seconds
(without alignments)
423.384 Million cell updates/sec

Title: US-10-735-916A-65
Perfect score: 595
Sequence: 1 DIVMTQSLSLPVTGPEPAS.....CFQGSHPVMTFGQTKVEIK 112

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA*
1: /cgn2_6/ptodata/1/1aa/5 COMB.pep.*
2: /cgn2_6/ptodata/1/1aa/6 COMB.pep.*
3: /cgn2_6/ptodata/1/1aa/H COMB.pep.*
4: /cgn2_6/ptodata/1/1aa/PCTUS COMB.pep.*
5: /cgn2_6/ptodata/1/1aa/RE COMB.pep.*
6: /cgn2_6/ptodata/1/1aa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	559	93.9	112	1 US-08-331-398A-50	Sequence 50, Appl
2	559	93.9	112	1 US-08-331-397B-50	Sequence 50, Appl
3	559	93.9	112	1 US-08-759-804A-50	Sequence 50, Appl
4	559	93.9	112	2 US-09-227-693-50	Sequence 50, Appl
5	557	93.6	112	1 US-08-053-171-15	Sequence 15, Appl
6	557	93.6	112	2 US-08-815-190A-14	Sequence 14, Appl
7	544	91.4	116	1 US-08-482-882-66	Sequence 66, Appl
8	544	91.4	116	1 US-08-483-389-66	Sequence 66, Appl
9	544	91.4	116	1 US-08-487-113D-66	Sequence 66, Appl
10	544	91.4	116	1 US-08-473-503-66	Sequence 66, Appl
11	544	91.4	116	1 US-08-483-932-66	Sequence 66, Appl
12	544	91.4	116	1 US-08-720-420A-66	Sequence 66, Appl
13	544	91.4	116	2 US-08-714-017-66	Sequence 66, Appl
14	544	91.4	116	2 US-08-475-680-66	Sequence 66, Appl
15	543	91.3	131	1 US-08-129-930B-95	Sequence 95, Appl
16	543	91.3	131	2 US-08-134-346A-50	Sequence 50, Appl
17	543	91.3	131	2 US-08-976-288A-95	Sequence 95, Appl
18	527	88.6	112	1 US-08-478-039-88	Sequence 88, Appl
19	527	88.6	112	1 US-08-476-349A-88	Sequence 88, Appl
20	521	87.6	149	2 US-09-192-838B-2	Sequence 2, Appl
21	521	87.6	149	2 US-09-324-191-2	Sequence 2, Appl
22	521	87.6	263	1 US-08-752-844-66	Sequence 66, Appl
23	521	87.6	263	2 US-09-293-533-66	Sequence 66, Appl
24	519	87.2	112	1 US-08-331-398A-48	Sequence 48, Appl
25	519	87.2	112	1 US-08-077-252B-3	Sequence 3, Appl
26	519	87.2	112	1 US-08-331-397B-48	Sequence 48, Appl
27	519	87.2	112	1 US-08-759-804A-48	Sequence 48, Appl

28	519	87.2	112	2 US-09-002-753A-3	Sequence 3, Appl
29	519	87.2	112	2 US-09-227-693-48	Sequence 48, Appl
30	519	87.2	112	2 US-09-657-274-3	Sequence 3, Appl
31	519	87.2	112	4 PCT-US94-06687-3	Sequence 3, Appl
32	519	87.2	125	1 US-08-331-398A-67	Sequence 67, Appl
33	519	87.2	125	1 US-08-331-397B-67	Sequence 67, Appl
34	519	87.2	125	1 US-08-759-804A-66	Sequence 66, Appl
35	519	87.2	149	1 US-08-752-844-2	Sequence 2, Appl
36	519	87.2	149	1 US-08-591-196-2	Sequence 2, Appl
37	519	87.2	149	2 US-09-293-533-2	Sequence 2, Appl
38	519	87.2	247	2 US-09-227-693-34	Sequence 34, Appl
39	519	87.2	248	1 US-08-331-398A-34	Sequence 34, Appl
40	519	87.2	248	1 US-08-331-397B-34	Sequence 34, Appl
41	519	87.2	248	1 US-08-759-804A-34	Sequence 34, Appl
42	517	86.9	112	1 US-08-859-649-19	Sequence 19, Appl
43	517	86.9	112	1 US-08-859-649-29	Sequence 29, Appl
44	517	86.9	112	2 US-08-207-861-19	Sequence 19, Appl
45	517	86.9	112	2 US-08-207-861-29	Sequence 29, Appl

ALIGNMENTS

RESULT 1
US-08-331-398A-50
; Sequence 50, Application US/08331398A
; Patent No. 5608039
; GENERAL INFORMATION:
; APPLICANT: Pastan, Ira
; APPLICANT: Willingham, Mark
; APPLICANT: FitzGerald, David
; APPLICANT: Brinkmann, Ulrich
; APPLICANT: Pai, Lee
; TITLE OF INVENTION: Single Chain B3 Antibody Fusion Proteins
; TITLE OF INVENTION: and Their Uses (as amended)
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew
; STREET: One Market Plaza, Steuart Street Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105-1492
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/331.398A
; FILING DATE: 28-OCT-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/767,331
; FILING DATE: 30-SEP-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/596,289
; FILING DATE: 12-OCT-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Hunter, Tom
; REGISTRATION NUMBER: 38,498
; REFERENCE/DOCKET NUMBER: 015280-1261100S
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 543-9600
; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:

```
; NAME/KEY: Protein
; LOCATION: 1..112
; OTHER INFORMATION: /note= "Humanized B3 Variable Light
; OTHER INFORMATION: chain (V-L) (Humb3V-L)"
US-08-331-398A-50

Query Match
Best Local Similarity 93.9%; Score 559; DB 1; Length 112;
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPGSPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVLMTQSPSLPVTGPGSPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVDPDRFGSGSGTDFTLKISRVEADVGVIYCFQGSHPVPTFGGQTKVEIK 112
Db 61 SGVDPDRFGSGSGTDFTLKISRVEADVGVIYCFQGSHPVPTFGGQTKVEIK 112

RESULT 2
US-08-331-397B-50
; Sequence 50, Application US/08331397B
; Patent No. 5981726
; GENERAL INFORMATION:
; APPLICANT: Pastan, Ira
; APPLICANT: Benhar, Itai
; TITLE OF INVENTION: Chimeric and Mutationally Stabilized Tumor-
; TITLE OF INVENTION: Specific Antibody Fragments, Fusion Proteins, and Uses
; TITLE OF INVENTION: Thereof
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew
; STREET: One Market Plaza, Stewart Street Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105-1492
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/331,397B
; FILING DATE: 28-OCT-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/767,331
; FILING DATE: 30-SEP-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/596,289
; FILING DATE: 12-OCT-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Hunter, Tom
; REGISTRATION NUMBER: 38,498
; REFERENCE/DOCKET NUMBER: 015280-126120US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 543-9600
; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..112
; OTHER INFORMATION: /note= "Humanized B3 Variable Light
; OTHER INFORMATION: chain (V-L) (Humb3V-L)"
US-08-331-397B-50
```

```
Query Match
Best Local Similarity 93.9%; Score 559; DB 1; Length 112;
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPGSPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVLMTQSPSLPVTGPGSPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVDPDRFGSGSGTDFTLKISRVEADVGVIYCFQGSHPVPTFGGQTKVEIK 112
Db 61 SGVDPDRFGSGSGTDFTLKISRVEADVGVIYCFQGSHPVPTFGGQTKVEIK 112

RESULT 3
US-08-759-804A-50
; Sequence 50, Application US/08759804A
; Patent No. 5990296
; GENERAL INFORMATION:
; APPLICANT: Pastan, Ira
; APPLICANT: Willingham, Mark
; APPLICANT: FitzGerald, David J.
; APPLICANT: Brinkmann, Ulrich
; APPLICANT: Pai, Lee
; TITLE OF INVENTION: Tumor-Specific Antibody Fragments,
; TITLE OF INVENTION: Fusion Proteins, and Uses Thereof
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/759,804A
; FILING DATE: 03-DEC-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/331,398
; FILING DATE: 28-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/767,331
; FILING DATE: 30-SEP-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/596,289
; FILING DATE: 12-OCT-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Ellen L.
; REGISTRATION NUMBER: 32,762
; REFERENCE/DOCKET NUMBER: 015280-126140US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..112
; OTHER INFORMATION: /note= "Humanized B3 Variable Light
; OTHER INFORMATION: chain (V-L) (Humb3V-L)"
US-08-759-804A-50

Query Match
93.9%; Score 559; DB 1; Length 112;
```


Best Local Similarity 93.8%; Pred. No. 2.6e-47; Mismatches 3; Indels 0; Gaps 0;
Matches 105; Conservative 4;

QY 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLOKFGQSPQLLIYKVSRL 60

Db 1 DVLMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLOKFGQSPQLLIYKVSRL 60

QY 61 YGVDPFRFGSGSGTDFTLKISRVEADVGVVYCFQGSHPVPTFGQTKVEIK 112

Db 61 SGVDPFRFGSGSGTDFTLKISRVEADVGVVYCFQGSHPVPTFGQTKVEIK 112

RESULT 4

US-09-227-693-50

; Sequence 50, Application US/09227693

; Patent No. 6287562

; GENERAL INFORMATION:

; APPLICANT: PASTAN, Ira

; APPLICANT: BENHAR, Itai

; APPLICANT: PADLAN, Eduardo A.

; APPLICANT: JUNG, Sun-Hee

; APPLICANT: LEE, Byungkook

; TITLE OF INVENTION: HUMANIZED TUMOR-SPECIFIC ANTIBODY

; NUMBER OF SEQUENCES: 50

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Townsend and Townsend Kourie and Crew

; STREET: Steuart Street Tower, One Market Plaza

; CITY: San Francisco

; STATE: California

; COUNTRY: US

; ZIP: 94105-1493

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/227,693

; FILING DATE:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/331,396

; FILING DATE:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 07/767,331

; FILING DATE: 30-SEP-1991

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 07/596,289

; FILING DATE: 12-OCT-1990

; ATTORNEY/AGENT INFORMATION:

; NAME: Weber, Ellen Lauver

; REGISTRATION NUMBER: 32,762

; REFERENCE/DOCKET NUMBER: 15280-126-1-3

; TELEPHONE: (415) 543-9600

; TELEFAX: (415) 543-5043

; INFORMATION FOR SEQ ID NO: 50:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 112 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; FEATURE:

; NAME/KEY: Protein

; LOCATION: 1..112

; OTHER INFORMATION: /note= "Humanized B3 VL region"

US-09-227-693-50

Query Match

Best Local Similarity 93.8%; Score 559; DB 2; Length 112;

Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLOKFGQSPQLLIYKVSRL 60

Db 1 DVLMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWYLOKFGQSPQLLIYKVSRL 60

QY 61 YGVDPFRFGSGSGTDFTLKISRVEADVGVVYCFQGSHPVPTFGQTKVEIK 112

Db 61 SGVDPFRFGSGSGTDFTLKISRVEADVGVVYCFQGSHPVPTFGQTKVEIK 112

RESULT 5

US-08-053-171-15

; Sequence 15, Application US/08053171

; Patent No. 5562903

; GENERAL INFORMATION:

; APPLICANT: Co, Loibner

; TITLE OF INVENTION: Antibody Derivatives

; NUMBER OF SEQUENCES: 32

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Townsend and Townsend Kourie and Crew

; STREET: 379 Lytton Avenue

; CITY: Palo Alto

; STATE: California

; COUNTRY: US

; ZIP: 94301

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/053,171

; FILING DATE: 22-APR-1993

; CLASSIFICATION: 424

; ATTORNEY/AGENT INFORMATION:

; NAME: Smith, William M

; REGISTRATION NUMBER: 30,223

; REFERENCE/DOCKET NUMBER: 11823-54-1

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (415) 326-2400

; TELEFAX: (415) 326-2422

; INFORMATION FOR SEQ ID NO: 15:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 112 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; HYPOTHETICAL: NO

; FEATURE:

; NAME/KEY: Peptide

; LOCATION: 1..112

; OTHER INFORMATION: /note= "Sequence of the Light Chain

; Patent No. 5562903

; OTHER INFORMATION: of Humanized BR55-2 Antibody"

; FEATURE:

; NAME/KEY: Region

; LOCATION: 24..39

; OTHER INFORMATION: /note= "Complementarity-determining

; OTHER INFORMATION: region"

; FEATURE:

; NAME/KEY: Region

; LOCATION: 55..61

; OTHER INFORMATION: /note= "Complementarity-determining

; OTHER INFORMATION: region"

; FEATURE:

; NAME/KEY: Region

; LOCATION: 94..102

; OTHER INFORMATION: /note= "Complementarity-determining

; OTHER INFORMATION: region"

; FEATURE:

; NAME/KEY: Modified-site

; LOCATION: 54

; OTHER INFORMATION: /note= "Residue that has been

; OTHER INFORMATION: replaced with mouse amino acid in the humanized

```
; OTHER INFORMATION: antibody."
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 108
; OTHER INFORMATION: /note= "Residue in the framework
; OTHER INFORMATION: that is replaced with mouse amino acid in the
; OTHER INFORMATION: humanized antibody."
US-08-053-171-15

Query Match          93.6%; Score 557; DB 1; Length 112;
Best Local Similarity 94.6%; Pred. No. 4.1e-47;
Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 DIVMTQSPVLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
DB 1 DIVMTQSPVLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVPDRFSGSGGTFTLKISRVEAEDVGVYCFQGSHPVPTFGGTKEIK 112
DB 61 SGVPRFSGSGGTFTLKISRVEAEDVGVYCFQGSHPVPTFGGTKEIK 112

RESULT 6
US-08-815-190A-14
; Sequence 14, Application US/08815190A
; Patent No. 6046310
; GENERAL INFORMATION:
; APPLICANT: Queen, Cary L.
; APPLICANT: Schneider, William P.
; APPLICANT: Vasquez, Maximiliano
; TITLE OF INVENTION: Fas Ligand Fusion Proteins and Their
; TITLE OF INVENTION: Uses
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/815,190A
; FILING DATE: 11-MAR-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/614,584
; FILING DATE: 13-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 011823-00671005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..112
; OTHER INFORMATION: /note= "mature light chain variable
; OTHER INFORMATION: region of humanized ABL 364 antibody"
US-08-815-190A-14

Query Match          93.6%; Score 557; DB 1; Length 112;
Best Local Similarity 94.6%; Pred. No. 4.1e-47;
Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 DIVMTQSPVLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
DB 1 DIVMTQSPVLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVPDRFSGSGGTFTLKISRVEAEDVGVYCFQGSHPVPTFGGTKEIK 112
DB 61 SGVPRFSGSGGTFTLKISRVEAEDVGVYCFQGSHPVPTFGGTKEIK 112

RESULT 7
US-08-482-882-66
; Sequence 66, Application US/08482882
; Patent No. 5773218
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/482,882
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/286,754
; FILING DATE:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5773218and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-482-882-66

Query Match          91.4%; Score 544; DB 1; Length 116;
Best Local Similarity 92.0%; Pred. No. 7.8e-46;
```

Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGEPASISCRSSQSLVHSGNTYLOWYLOKPGQSPQLLIYKVNRL 60
DB 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHSGNTYLOWYLOKPGQSPQLLIYKVNRF 64

QY 61 YGVPRFSGSGSDFTLKISRVEADVGVVYCFQSGSHVPWTFGGTKVEIK 112
DB 65 SGVPRFSGSGSDFTLKISRVEADVGVVYCSQSTHVPVTFGGTKVEIK 116

RESULT 8

US-08-483-389-66
; Sequence 66, Application US/08483389
; Patent No. 5811517

GENERAL INFORMATION:

; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-RELATED PROTEIN
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive/6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,389
; FILING DATE: 07-JUN-1995

CLASSIFICATION: 530

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992

; ATTORNEY/AGENT INFORMATION:
; NAME: Suh, Young J.
; REGISTRATION NUMBER: P-41,337

; REFERENCE/DOCKET NUMBER: 27866/32760

; TELEPHONE: (312) 474-6300

; TELEFAX: (312) 474-0448

; TELEX: (312) 474-6600

; INFORMATION FOR SEQ ID NO: 66:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 116 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: protein

US-08-483-389-66

Query Match 91.4%; Score 544; DB 1; Length 116;

Best Local Similarity 92.0%; Pred. No. 7.8e-46;

Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGEPASISCRSSQSLVHSGNTYLOWYLOKPGQSPQLLIYKVNRL 60
DB 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHSGNTYLOWYLOKPGQSPQLLIYKVNRF 64

Db 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHSGNTYLOWYLOKPGQSPQLLIYKVNRF 64

QY 61 YGVPRFSGSGSDFTLKISRVEADVGVVYCFQSGSHVPWTFGGTKVEIK 112
DB 65 SGVPRFSGSGSDFTLKISRVEADVGVVYCSQSTHVPVTFGGTKVEIK 116

RESULT 9

US-08-487-113D-66
; Sequence 66, Application US/08487113D
; Patent No. 5837822

GENERAL INFORMATION:

; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/487,113D
; FILING DATE:

CLASSIFICATION: 424

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992

; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5837822and, Greta E.
; REGISTRATION NUMBER: 35,302

; REFERENCE/DOCKET NUMBER: 32744

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300

; TELEFAX: (312) 474-0448

; TELEX: 25-3856

; INFORMATION FOR SEQ ID NO: 66:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 116 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: protein

US-08-487-113D-66

Query Match 91.4%; Score 544; DB 1; Length 116;

Best Local Similarity 92.0%; Pred. No. 7.8e-46;

Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGEPASISCRSSQSLVHSGNTYLOWYLOKPGQSPQLLIYKVNRL 60
DB 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHSGNTYLOWYLOKPGQSPQLLIYKVNRF 64

QY 61 YGVDRFSGSGTDTFTLKISRVEADVGYYVCFQGSHPVPTFGQGTKEIK 112
|||||
Db 65 SGVDRFSGSGTDTFTLKISRVEADVGYYVCSQSTHVPYTFGQGTKEIK 116
|||||

RESULT 10
US-08-473-503-66
; Sequence 66, Application US/08473503
; Patent No. 5869262
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/473,503
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5869262and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-473-503-66

Query Match 91.4%; Score 544; DB 1; Length 116;
Best Local Similarity 92.0%; Pred. No. 7.8e-46;
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;
QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVHNGNTYLYQWYLOKFGQSPQLLIYKVSRL 60
Db 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHNSGDTYLYHWYLOKFGQSPQLLIYKVSRL 64
QY 61 YGVDRFSGSGTDTFTLKISRVEADVGYYVCFQGSHPVPTFGQGTKEIK 112

Db 65 SGVDRFSGSGTDTFTLKISRVEADVGYYVCSQSTHVPYTFGQGTKEIK 116
|||||
RESULT 11
US-08-483-932-66
; Sequence 66, Application US/08483932
; Patent No. 5880268
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,932
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5880268and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-483-932-66

Query Match 91.4%; Score 544; DB 1; Length 116;
Best Local Similarity 92.0%; Pred. No. 7.8e-46;
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;
QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVHNGNTYLYQWYLOKFGQSPQLLIYKVSRL 60
Db 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHNSGDTYLYHWYLOKFGQSPQLLIYKVSRL 64
QY 61 YGVDRFSGSGTDTFTLKISRVEADVGYYVCFQGSHPVPTFGQGTKEIK 112
Db 65 SGVDRFSGSGTDTFTLKISRVEADVGYYVCSQSTHVPYTFGQGTKEIK 116
|||||

RESULT 12

US-08-720-420A-66
; Sequence 66, Application US/08720420A
; Patent No. 5989843
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/720,420A
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/487,113
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Williams, Joseph A., Jr.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 33282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-720-420A-66

Query Match 91.4%; Score 544; DB 1; Length 116;
Best Local Similarity 92.0%; Pred. No. 7.8e-46;
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIHNSNGNTYQLQWYLPKQPGSPQLLIYKVSRL 60
Db 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHNSNGDTYHLHWYLPKQPGSPQLLIYKVSRL 64
QY 61 YGVDPFRFSGSGGTDFTLKISRVEADVGYYCFQGSHPVPTFGGQTKVEIK 112

Db 65 SGVDPFRFSGSGGTDFTLKISRVEADVGYYCFQGSHPVPTFGGQTKVEIK 116

RESULT 13

US-08-714-017-66
; Sequence 66, Application US/08714017
; Patent No. 6040176
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/714,017
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6040176and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-714-017-66

Query Match 91.4%; Score 544; DB 2; Length 116;
Best Local Similarity 92.0%; Pred. No. 7.8e-46;
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIHNSNGNTYQLQWYLPKQPGSPQLLIYKVSRL 60
Db 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHNSNGDTYHLHWYLPKQPGSPQLLIYKVSRL 64
QY 61 YGVDPFRFSGSGGTDFTLKISRVEADVGYYCFQGSHPVPTFGGQTKVEIK 112
Db 65 SGVDPFRFSGSGGTDFTLKISRVEADVGYYCFQGSHPVPTFGGQTKVEIK 116

RESULT 14
US-08-475-680-66
; Sequence 66, Application US/08475680
; Patent No. 6100383
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemary
; TITLE OF INVENTION: ICM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESS: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6100383and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-475-680-66

Query Match 91.4%; Score 544; DB 2; Length 116;
Best Local Similarity 92.0%; Pred. No. 7.8e-46;
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;
Qy 1 DIVMTQPSLPLVPTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60
Db 5 DIVMTQPSLPLVPTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 64
Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGYVYCFQGSHPVPTFGQGTKEIK 112
Db 65 SCVPDRFSGSGGTDFTLKISRVEAEDVGYVYCSQSTHVPVPTFGQGTKEIK 116

RESULT 15
US-08-129-930B-95
; Sequence 95, Application US/08129930B
; Patent No. 5804187
; GENERAL INFORMATION:
; APPLICANT: do Couto Dr., Fernando J.R.
; APPLICANT: Ceriani Dr., Roberto L.
; APPLICANT: Peterson Dr., Jerry A.
; APPLICANT: Padlan Dr., Eduardo A.
; TITLE OF INVENTION: Analogue Peptides With Broad
; TITLE OF INVENTION: Carcinoma Specificity, and Kit and
; TITLE OF INVENTION: Diagnostic Vaccination and
; TITLE OF INVENTION: Therapeutic Methods
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: V. AMZEL & ASSOC.
; STREET: 2055 No. 5804187th Broadway, Suite 201
; CITY: Walnut Creek
; STATE: California
; COUNTRY: USA
; ZIP: 94596
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS 5.0
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/129,930B
; FILING DATE: September 30, 1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel Ph.D., Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: CRFCC-008A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 521-1333
; TELEFAX: (510) 521-3541
; TELEX: n.a.
; INFORMATION FOR SEQ ID NO: 95:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 131 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-129-930B-95

Query Match 91.3%; Score 543; DB 1; Length 131;
Best Local Similarity 90.2%; Pred. No. 1.1e-45;
Matches 101; Conservative 7; Mismatches 4; Indels 0; Gaps 0;
Qy 1 DIVMTQPSLPLVPTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60
Db 20 DVLMTQTPLSLPVTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 79
Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGYVYCFQGSHPVPTFGQGTKEIK 112
Db 80 SGVPDRFSGSGGTDFTLKISRVEAEDVGYVYCFQGSHPVPTFGGTKEIK 131

Search completed: January 10, 2006, 20:58:03
Job time : 21.8706 secs

Result No.	Score	Query		Length	DB	ID	Description
		Match	%				
1	519	87.2	248	2	K652Q7	9MURI	Q652q7 mus sp. b3 (
2	499	83.9	117	1	KV2E	HUMAN	P06309 homo sapien
3	499	83.9	133	1	KV2F	HUMAN	P06310 homo sapien
4	498	83.7	239	2	Q8NEK0	HUMAN	P08nek0 homo sapien
5	488	82.0	113	1	KV2D	HUMAN	P01617 homo sapien
6	484.5	81.4	114	2	Q9UL80	HUMAN	Q9ul80 homo sapien
7	483.5	81.3	115	2	Q5F210	MOUSE	Q5f210 mus musculu
8	482	81.0	113	1	KV2G	MOUSE	P01631 mus musculu
9	480	80.7	239	2	Q8TCG0	HUMAN	Q8tcg0 homo sapien
10	479	80.5	239	2	Q6P491	HUMAN	Q6p491 homo sapien
11	473.5	79.6	240	2	Q6P1H6	HUMAN	Q6p1h6 homo sapien
12	471.5	79.2	115	1	KV2A	HUMAN	P01614 homo sapien
13	471	79.2	119	2	Q53V88	MOUSE	Q53vp8 mus musculu
14	467	78.5	219	2	Q652C0	MOUSE	Q652c0 mus musculu
15	454	76.3	113	1	KV2B	HUMAN	P01615 homo sapien
16	450	75.6	239	2	Q585U8	MOUSE	Q58e8 mus musculu
17	449.5	75.5	112	1	KV2C	HUMAN	P01616 homo sapien
18	441	74.1	234	2	Q5XKG4	MOUSE	Q5xkg4 mus musculu
19	434	72.9	113	1	KV2F	MOUSE	P01630 mus musculu
20	430	72.3	113	1	KV2E	MOUSE	Q3976 mus musculu
21	419	70.4	112	2	Q6LEW8	MOUSE	Q6lew8 mus musculu
22	416	69.9	112	1	KV2D	MOUSE	P01629 mus musculu
23	398.5	67.0	108	1	KV1	CANFA	P01618 canis famill
24	397.5	66.8	134	1	KV4C	HUMAN	P06314 homo sapien
25	387	65.0	113	1	KV2C	MOUSE	P01628 mus musculu
26	385	64.7	112	1	KV2A	MOUSE	P01625 mus musculu
27	377.5	63.4	114	1	KV4A	HUMAN	P01625 homo sapien
28	377	63.4	129	1	KV3M	HUMAN	P18136 homo sapien
29	370	62.2	133	1	KV4B	HUMAN	P06313 homo sapien
30	368	61.8	109	1	KV3B	HUMAN	P01620 homo sapien
31	368	61.8	109	1	KV3D	HUMAN	P01622 homo sapien

```

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=84191506; PubMed=6325927;
RA Klobeck H.G., Solomon A., Zachau H.G.;
RT "Contribution of human V kappa II germ-line genes to light-chain
diversity.";
RL Nature 309:73-76(1984).
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC EMBL; Z00009; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR PIR; A01889; K2HUGM.
DR HSSP; Q99M37; 1191.
DR SMR; P06309; 5-117.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL <1 4
FT CHAIN 5 117 Ig kappa chain V-II region GM607.
FT REGION 5 27 Framework-1.
FT REGION 28 43 Complementarity-determining-1.
FT REGION 44 58 Framework-2.
FT REGION 59 65 Complementarity-determining-2.
FT REGION 66 97 Framework-3.
FT REGION 98 106 Complementarity-determining-3.
FT REGION 107 116 Framework-4.
FT DISULFID 27 97 By similarity.
FT NON_TER 1 1
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 12664 MW; 92C57DC719E558B1 CRC64;

Query Match 83.9%; Score 499; DB 1; Length 117;
Best Local Similarity 86.6%; Pred. No. 3.1e-44;
Matches 97; Conservative 2; Mismatches 13; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSLVHSGNTYLQWYLQKPGQSPQLLIYKVSRL 60
Db 5 DIVMTQSPSLPVTGPEPASISCRSSQSLVHSGNTYLQWYLQKPGQSPQLLIYKVSRL 64

QY 61 YGVDPFRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112
Db 65 SGVPDRFSGSGGTFTLKISRVEAEDVGVYYCMQGLTPQFPFGQGTKEIK 116

RESULT 3
KV2F HUMAN STANDARD; PRT; 133 AA.
AC P06310;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region RPMI 6410 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86041852; PubMed=2997711;

```

```

RA Klobeck H.G., Meindl A., Combratio G., Solomon A., Zachau H.G.;
RT "Human immunoglobulin kappa light chain genes of subgroups II and
III.";
RL Nucleic Acids Res. 13:6499-6513(1985).
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC EMBL; Z00020; CAA77315.1; -; Genomic_DNA.
DR PIR; A01890; K2HURP.
DR HSSP; Q99M37; 1191.
DR SMR; P06310; 21-133.
DR Ensembl; ENSG00000173758; Homo sapiens.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 20
FT CHAIN 21 133 Ig kappa chain V-II region RPMI 6410.
FT REGION 21 43 Framework-1.
FT REGION 44 59 Complementarity-determining-1.
FT REGION 60 74 Framework-2.
FT REGION 75 81 Complementarity-determining-2.
FT REGION 82 113 Framework-3.
FT REGION 114 122 Complementarity-determining-3.
FT REGION 123 132 Framework-4.
FT DISULFID 43 113 By similarity.
FT NON_TER 133 133
SQ SEQUENCE 133 AA; 14707 MW; 513CCAF3673009EE CRC64;

Query Match 83.9%; Score 499; DB 1; Length 133;
Best Local Similarity 83.9%; Pred. No. 3.7e-44;
Matches 94; Conservative 9; Mismatches 9; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSLVHSGNTYLQWYLQKPGQSPQLLIYKVSRL 60
Db 21 DIVMTQSPSLPVTGPEPASISCRSSQSLVSDGNTYLNWQRFQSPRRLLYKVSND 80

QY 61 YGVDPFRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112
Db 81 SGVPDRFSGSGGTFTLKISRVEAEDVGVYYCMQGTHTSWTFQGTKEIK 132

RESULT 4
Q8NEKO HUMAN PRELIMINARY; PRT; 239 AA.
ID Q8NEKO;
AC Q8NEKO;
DT 01-OCT-2002 (TRENBLrel. 22, Created)
DT 01-OCT-2002 (TRENBLrel. 22, Last sequence update)
DT 01-MAR-2004 (TRENBLrel. 26, Last annotation update)
DE IGKV1-5 protein.
GN Name=IGKV1-5;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Prostate;
RX MEDLINE=23389257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

```


RA Stapleton M., Soares M.B., Ronaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Uedlin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Ketterman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Prostate;
RA Director MSC Project;
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1601042;
RA Huber C., Klobeck H.G., Zachau H.G.;
RT "Ongoing V kappa-J kappa recombination after formation of a productive
RT V kappa-J kappa coding joint";
RL Eur. J. Immunol. 22:1561-1565 (1992).
RN [4]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=8436174;
RA Wagner S.D., Luzzatto L.;
RT "V kappa gene segments rearranged in chronic lymphocytic leukemia are
RT distributed over a large portion of the V kappa locus and do not show
RT somatic mutation";
RL Eur. J. Immunol. 23:391-397 (1993).
RN [5]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=8258341;
RA Klein R., Jaenichen R., Zachau H.G.;
RT "Expressed human immunoglobulin kappa genes and their hypermutation";
RL Eur. J. Immunol. 23:3248-3262 (1993).
DR EMBL, BC030814; AAH30814.1; -; mRNA.
DR PIR, S23638; S23638.
DR PIR, S34091; S34091.
DR PIR, S40342; S40342.
DR PIR, S40357; S40357.
DR HSP, P01834; I172.
DR SMR, Q8NEK0; 21-237.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; C1-set; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain.
SQ SEQUENCE 239 AA; 26024 MW; F5E20AD3B0552C0A CRC64;
Query Match 83.7%; Score 498; DB 2; Length 239;
Best Local Similarity 84.8%; Pred. No. 9.3e-44;
Matches 95; Conservative 5; Mismatches 12; Indels 0; Gaps 0;
QY 1 DIVMTQSPSLPVTPTGEPASISCRSSQSVHNSNGNTYLOWYLPKQSPQLLIYKSNRL 60
DB 21 DIVMTQSPSLPVTPTGEPASISCRSSQSLHSDGFDYLNWYLPKQSPQLLIYLSNRA 80
QY 61 YGVDPFRFSGSGGTDTFLKISRVEADVGYYFCQSGSHVPTFGQGTKEIK 112
DB 81 SGVPDRFSGSGGTDTFLKISRVEADVGYYICWQGLQTPQTFGQGTKEIK 132
RESULT 5

KV2D_HUMAN
ID KV2D_HUMAN STANDARD; PRT; 113 AA.
AC P01617;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region TEW.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE (BENCE-JONES PROTEIN TEW).
RX MEDLINE=74148480; PubMed=4596149;
RA Putnam F.W., Whitley E.J. Jr., Paul C., Davidson J.N.;
RT "Amino acid sequence of a kappa Bence Jones protein from a case of
RT primary amyloidosis";
RL Biochemistry 12:3763-3780 (1973).
RN [2]
RP PROTEIN SEQUENCE OF 1-27 (AMYLOID PROTEIN TEW).
RX MEDLINE=73166638; PubMed=4700495;
RA Terry W.D., Page D.L., Kimura S., Isobe T., Osseman E.F.,
RA Glenner G.G.;
RT "Structural identity of Bence Jones and amyloid fibril proteins in a
RT patient with plasma cell dyscrasia and amyloidosis";
RL J. Clin. Invest. 52:1276-1281 (1973).
CC -!- MISCELLANEOUS: The major amyloid protein appears to be identical
CC with the Bence Jones protein isolated from the same patient.
CC -!- MISCELLANEOUS: This protein was isolated from the urine of a
CC patient with plasma cell dyscrasia and amyloidosis.
CC -!- MISCELLANEOUS: The C region of this chain has the INV (1,2)
CC marker.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR PIR, A90370; K2HUTW.
DR HSP, Q99M37; I191.
DR SMR, P01617; 1-113.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig.v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Amyloid; Bence-Jones protein; Direct protein sequencing;
KW Immunoglobulin domain; Immunoglobulin V region.
FT REGION 1 23
FT REGION 24 39
FT REGION 40 54
FT REGION 55 61
FT REGION 62 93
FT REGION 94 102
FT REGION 103 112
FT REGION 103 112
FT DISULFID 23 93
FT NON_TER 113 113
SQ SEQUENCE 113 AA; 12316 MW; 0C3C38F81F1843CA CRC64;
Query Match 82.0%; Score 488; DB 1; Length 113;
Best Local Similarity 82.1%; Pred. No. 4.3e-43;
Matches 92; Conservative 8; Mismatches 12; Indels 0; Gaps 0;
QY 1 DIVMTQSPSLPVTPTGEPASISCRSSQSVHNSNGNTYLOWYLPKQSPQLLIYKSNRL 60
DB 1 DIVMTQSPSLPVTPTGEPASISCRSSQSLHSDGFDYLNWYLPKQSPQLLIYLSNRA 60
QY 61 YGVDPFRFSGSGGTDTFLKISRVEADVGYYFCQSGSHVPTFGQGTKEIK 112

[illegible]

RESULT 10

```
Q6P491 HUMAN PRELIMINARY; PRT; 239 AA.
AC Q6P491_
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Skin;
RX MEDLINE=2398257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallick D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Skin;
RA Strausberg R.;
RL Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC063599; AAH63599.1; -; mRNA.
DR HSSP; P01837; 1KCU.
DR SMR; Q6P491; 21-237.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; CI-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 1.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Hypothetical protein.
SQ SEQUENCE 239 AA; 26245 MW; CD7313DDFFD358B3 CRC64;
```

```
Query Match 80.5%; Score 479; DB 2; Length 239;
Best Local Similarity 80.4%; Pred. No. 9.1e-42;
Matches 90; Conservative 10; Mismatches 12; Indels 0; Gaps 0;
QY 1 DIVMTQSPVLTPTGEPASISCRSSQSIIVHSNGNTYLYQWYLRKPGQSPQLLIYKVSRL 60
DB 21 DIVMTQTPVLTGEPASISCRSSQSIIVHSNGNTYLYQWYLRKPGQSPQLLIYKVSRL 80
QY 61 YGVPRDPSGSGTGDTFTLKISRVEADGVVYCFQGSQSHV-PWTFGQGTKEIK 112
DB 81 SGVPRDPSGSGTGDTFTLKISRVEADGVVYCFQGSQSHV-PWTFGQGTKEIK 132
```

RESULT 11

RESULT 12
KV2A_HUMAN

```
Q6PIH6 HUMAN PRELIMINARY; PRT; 240 AA.
AC Q6PIH6_
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IGKV1-5 protein.
GN Name=IGKV1-5;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RX MEDLINE=22398257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallick D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RA Director MGC Project;
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC034142; AAH34142.1; -; mRNA.
DR HSSP; P01837; 1KB5.
DR SMR; Q6PIH6; 23-240.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; CI-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 1.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
SQ SEQUENCE 240 AA; 26234 MW; 188D4DD8BB781EC4 CRC64;
```

```
Query Match 79.6%; Score 473.5; DB 2; Length 240;
Best Local Similarity 82.3%; Pred. No. 3.5e-41;
Matches 93; Conservative 4; Mismatches 15; Indels 1; Gaps 1;
QY 1 DIVMTQSPVLTPTGEPASISCRSSQSIIVHSNGNTYLYQWYLRKPGQSPQLLIYKVSRL 60
DB 21 DIVMTQSPVLTGEPASISCRSSQSIIVHSNGNTYLYQWYLRKPGQSPQLLIYKVSRL 80
QY 61 YGVPRDPSGSGTGDTFTLKISRVEADGVVYCFQGSQSHV-PWTFGQGTKEIK 112
DB 81 SGVPRDPSGSGTGDTFTLKISRVEADGVVYCFQGSQSHV-PWTFGQGTKEIK 133
```

OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
[1]
RN NUCLEOTIDE SEQUENCE.
RP MEDLINE=86136012; PubMed=3937730;
RX Ollier P., Rocca-Serra J., Somme G., Theze J., Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
RT a germ-line network by paucigenic encoded Ab2 (anti-idiotypic)
RT antibodies in the GAT system.";
RL EMBO J. 4:3681-3688 (1985).
RN [2]
RN NUCLEOTIDE SEQUENCE OF 108-109.
RP Fougereau M.;
RA Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
RL EMBL; X03386; CAA27113.1; -, mRNA.
DR NON_TER 1 1
FT NON_TER 112 112
SQ SEQUENCE 112 AA; 12266 MW; C844B7881A89C18A CRC64;

Query Match 79.2%; Score 471; DB 2; Length 112;
Best Local Similarity 80.4%; Pred. No. 2.6e-41;
Matches 90; Conservative 10; Mismatches 12; Indels 0; Gaps 0;

QY 1 DIVMTQPSLPLVTPGEPASISCRSSQSVSHSNGNTYLOWLQKPGOSPOLLYKVSRL 60
DB 1 DIVMTQPSLPLVSLGDAQASISCRSSQSVISNGFTYLEWYLOKPGXXXXLLIYGISNRF 60
QY 61 YGVDPFSGSGSGTDTFTLKISRVEADVGYYVCFQGSHPWTFQGQTKVRIK 112
DB 61 SGVDPFSGSGSGTDTFTLKISRVEADVGYYVCFQGIHVPTFGGTRLEIK 112

RESULT 14
Q65ZC0 MOUSE
ID Q65ZC0 MOUSE PRELIMINARY; PRT; 219 AA.
AC Q65ZC0;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Kappa light chain C region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RN NUCLEOTIDE SEQUENCE.
RP STRAIN=Balb/c; TISSUE=Spleen;
RX MEDLINE=96319505; PubMed=8768802;
RA Klipp B., Schlaak M., Becker W.M.;
RT "Cloning and expression of a recombinant mouse Fab-fragment
RT recognising a defined linear epitope of Chironomus thummi major
RT allergen Chi I.";
RL Int. Arch. Allergy Immunol. 110:348-353 (1996).
DR EMBL; Z37499; CAA85724.1; -, mRNA.
DR SNR; Q65ZC0; 1-219.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGC1; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; 1.
DR NON_TER 1 1
FT NON_TER 219 219
SQ SEQUENCE 219 AA; 23944 MW; 7B1B82A14EAF8445 CRC64;

Query Match 78.5%; Score 467; DB 2; Length 219;
Best Local Similarity 79.5%; Pred. No. 1.5e-40;

```
Matches 89; Conservative 11; Mismatches 12; Indels 0; Gaps 0;
QY 1 DIVMTQSPSLPVLTGEPASISCRSSQSIIVHSNGNTYLQWYLOKPGQSPQLLIYKVSNRL 60
Db 1 ELVMTQSPSLVLTGEPASISCRSSQSIIVHSNGNTYLQWYLOKPGQSPQLLIYKVSNRF 60
QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDGIVYYCFQGSHPVPTFGGQTKVEIK 112
Db 61 SGVDPFRFSGSGGTDFTLKISRVEAEDLGIVYFCSQSTHVPGTFGGQTKLEIK 112

RESULT 15
KV2B HUMAN
ID KV2B HUMAN STANDARD; PRT; 113 AA.
AC P01615;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region FR.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=76253627; PubMed=821524;
RA Riesen W.F., Jaton J.-C.;
RT "Variable region sequence of the light chain from a Waldenstroms IgM
RT with specificity for phosphorylcholine.";
RL Biochemistry 15:3829-3833(1976).
CC -|- MISCELLANEOUS: This chain was isolated from a Waldenstrom's
CC macroglobulin that binds phosphorylcholine.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR PIR; A01886; K2HUFR.
DR HSP; Q99M37; I191.
DR SMR; P01615; 1-109.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region.
FT REGION 1 23 Framework-1.
FT REGION 24 39 Complementarity-determining-1.
FT REGION 40 54 Framework-2.
FT REGION 55 61 Complementarity-determining-2.
FT REGION 62 93 Framework-3.
FT REGION 94 102 Complementarity-determining-3.
FT REGION 103 112 Framework-4.
FT DISULFID 23 93 By similarity.
FT NON_TER 113 113
SQ SEQUENCE 113 AA; 12660 MW; 0C0DA39E46DB96BE CRC64;

Query Match 76.3%; Score 454; DB 1; Length 113;
Best Local Similarity 75.9%; Pred. No. 1.6e-39;
Matches 85; Conservative 12; Mismatches 15; Indels 0; Gaps 0;
QY 1 DIVMTQSPSLPVLTGEPASISCRSSQSIIVHSNGNTYLQWYLOKPGQSPQLLIYKVSNRL 60
Db 1 DVVMTQSPFLVLTGEPASIQCRSSQSLVYRGGTYLWYLOKPGQSPQLLIYLSYRD 60
QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDGIVYYCFQGSHPVPTFGGQTKVEIK 112
Db 61 SGVDPFRFSGSGGTDFTLKISRVEAEDLGIVYFCSQSTHVPGTFGGQTKLEIK 112
```

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:28:02 ; Search time 13.5124 Seconds
(without alignments)
797.508 Million cell updates/sec

Title: US-10-735-916A-65
Perfect score: 595
Sequence: 1 DIVMTQSLPLVTPGEPAS.....CFQGSHPVWTFGQTKVEIK 112

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 80:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	523	87.9	131	2 B39276	Ig light chain pre
2	522	87.7	113	2 PLO203	anti-DNA autoantib
3	516	86.7	219	2 S52028	Ig kappa chain - m
4	514	86.4	112	2 S58207	Ig light chain v r
5	514	86.4	112	2 S38719	Ig light chain v r
6	514	86.4	136	2 S40357	Ig kappa chain v-j
7	513	86.2	112	2 A31807	Ig kappa chain v r
8	513	86.2	219	2 PC4203	Ig kappa chain (mo
9	512	86.1	110	2 S26335	Ig kappa chain v r
10	509	85.5	114	2 A32967	Ig kappa chain v-i
11	508	85.4	118	2 PT0359	Ig kappa chain v r
12	508	85.4	131	2 B34904	Ig kappa chain pre
13	506	85.0	112	2 B31485	Ig kappa chain v r
14	504	84.7	112	2 C27887	Ig kappa chain v r
15	504	84.7	131	2 C34904	Ig kappa chain pre
16	502	84.4	112	2 A27887	Ig kappa chain v r
17	501	84.2	112	2 F27887	Ig kappa chain v r
18	501	84.2	115	2 S38715	Ig kappa chain v r
19	501	84.2	132	2 S26882	Ig kappa chain v r
20	500	84.0	114	2 B32967	Ig kappa chain v-i
21	500	84.0	135	2 S40342	Ig kappa chain - h
22	499	83.9	112	2 E27887	Ig kappa chain v r
23	499	83.9	117	1 K2HUGM	Ig kappa chain pre
24	499	83.9	131	2 B30577	Ig kappa chain pre
25	499	83.9	133	1 K2HURP	Ig kappa chain pre
26	499	83.9	219	2 S16112	Ig kappa chain v r
27	498	83.7	103	2 PH1043	Ig light chain v r
28	498	83.7	131	2 B34904	Ig kappa chain pre
29	498	83.7	131	2 B32513	Ig kappa chain pre

30	497	83.5	112	2 D28195	Ig kappa chain v r
31	496	83.4	111	2 PLO257	Ig kappa chain v r
32	496	83.4	112	2 A49715	Ig kappa chain v r
33	494.5	83.1	126	2 S40339	Ig kappa chain - h
34	494	83.0	112	2 S53750	antibody Fab Jel 1
35	494	83.0	113	2 B41940	Ig light chain v r
36	493	82.9	112	2 S32189	Ig kappa chain v r
37	493	82.9	225	2 JLO029	Ig kappa chain pre
38	492	82.7	142	2 S22902	Ig kappa chain v r
39	491	82.5	125	2 S40356	Ig kappa chain - h
40	491	82.5	133	1 A24452	Ig kappa chain pre
41	490	82.4	112	2 S58206	Ig light chain v r
42	490	82.4	112	2 D27887	Ig kappa chain v r
43	490	82.4	131	2 D29380	Ig kappa chain pre
44	490	82.4	133	2 S23230	Ig kappa chain pre
45	489	82.2	112	2 B27887	Ig kappa chain v r

ALIGNMENTS

RESULT 1

B39276
Ig light chain precursor V-D-J region (6-19) - mouse
C:Species: Mus musculus (house mouse)
C:Date: 18-Oct-1991 #sequence_revision 18-Oct-1991 #text_change 21-Jan-2000
C:Accession: B39276
R:Reininger, L.; Berney, T.; Shibata, T.; Spertini, F.; Merino, R.; Izui, S.
Proc. Natl. Acad. Sci. U.S.A. 87, 10038-10042, 1990
A:Title: Cryoglobulinemia induced by a murine ICG3 rheumatoid factor: skin vasculitis an
A:Reference number: A39276; MUID:91088540; PMID:2263605
A:Accession: B39276
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-131 <REI>
A:Cross-references: UNIPARC:UPI0000115153; GB:M55313; NID:g198095; PIDN:AAA63385.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:35-114/Domain: immunoglobulin homology <IMM>

Query Match 87.9%; Score 523; DB 2; Length 131;
Best Local Similarity 86.6%; Pred. No. 2.1e-42;
Matches 97; Conservative 10; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DIVMTQSLPLVTPGEPASISCRSSQSIHVSNGNTYLOWYLQKPGQSPQLLIYKVSRL 60
Db 20 DVLMTQTPLSLPVSLGDAQSISCRSSQSIHVSNGNTYLEWYLQKPGQSPKLLIYKVSNR 79
Qy 61 YGVDPDRFGSGSGTDTFTLKISRVEAEDVGVVYCFQGSHPVWTFGQTKVEIK 112
Db 80 SGVDPDRFGSGSGTDTFTLKISRVEAEDLGVVYCFQGSHPVPTFGSGTKLEIK 131

RESULT 2

PLO203
anti-DNA autoantibody BV17-31, kappa chain V region - mouse (fragment)
C:Species: Mus musculus (house mouse)
C:Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 21-Jan-2000
C:Accession: PLO203
R:Smith, R.G.; Voss Jr., E.W.
Mol. Immunol. 27, 463-470, 1990
A:Title: Variable region primary structure of monoclonal anti-DNA autoantibodies from N
A:Reference number: PLO198; MUID:90309768; PMID:2114528
A:Accession: PLO203
A:Molecule type: mRNA
A:Residues: 1-113 <SML>
A:Cross-references: UNIPARC:UPI0000113786; GB:X53643; NID:g50196; PIDN:CNA37694.1; PID:g
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:16-95/Domain: immunoglobulin homology <IMM>
F:24-39/Region: complementarity-determining 1
F:55-61/Region: complementarity-determining 2
F:94-102/Region: complementarity-determining 3
F:101-113/Region: D region

```
Query Match      87.7%; Score 522; DB 2; Length 113;
Best Local Similarity 86.6%; Pred. No. 2.3e-42;
Matches 97; Conservative 10; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWLYLQKPGQSPQLLIYKVSRL 60
Db 1 DVMTQTPLSLPVSLGDAQSIISCRSSQSIIVHSNGNTYLEWLYLQKPGQSPKLLIYKVSRRF 60

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVVYCFQGSHPVPTFGQGTKEIK 112
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDLVGVVYCFQGSHPVPTFGGTKEIK 112

RESULT 3
S58207
Ig kappa chain - mouse
C:Species: Mus musculus (house mouse)
C:Date: 07-May-1995 #sequence_revision 21-Jul-1995 #text_change 21-Jan-2000
C:Accession: S52028
R:van Engelen, F.; Schouten, A.; Moltzoff, J.W.; Roosien, J.; Dirkse, W.G.; Schots, A.;
submitted to the EMBL Data Library, August 1994
A:Description: Coordinate expression of antibody subunit genes yields high levels of fun
A:Reference number: S52028
A:Accession: S52028
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-219 <V>
A:Cross-references: UNIPARC:UPI0000114B22; EMBL:I35138; NID:G522336; PIDN:AAA67525.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
P:16-95/Domain: immunoglobulin homology <IMM>

Query Match      86.7%; Score 516; DB 2; Length 219;
Best Local Similarity 87.5%; Pred. No. 1.8e-41;
Matches 98; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWLYLQKPGQSPQLLIYKVSRL 60
Db 1 DVMTQTPLSLPVSLGDAQSIISCRSSQSIIVHSNGNTYLEWLYLQKPGQSPKLLIYKVSRRF 60

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVVYCFQGSHPVPTFGQGTKEIK 112
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDLVGVVYCFQGSHPVPTFGGTKEIK 112

RESULT 4
S58207
Ig light chain V region anti-F(ab')2 - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 13-Jan-1996 #sequence_revision 19-Apr-1996 #text_change 21-Jan-2000
C:Accession: S58207
R:Welschof, M.; Terness, P.; Stanescu, D.; Zewe, M.; Hain, C.H.; Doebel, S.; Breitling,
submitted to the EMBL Data Library, July 1995
A:Description: Characterization of heavy and light chain immunoglobulin variable region
A:Reference number: S58206
A:Accession: S58207
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-112 <WEL>
A:Cross-references: UNIPARC:UPI0000116253; EMBL:X89056; NID:G929642; PIDN:CAA61443.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
P:16-95/Domain: immunoglobulin homology <IMM>

Query Match      86.4%; Score 514; DB 2; Length 112;
Best Local Similarity 87.5%; Pred. No. 1.3e-41;
Matches 98; Conservative 2; Mismatches 12; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWLYLQKPGQSPQLLIYKVSRL 60
Db 1 DIVMTQSPSLPVTPTGEPASISCRSSQSLHSHNGNTYLDWLYLQKPGQSPQLLIYLGSRNA 60

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVVYCFQGSHPVPTFGQGTKEIK 112
Db 81 SGVPDRFSGSGGTDTFTLKISRVEAEDLVGVVYCFQGSHPVPTFGQGTKEIK 132

RESULT 7
A31807
Ig kappa chain V region (PAC1) - mouse
C:Species: Mus musculus (house mouse)
C:Date: 20-Jul-1989 #sequence_revision 20-Jul-1989 #text_change 09-Jul-2004
```

```
Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVVYCFQGSHPVPTFGQGTKEIK 112
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDLVGVVYCFQGSHPVPTFGQGTKEIK 112

RESULT 5
S38719
Ig light chain V region - mouse
C:Species: Mus musculus (house mouse)
C:Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 20-Jun-2000
C:Accession: S38719
R:Cimanis, A.Y.
submitted to the EMBL Data Library, November 1993
A:Reference number: S38713
A:Accession: S38719
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-112 <CIM>
A:Cross-references: UNIPARC:UPI0000117543; EMBL:X76021; NID:G416112; PIDN:CAA53608.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
P:16-95/Domain: immunoglobulin homology <IMM>

Query Match      86.4%; Score 514; DB 2; Length 112;
Best Local Similarity 86.6%; Pred. No. 1.3e-41;
Matches 97; Conservative 9; Mismatches 6; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWLYLQKPGQSPQLLIYKVSRL 60
Db 1 DIVMTQTPLSLPVSLGDAQSIISCRSSQSIIVSNGNTYLEWLYLQKPGQSPKLLIYKVSRRF 60

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVVYCFQGSHPVPTFGQGTKEIK 112
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDLVGVVYCFQGSHPVPTFGAGTKLELK 112

RESULT 6
S40357
Ig kappa chain V-J-C region - human
C:Species: Homo sapiens (man)
C:Date: 19-May-1994 #sequence_revision 26-May-1995 #text_change 31-Dec-2004
C:Accession: S40357
R:Klein, R.; Jaenichen, R.; Zachau, H.G.
Bur. J. Immunol. 23, 3248-3271, 1993
A:Title: Expressed human immunoglobulin chi genes and their hypermutation.
A:Reference number: S40312; MUID:94080891; PMID:8258341
A:Accession: S40357
A>Status: preliminary; translation not shown
A:Molecule type: mRNA
A:Residues: 1-136 <KLE>
A:Cross-references: UNIPROT:Q8NEK0; UNIPARC:UPI0000176CA8; EMBL:X72467
C:Superfamily: immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
P:36-115/Domain: immunoglobulin homology <IMM>

Query Match      86.4%; Score 514; DB 2; Length 136;
Best Local Similarity 87.5%; Pred. No. 1.6e-41;
Matches 98; Conservative 2; Mismatches 12; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTPTGEPASISCRSSQSIIVHSNGNTYLOWLYLQKPGQSPQLLIYKVSRL 60
Db 21 DIVMTQSPSLPVTPTGEPASISCRSSQSLHSHNGNTYLDWLYLQKPGQSPQLLIYLGSRNA 80

Qy 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVVYCFQGSHPVPTFGQGTKEIK 112
Db 81 SGVPDRFSGSGGTDTFTLKISRVEAEDLVGVVYCFQGSHPVPTFGQGTKEIK 132

RESULT 7
A31807
Ig kappa chain V region (PAC1) - mouse
C:Species: Mus musculus (house mouse)
C:Date: 20-Jul-1989 #sequence_revision 20-Jul-1989 #text_change 09-Jul-2004
```


C;Accession: A31807
J;Taub, R.; Gould, R.J.; Garsky, V.M.; Ciccarone, T.M.; Hoxie, J.; Friedman, P.A.; Shatto
J. Biol. Chem. 264, 259-265, 1989
A;Title: A monoclonal antibody against the platelet fibrinogen receptor contains a sequ
A;Reference number: A31807; MUID:89079661; PMID:2909518
A;Accession: A31807
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-112 <TAU>
A;Cross-references: UNIPROT:Q9M37; UNIPARC:UPI00001424F9
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.2%; Score 513; DB 2; Length 112;
Best Local Similarity 84.8%; Pred. No. 1.6e-41;
Matches 95; Conservative 12; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYQLQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVLMTQTPLSLPVSLGDAQSISCRSSQSIIVHSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 60

Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKVEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKLEIK 112

RESULT 8
PC4203
Ig kappa chain (monoclonal antibody MabaA34) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 31-Dec-1996 #sequence_revision 31-Dec-1996 #text_change 11-Jan-2000
C;Accession: PC4203
R;Kwak, J.W.; Lee, D.I.; Choi, B.K.; Cho, W.K.; Lee, S.H.; Park, Y.B.; Han, M.H.
Gene 173, 257-259, 1996
A;Title: Cloning and characterization of cDNAs coding for heavy and light chains of a m
A;Reference number: PC4202; MUID:97082978; PMID:8964510
A;Accession: PC4203
A;Molecule type: mRNA
A;Residues: 1-219 <KWA>
A;Cross-references: UNIPARC:UPI00001157E4; GB:U29147; NID:g1594225; PIDN:AACS2821.1; PID
C;Comment: This protein is specific for human plasma apolipoprotein A-I of high-density
C;Superfamily: immunoglobulin V region; immunoglobulin homology
F;1-112/Domain: V region #status predicted <VRG>
F;113-219/Domain: C region #status predicted <CRG>

Query Match 86.2%; Score 513; DB 2; Length 219;
Best Local Similarity 85.7%; Pred. No. 3.4e-41;
Matches 96; Conservative 10; Mismatches 6; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYQLQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVLMTQTPLSLPVSLGDAQSISCRSSQSIIVHSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 60

Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKVEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKLEIK 112

RESULT 9
S26335
Ig kappa chain V region - mouse
C;Species: Mus musculus (house mouse)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C;Accession: S26335
R;Stark, S.E.; Caton, A.J.
J. Exp. Med. 174, 613-624, 1991
A;Title: Antibodies that are specific for a single amino acid interchange in a protein e
A;Reference number: S26309; MUID:91341421; PMID:1908510
A;Accession: S26335
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-110 <STA>

A;Cross-references: UNIPARC:UPI0000115F78; EMBL:X59183; NID:g52314; PIDN:CAA41893.1; PII
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.1%; Score 512; DB 2; Length 110;
Best Local Similarity 86.4%; Pred. No. 1.9e-41;
Matches 95; Conservative 10; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYQLQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVLMTQTPLSLPVSLGDAQSISCRSSQSIIVHSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 60

Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKVEIK 110
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKLEIK 110

RESULT 10
A32967
Ig kappa chain V-II region TE33 - mouse
C;Species: Mus musculus (house mouse)
C;Date: 29-Jan-1990 #sequence_revision 29-Jan-1990 #text_change 21-Jan-2000
C;Accession: A32967
R;Levy, R.; Assulin, O.; Scherf, T.; Levitt, M.; Anglistter, J.
Biochemistry 28, 7168-7175, 1989
A;Title: Probing antibody diversity by 2D NMR: comparison of amino acid sequences, pred
A;Reference number: A32967; MUID:90057406; PMID:2819059
A;Accession: A32967
A;Status: preliminary; nucleic acid sequence not shown; not compared with conceptual tr
A;Molecule type: mRNA
A;Residues: 1-114 <LEW>
A;Cross-references: UNIPARC:UPI0000114F5D; GB:M30481; NID:g197157; PIDN:AAA38935.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;16-95/Domain: immunoglobulin homology <IMM>

Query Match 85.5%; Score 509; DB 2; Length 114;
Best Local Similarity 83.0%; Pred. No. 3.8e-41;
Matches 93; Conservative 13; Mismatches 6; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYQLQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVLMTQTPLSLPVSLGDAQSISCRSSQSIIVHSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 60

Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKVEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKLEIK 112

RESULT 11
PT0359
Ig kappa chain V region (R4A.12) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 31-Mar-1992 #sequence_revision 31-Mar-1992 #text_change 09-Jul-2004
C;Accession: PT0359
R;Shefner, R.; Kleiner, G.; Turken, A.; Papazian, L.; Diamond, B.
J. Exp. Med. 173, 287-296, 1991
A;Title: A novel class of anti-DNA antibodies identified in BALB/c mice.
A;Reference number: PT0352; MUID:91108325; PMID:1988536
A;Accession: PT0359
A;Molecule type: mRNA
A;Residues: 1-118 <SHE>
A;Cross-references: UNIPROT:Q8VCI6; UNIPARC:UPI0000176AF2
A;Experimental source: strain BALB/c
C;Comment: This protein is an anti-double-stranded DNA antibody.
C;Superfamily: immunoglobulin V region; immunoglobulin homology
F;19-98/Domain: immunoglobulin homology <IMM>

Query Match 85.4%; Score 508; DB 2; Length 118;
Best Local Similarity 83.9%; Pred. No. 5e-41;
Matches 94; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

```
Qy 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLTQWYLOKPGQSPQLLIYKVS NRL 60
Db 4 DVMVTQTPLSLPVSIGDQASISCRSSQSLVHSNGNTYLHWYLOKPGQSPKLLIYKVS NRF 63

Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTWTFGGTKVEIK 112
Db 64 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQSQTHTVPWTFGGGTTKLEIK 115

RESULT 12
B31485
Ig kappa chain precursor V region (12-40 and 5-14) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 27-Jul-1990 #sequence_revision 27-Jul-1990 #text_change 21-Jul-2000
C:Accession: B314904; H34903
R:Bedzyk, W.D.; Herron, J.N.; Edmondson, A.B.; Voss Jr., E.W.
J. Biol. Chem. 265, 133-138, 1990
A:Title: Active site structure and antigen binding properties of idiotypically cross-reactive
A:Superfamily: immunoglobulin V region; immunoglobulin homology
A:Reference number: A34903; MUID:90094387; PMID:2104617
A:Accession: B314904
A:Status: preliminary; not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-131 <BED>
A:Cross-references: UNIPROT:Q8VCI6; GB:M32384; GB:J05237; GB:J05238; NID:G639656;
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:35-114/Domain: immunoglobulin homology <IMM>

Query Match 85.4%; Score 508; DB 2; Length 131;
Best Local Similarity 83.9%; Pred. No. 5.6e-41;
Matches 94; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLTQWYLOKPGQSPQLLIYKVS NRL 60
Db 20 DVMVTQTPLSLPVSIGDQASISCRSSQSLVHSNGNTYLHWYLOKPGQSPKLLIYKVS NRF 79

Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTWTFGGTKVEIK 112
Db 80 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQSQTHTVPWTFGGGTTKLEIK 131

RESULT 13
B31485
Ig kappa chain V region (4-4-20) - mouse (fragment)
C:Species: Mus musculus (house mouse)
C>Date: 31-Jul-1989 #sequence_revision 31-Jul-1989 #text_change 09-Jul-2004
C:Accession: B31485
R:Bedzyk, W.D.; Johnson, L.S.; Riordan, G.S.; Voss Jr., E.W.
J. Biol. Chem. 264, 1565-1569, 1989
A:Title: Comparison of variable region primary structures within an anti-fluorescein idiotype
A:Reference number: A31485; MUID:89109167; PMID:2492278
A:Accession: B31485
A:Status: preliminary
A:Molecule type: protein
A:Residues: 1-112 <BED>
A:Cross-references: UNIPROT:Q8VCI6; UNIPARC:UPI0000176AF8
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 85.0%; Score 506; DB 2; Length 112;
Best Local Similarity 83.0%; Pred. No. 7.2e-41;
Matches 93; Conservative 12; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLTQWYLOKPGQSPQLLIYKVS NRL 60
Db 1 DVMVTQTPLSLPVSIGDQASISCRSSQSLVHSNGNTYLHWYLOKPGQSPKLLIYKVS NRF 60

Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTWTFGGTKVEIK 112
Db 61 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQSQTHTVPWTFGGGTTKLEIK 112
```

```
RESULT 14
C27887
Ig kappa chain V region (H37-82) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 15-Dec-1988 #sequence_revision 15-Dec-1988 #text_change 09-Jul-2004
C:Accession: C27887
R:Caton, A.J.; Brownlee, G.G.; Staudt, L.M.; Gerhard, W.
EMBO J. 5, 1577-1587, 1986
A:Title: Structural and functional implications of a restricted antibody response to a dominant
A:Reference number: A91043; MUID:86300658; PMID:2427335
A:Accession: C27887
A:Molecule type: DNA
A:Residues: 1-112 <CAT>
A:Cross-references: UNIPROT:Q8VCI6; UNIPARC:UPI0000176A17
A:Experimental source: strain Balb/c
A:Note: This sequence was determined from the germline gene
A:Comment: This chain was isolated from a hybridoma protein that binds influenza virus
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 84.7%; Score 504; DB 2; Length 112;
Best Local Similarity 83.0%; Pred. No. 1.1e-40;
Matches 93; Conservative 11; Mismatches 8; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLTQWYLOKPGQSPQLLIYKVS NRL 60
Db 1 DVMVTQTPLSLPVSIGDQASISCRSSQSLVHSNGNTYLHWYLOKPGQSPKLLIYKVS NRF 60

Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTWTFGGTKVEIK 112
Db 61 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQSQTHTVPWTFGGGTTKLEIK 112

RESULT 15
C34904
Ig kappa chain precursor V region (3-24) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 27-Jul-1990 #sequence_revision 27-Jul-1990 #text_change 09-Jul-2004
C:Accession: C34904; I31485
R:Bedzyk, W.D.; Herron, J.N.; Edmondson, A.B.; Voss Jr., E.W.
J. Biol. Chem. 265, 133-138, 1990
A:Title: Active site structure and antigen binding properties of idiotypically cross-reactive
A:Reference number: A34903; MUID:90094387; PMID:2104617
A:Accession: C34904
A:Status: preliminary; not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-131 <BED>
A:Cross-references: UNIPROT:Q8VCI6; UNIPARC:UPI00001767A8
R:Bedzyk, W.D.; Johnson, L.S.; Riordan, G.S.; Voss Jr., E.W.
J. Biol. Chem. 264, 1565-1569, 1989
A:Title: Comparison of variable region primary structures within an anti-fluorescein idiotype
A:Reference number: A31485; MUID:89109167; PMID:2492278
A:Accession: I31485
A:Status: preliminary
A:Molecule type: protein
A:Residues: 20-52 <BE2>
A:Cross-references: UNIPARC:UPI00001767A9
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:35-114/Domain: immunoglobulin homology <IMM>

Query Match 84.7%; Score 504; DB 2; Length 131;
Best Local Similarity 83.0%; Pred. No. 1.3e-40;
Matches 93; Conservative 10; Mismatches 9; Indels 0; Gaps 0;

Qy 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLTQWYLOKPGQSPQLLIYKVS NRL 60
Db 20 DVMVTQTPLSLPVSIGDQASISCRSSQSLVHSNGNTYLHWYLOKPGQSPKLLIYKVS NRF 79

Qy 61 YGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTWTFGGTKVEIK 112
Db 80 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQSQTHTVPWTFGGGTTKLEIK 131
```

Search completed: January 10, 2006, 20:55:14
Job time : 13.5124 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:07:41 ; Search time 77.3134 Seconds
(without alignments)
636.505 Million cell updates/sec

Title: US-10-735-916A-65
Perfect score: 595
Sequence: 1 DIVMTQSLPLVTPGEPAS.....CFQGSHPWTFPGTKVEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq 21:*

1: geneseqp1980a:*

2: geneseqp1990a:*

3: geneseqp2000a:*

4: geneseqp2001a:*

5: geneseqp2002a:*

6: geneseqp2003a:*

7: geneseqp2003bs:*

8: geneseqp2004a:*

9: geneseqp2005a:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	595	100.0	112	7	ADJ76899 Anti-IGF-
2	595	100.0	112	9	ADZ67069 Human ant
3	595	100.0	131	7	ADJ76901 Anti-IGF-
4	595	100.0	131	9	ADZ67071 Human ant
5	594	99.8	112	7	ADJ76895 Anti-IGF-
6	594	99.8	112	9	ADZ67065 Human ant
7	594	99.8	131	7	ADJ76897 Anti-IGF-
8	594	99.8	131	9	ADZ67067 Human ant
9	570	95.8	114	8	ADP84950 Variable
10	567	95.3	112	5	AAE15713 Mouse mon
11	566	95.1	114	8	ADP84948 Variable
12	564	94.8	112	5	AAE15712 Mouse mon
13	564	94.8	112	6	ABP72125 FGF-8 rel
14	564	94.8	112	7	ADZ67071 Human ant
15	564	94.8	114	8	ADP84946 Variable
16	564	94.8	114	8	ADP84951 Variable
17	564	94.8	131	7	ADP84950 Anti-IGF-
18	563	94.6	114	8	ADP84949 Variable
19	562	94.5	112	5	AAE15711 Mouse mon
20	560	94.1	114	8	ADP84944 Variable
21	559	93.9	112	7	ADZ67065 Anti-IGF-
22	559	93.9	112	7	ADZ67065 Human ant
23	559	93.9	114	8	ADP84947 Variable
24	559	93.9	132	7	AAZ42969 Humanised

25	557	93.6	112	2	AAE32239 Humanised
26	557	93.6	112	2	AAW27145 Mature li
27	557	93.6	112	3	AAZ87571 Humanised
28	557	93.6	112	7	ADZ67071 Anti-IGF-
29	557	93.6	114	8	ADP84945 Variable
30	556	93.4	112	6	ABP72129 FGF-8 rel
31	556	93.4	112	7	ADZ67071 Anti-IGF-
32	556	93.4	112	9	ADZ67071 Amino aci
33	556	93.4	114	8	ADP84952 Variable
34	553	92.9	114	8	ADP84943 Variable
35	552	92.8	112	7	ADZ67065 Anti-IGF-
36	549	92.3	112	7	ADJ80420 Hybrid hu
37	549	92.3	132	7	ADH61998 Human ant
38	547	91.9	112	6	ABR40268 Amino aci
39	547	91.9	112	7	ADZ67067 Humanised
40	547	91.9	112	7	ADZ67067 Anti-IGF-
41	547	91.9	112	7	ADJ80422 Murine an
42	547	91.9	112	9	ADZ67065 Anti-CCR4
43	547	91.9	112	9	AEA33234 CC chemok
44	546	91.8	112	6	ABR40272 Amino aci
45	546	91.8	112	7	ADZ67069 Humanised

ALIGNMENTS

RESULT 1

ADJ76899

ID ADJ76899 standard; protein; 112 AA.

XX

XX ADJ76899;

AC

DT 06-MAY-2004 (first entry)

XX

DE Anti-IGF-1R related protein #14.

XX

KW cytotatic; antipsoriatic; antibody;

KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;

KW or epidermal growth factor receptor; EGFR; signal transduction pathway;

KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;

KW CDR.

OS Homo sapiens.

XX

XX WO2003059951-A2.

PN 24-JUL-2003.

PD

XX

XX 20-JAN-2003; 2003WO-FR000178.

XX

XX 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.

XX

XX 07-MAY-2002; 2002FR-000005753.

XX

XX (FABR) FABRE MEDICAMENT SA PIERRE.

PA

XX

XX Goetsch L, Corvaia N, Leger O;

XX

XX WPI; 2003-569653/53.

XX

XX New antibodies that bind to human insulin-like growth factor receptor,

XX useful for treatment, prevention and diagnosis of cancers.

XX

XX Disclosure; SEQ ID NO 65; 164pp; French.

XX

XX The invention relates to an isolated antibody (Ab), and its functional

XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-

XX IR) and optionally: (i) inhibit natural binding of insulin-like growth

XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine

XX kinase activity of IGF-1R. Ab and its fragments are used to prevent or

XX treat diseases associated with overexpression and/or abnormal activity of

XX IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with

XX hyperactivity of signal transduction pathways mediated by interaction of

CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.
 XX
 SQ Sequence 112 AA;

Query Match 100.0%; Score 595; DB 7; Length 112;
 Best Local Similarity 100.0%; Pred. No. 2.5e-43;
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLIQWYLQKPGQSPQLLIYKVSNRL 60
 DB 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLIQWYLQKPGQSPQLLIYKVSNRL 60
 QY 61 YGVDPDRFSGSGGTDFTLKISRVEADVGYYCYFCGSHVPWTFGGTKVEIK 112
 DB 61 YGVDPDRFSGSGGTDFTLKISRVEADVGYYCYFCGSHVPWTFGGTKVEIK 112

RESULT 2
 ID ADZ67069 standard; protein; 112 AA.
 XX
 AC ADZ67069;
 XX
 DT 30-JUN-2005 (first entry)
 XX
 DE Human antibody 7C10 2 light chain variable region SEQ ID NO:65.
 XX
 KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW light chain variable region.

XX Homo sapiens.
 XX US2005084906-A1.
 XX
 PD 21-APR-2005.
 XX
 PF 16-DEC-2003; 2003US-00735916.
 XX
 PR 18-JAN-2002; 2002FR-00000653.
 PR 18-JAN-2002; 2002FR-00000654.
 PR 07-MAY-2002; 2002FR-00005753.
 PR 20-JAN-2003; 2003WO-FR000178.
 PR 11-JUL-2003; 2003FR-00008538.
 XX
 PA (GOET/) GOETSCH L.
 PA (CORV/) CORVAIA N.
 PA (LEGE/) LEGER O.
 PA (DUFL/) DUFLOS A.
 PA (HAUJ/) HAEUW J.
 PA (BECK/) BECK A.

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
 XX WPI; 2005-321968/33.
 XX
 PT Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 PT antibody or its functional fragment, being capable of binding human IGF-
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,
 PT useful for treating cancer.

XX Example 12; SEQ ID NO 65; 125pp; English.

CC The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-IR and, if necessary, capable of
 CC specifically inhibiting tyrosine kinase activity of the receptor,
 CC comprising a light or heavy chain having at least one fully defined 16 amino
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-IR and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
 CC the administration of the medicament does not induce or only slightly
 CC induces secondary effects connected with inhibition of the insulin
 CC receptor. The antibody is useful for preparation of a medicament intended
 CC to inhibit the transformation of normal cells into cells with tumoral
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
 CC useful for preparation of a medicament intended to inhibit the growth
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a
 CC medicament intended for prevention or for the treatment of cancer, where
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 CC preparation of a medicament intended for the prevention or for the
 CC treatment of psoriasis. (I) is useful in preparation of a medicament
 CC intended for the specific targeting of a biologically active compound to
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
 CC is useful for in vitro diagnosis of illnesses induced by an
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
 CC starting from a biological sample in which the abnormal presence, of IGF-
 CC IR and/or EGFR receptor is suspected, which involves contacting the
 CC biological sample with (I), which is optionally labeled. The present
 CC sequence is used in the exemplification of the invention.

SQ Sequence 112 AA;

Query Match 100.0%; Score 595; DB 9; Length 112;
 Best Local Similarity 100.0%; Pred. No. 2.5e-43;
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLIQWYLQKPGQSPQLLIYKVSNRL 60
 DB 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLIQWYLQKPGQSPQLLIYKVSNRL 60
 QY 61 YGVDPDRFSGSGGTDFTLKISRVEADVGYYCYFCGSHVPWTFGGTKVEIK 112
 DB 61 YGVDPDRFSGSGGTDFTLKISRVEADVGYYCYFCGSHVPWTFGGTKVEIK 112

RESULT 3
 ID ADJ76901 standard; protein; 131 AA.
 XX
 AC ADJ76901;

XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Anti-IGF-IR related protein #15.
 XX

KW cytosolic; antipsoriatic; antibody;
 KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
 KW CDR.

XX Homo sapiens.
 XX WO2003059951-A2.
 XX
 PD 24-JUL-2003.
 XX

PF 20-JAN-2003; 2003WO-FR000178.
XX 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
XX (FABR) FABRE MEDICAMENT SA PIERRE.
XX
XX Goetsch L, Corvaia N, Leger O;
XX WPI; 2003-569653/53.
XX
XX New antibodies that bind to human insulin-like growth factor receptor,
XX useful for treatment, prevention and diagnosis of cancers.
XX
XX Disclosure; SEQ ID NO 67; 164pp; French.
XX
XX The invention relates to an isolated antibody (Ab), and its functional
XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
XX IR) and optionally: (i) inhibit natural binding of insulin-like growth
XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
XX kinase activity of IGF-1R. Ab and its fragments are used to prevent or
XX treat diseases associated with overexpression and/or abnormal activity of
XX IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
XX hyperactivity of signal transduction pathways mediated by interaction of
XX these receptors with their ligands. Especially they inhibit
XX transformation of normal cells to tumor cells, inhibit growth and/or
XX proliferation of tumor cells, so are useful against cancers of the
XX prostate, lung, breast, endometrium and colon, also osteosarcoma, and
XX also for treating psoriasis. Ab are also used to diagnose diseases caused
XX by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
XX protein sequence used to generate the Ab of the invention.
XX
XX Sequence 131 AA;
XX
XX Query Match 100.0%; Score 595; DB 7; Length 131;
XX Best Local Similarity 100.0%; Pred. No. 3e-43;
XX Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLQWYLPKPGQSPQLLIYKVSRL 60
XX 20 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYQLQWYLPKPGQSPQLLIYKVSRL 79
XX
XX 61 YGVDPFRFGSGSGTDTFLKISRVEADVGYYVYCFQGSHPVMTFGGQTKVEIK 112
XX 80 YGVDPFRFGSGSGTDTFLKISRVEADVGYYVYCFQGSHPVMTFGGQTKVEIK 131
XX
XX
XX RESULT 4
XX ADZ67071
XX ID ADZ67071 standard; protein; 131 AA.
XX
XX AC ADZ67071;
XX
XX 30-JUN-2005 (first entry)
XX
XX Human antibody 7C10 2 light chain variable region SEQ ID NO:67.
XX
XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
XX neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
XX musculoskeletal disease; respiratory disease; lung tumor;
XX endocrine disease; gynecology and obstetrics; breast tumor;
XX endometrial carcinoma; gastrointestinal disease; colon tumor;
XX antipsoriatic; psoriasis; dermatological disease; immune disorder;
XX light chain variable region.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX FH 1..19
XX FT Peptide /note= "leader peptide"
XX FT 43..58
XX FT Region /note= "CDR1"
XX FT

FT Region 74..80
FT FT /note= "CDR2"
FT FT 113..121
FT FT /note= "CDR3"
XX
XX PN US2005084906-A1.
XX
XX PD 21-APR-2005.
XX
XX PF 16-DEC-2003; 2003US-00735916.
XX
XX PR 18-JAN-2002; 2002FR-00000653.
XX PR 18-JAN-2002; 2002FR-00000654.
XX PR 07-MAY-2002; 2002FR-00005753.
XX PR 20-JAN-2003; 2003WO-FR000178.
XX PR 11-JUL-2003; 2003FR-00008538.
XX
XX (GOET/) GOETSCH L.
XX PA (CORV/) CORVAIA N.
XX PA (LEGE/) LEGER O.
XX PA (DUFL/) DUFLOS A.
XX PA (HAEU/) HAEUW J.
XX PA (BECK/) BECK A.
XX
XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
XX WPI; 2005-321968/33.
XX N-PSDB; ADZ67070.
XX
XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
XX antibody or its functional fragment, being capable of binding human IGF-
XX IR and specifically inhibiting tyrosine kinase activity of receptor,
XX useful for treating cancer.
XX
XX Example 12; SEQ ID NO 67; 125pp; English.
XX
XX The invention relates to a novel isolated anti-insulin-like growth factor
XX I receptor (IGF-IR) antibody (I) or its functional fragment, being
XX capable of binding to human IGF-IR and, if necessary, capable of
XX specifically inhibiting tyrosine kinase activity of the receptor,
XX comprising a light or heavy chain having at least one complementary
XX determining region (CDR) consisting of one of two fully defined 16 amino
XX acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
XX the preparation of a medicament intended for the prevention or treatment
XX of an illness connected with an overexpression and/or an abnormal
XX activation of the IGF-IR and/or EGFR, and/or connected with a
XX hyperactivation of the transduction pathway of the signal mediated by the
XX interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
XX the administration of the medicament does not induce or only slightly
XX induces secondary effects connected with inhibition of the insulin
XX receptor. The antibody is useful for preparation of a medicament intended
XX to inhibit the transformation of normal cells into cells with tumoral
XX character, preferably IGF-dependent, especially IGF1 and/or IGF2-
XX dependent and/or EGF-dependent and/or HSR2/neu-dependent cells. (I) is
XX useful for preparation of a medicament intended to inhibit the growth
XX and/or the proliferation of tumor cells, preferably IGF-dependent,
XX especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
XX HSR2/neu-dependent cells. (I) is useful in the preparation of a
XX medicament intended for prevention or for the treatment of cancer, where
XX the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
XX breast cancer, endometrial cancer or colon cancer. (I) is useful in the
XX preparation of a medicament intended for the prevention or for the
XX treatment of psoriasis. (I) is useful in preparation of a medicament
XX intended for the specific targeting of a biologically active compound to
XX cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
XX is useful for in vitro diagnosis of illnesses induced by an
XX overexpression or an underexpression of the IGF-IR and/or EGFR receptor
XX starting from a biological sample in which the abnormal presence, of IGF-
XX IR and/or EGFR receptor is suspected, which involves contacting the
XX biological sample with (I), which is optionally labeled. The present
XX sequence is used in the exemplification of the invention.
XX
XX Sequence 131 AA;
XX SQ

Query Match 100.0%; Score 595; DB 9; Length 131;
 Best Local Similarity 100.0%; Pred. No. 3e-43;
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVS NRL 60
 Db :|||||
 Db 20 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVS NRL 79
 :|||||
 QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112
 :|||||
 Db 80 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 131
 :|||||

RESULT 5
 ADJ76895
 ID ADJ76895 standard; protein; 112 AA.

AC ADJ76895;
 AC
 DT 06-MAY-2004 (first entry)
 XX
 XX Anti-IGF-IR related protein #12.
 DE
 DE
 KW cytostatic; antipsoxiatic; antibody;
 KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
 CDR.
 KW
 XX

OS Homo sapiens.
 XX
 XX WO2003059951-A2.
 FN
 XX
 XX 24-JUL-2003.
 PD
 XX
 XX 20-JAN-2003; 2003WO-FR000178.
 PF
 XX
 PR 18-JAN-2002; 2002FR-00000653.
 PR 18-JAN-2002; 2002FR-00000654.
 PR 07-MAY-2002; 2002FR-00005753.
 PR

XX (FABR) FABRE MEDICAMENT SA PIERRE.
 PA
 XX Goetsch L, Corvaia N, Leger O;
 PI
 XX WPI; 2003-569653/53.
 DR
 XX New antibodies that bind to human insulin-like growth factor receptor,
 PT useful for treatment, prevention and diagnosis of cancers.
 XX
 PS Disclosure; SEQ ID NO 61; 164pp; French.
 CC
 CC The invention relates to an isolated antibody (Ab), and its functional
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
 CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
 CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or
 CC treat diseases associated with overexpression and/or abnormal activity of
 CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with
 CC hyperactivity of signal transduction pathways mediated by interaction of
 CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.
 XX

XX Sequence 112 AA;

Query Match 99.8%; Score 594; DB 7; Length 112;
 Best Local Similarity 99.1%; Pred. No. 3.1e-43;

Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVS NRL 60
 Db :|||||
 Db 1 DIVMTQSPSLSPVTPGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVS NRL 60
 :|||||
 QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112
 :|||||
 Db 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112
 :|||||

RESULT 6
 ADZ67065
 ID ADZ67065 standard; protein; 112 AA.

XX ADZ67065;
 AC
 DT 30-JUN-2005 (first entry)
 XX
 XX Human antibody 7C10 1 light chain variable region SEQ ID NO:61.
 DE
 DE
 KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoxiatic; psoriasis; dermatological disease; immune disorder;
 KW light chain variable region.
 KW
 XX

OS Homo sapiens.
 XX
 XX Location/Qualifiers
 FH Key 24..39
 FT Region /note= "CDR1"
 FT Region 55..61
 FT /note= "CDR2"
 FT Region 94..102
 FT /note= "CDR3"
 XX
 XX US2005084906-A1.

XX 21-APR-2005.
 PD
 XX
 XX 16-DEC-2003; 2003US-00735916.
 PF
 XX
 PR 18-JAN-2002; 2002FR-00000653.
 PR 18-JAN-2002; 2002FR-00000654.
 PR 07-MAY-2002; 2002FR-00005753.
 PR 20-JAN-2003; 2003WO-FR000178.
 PR 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.
 PA (CORV/) CORVAIA N.
 PA (LEGE/) LEGER O.
 PA (DUPL/) DUPLAS A.
 PA (HAU/) HAEUW J.
 PA (BECK/) BECK A.

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
 PI
 XX WPI; 2005-321968/33.
 DR N-PSDB; ADZ67066.
 DR
 XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 PT antibody or its functional fragment, being capable of binding human IGF-
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,
 PT useful for treating cancer.
 XX

PS Example 12; SEQ ID NO 61; 125pp; English.

XX The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-IR and, if necessary, capable of

specifically inhibiting tyrosine kinase activity of the receptor, comprising a light or heavy chain having at least one complementary determining region (CDR) consisting of one of two fully defined 16 amino acids (AD267006 and AD267014). An antibody of the invention is useful in the preparation of a medicament intended for the prevention or treatment of an illness connected with an overexpression and/or an abnormal activation of the IGF-IR and/or EGFR, and/or connected with a hyperactivation of the transduction pathway of the signal mediated by the interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where the administration of the medicament does not induce or only slightly induces secondary effects connected with inhibition of the insulin receptor. The antibody is useful for preparation of a medicament intended to inhibit the transformation of normal cells into cells with tumoral character, preferably IGF-dependent, especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is useful for the preparation of a medicament intended for the prevention of cancer, where the cancer is chosen from prostate cancer, osteosarcoma, lung cancer, breast cancer, endometrial cancer or colon cancer. (I) is useful in the preparation of a medicament intended for the prevention or for the treatment of psoriasis. (I) is useful in the preparation of a medicament intended for the specific targeting of a biologically active compound to cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I) is useful for in vitro diagnosis of illnesses induced by an overexpression or an underexpression of the IGF-IR and/or EGFR receptor starting from a biological sample in which the abnormal presence, of IGF-IR and/or EGFR receptor is suspected, which involves contacting the biological sample with (I), which is optionally labeled. The present sequence is used in the exemplification of the invention.

XX SQ Sequence 112 AA;

Query Match 99.8%; Score 594; DB 9; Length 112;
Best Local Similarity 99.1%; Pred. No. 3.1e-43;
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSNRL 60
Db 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSNRL 60
QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112
Db 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112

RESULT 7

ADJ76897
ID ADJ76897 standard; protein; 131 AA.

XX AC ADJ76897;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-1R related protein #13.

XX KW cytostatic; antipsoriatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDR.

XX OS Homo sapiens.

XX PN WO2003059951-A2.

XX XX 24-JUL-2003.

XX PD 20-JAN-2003; 2003WO-FR000178.

XX PF 18-JAN-2002; 2002PR-00000653.

PR 18-JAN-2002; 2002PR-00000654.
PR 07-MAY-2002; 2002PR-00005753.

XX PA (FABR) FABRE MEDICAMENT SA PIERRE.

XX PI Goetsch L, Corvaia N, Leger O;

XX XX WPI; 2003-569653/53.

XX DR New antibodies that bind to human insulin-like growth factor receptor,
XX PT useful for treatment, prevention and diagnosis of cancers.

XX PS Disclosure; SEQ ID NO 63; 164pp; French.

XX CC The invention relates to an isolated antibody (Ab), and its functional
XX CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
XX CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth
XX CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
XX CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
XX CC treat diseases associated with overexpression and/or abnormal activity of
XX CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
XX CC hyperactivity of signal transduction pathways mediated by interaction of
XX CC these receptors with their ligands. Especially they inhibit
XX CC transformation of normal cells to tumor cells, inhibit growth and/or
XX CC proliferation of tumor cells, so are useful against cancers of the
XX CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
XX CC also for treating psoriasis. Ab are also used to diagnose diseases caused
XX CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
XX CC protein sequence used to generate the Ab of the invention.

XX SQ Sequence 131 AA;

Query Match 99.8%; Score 594; DB 7; Length 131;
Best Local Similarity 99.1%; Pred. No. 3.6e-43;
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSNRL 60
Db 20 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSNRL 79
QY 61 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 112
Db 80 YGVDPFRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKEIK 131

RESULT 8

ADZ67067

ID ADZ67067 standard; protein; 131 AA.

XX AC ADZ67067;

XX DT 30-JUN-2005 (first entry)

XX DE Human antibody 7C10 1 light chain variable region SEQ ID NO:63.

XX KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
KW musculoskeletal disease; respiratory disease; lung tumor;
KW endocrine disease; gynecology and obstetrics; breast tumor;
KW endometroid carcinoma; gastrointestinal disease; colon tumor;
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
KW light chain variable region.

XX OS Homo sapiens.

XX XX Location/Qualifiers

XX FT Peptide 1..119

XX FT /note= "leader peptide"

XX FT Region 43..62

XX FT /note= "CDR1"

XX FT Region 74..80

XX FT /note= "CDR2"

XX FT Region 113..121

FT US2005084906-A1. /note= "CDR3"
PN 21-APR-2005.
XX
PD 16-DEC-2003; 2003US-00735916.
XX
PF 18-JAN-2002; 2002FR-00000653.
XX
PR 18-JAN-2002; 2002FR-00000654.
XX
PR 07-MAY-2002; 2002FR-00005753.
XX
PR 20-JAN-2003; 2003WO-FR000178.
XX
PR 11-JUL-2003; 2003FR-00008538.
XX
PA (GORT/) GOETSCH L.
PA (CORV/) CORVAIA N.
PA (LEGE/) LEGER O.
PA (DUFL/) DUFLOS A.
PA (HAUW/) HAEUW J.
PA (BECK/) BECK A.
XX
PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
XX
XX WPI; 2005-321968/33.
DR N-PSDB; ADZ67066.
XX
XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
PT antibody or its functional fragment, being capable of binding human IGF-
PT IR and specifically inhibiting tyrosine kinase activity of receptor,
PT useful for treating cancer.
XX
PS Example 12; SEQ ID NO 63; 125pp; English.
XX
XX The invention relates to a novel isolated anti-insulin-like growth factor
CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
CC capable of binding to human IGF-IR and, if necessary, capable of
CC specifically inhibiting tyrosine kinase activity of the receptor,
CC comprising a light or heavy chain having at least one complementary
CC determining region (CDR) consisting of one of two fully defined 16 amino
CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
CC the preparation of a medicament intended for the prevention or treatment
CC of an illness connected with an overexpression and/or an abnormal
CC activation of the IGF-IR and/or EGFR, and/or connected with a
CC hyperactivation of the transduction pathway of the signal mediated by the
CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
CC the administration of the medicament does not induce or only slightly
CC induces secondary effects connected with inhibition of the insulin
CC receptor. The antibody is useful for preparation of a medicament intended
CC to inhibit the transformation of normal cells into cells with tumoral
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
CC useful for preparation of a medicament intended to inhibit the growth
CC and/or the proliferation of tumor cells, preferably IGF-dependent,
CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
CC HER2/neu-dependent cells. (I) is useful in the preparation of a
CC medicament intended for prevention or for the treatment of cancer, where
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
CC preparation of a medicament intended for the prevention or for the
CC treatment of psoriasis. (I) is useful in preparation of a medicament
CC intended for the specific targeting of a biologically active compound to
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
CC is useful for in vitro diagnosis of illnesses induced by an
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
CC starting from a biological sample in which the abnormal presence, of IGF-
CC IR and/or EGFR receptor is suspected, which involves contacting the
CC biological sample with (I), which is optionally labeled. The present
CC sequence is used in the exemplification of the invention.
XX
SQ Sequence 131 AA;
Query Match 99.8%; Score 594; DB 9; Length 131;
Best Local Similarity 99.1%; Pred. No. 3.6e-43;

Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 DIVMTQSPPLSLPVTPGEPASISCRSSQSIHVSNGNTYLTQWYLQKPGQSPQLLIYKVSRL 60
Db :|||||
20 DVVMTQSPPLSLPVTPGEPASISCRSSQSIHVSNGNTYLTQWYLQKPGQSPQLLIYKVSRL 79
QY 61 YGVPDFRFGSGSGTDFTLTKISRVEADVGVVYFCQGSHPVMTFGGTVKEIK 112
Db :|||||
80 YGVPDFRFGSGSGTDFTLTKISRVEADVGVVYFCQGSHPVMTFGGTVKEIK 131
RESULT 9
ADP84950
ID ADP84950 standard; protein; 114 AA.
XX
AC ADP84950;
XX
DT 09-SEP-2004 (first entry)
XX
DE Variable light chain VL fragment Karo24 SEQ ID NO 92.
XX
KW antibody; Core-1 antigen; framework region; immunoglobulin superfamily;
KW protease inhibitor; lectin; helix-bundle protein; lipocalin;
KW variable heavy chain; VH; variable light chain; VL; vaccine; diagnosis;
KW alleviation; treatment; tumour; breast; colon; stomach; pancreas;
KW large/small intestine; ovary; cervix; lung; prostate; kidney; liver;
KW metastasis.
XX
OS Mus musculus.
OS Homo sapiens.
OS Chimeric.
XX
PN WO2004050707-A2.
XX
PD 17-JUN-2004.
XX
PF 01-DEC-2003; 2003WO-DE003994.
XX
PR 29-NOV-2002; 2002DE-01056900.
XX
PA (NEMO-) NEMOD BIOTHERAPEUTICS GMBH & CO KG.
PI Goletz S, Danielczyk A, Karsten U, Ravn P, Stahn R;
XX Christensen PA;
XX WPI; 2004-461095/43.
XX
XX New recognition molecules, e.g. antibodies (and nucleic acids) that bind
PT specifically to Core-1 antigens, useful for diagnosis, treatment and
PT prevention of tumors and metastases.
XX
PS Claim 15; SEQ ID NO 92; 136pp; German.
XX
XX This invention describes novel recognition molecules, especially
CC antibodies that bind specifically to the Core-1 antigen. The recognition
CC molecules are used to make constructs containing the framework regions
CC that separate, include and/or flank the specified sequences, especially
CC where the framework regions are from the immunoglobulin (Ig) superfamily,
CC protease inhibitors, lectins, helix-bundle proteins and/or lipocalins.
CC Most especially the framework regions are from antibodies, particularly
CC the variable heavy chain (VH) and the variable light chain (VL) of human
CC and/or murine origin. The constructs may also include a His or myc tag, a
CC lysine-rich region and/or a multimerisation domain, most particularly it
CC is a single-chain antibody fragment, multibody, Fab fragment, fusion
CC protein of an antibody fragment with peptide or protein, and/or an Ig of
CC types G, M, A, E or D and/or their subclasses. It may be human,
CC humanised, murine or chimeric, e.g. IGM without the J chain. The
CC additional sequences/structures in the constructs are Ig domains of
CC various species, interacting or stabilising domains, signal sequences,
CC fluorescent dyes, toxins, antibodies with catalytic activity or other
CC specificities, cytolytic agents, enzymes, chelators for radioactive labels,
CC effectors, MHC molecules, antigens, chelators for radioactive labels,
CC liposomes, transmembrane domains, viruses and/or cells, specifically

CC macrophages. The antibodies, also constructs containing them, nucleic
CC acid encoding them, and related vectors and host cells, are useful for
CC prevention (e.g. as vaccine), diagnosis, alleviation, treatment,
CC monitoring and/or secondary treatment of tumours (specifically of breast,
CC colon, stomach, pancreas, large/small intestine, ovary, cervix, lung,
CC prostate, kidney and/or liver) and/or metastases (particularly to liver),
CC specifically where these are positive for the CI antigen. The products of
CC the invention provide simple, reliable and efficient detection of
CC tumours. They are specific for carcinoma and show almost no binding to
CC healthy tissue.
XX
SQ Sequence 114 AA;

Query Match 95.8%; Score 570; DB 8; Length 114;
Best Local Similarity 96.4%; Pred. No. 3.5e-41;
Matches 108; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
QY 61 YGVPRFRFGSGSGTDTLTKISRVEADVGVYCFQSGSHVPVTFGGTKVEIK 112
Db 61 SGVPRFRFGSGSGTDTLTKISRVEADVGVYCFQSGSHVPVTFGGTKVEIK 112

RESULT 10
AAE15713
ID AAE15713 standard; protein; 112 AA.
AC AAE15713;
DT 12-MAR-2002 (first entry)
DE Mouse monoclonal antibody alpha 340 Vb region variant, 340VKD.
KW Mouse; humanised form; monoclonal antibody alpha 340; gene therapy;
KW epidermal growth factor receptor; EGF; cancer; colorectal; lung; breast;
KW gastric; ovarian; immune response; cytostatic; cell growth; apoptosis;
KW inhibitor; mutant; mutein; variant.
XX
OS Mus sp.
OS Synthetic.

Key Location/Qualifiers
FT Misc-difference 7 /note= "wild type Thr substituted with Ser"
FT Misc-difference 14 /note= "wild type Ser substituted with Thr"
FT Misc-difference 15 /note= "wild type Leu substituted with Pro"
FT Misc-difference 17 /note= "wild type Asp substituted with Glu"
FT Misc-difference 18 /note= "wild type Gln substituted with Pro"
FT Misc-difference 50 /note= "wild type Lys substituted with Gln"
FT Misc-difference 88 /note= "wild type Leu substituted with Val"
FT Misc-difference 109 /note= "wild type Leu substituted with Val"
FT Misc-difference 112 /note= "wild type Asn substituted with Lys"

WO200108138-A1.
XX
XX 22-NOV-2001.
XX
XX 21-MAY-2001; 2001WO-GB002226.
XX
XX 19-MAY-2000; 2000GB-00011981.
XX
XX 24-AUG-2000; 2000GB-00020794.

PA (SCAN-) SCANCELL LTD.
XX
PI Ellis JRM, Durrant LG;
XX
DR WPI; 2002-062384/08.
XX
XX New humanized form of mouse monoclonal antibody 340 which binds to
FT epidermal growth factor receptor and inhibits binding of growth factor,
FT useful for treating colorectal, lung, breast, gastric and ovarian cancer.
XX
PS Example 2; Fig 7; 53pp; English.
XX
CC The present invention relates to a humanised form of the antibody 340 (a
CC mouse monoclonal antibody which binds to epidermal growth factor (EGF)
CC receptor and inhibits binding of EGF), obtainable from the cell line
CC deposited with the ECACC under accession number 97021428. The humanised
CC form of the antibody 340 is useful in gene therapy, medicine and in the
CC manufacture of a medicament for treatment or prophylaxis of cancer. The
CC invention is useful for treating colorectal, lung, breast, gastric or
CC ovarian cancers or also for preventing the recurrence of cancer after
CC initial treatment or surgery. The invention is also useful for enhancing
CC a protective immune response against cancer by optimised immunisation
CC schedules. The humanised form of the antibody 340 has reduced
CC immunogenicity but shows similar binding to cells expressing EGF
CC receptor, as the original murine antibody and has increased ability to
CC inhibit the growth of EGF receptor expressing cells. The invention is
CC used as cell growth and apoptosis inhibitor. The present sequence is
CC mouse monoclonal antibody alpha 340 deimmunised light chain variable (VK)
CC region variant, 340VKD
XX
SQ Sequence 112 AA;

Query Match 95.3%; Score 567; DB 5; Length 112;
Best Local Similarity 93.8%; Pred. No. 6.3e-41;
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;
QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
QY 61 YGVPRFRFGSGSGTDTLTKISRVEADVGVYCFQSGSHVPVTFGGTKVEIK 112
Db 61 SGVPRFRFGSGSGTDTLTKISRVEADVGVYCFQSGSHVPVTFGGTKVEIK 112

RESULT 11
ADP84948
ID ADP84948 standard; protein; 114 AA.
XX
AC ADP84948;
DT 09-SEP-2004 (first entry)
DE Variable light chain VL fragment Karol1 SEQ ID NO 90.
XX
KW antibody; Core-1 antigen; framework region; immunoglobulin superfamily;
KW protease inhibitor; lectin; helix-bundle protein; lipocalin;
KW variable heavy chain; VH; variable light chain; VL; vaccine; diagnosis;
KW alleviation; treatment; tumour; breast; colon; stomach; pancreas;
KW large/small intestine; ovary; cervix; lung; prostate; kidney; liver;
KW metastasis.
XX
OS Mus musculus.
OS Homo sapiens.
OS Chimeric.
XX
XX WO2004050707-A2.
XX
XX 17-JUN-2004.
XX
XX 01-DEC-2003; 2003WO-DE003994.
XX
XX 29-NOV-2002; 2002DE-01056900.

```

XX (NEMO-) NEMOD BIOTHERAPEUTICS GMBH & CO KG.
XX PA
XX PI
XX PI Christensen P;
XX DR
XX DR WPI; 2004-461095/43.
XX PT
XX PT New recognition molecules, e.g. antibodies (and nucleic acids) that bind
XX PT specifically to Core-1 antigens, useful for diagnosis, treatment and
XX PT prevention of tumors and metastases.
XX PS
XX PS Claim 15; SEQ ID NO 90; 136pp; German.
XX CC
XX CC This invention describes novel recognition molecules, especially
XX CC antibodies that bind specifically to the Core-1 antigen. The recognition
XX CC molecules are used to make constructs containing the framework regions
XX CC that separate, include and/or flank the specified sequences, especially
XX CC where the framework regions are from the immunoglobulin (Ig) superfamily,
XX CC protease inhibitors, lectins, helix-bundle proteins and/or lipocalins.
XX CC Most especially the framework regions are from antibodies, particularly
XX CC the variable heavy chain (VH) and the variable light chain (VL) of human
XX CC and/or murine origin. The constructs may also include a His or myc tag, a
XX CC lysine-rich region and/or a multimerisation domain, most particularly it
XX CC is a single-chain antibody fragment, multibody, Fab fragment, fusion
XX CC protein of an antibody fragment with peptide or protein, and/or an Ig of
XX CC types G, M, A, E or D and/or their subclasses. It may be human,
XX CC humanised, murine or chimeric, e.g. IgM without the J chain. The
XX CC additional sequences/structures in the constructs are Ig domains of
XX CC various species, interacting or stabilising domains, signal sequences,
XX CC fluorescent dyes, toxins, antibodies with catalytic activity or other
XX CC specificities, cytolytic agents, enzymes, immuno-modulators or -
XX CC effectors, MHC molecules, antigens, chelators for radioactive labels,
XX CC liposomes, transmembrane domains, viruses and/or cells, specifically
XX CC macrophages. The antibodies, also constructs containing them, nucleic
XX CC acid encoding them, and related vectors and host cells, are useful for
XX CC prevention (e.g. as vaccine), diagnosis, alleviation, treatment,
XX CC monitoring and/or secondary treatment of tumours (specifically of breast,
XX CC colon, stomach, pancreas, large/small intestine, ovary, cervix, lung,
XX CC prostate, kidney and/or liver) and/or metastases (particularly to liver),
XX CC specifically where these are positive for the CI antigen. The products of
XX CC the invention provide simple, reliable and efficient detection of
XX CC tumours. They are specific for carcinoma and show almost no binding to
XX CC healthy tissue.
XX SQ Sequence 114 AA;

Query Match 95.1%; Score 566; DB 8; Length 114;
Best Local Similarity 95.5%; Pred. No. 7.8e-41;
Matches 107; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLYQWYLOKFGQSPQLLIYKVSRL 60
Db 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLYQWYLOKFGQSPQLLIYKVSRL 60
QY 61 YGVPDRFSGSGSGTDFTLKISRVEAEDGIVYYCFQGSHPVTFGQTKVEIK 112
Db 61 SGVPRFSGSGSGTDFTLKISRVEAEDGIVYYCFQGSHPVTFGQTKVEIK 112

RESULT 12
AAE15712
ID AAE15712 standard; protein; 112 AA.
AC AAE15712;
XX 12-MAR-2002 (first entry)
XX DE Mouse monoclonal antibody alpha 340 Vκ region variant, 340VKC.
XX KW Mouse; humanised form; monoclonal antibody alpha 340; gene therapy;
XX KW epidermal growth factor receptor; EGF; cancer; colorectal; lung; breast;
XX KW gastric; ovarian; immune response; cytostatic; cell growth; apoptosis;

inhibitor; mutant; mutein; variant.
Mus sp.
Synthetic.
Key Location/Qualifiers
Misc-difference 7 /note= "Wild type Thr substituted with Ser"
Misc-difference 14 /note= "Wild type Ser substituted with Thr"
Misc-difference 15 /note= "Wild type Leu substituted with Pro"
Misc-difference 17 /note= "Wild type Asp substituted with Glu"
Misc-difference 18 /note= "Wild type Gln substituted with Pro"
Misc-difference 50 /note= "Wild type Lys substituted with Gln"
Misc-difference 88 /note= "Wild type Leu substituted with Thr"
Misc-difference 90 /note= "Wild type Ile substituted with Val"
Misc-difference 109 /note= "Wild type Leu substituted with Val"
Misc-difference 112 /note= "Wild type Asn substituted with Lys"
WO200188138-A1.
22-NOV-2001.
21-MAY-2001; 2001WO-GB0022236.
19-MAY-2000; 2000GB-00011981.
24-AUG-2000; 2000GB-00020794.
(SCAN-) SCANCELL LTD.
Ellis JRM, Durrant LG;
WPI; 2002-062384/08.
New humanized form of mouse monoclonal antibody 340 which binds to
epidermal growth factor receptor and inhibits binding of growth factor,
useful for treating colorectal, lung, breast, gastric and ovarian cancer.
Example 2; Fig 7; 53pp; English.
The present invention relates to a humanised form of the antibody 340 (a
mouse monoclonal antibody which binds to epidermal growth factor (EGF)
receptor and inhibits binding of EGF), obtainable from the cell line
deposited with the ECACC under accession number 97021428. The humanised
form of the antibody 340 is useful in gene therapy, medicine and in the
manufacture of a medicament for treatment or prophylaxis of cancer. The
invention is useful for treating colorectal, lung, breast, gastric or
ovarian cancers or also for preventing the recurrence of cancer after
initial treatment or surgery. The invention is also useful for enhancing
a protective immune response against cancer by optimised immunisation
schedules. The humanised form of the antibody 340 has reduced
immunogenicity but shows similar binding to cells expressing EGF
receptor, as the original murine antibody and has increased ability to
inhibit the growth of EGF receptor expressing cells. The invention is
used as cell growth and apoptosis inhibitor. The present sequence is
mouse monoclonal antibody alpha 340 deimmunised light chain variable (VK)
region variant, 340VKC
Sequence 112 AA;

Query Match 94.8%; Score 564; DB 5; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.1e-40;
Matches 105; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLYQWYLOKFGQSPQLLIYKVSRL 60

```

```
Db 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLEWYLQKPGQSPQLLIYKVSRL 60
    61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVMTFGGTKEIK 112
    61 SGVDPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVMTFGGTKEIK 112

RESULT 13
ID ABP72125 standard; protein; 112 AA.
XX AC ABP72125;
XX DT 03-JUN-2003 (first entry)
XX DE FGF-8 related protein SEQ ID 17.
XX KW Humanised; antibody; fibroblast growth factor 8; FGF8; cytostatic;
XX KW cancer; prostate; breast; ovarian; testicular.
XX OS Synthetic.
XX PN WO2003002608-A1.
XX PS 09-JAN-2003.
XX PF 28-JUN-2002; 2002WO-JP006591.
XX PR 28-JUN-2001; 2001JP-00196176.
XX PA (KYOW ) KYOWA HAKKO KOGYO KK.
XX PI Shitara K, Nakamura K, Hirota M, Shimada N;
XX DR WPI; 2003-239169/23.
XX PT Humanised antibodies and antibody fragments reacting with fibroblast
XX PT growth factor 8 useful for the treatment and diagnosis of cancer.
XX PS Claim 19; Page 72; 86pp; Japanese.
XX CC The invention relates to novel humanised antibodies and antibody
XX CC fragments which react with fibroblast growth factor 8 (FGF8) and inhibit
XX CC its biological functions. The polypeptides of the invention have
XX CC cytostatic activity. The antibody is useful for the treatment of cancer,
XX CC including prostate, breast, ovarian and testicular cancer. The present
XX CC sequence is used in the exemplification of the invention
XX SQ Sequence 112 AA;

Query Match 94.8%; Score 564; DB 6; Length 112;
Best Local Similarity 94.6%; Pred. No. 1.1e-40;
Matches 106; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLEWYLQKPGQSPQLLIYKVSRL 60
Db 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLEWYLQKPGQSPQLLIYKVSRL 60
QY 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVMTFGGTKEIK 112
Db 61 SGVDPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVMTFGGTKEIK 112

RESULT 14
ADE36495
ID ADE36495 standard; protein; 112 AA.
XX AC ADE36495;
XX DT 29-JAN-2004 (first entry)
XX DE Anti-FGF-8 (sic fibroblast growth factor) antibody-related protein #2.
```

```
XX arthritis; anti-FGF-8; sic fibroblast growth factor;
KW cartilage protection agent; joint destruction inhibitor;
KW synovial proliferation inhibitor.
XX OS Unidentified.
XX PN WO2003057251-A1.
XX PD 17-JUL-2003.
XX PF 26-DEC-2002; 2002WO-JP013650.
XX PR 28-DEC-2001; 2001JP-00400677.
XX PA (KYOW ) KYOWA HAKKO KOGYO KK.
XX PI Tamura T, Uchii M, Suda T, Miki I, Tanaka A;
XX DR WPI; 2003-587078/55.
XX PT Treatment and prevention of arthritis comprising the use of anti-FGF-8
XX PT (sic fibroblast growth factor) antibody.
XX PS Claim 11; SEQ ID NO 19; 193pp; Japanese.
XX CC The invention comprises a method for treating and preventing arthritis,
XX CC the method involves the use of anti-FGF-8 (sic fibroblast growth factor)
XX CC antibody. The antibody and method of the invention is useful for: the
XX CC detection, treatment and prevention of arthritis; as a cartilage
XX CC protection agent; as a joint destruction inhibitor; and as a synovial
XX CC proliferation inhibitor. The present amino acid sequence represents a
XX CC protein of the invention.
XX SQ Sequence 112 AA;

Query Match 94.8%; Score 564; DB 7; Length 112;
Best Local Similarity 94.6%; Pred. No. 1.1e-40;
Matches 106; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLEWYLQKPGQSPQLLIYKVSRL 60
Db 1 DIVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLEWYLQKPGQSPQLLIYKVSRL 60
QY 61 YGVDPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVMTFGGTKEIK 112
Db 61 SGVDPDRFSGSGGTFTLKISRVEAEDVGVYYCFQGSHPVMTFGGTKEIK 112

RESULT 15
ADP84946
ID ADP84946 standard; protein; 114 AA.
XX AC ADP84946;
XX DT 09-SEP-2004 (first entry)
XX DE Variable light chain VL fragment Karo18 SEQ ID NO 88.
XX KW antibody; Core-1 antigen; framework region; immunoglobulin superfamily;
XX KW protease inhibitor; lectin; helix-bundle protein; lipocalin;
XX KW variable heavy chain; VH; variable light chain; VL; vaccine; diagnosis;
XX KW alleviation; treatment; tumour; breast; colon; stomach; pancreas;
XX KW large/small intestine; ovary; cervix; lung; prostate; kidney; liver;
XX KW metastasis.
XX OS Mus musculus.
XX OS Homo sapiens.
XX OS Chimeric.
XX PN WO2004050707-A2.
XX PD 17-JUN-2004.
```

```
XX 01-DEC-2003; 2003WO-DE003994.
XX PF
XX 29-NOV-2002; 2002DE-01056900.
XX PR
XX XX
XX (NEMO-) NEMOD BIOTHERAPEUTICS GMBH & CO KG.
XX PA
XX Goletz S, Danielczyk A, Karsten U, Ravn P, Stahn R;
XX PI Christensen PA;
XX DR WPI; 2004-461095/43.
XX XX
XX New recognition molecules, e.g. antibodies (and nucleic acids) that bind
XX PT specifically to Core-1 antigens, useful for diagnosis, treatment and
XX PT prevention of tumors and metastases.
XX PT
XX Claim 15; SEQ ID NO 88; 136pp; German.
XX PS
XX This invention describes novel recognition molecules, especially
XX CC antibodies that bind specifically to the Core-1 antigen. The recognition
XX CC molecules are used to make constructs containing the framework regions
XX CC that separate, include and/or flank the specified sequences, especially
XX CC where the framework regions are from the immunoglobulin (Ig) superfamily,
XX CC protease inhibitors, lectins, helix-bundle proteins and/or lipocalins.
XX CC Most especially the framework regions are from antibodies, particularly
XX CC the variable heavy chain (VH) and the variable light chain (VL) of human
XX CC and/or murine origin. The constructs may also include a His or myc tag, a
XX CC lysine-rich region and/or a multimerisation domain, most particularly it
XX CC is a single-chain antibody fragment, multibody, Fab fragment, fusion
XX CC protein of an antibody fragment with peptide or protein, and/or an Ig of
XX CC types G, M, A, E or D and/or their subclasses. It may be human,
XX CC humanised, murine or chimeric, e.g. IgM without the J chain. The
XX CC additional sequences/structures in the constructs are Ig domains of
XX CC various species, interacting or stabilising domains, signal sequences,
XX CC fluorescent dyes, toxins, antibodies with catalytic activity or other
XX CC specificities, cytolytic agents, enzymes, immuno-modulators or -
XX CC effectors, MHC molecules, antigens, chelators for radioactive labels,
XX CC liposomes, transmembrane domains, viruses and/or cells, specifically
XX CC macrophages. The antibodies, also constructs containing them, nucleic
XX CC acid encoding them, and related vectors and host cells, are useful for
XX CC prevention (e.g. as vaccine), diagnosis, alleviation, treatment,
XX CC monitoring and/or secondary treatment of tumours (specifically of breast,
XX CC colon, stomach, pancreas, large/small intestine, ovary, cervix, lung,
XX CC prostate, kidney and/or liver) and/or metastases (particularly to liver),
XX CC specifically where these are positive for the CI antigen. The products of
XX CC the invention provide simple, reliable and efficient detection of
XX CC tumours. They are specific for carcinoma and show almost no binding to
XX CC healthy tissue.
XX SQ Sequence 114 AA;
XX
XX Query Match 94.8%; Score 564; DB 8; Length 114;
XX Best Local Similarity 95.5%; Pred. No. 1.2e-40;
XX Matches 107; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 1 DIWMTQSPSLPVITGCEPASISCRSSQSIHSHNGNTYLYWYLOKPGQSPQLLIYKVSNRL 60
XX DB ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
XX 1 DIQMTQSPSLPVITGCEPASISCRSSQSIHSHNGNTYLYWYLOKPGQSPQLLIYKVSNRF 60
XX
XX QY 61 YGVPRFSGSGGTDTFTLKISRVEADGVVYCFQGSHPVPTFGQGTKVEIK 112
XX DB ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
XX 61 SGVPRFSGSGGTDTFTLKISRVEADGVVYCFQGSHPVPTFGQGTKVEIK 112
XX
XX Search completed: January 10, 2006, 20:44:15
XX Job time : 78.3134 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:55:23 ; Search time 5.71144 Seconds
(without alignments)
166.558 Million cell updates/sec

Title: US-10-735-916A-61

Perfect score: 595

Sequence: 1 DVMWTQSLPLSVTPGEPAS.....CFQSGSHVPTFGQTKVEIK 112

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 61141 seqs, 8493638 residues

Total number of hits satisfying chosen parameters: 61141

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA New:*

- 1: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
- 2: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
- 3: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
- 4: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
- 5: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
- 6: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
- 7: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
- 8: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	595	100.0	112	7 US-11-012-353-61	Sequence 61, Appl
2	595	100.0	131	7 US-11-012-353-63	Sequence 63, Appl
3	594	99.8	112	7 US-11-012-353-65	Sequence 65, Appl
4	594	99.8	131	7 US-11-012-353-67	Sequence 67, Appl
5	547	91.9	112	6 US-10-959-310-33	Sequence 33, Appl
6	546	91.8	112	6 US-10-959-310-26	Sequence 26, Appl
7	544	91.4	112	6 US-10-959-310-35	Sequence 35, Appl
8	543	91.3	112	6 US-10-959-310-34	Sequence 34, Appl
9	538	90.4	112	7 US-11-012-353-54	Sequence 49, Appl
10	538	90.4	122	7 US-11-012-353-49	Sequence 49, Appl
11	531	89.2	112	7 US-11-012-353-56	Sequence 56, Appl
12	524	88.1	131	7 US-11-125-837-23	Sequence 23, Appl
13	522	87.7	263	7 US-11-089-266-66	Sequence 66, Appl
14	520	87.4	112	7 US-11-012-353-55	Sequence 55, Appl
15	520	87.4	112	7 US-11-012-353-57	Sequence 57, Appl
16	520	87.4	149	7 US-11-089-266-2	Sequence 2, Appl
17	516	86.7	116	7 US-11-065-943-49	Sequence 49, Appl
18	515	86.6	112	7 US-11-089-266-15	Sequence 15, Appl
19	515	86.6	113	6 US-10-932-334-61	Sequence 61, Appl
20	514	86.4	113	6 US-10-932-334-69	Sequence 69, Appl
21	512	86.1	113	6 US-10-932-334-66	Sequence 66, Appl
22	512	86.1	113	6 US-10-932-334-68	Sequence 68, Appl
23	511	85.9	113	6 US-10-932-334-9	Sequence 9, Appl
24	511	85.9	113	6 US-10-932-334-12	Sequence 12, Appl
25	511	85.9	113	6 US-10-932-334-83	Sequence 83, Appl

26	511	85.9	113	6	US-10-932-334-86	Sequence 86, Appl
27	511	85.9	113	6	US-10-932-334-90	Sequence 90, Appl
28	510	85.7	113	6	US-10-932-334-65	Sequence 65, Appl
29	510	85.7	251	6	US-10-512-184-30	Sequence 30, Appl
30	510	85.7	320	6	US-10-512-184-67	Sequence 67, Appl
31	510	85.7	569	6	US-10-512-184-66	Sequence 66, Appl
32	510	85.7	618	6	US-10-512-184-48	Sequence 48, Appl
33	509	85.5	113	6	US-10-932-334-60	Sequence 60, Appl
34	508	85.4	113	6	US-10-932-334-10	Sequence 10, Appl
35	508	85.4	113	6	US-10-932-334-11	Sequence 11, Appl
36	508	85.4	113	6	US-10-932-334-59	Sequence 59, Appl
37	508	85.4	113	6	US-10-932-334-84	Sequence 84, Appl
38	508	85.4	113	6	US-10-932-334-85	Sequence 85, Appl
39	508	85.4	113	6	US-10-932-334-94	Sequence 94, Appl
40	503	84.5	113	6	US-10-932-334-8	Sequence 8, Appl
41	503	84.5	113	6	US-10-932-334-58	Sequence 58, Appl
42	503	84.5	113	6	US-10-932-334-62	Sequence 62, Appl
43	503	84.5	113	6	US-10-932-334-82	Sequence 82, Appl
44	503	84.5	132	6	US-10-932-334-50	Sequence 50, Appl
45	501	84.2	131	6	US-10-789-273-14	Sequence 14, Appl

ALIGNMENTS

RESULT 1
US-11-012-353-61
; Sequence 61, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILLIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012.353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: Patentin Ver. 3.3
; SEQ ID NO 61
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-61

Query Match 100.0%; Score 595; DB 7; Length 112;
Best Local Similarity 100.0%; Pred. No. 2.5e-40;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	DVMWTQSLPLSVTPGEPASISCRSSQIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNNRL	60
DB	1	DVMWTQSLPLSVTPGEPASISCRSSQIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNNRL	60
QY	61	YGVPRFSGSGSGTDTFLIKSRVEADVGYYVYCFQSGSHVPTFGQTKVEIK	112
DB	61	YGVPRFSGSGSGTDTFLIKSRVEADVGYYVYCFQSGSHVPTFGQTKVEIK	112

```
RESULT 2
US-11-012-353-63
; Sequence 63, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 63
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-63

Query Match      100.0%; Score 595; DB 7; Length 131;
Best Local Similarity 100.0%; Pred. No. 2.9e-40;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLPKPGQSPQLLIYKVSNRL 60
Db 20 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLPKPGQSPQLLIYKVSNRL 79

QY 61 YGVDPDRFSGSGGTDTLTKISRVEADGVVYCFQGSHPVPTFGGQTKVEIK 112
Db 80 YGVDPDRFSGSGGTDTLTKISRVEADGVVYCFQGSHPVPTFGGQTKVEIK 131

RESULT 3
US-11-012-353-65
; Sequence 65, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 65
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-65

Query Match      99.8%; Score 594; DB 7; Length 131;
Best Local Similarity 99.1%; Pred. No. 3.5e-40;
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLPKPGQSPQLLIYKVSNRL 60
Db 20 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLPKPGQSPQLLIYKVSNRL 79

QY 61 YGVDPDRFSGSGGTDTLTKISRVEADGVVYCFQGSHPVPTFGGQTKVEIK 112
Db 80 YGVDPDRFSGSGGTDTLTKISRVEADGVVYCFQGSHPVPTFGGQTKVEIK 131

RESULT 4
US-11-012-353-67
; Sequence 67, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 67
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-012-353-67

Query Match      99.8%; Score 594; DB 7; Length 131;
Best Local Similarity 99.1%; Pred. No. 3.5e-40;
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLPKPGQSPQLLIYKVSNRL 60
Db 20 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYQLQWYLPKPGQSPQLLIYKVSNRL 79

QY 61 YGVDPDRFSGSGGTDTLTKISRVEADGVVYCFQGSHPVPTFGGQTKVEIK 112
Db 80 YGVDPDRFSGSGGTDTLTKISRVEADGVVYCFQGSHPVPTFGGQTKVEIK 131
```


Db 61 SGVPRFSGSGGTDFTLKISRVEAEDGIVYCFQGSLLPWTFGQGTKEIK 112

RESULT 7

US-10-959-310-35
; Sequence 35, Application US/10959310
; Publication No. US20050287138A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD.
; TITLE OF INVENTION: CCR4-specific antibody composition
; FILE REFERENCE: 249-363
; CURRENT APPLICATION NUMBER: US/10/959,310
; CURRENT FILING DATE: 2004-10-07
; PRIOR APPLICATION NUMBER: JP 2003-350162
; PRIOR FILING DATE: 2003-10-08
; PRIOR APPLICATION NUMBER: US 60/572,784
; PRIOR FILING DATE: 2004-05-21
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 35
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic peptide
US-10-959-310-35

Query Match 91.9%; Score 547; DB 6; Length 112;
Best Local Similarity 92.0%; Pred. No. 1.3e-36;
Matches 103; Conservative 5; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60

Db 1 DVVMTQSPSLPVTGPEPASISCRSSRNIVHNGDTYLEWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVPRFSGSGGTDFTLKISRVEAEDGIVYCFQGSHPVPTFGQGTKEIK 112

Db 61 SGVPRFSGSGGTDFTLKISRVEAEDGIVYCFQGSLLPWTFGQGTKEIK 112

RESULT 6

US-10-959-310-26
; Sequence 26, Application US/10959310
; Publication No. US20050287138A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD.
; TITLE OF INVENTION: CCR4-specific antibody composition
; FILE REFERENCE: 249-363
; CURRENT APPLICATION NUMBER: US/10/959,310
; CURRENT FILING DATE: 2004-10-07
; PRIOR APPLICATION NUMBER: JP 2003-350162
; PRIOR FILING DATE: 2003-10-08
; PRIOR APPLICATION NUMBER: US 60/572,784
; PRIOR FILING DATE: 2004-05-21
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 26
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic peptide
US-10-959-310-26

Query Match 91.8%; Score 546; DB 6; Length 112;
Best Local Similarity 91.1%; Pred. No. 1.6e-36;
Matches 102; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60

Db 1 DVVMTQSPSLPVTGPEPASISCRSSRNIVHNGDTYLEWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVPRFSGSGGTDFTLKISRVEAEDGIVYCFQGSHPVPTFGQGTKEIK 112

RESULT 7

US-10-959-310-35
; Sequence 35, Application US/10959310
; Publication No. US20050287138A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD.
; TITLE OF INVENTION: CCR4-specific antibody composition
; FILE REFERENCE: 249-363
; CURRENT APPLICATION NUMBER: US/10/959,310
; CURRENT FILING DATE: 2004-10-07
; PRIOR APPLICATION NUMBER: JP 2003-350162
; PRIOR FILING DATE: 2003-10-08
; PRIOR APPLICATION NUMBER: US 60/572,784
; PRIOR FILING DATE: 2004-05-21
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 35
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic peptide
US-10-959-310-35

Query Match 91.4%; Score 544; DB 6; Length 112;
Best Local Similarity 91.1%; Pred. No. 2.2e-36;
Matches 102; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60

Db 1 DVVMTQSPSLPVTGPEPASISCRSSRNIVHNGDTYLEWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVPRFSGSGGTDFTLKISRVEAEDGIVYCFQGSHPVPTFGQGTKEIK 112

Db 61 SGVPRFSGSGGTDFTLKISRVEAEDGIVYCFQGSLLPWTFGQGTKEIK 112

RESULT 8

US-10-959-310-34
; Sequence 34, Application US/10959310
; Publication No. US20050287138A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD.
; TITLE OF INVENTION: CCR4-specific antibody composition
; FILE REFERENCE: 249-363
; CURRENT APPLICATION NUMBER: US/10/959,310
; CURRENT FILING DATE: 2004-10-07
; PRIOR APPLICATION NUMBER: JP 2003-350162
; PRIOR FILING DATE: 2003-10-08
; PRIOR APPLICATION NUMBER: US 60/572,784
; PRIOR FILING DATE: 2004-05-21
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 34
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic peptide
US-10-959-310-34

Query Match 91.3%; Score 543; DB 6; Length 112;
Best Local Similarity 90.2%; Pred. No. 2.7e-36;
Matches 101; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60

Db 1 DILMTQSPSLPVTGPEPASISCRSSRNIVHNGDTYLEWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVPRFSGSGGTDFTLKISRVEAEDGIVYCFQGSHPVPTFGQGTKEIK 112

```
Db 61 SGVPRFSGSGTDTLTKISRVEADVGYYCFQGSLLPWTFGGTVK 112
|||||
RESULT 9
US-11-012-353-54
; Sequence 54, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 54
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-54

Query Match 90.4%; Score 538; DB 7; Length 112;
Best Local Similarity 90.2%; Pred. No. 6.5e-36;
Matches 101; Conservative 6; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIHVHSGNGNTYLQWYLQKPGQSPOLLIIYKVSRL 60
Db 1 DVLMTQIPLSLPVSLGDSQASISCRSSQSIHVHSGNGNTYLQWYLQKPGQSPKLLIIYKVSRL 60

Qy 61 YGVPRFSGSGTDTLTKISRVEADVGYYCFQGSHPVPTFGGTVK 112
|||||
Db 61 YGVPRFSGSGTDTLTKISRVEADLGYYCFQGSHPVPTFGGTVK 112

RESULT 10
US-11-012-353-49
; Sequence 49, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
```

```
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 49
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-49

Query Match 90.4%; Score 538; DB 7; Length 122;
Best Local Similarity 90.2%; Pred. No. 7e-36;
Matches 101; Conservative 6; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIHVHSGNGNTYLQWYLQKPGQSPOLLIIYKVSRL 60
Db 1 DVLMTQIPLSLPVSLGDSQASISCRSSQSIHVHSGNGNTYLQWYLQKPGQSPKLLIIYKVSRL 70

Qy 61 YGVPRFSGSGTDTLTKISRVEADVGYYCFQGSHPVPTFGGTVK 112
|||||
Db 71 YGVPRFSGSGTDTLTKISRVEADLGYYCFQGSHPVPTFGGTVK 122

RESULT 11
US-11-012-353-56
; Sequence 56, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 56
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-56

Query Match 89.2%; Score 531; DB 7; Length 112;
Best Local Similarity 88.4%; Pred. No. 2.3e-35;
Matches 99; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIHVHSGNGNTYLQWYLQKPGQSPOLLIIYKVSRL 60
Db 1 DVLMTQIPLSLPVSLGDSQASISCRSSQSIHVHSGNGNTYLQWYLQKPGQSPKLLIIYKVSRL 60
```

```

; APPLICATION NUMBER: US 08/372,676
; FILING DATE: 1995-01-17
; APPLICATION NUMBER: US 08/591,196
; FILING DATE: 1996-01-16
; ATTORNEY/AGENT INFORMATION:
; NAME: Catherine M. Polizzi
; REGISTRATION NUMBER: 40,130
; REFERENCE/DOCKET NUMBER: 304142000202
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 263 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-11-089-266-66

Query Match      87.7%; Score 522; DB 7; Length 263;
Best Local Similarity 87.5%; Pred. No. 2.3e-34;
Matches 98; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPYPGEPASISCRSSQSIVHNSNGNTYLQWYLOKPGQSPOLLIYKVNRL 60
Db 152 DVLMTQTPLSLPVLSDGQASISCRSSQSIVHNSNGNTYLEWYLOKPGQSPNLLIYFVSNRF 211
Qy 61 YGVPDFRFGSGSGTDFTLKISRVEAEDGYYVCFQGSHPVPTFGQTKVEIK 112
Db 212 SGVPDRFSGSGSGTDFTLKISRVEAEDLGYVYCFQGSHPVPTFGGTKLEIK 263

RESULT 14
US-11-012-353-55
; Sequence 55, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETTSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 55
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
; US-11-012-353-55

Query Match      87.4%; Score 520; DB 7; Length 112;
Best Local Similarity 86.6%; Pred. No. 1.6e-34;
Matches 97; Conservative 10; Mismatches 5; Indels 0; Gaps 0;

```

Wed Jan 11 09:35:24 2006

QY	1	DVVMTQSP	SLSPVT	PCEP	ASIS	CRSSQ	SI	IVHNG	NTY	QWY	LQK	QSP	POLL	YK	VSN	NR	60	
Db	1	DLVMTQT	SLSPVSL	GDQAS	IS	CRSSQ	SI	IVHNG	NTY	LEWY	LQK	QSP	PKLL	YK	VSN	NR	60	
QY	61	YGVPDR	FGSGSG	TDFTL	KIS	RV	EA	DV	GVY	Y	CF	Q	SH	VP	TF	GG	TV	112
Db	61	SGVPDR	FGSGSG	TDFTL	KIS	RV	EA	DL	GVY	Y	CF	Q	SH	VP	TF	GG	TK	112

RESULT 15
 US-11-012-353-57
 / Sequence 57, Application US/11012353
 / Publication No. US20050249730A1
 / GENERAL INFORMATION:
 / APPLICANT: GOETSCH, LILIANE
 / APPLICANT: CORVAIA, NATHALIE
 / APPLICANT: DUFLOS, ALAIN
 / APPLICANT: HAEUW, JEAN-FRANCOIS
 / APPLICANT: LEGER, OLIVIER
 / APPLICANT: BECK, ALAIN
 / TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
 / TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
 / FILE REFERENCE: 017753-198
 / CURRENT APPLICATION NUMBER: US/11/012,353
 / CURRENT FILING DATE: 2004-12-16
 / PRIOR APPLICATION NUMBER: 10/735,916
 / PRIOR FILING DATE: 2003-12-16
 / PRIOR APPLICATION NUMBER: FR 0308538
 / PRIOR FILING DATE: 2003-07-11
 / PRIOR APPLICATION NUMBER: PCT/FR03/00178
 / PRIOR FILING DATE: 2003-01-20
 / PRIOR APPLICATION NUMBER: FR 0205753
 / PRIOR FILING DATE: 2002-05-07
 / PRIOR APPLICATION NUMBER: FR 0200653
 / PRIOR FILING DATE: 2002-01-18
 / PRIOR APPLICATION NUMBER: FR 0200654
 / PRIOR FILING DATE: 2002-01-18
 / NUMBER OF SEQ ID NOS: 162
 / SOFTWARE: PatentIn Ver. 3.3
 / SEQ ID NO 57
 / LENGTH: 112
 / TYPE: PRT
 / ORGANISM: Mus musculus
 US-11-012-353-57

Query Match	87.4%	Score 520;	DB 7;	Length 112;
Best Local Similarity	86.6%;	Pred. No. 1.6e-34;		
Matches 97: Conservative	10;	Mismatches 5;	Indels 0;	Gaps 0;

[illegible]

Search completed: January 10, 2006, 21:36:23
Job time : 6.71144 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:53:43 ; Search time 61.4328 Seconds
(without alignments)
761.757 Million cell updates/sec

Title: US-10-735-916A-61
Perfect score: 595
Sequence: 1 DVVMTQSPSLPVTGPEPAS.....CFQGSHPVWTFGGTKVEIK 112

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications_AA_Main:*
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	595	100.0	112	5	US-10-735-916A-61
2	595	100.0	131	5	US-10-735-916A-63
3	594	99.8	112	5	US-10-735-916A-65
4	594	99.8	131	5	US-10-735-916A-67
5	563	94.6	112	4	US-10-308-817-182
6	563	94.6	112	4	US-10-453-698-182
7	563	94.6	112	4	US-10-434-469-19
8	563	94.6	112	4	US-10-258-728-28
9	563	94.6	112	5	US-10-482-105-17
10	563	94.6	112	5	US-10-500-207A-19
11	560	94.1	112	5	US-10-500-207A-47
12	560	94.1	132	4	US-10-388-214A-6
13	559	93.9	112	4	US-10-258-728-27
14	558	93.8	112	4	US-10-258-728-26
15	557	93.6	112	4	US-10-434-469-41
16	557	93.6	112	5	US-10-482-105-39
17	557	93.6	112	5	US-10-858-855-7
18	557	93.6	112	5	US-10-500-207A-44
19	556	93.4	112	5	US-10-500-207A-46
20	553	92.9	112	5	US-10-500-207A-42
21	550	92.4	112	4	US-10-308-817-180
22	550	92.4	112	4	US-10-453-698-180
23	548	92.1	112	4	US-10-453-698-181
24	547	91.9	112	4	US-10-231-452-12
25	547	91.9	112	5	US-10-505-980-19
26	546	91.8	112	4	US-10-231-452-8
27	546	91.8	112	5	US-10-505-980-12

28	546	91.8	112	5	US-10-500-207A-43	Sequence 43, Appl
29	546	91.8	112	5	US-10-500-207A-51	Sequence 51, Appl
30	545	91.6	112	5	US-10-500-207A-45	Sequence 45, Appl
31	544	91.4	112	4	US-10-231-452-14	Sequence 14, Appl
32	544	91.4	112	5	US-10-505-980-21	Sequence 21, Appl
33	544	91.4	131	3	US-09-947-839-95	Sequence 95, Appl
34	543	91.3	112	4	US-10-231-452-13	Sequence 13, Appl
35	543	91.3	112	5	US-10-505-980-20	Sequence 20, Appl
36	543	91.3	116	3	US-09-753-436-66	Sequence 66, Appl
37	543	91.3	116	4	US-10-163-942-66	Sequence 66, Appl
38	543	91.3	116	5	US-10-745-115-66	Sequence 40, Appl
39	542	91.1	112	4	US-10-434-469-40	Sequence 38, Appl
40	542	91.1	112	5	US-10-482-105-38	Sequence 50, Appl
41	542	91.1	112	5	US-10-500-207A-50	Sequence 21, Appl
42	539	90.6	112	4	US-10-434-469-21	Sequence 19, Appl
43	539	90.6	112	5	US-10-482-105-19	Sequence 21, Appl
44	539	90.6	112	5	US-10-500-207A-21	Sequence 54, Appl
45	538	90.4	112	5	US-10-735-916A-54	

ALIGNMENTS

RESULT 1
US-10-735-916A-61
; Sequence 61, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 61
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-61

Query Match	100.0%	Score 595;	DB 5;	Length 112;
Best Local Similarity	100.0%	Pred. No. 1.7e-46;		
Matches 112;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	DVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLPKPGSPQLLIYKVSRL	60	
Db	1	DVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLPKPGSPQLLIYKVSRL	60	
QY	61	YGVPRFSGSGGTFTLKISRVEAEDGYYFCQGSHPVWTFGGTKVEIK	112	
Db	61	YGVPRFSGSGGTFTLKISRVEAEDGYYFCQGSHPVWTFGGTKVEIK	112	

RESULT 2
US-10-735-916A-63
; Sequence 63, Application US/10735916A
; Publication No. US20050084906A1

```
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-1R ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 01753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 63
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-63

Query Match      100.0%; Score 595; DB 5; Length 131;
Best Local Similarity 100.0%; Pred. No. 2e-46;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  DVVMTQSPSLPVTTPGEPASISCRSSQSIHVHSGNTYQLQWYLPKPGSPQLLIYKVSNRL 60
Db      20  DVVMTQSPSLPVTTPGEPASISCRSSQSIHVHSGNTYQLQWYLPKPGSPQLLIYKVSNRL 79

Qy      61  YGVDPFRFSGSGTDTFLKISRVEADVGVVYCFQGSHPVWTFGGTKVEIK 112
Db      80  YGVDPFRFSGSGTDTFLKISRVEADVGVVYCFQGSHPVWTFGGTKVEIK 131

RESULT 3
; Sequence 65, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-1R ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 01753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 65
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Homo sapiens

US-10-735-916A-65

Query Match      99.8%; Score 594; DB 5; Length 131;
Best Local Similarity 99.1%; Pred. No. 2.5e-46;
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1  DVVMTQSPSLPVTTPGEPASISCRSSQSIHVHSGNTYQLQWYLPKPGSPQLLIYKVSNRL 60
Db      20  DVVMTQSPSLPVTTPGEPASISCRSSQSIHVHSGNTYQLQWYLPKPGSPQLLIYKVSNRL 79

Qy      61  YGVDPFRFSGSGTDTFLKISRVEADVGVVYCFQGSHPVWTFGGTKVEIK 112
Db      80  YGVDPFRFSGSGTDTFLKISRVEADVGVVYCFQGSHPVWTFGGTKVEIK 131

RESULT 4
US-10-735-916A-67
; Sequence 67, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-1R ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 01753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR FILING DATE: 2003/08 538
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 67
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-735-916A-67

Query Match      99.8%; Score 594; DB 5; Length 131;
Best Local Similarity 99.1%; Pred. No. 2.5e-46;
Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1  DVVMTQSPSLPVTTPGEPASISCRSSQSIHVHSGNTYQLQWYLPKPGSPQLLIYKVSNRL 60
Db      20  DVVMTQSPSLPVTTPGEPASISCRSSQSIHVHSGNTYQLQWYLPKPGSPQLLIYKVSNRL 79

Qy      61  YGVDPFRFSGSGTDTFLKISRVEADVGVVYCFQGSHPVWTFGGTKVEIK 112
Db      80  YGVDPFRFSGSGTDTFLKISRVEADVGVVYCFQGSHPVWTFGGTKVEIK 131

RESULT 5
US-10-308-817-182
; Sequence 182, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; APPLICANT: Rother, Russell
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37
; CURRENT APPLICATION NUMBER: US/10/308,817
; CURRENT FILING DATE: 2002-12-03
; NUMBER OF SEQ ID NOS: 195
```

```
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 182
; LENGTH: 112
; TYPE: PRT
; ORGANISM: human
US-10-308-817-182

Query Match          94.6%; Score 563; DB 4; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.4e-43;
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLQKPGQSPQLLIYKVSNRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DIVMTQSPSLPVTPGEPASISCRSSQNIIVHSNGDTYLEWYLQKPGQSPQLLIYKVSNRF 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGGTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGGTKVEIK 112

RESULT 6
US-10-453-698-182
; Sequence 182, Application US/10453698
; Publication No. US20040038308A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 82 CIP (1087-37 CIP)
; CURRENT APPLICATION NUMBER: US/10/453,698
; PRIORITY FILING DATE: 2003-06-03
; NUMBER OF SEQ ID NOS: 196
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 182
; LENGTH: 112
; TYPE: PRT
; ORGANISM: human
US-10-453-698-182

Query Match          94.6%; Score 563; DB 4; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.4e-43;
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLQKPGQSPQLLIYKVSNRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DIVMTQSPSLPVTPGEPASISCRSSQNIIVHSNGDTYLEWYLQKPGQSPQLLIYKVSNRF 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGGTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGGTKVEIK 112

RESULT 7
US-10-434-469-19
; Sequence 19, Application US/10434469
; Publication No. US20040091480A1
; GENERAL INFORMATION:
; APPLICANT: Nobuo HANAI
; APPLICANT: Motoo YAMASAKI
; APPLICANT: Akiko FURUYA
; APPLICANT: Akira TANAKA
; APPLICANT: Kenya SHITARA
; APPLICANT: Naoki SHIMADA
; TITLE OF INVENTION: Anti-fib1roblast growth factor-8 monoclonal antibod
; FILE REFERENCE: 249-310
; CURRENT APPLICATION NUMBER: US/10/434,469
; PRIORITY FILING DATE: 2003-05-09
; PRIOR APPLICATION NUMBER: JP 08-081754
; PRIOR FILING DATE: 1996-04-03
; PRIOR APPLICATION NUMBER: US 08/832,236
; PRIOR FILING DATE: 1997-04-03
; PRIOR APPLICATION NUMBER: US 09/326,590
; PRIOR FILING DATE: 1999-06-07
; PRIOR APPLICATION NUMBER: US 09/876,040
```

```
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: VL synthetic peptide
US-10-434-469-19

Query Match          94.6%; Score 563; DB 4; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.4e-43;
Matches 105; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLQKPGQSPQLLIYKVSNRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DIVMTQSPSLPVTPGEPASISCRSSQSLVHSNGRTYLEWYLQKPGQSPQLLIYKVSNRI 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGGTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGGTKVEIK 112

RESULT 8
US-10-258-728-28
; Sequence 28, Application US/10258728
; Publication No. US20040091485A1
; GENERAL INFORMATION:
; APPLICANT: Durrant, John Robert Maxwell
; APPLICANT: Durrant, Linda Gillian
; TITLE OF INVENTION: Humanised Antibodies to the Epidermal Growth Factor Receptor
; FILE REFERENCE: 28438-101US01
; CURRENT APPLICATION NUMBER: US/10/258,728
; PRIORITY FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: GB 0011981.8
; PRIOR FILING DATE: 2000-05-19
; PRIOR APPLICATION NUMBER: GB 0020794.4
; PRIOR FILING DATE: 2000-08-24
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-258-728-28

Query Match          94.6%; Score 563; DB 4; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.4e-43;
Matches 105; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLQKPGQSPQLLIYKVSNRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 DVLTQSPSLPVTPGEPASASCRSSQSIIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRF 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGGTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGGTKVEIK 112

RESULT 9
US-10-482-105-17
; Sequence 17, Application US/10482105
; Publication No. US20040253234A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD
; TITLE OF INVENTION: Humanized anti-FGF-8 antibody and the antibody fragment thereof
; FILE REFERENCE: 11399WO1
; CURRENT APPLICATION NUMBER: US/10/482,105
; PRIORITY FILING DATE: 2003-12-24
; PRIOR APPLICATION NUMBER: JP2001-196176
; PRIOR FILING DATE: 2001-06-28
; NUMBER OF SEQ ID NOS: 41
```

```
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic protein
US-10-482-105-17

Query Match          94.6%; Score 563; DB 5; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.4e-43;
Matches 105; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 DVMVTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLOWYLQKPGQSPQLLIYKVSNRL 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||:
Db 1 DVMVTQSPSLSPVTPGEPASISCRSSQSLVHSGNTYLEWYLQKPGQSPQLLIYKVSNRI 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||:

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPMTFGGQTKVEIK 112
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPMTFGGQTKVEIK 112
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 10
US-10-500-207A-19
; Sequence 19, Application US/10500207A
; Publication No. US20050175608A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD
; TITLE OF INVENTION: AGENT FOR TREATING ARTHRITIS
; FILE REFERENCE: 1442
; CURRENT APPLICATION NUMBER: US/10/500,207A
; CURRENT FILING DATE: 2004-06-28
; PRIOR APPLICATION NUMBER: JP2001-400677
; PRIOR FILING DATE: 2001-12-28
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 19
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: LV.0, a designed amino acid sequence of VL of
; OTHER INFORMATION: an anti-FGF-8 CDR-grafted neutralizing antibody
US-10-500-207A-19

Query Match          94.6%; Score 563; DB 5; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.4e-43;
Matches 105; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 DVMVTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLOWYLQKPGQSPQLLIYKVSNRL 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||:
Db 1 DVMVTQSPSLSPVTPGEPASISCRSSQSLVHSGNTYLEWYLQKPGQSPQLLIYKVSNRI 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||:

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPMTFGGQTKVEIK 112
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPMTFGGQTKVEIK 112
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 11
US-10-500-207A-47
; Sequence 47, Application US/10500207A
; Publication No. US20050175608A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD
; TITLE OF INVENTION: AGENT FOR TREATING ARTHRITIS
; FILE REFERENCE: 1442
; CURRENT APPLICATION NUMBER: US/10/500,207A
; CURRENT FILING DATE: 2004-06-28
; PRIOR APPLICATION NUMBER: JP2001-400677
; PRIOR FILING DATE: 2001-12-28
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 47

; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic protein
US-10-482-105-17

Query Match          94.6%; Score 563; DB 5; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.4e-43;
Matches 105; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 DVMVTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLOWYLQKPGQSPQLLIYKVSNRL 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||:
Db 1 DVMVTQSPSLSPVTPGEPASISCRSSQSLVHSGNTYLEWYLQKPGQSPQLLIYKVSNRI 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||:

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPMTFGGQTKVEIK 112
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPMTFGGQTKVEIK 112
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 12
US-10-388-214A-6
; Sequence 6, Application US/10388214A
; Publication No. US20040082762A1
; GENERAL INFORMATION:
; APPLICANT: Basi, Gurig
; APPLICANT: Saidanha, Jose
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE BETA
; FILE REFERENCE: ELN-004
; CURRENT APPLICATION NUMBER: US/10/388,214A
; CURRENT FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/363,751
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 132
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: humanized 12BAVLv1
US-10-388-214A-6

Query Match          94.1%; Score 560; DB 4; Length 132;
Best Local Similarity 94.6%; Pred. No. 3.1e-43;
Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 DVMVTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLOWYLQKPGQSPQLLIYKVSNRL 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||:
Db 21 DVMVTQSPSLSPVTPGEPASISCRSSQSIHVSNGNTYLEWYLQKPGQSPQLLIYKVSNR 80
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||||||:

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPMTFGGQTKVEIK 112
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 81 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYFCFGSHVPMTFGGQTKLEIK 132
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 13
US-10-258-728-27
; Sequence 27, Application US/10258728
; Publication No. US20040091485A1
; GENERAL INFORMATION:
; APPLICANT: Ellis, John Robert Maxwell
; APPLICANT: Durrant, Linda Gillian
; TITLE OF INVENTION: Humanised Antibodies to the Epidermal Growth Factor Receptor
; FILE REFERENCE: 28438-101US01
; CURRENT APPLICATION NUMBER: US/10/258,728
; CURRENT FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: GB 0011981.8
```


; PRIOR FILING DATE: 2000-05-19
; PRIOR APPLICATION NUMBER: GB 0020794.4
; PRIOR FILING DATE: 2000-08-24
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 27
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-258-728-27

Query Match 93.9%; Score 559; DB 4; Length 112;
Best Local Similarity 92.9%; Pred. No. 3.2e-43;
Matches 104; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNRL 60
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 DVLMTQSPSLPVTTPGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNRF 60
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

QY 61 YGVDPFRFSGSGGTDTFTLKISRVEADVGVIYCFQGSHPVPTFGGQTKVEIK 112
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 SGVDPFRFSGSGGTDTFTLKISRVEADTGIYICFQGSHPVPTFGGQTKVEIK 112
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 14
US-10-258-728-26
; Sequence 26, Application US/10258728
; Publication No. US20040091485A1
; GENERAL INFORMATION:
; APPLICANT: Ellis, John Robert Maxwell
; APPLICANT: Durrant, Linda Gillian
; TITLE OF INVENTION: Humanised Antibodies to the Epidermal Growth Factor Receptor
; FILE REFERENCE: 28438-101US01
; CURRENT APPLICATION NUMBER: US/10/258,728
; CURRENT FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: GB 0011981.8
; PRIOR FILING DATE: 2000-05-19
; PRIOR APPLICATION NUMBER: GB 0020794.4
; PRIOR FILING DATE: 2000-08-24
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-258-728-26

Query Match 93.8%; Score 558; DB 4; Length 112;
Best Local Similarity 92.9%; Pred. No. 4e-43;
Matches 104; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNRL 60
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 DVLMTQSPSLPVTTPGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNRF 60
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

QY 61 YGVDPFRFSGSGGTDTFTLKISRVEADVGVIYCFQGSHPVPTFGGQTKVEIK 112
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 SGVDPFRFSGSGGTDTFTLKISRVEADTGIYICFQGSHPVPTFGGQTKVEIK 112
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 15
US-10-434-469-41
; Sequence 41, Application US/10434469
; Publication No. US20040091480A1
; GENERAL INFORMATION:
; APPLICANT: Nobuo HANAI
; APPLICANT: Motoo YAMASAKI
; APPLICANT: Akiko FURUYA
; APPLICANT: Akira TANAKA
; APPLICANT: Kenya SHITARA
; APPLICANT: Naoki SHIMADA
; TITLE OF INVENTION: Anti-fibrolblast growth factor-8 monoclonal antibod
; FILE REFERENCE: 249-310

; CURRENT APPLICATION NUMBER: US/10/434,469
; CURRENT FILING DATE: 2003-05-09
; PRIOR APPLICATION NUMBER: JP 08-081754
; PRIOR FILING DATE: 1996-04-03
; PRIOR APPLICATION NUMBER: US 08/832,236
; PRIOR FILING DATE: 1997-04-03
; PRIOR APPLICATION NUMBER: US 09/326,590
; PRIOR FILING DATE: 1999-06-07
; PRIOR APPLICATION NUMBER: US 09/876,040
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 41
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: LV.3-1 of VL of KM8036
US-10-434-469-41

Query Match 93.6%; Score 557; DB 4; Length 112;
Best Local Similarity 92.9%; Pred. No. 4.9e-43;
Matches 104; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPQLLIYKVSNRL 60
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 DVVMTQSPSLPVTTPGEPASISCRSSQSLVHSNGRTYLEWYLOKPGQSPQLLIYKVSNNRI 60
||:||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

QY 61 YGVDPFRFSGSGGTDTFTLKISRVEADVGVIYCFQGSHPVPTFGGQTKVEIK 112
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 SGVDPFRFSGSGGTDTFTLKISRVEADVGVIYCFQGSHPVPTFGGQTKVEIK 112
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Search completed: January 10, 2006, 21:35:30
Job time : 61.4328 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:34:27 ; Search time 21.8706 Seconds
(without alignments)
423.384 Million cell updates/sec

Title: US-10-735-916A-61

Perfect score: 595

Sequence: 1 DVNMTQSLPLVTPGRPAS.....CFQSHVPTFGQTKVEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA.*

1: /cgn2_6/ptodata/1/1aa/5 COMB.pcp.*

2: /cgn2_6/ptodata/1/1aa/6 COMB.pcp.*

3: /cgn2_6/ptodata/1/1aa/H COMB.pcp.*

4: /cgn2_6/ptodata/1/1aa/PCTUS COMB.pcp.*

5: /cgn2_6/ptodata/1/1aa/RE COMB.pcp.*

6: /cgn2_6/ptodata/1/1aa/backfiles1.pcp.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	560	94.1	112	1	US-08-331-398A-50
2	560	94.1	112	1	US-08-331-397B-50
3	560	94.1	112	1	US-08-759-804A-50
4	560	94.1	112	2	US-09-227-693-50
5	556	93.4	112	1	US-08-053-171-15
6	556	93.4	112	2	US-08-815-190A-14
7	544	91.4	131	1	US-08-129-930B-95
8	544	91.4	131	2	US-08-134-346A-50
9	544	91.4	131	2	US-08-976-288A-95
10	543	91.3	116	1	US-08-482-882-66
11	543	91.3	116	1	US-08-483-389-66
12	543	91.3	116	1	US-08-487-113D-66
13	543	91.3	116	1	US-08-473-503-66
14	543	91.3	116	1	US-08-483-932-66
15	543	91.3	116	1	US-08-720-420A-66
16	543	91.3	116	2	US-08-714-017-66
17	543	91.3	116	2	US-08-475-680-66
18	526	88.4	112	1	US-08-478-039-88
19	526	88.4	112	1	US-08-476-349A-88
20	522	87.7	149	2	US-09-192-838B-2
21	522	87.7	149	2	US-09-324-191-2
22	522	87.7	263	1	US-08-752-844-66
23	522	87.7	263	2	US-09-293-533-66
24	520	87.4	112	1	US-08-331-398A-48
25	520	87.4	112	1	US-08-077-252B-3
26	520	87.4	112	1	US-08-331-397B-48
27	520	87.4	112	1	US-08-759-804A-48

28	520	87.4	112	2	US-09-002-753A-3
29	520	87.4	112	2	US-09-227-693-48
30	520	87.4	112	2	US-09-657-274-3
31	520	87.4	112	4	PCT-US94-06687-3
32	520	87.4	125	1	US-08-331-398A-67
33	520	87.4	125	1	US-08-331-397B-67
34	520	87.4	125	1	US-08-759-804A-66
35	520	87.4	149	1	US-08-752-844-2
36	520	87.4	149	1	US-08-591-196-2
37	520	87.4	149	2	US-09-293-533-2
38	520	87.4	247	2	US-09-227-693-34
39	520	87.4	248	1	US-08-331-398A-34
40	520	87.4	248	1	US-08-331-397B-34
41	520	87.4	248	1	US-08-759-804A-34
42	518	87.1	112	1	US-08-859-649-19
43	518	87.1	112	1	US-08-859-649-29
44	518	87.1	112	2	US-08-207-861-19
45	518	87.1	112	2	US-08-207-861-29

ALIGNMENTS

RESULT 1
US-08-331-398A-50
; Sequence 50, Application US/08331398A
; Patent No. 5608039
; GENERAL INFORMATION:
; APPLICANT: Pastan, Ira
; APPLICANT: Willingham, Mark
; APPLICANT: Fitzgerald, David
; APPLICANT: Brinkmann, Ulrich
; APPLICANT: Pai, Lee
; TITLE OF INVENTION: Single Chain B3 Antibody Fusion Proteins
; TITLE OF INVENTION: and Their Uses (as amended)
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew
; STREET: One Market Plaza, Steuart Street Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105-1492

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/331.398A
; FILING DATE: 28-OCT-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/767.331
; FILING DATE: 30-SEP-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/596.289
; FILING DATE: 12-OCT-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Hunter, Tom
; REGISTRATION NUMBER: 38,498
; REFERENCE/DOCKET NUMBER: 015280-126110US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 543-9600
; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:

NAME/KEY: Protein
LOCATION: 1..112
OTHER INFORMATION: /note= "Humanized B3 Variable Light chain (V-L) (HumB3V-L)"
US-08-331-397B-50

Query Match 94.1%; Score 560; DB 1; Length 112;
Best Local Similarity 94.6%; Pred. No. 1.8e-47;
Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVMTQSPSLPVTGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVLMTQSPSLPVTGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPFRSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVPTFGQGTKEIK 112
Db 61 SGVDPFRSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVPTFGQGTKEIK 112

RESULT 2

US-08-331-397B-50
; Sequence 50, Application US/08331397B
; Patent No. 5981726
; GENERAL INFORMATION:
; APPLICANT: Pastan, Ira
; APPLICANT: Benhar, Itai
; TITLE OF INVENTION: Chimeric and Mutationally Stabilized Tumor-
; TITLE OF INVENTION: Specific Antibody Fragments, Fusion Proteins, and Uses
; TITLE OF INVENTION: Thereof
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew
; STREET: One Market Plaza, Steuart Street Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105-1492

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/331,397B
; FILING DATE: 28-OCT-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/767,331
; FILING DATE: 30-SEP-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/596,289
; FILING DATE: 12-OCT-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Hunter, Tom
; REGISTRATION NUMBER: 38,498
; REFERENCE/DOCKET NUMBER: 015280-126120US
; TELEPHONE: (415) 543-9600
; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..112
; OTHER INFORMATION: /note= "Humanized B3 Variable Light chain (V-L) (HumB3V-L)"
US-08-331-397B-50

Query Match 94.1%; Score 560; DB 1; Length 112;
Best Local Similarity 94.6%; Pred. No. 1.8e-47;
Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVMTQSPSLPVTGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVLMTQSPSLPVTGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPFRSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVPTFGQGTKEIK 112
Db 61 SGVDPFRSGSGGTDFTLKISRVEAEDVGVYCFQGSHPVPTFGQGTKEIK 112

RESULT 3

US-08-759-804A-50
; Sequence 50, Application US/08759804A
; Patent No. 5990296
; GENERAL INFORMATION:
; APPLICANT: Pastan, Ira
; APPLICANT: Willingham, Mark
; APPLICANT: Fitzgerald, David J.
; APPLICANT: Brinkmann, Ulrich
; APPLICANT: Pai, Lee
; TITLE OF INVENTION: Tumor-Specific Antibody Fragments,
; TITLE OF INVENTION: Fusion Proteins, and Uses Thereof
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/759,804A
; FILING DATE: 03-DEC-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/331,398
; FILING DATE: 28-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/767,331
; FILING DATE: 30-SEP-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/596,289
; FILING DATE: 12-OCT-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Ellen L.
; REGISTRATION NUMBER: 32,762
; REFERENCE/DOCKET NUMBER: 015280-126140US
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..112
; OTHER INFORMATION: /note= "Humanized B3 Variable Light chain (V-L) (HumB3V-L)"
US-08-759-804A-50

Query Match 94.1%; Score 560; DB 1; Length 112;


```
;
; OTHER INFORMATION: antibody."
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 108
; OTHER INFORMATION: /note= "Residue in the framework
; OTHER INFORMATION: that is replaced with mouse amino acid in the
; OTHER INFORMATION: humanized antibody."
US-08-053-171-15

Query Match      93.4%; Score 556; DB 1; Length 112;
Best Local Similarity 93.8%; Pred. No. 4.4e-47;
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLQKPGQSPQLLIYKVSRL 60
Db 1 DIVMTQSPSLPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLQKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPFRFGSGSGTDFTLKISRVEADVGVVYCFQGSHPVPTFGGTTKVEIK 112
Db 61 SGVDPFRFGSGSGTDFTLKISRVEADVGVVYCFQGSHPVPTFGGTTKLEIK 112

RESULT 6
US-08-815-190A-14
; Sequence 14, Application US/08815190A
; Patent No. 6046310
; GENERAL INFORMATION:
; APPLICANT: Queen, Cary L.
; APPLICANT: Schneider, William P.
; APPLICANT: Vasquez, Maximiliano
; TITLE OF INVENTION: Fas Ligand Fusion Proteins and Their
; TITLE OF INVENTION: Uses
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/815,190A
; FILING DATE: 11-MAR-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/614,584
; FILING DATE: 13-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 011823-006710US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..112
; OTHER INFORMATION: /note= "mature light chain variable
; OTHER INFORMATION: region of humanized ABL 364 antibody"
US-08-815-190A-14
```

```
Query Match      93.4%; Score 556; DB 2; Length 112;
Best Local Similarity 93.8%; Pred. No. 4.4e-47;
Matches 105; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLQKPGQSPQLLIYKVSRL 60
Db 1 DIVMTQSPSLPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLQKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPFRFGSGSGTDFTLKISRVEADVGVVYCFQGSHPVPTFGGTTKVEIK 112
Db 61 SGVDPFRFGSGSGTDFTLKISRVEADVGVVYCFQGSHPVPTFGGTTKLEIK 112

RESULT 7
US-08-129-930B-95
; Sequence 95, Application US/08129930B
; Patent No. 5804187
; GENERAL INFORMATION:
; APPLICANT: do Couto Dr., Fernando J.R.
; APPLICANT: Ceriani Dr., Roberto L.
; APPLICANT: Peterson Dr., Jerry A.
; APPLICANT: Padian Dr., Eduardo A.
; TITLE OF INVENTION: Analogue Peptides With Broad
; TITLE OF INVENTION: Carcinoma Specificity, and Kit and
; TITLE OF INVENTION: Diagnostic Vaccination and
; TITLE OF INVENTION: Therapeutic Methods
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: V. AMZEL & ASSOC.
; STREET: 2055 No. 5804187th Broadway, Suite 201
; CITY: Walnut Creek
; STATE: California
; COUNTRY: USA
; ZIP: 94596
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS 5.0
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/129,930B
; FILING DATE: September 30, 1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel Ph.D., Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: CRFCC-008A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 521-1333
; TELEFAX: (510) 521-3541
; TELEX: n.a.
; INFORMATION FOR SEQ ID NO: 95:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 131 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-129-930B-95

Query Match      91.4%; Score 544; DB 1; Length 131;
Best Local Similarity 91.1%; Pred. No. 7.7e-46;
Matches 102; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLQKPGQSPQLLIYKVSRL 60
Db 20 DVLMTQSPSLPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLQKPGQSPQLLIYKVSRL 79

Qy 61 YGVDPFRFGSGSGTDFTLKISRVEADVGVVYCFQGSHPVPTFGGTTKVEIK 112
Db 80 SGVDPFRFGSGSGTDFTLKISRVEADVGVVYCFQGSHPVPTFGGTTKLEIK 131

RESULT 8
```

US-08-134-346A-50
; Sequence 50, Application US/08134346A
; Patent No. 6281335
; GENERAL INFORMATION:
; APPLICANT: do Couto, F.J.R.
; APPLICANT: Ceriani, R.L.C.
; APPLICANT: Petersen, J.A.
; TITLE OF INVENTION: HYBRIDOMA AND ANTI-KC-4 HUMANIZED
; TITLE OF INVENTION: MONOCLONAL ANTIBODY AND DNA AND RNA ENCODING IT, KIT AND
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC METHODS
; NUMBER OF SEQUENCES: 51
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ostrager, Chong & Flaherty
; STREET: 300 Park Avenue
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10022-7499
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette-3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/134,346A
; FILING DATE: 08-OCT-1993
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Onofrio, Dara L.
; REGISTRATION NUMBER: 34,889
; REFERENCE/DOCKET NUMBER: CLT 149,608
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-826-6565
; TELEFAX: 212-826-5909
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 131 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-134-346A-50

Query Match 91.4%; Score 544; DB 2; Length 131;
Best Local Similarity 91.1%; Pred. No. 7.7e-46;
Matches 102; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVMTQSLPLPVTGEPASISCRSSQSIHVSNGNTYLOWLYLQKPGQSPOLLIVKVSRL 60
Db 20 DVLMTQTPLSLPVTGEPASISCRSSQSIHVSNGNTYLOWLYLQKPGQSPOLLIVKVSIRF 79

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGKTVEIK 112
Db 80 SGVDPDRFSGSGGTDTFTLKISRVEAEDVGIYYCFQGSHPVPTFGGKTLEIK 131

RESULT 9
US-08-976-288A-95
; Sequence 95, Application US/08976288A
; Patent No. 6315997
; GENERAL INFORMATION:
; APPLICANT: do Couto Dr., Fernando J.R.
; APPLICANT: Ceriani Dr., Roberto L.
; APPLICANT: Peterson Dr., Jerry A.
; APPLICANT: Padlan Dr., Eduardo A.
; TITLE OF INVENTION: Analogue Peptides With Broad
; TITLE OF INVENTION: Carcinoma Specificity, and Kit and
; TITLE OF INVENTION: Diagnostic Vaccination and
; TITLE OF INVENTION: Therapeutic Methods
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pretty, Schroeder & Poplawski
; STREET: 444 South Flower St., 19th Floor

CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS 5.0
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/976,288A
; FILING DATE: No. 6315997ember 21, 1997
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/129,930
; FILING DATE: September 30, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/977,696
; FILING DATE: No. 6315997ember 16, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Viviana Amzel Ph.D.
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: P6639938
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 622-7700
; TELEFAX: (213) 489-4210
; TELEX: n.a.
; INFORMATION FOR SEQ ID NO: 95:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 131 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-976-288A-95

Query Match 91.4%; Score 544; DB 2; Length 131;
Best Local Similarity 91.1%; Pred. No. 7.7e-46;
Matches 102; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVMTQSLPLPVTGEPASISCRSSQSIHVSNGNTYLOWLYLQKPGQSPOLLIVKVSRL 60
Db 20 DVLMTQTPLSLPVTGEPASISCRSSQSIHVSNGNTYLOWLYLQKPGQSPOLLIVKVSIRF 79

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGKTVEIK 112
Db 80 SGVDPDRFSGSGGTDTFTLKISRVEAEDVGIYYCFQGSHPVPTFGGKTLEIK 131

RESULT 10
US-08-482-882-66
; Sequence 66, Application US/08482882
; Patent No. 5773218
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/482,882
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435

```

RESULT 11
US-08-483-389-66
; Sequence 66, Application US/08483389
; Patent No. 5811517
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-RELATED PROTEIN
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray
; STREET: 233 South Wacker Drive/6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,389
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852

```

RESULT 12
US-08-487-113D-66
; Sequence 66, Application US/08487113D
; Patent No. 5837822
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/487,113D
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993


```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5837822and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32744
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-487-113D-66

Query Match 91.3%; Score 543; DB 1; Length 116;
Best Local Similarity 91.1%; Pred. No. 8.5e-46;
Matches 102; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPVLPVTGEPASISCRSSQSLVHSNGNTYLQWYLPKPGSPQLLIYKVSRL 60
Db 5 DIVMTQSPVLPVTGEPASISCRSSQSLVHSNGDTYHLHWYLPKPGSPQLLIYKVSRL 64

Qy 61 YGVDPDRFGSGSGDTFTLKISRVEADVGVIYCFQGSHPVMTFGGQTKVEIK 112
Db 65 SGVDPDRFGSGSGDTFTLKISRVEADVGVIYCSQSTHVPYTFGGQTKVEIK 116

RESULT 13
US-08-473-503-66
; Sequence 66, Application US/08473503
; Patent No. 5869262
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/473,503
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5869262and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-473-503-66

Query Match 91.3%; Score 543; DB 1; Length 116;
Best Local Similarity 91.1%; Pred. No. 8.5e-46;
Matches 102; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPVLPVTGEPASISCRSSQSLVHSNGNTYLQWYLPKPGSPQLLIYKVSRL 60
Db 5 DIVMTQSPVLPVTGEPASISCRSSQSLVHSNGDTYHLHWYLPKPGSPQLLIYKVSRL 64

Qy 61 YGVDPDRFGSGSGDTFTLKISRVEADVGVIYCFQGSHPVMTFGGQTKVEIK 112
Db 65 SGVDPDRFGSGSGDTFTLKISRVEADVGVIYCSQSTHVPYTFGGQTKVEIK 116

RESULT 14
US-08-483-932-66
; Sequence 66, Application US/08483932
; Patent No. 5880268
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,932
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5880268and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-483-932-66

Query Match          91.3%; Score 543; DB 1; Length 116;
Best Local Similarity 91.1%; Pred. No. 8.5e-46;
Matches 102; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLWYLRKPGSPQLLIYKVSRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHNSGDTYHLHWYLRKPGSPQLLIYKVSRL 64
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDVGVYYCQGSHPVPTFGQGTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 65 SGVPDRFSGSGGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGQGTKVEIK 116
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 15
US-08-720-420A-66
; Sequence 66, Application US/08720420A
; Patent No. 5989843
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/720,420A
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/487,113
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
```

```
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Williams, Joseph A., Jr.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 33282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-720-420A-66

Query Match          91.3%; Score 543; DB 1; Length 116;
Best Local Similarity 91.1%; Pred. No. 8.5e-46;
Matches 102; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYQLWYLRKPGSPQLLIYKVSRL 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 5 DIVMTQSPSLPVTGEPASISCRSSQSLVHNSGDTYHLHWYLRKPGSPQLLIYKVSRL 64
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDVGVYYCQGSHPVPTFGQGTKVEIK 112
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 65 SGVPDRFSGSGGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGQGTKVEIK 116
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Search completed: January 10, 2006, 20:58:03
Job time : 22.8706 secs
```

Result No.	Score	Query Match	Length	DB ID	Description	
1	524	88.1	131	2	B39276	Ig light chain pre
2	523	87.9	113	2	PL0203	anti-DNA autoantib
3	517	86.9	219	2	S52028	Ig kappa chain - m
4	514	86.4	112	2	A11807	Ig kappa chain v r
5	514	86.4	219	2	PC4203	Ig kappa chain (mo
6	513	86.2	110	2	S62335	Ig kappa chain v r
7	513	86.2	112	2	S58207	Ig light chain v r
8	513	86.2	112	2	S38719	Ig light chain v r
9	513	86.2	136	2	S40357	Ig kappa chain v-J
10	510	85.7	114	2	A32967	Ig kappa chain v-I
11	509	85.5	118	2	PT0359	Ig kappa chain v r
12	509	85.5	131	2	B34904	Ig kappa chain pre
13	507	85.2	112	2	B31485	Ig kappa chain v r
14	505	84.9	112	2	C27887	Ig kappa chain v r
15	505	84.9	131	2	C34904	Ig kappa chain pre
16	503	84.5	112	2	A27887	Ig kappa chain v r
17	502	84.4	112	2	F27887	Ig kappa chain v r
18	502	84.4	115	2	S38715	Ig kappa chain v-I
19	501	84.2	114	2	B32967	Ig kappa chain v r
20	500	84.0	112	2	E27887	Ig kappa chain v r
21	500	84.0	131	2	B30577	Ig kappa chain pre
22	500	84.0	132	2	S26882	Ig kappa chain v r
23	500	84.0	133	1	K2HURP	Ig kappa chain v r
24	500	84.0	219	2	S16112	Ig kappa chain v r
25	499	83.9	103	2	PH1043	Ig kappa chain pre
26	499	83.9	131	2	D34904	Ig kappa chain pre
27	499	83.9	131	2	B32513	Ig kappa chain pre
28	499	83.9	135	2	S40342	Ig kappa chain - h
29	498	83.7	112	2	D28195	Ig kappa chain v r

Query Match 87.9%; Score 523; DB 2; Length 113;
Best Local Similarity 87.5%; Pred. No. 1.7e-42; Mismatches 5; Indels 0; Gaps 0;
Matches 98; Conservative 9; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDGIVYYCFQGSHPVPTFGGTVKVEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDLGIVYYCFQGSHPVPTFGGTVKLEIK 112

RESULT 3
S52028
Ig kappa chain - mouse
C:Species: Mus musculus (house mouse)
C:Date: 07-May-1995 #sequence_revision 21-Jul-1995 #text_change 21-Jan-2000
C:Accession: S52028
R:van Engelen, P.; Schouten, A.; Molthoff, J.W.; Roosien, J.; Dirkse, W.G.; Schots, A.;
submitted to the EMBL Data Library, August 1994
A:Description: Coordinate expression of antibody subunit genes yields high levels of fun
A:Reference number: S52028
A:Accession: S52028
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-219 <VNA>
A:Cross-references: UNIPARC:UPI0000114B22; EMBL:L35138; NID:G522336; PIDN:AAA67525.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.9%; Score 517; DB 2; Length 219;
Best Local Similarity 88.4%; Pred. No. 1.3e-41;
Matches 99; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDGIVYYCFQGSHPVPTFGGTVKVEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDLGIVYYCFQGSHPVPTFGGTVKLEIK 112

RESULT 4
A31807
Ig kappa chain V region (PAC1) - mouse
C:Species: Mus musculus (house mouse)
C:Date: 20-Jul-1989 #sequence_revision 20-Jul-1989 #text_change 09-Jul-2004
C:Accession: A31807
R:Taub, R.; Gould, R.J.; Garasky, V.M.; Ciccarone, T.M.; Hoxie, J.; Friedman, P.A.; Shatt
J. Biol. Chem. 264, 259-265, 1989
A:Title: A monoclonal antibody against the platelet fibrinogen receptor contains a seque
A:Reference number: A31807; MUID:89079661; PMID:2909518
A:Accession: A31807
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-112 <TAU>
A:Cross-references: UNIPROT:Q9M37; UNIPARC:UPI00001424F9
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.4%; Score 514; DB 2; Length 112;
Best Local Similarity 85.7%; Pred. No. 1.2e-41;
Matches 96; Conservative 11; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDGIVYYCFQGSHPVPTFGGTVKVEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDLGIVYYCFQGSHPVPTFGGTVKLEIK 112

RESULT 5
PC4203
Ig kappa chain (monoclonal antibody MAbA34) - mouse (fragment)
C:Species: Mus musculus (house mouse)
C:Date: 31-Dec-1996 #sequence_revision 31-Dec-1996 #text_change 11-Jan-2000
C:Accession: PC4203
R:Kwak, J.W.; Lee, D.I.; Choi, B.K.; Cho, W.K.; Lee, S.H.; Park, Y.B.; Han, M.H.
Gene 173, 257-259, 1996
A:Title: Cloning and characterization of cDNAs coding for heavy and light chains of a m
A:Reference number: PC4202; MUID:97082978; PMID:8964510
A:Accession: PC4203
A:Molecule type: mRNA
A:Residues: 1-219 <KWA>
A:Cross-references: UNIPARC:UPI00001157E4; GB:U29147; NID:G1594225; PIDN:AAC52821.1; PID
C:Comment: This protein is specific for human plasma apolipoprotein A-I of high-density
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:1-112/Domain: V region #status predicted <VRG>
F:113-219/Domain: C region #status predicted <CRG>

Query Match 86.4%; Score 514; DB 2; Length 219;
Best Local Similarity 86.6%; Pred. No. 2.5e-41;
Matches 97; Conservative 9; Mismatches 6; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDGIVYYCFQGSHPVPTFGGTVKVEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDLGIVYYCFQGSHPVPTFGGTVKLEIK 112

RESULT 6
S26335
Ig kappa chain V region - mouse
C:Species: Mus musculus (house mouse)
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C:Accession: S26335
R:Stark, S.B.; Caton, A.J.
J. Exp. Med. 174, 613-624, 1991
A:Title: Antibodies that are specific for a single amino acid interchange in a protein e
A:Reference number: S26309; MUID:91341421; PMID:1908510
A:Accession: S26335
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-110 <STA>
A:Cross-references: UNIPARC:UPI0000115F78; EMBL:X59183; NID:G52314; PIDN:CAA41893.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.2%; Score 513; DB 2; Length 110;
Best Local Similarity 87.3%; Pred. No. 1.4e-41;
Matches 96; Conservative 9; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
Db 1 DVVMTQSPSLPVTGPEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDGIVYYCFQGSHPVPTFGGTVKVE 110
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDLGIVYYCFQGSHPVPTFGGTVKLE 110

RESULT 7
S58207
Ig light chain V region anti-F(ab')2 - human (fragment)
C:Species: Homo sapiens (man)

C>Date: 13-Jan-1996 #sequence_revision 19-Apr-1996 #text_change 21-Jan-2000
A:Accession: S58207
R:Weischhof, M.; Terness, P.; Stanescu, D.; Zewe, M.; Hain, C.H.; Doebel, S.; Breitling, submitted to the EMBL Data Library, July 1995
A:Description: Characterization of heavy and light chain immunoglobulin variable region
A:Reference number: S58206
A:Accession: S58207
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-112 <WEL>
A:Cross-references: UNIPARC:UPI0000116253; EMBL:X89056; NID:G929642; PIDN:CAA61443.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.2%; Score 513; DB 2; Length 112;
Best Local Similarity 86.6%; Pred. No. 1.5e-41;
Matches 97; Conservative 3; Mismatches 12; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVHNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 DIVMTQSPSLPVTGEPASISCRSSQSLHSGNYLDWYLOKPGQSPQLLIYLGSRNA 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEADVGYYCFQGSHPVPTFGQGTKEIK 112
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Db 61 SGVDPDRFSGSGGTDTFTLKISRVEADVGYYCQALQTPMTFGQGTKEIK 112
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 8

S38719
Ig light chain V region - mouse
C:Species: Mus musculus (house mouse)
C>Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 20-Jun-2000
C:Accession: S38719
R:Cimanis, A.Y.
submitted to the EMBL Data Library, November 1993
A:Reference number: S38713
A:Accession: S38719
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-112 <CIM>
A:Cross-references: UNIPARC:UPI0000117543; EMBL:X76021; NID:G416112; PIDN:CAAS3608.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.2%; Score 513; DB 2; Length 112;
Best Local Similarity 85.7%; Pred. No. 1.5e-41;
Matches 96; Conservative 10; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVHNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 DIVMTQSPSLPVTGEPASISCRSSQSIYVNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEADVGYYCFQGSHPVPTFGQGTKEIK 112
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Db 61 SGVDPDRFSGSGGTDTFTLKISRVEADLGYYCFQGSHPVPTFGAGTKLEK 112
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 9

S40357
Ig kappa chain V-J-C region - human
C:Species: Homo sapiens (man)
C>Date: 19-May-1994 #sequence_revision 26-May-1995 #text_change 31-Dec-2004
C:Accession: S40357
R:Klein, R.; Jaenichen, R.; Zachau, H.G.
Eur. J. Immunol. 23, 3248-3271, 1993
A:Title: Expressed human immunoglobulin chi genes and their hypermutation.
A:Reference number: S40312; MUID:94080891; PMID:8258341
A:Accession: S40357
A:Status: preliminary; translation not shown
A:Molecule type: mRNA
A:Residues: 1-136 <KLE>

Query Match 85.5%; Score 509; DB 2; Length 118;
Best Local Similarity 84.8%; Pred. No. 3.7e-41;
Matches 95; Conservative 9; Mismatches 8; Indels 0; Gaps 0;

A:Cross-references: UNIPROT:Q8NEK0; UNIPARC:UPI0000176CA8; EMBL:X72467
C:Superfamily: immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:36-115/Domain: immunoglobulin homology <IMM>

Query Match 86.2%; Score 513; DB 2; Length 136;
Best Local Similarity 86.6%; Pred. No. 1.8e-41;
Matches 97; Conservative 3; Mismatches 12; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVHNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Db 21 DIVMTQSPSLPVTGEPASISCRSSQSLHSGNYLDWYLOKPGQSPQLLIYLGSRNA 80
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEADVGYYCFQGSHPVPTFGQGTKEIK 112
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Db 81 SGVDPDRFSGSGGTDTFTLKISRVEADVGYYCQALQTPMTFGQGTKEIK 132
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 10

A32967
Ig kappa chain V-II region TE33 - mouse
C:Species: Mus musculus (house mouse)
C>Date: 29-Jan-1990 #sequence_revision 29-Jan-1990 #text_change 21-Jan-2000
C:Accession: A32967
R:Levy, R.; Asaulin, O.; Scherf, T.; Levitt, M.; Anglistter, J.
Biochemistry 28, 7168-7175, 1989
A:Title: Probing antibody diversity by 2D NMR: comparison of amino acid sequences, predicted from cDNA sequence, and from protein structure.
A:Reference number: A32967; MUID:90057406; PMID:2819059
A:Accession: A32967
A:Status: preliminary; nucleic acid sequence not shown; not compared with conceptual tra
A:Molecule type: mRNA
A:Residues: 1-114 <LEV>
A:Cross-references: UNIPARC:UPI0000114F5D; GB:M30481; NID:G197157; PIDN:AAA38935.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 85.7%; Score 510; DB 2; Length 114;
Best Local Similarity 83.9%; Pred. No. 2.9e-41;
Matches 94; Conservative 12; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVHNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Db 1 DIVMTQSPSLPVTGEPASISCRSSQSIHVHNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEADVGYYCFQGSHPVPTFGQGTKEIK 112
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Db 61 SGVDPDRFSGSGGTDTFTLKISRVEADLGYYCFQGSHPVPTFGSGTKLEIK 112
|:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 11

PT0359
Ig kappa chain V region (R4A.12) - mouse (fragment)
C:Species: Mus musculus (house mouse)
C>Date: 31-Mar-1992 #sequence_revision 31-Mar-1992 #text_change 09-Jul-2004
C:Accession: PT0359
R:Shetner, R.; Kleiner, G.; Turken, A.; Papazian, L.; Diamond, B.
J. Exp. Med. 173, 287-296, 1991
A:Title: A novel class of anti-DNA antibodies identified in BALB/c mice.
A:Reference number: PT0352; MUID:91108325; PMID:1988536
A:Accession: PT0359
A:Molecule type: mRNA
A:Residues: 1-118 <SHE>
A:Cross-references: UNIPROT:Q8VIC6; UNIPARC:UPI0000176AF2
A:Experimental source: strain BALB/c
C:Comment: This protein is an anti-double-stranded DNA antibody.
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:19-98/Domain: immunoglobulin homology <IMM>

Query Match 85.5%; Score 509; DB 2; Length 118;
Best Local Similarity 84.8%; Pred. No. 3.7e-41;
Matches 95; Conservative 9; Mismatches 8; Indels 0; Gaps 0;

Query Match 85.5%; Score 509; DB 2; Length 118;
Best Local Similarity 84.8%; Pred. No. 3.7e-41;
Matches 95; Conservative 9; Mismatches 8; Indels 0; Gaps 0;

Qy	1	DVWMTQSPSLPVTYPGPASISCRSSQSIVHNSNGNTYLQWYLOKQPGQSPOLLIVKVNRL	60
Db	4	DVWMTQSPSLPVTYPGPASISCRSSQSIVHNSNGNTYLHWYLOKQPGQSPKLLIVKVNRF	63
Qy	61	YGVDPDFSGSGSGTDFTLKISRVEADGVYVYCFQGSHPVTFPGQTKVEIK	112
Db	64	SGVPDFRFSGSGSGTDFTLKISRVEADGLVYVYCSQTHVTFPGGQTKLEIK	115

RESULT 12

B34904

Ig kappa chain precursor V region (12-40 and 5-14) - mouse

C:Species: Mus musculus (house mouse)

C:Date: 27-Jul-1990 #sequence_revision 27-Jul-1990 #text_change 21-Jul-2000

C:Accession: B34904; H34903

R:Bedzyk, W.D.; Herron, J.N.; Edmundson, A.B.; Voss Jr., E.W.

J. Biol. Chem. 265, 133-138, 1990

A:Title: Active site structure and antigen binding properties of idiotypically cross-reactive

A:Reference number: A34903; PMID:2104617

A:Accession: B34904

A:Status: preliminary; not compared with conceptual translation

A:Molecule type: mRNA

A:Residues: 1-131 <BED>

A:Cross-references: UNIPARC:UPI0000114FC8; GB:W32384; GB:J05237; GB:J05238; GB:g639656;

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotrimer; immunoglobulin

F:35-114/Domain: immunoglobulin homology <IMW>

[illegible]

RESULT 13

B31485

Ig kappa chain V region (4-4-20) - mouse (fragment)

C:Species: Mus musculus (house mouse)

C:Date: 31-Jul-1989 #sequence_revision 31-Jul-1989 #text_change 09-Jul-2004

C:Accession: B31485

R:Bedzyk, W.D.; Johnson, L.S.; Riordan, G.S.; Voss Jr., E.W.

J. Biol. Chem. 264, 1565-1569, 1989

A:Title: Comparison of variable region primary structures within an anti-fluorescein idi

A:Reference number: A31485; MUID:89109167; PMID:2492278

A:Accession: B31485

A>Status: preliminary

A:Molecule type: protein

A:Residues: 1-112 <BED>

A:Cross-references: UNIPROT:Q8VC16; UNIPARC:UPI0000176AF8

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:16-95/Domain: immunoglobulin homology <IMM>

	Query Match	85.2%	Score 507;	DB 2;	Length 112;	
	Best Local Similarity	83.9%	Pred. No. 5.4e-41;			
	Matches 94;	Conservative 11;	Mismatches 7;	Indels 0;	Gaps 0;	
Qy	1 DVVMTQSPLSLPVTPGPASISCRSSQSIIVHSNGNTYLQWLYKRPGPSQLLIYKVSNRL	60				
Dd	1 DVVMTQPSLSPVLGDAQSISCRSSQSLVHSNGNTYLRWLKRPGPSKVLIIYKVSNR	60				
Qy	61 YGVPDFRSGSGSDFTLKISRVAEDGVYYICFGSHVPWTFGGTKVEIK	112				
Dd	61 SGVPDFRSGSGSDFTLKISRVAEDLGVTFCFSQSTHPVPTFGGTGLEIK	112				

RESULT 14

C27887

IG kappa chain V region (H37-82) - mouse

C/Species: Mus musculus (house mouse)

C/Date: 15-Dec-1988 #sequence_revision 15-Dec-1988 #text_change 09-Jul-2004

C/Accession: C27887

R/Caton, A.J.; Brownlee, G.G.; Staudt, L.M.; Gerhard, W.

EMBO J. 5, 1577-1587, 1986

A/Title: Structural and functional implications of a restricted antibody response to a

A/Reference number: A91043; MUID:86300658; PMID:2427335

A/Accession: C27887

A/Molecule type: DNA

A/Residues: 1-112 <CAT>

A/Cross-references: UNIPROT:Q8VC16; UNIPARC:UPI0000176A17

A/Experimental source: strain Balb/C

A/Note: this sequence was determined from the germline gene

C/Comment: This chain was isolated from a hybridoma protein that binds influenza virus

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F/16-95/Domain: immunoglobulin homology <IMM>

[illegible]

RESULT 15

C34904

IG kappa chain precursor V region (3-24) - mouse

C/Species: Mus musculus (house mouse)

C/Date: 27-Jul-1990 #sequence_revision 27-Jul-1990 #text_change 09-Jul-2004

C/Accession: C34904; I31485

R/Bedzyk, W.D.; Herron, J.N.; Edmundson, A.B.; Voss Jr., E.W.

J. Biol. Chem. 265, 133-138, 1990

A/Title: Active site structure and antigen binding properties of idiotypically cross-reactive

A/Reference number: A34903; MUID:90094387; PMID:2104617

A/Accession: C34904

A/Status: preliminary; not compared with conceptual translation

A/Molecule type: mRNA

A/Residues: 1-131 <BED>

A/Cross-references: UNIPROT:Q9VC16; UNIPARC:UPI00001767A8

R/Bedzyk, W.D.; Johnson, L.S.; Riordan, G.S.; Voss Jr., E.W.

J. Biol. Chem. 264, 1565-1569, 1989

A/Title: Comparison of variable region primary structures within an anti-fluorescein id

A/Reference number: A31485; MUID:89109167; PMID:2492278

A/Accession: I31485

A/Status: preliminary

A/Molecule type: protein

A/Residues: 20-52 <BE2>

A/Cross-references: UNIPARC:UPI00001767A9

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

P:35-114/Domain: immunoglobulin homology <IMW>

	Query Match	84.9%	Score 505;	DB 2;	Length 131;
	Best Local Similarity	83.9%;	Pred. NO. 9.9e-41;		
	Matches 94;	Conservative	9;	Mismatches 9;	Indels 0; Gaps 0;
Qy	1	DVVMTOSPLSLPVTGPGEASISCRSSQSIVHSGNGTYLWYLOKPGOSPOLLIYKVSNNRL	60		
Db	20	DVVMTDTPLSLPVSIGDQASFCRSSQSIVHSGNGTYLWYLOKPGOSPOLLIYKVSNNRF	79		
Qy	61	YGVPDFRFGSGSGCTDFTLKISRVEAEADVYVYCFQGSHPVPTWTCFQGFVKVEIK	112		
Db	80	SGVDFRFGSGSGCTDFTLKISRVEAEADVYVYCFQGSHPVPTWTCFQGFVKLEIK	131		

Search completed: January 10, 2006, 20:55:14
Job time : 14.5124 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model
Run on: January 10, 2006, 20:26:41 ; Search time 75.5025 Seconds
(without alignment)
1046.577 Million cell updates/sec

Title: US-10-735-916A-61
Perfect score: 595
Sequence: 1 DVMWTSPLSLPVTGPEPAS.....CFQSGSHVPTWGQTKVEIK 112

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt_05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	520	87.4	248	Q65ZQ7_9MURI	Q65ZQ7 mus sp. b3(
2	500	84.0	133	KV2F_HUMAN	P06310 homo sapien
3	498	83.7	117	KV2E_HUMAN	P06309 homo sapien
4	497	83.5	239	Q8NEK0_HUMAN	Q8NEK0 homo sapien
5	487	81.8	113	KV2D_HUMAN	P01617 homo sapien
6	485	81.6	114	Q9UL80_HUMAN	Q9UL80 homo sapien
7	484.5	81.4	115	Q5F210_MOUSE	Q5F210 mus musculus
8	483	81.2	113	KV2G_MOUSE	P01631 mus musculus
9	481	80.8	239	Q8TCD0_HUMAN	Q8TCD0 homo sapien
10	478	80.3	239	Q6P491_HUMAN	Q6P491 homo sapien
11	472.5	79.4	240	Q6PIH6_HUMAN	Q6PIH6 homo sapien
12	470.5	79.1	115	KV2A_HUMAN	P01614 homo sapien
13	470	79.0	112	Q53VP8_MOUSE	Q53VP8 mus musculus
14	466	78.3	219	Q65ZC0_MOUSE	Q65ZC0 mus musculus
15	455	76.5	113	KV2B_HUMAN	P01615 homo sapien
16	451	75.8	239	Q58EU8_MOUSE	Q58EU8 mus musculus
17	448.5	75.4	112	KV2C_HUMAN	P01616 homo sapien
18	440	73.9	234	Q5XKG4_MOUSE	Q5XKG4 mus musculus
19	433	72.8	113	KV2F_MOUSE	P01630 mus musculus
20	429	72.1	113	KV2E_MOUSE	P03976 mus musculus
21	418	70.3	112	Q6LEM8_MOUSE	Q6LEM8 mus musculus
22	415	69.7	112	KV2D_MOUSE	P01629 mus musculus
23	397.5	66.8	108	KV1_CANFA	P01618 canis famil
24	396.5	66.6	134	KV4C_HUMAN	P06314 homo sapien
25	386	64.9	113	KV2A_MOUSE	P01628 mus musculus
26	384	64.5	112	KV2C_MOUSE	P01626 mus musculus
27	376.5	63.3	114	KV4A_HUMAN	P01625 homo sapien
28	376	63.2	129	KV3M_HUMAN	P18136 homo sapien
29	369	62.0	133	KV4B_HUMAN	P06313 homo sapien
30	367	61.7	109	KV3B_HUMAN	P01620 homo sapien
31	367	61.7	109	KV3D_HUMAN	P01622 homo sapien

32	367	61.7	129	1	KV3L_HUMAN	P18135 homo sapien
33	362	60.8	109	2	Q9UL78_HUMAN	Q9UL78 homo sapien
34	360	60.5	109	1	KV3E_HUMAN	P01623 homo sapien
35	359.5	60.4	111	1	KV3O_MOUSE	P01667 mus musculus
36	359.5	60.4	255	2	Q6KB05_MOUSE	Q6KB05 mus musculus
37	358	60.2	120	1	KV2B_MOUSE	P01627 mus musculus
38	356	59.8	108	1	KV3A_HUMAN	P01619 homo sapien
39	355.5	59.7	236	2	Q6PIL8_HUMAN	Q6PIL8 homo sapien
40	355	59.7	129	1	KV3H_HUMAN	P04207 homo sapien
41	353.5	59.4	111	1	KV3H_MOUSE	P01660 mus musculus
42	353	59.3	109	1	KV3F_HUMAN	P01624 homo sapien
43	353	59.3	110	1	KV3P_MOUSE	P01668 mus musculus
44	352.5	59.2	111	1	KV3Q_MOUSE	P01669 mus musculus
45	352.5	59.2	240	2	Q52L64_MOUSE	Q52L64 mus musculus

ALIGNMENTS

```
RESULT 1
Q55ZQ7_9MURI PRELIMINARY; PRT; 248 AA.
AC Q65ZQ7;
DT 25-OCT-2004 (Tremblrel. 28, Created)
DT 25-OCT-2004 (Tremblrel. 28, Last sequence update)
DT 25-OCT-2004 (Tremblrel. 28, Last annotation update)
DE B3(FV)-PE40 (Fragment).
GN Name=B3(FV)-PE40;
OS Mus sp.
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10095;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=92020904; PubMed=1924323;
RA Brinkmann U., Pai L.H., Fitzgerald D.J., Willingham M., Pastan I.;
RT "B3(FV)-PE38KDEL, a single-chain immunotoxin that causes complete
RT regression of a human carcinoma in mice.";
RL Proc. Natl. Acad. Sci. U.S.A. 88:8616-8620(1991).
DR EMBL; S57990; AAB19971.2; -; mRNA.
DR SMR; Q65ZQ7; 4-247.
DR InterPro; IPR003599; IG-like.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGV; 2.
DR PROSITE; PS00835; IG_LIKE; 2.
FT NON_TER 248
SQ SEQUENCE 248 AA; 26634 MW; 7A3759B43E570950 CRC64;
Query Match 87.4%; Score 520; DB 2; Length 248;
Best Local Similarity 87.5%; Pred. No. 5,5e-46;
Matches 98; Conservative 8; Mismatches 6; Indels 0; Gaps 0;
QY 1 DVMWTSPLSLPVTGPEPASISCRSSQIVHSNGNTYLTQWYLRKPGSPQLLIYKVSNRL 60
Db 136 DVLMTQSPSLSPVSLGDAQISCRSSQIIVHSNGNTYLTWYLRKPGSPQLLIYKVSNRF 195
QY 61 YGVDPRESGSGGTDFTLKISRVEADVGYYVCFQSGSHVPTWGQTKVEIK 112
Db 196 SGVDPDRFSGSGGTDFTLKISRVEADVGYYVCFQSGSHVPTWGQTKVEIK 247
RESULT 2
KV2F_HUMAN STANDARD; PRT; 133 AA.
AC Q6310;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region RPMI 6410 precursor.
OS Homo sapiens (Human).
```

```
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86041852; PubMed=2997711;
RA Klobeck H.G., Meindl A., Combiato G., Solomon A., Zachau H.G.;
RT "Human immunoglobulin kappa light chain genes of subgroups II and
RT III.";
RL Nucleic Acids Res. 13:6499-6513 (1985).
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC EMBL; Z00020; CAA77315.1; -; Genomic_DNA.
DR PIR; A01890; K2HURP.
DR HSSP; Q99M37; 1191.
DR SMR; P06310; 21-133.
DR Ensemble; ENSG00000173758; Homo sapiens.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 20
FT CHAIN 21 133 Ig kappa chain V-II region RPMI 6410.
FT REGION 21 43 Framework-1.
FT REGION 44 59 Complementarity-determining-1.
FT REGION 60 74 Framework-2.
FT REGION 75 81 Complementarity-determining-2.
FT REGION 82 113 Framework-3.
FT REGION 114 122 Complementarity-determining-3.
FT REGION 123 132 Framework-4.
FT DISULFID 43 113 By similarity.
FT NON_TER 133 133
SQ SEQUENCE 133 AA; 14707 MW; 513CCAP3673009EE CRC64;

Query Match 84.0%; Score 500; DB 1; Length 133;
Best Local Similarity 84.8%; Pred. No. 3.3e-44;
Matches 95; Conservative 8; Mismatches 9; Indels 0; Gaps 0;

QY 1 DVVMTQSPFLSPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLPQKPGQSPQLLIYKVSRL 60
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
21 DVVMTQSPFLSPVTPGEPASISCRSSQSLVSDGNTYLNWFQRPQSPFRLLIYKVSRLD 80

QY 61 YGVDPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPMTFGGQTKVEIK 112
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
81 SGVDPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHTSWTFGGQTKVEIK 132

RESULT 3
KV2E HUMAN STANDARD; PRT; 117 AA.
AC P06309;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region GM607 precursor (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=84191506; PubMed=6325927;
RA Klobeck H.G., Solomon A., Zachau H.G.;
RT "Contribution of human V kappa II germ-line genes to light-chain
RT diversity.";
RL Nature 309:73-76 (1984).
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC EMBL; Z00009; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR PIR; A01889; K2HUGM.
DR HSSP; Q99M37; 1191.
DR SMR; P06309; 5-117.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL <1 4
FT CHAIN 5 117 Ig kappa chain V-II region GM607.
FT REGION 5 27 Framework-1.
FT REGION 28 43 Complementarity-determining-1.
FT REGION 44 58 Framework-2.
FT REGION 59 65 Complementarity-determining-2.
FT REGION 66 97 Complementarity-determining-3.
FT REGION 98 106 Complementarity-determining-3.
FT REGION 107 116 Framework-4.
FT DISULFID 27 97 By similarity.
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 12664 MW; 92C57DC719E558B1 CRC64;

Query Match 83.7%; Score 498; DB 1; Length 117;
Best Local Similarity 85.7%; Pred. No. 4.5e-44;
Matches 96; Conservative 3; Mismatches 13; Indels 0; Gaps 0;

QY 1 DVVMTQSPFLSPVTPGEPASISCRSSQSIHVSNGNTYLYQWYLPQKPGQSPQLLIYKVSRL 60
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
5 DVVMTQSPFLSPVTPGEPASISCRSSQSLHSNGNYLDWYLPQKPGQSPQLLIYKVSRLA 64

QY 61 YGVDPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPMTFGGQTKVEIK 112
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
65 SGVDPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGLTPTQTPTGGQTKVEIK 116

RESULT 4
Q9NEKO HUMAN PRELIMINARY; PRT; 239 AA.
ID Q9NEKO;
AC Q9NEKO;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGKV1-5 protein.
GN Name=IGKV1-5;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
```

RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Uedini T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettaman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
 RA "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RT Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Prostate;
 RA Director MGC Project;
 RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
 RN [3]
 RP NUCLEOTIDE SEQUENCE.
 RX PubMed=1601042;
 RA Huber C., Klobeck H.G., Zachau H.G.;
 RT "Ongoing V kappa-J kappa recombination after formation of a productive
 RT V kappa-J kappa coding joint.";
 RL Eur. J. Immunol. 22:1561-1565(1992).
 RN [4]
 RP NUCLEOTIDE SEQUENCE.
 RX PubMed=8436174;
 RA Wagner S.D., Luzzatto L.;
 RT "V kappa gene segments rearranged in chronic lymphocytic leukemia are
 RT distributed over a large portion of the V kappa locus and do not show
 RT somatic mutation.";
 RL Eur. J. Immunol. 23:391-397(1993).
 RN [5]
 RP NUCLEOTIDE SEQUENCE.
 RX PubMed=8258341;
 RA Klein R., Jaenichen R., Zachau H.G.;
 RT "Expressed human immunoglobulin kappa genes and their hypermutation.";
 RL Eur. J. Immunol. 23:3248-3262(1993).
 DR EMBL, BC030814; AH30814.1; -; mRNA.
 DR PIR, S23638; S23638.
 DR PIR, S34091; S34091.
 DR PIR, S40342; S40342.
 DR PIR, S40357; S40357.
 DR HSP, P01834; I17Z.
 DR SMR, Q8NEK0; 21-237.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig.cl.
 DR InterPro; IPR003006; Ig.MHC.
 DR InterPro; IPR003596; Ig.v.
 DR Pfam; PF07654; Cl-set; 1.
 DR SMART; SM00406; Igv; 1.
 DR PROSITE; PS00835; IG_LIKE; 2.
 DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
 KW Immunoglobulin domain.
 SQ SEQUENCE 239 AA; 26024 MW; F5E20AD3B0552C0A CRC64;

Query Match 83.5%; Score 497; DB 2; Length 239;
 Best Local Similarity 83.9%; Pred. No. 1.3e-43;
 Matches 94; Conservative 6; Mismatches 12; Indels 0; Gaps 0;

QY 1 DVVMTQSPISLPVTPGEPASISCRSSQSIHVSNGNTYLVQWYLRKPKQSPQLLIYKVSRL 60
 DB 21 DIVMTQSPISLPVTPGEPASISCRSSQSLHSDGNYLDWYLRKPKQSPQLLIYGSNRA 80

QY 61 YGVPRFSGSGSGTDFTLKISRVEADGVVYFCQGSHPVTFGQGTKVEIK 112
 DB 81 SGVPRFSGSGSGTDFTLKISRVEADGVIIYVCMQGLQTPQIFGQGTKVEIK 132

RESULT 5

KV2D_HUMAN
 ID KV2D_HUMAN STANDARD; PRT; 113 AA.
 AC P01617;
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DE 10-MAY-2005 (Rel. 47, Last annotation update)
 DE Ig kappa chain V-II region TEW.
 OS Homo sapiens (Human)
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP PROTEIN SEQUENCE (BENCE-JONES PROTEIN TEW).
 RX MEDLINE=74148480; PubMed=4596149;
 RA Putnam F.W., Whitley E.J. Jr., Paul C., Davidson J.N.;
 RT "Amino acid sequence of a kappa Bence Jones protein from a case of
 RT primary amyloidosis.";
 RL Biochemistry 12:3763-3780(1973).
 RN [2]
 RP PROTEIN SEQUENCE OF 1-27 (AMYLOID PROTEIN TEW).
 RX MEDLINE=73166638; PubMed=4700495;
 RA Terry W.D., Page D.L., Kimura S., Isobe T., Osseman E.F.,
 RA Glenner G.G.;
 RT "Structural identity of Bence Jones and amyloid fibril proteins in a
 RT patient with plasma cell dyscrasia and amyloidosis.";
 RL J. Clin. Invest. 52:1276-1281(1973).
 CC -!- MISCELLANEOUS: The major amyloid protein appears to be identical
 CC with the Bence Jones protein isolated from the same patient.
 CC -!- MISCELLANEOUS: This protein was isolated from the urine of a
 CC patient with plasma cell dyscrasia and amyloidosis.
 CC -!- MISCELLANEOUS: The C region of this chain has the INV (1,2)
 CC marker.
 CC -----
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.
 CC -----
 DR PIR; A90370; K2HUTW.
 DR HSP; Q99M37; I19I.
 DR SMR; P01617; 1-113.
 DR GO; GO:0005576; Extracellular region; NAS.
 DR GO; GO:0003823; P:antigen binding; NAS.
 DR GO; GO:0006955; P:immune response; NAS.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003596; Ig_v.
 DR SMART; SM00406; Igv; 1.
 DR PROSITE; PS00835; IG_LIKE; 1.
 KW Amyloid; Bence-Jones protein; Direct protein sequencing;
 KW Immunoglobulin domain; Immunoglobulin V region.
 FT REGION 1 23
 FT REGION 24 39
 FT REGION 40 54
 FT REGION 55 61
 FT REGION 62 93
 FT REGION 94 102
 FT REGION 103 112
 FT REGION 113 113
 FT DISULFID 23 93
 FT NON_TER 113 113
 SQ SEQUENCE 113 AA; 12316 MW; 0C3C38F81F1843CA CRC64;
 Query Match 81.8%; Score 487; DB 1; Length 113;
 Best Local Similarity 81.2%; Pred. No. 6.2e-43;
 Matches 91; Conservative 9; Mismatches 12; Indels 0; Gaps 0;

QY 1 DVVMTQSPISLPVTPGEPASISCRSSQSIHVSNGNTYLVQWYLRKPKQSPQLLIYKVSRL 60
 DB 1 DIVMTQSPISLPVTPGEPASISCRSSQSLHSDGNYLDWYLRKPKQSPQLLIYALSRA 60

QY 61 YGVPRFSGSGSGTDFTLKISRVEADGVVYFCQGSHPVTFGQGTKVEIK 112
 |||||
 |||||

```
Db 61 SGVDFRFGSGSGTDTLTKISRVEADVGVVYCMZALQAPITFGQGTREIK 112
RESULT 6
Q9UL80 HUMAN PRELIMINARY; PRT; 114 AA.
AC Q9UL80;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin light chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1322670;
RA Stuber F., Lee S.K., Bridges S.L. Jr, Koopman W.J., Schroeder H.W. Jr,
RA Gaskin F., Fu S.M.;
RT "A rheumatoid factor from a normal individual encoded by VH2 and V
RT kappa II gene segments.";
RL Arthritis Rheum. 35:900-904(1992).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=8436174;
RA Wagner S.D., Luzzatto L.;
RT "V kappa gene segments rearranged in chronic lymphocytic leukemia are
RT distributed over a large portion of the V kappa locus and do not show
RT somatic mutation.";
RL Eur. J. Immunol. 23:391-397(1993).
RN [4]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1601042;
RA Huber C., Klobeck H.G., Zachau H.G.;
RT "Ongoing V kappa-J kappa recombination after formation of a productive
RT V kappa-J kappa coding joint.";
RL Eur. J. Immunol. 22:1561-1565(1992).
DR EMBL; AF035034; AAD56270.1; -; mRNA.
DR PIR; B49002; B49002.
DR PIR; S23638; S23638.
DR PIR; S34094; S34094.
DR PIR; S34095; S34095.
DR HSP; P01625; 1LVE.
DR SMR; Q9UL80; 1-114.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig.V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 1.
FT NON_TER 1
FT NON_TER 114
SQ SEQUENCE 114 AA; 12775 MW; 070E31E210D1CEB01 CRC64;
Query Match 81.6%; Score 485.5; DB 2; Length 114;
Best Local Similarity 84.1%; Pred. No. 8.9e-43;
Matches 95; Conservative 7; Mismatches 10; Indels 1; Gaps 1;
QY 1 DVVMTQSPVLSPLPVTPGEPAISCRSSQSIHVSNGNTYLQWYLQKPGQSPOLLIVKVSRL 60
DB 1 DVVMTQSPVLSPLPVTPGEPAISCRSSQSIHVSNGNTYLQWYLQKPGQSPOLLIVKVSRL 60
QY 61 YGVDFRFGSGSGTDTLTKISRVEADVGVVYCFQGSN-VPMTFGQGTREIK 112
DB 61 YGVDFRFGSGSGTDTLTKISRVEADVGVVYCFQGSN-VPMTFGQGTREIK 112
Db 61 SGVDFRFGSGSGTDTLTKISRVEADLVGVYFCSQTHVPPVTFGGGKLEMK 113
RESULT 8
KV2G MOUSE STANDARD; PRT; 113 AA.
AC P01631;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region 26-10.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP PROTEIN SEQUENCE.
RC STRAIN=A/J;
EX MEDLINE=83178921; PubMed=6404298;
RA Novotny J., Margolies M.N.;
RT "Amino acid sequence of the light chain variable region from a mouse
RT anti-digoxin hybridoma antibody.";
RL Biochemistry 22:1153-1158(1983).
```

```
CC -!- MISCELLANEOUS: This chain was isolated from an IgG2a hybridoma
CC protein that binds digoxin.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC PIR; A01914; KVM526.
CC HSSP; Q99M37; 1191.
CC Ensembl; ENSMUSG0000055315; Mus musculus.
CC InterPro; IPR007110; Ig-like.
CC SMART; SM00406; IGV; 1.
CC PROSITE; PS50835; IG LIKE; 1.
KW Direct protein sequencing; Hybridoma; Immunoglobulin domain;
KW Immunoglobulin V region; Monoclonal antibody.
FT REGION 1 23
FT REGION 24 39
FT REGION 40 54
FT REGION 55 61
FT REGION 62 93
FT REGION 94 102
FT REGION 103 112
FT DISULFID 23 93
FT NON TER 113 113
SQ SEQUENCE 113 AA; 12273 MW; F9F39CE949A84C2A CRC64;

Query Match 81.2%; Score 483; DB 1; Length 113;
Best Local Similarity 82.1%; Pred. No. 1.6e-42;
Matches 92; Conservative 10; Mismatches 10; Indels 0; Gaps 0;

QY 1 DVMWTSPLSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
DB 1 DVMWTSPLSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVDPFRFSGSGTGDTFTLKISRVEADVGVIYFCQGSHPVPTFGGTVKEIK 112
DB 61 SGVDPFRFSGSGTGDTFTLKISRVEADVGVIYFCQGSHPVPTFGGTVKEIK 112

RESULT 9
Q8TCD0 HUMAN PRELIMINARY; PRT; 239 AA.
AC Q8TCD0;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Schuler G.D.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ulsdn T.B., Roschlyki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
```

```
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RA Strausberg R.;
RL Submitted (FEB-2002) to the EMBL/GenBank/DBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1598223;
RA Hirabayashi Y., Munakata Y., Sasaki T., Sano H.;
RT "Variable regions of a human anti-DNA antibody O-81 possessing lupus
RT nephritis-associated idiotype.";
RL Nucleic Acids Res. 20:2601-0(1992).
RN [4]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1551402;
RA Lautner-Rieske A., Huber C., Meindl A., Pargent W., Schable K.F.,
RA Thiebe R., Zocher I., Zachau H.G.;
RT "The human immunoglobulin kappa locus. Characterization of the
RT duplicated A regions.";
RL Eur. J. Immunol. 22:1023-1029(1992).
RN [5]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=8258341;
RA Klein R., Jaenichen R., Zachau H.G.;
RT "Expressed human immunoglobulin kappa genes and their hypermutation.";
RL Eur. J. Immunol. 23:3248-3262(1993).
RN [6]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=8436174;
RA Wagner S.D., Luzzatto L.;
RT "V kappa gene segments rearranged in chronic lymphocytic leukemia are
RT distributed over a large portion of the V kappa locus and do not show
RT somatic mutation.";
RL Eur. J. Immunol. 23:391-397(1993).
DR EMBL; BC022362; AAH22362.1; -; mRNA.
DR PIR; S22658; S22658.
DR PIR; S34095; S34095.
DR PIR; S40324; S40324.
DR PIR; S40374; S40374.
DR PIR; S42267; S42267.
DR PIR; S42268; S42268.
DR HSSP; P01834; 1172.
DR SMR; Q8TCD0; 21-237.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF07654; C1-set; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG-LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.
KW Hypothetical protein; Immunoglobulin domain.
SQ SEQUENCE 239 AA; 26235 MW; FAGEDC3A3B03871D CRC64;
```

```
Query Match 80.8%; Score 481; DB 2; Length 239;
Best Local Similarity 81.2%; Pred. No. 6.3e-42;
Matches 91; Conservative 12; Mismatches 9; Indels 0; Gaps 0;
```

```
QY 1 DVMWTSPLSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 60
DB 21 DVMWTSPLSLPVTPGEPASISCRSSQSIIVHSNGNTYLYQWYLOKPGQSPQLLIYKVSRL 80

QY 61 YGVDPFRFSGSGTGDTFTLKISRVEADVGVIYFCQGSHPVPTFGGTVKEIK 112
DB 81 SGVDPFRFSGSGTGDTFTLKISRVEADVGVIYFCQGSHPVPTFGGTVKEIK 132
```

RESULT 10

```
Q6P491 HUMAN
ID Q6P491 HUMAN PRELIMINARY; PRT; 239 AA.
AC Q6P491
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Skin;
RX MEDLINE=23388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Boak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalios D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Skin;
RA Strausberg R.;
RL Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC063599; AAH34599.1; -; mRNA.
DR HSSP; P01837; 1KC1.
DR SMR; Q6P491; 21-237.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.c1.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; C1-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGc1; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Hypothetical protein.
SQ SEQUENCE 239 AA; 26245 MW; CD7313DDFFD358B3 CRC64;
```

```
Query Match 80.3%; Score 478; DB 2; Length 239;
Best Local Similarity 79.5%; Pred. No. 1.3e-41;
Matches 89; Conservative 11; Mismatches 12; Indels 0; Gaps 0;
QY 1 DVVMTQSPVLSLPVTGEPASISCRSSQSIIVHSNGNTYLYQWYLPKPGQSPQLLIYKSNRL 60
Db 21 DIVMTQTPLSPVLTGEPASISCRSSQSIIVHSNGNTYLYQWYLPKPGQSPQLLIYKSNRF 80
QY 61 YGVPRFSGSGGTFTLKISRVEAEDGIVYYCFQGSHPVTFGGTKVEIK 112
Db 81 SGVPRFSGSGGTFTLKISRVEAEDGIVYYCMQVSHFPRTFGGTRVEIK 132
```

RESULT 11

```
Q6PIH6 HUMAN
ID Q6PIH6 HUMAN PRELIMINARY; PRT; 240 AA.
AC Q6PIH6
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IGKV1-5 protein.
GN Name=IGKV1-5;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RX MEDLINE=23388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Boak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalios D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RA Strausberg R.;
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC034142; AAH34142.1; -; mRNA.
DR HSSP; P01837; 1KB5.
DR SMR; Q6PIH6; 23-240.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.c1.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; C1-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGc1; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
SQ SEQUENCE 240 AA; 26234 MW; 18D4DD8BB781EC4 CRC64;
```

```
Query Match 79.4%; Score 472.5; DB 2; Length 240;
Best Local Similarity 81.4%; Pred. No. 4.9e-41;
Matches 92; Conservative 5; Mismatches 15; Indels 1; Gaps 1;
QY 1 DVVMTQSPVLSLPVTGEPASISCRSSQSIIVHSNGNTYLYQWYLPKPGQSPQLLIYKSNRL 60
Db 21 DIVMTQTPLSPVLTGEPASISCRSSQSIIVHSNGNTYLYQWYLPKPGQSPQLLIYKSNRA 80
QY 61 YGVPRFSGSGGTFTLKISRVEAEDGIVYYCFQGSHPVTFGGTKVEIK 112
Db 81 SGVPRFSGSGGTFTLKISRVEAEDGIVYYCMQALQTPPTFGGTKLEIK 133
```

RESULT 12
KV2A_HUMAN

```
ID KV2A HUMAN STANDARD; PRT; 115 AA.
AC P01614;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE IG kappa chain V-II region CUM.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=68242259; PubMed=5586923;
RA Hilschmann N.;
RT "The complete amino acid sequence of Bence Jones protein Cum (kappa-
type).";
FT NON_TER 1
FT NON_TER 112
RN [2]
RP SEQUENCE REVISION TO 50; 52; 96 AND 97.
RX MEDLINE=70063440; PubMed=4188189;
RA Hilschmann N.;
RT "Molecular basis of antibody formation.";
RL Naturwissenschaften 56:195-205(1969).
CC -!- MISCELLANEOUS: The C region of this chain has the INV (3) marker.
CC -!- MISCELLANEOUS: This is a Bence-Jones protein.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR PIR; B91639; K2HUCM.
DR HSP; P01751; INOB.
DR SMR; P01614; 2-115.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Bence-Jones protein; Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region.
FT DISULFID 24 95
FT NON_TER 115 115 By similarity.
SQ SEQUENCE 115 AA; 12676 MW; 595F90A379569EC CRC64;

Query Match 79.1%; Score 470.5; DB 1; Length 115;
Best Local Similarity 79.6%; Pred. No. 3.4e-41;
Matches 90; Conservative 11; Mismatches 11; Indels 1; Gaps 1;

QY 1 DVWMTQSLSLPVTGEPASISCRSSQSVHS-NGNTYLOWYLOKPGSQPOLLYKVSNR 59
DB 2 DIVMTQTPLSLPVTGEPASISCRSSQSLDSDGNTLYNLYLOKAGOSQPOLLYTLYSR 61

QY 60 LYGVDPFRSGSGSGDTFTLKISRVAEDVGVYCFQGSHPVMTFGQTKVEIK 112
DB 62 ASGVDPFRSGSGSGDTFTLKISRVAEDVGVYCFQGSHPVMTFGQTKLEIR 114

RESULT 13
Q53VP8 MOUSE
ID Q53VP8_MOUSE PRELIMINARY; PRT; 112 AA.
AC Q53VP8;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DE Kappa chain (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
```

```
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., These J., Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
antibodies in the GAT system.";
RL EMBO J. 4:3681-3688(1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 108-109.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DDBJ databases.
DR EMBL; X03386; CAA27113.1; -, mRNA.
FT NON_TER 1
FT NON_TER 112
SQ SEQUENCE 112 AA; 12266 MW; C844B7881A89C18A CRC64;

Query Match 79.0%; Score 470; DB 2; Length 112;
Best Local Similarity 79.5%; Pred. No. 3.7e-41;
Matches 89; Conservative 11; Mismatches 12; Indels 0; Gaps 0;

QY 1 DVWMTQSLSLPVTGEPASISCRSSQSVHSNGNTYLOWYLOKPGSQPOLLYKVSNR 60
DB 1 DIVMTQTPLSLPVTGEPASISCRSSQSVHSNGNTYLOWYLOKPGSQPOLLYKVSNR 60

QY 61 YGVDPFRSGSGSGDTFTLKISRVAEDVGVYCFQGSHPVMTFGQTKVEIK 112
DB 61 SGVDPFRSGSGSGDTFTLKISRVAEDVGVYCFQGIHVPVTFGGGTRLEIK 112

RESULT 14
Q65ZC0 MOUSE
ID Q65ZC0_MOUSE PRELIMINARY; PRT; 219 AA.
AC Q65ZC0;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Kappa light chain C region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Balb/c; TISSUE=Spleen;
RX MEDLINE=96319505; PubMed=8768802;
RA Kipp B., Schlaak M., Becker W.M.;
RT "Cloning and expression of a recombinant mouse Fab-fragment
recognizing a defined linear epitope of Chironomus thummi major
allergen Chi t 1.";
RL Int. Arch. Allergy Immunol. 110:348-353(1996).
DR EMBL; Z37499; CAA85724.1; -, mRNA.
DR SMR; Q65ZC0; 1-219.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG_c1.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; C1-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGV; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; 1.
FT NON_TER 1
FT NON_TER 219
SQ SEQUENCE 219 AA; 23944 MW; 7E1B82A14EAP8445 CRC64;

Query Match 78.3%; Score 466; DB 2; Length 219;
Best Local Similarity 79.5%; Pred. No. 2.1e-40;
```

```
Matches 89; Conservative 11; Mismatches 12; Indels 0; Gaps 0;
QY 1 DVVMTQSPSLPVTGEPASISCRSSQSLVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRL 60
Db 1 ELVMTQSPSLVSGDSQSLVHSNGNTYLHWYLQKPGSLPKLLIYIVSNRF 60
QY 61 YGVPRFSGSGSDTFTLKISRVEAEDVGVYFCQSHVPTWTFGGQTKVEIK 112
Db 61 SGVPRFSGSGSDTFTLKISRVEAEDLGVPFCSTHVPCTGGGTXLEIK 112

RESULT 15
KV2B HUMAN
ID KV2B HUMAN STANDARD; PRT; 113 AA.
AC P01615;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE IG kappa chain V-II region FR.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=76253627; PubMed=821524;
RA Riesen W.F., Jaton J.-C.;
RT "variable region sequence of the light chain from a Waldenstroms Igm
RT with specificity for phosphorylcholine.";
RL Biochemistry 15:3829-3833(1976).
CC -!- MISCELLANEOUS: this chain was isolated from a Waldenstrom's
CC macroglobulin that binds phosphorylcholine.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC PIR; A01886; K2HUPR.
CC HSP; Q99W37; I191.
CC SMR; P01615; 1-109.
CC GO; GO:0005576; C:extracellular region; NAS.
CC GO; GO:0003823; F:antigen binding; NAS.
CC GO; GO:0006955; P:immune response; NAS.
CC InterPro; IPR007110; IG-like.
CC InterPro; IPR003596; IG_V.
CC SMART; SM00406; IGv_1.
CC PROSITE; PS50835; IG_LIKE; 1.
CC Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region.
FT REGION 1 23 Framework-1.
FT REGION 24 39 Complementarity-determining-1.
FT REGION 40 54 Framework-2.
FT REGION 55 61 Complementarity-determining-2.
FT REGION 62 93 Framework-3.
FT REGION 94 102 Complementarity-determining-3.
FT REGION 103 112 Framework-4.
FT DISULFID 23 93 By similarity.
FT NON_TER 113 113
SQ SEQUENCE 113 AA; 12660 MW; 0C0DA39E46DB96BE CRC64;
```

```
Query Match 76.5%; Score 455; DB 1; Length 113;
Best Local Similarity 76.8%; Pred. No. 1.4e-39;
Matches 86; Conservative 11; Mismatches 15; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGEPASISCRSSQSLVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRL 60
Db 1 DVVMTQSPSLPVTGEPASISCRSSQSLVHSNGNTYLHWYLQKPGSLPKLLIYIVSNRF 60
QY 61 YGVPRFSGSGSDTFTLKISRVEAEDVGVYFCQSHVPTWTFGGQTKVEIK 112
```


GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:07:41 ; Search time 77.3134 Seconds
(without alignments)
636.505 Million cell updates/sec

Title: US-10-735-916A-61
Perfect score: 595
Sequence: 1 DVWMTQSLPLVPTGEPAS.....CFQGSHPVWTFQGQTKVEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A.Geneseq.21.*

- 1: Geneseqp1980s.*
- 2: Geneseqp1990s.*
- 3: Geneseqp2000s.*
- 4: Geneseqp2001s.*
- 5: Geneseqp2002s.*
- 6: Geneseqp2003as.*
- 7: Geneseqp2003bs.*
- 8: Geneseqp2004s.*
- 9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	595	100.0	112	7	ADJ76895 Anti-IGF-
2	595	100.0	112	9	ADZ67065 Human ant
3	595	100.0	131	7	ADJ76897 Anti-IGF-
4	595	100.0	131	9	ADZ67067 Human ant
5	594	99.8	112	7	ADJ76899 Anti-IGF-
6	594	99.8	112	9	ADZ67069 Human ant
7	594	99.8	131	7	ADJ76901 Anti-IGF-
8	594	99.8	131	9	ADZ67071 Human ant
9	569	95.6	114	8	ADP84950 Variable
10	568	95.5	112	5	AAE15713 Mouse mon
11	565	95.0	112	5	AAE15712 Mouse mon
12	565	95.0	114	8	ADP84948 Variable
13	563	94.6	112	5	AAE15711 Mouse mon
14	563	94.6	112	6	ABP72125 FGF-8 rel
15	563	94.6	112	7	ADP84950 Anti-IGF-
16	563	94.6	114	8	ADP84946 Variable
17	563	94.6	114	8	ADP84951 Variable
18	563	94.6	111	7	ADZ6530 Anti-IGF-
19	562	94.5	114	8	ADP84949 Variable
20	560	94.1	112	7	ADZ6523 Anti-IGF-
21	560	94.1	112	7	AAE15712 Humanised
22	560	94.1	132	7	AAE15712 Humanised
23	559	93.9	114	8	ADP84944 Variable
24	558	93.8	114	8	ADP84947 Variable

25	557	93.6	112	6	ABP72129 FGF-8 rel
26	557	93.6	112	7	ADZ6520 Anti-FGF-
27	557	93.6	112	9	ADV67310 Amino aci
28	556	93.4	112	2	AAR32239 Humanised
29	556	93.4	112	2	AAW27145 Mature li
30	556	93.4	112	3	AAE15711 Humanised
31	556	93.4	112	3	AAE15711 Anti-FGF-
32	556	93.4	114	8	ADP84945 Variable
33	555	93.3	114	8	ADP84952 Variable
34	553	92.9	112	7	ADZ6518 Anti-FGF-
35	552	92.8	114	8	ADP84943 Variable
36	550	92.4	112	7	ADJ80420 Hybrid hu
37	550	92.4	132	7	ADH61998 Human ant
38	547	91.9	112	6	ABR40272 Amino aci
39	547	91.9	112	7	ADZ67694 Humanised
40	547	91.9	112	9	ADZ65252 Anti-CCR4
41	546	91.8	112	6	ABR40268 Amino aci
42	546	91.8	112	7	ADZ67687 Humanised
43	546	91.8	112	7	ADZ6519 Anti-FGF-
44	546	91.8	112	7	ADZ6527 Anti-FGF-
45	546	91.8	112	7	ADJ80422 Murine an

ALIGNMENTS

RESULT 1
ADJ76895
ID ADJ76895 standard; protein; 112 AA.
XX
AC ADJ76895;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-IGF-IR related protein #12.
XX
KW cytostatic; antipsoxiatic; antibody;
KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDR.
XX
OS Homo sapiens.
XX
PN WO2003059951-A2.
XX
PD 24-JUL-2003.
XX
PF 20-JAN-2003; 2003WO-FR000178.
XX
PR 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
XX
PA (FABR) FABRE MEDICAMENT SA PIERRE.
XX
PI Goetsch L, Corvaia N, Leger O;
XX
DR WPI; 2003-569653/53.
XX
PT New antibodies that bind to human insulin-like growth factor receptor,
XX useful for treatment, prevention and diagnosis of cancers.
XX
PS Disclosure; SEQ ID NO 61; 164pp; French.
XX
CC The invention relates to an isolated antibody (Ab), and its functional
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
CC IR) and optionally: (i) inhibit natural binding of insulin-like growth
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or
CC treat diseases associated with overexpression and/or abnormal activity of
CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with
CC hyperactivity of signal transduction pathways mediated by interaction of

CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.
 XX
 SQ Sequence 112 AA;

Query Match 100.0%; Score 595; DB 7; Length 112;
 Best Local Similarity 100.0%; Pred. No. 2.4e-43;
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYIQWYLOKPGQSPQLLIYKVSRL 60

Db 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYIQWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVPRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKVEIK 112

Db 61 YGVPRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKVEIK 112

RESULT 2

ADZ67065
 ID ADZ67065 standard; protein; 112 AA.

AC ADZ67065;

DT 30-JUN-2005 (first entry)

XX Human antibody 7C10 1 light chain variable region SEQ ID NO:61.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW light chain variable region.

XX Homo sapiens.

XX Key Location/Qualifiers

FT Region 24..39

FT /note= "CDR1"

FT Region 55..61

FT /note= "CDR2"

FT Region 94..102

FT /note= "CDR3"

XX US2005084906-A1.

XX 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.

PR 07-MAY-2002; 2002FR-00005753.

PR 20-JAN-2003; 2003WO-FR000178.

XX 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.

PA (CORV/) CORVAIA N.

PA (LEGE/) LEGER O.

PA (DUF/) DUFLOS A.

PA (HAU/) HAEUW J.

PA (BECK/) BECK A.

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

PI WPI; 2005-321968/33.

XX

DR

DR N-PSDB; ADZ67066.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 PT antibody or its functional fragment, being capable of binding human IGF-
 PT IR and specifically inhibiting tyrosine kinase activity of receptor,
 PT useful for treating cancer.
 XX

PS Example 12; SEQ ID NO 61; 125pp; English.

XX The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-IR and, if necessary, capable of
 CC specifically inhibiting tyrosine kinase activity of the receptor,
 CC comprising a light or heavy chain having at least one complementary
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-IR and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
 CC the administration of the medicament does not induce or only slightly
 CC induces secondary effects connected with inhibition of the insulin
 CC receptor. The antibody is useful for preparation of a medicament intended
 CC to inhibit the transformation of normal cells into cells with tumoral
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
 CC useful for preparation of a medicament intended to inhibit the growth
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a
 CC medicament intended for prevention or for the treatment of cancer, where
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 CC preparation of a medicament intended for the prevention or for the
 CC treatment of psoriasis. (I) is useful in preparation of a medicament
 CC intended for the specific targeting of a biologically active compound to
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
 CC is useful for in vitro diagnosis of illnesses induced by an
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
 CC starting from a biological sample in which the abnormal presence, of IGF-
 CC IR and/or EGFR receptor is suspected, which involves contacting the
 CC biological sample with (I), which is optionally labeled. The present
 CC sequence is used in the exemplification of the invention.
 XX

SQ Sequence 112 AA;

Query Match 100.0%; Score 595; DB 9; Length 112;

Best Local Similarity 100.0%; Pred. No. 2.4e-43;

Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYIQWYLOKPGQSPQLLIYKVSRL 60

Db 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYIQWYLOKPGQSPQLLIYKVSRL 60

QY 61 YGVPRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKVEIK 112

Db 61 YGVPRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGQGTKVEIK 112

RESULT 3

ADJ76897

ID ADJ76897 standard; protein; 131 AA.

XX ADJ76897;

DT 06-MAY-2004 (first entry)

XX Anti-IGF-IR related protein #13.

XX cytostatic; antipsoriatic; antibody;
 KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;

KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
 KW CDR.
 XX
 OS Homo sapiens.
 XX
 XX WO2003059951-A2.
 XX
 XX 24-JUL-2003.
 XX
 XX 20-JAN-2003; 2003WO-FR000178.
 XX
 XX 18-JAN-2002; 2002FR-00000653.
 XX
 XX 18-JAN-2002; 2002FR-00000654.
 XX
 XX 07-MAY-2002; 2002FR-00005753.
 XX
 XX (FABR) FABRE MEDICAMENT SA PIERRE.
 XX
 XX Goetsch L, Corvaia N, Leger O;
 XX
 XX WPI; 2003-569653/53.
 XX
 XX New antibodies that bind to human insulin-like growth factor receptor,
 XX useful for treatment, prevention and diagnosis of cancers.
 XX
 XX Disclosure; SEQ ID NO 63; 164pp; French.
 XX
 XX The invention relates to an isolated antibody (Ab), and its functional
 XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
 XX 1R) and optionally: (i) inhibit natural binding of insulin-like growth
 XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
 XX kinase activity of IGF-1R. Ab and its fragments are used to prevent or
 XX treat diseases associated with overexpression and/or abnormal activity of
 XX IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
 XX hyperactivity of signal transduction pathways mediated by interaction of
 XX these receptors with their ligands. Especially they inhibit
 XX transformation of normal cells to tumor cells, inhibit growth and/or
 XX proliferation of tumor cells, so are useful against cancers of the
 XX prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 XX also for treating psoriasis. Ab are also used to diagnose diseases caused
 XX by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
 XX protein sequence used to generate the Ab of the invention.
 XX
 XX Sequence 131 AA;
 SQ

Query Match
 Best Local Similarity 100.0%; Score 595; DB 7; Length 131;
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLPKPGQSPQLLIYKVSNRL 60
 Db 20 DVVMTQSPSLPVTGPEPASISCRSSQSIHVSNGNTYLYQWYLPKPGQSPQLLIYKVSNRL 79
 QY 61 YGVPRFSGSGGTDFTLKISRVEADVGYYCFQGSHPVPTFGGQTKVEIK 112
 Db 80 YGVPRFSGSGGTDFTLKISRVEADVGYYCFQGSHPVPTFGGQTKVEIK 131

RESULT 4
 ADZ67067
 ID ADZ67067 standard; protein; 131 AA.
 XX
 AC ADZ67067;
 XX
 DT 30-JUN-2005 (first entry)
 XX
 DE Human antibody 7C10 1 light chain variable region SEQ ID NO:63.
 XX
 XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;

KW light chain variable region.
 XX
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 XX Peptide 1..19
 XX /note= "leader peptide"
 XX Region 43..62
 XX /note= "CDR1"
 XX Region 74..80
 XX /note= "CDR2"
 XX Region 113..121
 XX /note= "CDR3"
 XX
 XX US2005084906-A1.
 XX
 XX 21-APR-2005.
 XX
 XX 16-DEC-2003; 2003US-00735916.
 XX
 XX 18-JAN-2002; 2002FR-00000653.
 XX
 XX 18-JAN-2002; 2002FR-00000654.
 XX
 XX 07-MAY-2002; 2002FR-00005753.
 XX
 XX 20-JAN-2003; 2003WO-FR000178.
 XX
 XX 11-JUL-2003; 2003FR-00008538.
 XX
 XX (GOET/) GOETSCH L.
 XX (CORV/) CORVAIA N.
 XX (LEGE/) LEGER O.
 XX (DUFL/) DUFLOS A.
 XX (HAEU/) HAEUW J.
 XX (BECK/) BECK A.
 XX
 XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
 XX
 XX WPI; 2005-321968/33.
 XX
 XX N-PSDB; ADZ67066.
 XX
 XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 XX antibody or its functional fragment, being capable of binding human IGF-
 XX IR and specifically inhibiting tyrosine kinase activity of receptor,
 XX useful for treating cancer.
 XX
 XX Example 12; SEQ ID NO 63; 125pp; English.
 XX
 XX The invention relates to a novel isolated anti-insulin-like growth factor
 XX I receptor (IGF-IR) antibody (I) or its functional fragment, being
 XX capable of binding to human IGF-IR and, if necessary, capable of
 XX specifically inhibiting tyrosine kinase activity of the receptor,
 XX comprising a light or heavy chain having at least one complementary
 XX determining region (CDR) consisting of one of two fully defined 16 amino
 XX acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 XX the preparation of a medicament intended for the prevention or treatment
 XX of an illness connected with an overexpression and/or an abnormal
 XX activation of the IGF-IR and/or EGFR, and/or connected with a
 XX hyperactivation of the transduction pathway of the signal mediated by the
 XX interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
 XX the administration of the medicament does not induce or only slightly
 XX induces secondary effects connected with inhibition of the insulin
 XX receptor. The antibody is useful for preparation of a medicament intended
 XX to inhibit the transformation of normal cells into cells with tumoral
 XX character, preferably IGF-dependent, especially IGF1 and/or IGF2-
 XX dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
 XX useful for preparation of a medicament intended to inhibit the growth
 XX and/or the proliferation of tumor cells, preferably IGF-dependent,
 XX especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or
 XX HER2/neu-dependent cells. (I) is useful in the preparation of a
 XX medicament intended for prevention or for the treatment of cancer, where
 XX the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
 XX breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 XX preparation of a medicament intended for the prevention or for the
 XX treatment of psoriasis. (II) is useful in preparation of a medicament
 XX intended for the specific targeting of a biologically active compound to

CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
 CC is useful for in vitro diagnosis of illnesses induced by an
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
 CC starting from a biological sample in which the abnormal presence, of IGF-
 CC IR and/or EGFR receptor is suspected, which involves contacting the
 CC biological sample with (I), which is optionally labeled. The present
 CC sequence is used in the exemplification of the invention.

XX SQ Sequence 131 AA;

Query Match 100.0%; Score 595; DB 9; Length 131;
 Best Local Similarity 100.0%; Pred. No. 2.9e-43;
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60
 DB 20 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 79
 QY 61 YGVPDRFSGSGGTDFTLKISRVEADGVVYCFQGSHPVPTFGQGTKEIK 112
 DB 80 YGVPDRFSGSGGTDFTLKISRVEADGVVYCFQGSHPVPTFGQGTKEIK 131

RESULT 5

ADJ76899
 ID ADJ76899 standard; protein; 112 AA.

XX AC ADJ76899;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-IR related protein #14.

XX KW cytostatic; antipsoriatic; antibody;
 KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
 KW CDR.

XX OS Homo sapiens.

XX PN WO2003059951-A2.

XX PD 24-JUL-2003.

XX PF 20-JAN-2003; 2003WO-FR000178.

XX PR 18-JAN-2002; 2002FR-00000653.

XX PR 18-JAN-2002; 2002FR-00000654.

XX PR 07-MAY-2002; 2002FR-00005753.

XX PA (FABR) FABRE MEDICAMENT SA PIERRE.

XX PA Goetsch L, Corvaia N, Leger O;

XX DR WPI; 2003-569653/53.

XX PT New antibodies that bind to human insulin-like growth factor receptor,
 XX useful for treatment, prevention and diagnosis of cancers.

XX PS Disclosure; SEQ ID NO 65; 164pp; French.

XX The invention relates to an isolated antibody (Ab), and its functional
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
 CC IR) and optionally: (i) inhibit natural binding of insulin-like growth
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
 CC kinase activity of IGF-IR. Ab and its fragments are used to prevent or
 CC treat diseases associated with overexpression and/or abnormal activity of
 CC IGF-IR and/or epidermal growth factor receptor (EGFR) and/or with
 CC hyperactivity of signal transduction pathways mediated by interaction of
 CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the

CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.

XX SQ Sequence 112 AA;

Query Match 99.8%; Score 594; DB 7; Length 112;
 Best Local Similarity 99.1%; Pred. No. 3e-43;
 Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60
 DB 1 DVVMTQSPSLPVTGEPASISCRSSQSIHVSNGNTYLOWYLOKPGQSPQLLIYKVSRL 60
 QY 61 YGVPDRFSGSGGTDFTLKISRVEADGVVYCFQGSHPVPTFGQGTKEIK 112
 DB 61 YGVPDRFSGSGGTDFTLKISRVEADGVVYCFQGSHPVPTFGQGTKEIK 112

RESULT 6

ADZ67069
 ID ADZ67069 standard; protein; 112 AA.

XX AC ADZ67069;

XX DT 30-JUN-2005 (first entry)

XX DE Human antibody 7C10 2 light chain variable region SEQ ID NO:65.

XX KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW light chain variable region.

XX OS Homo sapiens.

XX PN US2005084906-A1.

XX PD 21-APR-2005.

XX PF 16-DEC-2003; 2003US-00735916.

XX PR 18-JAN-2002; 2002FR-00000653.

XX PR 18-JAN-2002; 2002FR-00000654.

XX PR 07-MAY-2002; 2002FR-00005753.

XX PR 20-JAN-2003; 2003WO-FR000178.

XX PR 11-JUL-2003; 2003FR-00008538.

XX PA (GOET/) GOETSCH L.

XX PA (CORV/) CORVAIA N.

XX PA (LEGE/) LEGER O.

XX PA (DUFL/) DUFLOS A.

XX PA (HAEU/) HAEUW J.

XX PA (BECK/) BECK A.

XX PI Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

XX DR WPI; 2005-321968/33.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 CC antibody or its functional fragment, being capable of binding human IGF-
 CC IR and specifically inhibiting tyrosine kinase activity of receptor,
 CC useful for treating cancer.

XX Example 12; SEQ ID NO 65; 125pp; English.

XX The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-IR and, if necessary, capable of

CC specifically inhibiting tyrosine kinase activity of the receptor,
 CC comprising a light or heavy chain having at least one complementary
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-IR and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
 CC the administration of the medicament does not induce or only slightly
 CC induces secondary effects connected with inhibition of the insulin
 CC receptor. The antibody is useful for preparation of a medicament intended
 CC to inhibit the transformation of normal cells into cells with tumoral
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
 CC useful for preparation of a medicament intended to inhibit the growth
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,
 CC especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a
 CC medicament intended for prevention or for the treatment of cancer, where
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 CC preparation of a medicament intended for the prevention or for the
 CC treatment of psoriasis. (I) is useful in preparation of a medicament
 CC intended for the specific targeting of a biologically active compound to
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
 CC is useful for in vitro diagnosis of illnesses induced by an
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
 CC starting from a biological sample in which the abnormal presence, of IGF-
 CC IR and/or EGFR receptor is suspected, which involves contacting the
 CC biological sample with (I), which is optionally labeled. The present
 CC sequence is used in the exemplification of the invention.

XX SQ Sequence 112 AA;

Query Match 99.8%; Score 594; DB 9; Length 112;
 Best Local Similarity 99.1%; Pred. No. 3e-43; Indels 0; Gaps 0;
 Matches 111; Conservative 1; Mismatches 0;
 QY 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIIVHSNGNTYLYQWYLYQKPGQSPQLLIYKVSNRL 60
 DB 1 DIVMTQSPSLPVTTPGEPASISCRSSQSIIVHSNGNTYLYQWYLYQKPGQSPQLLIYKVSNRL 60
 QY 61 YGVPRDFSGSGGTDTFLKISRVEADVGVIYCFQGSHPVPTFGQGTKEIK 112
 DB 61 YGVPRDFSGSGGTDTFLKISRVEADVGVIYCFQGSHPVPTFGQGTKEIK 112

RESULT 7
 ADJ76901
 ID ADJ76901 standard; protein; 131 AA.
 XX AC ADJ76901;
 XX DT 06-MAY-2004 (first entry)

XX DE Anti-IGF-1R related protein #15.
 XX KW cytostatic; antiporiatic; antibody;
 KW insulin-like growth factor-1 receptor; IGF-IR; tyrosine kinase activity;
 KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
 KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
 KW CDR.

XX OS Homo sapiens.
 XX PN WO2003059951-A2.
 XX PD 24-JUL-2003.
 XX PF 20-JAN-2003; 2003WO-FR000178.
 XX PR 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.
 PR 07-MAY-2002; 2002FR-00005753.

XX PA (FABR) FABRE MEDICAMENT SA PIERRE.

XX PI Goetsch L, Corvaia N, Leger O;

XX XX WPI; 2003-569653/53.

XX PT New antibodies that bind to human insulin-like growth factor receptor,
 PT useful for treatment, prevention and diagnosis of cancers.

XX PS Disclosure; SEQ ID NO 67; 164pp; French.

XX CC The invention relates to an isolated antibody (Ab) and its functional
 CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
 CC IR) and optionally: (i) inhibit natural binding of insulin-like growth
 CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
 CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
 CC treat diseases associated with overexpression and/or abnormal activity of
 CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
 CC hyperactivity of signal transduction pathways mediated by interaction of
 CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.

XX SQ Sequence 131 AA;

Query Match 99.8%; Score 594; DB 7; Length 131;
 Best Local Similarity 99.1%; Pred. No. 3.5e-43;
 Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIIVHSNGNTYLYQWYLYQKPGQSPQLLIYKVSNRL 60
 DB 20 DIVMTQSPSLPVTTPGEPASISCRSSQSIIVHSNGNTYLYQWYLYQKPGQSPQLLIYKVSNRL 79
 QY 61 YGVPRDFSGSGGTDTFLKISRVEADVGVIYCFQGSHPVPTFGQGTKEIK 112
 DB 80 YGVPRDFSGSGGTDTFLKISRVEADVGVIYCFQGSHPVPTFGQGTKEIK 131

RESULT 8

ADZ67071
 ID ADZ67071 standard; protein; 131 AA.
 XX AC ADZ67071;
 XX DT 30-JUN-2005 (first entry)

XX DE Human antibody 7C10 2 light chain variable region SEQ ID NO:67.
 XX KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometroid carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW light chain variable region.

XX OS Homo sapiens.
 XX FH Key Location/Qualifiers
 FT Peptide 1..119 /note= "leader peptide"
 FT Region 43..58 /note= "CDR1"
 FT Region 74..80 /note= "CDR2"
 FT Region 113..121

FT US2005084906-A1. /note= "CDR3"
PN 21-APR-2005.
XX 16-DEC-2003; 2003US-00735916.
XX 18-JAN-2002; 2002FR-00000653.
XX 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
PR 20-JAN-2003; 2003WO-FR000178.
PR 11-JUL-2003; 2003FR-00008538.
XX (GORT/) GOETSCH L.
PA (CORV/) CORVAIA N.
PA (LEGE/) LEGER O.
PA (DUFL/) DUFLOS A.
PA (HAU/) HAEUW J.
PA (BECK/) BECK A.
XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
PI WPI; 2005-321968/33.
XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
PT antibody or its functional fragment, being capable of binding human IGF-
PT IR and specifically inhibiting tyrosine kinase activity of receptor,
PT useful for treating cancer.
XX
PS Example 12; SEQ ID NO 67; 125pp; English.
XX
CC The invention relates to a novel isolated anti-insulin-like growth factor
CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
CC capable of binding to human IGF-IR and, if necessary, capable of
CC specifically inhibiting tyrosine kinase activity of the receptor,
CC comprising a light or heavy chain having at least one complementary
CC determining region (CDR) consisting of one of two fully defined 16 amino
CC acids (AD267006 and AD267014). An antibody of the invention is useful in
CC the preparation of a medicament intended for the prevention or treatment
CC of an illness connected with an overexpression and/or an abnormal
CC activation of the IGF-IR and/or EGFR, and/or connected with a
CC hyperactivation of the transduction pathway of the signal mediated by the
CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
CC the administration of the medicament does not induce or only slightly
CC induces secondary effects connected with inhibition of the insulin
CC receptor. The antibody is useful for preparation of a medicament intended
CC to inhibit the transformation of normal cells into cells with tumoral
CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
CC useful for preparation of a medicament intended to inhibit the growth
CC and/or the proliferation of tumor cells, preferably IGF-dependent,
CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
CC HER2/neu-dependent cells. (I) is useful in the preparation of a
CC medicament intended for prevention or for the treatment of cancer, where
CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
CC preparation of a medicament intended for the prevention or for the
CC treatment of psoriasis. (I) is useful in preparation of a medicament
CC intended for the specific targeting of a biologically active compound to
CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
CC is useful for in vitro diagnosis of illnesses induced by an
CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
CC starting from a biological sample in which the abnormal presence, of IGF-
CC IR and/or EGFR receptor is suspected, which involves contacting the
CC biological sample with (I), which is optionally labeled. The present
CC sequence is used in the exemplification of the invention.
XX
SQ Sequence 131 AA;

Query Match 99.8%; Score 594; DB 9; Length 131;
Best Local Similarity 99.1%; Pred. No. 3.5e-43;

Matches 111; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 DVNVTQSLSLPVTGPASPASISCRSSQSIHVSNGNTYLTQWYLOKPGQSPQLLIYKVSNRL 60
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 20 DIVMTQSLSLPVTGPASPASISCRSSQSIHVSNGNTYLTQWYLOKPGQSPQLLIYKVSNRL 79
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 61 YGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGTKEIK 112
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 80 YGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCFQGSHPVPTFGGTKEIK 131
|:|||||||||||||||||||||||||||||||||||||||||||||||||||||
RESULT 9
ADP84950
ID ADP84950 standard; protein; 114 AA.
XX
AC ADP84950;
XX
DT 09-SEP-2004 (first entry)
XX
DE Variable light chain VL fragment Karo24 SEQ ID NO 92.
XX
KW antibody; Core-1 antigen; framework region; immunoglobulin superfamily;
KW protease inhibitor; lectin; helix-bundle protein; lipocalin;
KW variable heavy chain; VH; variable light chain; VL; vaccine; diagnosis;
KW alleviation; treatment; tumour; breast; colon; stomach; pancreas;
KW large/small intestine; ovary; cervix; lung; prostate; kidney; liver;
KW metastasis.
XX
OS Mus musculus.
OS Homo sapiens.
OS Chimeric.
PN WO2004050707-A2.
XX
PD 17-JUN-2004.
XX
PF 01-DEC-2003; 2003WO-DE003994.
XX
PR 29-NOV-2002; 2002DE-01056900.
XX
PA (NEMO-) NEMOD BIOTHERAPEUTICS GMBH & CO KG.
XX
PI Goletz S, Danielczyk A, Karsten U, Ravn P, Stahn R;
PI Christensen PA;
XX
DR WPI; 2004-461095/43.
XX
PT New recognition molecules, e.g. antibodies (and nucleic acids) that bind
PT specifically to Core-1 antigens, useful for diagnosis, treatment and
PT prevention of tumors and metastases.
XX
PS Claim 15; SEQ ID NO 92; 136pp; German.
XX
CC This invention describes novel recognition molecules, especially
CC antibodies that bind specifically to the Core-1 antigen. The recognition
CC molecules are used to make constructs containing the framework regions
CC that separate, include and/or flank the specified sequences, especially
CC where the framework regions are from the immunoglobulin (Ig) superfamily,
CC protease inhibitors, lectins, helix-bundle proteins and/or lipocalins.
CC Most especially the framework regions are from antibodies, particularly
CC the variable heavy chain (VH) and the variable light chain (VL) of human
CC and/or murine origin. The constructs may also include a His or myc tag, a
CC lysine-rich region and/or a multimerisation domain, most particularly it
CC is a single-chain antibody fragment, multibody, Fab fragment, fusion
CC protein of an antibody fragment with peptide or protein, and/or an Ig of
CC types G, M, A, E or D and/or their subclasses. It may be human,
CC humanised, murine or chimeric, e.g. IGM without the J chain. The
CC additional sequences/structures in the constructs are Ig domains of
CC various species, interacting or stabilising domains, signal sequences,
CC fluorescent dyes, toxins, antibodies with catalytic activity or other
CC specificities, cytolytic agents, enzymes, immuno-modulators or -
CC effectors, MHC molecules, antigens, chelators for radioactive labels,
CC liposomes, transmembrane domains, viruses and/or cells, specifically

CC macrophages. The antibodies, also constructs containing them, nucleic
 CC acid encoding them, and related vectors and host cells, are useful for
 CC prevention (e.g. as vaccine), diagnosis, alleviation, treatment,
 CC monitoring and/or secondary treatment of tumours (specifically of breast,
 CC colon, stomach, pancreas, large/small intestine, ovary, cervix, lung,
 CC prostate, kidney and/or liver) and/or metastases (particularly to liver),
 CC specifically where these are positive for the C1 antigen. The products of
 CC the invention provide simple, reliable and efficient detection of
 CC tumours. They are specific for carcinoma and show almost no binding to
 CC healthy tissue.

XX Sequence 114 AA;

Query Match 95.6%; Score 569; DB 8; Length 114;
 Best Local Similarity 95.5%; Pred. No. 4.2e-41;
 Matches 107; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIHVHSGNTYLYLQKPGSPQLLIYKVSNNRL 60
 Db 1 DIVMTQSPSLPVTTPGEPASISCRSSQSIHVHSGNTYLYLQKPGSPQLLIYKVSNNRF 60

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDVGVYFCQSGSHVPWTFQGTKEIK 112
 Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDVGVYFCQSGSHVPWTFQGTKEIK 112

RESULT 10

AAE15713
 ID AAE15713 standard; protein; 112 AA.

AC AAE15713;

DT 12-MAR-2002 (first entry)

DE Mouse monoclonal antibody alpha 340 V_k region variant, 340VKd.

XX Mouse; humanised form; monoclonal antibody alpha 340; Gene therapy;
 KW epidermal growth factor receptor; EGF; cancer; colorectal; lung; breast;
 KW gastric; ovarian; immune response; cytostatic; cell growth; apoptosis;
 KW inhibitor; mutant; mutein; variant.

XX Mus sp.

OS Synthetic.

XX Key Location/Qualifiers

FT Misc-difference 7 /note= "Wild type Thr substituted with Ser"

FT Misc-difference 14 /note= "Wild type Ser substituted with Thr"

FT Misc-difference 15 /note= "Wild type Leu substituted with Pro"

FT Misc-difference 17 /note= "Wild type Asp substituted with Glu"

FT Misc-difference 18 /note= "Wild type Gln substituted with Pro"

FT Misc-difference 50 /note= "Wild type Lys substituted with Gln"

FT Misc-difference 88 /note= "Wild type Leu substituted with Val"

FT Misc-difference 109 /note= "Wild type Leu substituted with Val"

FT Misc-difference 112 /note= "Wild type Asn substituted with Lys"

XX WO200188138-A1.

XX 22-NOV-2001.

XX 21-MAY-2001; 2001WO-GB002226.

XX 19-MAY-2000; 2000GB-00011981.

XX 24-AUG-2000; 2000GB-00020794.

PA (SCAN-) SCANCELL LTD.

XX Ellis JRM, Durrant LG;

XX WPI; 2002-062384/08.

XX New humanized form of mouse monoclonal antibody 340 which binds to
 PT epidermal growth factor receptor and inhibits binding of growth factor,
 PT useful for treating colorectal, lung, breast, gastric and ovarian cancer.
 XX Example 2; Fig 7; 53pp; English.

XX The present invention relates to a humanised form of the antibody 340 (a
 CC mouse monoclonal antibody which binds to epidermal growth factor (EGF)
 CC receptor and inhibits binding of EGF), obtainable from the cell line
 CC deposited with the ECACC under accession number 97021428. The humanised
 CC form of the antibody 340 is useful in gene therapy, medicine and in the
 CC manufacture of a medicament for treatment or prophylaxis of cancer. The
 CC invention is useful for treating colorectal, lung, breast, gastric or
 CC ovarian cancers or also for preventing the recurrence of cancer after
 CC initial treatment or surgery. The invention is also useful for enhancing
 CC a protective immune response against cancer by optimised immunisation
 CC schedules. The humanised form of the antibody 340 has reduced
 CC immunogenicity but shows similar binding to cells expressing EGF
 CC receptor, as the original murine antibody and has increased ability to
 CC inhibit the growth of EGF receptor expressing cells. The invention is
 CC used as cell growth and apoptosis inhibitor. The present sequence is
 CC mouse monoclonal antibody alpha 340 deimmunised light chain variable (VK)
 CC region variant, 340VKd

XX Sequence 112 AA;

Query Match 95.5%; Score 568; DB 5; Length 112;

Best Local Similarity 94.6%; Pred. No. 5e-41;
 Matches 106; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTTPGEPASISCRSSQSIHVHSGNTYLYLQKPGSPQLLIYKVSNNRL 60
 Db 1 DVLMTQSPSLPVTTPGEPASISCRSSQSIHVHSGNTYLYLQKPGSPQLLIYKVSNNRF 60

Qy 61 YGVDPDRFSGSGGTDFTLKISRVEAEDVGVYFCQSGSHVPWTFQGTKEIK 112

Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDVGVYFCQSGSHVPWTFQGTKEIK 112

RESULT 11

AAE15712
 ID AAE15712 standard; protein; 112 AA.

AC AAE15712;

DT 12-MAR-2002 (first entry)

DE Mouse monoclonal antibody alpha 340 V_k region variant, 340VKc.

XX Mouse; humanised form; monoclonal antibody alpha 340; gene therapy;
 KW epidermal growth factor receptor; EGF; cancer; colorectal; lung; breast;
 KW gastric; ovarian; immune response; cytostatic; cell growth; apoptosis;
 KW inhibitor; mutant; mutein; variant.

XX Mus sp.

OS Synthetic.

XX Key Location/Qualifiers

FT Misc-difference 7 /note= "Wild type Thr substituted with Ser"

FT Misc-difference 14 /note= "Wild type Ser substituted with Thr"

FT Misc-difference 15 /note= "Wild type Leu substituted with Pro"

FT Misc-difference 17 /note= "Wild type Asp substituted with Glu"

FT Misc-difference 18

```

FT      /note= "Wild type Gln substituted with Pro"
FT Misc-difference 50
FT      /note= "Wild type Lys substituted with Gln"
FT Misc-difference 88
FT      /note= "Wild type Leu substituted with Thr"
FT Misc-difference 90
FT      /note= "Wild type Ile substituted with Val"
FT Misc-difference 109
FT      /note= "Wild type Leu substituted with Val"
FT Misc-difference 112
FT      /note= "Wild type Asn substituted with Lys"
XX
XX W0200188138-A1.
XX
XX 22-NOV-2001.
XX
XX 21-MAY-2001; 2001WO-GB002226.
XX
XX 19-MAY-2000; 2000GB-00011981.
XX
XX 24-AUG-2000; 2000GB-00020794.
XX
XX (SCAN-) SCANCELL LTD.
XX
XX Ellis JRM, Durrant LG;
XX
XX WPI; 2002-062384/08.
XX
XX New humanized form of mouse monoclonal antibody 340 which binds to
XX epidermal growth factor receptor and inhibits binding of growth factor,
XX useful for treating colorectal, lung, breast, gastric and ovarian cancer.
XX
XX Example 2; Fig 7; 53pp; English.
XX
XX The present invention relates to a humanised form of the antibody 340 (a
XX mouse monoclonal antibody which binds to epidermal growth factor (EGF)
XX receptor and inhibits binding of EGF), obtainable from the cell line
XX deposited with the ECACC under accession number 97021428. The humanised
XX form of the antibody 340 is useful in gene therapy, medicine and in the
XX manufacture of a medicament for treatment or prophylaxis of cancer. The
XX invention is useful for treating colorectal, lung, breast, gastric or
XX ovarian cancers or also for preventing the recurrence of cancer after
XX initial treatment or surgery. The invention is also useful for enhancing
XX a protective immune response against cancer by optimised immunisation
XX schedules. The humanised form of the antibody 340 has reduced EGF
XX immunogenicity but shows similar binding to cells expressing EGF
XX receptor, as the original murine antibody and has increased ability to
XX inhibit the growth of EGF receptor expressing cells. The invention is
XX used as cell growth and apoptosis inhibitor. The present sequence is
XX mouse monoclonal antibody alpha 340 deimmunised light chain variable
XX region variant, 340VKC
XX
XX Sequence 112 AA;
XX
XX Query Match          95.0%; Score 565; DB 5; Length 112;
XX Best Local Similarity 94.6%; Pred. No. 9.1e-41;
XX Matches 106; Conservative 2; Mismatches 4; Indels 0; Gaps 0;
XX
Qy      1 DVVMTQSPSLPVTTPGEPASISCRSSQSI VHSNGNTYLOWYLPKPGQSPQLLIYKVS NRL 60
Db      1 DVLMTQSPSLPVTTPGEPASISCRSSQSI VHSNGNTYLTWYLPKPGQSPQLLIYKVS NRF 60
Qy      61 YGVDPDRFSGSGGTDFTLKISRVEAEDTGVYFCQQGSHVPWTFQGTKEIK 112
Db      61 SGVDPDRFSGSGGTDFTLKISRVEAEDTGVYFCQQGSHVPWTFQGTKEIK 112
XX
XX RESULT 12
XX ADP84948
XX ID ADP84948 standard; protein; 114 AA.
XX
XX AC ADP84948;
XX
XX DT 09-SEP-2004 (first entry)

```

```

XX DE Variable light chain VL fragment Karoll SEQ ID NO 90.
XX
XX antibody; Core-1 antigen; framework region; immunoglobulin superfamily;
XX protease inhibitor; lectin; helix-bundle protein; lipocalin;
XX variable heavy chain; VH; variable light chain; VL; vaccine; diagnosis;
XX alleviation; treatment; tumour; breast; colon; stomach; pancreas;
XX large/small intestine; ovary; cervix; lung; prostate; kidney; liver;
XX metastasis.
XX
XX Mus musculus.
XX OS Homo sapiens.
XX Chimeric.
XX
XX W02004050707-A2.
XX
XX 17-JUN-2004.
XX
XX 01-DEC-2003; 2003WO-DE003994.
XX
XX 29-NOV-2002; 2002DE-01056900.
XX
XX (NEMO-) NEMOD BIOTHERAPEUTICS GMBH & CO KG.
XX
XX Goletz S, Danielczyk A, Karsten U, Ravn P, Stahn R;
XX Christensen PA;
XX
XX WPI; 2004-461095/43.
XX
XX New recognition molecules, e.g. antibodies (and nucleic acids) that bind
XX specifically to Core-1 antigens, useful for diagnosis, treatment and
XX prevention of tumors and metastases.
XX
XX Claim 15; SEQ ID NO 90; 136pp; German.
XX
XX This invention describes novel recognition molecules, especially
XX antibodies that bind specifically to the Core-1 antigen. The recognition
XX molecules are used to make constructs containing the framework regions
XX that separate, include and/or flank the specified sequences, especially
XX where the framework regions are from the immunoglobulin (Ig) superfamily.
XX Protease inhibitors, lectins, helix-bundle proteins and/or lipocalins.
XX Most especially the framework regions are from antibodies, particularly
XX the variable heavy chain (VH) and the variable light chain (VL) of human
XX and/or murine origin. The constructs may also include a His or myc tag, a
XX lysine-rich region and/or a multimerisation domain, most particularly it
XX is a single-chain antibody fragment, multibody, Fab fragment, fusion
XX protein of an antibody fragment with peptide or protein, and/or an Ig of
XX types G, M, A, E or D and/or their subclasses. It may be human,
XX humanised, murine or chimeric, e.g. IGM without the J chain. The
XX additional sequences/structures in the constructs are Ig domains of
XX various species, interacting or stabilising domains, signal sequences,
XX fluorescent dyes, toxins, antibodies with catalytic activity or other
XX specificities, cytolytic agents, enzymes, immuno-modulators or -
XX effectors, MHC molecules, antigens, chelators for radioactive labels,
XX liposomes, transmembrane domains, viruses and/or cells, specifically
XX macrophages. The antibodies, also constructs containing them, nucleic
XX acid encoding them, and related vectors and host cells, are useful for
XX prevention (e.g. as vaccine), diagnosis, alleviation, treatment,
XX monitoring and/or secondary treatment of tumours (specifically of breast,
XX colon, stomach, pancreas, large/small intestine, ovary, cervix, lung,
XX prostate, kidney and/or liver) and/or metastases (particularly to liver),
XX specifically where these are positive for the C1 antigen. The products of
XX the invention provide simple, reliable and efficient detection of
XX tumours. They are specific for carcinoma and show almost no binding to
XX healthy tissue.
XX
XX Sequence 114 AA;
XX
XX Query Match          95.0%; Score 565; DB 8; Length 114;
XX Best Local Similarity 94.6%; Pred. No. 9.2e-41;
XX Matches 106; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
XX
Qy      1 DVVMTQSPSLPVTTPGEPASISCRSSQSI VHSNGNTYLOWYLPKPGQSPQLLIYKVS NRL 60

```


Db 1 DVMTQSPSLPVTPGEPASISCRSSQSIHVSNGNTYLYWYQKPGQSPKLLIYKVSNR 60
Qy 61 YGVDPFRFGSGSGTDTFLKISRVEADGVVYCFQGSHPVPTFGGTVKEIK 112
Db 61 SGVDPFRFGSGSGTDTFLKISRVEADGVVYCFQGSHPVPTFGGTVKEIK 112

RESULT 13
AAE15711
ID AAE15711 standard; protein; 112 AA.
XX AAE15711;
XX DT 12-MAR-2002 (first entry)
XX Mouse monoclonal antibody alpha 340 Vb region variant, 340Vkb.
XX Mouse; humanised form; monoclonal antibody alpha 340; gene therapy;
KW epidermal growth factor receptor; EGF; cancer; colorectal; lung; breast;
KW gastric; ovarian; immune response; cytostatic; cell growth; apoptosis;
KW inhibitor; mutant; mutein; variant.
XX Mus sp.
OS Synthetic.

Key Location/Qualifiers
FH Misc-difference 7 /note= "Wild type Thr substituted with Ser"
FT Misc-difference 14 /note= "Wild type Ser substituted with Thr"
FT Misc-difference 15 /note= "Wild type Leu substituted with Pro"
FT Misc-difference 17 /note= "Wild type Asp substituted with Glu"
FT Misc-difference 18 /note= "Wild type Gln substituted with Pro"
FT Misc-difference 29 /note= "Wild type Ile substituted with Leu"
FT Misc-difference 50 /note= "Wild type Lys substituted with Gln"
FT Misc-difference 88 /note= "Wild type Leu substituted with Thr"
FT Misc-difference 90 /note= "Wild type Ile substituted with Val"
FT Misc-difference 109 /note= "Wild type Leu substituted with Val"
FT Misc-difference 112 /note= "Wild type Asn substituted with Lys"
XX WO200188138-A1.
XX 22-NOV-2001.
XX 21-MAY-2001; 2001WO-GB002226.
XX 19-MAY-2000; 2000GB-00011981.
XX 24-AUG-2000; 2000GB-00020794.
XX (SCAN-) SCANCELL LTD.
XX Ellis JRM, Durrant LG;
XX WPI; 2002-062384/08.
XX New humanized form of mouse monoclonal antibody 340 which binds to
XX epidermal growth factor receptor and inhibits binding of growth factor,
XX useful for treating colorectal, lung, breast, gastric and ovarian cancer.
XX Example 2; Fig 7; 53pp; English.
XX The present invention relates to a humanised form of the antibody 340 (a
XX mouse monoclonal antibody which binds to epidermal growth factor (EGF)

CC receptor and inhibits binding of EGF), obtainable from the cell line
CC deposited with the ECACC under accession number 97021428. The humanised
CC form of the antibody 340 is useful in gene therapy, medicine and in the
CC manufacture of a medicament for treatment or prophylaxis of cancer. The
CC invention is useful for treating colorectal, lung, breast, gastric or
CC ovarian cancers or also for preventing the recurrence of cancer after
CC initial treatment or surgery. The invention is also useful for enhancing
CC a protective immune response against cancer by optimised immunisation
CC schedules. The humanised form of the antibody 340 has reduced
CC immunogenicity but shows similar binding to cells expressing EGF
CC receptor, as the original murine antibody and has increased ability to
CC inhibit the growth of EGF receptor expressing cells. The invention is
CC used as cell growth and apoptosis inhibitor. The present sequence is
CC mouse monoclonal antibody alpha 340 deimmunised light chain variable (VK)
XX region variant, 340Vkb
SQ Sequence 112 AA;

Query Match 94.6%; Score 563; DB 5; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.3e-40;
Matches 105; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVMTQSPSLPVTPGEPASISCRSSQSIHVSNGNTYLYWYQKPGQSPKLLIYKVSNR 60
Db 1 DVMTQSPSLPVTPGEPASISCRSSQSIHVSNGNTYLYWYQKPGQSPKLLIYKVSNR 60

Qy 61 YGVDPFRFGSGSGTDTFLKISRVEADGVVYCFQGSHPVPTFGGTVKEIK 112
Db 61 SGVDPFRFGSGSGTDTFLKISRVEADGVVYCFQGSHPVPTFGGTVKEIK 112

RESULT 14
ABP72125
ID ABP72125 standard; protein; 112 AA.
XX ABP72125;
XX 03-JUN-2003 (first entry)
XX FGF-8 related protein SEQ ID 17.
XX Humanised; antibody; fibroblast growth factor 8; FGF8; cytostatic;
KW cancer; prostate; breast; ovarian; testicular.
XX Synthetic.
XX WO2003002608-A1.
XX 09-JAN-2003.
XX 28-JUN-2002; 2002WO-JP006591.
XX 28-JUN-2001; 2001JP-00196176.
XX (KYOW) KYOWA HAKKO KOGYO KK.
XX Shitara K, Nakamura K, Hirota M, Shimada N;
XX WPI; 2003-239169/23.
XX Humanised antibodies and antibody fragments reacting with fibroblast
XX growth factor 8 useful for the treatment and diagnosis of cancer.
XX Claim 19; Page 72; 86pp; Japanese.
XX The invention relates to novel humanised antibodies and antibody
XX fragments which react with fibroblast growth factor 8 (FGF8) and inhibit
XX its biological functions. The polypeptides of the invention have
XX cytostatic activity. The antibody is useful for the treatment of cancer,
XX including prostate, breast, ovarian and testicular cancer. The present
XX sequence is used in the exemplification of the invention
XX Sequence 112 AA;

Job time : 78.3134 secs

Query Match 94.6%; Score 563; DB 6; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.3e-40;
Matches 105; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 DVVMTQSP LSLP VTPGEPASISCRSSQSI VHSNGNTY LQWYLQKPGQSPQLLIYKVSNRL 60

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840.

QV 61 YGVDPFSGSGTDFTLKISRVEADVGVYCFQSGHVPWTFGQGTKVEIK 112

— — — — —

RESULT 15

AD E36495

ID ADE36495 standard; protein; 112 AA.

AC ADE36495;

29-JAN-2004 (first entry)

DE Anti-FGF-8 (sic fibroblast growth factor) antibody-related protein #2.

arthritis: anti-EGF-8: sic fibroblast growth factor:

KW cartilage protection agent: joint destruction inhibitor;
KW arthritis; anti-PPF-8; sic fibroblast growth factor;

KW carcinoma of the prostate gland; joint
carcinoma of the prostate gland; joint
synovial proliferation inhibitor.

OS Unidentified.

AA WO2003057251-A1.

17-ЖИЛ.-2003-

XX
PF
26-DEC-2002: 2002WO-JP013650-

PR 28-DEC-2001: 2001JP-00400677.

PA (KYOW) KYOWA HAKKO KOGYO KK.

XX
PT Tamura T. Uchii M. Suda T. Miki T. Tanaka A:

XX
DR WPI: 2003-587078/55.

Treatment and prevention of arthritis comprising the use of anti-PGF-8 (sic fibroblast growth factor) antibody.

PS Claim 11: SEO ID NO 19: 193pp: Japanese.

XX The invention comprises a method for treating and preventing arthritis, CC
CC the method involves the use of anti-FGF-8 (sic fibroblast growth factor, CC
CC antibody. The antibody and method of the invention is useful for: the CC
CC detection, treatment and prevention of arthritis; as a cartilage CC
CC protection agent; as a joint destruction inhibitor; and as a synovial CC
CC proliferation inhibitor. The present amino acid sequence represents a CC
CC protein of the invention. CC

Sequence 112 AA:

| | | | | |
|---------------------------|-------|--------------------|-----------|-------------|
| Query Match | 94.6% | Score 563; | DB 7; | Length 112; |
| Best Local Similarity | 93.8% | Pred. No. 1.3e-40; | | |
| Matches 105: Conservative | 5; | Mismatches 2; | Indels 0; | Gaps 0; |

QV 1 DVVMTOSPLSLPVTTPGEPASISCRSSOSIVHSNGNTTYLOWYLOKPGOSPOLLTYKVS NRL 60

[illegible]

61 YGVDPDRFSGSGGTDFTLKISRVEAEDVGVYYCFQGSHPVPTFGOGTKVEIK 112

[illegible]

Search completed: January 10, 2006, 20:44:14

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:55:23 ; Search time 5.71144 Seconds
(without alignments)
166.558 Million cell updates/sec

Title: US-10-735-916A-54

Perfect score: 590

Sequence: 1 DVLMTQIPLSLPSVLGDOAS.....CFQGSHPVPTFGGTTKLEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 61141 seqs, 8493638 residues

Total number of hits satisfying chosen parameters: 61141

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA_New.*
1: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pap.*
2: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pap.*
3: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pap.*
4: /cgn2_6/ptodata/1/pubpaa/PTCT_NEW_PUB.pap.*
5: /cgn2_6/ptodata/1/pubpaa/US05_NEW_PUB.pap.*
6: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pap.*
7: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pap.*
8: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pap.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|-------|-------------|--------|--------------------|-------------------|
| 1 | 590 | 100.0 | 112 | 7 US-11-012-353-54 | Sequence 54, Appl |
| 2 | 590 | 100.0 | 122 | 7 US-11-012-353-49 | Sequence 49, Appl |
| 3 | 564 | 95.6 | 112 | 7 US-11-012-353-56 | Sequence 56, Appl |
| 4 | 557 | 94.4 | 131 | 7 US-11-125-837-23 | Sequence 23, Appl |
| 5 | 551 | 93.4 | 263 | 7 US-11-089-266-66 | Sequence 66, Appl |
| 6 | 548 | 92.9 | 112 | 7 US-11-089-266-15 | Sequence 15, Appl |
| 7 | 547 | 92.7 | 112 | 7 US-11-012-353-57 | Sequence 57, Appl |
| 8 | 547 | 92.7 | 113 | 6 US-10-932-334-69 | Sequence 69, Appl |
| 9 | 547 | 92.7 | 149 | 7 US-11-089-266-2 | Sequence 2, Appl |
| 10 | 545 | 92.4 | 112 | 7 US-11-012-353-55 | Sequence 55, Appl |
| 11 | 544 | 92.2 | 113 | 6 US-10-932-334-61 | Sequence 61, Appl |
| 12 | 543 | 92.0 | 251 | 6 US-10-512-184-30 | Sequence 30, Appl |
| 13 | 543 | 92.0 | 320 | 6 US-10-512-184-67 | Sequence 67, Appl |
| 14 | 543 | 92.0 | 619 | 6 US-10-512-184-66 | Sequence 66, Appl |
| 15 | 543 | 92.0 | 618 | 6 US-10-512-184-48 | Sequence 48, Appl |
| 16 | 542 | 91.9 | 113 | 6 US-10-932-334-60 | Sequence 60, Appl |
| 17 | 541 | 91.7 | 113 | 6 US-10-932-334-59 | Sequence 59, Appl |
| 18 | 541 | 91.7 | 116 | 7 US-11-065-943-49 | Sequence 49, Appl |
| 19 | 538 | 91.2 | 112 | 7 US-11-012-353-61 | Sequence 61, Appl |
| 20 | 538 | 91.2 | 131 | 7 US-11-012-353-63 | Sequence 63, Appl |
| 21 | 537 | 91.0 | 112 | 7 US-11-012-353-65 | Sequence 65, Appl |
| 22 | 537 | 91.0 | 113 | 6 US-10-932-334-66 | Sequence 66, Appl |
| 23 | 537 | 91.0 | 113 | 6 US-10-932-334-68 | Sequence 68, Appl |
| 24 | 537 | 91.0 | 131 | 7 US-11-012-353-67 | Sequence 67, Appl |
| 25 | 536 | 90.8 | 113 | 6 US-10-932-334-8 | Sequence 8, Appl |

| | | | | | | |
|----|-----|------|-----|---|------------------|-------------------|
| 26 | 536 | 90.8 | 113 | 6 | US-10-932-334-58 | Sequence 58, Appl |
| 27 | 536 | 90.8 | 113 | 6 | US-10-932-334-62 | Sequence 62, Appl |
| 28 | 536 | 90.8 | 113 | 6 | US-10-932-334-82 | Sequence 82, Appl |
| 29 | 536 | 90.8 | 132 | 6 | US-10-932-334-50 | Sequence 50, Appl |
| 30 | 535 | 90.7 | 113 | 6 | US-10-932-334-65 | Sequence 65, Appl |
| 31 | 531 | 90.0 | 131 | 6 | US-10-789-273-14 | Sequence 14, Appl |
| 32 | 527 | 89.3 | 113 | 6 | US-10-932-334-10 | Sequence 10, Appl |
| 33 | 527 | 89.3 | 113 | 6 | US-10-932-334-84 | Sequence 84, Appl |
| 34 | 527 | 89.3 | 113 | 6 | US-10-932-334-94 | Sequence 94, Appl |
| 35 | 525 | 89.0 | 113 | 6 | US-10-932-334-63 | Sequence 63, Appl |
| 36 | 524 | 88.8 | 113 | 6 | US-10-932-334-11 | Sequence 11, Appl |
| 37 | 524 | 88.8 | 113 | 6 | US-10-932-334-12 | Sequence 12, Appl |
| 38 | 524 | 88.8 | 113 | 6 | US-10-932-334-85 | Sequence 85, Appl |
| 39 | 524 | 88.8 | 113 | 6 | US-10-932-334-86 | Sequence 86, Appl |
| 40 | 523 | 88.6 | 113 | 6 | US-10-959-330-23 | Sequence 23, Appl |
| 41 | 523 | 88.6 | 144 | 7 | US-11-055-163-15 | Sequence 15, Appl |
| 42 | 522 | 88.5 | 113 | 6 | US-10-932-334-67 | Sequence 67, Appl |
| 43 | 521 | 88.3 | 113 | 6 | US-10-932-334-9 | Sequence 9, Appl |
| 44 | 521 | 88.3 | 113 | 6 | US-10-932-334-83 | Sequence 83, Appl |
| 45 | 521 | 88.3 | 113 | 6 | US-10-932-334-90 | Sequence 90, Appl |

ALIGNMENTS

RESULT 1
US-11-012-353-54
; Sequence 54, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFIOS, ALAIN
; APPLICANT: HAEUM, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; TITLE OF INVENTION: RECEPTORS ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: Patentin ver. 3.3
; SEQ ID NO 54
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-54

Query Match 100.0%; Score 590; DB 7; Length 112;
Best Local Similarity 100.0%; Pred. No. 1.1e-39;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPSVLGDOASISCRSSQIVHSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
Db 1 DVLMTQIPLSLPSVLGDOASISCRSSQIVHSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
QY 61 YGVDPFSGSGSGTDTFLTKISSVEADLGVYFCFGSHVPWTFGGTGTLEIK 112
Db 61 YGVDPFSGSGSGTDTFLTKISSVEADLGVYFCFGSHVPWTFGGTGTLEIK 112

```
RESULT 2
US-11-012-353-49
; Sequence 49, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETTSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 0205753
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 49
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-49

Query Match          100.0%; Score 590; DB 7; Length 122;
Best Local Similarity 100.0%; Pred. No. 1.1e-39;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLWYLPQSPKLLIYKVSNRL 60
Db      11 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLWYLPQSPKLLIYKVSNRL 70

Qy      61 YGVDPFRFSGSGTDFTLKISSVEAEDLGVIYCFQGSHPVWTFGGTGLEIK 112
Db      71 YGVDPFRFSGSGTDFTLKISSVEAEDLGVIYCFQGSHPVWTFGGTGLEIK 122

RESULT 3
US-11-012-353-56
; Sequence 56, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETTSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUFLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; FILE REFERENCE: 017753-198
; CURRENT APPLICATION NUMBER: US/11/012,353
; CURRENT FILING DATE: 2004-12-16
; PRIOR APPLICATION NUMBER: 10/735,916
; PRIOR FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 0308538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR03/00178
; PRIOR FILING DATE: 2003-01-20
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 56
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-56

Query Match          95.6%; Score 564; DB 7; Length 112;
Best Local Similarity 95.5%; Pred. No. 1.1e-37;
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy      1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLWYLPQSPKLLIYKVSNRL 60
Db      1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLWYLPQSPKLLIYKVSNRF 60

Qy      61 YGVDPFRFSGSGTDFTLKISSVEAEDLGVIYCFQGSHPVWTFGGTGLEIK 112
Db      61 SGVDPFRFSGSGTDFTLKISRVEAEDLGVIYCFQGSHPVWTFGGTGLEIK 112

RESULT 4
US-11-125-837-23
; Sequence 23, Application US/11125837
; Publication No. US20050266003A1
; GENERAL INFORMATION:
; APPLICANT: Lin, Rong-Hwa
; APPLICANT: Chang, Chung Nan
; APPLICANT: Chen, Pei-Jiun
; APPLICANT: Huang, Chiu-Chen
; TITLE OF INVENTION: ANTIBODIES
; FILE REFERENCE: 13062-011001
; CURRENT APPLICATION NUMBER: US/11/125,837
; CURRENT FILING DATE: 2005-05-10
; PRIOR APPLICATION NUMBER: US 60/569,892
; PRIOR FILING DATE: 2004-05-10
; NUMBER OF SEQ ID NOS: 100
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-125-837-23

Query Match          94.4%; Score 557; DB 7; Length 131;
Best Local Similarity 94.6%; Pred. No. 4.2e-37;
Matches 106; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy      1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLWYLPQSPKLLIYKVSNRL 60
Db      20 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLWYLPQSPKLLIYKVSNRF 79

Qy      61 YGVDPFRFSGSGTDFTLKISSVEAEDLGVIYCFQGSHPVWTFGGTGLEIK 112
Db      80 SGVDPFRFSGSGTDFTLKISRVEAEDLGVIYCFQGSHPVWTFGGTGLEIK 131

RESULT 5
US-11-089-266-66
; Sequence 66, Application US/11089266
; Publication No. US20050287148A1
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Foon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TITLE OF INVENTION: TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
```

```
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: FR 0200653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 56
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-012-353-56
```

```
Query Match          95.6%; Score 564; DB 7; Length 112;
Best Local Similarity 95.5%; Pred. No. 1.1e-37;
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy      1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLWYLPQSPKLLIYKVSNRL 60
Db      1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLWYLPQSPKLLIYKVSNRF 60

Qy      61 YGVDPFRFSGSGTDFTLKISSVEAEDLGVIYCFQGSHPVWTFGGTGLEIK 112
Db      61 SGVDPFRFSGSGTDFTLKISRVEAEDLGVIYCFQGSHPVWTFGGTGLEIK 112
```

```
RESULT 4
US-11-125-837-23
; Sequence 23, Application US/11125837
; Publication No. US20050266003A1
; GENERAL INFORMATION:
; APPLICANT: Lin, Rong-Hwa
; APPLICANT: Chang, Chung Nan
; APPLICANT: Chen, Pei-Jiun
; APPLICANT: Huang, Chiu-Chen
; TITLE OF INVENTION: ANTIBODIES
; FILE REFERENCE: 13062-011001
; CURRENT APPLICATION NUMBER: US/11/125,837
; CURRENT FILING DATE: 2005-05-10
; PRIOR APPLICATION NUMBER: US 60/569,892
; PRIOR FILING DATE: 2004-05-10
; NUMBER OF SEQ ID NOS: 100
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-125-837-23
```

```
Query Match          94.4%; Score 557; DB 7; Length 131;
Best Local Similarity 94.6%; Pred. No. 4.2e-37;
Matches 106; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy      1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLWYLPQSPKLLIYKVSNRL 60
Db      20 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLWYLPQSPKLLIYKVSNRF 79

Qy      61 YGVDPFRFSGSGTDFTLKISSVEAEDLGVIYCFQGSHPVWTFGGTGLEIK 112
Db      80 SGVDPFRFSGSGTDFTLKISRVEAEDLGVIYCFQGSHPVWTFGGTGLEIK 131
```

```
RESULT 5
US-11-089-266-66
; Sequence 66, Application US/11089266
; Publication No. US20050287148A1
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Foon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TITLE OF INVENTION: TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
```

CORRESPONDENCE ADDRESS:
 ADDRESSEE: MORRISON & FOERSTER
 STREET: 755 PAGE MILL ROAD
 CITY: PALO ALTO
 STATE: CA
 COUNTRY: USA
 ZIP: 94304-1018
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/11/089,266
 FILING DATE: 23-Mar-2005
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/10/153,401
 FILING DATE: 27-Aug-2002
 APPLICATION NUMBER: US 09/293,533
 FILING DATE: 1999-04-15
 APPLICATION NUMBER: US 08/372,676
 FILING DATE: 1995-01-17
 APPLICATION NUMBER: US 08/591,196
 FILING DATE: 1996-01-16
 ATTORNEY/AGENT INFORMATION:
 NAME: Catherine M. Polizzi
 REGISTRATION NUMBER: 40,130
 REFERENCE/DOCKET NUMBER: 304142000202
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (415) 813-5600
 TELEFAX: (415) 494-0792
 TELEX: 706141
 INFORMATION FOR SEQ ID NO: 66:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 263 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-11-089-266-66
 Query Match 93.4%; Score 551; DB 7; Length 263;
 Best Local Similarity 93.8%; Pred. No. 2.1e-36;
 Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;
 QY 1 DVLMTQIPLSLPSVLGDAQSISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
 DB 152 DVLMTQTPLSLPSVLGDAQSISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYFVSNRF 211
 QY 61 YGVDPFRFSGSGTDTFTLKISVVEADLGVYCFQGSHPVWTFGGGKLEIK 112
 DB 212 SGVDPFRFSGSGTDTFTLKISVVEADLGVYCFQGSHPVWTFGGGKLEIK 263
 RESULT 6
 US-11-089-266-15
 Sequence 15, Application US/11089266
 Publication No. US20050287148A1
 GENERAL INFORMATION:
 APPLICANT: Chatterjee, Malaya
 APPLICANT: Foon, Kenneth A.
 APPLICANT: Chatterjee, Sunil K.
 TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
 TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
 NUMBER OF SEQUENCES: 66
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: MORRISON & FOERSTER
 STREET: 755 PAGE MILL ROAD
 CITY: PALO ALTO
 STATE: CA
 COUNTRY: USA
 ZIP: 94304-1018
 COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/11/089,266
 FILING DATE: 23-Mar-2005
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/10/153,401
 FILING DATE: 27-Aug-2002
 APPLICATION NUMBER: US 09/293,533
 FILING DATE: 1999-04-15
 APPLICATION NUMBER: US 08/372,676
 FILING DATE: 1995-01-17
 APPLICATION NUMBER: US 08/591,196
 FILING DATE: 1996-01-16
 ATTORNEY/AGENT INFORMATION:
 NAME: Catherine M. Polizzi
 REGISTRATION NUMBER: 40,130
 REFERENCE/DOCKET NUMBER: 304142000202
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (415) 813-5600
 TELEFAX: (415) 494-0792
 TELEX: 706141
 INFORMATION FOR SEQ ID NO: 15:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 112 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-11-089-266-15
 Query Match 92.9%; Score 548; DB 7; Length 112;
 Best Local Similarity 93.8%; Pred. No. 1.8e-36;
 Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;
 QY 1 DVLMTQIPLSLPSVLGDAQSISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
 DB 1 DVLMTQTPLSLPSVLGDAQSISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYFVSNRF 60
 QY 61 YGVDPFRFSGSGTDTFTLKISVVEADLGVYCFQGSHPVWTFGGGKLEIK 112
 DB 61 SGVDPFRFSGSGTDTFTLKISVVEADLGVYCFQGSHPVWTFGGGKLEIK 112
 RESULT 7
 US-11-012-353-57
 Sequence 57, Application US/11012353
 Publication No. US20050249730A1
 GENERAL INFORMATION:
 APPLICANT: GOETSCH, LILIANE
 APPLICANT: CORVAIA, NATHALIE
 APPLICANT: DUFLOS, ALAIN
 APPLICANT: HAEUW, JEAN-FRANCOIS
 APPLICANT: LEGER, OLIVIER
 APPLICANT: BECK, ALAIN
 TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
 RECEPTORS ANTIBODIES AND USES THEREOF
 FILE REFERENCE: 017753-198
 CURRENT APPLICATION NUMBER: US/11/012,353
 CURRENT FILING DATE: 2004-12-16
 PRIOR APPLICATION NUMBER: 10/735,916
 PRIOR FILING DATE: 2003-12-16
 PRIOR APPLICATION NUMBER: FR 0308538
 PRIOR FILING DATE: 2003-07-11
 PRIOR APPLICATION NUMBER: PCT/FR03/00178
 PRIOR FILING DATE: 2003-01-20
 PRIOR APPLICATION NUMBER: FR 0205753
 PRIOR FILING DATE: 2002-05-07
 PRIOR APPLICATION NUMBER: FR 0200653
 PRIOR FILING DATE: 2002-01-18

; PRIOR APPLICATION NUMBER: FR 0200654
; PRIOR FILING DATE: 2002-01-18
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 57
; LENGTH: 112
; TYPE: PRP
; ORGANISM: Mus musculus
US-11-012-353-57

Query Match 92.7%; Score 547; DB 7; Length 112;
Best Local Similarity 92.0%; Pred. No. 2.2e-36;
Matches 103; Conservative 5; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPKLLIYKVSRL 60
DB 1 DVMFTQTPLSLPVSIGDQASISCRSSQSIHVSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 60

QY 61 YGVDPFRFSGSGGTDFTLKISSVEAEIDLGVYFCQGSHPVPTFGGTTKLEIK 112
DB 61 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKLEIK 112

RESULT 8
US-10-932-334-69
; Sequence 69, Application US/10932334
; Publication No. US20050249728A1
; GENERAL INFORMATION:
; APPLICANT: ImmunoGen, Inc.
; FILE REFERENCE: A8689
; CURRENT APPLICATION NUMBER: US/10/932,334
; CURRENT FILING DATE: 2004-09-02
; PRIOR APPLICATION NUMBER: US/10/729,441
; PRIOR FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: 10/170,390
; PRIOR FILING DATE: 2002-06-14
; NUMBER OF SEQ ID NOS: 96
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 69
; LENGTH: 113
; TYPE: PRP
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic antibody structure
; NAME/KEY: MISC_FEATURE
; LOCATION: (28)..(28)
; OTHER INFORMATION: "X" may be any amino acid
; FEATURE:
; NAME/KEY: MISC_FEATURE
; LOCATION: (101)..(101)
; OTHER INFORMATION: "X" may be any amino acid
US-10-932-334-69

Query Match 92.7%; Score 547; DB 6; Length 113;
Best Local Similarity 93.8%; Pred. No. 2.2e-36;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPKLLIYKVSRL 60
DB 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 60

QY 61 YGVDPFRFSGSGGTDFTLKISSVEAEIDLGVYFCQGSHPVPTFGGTTKLEIK 112
DB 61 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKLEIK 112

RESULT 9
US-11-089-266-2
; Sequence 2, Application US/11089266
; Publication No. US20050287148A1
; GENERAL INFORMATION:

; APPLICANT: Chatterjee, Malaya
; APPLICANT: Foon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/11/089,266
; FILING DATE: 23-Mar-2005
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/153,401
; FILING DATE: 27-Aug-2002
; APPLICATION NUMBER: US 09/293,533
; FILING DATE: 1999-04-15
; APPLICATION NUMBER: US 08/372,676
; FILING DATE: 1995-01-17
; APPLICATION NUMBER: US 08/591,196
; FILING DATE: 1996-01-16
; ATTORNEY/AGENT INFORMATION:
; NAME: Catherine M. Polizzi
; REGISTRATION NUMBER: 40,130
; REFERENCE/DOCKET NUMBER: 304142000202
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 149 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-11-089-266-2

Query Match 92.7%; Score 547; DB 7; Length 149;
Best Local Similarity 92.9%; Pred. No. 2.7e-36;
Matches 104; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPKLLIYKVSRL 60
DB 20 DVMFTQTPLSLPVSIGDQASISCRSSQSIHVSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 79

QY 61 YGVDPFRFSGSGGTDFTLKISSVEAEIDLGVYFCQGSHPVPTFGGTTKLEIK 112
DB 80 SGVDPFRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTTKLEIK 131

RESULT 10
US-11-012-353-55
; Sequence 55, Application US/11012353
; Publication No. US20050249730A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, LILIANE
; APPLICANT: CORVAIA, NATHALIE
; APPLICANT: DUPLOS, ALAIN
; APPLICANT: HAEUW, JEAN-FRANCOIS
; APPLICANT: LEGER, OLIVIER
; APPLICANT: BECK, ALAIN
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID
; RECEPTORS ANTIBODIES AND USES THEREOF

FILE REFERENCE: 017753-198
CURRENT APPLICATION NUMBER: US/11/012,353
CURRENT FILING DATE: 2004-12-16
PRIOR APPLICATION NUMBER: 10/735,916
PRIOR FILING DATE: 2003-12-16
PRIOR APPLICATION NUMBER: FR 0308538
PRIOR FILING DATE: 2003-07-11
PRIOR APPLICATION NUMBER: PCT/FR03/00178
PRIOR FILING DATE: 2003-01-20
PRIOR APPLICATION NUMBER: FR 0205753
PRIOR FILING DATE: 2002-05-07
PRIOR APPLICATION NUMBER: FR 0200653
PRIOR FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: FR 0200654
PRIOR FILING DATE: 2002-01-18
NUMBER OF SEQ ID NOS: 162
SOFTWARE: PatentIn Ver. 3.3
SEQ ID NO 55
LENGTH: 112
TYPE: PRT
ORGANISM: Mus musculus
US-11-012-353-55

Query Match 92.4%; Score 545; DB 7; Length 112;
Best Local Similarity 92.9%; Pred. No. 3.1e-36;
Matches 104; Conservative 3; Mismatches 5; Indels 0; Gaps 0;
QY 1 DVLMTQIPLSVSLGDAQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
Db 1 DVLMTQIPLSVSLGDAQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPWTFGGGTGLEIK 112
Db 61 SGVPRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPWTFGGGTGLEIK 112

RESULT 11
US-10-932-334-61
Sequence 61, Application US/10932334
Publication No. US20050249728A1
GENERAL INFORMATION:
APPLICANT: ImmunoGen, Inc.
TITLE OF INVENTION: ANTI-IGF-I RECEPTOR ANTIBODY
FILE REFERENCE: A8689
CURRENT APPLICATION NUMBER: US/10/932,334
CURRENT FILING DATE: 2004-09-02
PRIOR APPLICATION NUMBER: US/10/729,441
PRIOR FILING DATE: 2003-12-08
PRIOR APPLICATION NUMBER: 10/170,390
PRIOR FILING DATE: 2002-06-14
NUMBER OF SEQ ID NOS: 96
SOFTWARE: PatentIn version 3.2
SEQ ID NO 61
LENGTH: 113
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: synthetic antibody structure
US-10-932-334-61

Query Match 92.2%; Score 544; DB 6; Length 113;
Best Local Similarity 92.0%; Pred. No. 3.7e-36;
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;
QY 1 DVLMTQIPLSVSLGDAQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
Db 1 DVLMTQIPLSVSLGDAQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPWTFGGGTGLEIK 112
Db 61 SGVPRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPWTFGGGTGLEIK 112

RESULT 12
US-10-512-184-30
Sequence 30, Application US/10512184
Publication No. US20050244901A1
GENERAL INFORMATION:
APPLICANT: Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant
TITLE OF INVENTION: antibody fragments and fusions mediated plant disease
TITLE OF INVENTION: resistance against fungi
FILE REFERENCE: 3581.01US01
CURRENT APPLICATION NUMBER: US/10/512,184
CURRENT FILING DATE: 2004-10-22
NUMBER OF SEQ ID NOS: 72
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 30
LENGTH: 251
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: scFv VD2 with
specificity against Verticillium dahliae;
OTHER INFORMATION: originates from Mus musculus.
US-10-512-184-30

Query Match 92.0%; Score 543; DB 6; Length 251;
Best Local Similarity 92.9%; Pred. No. 8.4e-36;
Matches 104; Conservative 2; Mismatches 6; Indels 0; Gaps 0;
QY 1 DVLMTQIPLSVSLGDAQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
Db 138 DVLMTQIPLSVSLGDAQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKASRNF 197
QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPWTFGGGTGLEIK 112
Db 198 SGVPRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPWTFGGGTGLEIK 249

RESULT 13
US-10-512-184-67
Sequence 67, Application US/10512184
Publication No. US20050244901A1
GENERAL INFORMATION:
APPLICANT: Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant
TITLE OF INVENTION: antibody fragments and fusions mediated plant disease
TITLE OF INVENTION: resistance against fungi
FILE REFERENCE: 3581.01US01
CURRENT APPLICATION NUMBER: US/10/512,184
CURRENT FILING DATE: 2004-10-22
NUMBER OF SEQ ID NOS: 72
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 67
LENGTH: 320
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: precursor
OTHER INFORMATION: fusion protein comprising AG - linker - scFv VD2.
US-10-512-184-67

Query Match 92.0%; Score 543; DB 6; Length 320;
Best Local Similarity 92.9%; Pred. No. 1e-35;
Matches 104; Conservative 2; Mismatches 6; Indels 0; Gaps 0;
QY 1 DVLMTQIPLSVSLGDAQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
Db 207 DVLMTQIPLSVSLGDAQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKASRNF 266
QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPWTFGGGTGLEIK 112
Db 267 SGVPRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPWTFGGGTGLEIK 318

RESULT 14

| | | | | |
|-----------------------|-----------------|--------------------|-----------|-------------|
| Query Match | 92.0% | Score 543; | DB 6; | Length 569; |
| Best Local Similarity | 92.9% | Pred. No. 1.6e-35; | | |
| Matches 10; | Conservative 2; | Mismatches 6; | Indels 0; | Gaps 0; |

| | | | |
|----|-----|--|-----|
| Qy | 1 | DVLMTQIPLSLPSVLGQOASISCSRSSQSIVHSNGNTYLOWLYQKPGQSKLLIYKVSNRL | 60 |
| | | | |
| Db | 456 | DVLMTQIPLSLPSVLGQOASISCSRSSQSIVHSNGNTYLOWLYQKPGQSKLLIYKASNR | 515 |
| | | | |
| Qy | 61 | YGVPDFRSGSGGDFTLKISSVBAEDLVVYICFGSHVPVTFGGGTLKLEIK | 112 |
| | | | |
| Db | 516 | SGVPAFSGSGGDFTLKISRBAEDLVVYICFGSHVPVTFGGGTLKLEIK | 567 |
| | | | |

| | | | | | | |
|----|---------------------------|---|---|-----------|-------------|--|
| | Query Match | 92.0%; | Score 543; | DB 6; | Length 618; | |
| | Best Local Similarity | 92.9%; | Pred. No. 1.8e-35; | | | |
| | Matches 104; Conservative | 2; | Mismatches 6; | Indels 0; | Gaps 0 | |
| Qy | 1 | DVLMQTPLSLPVSILGDAQS | ISCRSSQSIVHSNGNTYLOWLQKPGSQPKLLIYKVSNRL | 60 | | |
| | | | | | | |
| Db | 479 | DVLMQTPLSLPVSILGDAQS | ISCRSSQNIVHSNGNTYLOWLQKPGSQPKLLIYKASNRF | 538 | | |
| | | | | | | |
| Qy | 61 | YGVPDRFGSGSGGDFTLKISSVAEDLVGYCYCQGSHPVPTFGGGTKLEIK | 112 | | | |
| | | | | | | |
| Db | 539 | SGVPARTSGSGSGGDFTLKISRVAEDLVGYCYCQGSHPVPTFGGGTKLEIK | 590 | | | |
| | | | | | | |

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:34:27 ; Search time 21.8706 Seconds
(without alignments)
423.384 Million cell updates/sec

Title: US-10-735-916A-54
Perfect score: 590
Sequence: 1 DVLMTQPLSLPVLGDOAS.....CFQSHVPWTFGGGTGLEIK 112

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA.*
1: /cgn2_6/ptodata/1/iaa/5 COMB.pep.*
2: /cgn2_6/ptodata/1/iaa/6 COMB.pep.*
3: /cgn2_6/ptodata/1/iaa/H COMB.pep.*
4: /cgn2_6/ptodata/1/iaa/PCTUS COMB.pep.*
5: /cgn2_6/ptodata/1/iaa/RE COMB.pep.*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|-------|-------------|--------|----|--------------------|
| 1 | 551 | 93.4 | 149 | 2 | US-09-192-838B-2 |
| 2 | 551 | 93.4 | 149 | 2 | US-09-324-191-2 |
| 3 | 551 | 93.4 | 263 | 1 | US-08-752-844-66 |
| 4 | 551 | 93.4 | 263 | 2 | US-09-293-533-66 |
| 5 | 548 | 92.9 | 112 | 1 | US-08-752-844-15 |
| 6 | 548 | 92.9 | 112 | 2 | US-08-591-196-15 |
| 7 | 548 | 92.9 | 112 | 2 | US-09-293-533-15 |
| 8 | 547 | 92.7 | 149 | 1 | US-08-752-844-2 |
| 9 | 547 | 92.7 | 149 | 1 | US-08-591-196-2 |
| 10 | 547 | 92.7 | 149 | 2 | US-09-293-533-2 |
| 11 | 545 | 92.4 | 113 | 1 | US-08-497-312-18 |
| 12 | 545 | 92.4 | 114 | 1 | US-08-560-558E-27 |
| 13 | 545 | 92.4 | 125 | 1 | US-08-331-398A-67 |
| 14 | 545 | 92.4 | 125 | 1 | US-08-331-397B-67 |
| 15 | 545 | 92.4 | 125 | 1 | US-08-759-804A-66 |
| 16 | 544 | 92.2 | 249 | 2 | US-09-726-219A-190 |
| 17 | 544 | 92.2 | 249 | 2 | US-09-196-522-190 |
| 18 | 543 | 92.0 | 112 | 1 | US-08-859-649-19 |
| 19 | 543 | 92.0 | 112 | 1 | US-08-859-649-29 |
| 20 | 543 | 92.0 | 112 | 2 | US-08-207-861-19 |
| 21 | 543 | 92.0 | 112 | 2 | US-08-207-861-29 |
| 22 | 543 | 92.0 | 112 | 2 | US-08-859-648-19 |
| 23 | 543 | 92.0 | 112 | 2 | US-08-859-648-29 |
| 24 | 543 | 92.0 | 238 | 2 | US-09-192-545-4 |
| 25 | 542 | 91.9 | 112 | 1 | US-08-888-366-16 |
| 26 | 541 | 91.7 | 112 | 1 | US-08-331-398A-48 |
| 27 | 541 | 91.7 | 112 | 1 | US-08-077-252B-3 |

| | | | | | |
|----|-----|------|-----|---|--------------------|
| 28 | 541 | 91.7 | 112 | 1 | US-08-331-397B-48 |
| 29 | 541 | 91.7 | 112 | 1 | US-08-759-804A-48 |
| 30 | 541 | 91.7 | 112 | 2 | US-09-002-753A-3 |
| 31 | 541 | 91.7 | 112 | 2 | US-09-227-693-48 |
| 32 | 541 | 91.7 | 112 | 2 | US-09-657-274-3 |
| 33 | 541 | 91.7 | 112 | 4 | PCT-US94-06687-3 |
| 34 | 541 | 91.7 | 247 | 2 | US-09-227-693-34 |
| 35 | 541 | 91.7 | 248 | 1 | US-08-331-398A-34 |
| 36 | 541 | 91.7 | 248 | 1 | US-08-331-397B-34 |
| 37 | 541 | 91.7 | 248 | 1 | US-08-759-804A-34 |
| 38 | 539 | 91.4 | 131 | 1 | US-08-053-171-5 |
| 39 | 539 | 91.4 | 131 | 1 | US-08-053-171-9 |
| 40 | 539 | 91.4 | 149 | 2 | US-10-226-795-27 |
| 41 | 538 | 91.2 | 114 | 2 | US-09-217-268B-27 |
| 42 | 535 | 90.7 | 216 | 2 | US-09-254-180C-132 |
| 43 | 535 | 90.7 | 216 | 2 | US-09-254-180C-183 |
| 44 | 534 | 90.5 | 114 | 1 | US-08-285-936-4 |
| 45 | 534 | 90.5 | 114 | 1 | US-08-487-860-4 |

ALIGNMENTS

RESULT 1

US-09-192-838B-2
; Sequence 2, Application US/09192838B
; Patent No. 6355244
; GENERAL INFORMATION:
; APPLICANT: FOON, Kenneth A.
; APPLICANT: CHATTERJEE, Malaya
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSORIASIS
; FILE REFERENCE: 304142000500
; CURRENT APPLICATION NUMBER: US/09/192.838B
; CURRENT FILING DATE: 1998-11-16
; PRIOR APPLICATION NUMBER: 60/065,774
; PRIOR FILING DATE: 1997-11-17
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 149
; TYPE: PRT
; ORGANISM: Mus Musculus
US-09-192-838B-2

Query Match 93.4%; Score 551; DB 2; Length 149;
Best Local Similarity 93.8%; Pred. No. 7.6e-46;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

| | | | |
|----|----|--|-----|
| Qy | 1 | DVLMTQPLSLPVLGDOASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSNRL | 60 |
| Db | 20 | DVLMTQPLSLPVLGDOASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSNRF | 79 |
| Qy | 61 | YGVPDRFSGSGGTDTFTLKISSVEAEGLGVYFCFGSHVPWTFGGGTGLEIK | 112 |
| Db | 80 | SGVPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPWTFGGGTGLEIK | 131 |

RESULT 2

US-09-324-191-2
; Sequence 2, Application US/09324191
; Patent No. 6562798
; GENERAL INFORMATION:
; APPLICANT: THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
; APPLICANT: CHATTERJEE, Malaya
; APPLICANT: FOON, Kenneth A.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSORIASIS
; FILE REFERENCE: 304142000540
; CURRENT APPLICATION NUMBER: US/09/324.191
; CURRENT FILING DATE: 1999-06-02
; EARLIER APPLICATION NUMBER: 60/065,774
; EARLIER FILING DATE: 1997-11-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 2
; LENGTH: 149
; TYPE: PRT
; ORGANISM: Mus Musculus
US-09-324-191-2

Query Match 93.4%; Score 551; DB 2; Length 149;
Best Local Similarity 93.8%; Pred. No. 7.6e-46;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQITPLSLPVSLGDAQASISCRSSQSIHVHSGNTYLYQWYLOKPGQSPKLLIYKVSRL 60
|||||
DB 20 DVLMTQTPLSLPVSLGDAQASISCRSSQSIHVHSGNTYLYEWYLOKPGQSPNLLIYFVSNRF 79
|||||

QY 61 YGVDPFRFSGSGGTDTFLKISVVEADLGVVYCFQGSHPVPTFGGTTKLEIK 112
|||||
DB 80 SGVPDRFSGSGGTDTFLKISRVEADLGVVYCFQGSHPVPTFGGTTKLEIK 131
|||||

RESULT 3
US-08-752-844-66
; Sequence 66, Application US/08752844
; Patent No. 5935821
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Foon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/752,844
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Schiff, J. Michael
; REGISTRATION NUMBER: 40,253
; REFERENCE/DOCKET NUMBER: 30414-20002.21
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 263 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-752-844-66

Query Match 93.4%; Score 551; DB 1; Length 263;
Best Local Similarity 93.8%; Pred. No. 1.4e-45;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQITPLSLPVSLGDAQASISCRSSQSIHVHSGNTYLYQWYLOKPGQSPKLLIYKVSRL 60
|||||
DB 152 DVLMTQTPLSLPVSLGDAQASISCRSSQSIHVHSGNTYLYEWYLOKPGQSPNLLIYFVSNRF 211
|||||

QY 61 YGVDPFRFSGSGGTDTFLKISVVEADLGVVYCFQGSHPVPTFGGTTKLEIK 112
|||||
DB 212 SGVPDRFSGSGGTDTFLKISRVEADLGVVYCFQGSHPVPTFGGTTKLEIK 263
|||||

RESULT 4
US-09-293-533-66
; Sequence 66, Application US/09293533
; Patent No. 6509016
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Foon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/293,533
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/752,844
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Schiff, J. Michael
; REGISTRATION NUMBER: 40,253
; REFERENCE/DOCKET NUMBER: 30414-20002.21
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 263 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-293-533-66

Query Match 93.4%; Score 551; DB 2; Length 263;
Best Local Similarity 93.8%; Pred. No. 1.4e-45;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQITPLSLPVSLGDAQASISCRSSQSIHVHSGNTYLYQWYLOKPGQSPKLLIYKVSRL 60
|||||
DB 152 DVLMTQTPLSLPVSLGDAQASISCRSSQSIHVHSGNTYLYEWYLOKPGQSPNLLIYFVSNRF 211
|||||

QY 61 YGVDPFRFSGSGGTDTFLKISVVEADLGVVYCFQGSHPVPTFGGTTKLEIK 112
|||||
DB 212 SGVPDRFSGSGGTDTFLKISRVEADLGVVYCFQGSHPVPTFGGTTKLEIK 263
|||||

RESULT 5
US-08-752-844-15
; Sequence 15, Application US/08752844
; Patent No. 5935821
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Foon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:

```
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/752,844
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Schiff, J. Michael
; REGISTRATION NUMBER: 40,253
; REFERENCE/DOCKET NUMBER: 30414-20002.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-752-844-15

Query Match          92.9%; Score 548; DB 1; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.le-45;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLQWYLOKQSPKLIYKVSNRL 60
Db 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLQWYLOKQSPKLIYFVSNRF 60

QY 61 YGVDPFRFSGSGTDTFLKISSVEAEDLGVIYCFQGSHPVPTFGGKTLEIK 112
Db 61 SGVPDRFSGSGTDTFLKISRVEAEDLGVIYCFQGSHPVPTFGGKTLEIK 112

RESULT 6
US-08-591-196-15
; Sequence 15, Application US/08591196
; Patent No. 5977316
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Foon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/591,196
; FILING DATE: 16-JAN-1996
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
```

```
; NAME: Schiff, J. Michael
; REGISTRATION NUMBER: 40,253
; REFERENCE/DOCKET NUMBER: 30414-20002.20
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-591-196-15

Query Match          92.9%; Score 548; DB 1; Length 112;
Best Local Similarity 93.8%; Pred. No. 1.le-45;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLQWYLOKQSPKLIYKVSNRL 60
Db 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLQWYLOKQSPKLIYFVSNRF 60

QY 61 YGVDPFRFSGSGTDTFLKISSVEAEDLGVIYCFQGSHPVPTFGGKTLEIK 112
Db 61 SGVPDRFSGSGTDTFLKISRVEAEDLGVIYCFQGSHPVPTFGGKTLEIK 112

RESULT 7
US-09-293-533-15
; Sequence 15, Application US/09293533
; Patent No. 6509016
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; APPLICANT: Foon, Kenneth A.
; APPLICANT: Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/293,533
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/752,844
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Schiff, J. Michael
; REGISTRATION NUMBER: 40,253
; REFERENCE/DOCKET NUMBER: 30414-20002.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```


COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/293.533
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/752.844
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Schiff, J. Michael
REGISTRATION NUMBER: 40,253
REFERENCE/DOCKET NUMBER: 30414-20002.21
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 813-5600
TELEFAX: (415) 494-0792
TELEX: 706141
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 149 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-293-533-2

Query Match 92.7%; Score 547; DB 2; Length 149;
Best Local Similarity 92.9%; Pred. No. 1.8e-45;
Matches 104; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DVLMTQPLSLPVSILGDAQISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
Db 20 DVFMTQTPLSLPVSILGDAQISCRSSQSIHVSNGNTYLOWYLOKPGQSPNLLIYFVSNRF 79

Qy 61 YGVDPFRSGSGTDFTLKISVRAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112
Db 80 SGVDPFRSGSGTDFTLKISVRAEDLGVIYCFQGSHPVPTFGGTTKLEIK 131

RESULT 11
US-08-497-312-18
Sequence 18, Application US/08497312
Patent No. 5712120
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: Method for obtaining modified
TITLE OF INVENTION: immunoglobulins with reduced immunogenicity of murine
TITLE OF INVENTION: antibody variable domains, compositions containing them.
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: CENTRO DE INMUNOLOGIA MOLECULAR
STREET: 215 Y 15, ATABEY PLAYA
CITY: HAVANA
STATE:
COUNTRY: CUBA
ZIP: 11600
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/497,312
FILING DATE: 30-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: CU 80/94
FILING DATE: 30-JUN-1994
ATTORNEY/AGENT INFORMATION:
NAME: BOND, LAURENCE B.
REGISTRATION NUMBER: 30,549
REFERENCE/DOCKET NUMBER: 262995

TELECOMMUNICATION INFORMATION:
TELEPHONE: 801/532-1922
TELEFAX: 801/531-9168
TELEX: 388961 1PM04UT
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 113 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: protein
HYPOTHETICAL: NO
US-08-497-312-18

Query Match 92.4%; Score 545; DB 1; Length 113;
Best Local Similarity 92.9%; Pred. No. 2.1e-45;
Matches 104; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DVLMTQPLSLPVSILGDAQISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
Db 1 DVLMTQPLSLPVSILGDAQISCRSSQSIHVSNGNTYLOWYLOKPGQSPNLLIYKVSRL 60

Qy 61 YGVDPFRSGSGTDFTLKISVRAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112
Db 61 SGVDPFRSGSGTDFTLKISVRAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112

RESULT 12
US-08-560-558E-27
Sequence 27, Application US/08560558E
Patent No. 5891996
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: Humanized and chimeric monoclonal
TITLE OF INVENTION: antibodies that recognize epidermal growth factor receptor
TITLE OF INVENTION: EGF-R; diagnostic and therapeutic use.
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: Allen C. Turner, TRASK, BRITT & ROSSA
STREET: P.O. Box 2250
CITY: Salt Lake City
STATE: Utah
COUNTRY: United States of America
ZIP: 84110
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: WINDOWS95
SOFTWARE: WordPerfect 5.1/5.2
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/560.558E
FILING DATE: No. 5891996ember 17, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Turner, Allen C.
REGISTRATION NUMBER: 33,041
REFERENCE/DOCKET NUMBER: 272005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (801) 532-1922
TELEFAX: (801) 531-9168
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 114 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: protein
HYPOTHETICAL: NO
US-08-560-558E-27

Query Match 92.4%; Score 545; DB 1; Length 114;
Best Local Similarity 92.9%; Pred. No. 2.1e-45;
Matches 104; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

US-08-759-804A-66
; Sequence 66, Application US/08759804A
; Patent No. 5990296
; GENERAL INFORMATION:
; APPLICANT: Pastan, Ira
; APPLICANT: Willingham, Mark
; APPLICANT: FitzGerald, David J.
; APPLICANT: Brinkmann, Ulrich
; APPLICANT: Pai, Lee
; TITLE OF INVENTION: Tumor-Specific Antibody Fragments,
; TITLE OF INVENTION: Fusion Proteins, and Uses Thereof
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/759,804A
; FILING DATE: 03-DEC-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/331,398
; FILING DATE: 28-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/767,331
; FILING DATE: 30-SEP-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/596,289
; FILING DATE: 12-OCT-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Ellen L.
; REGISTRATION NUMBER: 32,762
; REFERENCE/DOCKET NUMBER: 015280-126140US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 125 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Region
; LOCATION: 1..125
; OTHER INFORMATION: /note= "Mouse monoclonal antibody B5 Fv
; OTHER INFORMATION: Light chain region"
US-08-759-804A-66

Query Match 92.4%; Score 545; DB 1; Length 125;
Best Local Similarity 92.9%; Pred. No. 2.4e-45;
Matches 104; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 DVLMTQPLSLPVLGDAQISCRSSQSI VHSNGNTYLOWYLOKPGQSPKLLIYKVSREL 60
Db 1 DVLTTQPLSLPVLGDAQISCRSSQSI VHSNGNTYLEWYLOKPGQSPKLLIYKVSRLF 60

QY 61 YGVPRFSGSGSGTDFTLKISSVEAEDLGYYCFQGSHPVPTFGGSKLEIK 112
Db 61 SGVPRFSGSGSGTDFTLKISRVEAEDLGYYCFQGSHPVPTFGGSKLEIK 112

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:53:43 ; Search time 61.4328 Seconds
(without alignments)
761.757 Million cell updates/sec

Title: US-10-735-916A-54
Perfect score: 590
Sequence: 1 DVLMTQIPLSLPSVLGDQAS.....CFQGSHPVPTFGGTTKLEIK 112

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA Main:
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|-------|-------------|--------|----|--------------------------------------|
| 1 | 590 | 100.0 | 112 | 5 | US-10-735-916A-54 Sequence 54, Appl |
| 2 | 590 | 100.0 | 122 | 5 | US-10-735-916A-49 Sequence 49, Appl |
| 3 | 564 | 95.6 | 112 | 3 | US-09-995-529-10 Sequence 10, Appl |
| 4 | 564 | 95.6 | 112 | 3 | US-09-995-529-10 Sequence 10, Appl |
| 5 | 564 | 95.6 | 112 | 5 | US-10-735-916A-56 Sequence 56, Appl |
| 6 | 558 | 94.6 | 112 | 4 | US-10-258-728-4 Sequence 4, Appl |
| 7 | 553 | 93.7 | 112 | 4 | US-10-258-728-4 Sequence 4, Appl |
| 8 | 551 | 93.4 | 149 | 3 | US-09-990-205-2 Sequence 2, Appl |
| 9 | 551 | 93.4 | 263 | 4 | US-10-153-401-66 Sequence 66, Appl |
| 10 | 550 | 93.2 | 219 | 4 | US-10-454-660-10 Sequence 10, Appl |
| 11 | 548 | 92.9 | 112 | 4 | US-10-153-401-15 Sequence 15, Appl |
| 12 | 547 | 92.7 | 112 | 5 | US-10-735-916A-57 Sequence 57, Appl |
| 13 | 547 | 92.7 | 113 | 5 | US-10-735-916A-57 Sequence 57, Appl |
| 14 | 547 | 92.7 | 113 | 5 | US-10-729-441-69 Sequence 69, Appl |
| 15 | 547 | 92.7 | 113 | 5 | US-10-897-406-69 Sequence 69, Appl |
| 16 | 547 | 92.7 | 149 | 4 | US-10-153-401-2 Sequence 2, Appl |
| 17 | 545 | 92.4 | 249 | 6 | US-11-093-103-84 Sequence 84, Appl |
| 18 | 545 | 92.4 | 237 | 5 | US-10-735-916A-55 Sequence 55, Appl |
| 19 | 544 | 92.2 | 113 | 5 | US-10-828-782A-16 Sequence 16, Appl |
| 20 | 544 | 92.2 | 113 | 5 | US-10-729-441-61 Sequence 61, Appl |
| 21 | 544 | 92.2 | 113 | 5 | US-10-897-406-61 Sequence 61, Appl |
| 22 | 544 | 92.2 | 249 | 4 | US-10-803-622-190 Sequence 190, Appl |
| 23 | 543 | 92.0 | 114 | 6 | US-10-803-653-190 Sequence 190, Appl |
| 24 | 542 | 91.9 | 112 | 4 | US-11-009-443-29 Sequence 29, Appl |
| 25 | 542 | 91.9 | 112 | 4 | US-10-434-469-43 Sequence 43, Appl |
| 26 | 542 | 91.9 | 112 | 5 | US-10-482-105-41 Sequence 41, Appl |
| 27 | 542 | 91.9 | 113 | 5 | US-10-500-207A-6 Sequence 6, Appl |
| | | | | | US-10-729-441-60 Sequence 60, Appl |

| | | | | | |
|----|-----|------|-----|---|--------------------------------------|
| 28 | 542 | 91.9 | 113 | 5 | US-10-897-406-60 Sequence 60, Appl |
| 29 | 542 | 91.9 | 131 | 4 | US-10-434-469-6 Sequence 6, Appl |
| 30 | 542 | 91.9 | 131 | 5 | US-10-482-105-4 Sequence 4, Appl |
| 31 | 542 | 91.9 | 131 | 5 | US-10-409-611-75 Sequence 75, Appl |
| 32 | 542 | 91.9 | 131 | 5 | US-10-409-608A-17 Sequence 17, Appl |
| 33 | 542 | 91.9 | 131 | 5 | US-10-500-207A-4 Sequence 4, Appl |
| 34 | 541 | 91.7 | 113 | 5 | US-10-729-441-59 Sequence 59, Appl |
| 35 | 541 | 91.7 | 113 | 5 | US-10-897-406-59 Sequence 59, Appl |
| 36 | 541 | 91.7 | 114 | 6 | US-11-009-443-75 Sequence 49, Appl |
| 37 | 541 | 91.7 | 116 | 5 | US-10-787-219A-49 Sequence 49, Appl |
| 38 | 540 | 91.5 | 131 | 4 | US-10-388-214A-2 Sequence 2, Appl |
| 39 | 540 | 91.5 | 220 | 6 | US-11-013-537-55 Sequence 55, Appl |
| 40 | 539 | 91.4 | 149 | 4 | US-10-226-795-27 Sequence 27, Appl |
| 41 | 538 | 91.2 | 112 | 4 | US-10-308-817-172 Sequence 172, Appl |
| 42 | 538 | 91.2 | 112 | 4 | US-10-308-817-181 Sequence 181, Appl |
| 43 | 538 | 91.2 | 112 | 4 | US-10-453-698-172 Sequence 172, Appl |
| 44 | 538 | 91.2 | 112 | 5 | US-10-735-916A-61 Sequence 61, Appl |
| 45 | 538 | 91.2 | 114 | 3 | US-09-217-268B-27 Sequence 27, Appl |

ALIGNMENTS

RESULT 1
US-10-735-916A-54
; Sequence 54, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUM, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 017753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 54
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-735-916A-54
Query Match 100.0%; Score 590; DB 5; Length 112;
Best Local Similarity 100.0%; Pred. No. 3.4e-49;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 DVLMTQIPLSLPSVLGDQASISCRSSQSIHVSNGNTYQLQWYLPKQSPKLIYKVSRL 60
Db 1 DVLMTQIPLSLPSVLGDQASISCRSSQSIHVSNGNTYQLQWYLPKQSPKLIYKVSRL 60
QY 61 YGVPRFSGSGSGTDTLTKISSVEAEDLGYYVYCFQGSHPVPTFGGTTKLEIK 112
Db 61 YGVPRFSGSGSGTDTLTKISSVEAEDLGYYVYCFQGSHPVPTFGGTTKLEIK 112
RESULT 2
US-10-735-916A-49
; Sequence 49, Application US/10735916A
; Publication No. US20050084906A1

; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 01753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 49
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-735-916A-49

Query Match 100.0%; Score 590; DB 5; Length 122;
Best Local Similarity 100.0%; Pred. No. 3.7e-49;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSRL 60
Db 11 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSRL 70

QY 61 YGVPDRFSGSGGTDTFTLKISRVEAEDLGVVYCFQGSHPVPTFGGTTKLEIK 112
Db 71 YGVPDRFSGSGGTDTFTLKISRVEAEDLGVVYCFQGSHPVPTFGGTTKLEIK 122

RESULT 3

US-09-995-529-10
; Sequence 10, Application US/09995529
; Publication No. US2003009965A1
; GENERAL INFORMATION:
; APPLICANT: WATKINS, Jeffrey D.
; APPLICANT: HUSE, William D.
; APPLICANT: TANG, Ying
; TITLE OF INVENTION: Humanized Collagen Antibodies and
; TITLE OF INVENTION: Related Methods
; FILE REFERENCE: P-IX 4976
; CURRENT APPLICATION NUMBER: US/09/995,529
; CURRENT FILING DATE: 2001-11-26
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-995-529-10

Query Match 95.6%; Score 564; DB 3; Length 112;
Best Local Similarity 95.5%; Pred. No. 1.1e-46;
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSRL 60
Db 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSRL 60

QY 61 YGVPDRFSGSGGTDTFTLKISRVEAEDLGVVYCFQGSHPVPTFGGTTKLEIK 112
|||||

Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDLGVVYCFQGSHPVPTFGGTTKLEIK 112

RESULT 4
US-09-995-529-10
; Sequence 10, Application US/09995529
; Publication No. US20040091482A9
; GENERAL INFORMATION:
; APPLICANT: WATKINS, Jeffrey D.
; APPLICANT: HUSE, William D.
; APPLICANT: TANG, Ying
; TITLE OF INVENTION: Humanized Collagen Antibodies and
; TITLE OF INVENTION: Related Methods
; FILE REFERENCE: P-IX 4976
; CURRENT APPLICATION NUMBER: US/09/995,529
; CURRENT FILING DATE: 2001-11-26
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-995-529-10

Query Match 95.6%; Score 564; DB 3; Length 112;
Best Local Similarity 95.5%; Pred. No. 1.1e-46;
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSRL 60
Db 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLYQWYLOKPGQSPKLLIYKVSRL 60

QY 61 YGVPDRFSGSGGTDTFTLKISRVEAEDLGVVYCFQGSHPVPTFGGTTKLEIK 112
Db 61 SGVPDRFSGSGGTDTFTLKISRVEAEDLGVVYCFQGSHPVPTFGGTTKLEIK 112

RESULT 5

US-10-735-916A-56
; Sequence 56, Application US/10735916A
; Publication No. US20050084906A1
; GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; FILE REFERENCE: 01753-183
; CURRENT APPLICATION NUMBER: US/10/735,916A
; CURRENT FILING DATE: 2003-12-16
; PRIOR APPLICATION NUMBER: FR 03/08 538
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 56
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-735-916A-56

Query Match 95.6%; Score 564; DB 5; Length 112;
Best Local Similarity 95.5%; Pred. No. 1.1e-46;
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVS NRL 60
Db 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVS NRL 60
QY 61 YGVPRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEI 112
Db 61 SGVPRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEI 112

RESULT 6

US-10-258-728-4
; Sequence 4, Application US/10258728
; Publication No. US20040091485A1
; GENERAL INFORMATION:
; APPLICANT: Durrant, Linda Gillian
; APPLICANT: Durrant, John Robert Maxwell
; TITLE OF INVENTION: Humanised Antibodies to the Epidermal Growth Factor Receptor
; FILE REFERENCE: 28438-101US01
; CURRENT APPLICATION NUMBER: US/10/258,728
; PRIOR FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: GB 0011981.8
; PRIOR FILING DATE: 2000-05-19
; PRIOR APPLICATION NUMBER: GB 0020794.4
; PRIOR FILING DATE: 2000-08-24
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-258-728-4

Query Match 94.6%; Score 558; DB 4; Length 112;
Best Local Similarity 94.6%; Pred. No. 4.1e-46;
Matches 105; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVS NRL 60
Db 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVS NRL 60
QY 61 YGVPRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEI 111
Db 61 SGVPRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEI 111

RESULT 7

US-10-258-728-25
; Sequence 25, Application US/10258728
; Publication No. US20040091485A1
; GENERAL INFORMATION:
; APPLICANT: Ellis, John Robert Maxwell
; APPLICANT: Durrant, Linda Gillian
; TITLE OF INVENTION: Humanised Antibodies to the Epidermal Growth Factor Receptor
; FILE REFERENCE: 28438-101US01
; CURRENT APPLICATION NUMBER: US/10/258,728
; CURRENT FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: GB 0011981.8
; PRIOR FILING DATE: 2000-05-19
; PRIOR APPLICATION NUMBER: GB 0020794.4
; PRIOR FILING DATE: 2000-08-24
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-258-728-25

Query Match 93.7%; Score 553; DB 4; Length 112;
Best Local Similarity 93.7%; Pred. No. 1.3e-45;
Matches 104; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVS NRL 60
Db 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVS NRL 60
QY 61 YGVPRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEI 111
Db 61 SGVPRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEI 111

RESULT 8

US-09-990-205-2
; Sequence 2, Application US/09990205
; Patent No. US20020150572A1
; GENERAL INFORMATION:
; APPLICANT: FOON, Kenneth A.
; APPLICANT: CHATTERJEE, Malaya
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSORIASIS
; FILE REFERENCE: 304142000501
; CURRENT APPLICATION NUMBER: US/09/990,205
; CURRENT FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: U.S. 09/192,838
; PRIOR FILING DATE: 1998-11-16
; PRIOR APPLICATION NUMBER: U.S. 60/065,774
; PRIOR FILING DATE: 1997-11-17
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 149
; TYPE: PRT
; ORGANISM: Mus Musculus
US-09-990-205-2

Query Match 93.4%; Score 551; DB 3; Length 149;
Best Local Similarity 93.8%; Pred. No. 2.7e-45;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVS NRL 60
Db 20 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVS NRL 79
QY 61 YGVPRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEI 112
Db 80 SGVPRFSGSGGTDFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEI 131

RESULT 9

US-10-153-401-66
; Sequence 66, Application US/10153401
; Publication No. US20030114398A1
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Sunil K.
; Foon, Kenneth A.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/153,401
; FILING DATE: 27-Aug-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:

```

; APPLICATION NUMBER: US 09/293,533
; FILING DATE: 1999-04-15
; APPLICATION NUMBER: US 08/372,676
; FILING DATE: 1995-01-17
; APPLICATION NUMBER: US 08/591,196
; FILING DATE: 1996-01-16
; ATTORNEY/AGENT INFORMATION:
; NAME: Catherine M. Polizzi
; REGISTRATION NUMBER: 40,130
; REFERENCE/DOCKET NUMBER: 304142000202
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 263 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 66:
US-10-153-401-66

Query Match 93.4%; Score 551; DB 4; Length 263;
Best Local Similarity 93.8%; Pred. No. 5e-45;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQITPLSLPSVLGDAQISCRSSOSIVHSNGNTYLOWLYLQKPGSPKLLIIYKVNRL 60
DB 152 DVLMTQITPLSLPSVLGDAQISCRSSOSIVHSNGNTYLEWLYLQKPGSPNLLIIFVSNRF 211

QY 61 YGVDPFRSGSGSGDTFTLKTISSVEAEDLVGVYCFQSGHPVMTFGGTKLEIK 112
DB 212 SGVPDRFSGSGSGDTFTLKISRVEAEDLVGVYCFQSGHPVMTFGGTKLEIK 263

```

```

RESULT 10
US-10-454-660-10
; Sequence 10, Application US/10454660
; Publication No. US20040005550A1
; GENERAL INFORMATION:
; APPLICANT: Shattil, Sanford J.
; APPLICANT: Nemerow, Glen
; APPLICANT: Hato, Taka
; APPLICANT: Stupack, Wayne
; APPLICANT: Bampori, Nisar
; TITLE OF INVENTION: METHODS AND COMPOSITIONS USEFUL FOR TARGETING
; TITLE OF INVENTION: ACTIVATED VITRONECTIN RECEPTOR ALPHA V BETA 3
; FILE REFERENCE: NOV0149S
; CURRENT APPLICATION NUMBER: US/10/454,660
; CURRENT FILING DATE: 2003-06-03
; PRIOR APPLICATION NUMBER: PRIOR APPLICATION NUMBER: US/09/454,925A
; PRIOR FILING DATE: 1999-12-03
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 219
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:WOW-1 Fab light
; OTHER INFORMATION: chain amino acid sequence
US-10-454-660-10

```

| | | |
|----|---------------------------|--|
| | Query Match | 93.2%; Score 550; DB 4; Length 219; |
| | Best Local Similarity | 93.8%; Pred. No.5.1e-45; |
| | Matches 105; Conservative | 2; Mismatches 5; Indels 0; Gaps 0; |
| Qy | 1 | DVLMTQTPLSLPVSILGDAQISCRSSOSIVHSNGNTYLQWYLRQPGSQKLLIYKVSNRL 60 |
| | | : |
| Db | 1 | DVLMTQTPLSLPVSILGDAQISPCRSSOSIVHSNGNTYLEWLQKPGSQKLLIYKVSNR 60 |
| | | : |
| Ov | 61 | YGVPDRFGSGSGDTFTLKISSVRAEDLGVYYCYFQGSHVPWTFFGGTGLEIK 112 |

```

Db      61  SGVPDRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTKLEIK 112
|||||
RESULT 11
US-10-153-401-15
; Sequence 15, Application US/10153401
; Publication No. US20030114398A1
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malaya
; Foon, Kenneth A.
; Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS: 66
; ADDRESSER: MORRISON & FORRESTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/153,401
; FILING DATE: 27-Aug-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 09/293,533
; FILING DATE: 1999-04-15
; APPLICATION NUMBER: US 08/372,676
; FILING DATE: 1995-01-17
; APPLICATION NUMBER: US 08/591,196
; FILING DATE: 1996-01-16
; ATTORNEY/AGENT INFORMATION:
; NAME: Catherine M. Polizzi
; REGISTRATION NUMBER: 40,130
; REFERENCE/DOCKET NUMBER: 304142000202
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 813-5600
; TELEFAX: (415) 494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 112 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
;
US-10-153-401-15
Query Match 92.9%; Score 548; DB 4; Length 112;
Best Local Similarity 93.8%; Pred. No. 3.8e-45;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy      1  DVLMTQIPLSLPVLSDQASISCRSSQSI VHSNGNTYLQWYLOKPGQSPKLLIYKVSNRL 60
Db      1  DVLMTQIPLSLPVLSDQASISCRSSQSI VHSNGNTYLQWYLOKPGQSPKLLIYFVSNRF 60
Qy      61  YGVDPDRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTKLEIK 112
Db      61  SGVPDRFSGSGGTDFTLKISRVEAEDLGVYFCQGSHPVPTFGGTKLEIK 112
|||||
RESULT 12
US-10-735-916A-57
; Sequence 57, Application US/10735916A
; Publication No. US20050084906A1

```

GENERAL INFORMATION:
; APPLICANT: GOETSCH, Liliane
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: LEGER, Olivier
; APPLICANT: DUFLOS, Alain
; APPLICANT: BECK, Alain
; APPLICANT: HAEUW, Jean-Francois
; TITLE OF INVENTION: NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
; CURRENT APPLICATION NUMBER: 017753-183
; CURRENT FILING DATE: 2003-12-16
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/FR 03/00 178
; PRIOR FILING DATE: 2003-01-20
; PRIOR APPLICATION NUMBER: FR 02/00 653
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/00 654
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: FR 02/05 753
; PRIOR FILING DATE: 2002-05-07
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 57
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-735-916A-57

Query Match 92.7%; Score 547; DB 5; Length 112;
Best Local Similarity 92.0%; Pred. No. 4.8e-45;
Matches 103; Conservative 5; Mismatches 4; Indels 0; Gaps 0;
QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVHNGNTYQLQWYLOKPGQSPKLLIYKVSNRL 60
Db 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVHNGNTYQLQWYLOKPGQSPKLLIYKVSNRF 60
QY 61 YGVDPFRFSGSGTGDTFTLKISVVEADLGVYCYFCQGSHPVPTFGGTTKLEIK 112
Db 61 SGVDPFRFSGSGTGDTFTLKISVVEADLGVYCYFCQGSHPVPTFGGTTKLEIK 112

RESULT 13
US-10-729-441-69
; Sequence 69, Application US/10729441
; Publication No. US20040265307A1
; GENERAL INFORMATION:
; APPLICANT: ImmunoGen, Inc.
; TITLE OF INVENTION: ANTI-IGF-I RECEPTOR ANTIBODY
; FILE REFERENCE: A8689
; CURRENT APPLICATION NUMBER: US/10/729,441
; CURRENT FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: 10/170,390
; PRIOR FILING DATE: 2002-06-14
; NUMBER OF SEQ ID NOS: 96
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 69
; LENGTH: 113
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic antibody structure
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (28)..(28)
; OTHER INFORMATION: "X" may be any amino acid
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (101)..(101)
; OTHER INFORMATION: "X" may be any amino acid
US-10-729-441-69
Query Match 92.7%; Score 547; DB 5; Length 113;

Best Local Similarity 93.8%; Pred. No. 4.8e-45;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;
QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVHNGNTYQLQWYLOKPGQSPKLLIYKVSNRL 60
Db 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVHNGNTYQLQWYLOKPGQSPKLLIYKVSNRF 60
QY 61 YGVDPFRFSGSGTGDTFTLKISVVEADLGVYCYFCQGSHPVPTFGGTTKLEIK 112
Db 61 SGVDPFRFSGSGTGDTFTLKISVVEADLGVYCYFCQGSHPVPTFGGTTKLEIK 112

RESULT 14
US-10-897-406-69
; Sequence 69, Application US/10897406
; Publication No. US20050186203A1
; GENERAL INFORMATION:
; APPLICANT: ImmunoGen, Inc.
; TITLE OF INVENTION: ANTI-IGF-I RECEPTOR ANTIBODY
; FILE REFERENCE: A8338
; CURRENT APPLICATION NUMBER: US/10/897,406
; CURRENT FILING DATE: 2004-07-23
; PRIOR APPLICATION NUMBER: US/10/170,390
; PRIOR FILING DATE: 2002-06-14
; NUMBER OF SEQ ID NOS: 96
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 69
; LENGTH: 113
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic antibody structure
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (28)..(28)
; OTHER INFORMATION: "X" may be any amino acid
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (101)..(101)
; OTHER INFORMATION: "X" may be any amino acid
US-10-897-406-69

Query Match 92.7%; Score 547; DB 5; Length 113;
Best Local Similarity 93.8%; Pred. No. 4.8e-45;
Matches 105; Conservative 1; Mismatches 6; Indels 0; Gaps 0;
QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVHNGNTYQLQWYLOKPGQSPKLLIYKVSNRL 60
Db 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVHNGNTYQLQWYLOKPGQSPKLLIYKVSNRF 60
QY 61 YGVDPFRFSGSGTGDTFTLKISVVEADLGVYCYFCQGSHPVPTFGGTTKLEIK 112
Db 61 SGVDPFRFSGSGTGDTFTLKISVVEADLGVYCYFCQGSHPVPTFGGTTKLEIK 112

RESULT 15
US-10-153-401-2
; Sequence 2, Application US/10153401
; Publication No. US20030114398A1
; GENERAL INFORMATION:
; APPLICANT: Chatterjee, Malay
; Foon, Kenneth A.
; Chatterjee, Sunil K.
; TITLE OF INVENTION: MONOCLONAL ANTIBODY 1A7 AND USE FOR THE
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/153,401
FILING DATE: 27-Aug-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 09/293,533
FILING DATE: 1999-04-15
APPLICATION NUMBER: US 08/372,676
FILING DATE: 1995-01-17
APPLICATION NUMBER: US 08/591,196
FILING DATE: 1996-01-16
ATTORNEY/AGENT INFORMATION:
NAME: Catherine M. Polizzi
REGISTRATION NUMBER: 40,130
REFERENCE/DOCKET NUMBER: 304142000202
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 813-5600
TELEFAX: (415) 494-0792
TELEX: 706141
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 149 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-153-401-2

Query Match 92.7%; Score 547; DB 4; Length 149;
Best Local Similarity 92.9%; Pred. No. 6.5e-45;
Matches 104; Conservative 1; Mismatches 7; Indels 0; Gaps 0;
QY 1 DVLMTQIPLSLPVSLGDAQSISCRSSQSIIVHSNGNTYLQWYLOKPKQSPKLLIYKVSNRL 60
Db 20 DVFMTQTPLSLPVLGDAQSISCRSSQSIIVHSNGNTYLEWYLOKPKQSPNLLIYFVSNRF 79
QY 61 YGVPPDRFSGSGGTDFTLKISVVEAEDLGYYVYCFQGSHPVPTFGGTTKLEIK 112
Db 80 SGVPPDRFSGSGGTDFTLKISRVEAEDLGVYYVYCFQGSHPVPTFGGTTKLEIK 131

Search completed: January 10, 2006, 21:35:30
Job time : 62.4328 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:07:41 ; Search time 77.3134 Seconds
(without alignments)
636.505 Million cell updates/sec

Title: US-10-735-916A-54
Perfect score: 590
Sequence: 1 DVLMTQIPSLFVSLGDAQS.....CFQGSHPVTFGGTKLEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq 21.*
1: Geneseqp1980s.*
2: Geneseqp1990s.*
3: Geneseqp2000s.*
4: Geneseqp2001s.*
5: Geneseqp2002s.*
6: Geneseqp2003as.*
7: Geneseqp2003bs.*
8: Geneseqp2004s.*
9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|-------|-------------|--------|----|---------------------|
| 1 | 590 | 100.0 | 112 | 7 | ADJ76888 Anti-IGF- |
| 2 | 590 | 100.0 | 112 | 9 | ADZ67058 Murine im |
| 3 | 590 | 100.0 | 122 | 7 | ADJ76883 Anti-IGF- |
| 4 | 590 | 100.0 | 122 | 9 | ADZ67053 Murine im |
| 5 | 564 | 95.6 | 112 | 7 | ADD94125 Mouse HUI |
| 6 | 564 | 95.6 | 112 | 7 | ADJ76890 Anti-IGF- |
| 7 | 564 | 95.6 | 112 | 9 | ADZ67060 Mouse ant |
| 8 | 558 | 94.6 | 112 | 5 | AAE15704 Mouse mon |
| 9 | 558 | 94.6 | 114 | 9 | AE21358 Mouse ant |
| 10 | 558 | 94.6 | 114 | 9 | AE21358 Mouse ant |
| 11 | 556 | 94.2 | 114 | 8 | ADI26498 Human ECL |
| 12 | 555 | 94.1 | 114 | 8 | ADI26490 Human ECL |
| 13 | 555 | 94.1 | 114 | 8 | ADP84941 Variable |
| 14 | 555 | 94.1 | 139 | 9 | AEC21825 Mouse lig |
| 15 | 555 | 94.1 | 238 | 8 | ADP88785 Sequence |
| 16 | 553 | 93.7 | 114 | 8 | ADP84942 Variable |
| 17 | 552 | 93.6 | 249 | 1 | ADP80154 Biosynthe |
| 18 | 551 | 93.4 | 149 | 2 | AAW03199 Anti-idio |
| 19 | 551 | 93.4 | 149 | 2 | AAW03199 Anti-idio |
| 20 | 551 | 93.4 | 263 | 2 | AAV21545 Monoclonal |
| 21 | 551 | 93.4 | 263 | 2 | AAV28470 Vh-(Lk)-v |
| 22 | 551 | 93.4 | 263 | 6 | ADA14828 Anti-idio |
| 23 | 551 | 93.4 | 263 | 7 | ADC35357 Monoclonal |
| 24 | 550 | 93.2 | 113 | 8 | ADP88781 Amino aci |
| 25 | 550 | 93.2 | 115 | 1 | ADP81364 Light cha |

| | | | | | | |
|----|-----|------|-----|---|----------|--------------------|
| 25 | 550 | 93.2 | 115 | 1 | AA662301 | Aab62301 Chimeric |
| 26 | 550 | 93.2 | 219 | 3 | AA95258 | Aay95258 WOW-1 Fab |
| 27 | 550 | 93.2 | 298 | 8 | ADS88777 | Ad888777 Amino aci |
| 28 | 549 | 93.1 | 109 | 5 | ABP52310 | Abp52310 Fv region |
| 29 | 548 | 92.9 | 112 | 2 | AAV49217 | Aay49217 Light cha |
| 30 | 548 | 92.9 | 112 | 6 | ADA14777 | Ada14777 Peptide f |
| 31 | 548 | 92.9 | 112 | 7 | ADC35319 | Adc35319 Anti-idio |
| 32 | 548 | 92.9 | 114 | 8 | ADP84938 | Adp84938 Variable |
| 33 | 548 | 92.9 | 219 | 8 | ADP84966 | Adp84966 Murine an |
| 34 | 548 | 92.9 | 219 | 8 | ADP84971 | Adp84971 Chimeric |
| 35 | 548 | 92.9 | 257 | 8 | ADP84964 | Adp84964 Single ch |
| 36 | 548 | 92.9 | 258 | 8 | ADP84963 | Adp84963 Single ch |
| 37 | 548 | 92.9 | 259 | 8 | ADP84962 | Adp84962 Single ch |
| 38 | 548 | 92.9 | 260 | 8 | ADP84961 | Adp84961 Single ch |
| 39 | 548 | 92.9 | 261 | 8 | ADP84960 | Adp84960 Single ch |
| 40 | 548 | 92.9 | 262 | 8 | ADP84959 | Adp84959 Single ch |
| 41 | 548 | 92.9 | 263 | 8 | ADP84958 | Adp84958 Single ch |
| 42 | 548 | 92.9 | 264 | 8 | ADP84957 | Adp84957 Single ch |
| 43 | 548 | 92.9 | 265 | 8 | ADP84956 | Adp84956 Single ch |
| 44 | 548 | 92.9 | 266 | 8 | ADP84955 | Adp84955 Single ch |
| 45 | 548 | 92.9 | 267 | 8 | ADP84954 | Adp84954 Single ch |

ALIGNMENTS

RESULT 1

| | | |
|----|---|----------------------------|
| ID | ADJ76888 | standard; protein; 112 AA. |
| XX | ADJ76888; | |
| AC | ADJ76888; | |
| DT | 06-MAY-2004 (first entry) | |
| XX | | |
| DE | Anti-IGF-1R related protein #5. | |
| XX | | |
| KW | cytostatic; antiproliferative; antibody; | |
| KW | insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity; | |
| KW | or epidermal growth factor receptor; EGFR; signal transduction pathway; | |
| KW | ligand; tumor; cancer; osteosarcoma; complementarity determining region; | |
| KW | CDR. | |
| OS | Mus musculus. | |
| XX | | |
| XX | WO2003059951-A2. | |
| FN | | |
| PD | 24-JUL-2003. | |
| XX | | |
| XX | | |
| PF | 20-JAN-2003; 2003WO-FR000178. | |
| XX | | |
| PR | 18-JAN-2002; 2002FR-00000653. | |
| PR | 18-JAN-2002; 2002FR-00000654. | |
| XX | 07-MAY-2002; 2002FR-00005753. | |
| XX | | |
| PA | (FABR) FABRE MEDICAMENT SA PIERRE. | |
| XX | | |
| PI | Goetsch L, Corvaia N, Leger O; | |
| XX | | |
| DR | WPI; 2003-569653/53. | |
| XX | | |
| PT | New antibodies that bind to human insulin-like growth factor receptor, | |
| PT | useful for treatment, prevention and diagnosis of cancers. | |
| XX | | |
| PS | Disclosure; SEQ ID NO 54; 164pp; French. | |
| XX | | |
| CC | The invention relates to an isolated antibody (Ab), and its functional | |
| CC | fragments, that bind to human insulin-like growth factor-1 receptor (IGF- | |
| CC | 1R) and optionally: (i) inhibit natural binding of insulin-like growth | |
| CC | factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine | |
| CC | kinase activity of IGF-1R. Ab and its fragments are used to prevent or | |
| CC | treat diseases associated with overexpression and/or abnormal activity of | |
| CC | IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with | |
| CC | hyperactivity of signal transduction pathways mediated by interaction of | |

CC these receptors with their ligands. Especially they inhibit
 CC transformation of normal cells to tumor cells, inhibit growth and/or
 CC proliferation of tumor cells, so are useful against cancers of the
 CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
 CC also for treating psoriasis. Ab are also used to diagnose diseases caused
 CC by abnormal expression of IGF-IR and/or EGFR. This sequence represents a
 CC protein sequence used to generate the Ab of the invention.
 XX
 SQ Sequence 112 AA;

Query Match 100.0%; Score 590; DB 7; Length 112;
 Best Local Similarity 100.0%; Pred. No. 1.2e-45;
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQISCRSSQSIIVHSNGNTYIQLWYLQKPGQSPKLLIYKVSNRL 60

DB 1 DVLMTQIPLSLPVSLGDAQISCRSSQSIIVHSNGNTYIQLWYLQKPGQSPKLLIYKVSNRL 60

QY 61 YGVDPFRFSGSGGTDTFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112

DB 61 YGVDPFRFSGSGGTDTFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112

RESULT 2

ID ADZ67058

ADZ67058 standard; protein; 112 AA.

AC ADZ67058;

XX 30-JUN-2005 (first entry)

DE Murine immunoglobulin light chain variable region 7C10 VL SEQ ID NO:54.

XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
 KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
 KW musculoskeletal disease; respiratory disease; lung tumor;
 KW endocrine disease; gynecology and obstetrics; breast tumor;
 KW endometrial carcinoma; gastrointestinal disease; colon tumor;
 KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
 KW immunoglobulin; light chain variable region.

OS Mus musculus.

PN US2005084906-A1.

XX 21-APR-2005.

XX 16-DEC-2003; 2003US-00735916.

XX 18-JAN-2002; 2002FR-00000653.

PR 18-JAN-2002; 2002FR-00000654.

PR 07-MAY-2002; 2002FR-00005753.

PR 20-JAN-2003; 2003WO-FR000178.

PR 11-JUL-2003; 2003FR-00008538.

XX (GOET/) GOETSCH L.

PA (CORV/) CORVAIA N.

PA (LEGE/) LEGER O.

PA (DUFL/) DUFLOS A.

PA (HAUW/) HAEUW J.

PA (BECK/) BECK A.

XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;

XX WPI; 2005-321968/33.

XX Novel isolated anti-insulin-like growth factor I receptor (IGF-IR)
 PT antibody or its functional fragment, being capable of binding human IGF-
 IR and specifically inhibiting tyrosine kinase activity of receptor,
 PT useful for treating cancer.

XX Example 12; SEQ ID NO 54; 125pp; English.

CC The invention relates to a novel isolated anti-insulin-like growth factor
 CC I receptor (IGF-IR) antibody (I) or its functional fragment, being
 CC capable of binding to human IGF-IR and, if necessary, capable of
 CC specifically inhibiting tyrosine kinase activity of the receptor,
 CC comprising a light or heavy chain having at least one complementary
 CC determining region (CDR) consisting of one of two fully defined 16 amino
 CC acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
 CC the preparation of a medicament intended for the prevention or treatment
 CC of an illness connected with an overexpression and/or an abnormal
 CC activation of the IGF-IR and/or EGFR, and/or connected with a
 CC hyperactivation of the transduction pathway of the signal mediated by the
 CC interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where
 CC the administration of the medicament does not induce or only slightly
 CC induces secondary effects connected with inhibition of the insulin
 CC receptor. The antibody is useful for preparation of a medicament intended
 CC to inhibit the transformation of normal cells into cells with tumoral
 CC character, preferably IGF-dependent, especially IGF1 and/or IGF2-
 CC dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
 CC useful for preparation of a medicament intended to inhibit the growth
 CC and/or the proliferation of tumor cells, preferably IGF-dependent,
 CC especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
 CC HER2/neu-dependent cells. (I) is useful in the preparation of a
 CC medicament intended for prevention or for the treatment of cancer, where
 CC the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
 CC breast cancer, endometrial cancer or colon cancer. (I) is useful in the
 CC preparation of a medicament intended for the prevention or for the
 CC treatment of psoriasis. (I) is useful in preparation of a medicament
 CC intended for the specific targeting of a biologically active compound to
 CC cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I)
 CC is useful for in vitro diagnosis of illnesses induced by an
 CC overexpression or an underexpression of the IGF-IR and/or EGFR receptor
 CC starting from a biological sample in which the abnormal presence, of IGF-
 CC IR and/or EGFR receptor is suspected, which involves contacting the
 CC biological sample with (I), which is optionally labeled. The present
 CC sequence is used in the exemplification of the invention.
 XX

SQ Sequence 112 AA;

Query Match 100.0%; Score 590; DB 9; Length 112;

Best Local Similarity 100.0%; Pred. No. 1.2e-45;

Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQISCRSSQSIIVHSNGNTYIQLWYLQKPGQSPKLLIYKVSNRL 60

DB 1 DVLMTQIPLSLPVSLGDAQISCRSSQSIIVHSNGNTYIQLWYLQKPGQSPKLLIYKVSNRL 60

QY 61 YGVDPFRFSGSGGTDTFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112

DB 61 YGVDPFRFSGSGGTDTFTLKISSVEAEDLGVIYCFQGSHPVPTFGGTTKLEIK 112

RESULT 3

ADJ76883

ID ADJ76883 standard; protein; 122 AA.

XX AC ADJ76883;

XX 06-MAY-2004 (first entry)

XX Anti-IGF-1R related protein #3.

XX Cytostatic; antipsoriatic; antibody;

KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;

KW or epidermal growth factor receptor; EGFR; signal transduction pathway;

KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;

KW CDR.

XX Mus musculus.

OS WO2003059951-A2.

XX PD 24-JUL-2003.

XX


```

PF 20-JAN-2003; 2003WO-FR000178.
XX
XX 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
XX
XX (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
XX Goetsch L, Corvaia N, Leger O;
XX
XX WPI; 2003-569653/53.
XX
XX New antibodies that bind to human insulin-like growth factor receptor,
XX useful for treatment, prevention and diagnosis of cancers.
XX
XX Disclosure; SEQ ID NO 49; 164pp; French.
XX
XX The invention relates to an isolated antibody (Ab), and its functional
XX fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
XX 1R) and optionally: (i) inhibit natural binding of insulin-like growth
XX factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
XX kinase activity of IGF-1R. Ab and its fragments are used to prevent or
XX treat diseases associated with overexpression and/or abnormal activity of
XX IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
XX hyperactivity of signal transduction pathways mediated by interaction of
XX these receptors with their ligands. Especially they inhibit
XX transformation of normal cells to tumor cells, inhibit growth and/or
XX proliferation of tumor cells, so are useful against cancers of the
XX prostate, lung, breast, endometrium and colon, also osteosarcoma, and
XX also for treating psoriasis. Ab are also used to diagnose diseases caused
XX by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
XX protein sequence used to generate the Ab of the invention.
XX
XX Sequence 122 AA;
XX
XX Query Match 100.0%; Score 590; DB 7; Length 122;
XX Best Local Similarity 100.0%; Pred. No. 1.3e-45;
XX Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 DVLMTQIPLSLPVSLGDAQSIQSSQSIIVHSNGNTYQLWYLOKPGQSPKLLIYKVSRL 60
XX DB 11 DVLMTQIPLSLPVSLGDAQSIQSSQSIIVHSNGNTYQLWYLOKPGQSPKLLIYKVSRL 70
XX
XX QY 61 YGVDPFRFSGSGGTDTFTLKISSVEAEDLGVIYCFQGSHPVPTFGGGTKLEIK 112
XX DB 71 YGVDPFRFSGSGGTDTFTLKISSVEAEDLGVIYCFQGSHPVPTFGGGTKLEIK 122
XX
XX RESULT 4
XX ADZ67053
XX ID ADZ67053 standard; protein; 122 AA.
XX
XX AC ADZ67053;
XX
XX 30-JUN-2005 (first entry)
XX
XX Murine immunoglobulin light chain variable region 7C10 VL SEQ ID NO:49.
XX
XX Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
XX neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
XX musculoskeletal disease; respiratory disease; lung tumor;
XX endocrine disease; gynecology and obstetrics; breast tumor;
XX endometroid carcinoma; gastrointestinal disease; colon tumor;
XX antipsoriatic; psoriasis; dermatological disease; immune disorder;
XX immunoglobulin; light chain variable region.
XX
XX Mus musculus.
XX
XX Key Location/Qualifiers
XX Peptide 1..10
XX FT /note= "leader peptide"
XX FT 34..49
XX FT /note= "CDR1"
XX

```

```

FT 65..71
FT /note= "CDR2"
FT 104..111
FT /note= "CDR3"
XX
XX US2005084906-A1.
XX
XX 21-APR-2005.
XX
XX 16-DEC-2003; 2003US-00735916.
XX
XX 18-JAN-2002; 2002FR-00000653.
XX 18-JAN-2002; 2002FR-00000654.
XX 07-MAY-2002; 2002FR-00005753.
XX 20-JAN-2003; 2003WO-FR000178.
XX 11-JUL-2003; 2003FR-00008538.
XX
XX (GOET/ GOETSCH L.
XX (CORV/ CORVAIA N.
XX (LSGE/ LAGER O.
XX (DUFL/ DUFLOS A.
XX (HAEU/ HAEUW J.
XX (BECK/ BECK A.
XX
XX Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
XX
XX WPI; 2005-321968/33.
XX N-PSDB; ADZ67052.
XX
XX Novel isolated anti-insulin-like growth factor I receptor (IGF-1R)
XX antibody or its functional fragment, being capable of binding human IGF-
XX 1R and specifically inhibiting tyrosine kinase activity of receptor,
XX useful for treating cancer.
XX
XX Example 8; SEQ ID NO 49; 125pp; English.
XX
XX The invention relates to a novel isolated anti-insulin-like growth factor
XX I receptor (IGF-1R) antibody (I) or its functional fragment, being
XX capable of binding to human IGF-1R and, if necessary, capable of
XX specifically inhibiting tyrosine kinase activity of the receptor,
XX comprising a light or heavy chain having at least one complementary
XX determining region (CDR) consisting of one of two fully defined 16 amino
XX acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in
XX the preparation of a medicament intended for the prevention or treatment
XX of an illness connected with an overexpression and/or an abnormal
XX activation of the IGF-1R and/or EGFR, and/or connected with a
XX hyperactivation of the transduction pathway of the signal mediated by the
XX interaction of IGF1 or IGF2 with IGF-1R and/or of EGF with EGFR, where
XX the administration of the medicament does not induce or only slightly
XX induces secondary effects connected with inhibition of the insulin
XX receptor. The antibody is useful for preparation of a medicament intended
XX to inhibit the transformation of normal cells into cells with tumoral
XX character, preferably IGF-dependent, especially IGF1 and/or IGF2-
XX dependent and/or EGF-dependent and/or HER2/neu-dependent cells. (I) is
XX useful for preparation of a medicament intended to inhibit the growth
XX and/or the proliferation of tumor cells, preferably IGF-dependent,
XX especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or
XX HER2/neu-dependent cells. (I) is useful in the preparation of a
XX medicament intended for prevention or for the treatment of cancer, where
XX the cancer is chosen from prostate cancer, osteosarcoma, lung cancer,
XX breast cancer, endometrial cancer or colon cancer. (I) is useful in the
XX preparation of a medicament intended for the prevention or for the
XX treatment of psoriasis. (I) is useful in preparation of a medicament
XX intended for the specific targeting of a biologically active compound to
XX cells expressing or overexpressing the IGF-1R and/or EGFR receptor. (I)
XX is useful for in vitro diagnosis of illnesses induced by an
XX overexpression or an underexpression of the IGF-1R and/or EGFR receptor
XX starting from a biological sample in which the abnormal presence, of IGF-
XX 1R and/or EGFR receptor is suspected, which involves contacting the
XX biological sample with (I), which is optionally labeled. The present
XX sequence is used in the exemplification of the invention.
XX
XX Sequence 122 AA;
XX

```

Query Match 100.0%; Score 590; DB 9; Length 122;
Best Local Similarity 100.0%; Pred. No. 1.3e-45;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYQLQWYLPQPGQSPKLLIYKVSRL 60
Db 11 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYQLQWYLPQPGQSPKLLIYKVSRL 70

Qy 61 YGVDPFRFSGSGTDFTLKISSVEADLGYYVYCFQGSHPVMTFGGTTKLEIK 112
Db 71 YGVDPFRFSGSGTDFTLKISSVEADLGYYVYCFQGSHPVMTFGGTTKLEIK 122

RESULT 5
ADD94125
ID ADD94125 standard; protein; 112 AA.
XX
AC ADD94125;
XX
DT 29-JAN-2004 (first entry)
XX
DE Mouse HUI77 variable region light chain partial amino acid sequence.
XX
KW grafted antibody; complementarity determining region; CDR; light CDR;
KW heavy CDR; cryptic collagen epitope; solid tumour;
KW new blood vessel growth; angiogenesis; tumour growth; cytostatic;
KW collagen agonist; collagen antagonist; cancer metastasis;
KW anti-cryptic collagen; antibody; HUI77; variable region light chain;
KW mouse; murine.
XX
OS Mus musculus.
XX
FN WO2003046204-A2.
XX
PD 05-JUN-2003.
XX
PF 26-NOV-2002; 2002WO-US038147.
XX
PR 26-NOV-2001; 2001US-00995529.
XX
PR 06-DEC-2001; 2001US-00011250.
XX
PA (CELL-) CELL MATRIX INC.
XX
PI Watling JD, Huse WD, Tang Y, Broek D, Brooks PC;
XX
DR WPI; 2003-513649/48.
XX
DR N-PSDB; ADD94124.
XX
PT New cryptic collagen antibody with one or more complementarity
PT determining regions, useful for diagnosing and treating disorders
PT associated with angiogenesis, tumor growth and/or cancer metastasis.
XX
PS Example 1; SEQ ID NO 10; 232pp; English.

XX This invention relates to a novel grafted antibody or its functional
CC fragment comprising one or more complementarity determining regions
CC (CDRs) of a defined light CDR and a heavy CDR with at least one amino
CC acid (aa) substitution where the antibody has specific binding activity
CC for a cryptic collagen epitope. The growth of all solid tumours requires
CC new blood vessel growth, angiogenesis, inhibition of which is an approach
CC to limiting tumour growth. The invention may allow development of
CC therapeutics with a cytostatic activity as a collagen agonist or
CC antagonist. The invention is useful for diagnosing and treating disorders
CC associated with angiogenesis, tumour growth and/or cancer metastasis. The
CC present sequence is the partial amino acid sequence of the mouse anti-
CC cryptic collagen site antibody HUI77 variable region light chain used
CC during the creation of the antibody of the invention.

XX Sequence 112 AA;

Query Match 95.6%; Score 564; DB 7; Length 112;
Best Local Similarity 95.5%; Pred. No. 2.6e-43;

Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYQLQWYLPQPGQSPKLLIYKVSRL 60
Db 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYQLQWYLPQPGQSPKLLIYKVSRL 60

Qy 61 YGVDPFRFSGSGTDFTLKISSVEADLGYYVYCFQGSHPVMTFGGTTKLEIK 112
Db 61 SGVDPFRFSGSGTDFTLKISRVEADLGYYVYCFQGSHPVMTFGGTTKLEIK 112

RESULT 6
ADJ76890
ID ADJ76890 standard; protein; 112 AA.
XX
AC ADJ76890;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-IGF-1R related protein #7.
XX
KW cytostatic; antiproliferative; antibody;
KW insulin-like growth factor-1 receptor; IGF-1R; tyrosine kinase activity;
KW or epidermal growth factor receptor; EGFR; signal transduction pathway;
KW ligand; tumor; cancer; osteosarcoma; complementarity determining region;
KW CDR.
XX
OS Mus musculus.
XX
FN WO2003059951-A2.
XX
PD 24-JUL-2003.
XX
PF 20-JAN-2003; 2003WO-FR000178.
XX
PR 18-JAN-2002; 2002FR-00000653.
XX
PR 18-JAN-2002; 2002FR-00000654.
XX
PR 07-MAY-2002; 2002FR-00005753.
XX
PA (FABR) FABRE MEDICAMENT SA PIERRE.
XX
PI Goetsch L, Corvaia N, Leger O;
XX
DR WPI; 2003-569653/53.
XX
PT New antibodies that bind to human insulin-like growth factor receptor,
PT useful for treatment, prevention and diagnosis of cancers.

XX Disclosure; SEQ ID NO 56; 164pp; French.
XX The invention relates to an isolated antibody (Ab), and its functional
CC fragments, that bind to human insulin-like growth factor-1 receptor (IGF-
CC 1R) and optionally: (i) inhibit natural binding of insulin-like growth
CC factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine
CC kinase activity of IGF-1R. Ab and its fragments are used to prevent or
CC treat diseases associated with overexpression and/or abnormal activity of
CC IGF-1R and/or epidermal growth factor receptor (EGFR) and/or with
CC hyperactivity of signal transduction pathways mediated by interaction of
CC these receptors with their ligands. Especially they inhibit
CC transformation of normal cells to tumor cells, inhibit growth and/or
CC proliferation of tumor cells, so are useful against cancers of the
CC prostate, lung, breast, endometrium and colon, also osteosarcoma, and
CC also for treating psoriasis. Ab are also used to diagnose diseases caused
CC by abnormal expression of IGF-1R and/or EGFR. This sequence represents a
CC protein sequence used to generate the Ab of the invention.

XX Sequence 112 AA;

Query Match 95.6%; Score 564; DB 7; Length 112;
Best Local Similarity 95.5%; Pred. No. 2.6e-43;
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYQLQWYLPQPGQSPKLLIYKVSRL 60

Db 1 DVLMTQITPLSLPVSLGDAQSISCRSSQSIHVSNGNTYLEWYLOKFGQSPKLLIYKVSNR 60
QY 61 YGVPRFSGSGSGTDTLTKISVEAEDLGYYCFQGSHPVPTFFGGTGLEIK 112
Db 61 SGVPRFSGSGSGTDTLTKISVEAEDLGYYCFQGSHPVPTFFGGTGLEIK 112

RESULT 7
ADZ67060
ID ADZ67060 standard; protein; 112 AA.
XX
AC ADZ67060;
XX
DT 30-JUN-2005 (first entry)
XX
DE Mouse antibody light chain variable region SEQ ID NO:56.
XX
KW Insulin-like growth factor 1 receptor; antibody; tumor; cytostatic;
KW neoplasm; prostate tumor; andrology; genitourinary disease; osteosarcoma;
KW musculoskeletal disease; respiratory disease; lung tumor;
KW endocrine disease; gynecology and obstetrics; breast tumor;
KW endometroid carcinoma; gastrointestinal disease; colon tumor;
KW antipsoriatic; psoriasis; dermatological disease; immune disorder;
KW light chain variable region.
XX
OS Mus musculus.
XX
PN US2005084906-A1.
XX
PD 21-APR-2005.
XX
PF 16-DEC-2003; 2003US-00735916.
XX
PR 18-JAN-2002; 2002FR-00000653.
PR 18-JAN-2002; 2002FR-00000654.
PR 07-MAY-2002; 2002FR-00005753.
PR 20-JAN-2003; 2003WO-FR000178.
PR 11-JUL-2003; 2003FR-00008539.
XX
(GOET/) GOETSCH L.
PA (CORV/) CORVAIA N.
PA (LEGE/) LEGER O.
PA (DUFLO/) DUFLOS A.
PA (HAEU/) HAEUW J.
PA (BECK/) BECK A.
XX
Goetsch L, Corvaia N, Leger O, Duflos A, Haeuw J, Beck A;
WPI; 2005-321968/33.

Novel isolated anti-insulin-like growth factor I receptor (IGF-IR) antibody or its functional fragment, being capable of binding human IGF-IR and specifically inhibiting tyrosine kinase activity of receptor, useful for treating cancer.

Example 12; SEQ ID NO 56; 125pp; English.

The invention relates to a novel isolated anti-insulin-like growth factor I receptor (IGF-IR) antibody (I) or its functional fragment, being capable of binding to human IGF-IR and, if necessary, capable of specifically inhibiting tyrosine kinase activity of the receptor, comprising a light or heavy chain having at least one fully defined 16 amino acid determining region (CDR) consisting of one of two fully defined 16 amino acids (ADZ67006 and ADZ67014). An antibody of the invention is useful in the preparation of a medicament intended for the prevention or treatment of an illness connected with an overexpression and/or an abnormal activation of the IGF-IR and/or EGFR, and/or connected with a hyperactivation of the transduction pathway of the signal mediated by the interaction of IGF1 or IGF2 with IGF-IR and/or of EGF with EGFR, where the administration of the medicament does not induce or only slightly induces secondary effects connected with inhibition of the insulin receptor. The antibody is useful for preparation of a medicament intended

to inhibit the transformation of normal cells into cells with tumoral character, preferably IGF-dependent, especially IGF1 and/or IGF2-dependent and/or EGF-dependent and/or HGF2/neu-dependent cells. (I) is useful for preparation of a medicament intended to inhibit the growth and/or the proliferation of tumor cells, preferably IGF-dependent, especially IGF1-and/or IGF2-dependent and/or EGF-dependent and/or HGF2/neu-dependent cells. (I) is useful in the preparation of a medicament intended for prevention or for the treatment of cancer, where the cancer is chosen from prostate cancer, osteosarcoma, lung cancer, breast cancer, endometrial cancer or colon cancer. (I) is useful in the preparation of a medicament intended for the prevention or for the treatment of psoriasis. (I) is useful in preparation of a medicament intended for the specific targeting of a biologically active compound to cells expressing or overexpressing the IGF-IR and/or EGFR receptor. (I) is useful for in vitro diagnosis of illnesses induced by an overexpression or an underexpression of the IGF-IR and/or EGFR receptor starting from a biological sample in which the abnormal presence, of IGF-IR and/or EGFR receptor is suspected, which involves contacting the biological sample with (I), which is optionally labeled. The present sequence is used in the exemplification of the invention.

Sequence 112 AA;
Query Match 95.6%; Score 564; DB 9; Length 112;
Best Local Similarity 95.5%; Fred. No. 2.6e-43;
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQITPLSLPVSLGDAQSISCRSSQSIHVSNGNTYLEWYLOKFGQSPKLLIYKVSNR 60
Db 1 DVLMTQITPLSLPVSLGDAQSISCRSSQSIHVSNGNTYLEWYLOKFGQSPKLLIYKVSNR 60
QY 61 YGVPRFSGSGSGTDTLTKISVEAEDLGYYCFQGSHPVPTFFGGTGLEIK 112
Db 61 SGVPRFSGSGSGTDTLTKISVEAEDLGYYCFQGSHPVPTFFGGTGLEIK 112

RESULT 8
AAE15704
ID AAE15704 standard; protein; 112 AA.
XX
AC AAE15704;
XX
DT 12-MAR-2002 (first entry)
XX
DE Mouse monoclonal antibody alpha 340 light chain variable (VK) region.
XX
KW Mouse; humanised form; monoclonal antibody alpha 340; gene therapy;
KW epidermal growth factor receptor; EGF; cancer; colorectal; lung; breast;
KW gastric; ovarian; immune response; cytostatic; cell growth; apoptosis;
KW inhibitor.
XX
OS Mus sp.
XX
FH Key
FH Region
FT
FT /label= CDR1
FT /note= "Complementarity determining region 1"
FT
FT 55. .68
FT /label= CDR2
FT /note= "Complementarity determining region 2"
FT
FT 95. .102
FT /label= CDR3
FT /note= "Complementarity determining region 3"
XX
WO200188138-A1.
XX
PD 22-NOV-2001.
XX
PF 21-MAY-2001; 2001WO-GB002226.
XX
PR 19-MAY-2000; 2000GB-00011981.
PR 24-AUG-2000; 2000GB-00020794.
XX

PA (SCAN-) SCANCELL LTD.
XX Ellis JRM, Durrant LG;
XX WPI; 2002-062384/08.
DR N-PSDB; AAD25247.
XX
PT New humanized form of mouse monoclonal antibody 340 which binds to
PT epidermal growth factor receptor and inhibits binding of growth factor.
PT useful for treating colorectal, lung, breast, gastric and ovarian cancer.
XX
PS Claim 6; Fig 2; 53pp; English.
XX
CC The present invention relates to a humanised form of the antibody 340 (a
CC mouse monoclonal antibody which binds to epidermal growth factor (EGF)
CC receptor and inhibits binding of EGF), obtainable from the cell line
CC deposited with the ECACC under accession number 97021428. The humanised
CC form of the antibody 340 is useful in gene therapy, medicine and in the
CC manufacture of a medicament for treatment or prophylaxis of cancer. The
CC invention is useful for treating colorectal, lung, breast, gastric or
CC ovarian cancers or also for preventing the recurrence of cancer after
CC initial treatment or surgery. The invention is also useful for enhancing
CC a protective immune response against cancer by optimised immunisation
CC schedules. The humanised form of the antibody 340 has reduced
CC immunogenicity but shows similar binding to cells expressing EGF
CC receptor, as the original murine antibody and has increased ability to
CC inhibit the growth of EGF receptor expressing cells. The invention is
CC used as cell growth and apoptosis inhibitor. The present sequence is
CC mouse monoclonal antibody alpha 340 light chain variable (VK) region
XX
SQ Sequence 112 AA;
Query Match 94.6%; Score 558; DB 5; Length 112;
Best Local Similarity 94.6%; Pred. No. 9.1e-43;
Matches 105; Conservative 2; Mismatches 4; Indels 0; Gaps 0;
Qy 1 DVLMTQIPLSLPVSLGDAQSISCRSSQSIHVSNGNTYLTQWYLPQPGQSPKLLIYKVSRL 60
Db 1 DVLMTQIPLSLPVSLGDAQSISCRSSQSIHVSNGNTYLTQWYLPQPGQSPKLLIYKVSRL 60
Qy 61 YGVDPFRSGSGGTDFTLKISSVEAEDLGVIYFCQGSHPVPTFGGTTKLEI 111
Db 61 SGVDPFRSGSGGTDFTLKISSVEAEDLGVIYFCQGSHPVPTFGGTTKLEI 111
RESULT 9
AEB21358
ID AEB21358 standard; protein; 114 AA.
XX
AC AEB21358;
XX
DT 22-SEP-2005 (first entry)
XX
DE Mouse anti-IL-13 antibody 227-26 light chain variable region (VK).
XX
KW Interleukin-13; IL-13; antibody engineering; humanized antibody;
KW Antiasthmatic; Antiinflammatory; Dermatological; Antiallergic;
KW Respiratory-Gen.; Antiulcer; Gastrointestinal-Gen.; Ophthalmological;
KW Osteopathic; Virucide; asthma; allergic rhinitis; atopic dermatitis;
KW allergic conjunctivitis; eczema; urticaria; allergy;
KW chronic obstructive pulmonary disease; ulcerative colitis;
KW respiratory syncytial virus infection; uveitis; scleroderma;
KW osteoporosis; monoclonal antibody; light chain variable region.
XX
OS Mus sp.
XX
XX WO2005062967-A2.
XX
XX 14-JUL-2005.
XX
XX 23-DEC-2004; 2004WO-US043501.
XX
XX 23-DEC-2003; 2003US-0532130P.
XX

XX (TANO-) TANOX INC.
XX Fung SC, Moyle M, Lu M, Yan C, Singh S, Huang D;
XX WPI; 2005-506603/51.
XX
PT New antibody or its antigen-binding fragment that binds specifically and
PT with high affinity to glycosylated and non-glycosylated human interleukin
PT -13 (IL-13), useful for treating IL-13-mediated disorders, such as asthma
PT and eczema.
XX
PS Claim 10; SEQ ID NO 7; 129pp; English.
XX
CC The invention relates to an antibody or its antigen-binding fragment that
CC binds specifically and with high affinity to glycosylated and non-
CC glycosylated human interleukin-13 (IL-13), does not bind mouse IL-13, and
CC neutralizes human IL-13 activity at an approximate molar ratio of 1:2
CC (Mab:IL13). Also included are an antibody that binds to the same epitope
CC as the antibody cited above, an antibody comprising antigen binding
CC regions derived from the light and heavy chain variable regions of the
CC novel antibody, a hybridoma cell line that produces a monoclonal antibody
CC (selected from 228B/C-1, 228A-4, 227-26, and 227-43 and designated with
CC the ATCC deposit number PTA-5657, PTA-5656, PTA-5654, and PTA-5655,
CC respectively), a cell line comprising a nucleic acid encoding the
CC antibody, a vector comprising the nucleic acid encoding the antibody, a
CC composition (comprising the antibody and a physiologically acceptable
CC carrier, diluent, excipient, or stabilizer), a variable light chain
CC region (comprising an amino acid sequence having the formula: FRL1-CDRL1-
CC FRL2-CDRL2-FRL3-CDRL3-FRL4) a variable heavy chain region (comprising an
CC amino acid sequence having the formula: FRH1-CDRH1-FRH2-CDRH2-FRH3-
CC FRH4), an antibody (or its antigen binding fragment, comprising the
CC variable light or heavy chain region, where the antibody binds
CC specifically to IL-13), treating a subject suffering from asthmatic
CC symptoms (comprising administering an antibody to reduce the asthmatic
CC symptoms), an inhalation device that delivers the antibody to a patient,
CC detecting interleukin-13 protein in a sample, diagnosing overexpression
CC of IL-13 in a subject, producing the antibody, a recombinant antibody
CC molecule (or an IL-13-binding fragment, comprising at least one antibody
CC heavy chain, or an IL-13-binding fragment, comprising non-human CDRA at
CC positions 31-35 (CDR1), 50-65 (CDR2) and 95-102 (CDR3) (Kabat numbering)
CC from a mouse anti-IL-13 antibody, where positions 27-30 have the amino
CC acid Gly 26, Phe 27, Ser 28, Leu 29, Asn 30), and at least one antibody
CC light chain (or an IL-13-binding fragment, comprising non-human CDRA at
CC positions 24-34 (CDR1), 50-56 (CDR2) and 89-97 (CDR3) from a mouse anti-
CC IL13 antibody and framework regions from a monoclonal antibody), a vector
CC comprising the DNA sequence, a host cell comprising the vector,
CC inhibiting IgG antibody production in a patient, treating an IL-13-
CC mediated disorder in a patient, reducing the severity of asthma in a
CC mammal, and an IL-13 epitope peptide appearing as AEB21369 or AEB21370.
CC The antibody and methods are useful for treating IL-13-mediated
CC disorders, such as allergic asthma, non-allergic (intrinsic) asthma,
CC allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema,
CC urticaria, food allergies, chronic obstructive pulmonary disease,
CC ulcerative colitis, RSV infection, uveitis, scleroderma, or osteoporosis.
CC The present sequence represents a the light chain variable region of a
CC mouse anti-IL-13 monoclonal antibody.
XX
SQ Sequence 114 AA;
Query Match 94.6%; Score 558; DB 9; Length 114;
Best Local Similarity 95.5%; Pred. No. 9.3e-43;
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
Qy 1 DVLMTQIPLSLPVSLGDAQSISCRSSQSIHVSNGNTYLTQWYLPQPGQSPKLLIYKVSRL 60
Db 1 DVLMTQIPLSLPVSLGDAQSISCRSSQSIHVSNGNTYLTQWYLPQPGQSPKLLIYKVSRL 60
Qy 61 YGVDPFRSGSGGTDFTLKISSVEAEDLGVIYFCQGSHPVPTFGGTTKLEI 112
Db 61 SGVDPFRSGSGGTDFTLKISSVEAEDLGVIYFCQGSHPVPTFGGTTKLEI 112

RESULT 10
ID AEB31116 standard; protein; 114 AA.
XX
AC AEB31116;
DT 22-SEP-2005 (first entry)
XX
DE Antibody 227-26/227-26.1 variable light chain.
XX
KW cytostatic; antibody therapy; neoplasm; interleukin 13; IL-13; cancer;
KW diagnosis; tumor; humanized antibody; cell proliferation;
KW Hodgkins disease; cytotoxin; chemotherapy; lymphoma; skin tumor;
KW stomach tumor; colon tumor; breast tumor; pancreatic tumor; liver tumor;
KW prostate tumor; lung tumor; head and neck tumor; renal tumor;
KW squamous cell carcinoma; brain tumor; Kaposi's carcinoma; solid tumor;
KW monoclonal antibody; 227-26; 227-26.1; light chain variable region.
XX
OS Mus sp.
OS Synthetic.
XX
PN WO2005062972-A2.
XX
PD 14-JUL-2005.
XX
PF 23-DEC-2004; 2004WO-US043541.
XX
PR 23-DEC-2003; 2003US-0532130P.
XX
PA (TANO-) TANOX INC.
XX
PI Fung SC, Moyle M;
XX
DR WPI; 2005-506604/51.
XX
PT Treating a neoplasm, e.g. Hodgkin's disease, that expresses and/or binds
PT interleukin-13 (IL-13) comprises administering an anti-IL-13 antibody or
PT its binding fragment that binds to both glycosylated and non-glycosylated
PT human IL-13.
XX
PS Claim 13; SEQ ID NO 7; 98pp; English.
XX
CC This invention describes a novel method for treating a neoplasm that
CC expresses and/or binds interleukin-13 (IL-13). The method comprises
CC administering an anti-IL-13 antibody or its binding fragment that binds
CC specifically and with high affinity to both glycosylated and non-
CC glycosylated human IL-13, and neutralizes human IL-13 activity at an
CC approximate molar ratio of 1:2 (Mab:IL-13). The method also describes 1)
CC a method for treating Hodgkin's disease comprising administering a
CC humanized or chimeric antibody or binding fragment to a patient; 2)
CC inhibiting IL-13 dependent proliferation of neoplastic cells in a mammal
CC comprising administering the antibody, or a binding fragment that
CC inhibits the biological activity of IL-13 and 3) diagnosing a cancer or
CC tumor overexpressing IL-13 comprising the use of the anti-IL-13 antibody
CC to detect overexpression of IL-13 in the biological sample taken from a
CC patient suspected of having the cancer or tumor. The antibodies used in
CC the method of the invention are 228B/C produced by the hybridoma
CC designated PTA-5657, 228A-4 and produced by the hybridoma designated PTA-
CC 5656; 227-26 produced by the hybridoma designated PTA-5655. The antibody is a human
CC produced by the hybridoma designated PTA-5655. The antibody is a human
CC antibody, a chimeric antibody, a single domain antibody or a humanized
CC antibody. The antibody is a fragment, such as Fv, Fab, and F(ab')₂
CC fragments, single-chain antibodies such as scFv, and various chain
CC combinations. The antibody further comprises a physiologically acceptable
CC carrier, diluent, excipient, or stabilizer. The antibody mediates killing
CC by antibody dependent cell-mediated cytotoxicity and/or complement
CC mediated cytotoxicity. The antibody comprises at least a variable light
CC chain region comprising an amino acid sequence having the formula: FRL1-
CC CDRL1-FRL2-CDRL2-FRL3-CDRL3-FRL4. The antibody comprises at least a
CC variable light or heavy chain region. The variable light or heavy chain
CC region further comprises a constant region. The constant region is from
CC an IgG antibody. The IgG antibody is an IgG1, IgG2, IgG3 or an IgG4
CC antibody. The antibody further comprises the heavy chain. The antibody is

CC associated with a cytotoxic agent, such as a radioisotope or a
CC chemotherapeutic agent. The methods and antibodies are useful for
CC treating neoplasms such as Hodgkin's lymphoma, skin cancer, stomach
CC cancer, colon cancer, breast cancer, pancreatic cancer, liver cancer,
CC prostate cancer, lung cancer, head-and-neck cancer, renal cell cancer,
CC squamous cell carcinoma, AIDS-associated Kaposi's carcinoma and brain
CC cancer. This sequence represents the humanized mouse monoclonal antibody
CC 227-26 and 227-26.1 variable light chain.
XX
SQ Sequence 114 AA;
Query Match 94.6%; Score 558; DB 9; Length 114;
Best Local Similarity 95.5%; Pred No. 9.3e-43;
Matches 107; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
QY 1 DVLMTQIFLSPVSLGDAQSISCRSSQSIHVSNGNTYQLQWYLPKQSPKLLIYKVSRL 60
DB 1 DVLMTQIFLSPVSLGDAQSISCRSSQSIHVSNGNTYQLQWYLPKQSPKLLIYKVSRL 60
QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVVYCFQGSHPVPTFGGTTKLEIK 112
DB 61 SGVPDRFSGSGGTDTFTLKISRVEAEDLGVVYCFQGSHPVPTFGGTTKLEIK 112
RESULT 11
AD126498
ID AD126498 standard; protein; 114 AA.
XX
AC AD126498;
XX
DT 15-APR-2004 (first entry)
XX
DE Human ECL2B-4-L SEQ ID NO:34.
XX
KW antibody; enzyme; virucide; anti-HIV; cytostatic; antibacterial;
KW helicobacter pylori urease inhibitor;
KW chemokine receptor CCR-5 antagonist; cancer; infectious disease;
KW Helicobacter pylori; HIV; human.
XX
OS Homo sapiens.
XX
PN WO2004009805-A1.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-JP009147.
XX
PR 19-JUL-2002; 2002JP-00211756.
PR 19-JUL-2002; 2002JP-00211768.
PR 27-FEB-2003; 2003JP-00051943.
PR 17-JUL-2003; 2003JP-00198270.
PR 17-JUL-2003; 2003JP-00198281.
PR 17-JUL-2003; 2003JP-00198292.
XX
PA (NTSC-) JAPAN SCI & TECHNOLOGY CORP.
XX
PI Uda T, Hifumi E;
XX
DR WPI; 2004-132963/13.
XX
DR N-PSDB; AD126499.
XX
PT Screening potential antibody enzymes by identification of a catalytic
PT triplet residue in the stereostructure for production of antibody enzymes
PT as diagnostic and therapeutic agents for cancer and infectious diseases
PT including HIV infection.
XX
PS Claim 41; SEQ ID NO 34; 232pp; Japanese.
XX
CC The invention relates to a novel method for producing antibody enzymes
CC comprising a structural analysis step which confirms the existence in the
CC predicted stereostructure of the antibody based on its amino acid
CC sequence of a catalytic triplet residue structure in which a serine
CC residue, an aspartic acid residue, and a histidine or glutamic acid

CC lysine-rich region and/or a multimerisation domain, most particularly it
CC is a single-chain antibody fragment, multibody, Fab fragment, fusion
CC protein of an antibody fragment with peptide or protein, and/or an Ig of
CC types G, M, A, E or D and/or their subclasses. It may be human,
CC humanised, murine or chimeric, e.g. IgM without the J chain. The
CC additional sequences/structures in the constructs are Ig domains of
CC various species, interacting or stabilising domains, signal sequences,
CC fluorescent dyes, toxins, antibodies with catalytic activity or other
CC specificities, cytolytic agents, enzymes, immuno-modulators or -
CC effectors, MHC molecules, antigens, chelators for radioactive labels,
CC liposomes, transmembrane domains, viruses and/or cells, specifically
CC macrophages. The antibodies, also constructs containing them, nucleic
CC acid encoding them, and related vectors and host cells, are useful for
CC prevention (e.g. as vaccine), diagnosis, alleviation, treatment,
CC monitoring and/or secondary treatment of tumours (specifically of breast,
CC colon, stomach, pancreas, large/small intestine, ovary, cervix, lung,
CC prostate, kidney and/or liver) and/or metastases (particularly to liver),
CC specifically where these are positive for the C1 antigen. The products of
CC the invention provide simple, reliable and efficient detection of
CC tumours. They are specific for carcinoma and show almost no binding to
CC healthy tissue.

XX SQ Sequence 114 AA;

Query Match 94.1%; Score 555; DB 8; Length 114;
Best Local Similarity 94.6%; Pred. No. 1.7e-42;
Matches 106; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSIPVSLGDOASISCRSSQSIHVSNGNTYLOWLYOKPGQSPKLLIYKVSNRL 60
DB 1 DVLMTQIPLSIPVSLGDOASISCRSSQSIHVSNGNTYLOWLYOKPGQSPKLLIYKVSNRF 60
QY 61 YGVPRFSGSGGTDTFLKISVREAE DLGVYCFQGSHPVPTFGGTTKLEIK 112
DB 61 SGVPRFSGSGGTDTFLKISVREAE DLGVYCFQGSHPVPTFGGTTKLEIK 112

RESULT 14

AEC21825

ID AEC21825 standard; protein; 139 AA.

AC AEC21825;

XX 20-OCT-2005 (first entry)

XX Mouse light chain variable region amino acid sequence SEQ ID NO.1.

XX chimeric antibody; basic fibroblast growth factor;
KW light chain variable region; pulmonary fibrosis.

XX Mus sp.

XX CN1560082-A.

XX 05-JAN-2005.

XX 08-MAR-2004; 2004CN-00015583.

XX 08-MAR-2004; 2004CN-00015583.

XX (UYJI-) UNIV JINAN.

XX Xiang J, Deng N, Li H;

XX WPI; 2005-296785/31.

DR N-PSDB; AEC21824.

XX Chimeric antibody specific for human basic fibroblast growth factor,
PT useful for preventing and treating pneumosilicosis.

XX Claim 2; SEQ ID NO 1; 17pp; Chinese.

XX The invention relates to a chimeric antibody specific for human basic

CC fibroblast growth factor (bFGF) and its encoding gene. The chimeric
CC antibody contains mouse variable regions and human constant regions of
CC human IgG1C. The antibody is useful for preventing and treating
CC pneumosilicosis. The present sequence represents a mouse light chain
CC variable region which can be used in a chimeric antibody of the
CC invention.

XX SQ Sequence 139 AA;

Query Match 94.1%; Score 555; DB 9; Length 139;

Best Local Similarity 94.6%; Pred. No. 2.2e-42;

Matches 106; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSIPVSLGDOASISCRSSQSIHVSNGNTYLOWLYOKPGQSPKLLIYKVSNRL 60
DB 20 DVLMTQIPLSIPVSLGDOASISCRSSQSIHVSNGNTYLOWLYOKPGQSPKLLIYKVSNRF 79

QY 61 YGVPRFSGSGGTDTFLKISVREAE DLGVYCFQGSHPVPTFGGTTKLEIK 112

DB 80 SGVPRFSGSGGTDTFLKISVREAE DLGVYCFQGSHPVPTFGGTTKLEIK 131

RESULT 15

ADS88785

ID ADS88785 standard; protein; 238 AA.

AC ADS88785;

XX 16-DEC-2004 (first entry)

XX Sequence of the chimeric IC2 kappa light chain in M13mp19 clone M609.

KW G glycoprotein; respiratory syncytial virus;

KW respiratory syncytial virus infection; RSV; RSV infection; IC2; IgG1;
KW chimeric.

XX Mus sp.

XX Homo sapiens.

XX Chimeric.

XX Key Location/Qualifiers

FT Peptide 1..19
/note= "Ig leader sequence"

XX WO2004083373-A2.

XX 30-SEP-2004.

XX 22-MAR-2004; 2004WO-GB001239.

XX 22-MAR-2003; 2003GB-00006618.

XX (UYNE-) UNIV NEWCASTLE-UPON-TYNE.

XX Toms G, Routledge B, Mekseepalard C;

XX WPI; 2004-691033/67.

DR N-PSDB; ADS88784.

XX New antibody against the G glycoprotein of RSV with a variable region
PT having a first and second domain from a VL and VH region, respectively,
PT useful for treating respiratory syncytial virus (RSV) infections.

XX Example 4; SEQ ID NO 55; 93pp; English.

XX The specification describes an against the G glycoprotein of respiratory
CC syncytial virus, with a variable region comprising a first domain from a
CC variable light chain region and a second domain comprising a first domain from a
CC region. The antibodies of the invention are useful for treating and
CC preventing the development of infections caused by the respiratory
CC syncytial virus (RSV). The present sequence represents the chimeric IC2
CC kappa light chain carried by pEE12 plasmid p533. IC2 is a murine
CC monoclonal antibody known to bind to the RSV G glycoprotein. The above

CC clone carries a mouse-human IgG1 chimeric antibody comprising IC2
CC variable regions and human kappa light chain and gamma1 heavy chain
CC constant regions.

XX
SQ Sequence 238 AA;

Query Match 94.1%; Score 555; DB 8; Length 238;
Best Local Similarity 92.9%; Pred. No. 3.8e-42;
Matches 104; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVLMTQIPLSLPVSLGDOASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
Db 20 DVLMTQTPLSLPVSLGDOASISCRSSQSIIVHSNGNTYLOWYLOKPGQSPKLLIYKVSRL 79

Qy 61 YGVDPDRFSSGSGTDFTLKISSVRAEDIGVYVCPOGSHVPWTFGGGTKLEIK 112
Db 80 SGVDPDRFSSGSGTDFTLKISRVEADLGVIYFCPOGSHIPWTFGGGTKLEIK 131

Search completed: January 10, 2006, 20:44:13
Job time : 79.3134 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:28:02 ; Search time 13.5124 Seconds
(without alignments)
797.508 Million cell updates/sec

Title: US-10-735-916A-54
Perfect score: 590
Sequence: 1 DVLMTQIPLSLPVSIGDQAS.....CFQGSHPVPTFGGTYKLEIK 112

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|-------|-------------|--------|----------|--------------------|
| 1 | 549 | 93.1 | 131 | 2 B39276 | Ig light chain pre |
| 2 | 547 | 92.7 | 112 | 2 A31807 | Ig kappa chain v r |
| 3 | 547 | 92.7 | 219 | 2 FC4203 | Ig kappa chain (no |
| 4 | 546 | 92.5 | 110 | 2 S26335 | Ig kappa chain v r |
| 5 | 542 | 91.9 | 113 | 2 PL0203 | anti-DNA autoantib |
| 6 | 540 | 91.5 | 219 | 2 S52028 | Ig kappa chain - m |
| 7 | 536 | 90.8 | 118 | 2 PT0359 | Ig kappa chain v r |
| 8 | 536 | 90.8 | 131 | 2 B34904 | Ig kappa chain pre |
| 9 | 535 | 90.7 | 112 | 2 F27887 | Ig kappa chain v r |
| 10 | 535 | 90.7 | 114 | 2 A32967 | Ig kappa chain v-I |
| 11 | 534 | 90.5 | 112 | 2 B31485 | Ig kappa chain v r |
| 12 | 533 | 90.3 | 112 | 2 S38719 | Ig light chain v r |
| 13 | 532 | 90.2 | 131 | 2 C34904 | Ig kappa chain pre |
| 14 | 531 | 90.0 | 225 | 2 JL0029 | Ig kappa chain pre |
| 15 | 530 | 89.8 | 112 | 2 A27887 | Ig kappa chain v r |
| 16 | 528 | 89.5 | 112 | 2 D28195 | Ig kappa chain v r |
| 17 | 527 | 89.3 | 112 | 2 E27887 | Ig kappa chain v r |
| 18 | 527 | 89.3 | 112 | 2 C27887 | Ig kappa chain v r |
| 19 | 527 | 89.3 | 219 | 2 S16112 | Ig kappa chain v-I |
| 20 | 526 | 89.2 | 114 | 2 B32967 | Ig kappa chain v-I |
| 21 | 526 | 89.2 | 131 | 2 B32513 | Ig kappa chain pre |
| 22 | 524 | 88.8 | 112 | 2 A49715 | Ig kappa chain v r |
| 23 | 522 | 88.5 | 112 | 2 S53750 | antibody Fab Jel 1 |
| 24 | 521 | 88.3 | 112 | 2 S32189 | Ig kappa chain v r |
| 25 | 521 | 88.3 | 115 | 2 S38715 | Ig kappa chain v r |
| 26 | 521 | 88.3 | 131 | 2 S09259 | Ig kappa chain pre |
| 27 | 519 | 88.0 | 114 | 2 A34353 | anti-peptide Fab' |
| 28 | 518 | 87.8 | 112 | 2 D27887 | Ig kappa chain v r |
| 29 | 518 | 87.8 | 131 | 2 D34904 | Ig kappa chain pre |

ALIGNMENTS

RESULT 1

B39276
Ig light chain precursor V-D-J region (6-19) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 18-Oct-1991 #sequence_revision 18-Oct-1991 #text_change 21-Jan-2000
C:Accession: B39276
R:Reininger, L.; Berney, T.; Shibata, T.; Spertini, F.; Merino, R.; Izui, S.
Proc. Natl. Acad. Sci. U.S.A. 87, 10038-10042, 1990
A>Title: Cryoglobulinemia induced by a murine IgG3 rheumatoid factor: skin vasculitis a
A:Reference number: A39276; MUID:91088540; PMID:2263605
A:Accession: B39276
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-131 <RET>
A:Cross-references: UNIPARC:UPI0000115153; GB:M55313; NID:q198095; PIDN:AAA63385.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:35-114/Domain: immunoglobulin homology <IMM>

Query Match 93.1%; Score 549; DB 2; Length 131;
Best Local Similarity 93.8%; Pred. No. 3.3e-43;
Matches 105; Conservative 2; Mismatches 5; Indels 0; Gaps 0;
QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIVHSNGNTYQLQWYLPKQSPKLLIYKVSRL 60
Db 20 DVLMTQIPLSLPVSIGDQASISCRSSQSIVHSNGNTYQLQWYLPKQSPKLLIYKVSRL 79
QY 61 YGVPPDRFSGSGSDTFTLKISVEAEDLGYYVYCFQGSHPVPTFGGTYKLEIK 112
Db 80 YGVPPDRFSGSGSDTFTLKISVEAEDLGYYVYCFQGSHPVPTFGGTYKLEIK 131

RESULT 2

A31807
Ig kappa chain V region (PAC1) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 20-Jul-1989 #sequence_revision 20-Jul-1989 #text_change 09-Jul-2004
C:Accession: A31807
R:Taub, R.; Gould, R.J.; Garsky, V.M.; Ciccarone, T.M.; Hoxie, J.; Friedman, P.A.; Shatt
J. Biol. Chem. 264, 259-265, 1989
A>Title: A monoclonal antibody against the platelet fibrinogen receptor contains a sequ
A:Reference number: A31807; MUID:89079661; PMID:2909518
A:Accession: A31807
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-112 <TAU>
A:Cross-references: UNIPROT:Q9M37; UNIPARC:UPI00001424F9
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotrimer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 92.7%; Score 547; DB 2; Length 112;

Best Local Similarity 92.9%; Pred. No. 4.3e-43;
Matches 104; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPKLLIYKVS NRL 60
Db 1 DVLMTQTPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLEWYLOKPGQSPKLLIYKVS NRF 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPTFFGGGTTKLEIK 112
Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCWGQSHVPTFFGGGTTKLEIK 112

RESULT 3
PC4203
Ig kappa chain (monoclonal antibody MAbA34) - mouse (fragment)
C:Species: Mus musculus (house mouse)
C:Date: 31-Dec-1996 #sequence_revision 31-Dec-1996 #text_change 11-Jan-2000
C:Accession: PC4203
R:Kwak, J.W.; Lee, D.I.; Choi, B.K.; Cho, W.K.; Lee, S.H.; Park, Y.B.; Han, M.H.
Gene 173, 257-259, 1996
A:Title: Cloning and characterization of cDNAs coding for heavy and light chains of a monoclonal antibody
A:Reference number: PC4202; MUID:97082978; PMID:8964510
A:Accession: PC4203
A:Molecule type: mRNA
A:Residues: 1-219 <KWA>
A:CROSS-references: UNIPARC:UPI00001157E4; GB:U29147; NID:G1594225; PIDN:AAC52821.1; PID
C:Comment: This protein is specific for human plasma apolipoprotein A-I of high-density
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:112-Domain: V region #status predicted <VRG>
F:113-219/Domain: C region #status predicted <CRG>

Query Match 92.7%; Score 547; DB 2; Length 219;
Best Local Similarity 93.8%; Pred. No. 8.7e-43; Mismatches 5; Indels 0; Gaps 0;
Matches 105; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPKLLIYKVS NRL 60
Db 1 DVLMTQTPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLEWYLOKPGQSPKLLIYKVS NRF 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPTFFGGGTTKLEIK 112
Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPTFFGGGTTKLEIK 112

RESULT 4
S26335
Ig kappa chain V region - mouse
C:Species: Mus musculus (house mouse)
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C:Accession: S26335
R:Stark, S.E.; Caton, A.J.
J. Exp. Med. 174, 613-624, 1991
A:Title: Antibodies that are specific for a single amino acid interchange in a protein e
A:Reference number: S26309; MUID:91341421; PMID:1908510
A:Accession: S26335
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-110 <STA>
A:CROSS-references: UNIPARC:UPI0000115F78; EMBL:X59183; NID:G52314; PIDN:CAA41893.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 92.5%; Score 546; DB 2; Length 110;
Best Local Similarity 94.5%; Pred. No. 5.2e-43;
Matches 104; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPKLLIYKVS NRL 60
Db 1 DVLMTQTPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLEWYLOKPGQSPKLLIYKVS NRF 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPTFFGGGTTKLE 110
Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPTFFGGGTTKLE 110

Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPTFFGGGTTKLE 110

RESULT 5
PL0203
anti-DNA autoantibody BV17-31, kappa chain V region - mouse (fragment)
C:Species: Mus musculus (house mouse)
C:Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 21-Jan-2000
C:Accession: PL0203
R:Smith, R.G.; Voss Jr., E.W.
Mol. Immunol. 27, 463-470, 1990
A:Title: Variable region primary structures of monoclonal anti-DNA autoantibodies from n
A:Reference number: PL0198; MUID:90309768; PMID:2114528
A:Accession: PL0203
A:Molecule type: mRNA
A:Residues: 1-113 <SMI>
A:CROSS-references: UNIPARC:UPI0000113786; GB:X53643; NID:G50196; PIDN:CMA37694.1; PID:5
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:16-95/Domain: immunoglobulin homology <IMM>
F:24-39/Region: complementarity-determining 1
F:55-61/Region: complementarity-determining 2
F:94-102/Region: complementarity-determining 3
F:101-113/Region: D region

Query Match 91.9%; Score 542; DB 2; Length 113;
Best Local Similarity 92.0%; Pred. No. 1.2e-42;
Matches 103; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPKLLIYKVS NRL 60
Db 1 DVLMTQTPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLEWYLOKPGQSPKLLIYKVS NRF 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPTFFGGGTTKLEIK 112
Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPTFFGGGTTKLEIK 112

RESULT 6
S52028
Ig kappa chain - mouse
C:Species: Mus musculus (house mouse)
C:Date: 07-May-1995 #sequence_revision 21-Jul-1995 #text_change 21-Jan-2000
C:Accession: S52028
R:van Engelen, F.; Schouten, A.; Moltisoff, J.W.; Roosien, J.; Dirkse, W.G.; Schots, A.;
submitted to the EMBL Data Library, August 1994
A:Description: Coordinate expression of antibody subunit genes yields high levels of fur
A:Reference number: S52028
A>Status: preliminary
A:Accession: S52028
A:Molecule type: mRNA
A:Residues: 1-219 <VAN>
A:CROSS-references: UNIPARC:UPI0000114B22; EMBL:L35138; NID:G522336; PIDN:AAA67525.1; P
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 91.5%; Score 540; DB 2; Length 219;
Best Local Similarity 92.9%; Pred. No. 3.8e-42;
Matches 104; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSLGDAQASISCRSSQSIHVSNGNTYQLQWYLOKPGQSPKLLIYKVS NRL 60
Db 1 DVLMTQTPLSLPVSLGDAQASISCRSSQSIHVSNGNTYLEWYLOKPGQSPKLLIYKVS NRF 60

QY 61 YGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPTFFGGGTTKLEIK 112
Db 61 SGVDPDRFSGSGGTDTFTLKISRVEAEDLGVYFCFGSHVPTFFGGGTTNLEIK 112

RESULT 7
PT0359
Ig kappa chain V region (R4A.12) - mouse (fragment)
C:Species: Mus musculus (house mouse)

C>Date: 31-Mar-1992 #sequence_revision 31-Mar-1992 #text_change 09-Jul-2004
C:Accession: PT0359
R:Shethner, R.; Kleiner, G.; Turken, A.; Papazian, L.; Diamond, B.
J. Exp. Med. 173, 287-296, 1991
A>Title: A novel class of anti-DNA antibodies identified in BALB/c mice.
A:Reference number: PT0352; MUID:91108325; PMID:1988536
A:Accession: PT0359
A:Molecule type: mRNA
A:Residues: 1-118 <SHE>
A:CROSS-references: UNIPROT:Q8VC16; UNIPARC:UPI0000176AF2
A:Experimental source: strain BALB/c
C:Comment: This protein is an anti-double-stranded DNA antibody.
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:19-98/Domain: immunoglobulin homology <IMM>

Query Match 90.8%; Score 536; DB 2; Length 118;
Best Local Similarity 90.2%; Pred. No. 4.5e-42;
Matches 101; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
DB 4 DVVMTQTPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 63

QY 61 YGVPRFSGSGSDTFTLKISSVEAEDLGYYCFQGSHPVPTFGGTTKLEIK 112
DB 64 SGVPRFSGSGSDTFTLKISSVEAEDLGYYCFQGSHPVPTFGGTTKLEIK 115

RESULT 8
B34904
Ig kappa chain precursor V region (12-40 and 5-14) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 27-Jul-1990 #sequence_revision 27-Jul-1990 #text_change 21-Jul-2000
C:Accession: B34904; H34903
R:Bedzyk, W.D.; Herron, J.N.; Edmundson, A.B.; Voss Jr., E.W.
J. Biol. Chem. 265, 133-138, 1990
A>Title: Active site structure and antigen binding properties of idiotypically cross-reacting antibodies to the variable region of the kappa chain of mouse immunoglobulin G.
A:Reference number: A34903; MUID:90094387; PMID:2104617
A:Accession: B34904
A>Status: preliminary; not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-131 <BED>
A:CROSS-references: UNIPARC:UPI0000114FC8; GB:M32384; GB:J05237; GB:J05238; NID:9639656;
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:35-114/Domain: immunoglobulin homology <IMM>

Query Match 90.8%; Score 536; DB 2; Length 131;
Best Local Similarity 90.2%; Pred. No. 5.1e-42;
Matches 101; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
DB 20 DVVMTQTPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 79

QY 61 YGVPRFSGSGSDTFTLKISSVEAEDLGYYCFQGSHPVPTFGGTTKLEIK 112
DB 80 SGVPRFSGSGSDTFTLKISSVEAEDLGYYCFQGSHPVPTFGGTTKLEIK 131

RESULT 9
F27887
Ig kappa chain V region (HIC5-4D1) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 15-Dec-1988 #sequence_revision 15-Dec-1988 #text_change 09-Jul-2004
C:Accession: F27887
R:Caton, A.J.; Brownlee, G.G.; Staudt, L.M.; Gerhard, W.
EMBO J. 5, 1577-1587, 1986
A>Title: Structural and functional implications of a restricted antibody response to a dominant epitope of the variable region of the kappa chain of mouse immunoglobulin G.
A:Reference number: A91043; MUID:86300658; PMID:2427335
A:Accession: F27887
A:Molecule type: DNA
A:Residues: 1-112 <CAT>

A:CROSS-references: UNIPROT:Q9M37; UNIPARC:UPI0000176A19
A:Experimental source: strain Balb/c
A>Note: This sequence was determined from the germline gene
C:Comment: This chain was isolated from a hybridoma protein that binds influenza virus
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 90.7%; Score 535; DB 2; Length 112;
Best Local Similarity 92.0%; Pred. No. 5.3e-42;
Matches 103; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
DB 1 DVLMTQTPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60

QY 61 YGVPRFSGSGSDTFTLKISSVEAEDLGYYCFQGSHPVPTFGGTTKLEIK 112
DB 61 SGVPRFSGSGSDTFTLKISSVEAEDLGYYCFQGSHPVPTFGGTTKLEIK 112

RESULT 10
A32967
Ig kappa chain V-II region TE33 - mouse
C:Species: Mus musculus (house mouse)
C>Date: 29-Jan-1990 #sequence_revision 29-Jan-1990 #text_change 21-Jan-2000
C:Accession: A32967
R:Levy, R.; Assulin, O.; Scherf, T.; Levitt, M.; Anglistter, J.
Biochemistry 28, 7168-7175, 1989
A>Title: Probing antibody diversity by 2D NMR: comparison of amino acid sequences, predicted structures, and antigen binding properties of the variable region of the kappa chain of mouse immunoglobulin G.
A:Reference number: A32967; MUID:90057406; PMID:2819059
A:Accession: A32967
A>Status: preliminary; nucleic acid sequence not shown; not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-114 <LEV>
A:CROSS-references: UNIPARC:UPI0000114F5D; GB:M30481; NID:917157; PIDN:AAA38935.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 90.7%; Score 535; DB 2; Length 114;
Best Local Similarity 90.2%; Pred. No. 5.4e-42;
Matches 101; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60
DB 1 DVLMTQTPLSLPVSIGDQASISCRSSQSIHVSNGNTYLOWYLOKPGQSPKLLIYKVSRL 60

QY 61 YGVPRFSGSGSDTFTLKISSVEAEDLGYYCFQGSHPVPTFGGTTKLEIK 112
DB 61 SGVPRFSGSGSDTFTLKISSVEAEDLGYYCFQGSHPVPTFGGTTKLEIK 112

RESULT 11
B31485
Ig kappa chain V region (4-4-20) - mouse (fragment)
C:Species: Mus musculus (house mouse)
C>Date: 31-Jul-1989 #sequence_revision 31-Jul-1989 #text_change 09-Jul-2004
C:Accession: B31485
R:Bedzyk, W.D.; Johnson, L.S.; Riordan, G.S.; Voss Jr., E.W.
J. Biol. Chem. 264, 1565-1569, 1989
A>Title: Comparison of variable region primary structures within an anti-fluorescein idiotype
A:Reference number: A31485; MUID:89109167; PMID:2492278
A:Accession: B31485
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-112 <BED>
A:CROSS-references: UNIPROT:Q8VC16; UNIPARC:UPI0000176AF8
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 90.5%; Score 534; DB 2; Length 112;

| | Matches | 99; | Conservative | 6; | Mismatches | 7; | Indels | 0; | Gaps | 0; |
|----|---------|---------------|----------------------------|------------------|------------------|-----|--------|----|------|----|
| Qy | 1 | DVLTQIPLSLPVS | LGDDASISCRSSQSI | VHSGNTYLQWY | LQKPGQSPKLLIYKVS | NRL | 60 | | | |
| Db | 1 | DVMTQTPLSLPVS | LGDDASISCRSSQSLVHSGNTYLHWY | LQKPGQSPKLLIYKVS | NRF | 60 | | | | |
| Qy | 61 | YGVPRDFSGSGT | DTLTKISSVHAEDLGVY | CFQGSHPVPTFGG | TKLEIK | 112 | | | | |
| Db | 61 | SGVPRDFSGSGT | DTLTKISSVHAEDLGVY | CFQGSHPVPTFGG | TKLEIK | 112 | | | | |

Search completed: January 10, 2006, 20:55:13
Job time : 14.5124 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 10, 2006, 20:26:41 ; Search time 75.5025 Seconds
(without alignments)
1046.577 Million cell updates/sec

Title: US-10-735-916A-54
Perfect score: 590
Sequence: 1 DVLMTQIPLSLVSLGDOAS.....CFQGSHPVPTFGGKLEIK 112

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt 05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|-------|-------------|--------|-------------|-------------|
| 1 | 541 | 91.7 | 248 | 2 Q65ZQ7 | 9MURI |
| 2 | 511.5 | 86.7 | 115 | 2 Q5F210 | MOUSE |
| 3 | 510 | 86.4 | 113 | 1 KV2G | MOUSE |
| 4 | 491 | 83.2 | 112 | 2 Q53VP8 | MOUSE |
| 5 | 489 | 82.9 | 219 | 2 Q65ZC0 | MOUSE |
| 6 | 466 | 79.0 | 133 | 1 KV2F | HUMAN |
| 7 | 453 | 76.8 | 239 | 2 Q8TCD0 | HUMAN |
| 8 | 451.5 | 76.5 | 114 | 2 Q9UL80 | HUMAN |
| 9 | 449 | 76.1 | 239 | 2 Q58E08 | MOUSE |
| 10 | 448 | 75.9 | 239 | 2 Q6P491 | HUMAN |
| 11 | 444 | 75.3 | 239 | 2 Q8NEK0 | HUMAN |
| 12 | 441 | 74.7 | 117 | 1 KV2E | HUMAN |
| 13 | 438 | 74.2 | 113 | 1 KV2D | HUMAN |
| 14 | 426 | 72.2 | 113 | 1 KV2E | MOUSE |
| 15 | 424 | 71.9 | 113 | 1 KV2B | HUMAN |
| 16 | 423.5 | 71.8 | 115 | 1 KV2A | HUMAN |
| 17 | 421.5 | 71.4 | 240 | 2 Q6PIH6 | HUMAN |
| 18 | 417 | 70.7 | 234 | 2 Q5XKG4 | MOUSE |
| 19 | 410 | 69.8 | 112 | 1 KV2D | MOUSE |
| 20 | 410 | 69.5 | 113 | 1 KV2F | MOUSE |
| 21 | 408.5 | 69.2 | 112 | 1 KV2C | HUMAN |
| 22 | 395 | 66.9 | 112 | 2 Q6LEM8 | MOUSE |
| 23 | 393.5 | 66.7 | 134 | 1 KV4C | HUMAN |
| 24 | 381 | 64.6 | 133 | 1 KV4B | HUMAN |
| 25 | 379.5 | 64.3 | 114 | 1 KV4A | HUMAN |
| 26 | 369 | 62.5 | 113 | 1 KV2C | MOUSE |
| 27 | 368.5 | 62.5 | 111 | 1 KV3H | MOUSE |
| 28 | 368.5 | 62.5 | 111 | 1 KV3Q | MOUSE |
| 29 | 368.5 | 62.5 | 255 | 2 Q6K805 | MOUSE |
| 30 | 366.5 | 62.1 | 131 | 1 KV3I | MOUSE |
| 31 | 364.5 | 61.8 | 108 | 1 KV1_CANFA | |

| | | | | | | | | |
|----|-------|------|-----|----------|-------|--------|-----|---------|
| 32 | 364.5 | 61.8 | 111 | 1 KV3L | MOUSE | P01664 | mus | musculu |
| 33 | 364.5 | 61.8 | 240 | 2 Q52L64 | MOUSE | Q52L64 | mus | musculu |
| 34 | 362 | 61.4 | 110 | 1 KV3P | MOUSE | P01668 | mus | musculu |
| 35 | 362 | 61.4 | 112 | 1 KV2A | MOUSE | P01626 | mus | musculu |
| 36 | 361.5 | 61.3 | 111 | 1 KV3Q | MOUSE | P01669 | mus | musculu |
| 37 | 360.5 | 61.1 | 111 | 1 KV3C | MOUSE | P01656 | mus | musculu |
| 38 | 360.5 | 61.1 | 111 | 2 Q920E9 | MOUSE | Q920E9 | mus | musculu |
| 39 | 358.5 | 60.8 | 111 | 1 KV3M | MOUSE | P01665 | mus | musculu |
| 40 | 357.5 | 60.6 | 111 | 1 KV3A | MOUSE | P01654 | mus | musculu |
| 41 | 357.5 | 60.6 | 111 | 1 KV3J | MOUSE | P01659 | mus | musculu |
| 42 | 356.5 | 60.4 | 112 | 1 KV3B | MOUSE | P01634 | mus | musculu |
| 43 | 356.5 | 60.4 | 136 | 1 KV5B | MOUSE | P01670 | mus | musculu |
| 44 | 355.5 | 60.3 | 111 | 1 KV3R | MOUSE | P01658 | mus | musculu |
| 45 | 355.5 | 60.3 | 132 | 1 KV3F | MOUSE | | | |

ALIGNMENTS

RESULT 1
Q65ZQ7 9MURI PRELIMINARY; PRT; 248 AA.
AC Q65ZQ7
DT 25-OCT-2004 (Tremblrel. 28, Created)
DT 25-OCT-2004 (Tremblrel. 28, Last sequence update)
DT 25-OCT-2004 (Tremblrel. 28, Last annotation update)
DE B3(Fv)-PE40 (Fragment).
GN Name=B3(Fv)-PE40;
OS Mus sp.
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10095;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=92020904; PubMed=1924323;
RA Brinkmann U., Pai L.H., Fitzgerald D.J., Willingham M., Pastan I.;
RT "B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete
RT regression of a human carcinoma in mice."
RL Proc. Natl. Acad. Sci. U.S.A. 88:8616-8620(1991).
DR EMBL; S57990; AAB19971.2; -; mRNA.
DR SMR; Q65ZQ7; 4-247.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGV; 2.
DR PROSITE; PS50835; IG LIKE; 2.
FT NON TER 248 248
SQ SEQUENCE 248 AA; 26634 MW; 7A3759B43E570950 CRC64;

Query Match 91.7%; Score 541; DB 2; Length 248;
Best Local Similarity 92.9%; Pred. No. 1.4e-49;
Matches 104; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLVSLGDOASISCRSSQSIIVHNGNTYLQWYKQKQSPKLIYKVNRL 60
Db 136 DVLMTQSPLSLVSLGDOASISCRSSQSIIVHNGNTYLQWYKQKQSPKLIYKVNRF 195
QY 61 YGVPPRFSGSGSGTDFTLKISVEAEEDLGYYVYFCQGSHPVPTFGGKLEIK 112
Db 196 YGVPPRFSGSGSGTDFTLKISVEAEEDLGYYVYFCQGSHPVPTFGGKLEIK 247

RESULT 2

Q5F210 MOUSE PRELIMINARY; PRT; 115 AA.
AC Q5F210;
DT 10-MAY-2005 (Tremblrel. 30, Created)
DT 10-MAY-2005 (Tremblrel. 30, Last sequence update)
DT 10-MAY-2005 (Tremblrel. 30, Last annotation update)
DE Kappa light chain variable region (Fragment).
GN Name=IgG1 anti-TS1 V1;

```
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Erlandson A.; Holm P.; Ullen A.; Stigbrand T.; Sundstrom B.E.;
RT "Studies of the interactions between the anticytokerin 8 monoclonal
antibody T51, its antigen and its anti-idiotypic antibody alphaTS1.";
RL J. Mol. Recognit. 16:157-163(2003).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RA Erlandson A.;
RL Submitted (FEB-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ848575; CA156337.1; -; mRNA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR Pfam; PF07686; V-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
FT NON_TER 1
FT NON_TER 115
SQ SEQUENCE 115 AA; 12560 MW; E4D3BF3D63E88007 CRC64;

Query Match 86.7%; Score 511.5; DB 2; Length 115;
Best Local Similarity 87.6%; Pred. No. 8.1e-47;
Matches 99; Conservative 6; Mismatches 7; Indels 1; Gaps 1;

QY 1 DVLMTQPLSLPVSIGDQASISCRSSQSLVHSGNTYLOWLYLQKPGQSPKLLIYKVSRL 60
DB 1 DVMVTQTPLSLPVSIGDQASISCRSSQSLVHSGNTYLNWLYLQKAGQSPKLLIYKVSRRF 60

QY 61 YGVDPDRFSGSGGTDTFTLKISVVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112
DB 61 SGVDPDRFSGSGGTDTFTLKISRVEADLGIVFCSTQTHVPTFGGTTKLEIK 112

RESULT 3
KV2G MOUSE STANDARD; PRT; 113 AA.
AC P01631;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region 26-10.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP PROTEIN SEQUENCE.
RC STRAIN=A/J;
RX MEDLINE=83178921; PubMed=6404298;
RA Novotny J.; Margolies M.N.;
RT "Amino acid sequence of the light chain variable region from a mouse
anti-digoxin hybridoma antibody.";
RL Biochemistry 22:1153-1158(1983).
CC -!- MISCELLANEOUS: This chain was isolated from an IgG2a hybridoma
protein that binds digoxin.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC PIR; A01914; KIMS26.
DR HSP; O99M37; 1191.
DR Ensembl; ENSMUSG00000055315; Mus musculus.
```

```
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Direct protein sequencing; Hybridoma; Immunoglobulin domain;
KW Immunoglobulin V region; Monoclonal antibody.
FT REGION 1 23
FT REGION 24 39
FT REGION 40 54
FT REGION 55 61
FT REGION 62 93
FT REGION 94 102
FT REGION 103 112
FT DISULFID 23 93
FT NON_TER 113
SQ SEQUENCE 113 AA; 12273 MW; F9F39CE949A84C2A CRC64;

Query Match 86.4%; Score 510; DB 1; Length 113;
Best Local Similarity 87.5%; Pred. No. 1.1e-46;
Matches 98; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY 1 DVLMTQPLSLPVSIGDQASISCRSSQSLVHSGNTYLOWLYLQKPGQSPKLLIYKVSRL 60
DB 1 DVMVTQTPLSLPVSIGDQASISCRSSQSLVHSGNTYLNWLYLQKAGQSPKLLIYKVSRRF 60

QY 61 YGVDPDRFSGSGGTDTFTLKISVVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112
DB 61 SGVDPDRFSGSGGTDTFTLKISRVEADLGIVFCSTQTHVPTFGGTTKLEIK 112

RESULT 4
Q53VP8 MOUSE PRELIMINARY; PRT; 112 AA.
ID Q53VP8_MOUSE PRELIMINARY;
AC Q53VP8;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE Kappa chain (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P.; Rocca-Serra J.; Somme G.; Theze J.; Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
a germ-line network by paucigene encoded Ab2 (anti-idiotypic)
antibodies in the GAT system.";
RL EMO J. 4:3681-3688(1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 108-109.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
DR EMBL; X03386; CA227113.1; -; mRNA.
FT NON_TER 1
FT NON_TER 112
SQ SEQUENCE 112 AA; 12266 MW; C844B7881A89C18A CRC64;

Query Match 83.2%; Score 491; DB 2; Length 112;
Best Local Similarity 83.0%; Pred. No. 1.2e-44;
Matches 93; Conservative 8; Mismatches 11; Indels 0; Gaps 0;

QY 1 DVLMTQPLSLPVSIGDQASISCRSSQSLVHSGNTYLOWLYLQKPGQSPKLLIYKVSRL 60
DB 1 DVMVTQTPLSLPVSIGDQASISCRSSQSLVHSGNTYLNWLYLQKAGQSPKLLIYKVSRRF 60

QY 61 YGVDPDRFSGSGGTDTFTLKISVVEADLGVIYCFQGSHPVPTFGGTTKLEIK 112
DB 61 SGVDPDRFSGSGGTDTFTLKISRVEADLGIVFCSTQTHVPTFGGTTKLEIK 112
```



```

RESULT 5
Q65ZCO_MOUSE PRELIMINARY; PRT; 219 AA.
ID Q65ZCO_MOUSE
AC Q65ZCO;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Kappa light chain C region (fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Balb/c; TISSUE=Spleen;
RX MEDLINE=96319505; PubMed=8768802;
RA Kipp B., Schlaak M., Becker W.M.;
RT "Cloning and expression of a recombinant mouse Fab-fragment
RT recognizing a defined linear epitope of Chironomus thummi major
RT allergen Chi t I."
RL Int. Arch. Allergy Immunol. 110:348-353 (1996).
DR EMBL; Z37499; CAA85724.1; -; mRNA.
DR SMR; Q65ZCO; 1-219.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGC1; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 2.
DR PROSITE; PS00290; IG_MHC; 1.
FT NON_TER 1
FT NON_TER 219
SQ SEQUENCE 219 AA; 23944 MW; 7E1B82A14EAF8445 CRC64;

Query Match 82.9%; Score 489; DB 2; Length 219;
Best Local Similarity 83.9%; Pred. No. 4.5e-44;
Matches 94; Conservative 7; Mismatches 11; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHNGNTYLYQWYKQPSKLLIYKVNRL 60
Db 1 ELVMTQSLSLPVSIGDQASISCRSSQSIHNGNTYLYQWYKQPSKLLIYKVNRF 60
QY 61 YGVDPFRFSGSGGDTFTLKISVREADLGYYCFQGSHPVTFGGTKLEIK 112
Db 61 SGVDPFRFSGSGGDTFTLKISVREADLGYYCFQGSHPVTFGGTKLEIK 112

RESULT 6
KV2F_HUMAN STANDARD; PRT; 133 AA.
ID KV2F_HUMAN
AC P06310;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region RPMI 6410 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86041852; PubMed=2997711;
RA Klobbeck H.G., Meindl A., Combrato G., Solomon A., Zachau H.G.;
RT "Human immunoglobulin kappa light chain genes of subgroups II and
RT III."
RL Nucleic Acids Res. 13:6499-6513 (1985).
CC -----

```

```

CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR EMBL; Z00020; CAA77315.1; -; Genomic_DNA.
DR PIR; A01890; K2HURP.
DR HSSP; Q99M37; 1191.
DR SMR; P06310; 21-133.
DR Ensembl; ENSG00000173758; Homo sapiens.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 20
FT CHAIN 21 133 Ig kappa chain V-II region RPMI 6410.
FT REGION 21 43 Framework-1.
FT REGION 44 59 Complementarity-determining-1.
FT REGION 60 74 Framework-2.
FT REGION 75 81 Complementarity-determining-2.
FT REGION 82 113 Framework-3.
FT REGION 114 122 Complementarity-determining-3.
FT REGION 123 132 Framework-4.
FT DISULFID 43 113 By similarity.
FT NON_TER 133
SQ SEQUENCE 133 AA; 14707 MW; 513CCAF3673009EE CRC64;

Query Match 79.0%; Score 466; DB 1; Length 133;
Best Local Similarity 78.6%; Pred. No. 7.4e-42;
Matches 88; Conservative 11; Mismatches 13; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPVSIGDQASISCRSSQSIHNGNTYLYQWYKQPSKLLIYKVNRL 60
Db 21 DVVMTQSLSLPVSIGDQASISCRSSQSIHNGNTYLYQWYKQPSKLLIYKVNRF 80
QY 61 YGVDPFRFSGSGGDTFTLKISVREADLGYYCFQGSHPVTFGGTKLEIK 112
Db 81 SGVDPFRFSGSGGDTFTLKISVREADLGYYCFQGSHPVTFGGTKLEIK 132

RESULT 7
Q8TCD0_HUMAN PRELIMINARY; PRT; 239 AA.
ID Q8TCD0_HUMAN
AC Q8TCD0;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RX MEDLINE=23388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

```


QY 61 YGVDPFGSGSGDTFLKISSVEADPLGVVYCFQGSHPVWTFGGGKLEIK 112

Db 81 SGVDPFGSGSGDTFLKISRVEADPLGVVYCLATHPRPFGGGKLEIK 132

| | |
|--------------|--|
| RESULT | 10 |
| Q6P491_HUMAN | |
| ID | Q6P491_HUMAN PRELIMINARY; PRT; 239 AA. |
| AC | Q6P491; |
| DT | 05-JUL-2004 (TrEMBLrel. 27, Created) |
| DT | 05-JUL-2004 (TrEMBLrel. 27, Last sequence update) |
| DT | 05-JUL-2004 (TrEMBLrel. 27, Last annotation update) |
| DE | Hypothetical protein. |
| OS | Homo sapiens (Human). |
| OC | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; |
| OC | Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; |
| OC | Homo. |
| OX | NCBI_TaxID=9606; |
| [1] | |
| RN | NUCLEOTIDE SEQUENCE. |
| RP | TSSUE=Skin; |
| RC | MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899; |
| RA | Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., |
| RA | Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D., |
| RA | Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K., |
| RA | Hopkins R.F., Jordan H., Moore T., Max A.I., Wang J., Hsieh L., |
| RA | Datchenko L., Marusina K., Farmer A.E., Rubin G.M., Hong L., |
| RA | Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., |
| RA | Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C., |
| RA | Raha S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J., |
| RA | Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., |
| RA | Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., |
| RA | Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., |
| RA | Fahay J., Helton E., Kerteman M., Madan A., Rodrigues S., Sanchez A., |
| RA | Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., |
| RA | Blakesley R.W., Truchman J.W., Green E.D., Dickson M.C., |
| RA | Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., |
| RA | Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalls D.E., |
| RA | Schnurch A., Schein J.E., Jones S.J.M., Marra M.A.; |
| RT | "Generation and initial analysis of more than 15,000 full-length human |
| RL | and mouse cDNA sequences."; |
| RL | Proc. Natl. Acad. Sci. U.S.A. 99:16999-16903(2002). |

```

RA Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.
RL EMBL; BC063599; AAH63599.1; -; mRNA.
DR HSP; P01837; ILCU.
DR SMR; O6P491; 21-237.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Hypothetical protein.
SQ SEQUENCE 239 AA; 26245 MW; CD7313DDFFD358B3 CRC64;

Query Match 75.9%; Score 448; DB 2; Length 239;
Best Local Similarity 74.1%; Pred. No. 1.3e-39;
Matches 83; Conservative 13; Mismatches 16; Indels 0; Gaps 0;

Qy 1 DVLMTQPLSLPSVLGPDASISCRSSOSIVHSNGNTYLOWYLOKPGQSPKLLIYKVNRL 60
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 21 DIVMTQPLSPVTLGPDASISCRSSSELHNSGNTYLSWLNHDPGQFPRLLIYKISNRF 80

```



```

FT REGION 98 106 Complementarity-determining-3.
FT REGION 107 116 Framework-4.
FT DISULFID 27 97 By similarity.
FT NON_TER 1 1
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 12664 MW; 92C57DC719E558B1 CRC64;

Query Match
Best Local Similarity 74.7%; Score 441; DB 1; Length 117;
Matches 85; Conservative 9; Mismatches 18; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPSVSLGDOASISCRSSQSIIVHSNGNTYLQWYLRKQSPKLLIYKVSRL 60
Db 5 DIVMTQSPSLPVTGPBPASISCRSSQSLHSDGFDYLNWYLRKQSPKLLIYKVSRL 64

QY 61 YGVDPFRFSGSGSDTFTLKISSVEADLGVVYCFQGSHPVWTFGGTGLEIK 112
Db 65 SGVDPFRFSGSGSDTFTLKISRVEADGVVYCMZALQAPITFGQGTGLEIK 116

RESULT 13
KV2D HUMAN STANDARD; PRT; 113 AA.
ID KV2D HUMAN STANDARD; PRT; 113 AA.
AC P01617;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE IG kappa chain V-II region TEW.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE (BENCE-JONES PROTEIN TEW).
RX MEDLINE=74148480; PubMed=4596149;
RA Putnam F.W., Whitley E.J. Jr., Paul C., Davidson J.N.;
RT Terry W.D., Page D.L., Kimura S., Isobe T., Osseerman E.F.,
RA Glenner G.G.;
RT "Structural identity of Bence Jones and amyloid fibril proteins in a
RT patient with plasma cell dyscrasia and amyloidosis.";
RL J. Clin. Invest. 52:1276-1281(1973).
CC -!- MISCELLANEOUS: The major amyloid protein appears to be identical
CC with the Bence Jones protein isolated from the same patient.
CC -!- MISCELLANEOUS: This protein was isolated from the urine of a
CC patient with plasma cell dyscrasia and amyloidosis.
CC -!- MISCELLANEOUS: The C region of this chain has the INV (1,2)
CC marker.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC PIR; A90370; K2HUTW.
CC HSSP; Q99M37; 1191.
CC SMR; P01617; 1-113.
CC GO; GO:0005576; C:extracellular region; NAS.
CC GO; GO:0003823; F:antigen binding; NAS.
CC GO; GO:0006955; P:immune response; NAS.
CC InterPro; IPR007110; IG-like.
CC InterPro; IPR003596; IG_v.
CC SMART; SM00406; IGV; 1.
CC PROSITE; PS50835; IG_LIKE; 1.
CC Amyloid; Bence-Jones protein; Direct protein sequencing;
KW Immunoglobulin domain; Immunoglobulin V region.

```

```

FT REGION 1 23 Framework-1.
FT REGION 24 39 Complementarity-determining-1.
FT REGION 40 54 Framework-2.
FT REGION 55 61 Complementarity-determining-2.
FT REGION 62 93 Framework-3.
FT REGION 94 102 Complementarity-determining-3.
FT REGION 103 112 Framework-4.
FT DISULFID 23 93 By similarity.
FT NON_TER 113 113
SQ SEQUENCE 113 AA; 12316 MW; 0C3C9F81F1843CA CRC64;

Query Match
Best Local Similarity 74.2%; Score 438; DB 1; Length 113;
Matches 83; Conservative 12; Mismatches 17; Indels 0; Gaps 0;

QY 1 DVLMTQIPLSLPSVSLGDOASISCRSSQSIIVHSNGNTYLQWYLRKQSPKLLIYKVSRL 60
Db 1 DIVMTQSPSLPVTGPBPASISCRSSQSLHSDGFDYLNWYLRKQSPKLLIYKVSRL 60

QY 61 YGVDPFRFSGSGSDTFTLKISSVEADLGVVYCFQGSHPVWTFGGTGLEIK 112
Db 61 SGVDPFRFSGSGSDTFTLKISRVEADGVVYCMZALQAPITFGQGTGLEIK 112

RESULT 14
KV2E MOUSE STANDARD; PRT; 113 AA.
ID KV2E MOUSE STANDARD; PRT; 113 AA.
AC P03976;
DT 23-OCT-1986 (Rel. 02, Created)
DT 23-OCT-1986 (Rel. 02, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE IG kappa chain V-II region 17S29.1.
OS Mus musculus (Mouse)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridea; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=85128968; PubMed=6441768;
RA Aebersold R., Herbst H., Grutter T., Chang J.Y., Braun D.G.;
RT "Murine V kappa 25 and V kappa 27 amino-acid sequences of C57B1/6
RT origin: monoclonal antibodies 17S29.1 and 2S25.1 specific for the
RT group A-streptococcal polysaccharide.";
RL Hoppe-Seyler's Z. Physiol. Chem. 365:1375-1383(1984).
CC -!- FUNCTION: Anti-streptococcal group A carbohydrate antibody.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC PIR; A01912; KVM517.
CC HSSP; Q99M37; 1191.
CC SMR; P03976; 1-113.
CC Ensembl; ENSMUSG0000055315; Mus musculus.
CC InterPro; IPR007110; IG-like.
CC InterPro; IPR003596; IG_v.
CC SMART; SM00406; IGV; 1.
CC PROSITE; PS50835; IG_LIKE; 1.
CC Direct protein sequencing; Hybridoma; Immunoglobulin domain;
KW Immunoglobulin V region.
FT REGION 1 23 Framework-1.
FT REGION 24 39 Complementarity-determining-1.
FT REGION 40 54 Framework-2.
FT REGION 55 61 Complementarity-determining-2.
FT REGION 62 93 Framework-3.
FT REGION 94 102 Complementarity-determining-3.
FT REGION 103 112 Framework-4.
FT DISULFID 23 93 By similarity.
FT NON_TER 113 113

```

